Identification	O
of	O
novel	O
FLT3	S-geneY
kinase	S-geneN
inhibitors	O
.	O

FLT3	S-geneY
and	O
PDGFR	S-geneN
tyrosine	B-geneN
kinases	E-geneN
are	O
important	O
targets	O
for	O
therapy	O
of	O
different	O
types	O
of	O
leukemia	O
.	O

Several	O
FLT3	S-geneY
/	O
PDGFR	S-geneN
inhibitors	O
are	O
currently	O
under	O
clinical	O
investigation	O
for	O
combination	O
with	O
standard	O
therapy	O
for	O
treatment	O
of	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
however	O
these	O
agents	O
only	O
induce	O
partial	O
remission	O
and	O
development	O
of	O
resistance	O
has	O
been	O
reported	O
.	O

In	O
this	O
work	O
we	O
describe	O
the	O
identification	O
of	O
potent	O
and	O
novel	O
dual	O
FLT3	S-geneY
/	O
PDGFR	S-geneN
inhibitors	O
that	O
resulted	O
from	O
our	O
efforts	O
to	O
screen	O
a	O
library	O
of	O
25,607	O
small	O
molecules	O
against	O
the	O
FLT3	S-geneY
dependent	O
cell	O
line	O
MOLM	O
-	O
13	O
and	O
the	O
PDGFR	S-geneN
dependent	O
cell	O
line	O
EOL	O
-	O
1	O
.	O

This	O
effort	O
led	O
to	O
the	O
identification	O
of	O
five	O
compounds	O
that	O
were	O
confirmed	O
to	O
be	O
active	O
on	O
additional	O
FLT3	S-geneY
dependent	O
cell	O
lines	O
(	O
cellular	O
EC50	O
values	O
between	O
35	O
and	O
700	O
nM	O
)	O
,	O
while	O
having	O
no	O
significant	O
effect	O
on	O
24	O
other	O
tyrosine	O
kinases	I-geneN
.	E-geneN

Vitamin	B-chem
C	E-chem
forestalls	O
cigarette	O
smoke	O
induced	O
NF	B-geneN
-	I-geneN
κB	E-geneN
activation	O
in	O
alveolar	O
epithelial	O
cells	O
.	O

Cigarette	O
smoking	O
causes	O
cellular	O
oxidative	O
stress	O
resulting	O
in	O
inflammatory	O
diseases	O
of	O
lung	O
wherein	O
transcription	O
factor	O
NF	B-geneN
-	I-geneN
κB	E-geneN
plays	O
an	O
important	O
role	O
.	O

It	O
is	O
possible	O
that	O
vitamin	B-chem
C	E-chem
,	O
an	O
antioxidant	O
,	O
may	O
prevent	O
cigarette	O
smoke	O
(	O
CS	O
)	O
-	O
induced	O
NF	B-geneN
-	I-geneN
κB	E-geneN
activation	O
that	O
involves	O
degradation	O
of	O
I	B-geneY
-	I-geneY
κBε	E-geneY
and	O
nuclear	O
translocation	O
of	O
c	B-geneY
-	I-geneY
Rel	E-geneY
/	O
p50	S-geneY
in	O
alveolar	O
epithelial	O
cells	O
.	O

Therefore	O
,	O
to	O
examine	O
the	O
hypothesis	O
,	O
we	O
verified	O
the	O
effect	O
of	O
vitamin	B-chem
C	E-chem
on	O
CS	O
-	O
induced	O
expression	O
of	O
NF	B-geneN
-	I-geneN
κB	E-geneN
driven	O
luciferase	O
reporter	O
and	O
NF	B-geneN
-	I-geneN
κB	E-geneN
binding	O
at	O
its	O
target	O
DNA	O
by	O
EMSA	O
in	O
alveolar	O
epithelial	O
A549	O
cells	O
.	O

We	O
also	O
examined	O
the	O
level	O
of	O
I	B-geneY
-	I-geneY
κBε	E-geneY
and	O
sub	O
-	O
cellular	O
distribution	O
of	O
c	B-geneY
-	I-geneY
Rel	E-geneY
by	O
western	O
blotting	O
and	O
immunofluorescence	O
respectively	O
in	O
CSE	O
-	O
treated	O
A549	O
cells	O
with	O
or	O
without	O
vitamin	B-chem
C	E-chem
pretreatment	O
.	O

We	O
observed	O
a	O
significant	O
reduction	O
in	O
CSE	O
induced	O
luciferase	O
expression	O
,	O
NF	B-geneN
-	I-geneN
κB	E-geneN
DNA	O
binding	O
,	O
I	B-geneY
-	I-geneY
κBε	E-geneY
degradation	O
and	O
c	B-geneY
-	I-geneY
Rel	E-geneY
nuclear	O
translocation	O
in	O
cells	O
pretreated	O
with	O
vitamin	B-chem
C	E-chem
.	O

To	O
further	O
validate	O
the	O
result	O
,	O
we	O
examined	O
sub	O
-	O
cellular	O
distribution	O
of	O
c	B-geneY
-	I-geneY
Rel	E-geneY
in	O
lungs	O
of	O
CS	O
-	O
exposed	O
guinea	O
pigs	O
treated	O
or	O
untreated	O
with	O
vitamin	B-chem
C	E-chem
.	O

Result	O
showed	O
that	O
vitamin	B-chem
C	E-chem
treatment	O
resulted	O
in	O
markedly	O
reduced	O
c	B-geneY
-	I-geneY
Rel	E-geneY
nuclear	O
translocation	O
.	O

All	O
these	O
results	O
demonstrate	O
that	O
vitamin	B-chem
C	E-chem
prevents	O
CS	O
(	O
E	O
)	O
-	O
induced	O
NF	B-geneN
-	I-geneN
κB	E-geneN
activation	O
and	O
thus	O
it	O
could	O
be	O
used	O
for	O
the	O
prevention	O
of	O
CS	O
-	O
induced	O
inflammatory	O
diseases	O
.	O

Adverse	O
outcome	O
pathways	O
during	O
zebrafish	O
embryogenesis	O
:	O
a	O
case	O
study	O
with	O
paraoxon	S-chem
.	O

Using	O
paraoxon	S-chem
as	O
a	O
reference	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
inhibitor	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
adverse	O
outcome	O
pathway	O
(	O
AOP	O
)	O
that	O
provided	O
quantitative	O
linkages	O
across	O
levels	O
of	O
biological	O
organization	O
during	O
zebrafish	O
embryogenesis	O
.	O

Within	O
normal	O
zebrafish	O
embryos	O
,	O
we	O
first	O
demonstrated	O
that	O
ache	S-geneY
transcripts	O
and	O
AChE	S-geneY
activity	O
increased	O
in	O
a	O
stage	O
-	O
dependent	O
manner	O
following	O
segmentation	O
.	O

We	O
then	O
showed	O
that	O
static	O
exposure	O
of	O
embryos	O
to	O
paraoxon	S-chem
(	O
31.2	O
-	O
500	O
nM	O
)	O
from	O
5	O
to	O
96	O
hpf	O
resulted	O
in	O
significant	O
stage	O
-	O
and	O
concentration	O
-	O
dependent	O
AChE	S-geneY
inhibition	O
,	O
albeit	O
these	O
effects	O
were	O
fully	O
reversible	O
within	O
48	O
h	O
following	O
transfer	O
to	O
clean	O
water	O
.	O

However	O
,	O
even	O
in	O
the	O
presence	O
of	O
significant	O
AChE	S-geneY
inhibition	O
,	O
exposure	O
to	O
non	O
-	O
teratogenic	O
paraoxon	S-chem
concentrations	O
(	O
≤	O
250	O
nM	O
)	O
did	O
not	O
adversely	O
impact	O
secondary	O
motoneuron	O
development	O
at	O
96	O
hpf	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
potential	O
effects	O
of	O
paraoxon	S-chem
exposure	O
on	O
spontaneous	O
tail	O
contractions	O
at	O
26	O
hpf	O
-	O
an	O
early	O
locomotor	O
behavior	O
that	O
results	O
from	O
innervation	O
of	O
primary	O
(	O
not	O
secondary	O
)	O
motoneuron	O
axons	O
to	O
target	O
axial	O
muscles	O
.	O

Based	O
on	O
these	O
studies	O
,	O
the	O
frequency	O
of	O
spontaneous	O
tail	O
contractions	O
at	O
26	O
hpf	O
-	O
a	O
developmental	O
stage	O
with	O
minimal	O
AChE	S-geneY
expression	O
and	O
activity	O
-	O
was	O
significantly	O
higher	O
following	O
exposure	O
to	O
paraoxon	S-chem
concentrations	O
as	O
low	O
as	O
31.2	O
nM	O
.	O

Overall	O
,	O
our	O
data	O
suggest	O
that	O
(	O
1	O
)	O
normal	O
AChE	S-geneY
activity	O
is	O
not	O
required	O
for	O
secondary	O
motoneuron	O
development	O
and	O
(	O
2	O
)	O
spontaneous	O
tail	O
contractions	O
at	O
26	O
hpf	O
are	O
sensitive	O
to	O
paraoxon	S-chem
exposure	O
,	O
an	O
effect	O
that	O
may	O
be	O
independent	O
of	O
AChE	S-geneY
inhibition	O
.	O

Using	O
a	O
well	O
-	O
studied	O
reference	O
chemical	O
,	O
this	O
study	O
highlights	O
the	O
potential	O
challenges	O
in	O
developing	O
quantitative	O
AOPs	O
to	O
support	O
chemical	O
screening	O
and	O
prioritization	O
strategies	O
.	O

NMDA	B-geneN
and	I-geneN
AMPA	I-geneN
receptor	E-geneN
mediated	O
excitotoxicity	O
in	O
cerebral	O
cortex	O
of	O
streptozotocin	S-chem
induced	O
diabetic	O
rat	O
:	O
ameliorating	O
effects	O
of	O
curcumin	S-chem
.	O

Functional	O
activity	O
of	O
neurotransmitter	B-geneN
receptor	E-geneN
and	O
their	O
sensitivity	O
to	O
regulation	O
are	O
altered	O
in	O
DM	O
.	O

We	O
evaluated	O
the	O
neuroprotective	O
effect	O
of	O
curcumin	S-chem
in	O
glutamate	S-chem
mediated	O
excitotoxicity	O
in	O
cerebral	O
cortex	O
of	O
streptozotocin	S-chem
induced	O
diabetic	O
rats	O
.	O

Gene	O
expression	O
studies	O
in	O
diabetic	O
rats	O
showed	O
a	O
down	O
regulation	O
of	O
glutamate	B-geneY
decarboxylase	E-geneY
mRNA	O
leading	O
to	O
accumulation	O
of	O
glutamate	S-chem
.	O

Radioreceptor	O
binding	O
assays	O
showed	O
a	O
significant	O
increase	O
in	O
α	B-geneN
-	I-geneN
amino	I-geneN
-	I-geneN
3	I-geneN
-	I-geneN
hydroxy	I-geneN
-	I-geneN
5	I-geneN
-	I-geneN
methyl	I-geneN
-	I-geneN
4	I-geneN
-	I-geneN
isoxazole	I-geneN
propionate	I-geneN
and	I-geneN
N	I-geneN
-	I-geneN
methyl	I-geneN
-	I-geneN
D	I-geneN
-	I-geneN
aspartate	I-geneN
receptors	E-geneN
density	O
which	O
was	O
confirmed	O
by	O
immunohistochemical	O
studies	O
.	O

Decreased	O
glutathione	B-geneN
peroxidases	E-geneN
gene	O
expression	O
indicates	O
enhanced	O
oxidative	O
stress	O
in	O
diabetic	O
rats	O
.	O

This	O
leads	O
to	O
decreased	O
expression	O
of	O
glutamate	B-geneY
aspartate	I-geneY
transporter	E-geneY
,	O
which	O
in	O
turn	O
reduces	O
glutamate	S-chem
transport	O
.	O

All	O
these	O
events	O
lead	O
to	O
excitotoxic	O
neuronal	O
death	O
in	O
the	O
cerebral	O
cortex	O
,	O
which	O
was	O
confirmed	O
by	O
the	O
increased	O
expression	O
of	O
caspase	B-geneY
3	E-geneY
,	O
caspase	B-geneY
8	E-geneY
and	O
BCL2	B-geneY
-	I-geneY
associated	I-geneY
X	I-geneY
protein	E-geneY
.	O

Curcumin	S-chem
and	O
insulin	S-geneY
treatment	O
reversed	O
these	O
altered	O
parameters	O
to	O
near	O
control	O
.	O

We	O
establish	O
,	O
a	O
novel	O
therapeutic	O
role	O
of	O
curcumin	S-chem
by	O
reducing	O
the	O
glutamate	S-chem
mediated	O
excitotoxicity	O
in	O
cerebral	O
cortex	O
of	O
diabetes	O
through	O
modulating	O
the	O
altered	O
neurochemical	O
parameters	O
.	O

Juglone	S-chem
,	O
isolated	O
from	O
Juglans	O
mandshurica	O
Maxim	O
,	O
induces	O
apoptosis	O
via	O
down	O
-	O
regulation	O
of	O
AR	S-geneY
expression	O
in	O
human	O
prostate	O
cancer	O
LNCaP	O
cells	O
.	O

Juglone	S-chem
is	O
a	O
natural	O
compound	O
which	O
has	O
been	O
isolated	O
from	O
Juglans	O
mandshurica	O
Maxim	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
juglone	S-chem
had	O
various	O
pharmacological	O
effects	O
such	O
as	O
anti	O
-	O
viral	O
,	O
anti	O
-	O
bacterial	O
and	O
anti	O
-	O
cancer	O
.	O

However	O
,	O
its	O
anti	O
-	O
cancer	O
activity	O
on	O
human	O
prostate	O
cancer	O
LNCaP	O
cell	O
has	O
not	O
been	O
examined	O
.	O

Thus	O
,	O
the	O
current	O
study	O
was	O
designed	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
juglone	S-chem
in	O
androgen	S-chem
-	O
sensitive	O
prostate	O
cancer	O
LNCaP	O
cells	O
.	O

MTT	S-chem
assay	O
was	O
performed	O
to	O
examine	O
the	O
anti	O
-	O
proliferative	O
effect	O
of	O
juglone	S-chem
.	O

Occurrence	O
of	O
apoptosis	O
was	O
detected	O
by	O
Hoechst	B-chem
33342	E-chem
staining	O
and	O
flow	O
cytometry	O
in	O
LNCaP	O
cells	O
treated	O
with	O
juglone	S-chem
for	O
24h	O
.	O

The	O
result	O
shown	O
that	O
juglone	S-chem
inhibited	O
the	O
growth	O
of	O
LNCaP	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Morphological	O
changes	O
of	O
apoptotic	O
body	O
formation	O
after	O
juglone	S-chem
treatment	O
were	O
observed	O
by	O
Hoechst	B-chem
33342	E-chem
staining	O
.	O

This	O
apoptotic	O
induction	O
was	O
associated	O
with	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
,	O
and	O
caspase	B-geneN
-	I-geneN
3	I-geneN
,	I-geneN
-	I-geneN
9	E-geneN
activation	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
juglone	S-chem
significantly	O
inhibited	O
the	O
expression	O
levels	O
of	O
androgen	B-geneY
receptor	E-geneY
(	O
AR	S-geneY
)	O
and	O
prostate	B-geneY
-	I-geneY
specific	I-geneY
antigen	E-geneY
(	O
PSA	S-geneY
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
as	O
well	O
as	O
abrogated	O
up	O
-	O
regulation	O
of	O
AR	S-geneY
and	O
PSA	S-geneY
genes	O
with	O
and	O
/	O
or	O
without	O
dihydrotestosterone	S-chem
(	O
DHT	S-chem
)	O
.	O

Take	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
juglone	S-chem
might	O
induce	O
the	O
apoptosis	O
in	O
LNCaP	O
cell	O
via	O
down	O
-	O
regulation	O
of	O
AR	S-geneY
expression	O
.	O

Therefore	O
,	O
our	O
results	O
indicated	O
that	O
juglone	S-chem
may	O
be	O
a	O
potential	O
candidate	O
of	O
drug	O
for	O
androgen	S-chem
-	O
sensitive	O
prostate	O
cancer	O
.	O

Antagonism	O
of	O
meta	B-chem
-	I-chem
chlorophenylpiperazine	E-chem
-	O
induced	O
inhibition	O
of	O
exploratory	O
activity	O
in	O
an	O
emergence	O
procedure	O
,	O
the	O
open	O
field	O
test	O
,	O
in	O
rats	O
.	O

The	O
effects	O
of	O
meta	B-chem
-	I-chem
chlorophenylpiperazine	E-chem
(	O
mCPP	S-chem
)	O
were	O
studied	O
on	O
exploratory	O
behaviour	O
in	O
the	O
open	O
field	O
test	O
,	O
using	O
a	O
procedure	O
designed	O
to	O
evaluate	O
the	O
emergence	O
of	O
rats	O
into	O
a	O
novel	O
environment	O
.	O
mCPP	S-chem
reduced	O
the	O
exploratory	O
activity	O
in	O
a	O
dose	O
-	O
related	O
manner	O
after	O
subcutaneous	O
(	O
s.c.	O
)	O
,	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O
and	O
intravenous	O
(	O
i.v	O
.	O
)	O
administration	O
.	O

The	O
inhibition	O
was	O
manifest	O
in	O
all	O
the	O
parameters	O
used	O
to	O
quantify	O
the	O
exploration	O
of	O
the	O
open	O
field	O
area	O
.	O

Additional	O
neuroendocrine	O
experiments	O
in	O
a	O
parallel	O
group	O
of	O
rats	O
revealed	O
a	O
dose	O
-	O
related	O
increase	O
in	O
plasma	B-geneY
prolactin	E-geneY
and	O
ACTH	S-geneY
levels	O
after	O
i.v	O
.	O
mCPP	S-chem
,	O
pointing	O
to	O
a	O
general	O
state	O
of	O
arousal	O
in	O
these	O
mCPP	S-chem
-	O
treated	O
animals	O
.	O

A	O
number	O
of	O
5	B-chem
-	I-chem
HT	E-chem
antagonists	O
were	O
tested	O
for	O
their	O
ability	O
to	O
prevent	O
or	O
reverse	O
the	O
behavioural	O
inhibition	O
induced	O
by	O
an	O
i.v	O
.	O
injection	O
of	O
1.0	O
g	O
/	O
kg	O
mCPP	S-chem
given	O
15	O
min	O
before	O
testing	O
in	O
the	O
open	O
field	O
.	O

The	O
antagonists	O
were	O
injected	O
s.c.	O
or	O
given	O
orally	O
at	O
various	O
time	O
intervals	O
before	O
mCPP	S-chem
,	O
or	O
they	O
were	O
injected	O
i.v	O
.	O

10	O
min	O
after	O
mCPP	S-chem
.	O

The	O
lowest	O
active	O
doses	O
for	O
the	O
attentuation	O
of	O
the	O
mCPP	S-chem
-	O
induced	O
behavioural	O
inhibition	O
after	O
s.c.	O
,	O
oral	O
and	O
i.v	O
.	O
administration	O
,	O
respectively	O
,	O
were	O
0.04	O
,	O
40	O
and	O
10	O
mg	O
/	O
kg	O
for	O
pizotifen	O
;	O
0.16	O
,	O
0.16	O
and	O
0.16	O
mg	O
/	O
kg	O
for	O
mianserin	O
;	O
0.63	O
,	O
0.16	O
and	O
0.16	O
mg	O
/	O
kg	O
for	O
methysergide	S-chem
,	O
and	O
0.16	O
,	O
2.5	O
and	O
2.5	O
mg	O
/	O
kg	O
for	O
ritanserin	S-chem
.	O

The	O
lowest	O
active	O
doses	O
of	O
mirtazapine	S-chem
after	O
s.c.	O
and	O
i.v	O
.	O
treatment	O
were	O
0.01	O
and	O
0.16	O
mg	O
/	O
kg	O
.	O

These	O
data	O
indicate	O
that	O
mixed	O
5	B-geneN
-	I-geneN
HT1	E-geneN
/	O
5	B-geneY
-	I-geneY
HT2	E-geneY
receptor	O
antagonists	O
such	O
as	O
pizotifen	S-chem
and	O
methysergide	S-chem
,	O
and	O
mixed	O
5	B-chem
-	I-chem
HT	E-chem
and	O
catecholamine	S-chem
antagonists	O
such	O
as	O
mianserin	S-chem
and	O
mirtazapine	S-chem
are	O
more	O
potent	O
antagonists	O
of	O
mCPP	S-chem
-	O
induced	O
behavioural	O
inhibition	O
in	O
rats	O
than	O
the	O
more	O
selective	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
/	O
5	B-geneY
-	I-geneY
HT2C	E-geneY
antagonist	O
ritanserin	S-chem
.	O

Modulation	O
of	O
TNF	S-geneY
and	O
GM	B-geneY
-	I-geneY
CSF	E-geneY
release	O
from	O
dispersed	O
human	O
nasal	O
polyp	O
cells	O
and	O
human	O
whole	O
blood	O
by	O
inhibitors	O
of	O
different	O
PDE	S-geneN
isoenzymes	O
and	O
glucocorticoids	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
inhibitors	O
of	O
different	O
PDE	S-geneN
isoenzymes	O
(	O
PDE	B-geneN
1	I-geneN
-	I-geneN
5	E-geneN
)	O
on	O
the	O
production	O
of	O
two	O
pro	O
-	O
inflammatory	O
cytokines	S-geneN
-	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
alpha	E-geneY
(	O
TNF	S-geneY
)	O
and	O
granulocyte	B-geneY
-	I-geneY
macrophage	I-geneY
colony	I-geneY
-	I-geneY
stimulating	I-geneY
factor	E-geneY
(	O
GM	B-geneY
-	I-geneY
CSF	E-geneY
)	O
.	O

Two	O
in	O
vitro	O
models	O
were	O
used	O
to	O
compare	O
the	O
antiinflammatory	O
properties	O
of	O
PDE	S-geneN
inhibitors	O
with	O
that	O
of	O
glucocorticoids	O
.	O

The	O
effect	O
on	O
TNF	S-geneY
release	O
from	O
diluted	O
human	O
blood	O
following	O
lipopolysaccharide	O
(	O
LPS	O
from	O
Salmonella	O
abortus	O
equi	O
)	O
stimulation	O
as	O
well	O
as	O
the	O
GM	B-geneY
-	I-geneY
CSF	E-geneY
and	O
TNF	S-geneY
release	O
from	O
human	O
nasal	O
polyp	O
cells	O
following	O
allergic	O
stimulation	O
were	O
investigated	O
.	O

Both	O
models	O
proofed	O
to	O
be	O
well	O
suited	O
for	O
the	O
characterisation	O
of	O
the	O
antiinflammatory	O
properties	O
of	O
new	O
chemical	O
entities	O
.	O

In	O
diluted	O
human	O
blood	O
and	O
dispersed	O
human	O
nasal	O
polyp	O
cells	O
the	O
induced	O
TNF	S-geneY
release	O
was	O
most	O
potently	O
suppressed	O
by	O
selective	O
PDE4	S-geneN
inhibitors	O
.	O

Amrinone	S-chem
and	O
milrinone	S-chem
,	O
selective	O
PDE3	S-geneN
inhibitors	O
,	O
suppressed	O
TNF	S-geneY
secretion	O
to	O
a	O
lesser	O
extent	O
.	O

The	O
effects	O
of	O
theophylline	S-chem
(	O
unspecific	O
PDE	S-geneN
inhibitor	O
)	O
,	O
vinpocetine	S-chem
(	O
PDE1	S-geneN
inhibitor	O
)	O
,	O
EHNA	O
(	O
PDE2	S-geneY
inhibitor	O
)	O
and	O
the	O
PDE5	S-geneY
inhibitors	O
zaprinast	S-chem
and	O
E	B-chem
4021	E-chem
were	O
weak	O
.	O

In	O
human	O
blood	O
,	O
the	O
tested	O
glucocorticoids	O
beclomethasone	S-chem
,	O
dexamethasone	S-chem
and	O
fluticasone	S-chem
inhibited	O
the	O
LPS	O
induced	O
TNF	S-geneY
release	O
potently	O
in	O
a	O
concentration	O
dependent	O
manner	O
,	O
whereas	O
in	O
dispersed	O
human	O
nasal	O
polyp	O
cells	O
,	O
the	O
effect	O
of	O
the	O
glucocorticoids	O
on	O
allergically	O
induced	O
TNF	S-geneY
release	O
,	O
with	O
the	O
exception	O
of	O
dexamethasone	S-chem
,	O
was	O
much	O
less	O
pronounced	O
.	O

Glucocorticoids	O
were	O
the	O
most	O
potent	O
inhibitors	O
of	O
GM	B-geneY
-	I-geneY
CSF	E-geneY
release	O
and	O
the	O
effect	O
correlates	O
well	O
with	O
the	O
affinity	O
to	O
the	O
glucocorticoid	B-geneY
receptor	E-geneY
.	O

The	O
selective	O
PDE	B-geneN
4	E-geneN
inhibitors	O
,	O
and	O
to	O
a	O
certain	O
extent	O
the	O
PDE3	S-geneN
inhibitors	O
amrinone	S-chem
and	O
milrinone	S-chem
,	O
reduced	O
the	O
GM	B-geneY
-	I-geneY
CSF	E-geneY
release	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

In	O
all	O
investigations	O
selective	O
PDE4	S-geneN
inhibitors	O
reduced	O
TNF	S-geneY
release	O
to	O
a	O
much	O
higher	O
degree	O
(	O
4	O
-	O
10	O
fold	O
)	O
than	O
GM	B-geneY
-	I-geneY
CSF	E-geneY
release	O
.	O

NMR	O
characterisation	O
of	O
dynamics	O
in	O
solvates	O
and	O
desolvates	O
of	O
formoterol	B-chem
fumarate	E-chem
.	O

Solid	O
-	O
state	O
NMR	O
is	O
used	O
to	O
characterise	O
dynamics	O
in	O
the	O
ethanol	S-chem
solvate	O
of	O
the	O
pharmaceutical	O
material	O
formoterol	B-chem
fumarate	E-chem
and	O
its	O
associated	O
desolvate	O
.	O

Jump	O
rates	O
and	O
activation	O
barriers	O
for	O
dynamic	O
processes	O
such	O
as	O
phenyl	S-chem
ring	O
rotation	O
and	O
methyl	S-chem
group	O
rotational	O
diffusion	O
are	O
derived	O
from	O
1D	O
-	O
EXSY	O
and	O
(	B-chem
13	I-chem
)	I-chem
C	E-chem
spin	O
-	O
lattice	O
relaxation	O
times	O
respectively	O
.	O

(	B-chem
2	I-chem
)	I-chem
H	E-chem
and	O
(	B-chem
13	I-chem
)	I-chem
C	E-chem
spin	O
-	O
lattice	O
relaxation	O
times	O
measured	O
under	O
magic	O
-	O
angle	O
spinning	O
conditions	O
are	O
used	O
to	O
show	O
that	O
the	O
fumarate	S-chem
ion	O
in	O
the	O
desolvate	O
is	O
undergoing	O
small	O
-	O
amplitude	O
motion	O
on	O
a	O
frequency	O
scale	O
of	O
100s	O
of	O
MHz	O
at	O
ambient	O
temperature	O
with	O
an	O
activation	O
parameter	O
of	O
about	O
32	O
kJ	O
mol	O
(	O
-	O
1	O
)	O
.	O

Exact	O
calculations	O
of	O
relaxation	O
times	O
under	O
MAS	O
provide	O
a	O
simple	O
and	O
robust	O
means	O
to	O
test	O
motional	O
models	O
in	O
cases	O
where	O
relaxation	O
rate	O
maxima	O
are	O
observed	O
,	O
including	O
for	O
systems	O
where	O
the	O
crystal	O
structure	O
of	O
the	O
material	O
is	O
unknown	O
.	O

Glucocorticosteroids	O
affect	O
functions	O
of	O
airway	O
-	O
and	O
blood	O
-	O
derived	O
human	O
T	O
-	O
cell	O
clones	O
,	O
favoring	O
the	O
Th1	O
profile	O
through	O
two	O
mechanisms	O
.	O

Glucocorticosteroids	O
(	O
GCS	S-chem
)	O
are	O
beneficial	O
in	O
allergic	O
asthma	O
.	O

GCS	S-chem
therapy	O
results	O
in	O
reduced	O
mRNA	O
expression	O
of	O
interleukin	B-geneY
-	I-geneY
4	E-geneY
(	O
IL	B-geneY
-	I-geneY
4	E-geneY
)	O
and	O
IL	B-geneY
-	I-geneY
5	E-geneY
in	O
cells	O
from	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
but	O
not	O
of	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
.	O

In	O
vitro	O
studies	O
with	O
blood	O
-	O
derived	O
T	O
cells	O
,	O
however	O
,	O
show	O
inhibition	O
of	O
all	O
three	O
cytokines	S-geneN
by	O
GCS	S-chem
.	O

We	O
studied	O
the	O
effects	O
of	O
GCS	S-chem
on	O
T	O
cells	O
from	O
BAL	O
in	O
vitro	O
,	O
namely	O
Th0	O
-	O
,	O
Th1	O
,	O
and	O
Th2	O
-	O
like	O
clones	O
;	O
and	O
we	O
compared	O
BAL	O
-	O
with	O
blood	O
-	O
derived	O
clones	O
.	O

Dexamethasone	S-chem
(	O
DEX	S-chem
)	O
inhibited	O
the	O
anti	O
-	O
CD3	S-geneN
-	O
induced	O
production	O
of	O
IL	B-geneY
-	I-geneY
4	E-geneY
,	O
IL	B-geneY
-	I-geneY
5	E-geneY
and	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
in	O
all	O
20	O
clones	O
tested	O
.	O

IFN	B-geneY
-	I-geneY
gamma	E-geneY
production	O
was	O
inhibited	O
significantly	O
less	O
than	O
IL	B-geneY
-	I-geneY
4	E-geneY
and	O
IL	B-geneY
-	I-geneY
5	E-geneY
.	O

DEX	S-chem
enhanced	O
the	O
ratio	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
/	O
IL	B-geneY
-	I-geneY
4	E-geneY
(	O
mean	O
+	O
/	O
-	O
SEM	O
:	O
control	O
,	O
28.7	O
+	O
/	O
-	O
17.6	O
;	O
with	O
10	O
-	O
7	O
M	O
DEX	O
,	O
55.0	O
+	O
/	O
-	O
27.5	O
,	O
P	O
<	O
0.005	O
)	O
.	O

Interestingly	O
,	O
two	O
categories	O
of	O
clones	O
were	O
distinguished	O
based	O
on	O
the	O
effects	O
of	O
GCS	S-chem
on	O
IL	B-geneY
-	I-geneY
2	E-geneY
production	O
and	O
IL	B-geneY
-	I-geneY
2R	I-geneY
alpha	E-geneY
expression	O
and	O
proliferation	O
;	O
1	O
)	O
In	O
low	O
IL	B-geneY
-	I-geneY
2	E-geneY
producers	O
DEX	S-chem
blocked	O
IL	B-geneY
-	I-geneY
2	E-geneY
production	O
and	O
decreased	O
IL	B-geneY
-	I-geneY
2R	I-geneY
alpha	E-geneY
expression	O
and	O
proliferation	O
;	O
2	O
)	O
In	O
high	O
IL	B-geneY
-	I-geneY
2	E-geneY
producers	O
DEX	S-chem
inhibited	O
IL	B-geneY
-	I-geneY
2	E-geneY
production	O
partially	O
and	O
enhanced	O
IL	B-geneY
-	I-geneY
2R	I-geneY
alpha	E-geneY
expression	O
and	O
proliferation	O
.	O

Anti	O
-	O
IL	B-geneY
-	I-geneY
2	E-geneY
and	O
anti	O
-	O
IL2R	B-geneY
alpha	E-geneY
blocked	O
the	O
DEX	S-chem
-	O
induced	O
increase	O
in	O
proliferation	O
.	O

High	O
levels	O
of	O
added	O
IL	B-geneY
-	I-geneY
2	E-geneY
induced	O
the	O
second	O
type	O
of	O
response	O
.	O

In	O
conclusion	O
,	O
the	O
production	O
of	O
IL	B-geneY
-	I-geneY
4	E-geneY
and	O
IL	B-geneY
-	I-geneY
5	E-geneY
by	O
T	O
-	O
cell	O
clones	O
(	O
derived	O
either	O
from	O
BAL	O
or	O
blood	O
)	O
was	O
more	O
sensitive	O
to	O
inhibition	O
by	O
DEX	S-chem
than	O
that	O
of	O
IFN	B-geneY
-	I-geneY
gamma	E-geneY
,	O
which	O
may	O
account	O
for	O
the	O
therapeutic	O
effects	O
of	O
glucocorticosteroids	O
in	O
patients	O
with	O
asthma	O
.	O

The	O
differential	O
effects	O
of	O
DEX	S-chem
on	O
the	O
proliferation	O
of	O
high	O
and	O
low	O
IL	B-geneY
-	I-geneY
2	E-geneY
producers	O
in	O
vitro	O
may	O
implicate	O
a	O
selective	O
outgrowth	O
of	O
Th1	O
-	O
like	O
T	O
cells	O
in	O
vivo	O
in	O
patients	O
treated	O
with	O
steroids	S-chem
.	O

Cloning	O
and	O
expression	O
of	O
a	O
heme	B-geneN
binding	I-geneN
protein	E-geneN
from	O
the	O
genome	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
YLR205c	S-geneY
gene	O
of	O
Saccharomyces	O
cerevisiae	O
does	O
not	O
show	O
significant	O
sequence	O
identity	O
to	O
any	O
known	O
gene	O
,	O
except	O
for	O
heme	B-geneN
oxygenase	E-geneN
(	O
22	O
%	O
to	O
human	B-geneY
HO	I-geneY
-	I-geneY
1	E-geneY
)	O
.	O

The	O
YLR205	B-geneN
ORF	E-geneN
was	O
cloned	O
and	O
overexpressed	O
in	O
both	O
Escherichia	O
coli	O
and	O
S.	O
cerevisiae	O
.	O

Both	O
expression	O
systems	O
yielded	O
proteins	O
that	O
bound	O
heme	O
tightly	O
.	O

The	O
isolated	O
YLR205c	S-geneY
protein	O
underwent	O
reduction	O
in	O
the	O
presence	O
of	O
either	O
NADPH	B-geneY
-	I-geneY
cytochrome	I-geneY
P450	I-geneY
reductase	E-geneY
or	O
NADH	B-geneN
-	I-geneN
putidaredoxin	I-geneN
-	I-geneN
putidaredoxin	I-geneN
reductase	E-geneN
but	O
did	O
not	O
exhibit	O
heme	B-geneN
oxygenase	E-geneN
activity	O
.	O

The	O
protein	O
exhibited	O
modest	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
O	I-chem
(	I-chem
2	I-chem
)	E-chem
-	O
dependent	O
peroxidase	S-geneN
activities	O
with	O
guaiacol	S-chem
,	O
potassium	B-chem
iodide	E-chem
,	O
and	O
2,2	B-chem
(	I-chem
'	I-chem
)	I-chem
-	I-chem
azino	I-chem
-	I-chem
bis	I-chem
(	I-chem
3	I-chem
-	I-chem
ethylbenzothiazoline	I-chem
-	I-chem
6	I-chem
-	I-chem
sulfonic	I-chem
acid	E-chem
(	O
ABTS	S-chem
)	O
.	O

Thus	O
,	O
YLR205c	S-geneY
codes	O
for	O
a	O
hemoprotein	S-geneN
of	O
unknown	O
physiological	O
function	O
that	O
exhibits	O
peroxidase	S-geneN
activity	O
.	O

NADPH	B-geneY
Oxidase	I-geneY
NOX5	I-geneY
-	I-geneY
S	E-geneY
and	O
Nuclear	B-geneY
Factor	I-geneY
κB1	E-geneY
Mediate	O
Acid	O
-	O
Induced	O
Microsomal	B-geneY
Prostaglandin	I-geneY
E	I-geneY
Synthase	I-geneY
-	I-geneY
1	E-geneY
Expression	O
in	O
Barrett	O
's	O
Esophageal	O
Adenocarcinoma	O
Cells	O
.	O

The	O
mechanisms	O
of	O
progression	O
from	O
Barrett	O
's	O
esophagus	O
(	O
BE	O
)	O
to	O
esophageal	O
adenocarcinoma	O
(	O
EA	O
)	O
are	O
not	O
known	O
.	O

Cycloxygenase	B-geneY
-	I-geneY
2	E-geneY
(	O
COX	B-geneY
-	I-geneY
2	E-geneY
)	O
-	O
derived	O
prostaglandin	B-chem
E2	E-chem
(	O
PGE2	S-chem
)	O
has	O
been	O
shown	O
to	O
be	O
important	O
in	O
esophageal	O
tumorigenesis	O
.	O

We	O
have	O
shown	O
that	O
COX	B-geneY
-	I-geneY
2	E-geneY
mediates	O
acid	O
-	O
induced	O
PGE2	S-chem
production	O
.	O

The	O
prostaglandin	B-geneY
E	I-geneY
synthase	E-geneY
(	O
PGES	S-geneY
)	O
responsible	O
for	O
acid	O
-	O
induced	O
PGE2	S-chem
production	O
in	O
BE	O
,	O
however	O
,	O
is	O
not	O
known	O
.	O

We	O
found	O
that	O
microsomal	B-geneY
PGES1	E-geneY
(	O
mPGES1	S-geneY
)	O
,	O
mPGES2	S-geneY
,	O
and	O
cytosolic	B-geneY
PGES	E-geneY
(	O
cPGES	S-geneY
)	O
were	O
present	O
in	O
FLO	O
EA	O
cells	O
.	O

Pulsed	O
acid	O
treatment	O
significantly	O
increased	O
mPGES1	S-geneY
mRNA	O
and	O
protein	O
levels	O
but	O
had	O
little	O
or	O
no	O
effect	O
on	O
mPGES2	S-geneY
or	O
cPGES	S-geneY
mRNA	O
.	O

Knockdown	O
of	O
mPGES1	S-geneY
by	O
mPGES1	S-geneY
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
blocked	O
acid	O
-	O
induced	O
increase	O
in	O
PGE2	S-chem
production	O
and	O
thymidine	S-chem
incorporation	O
.	O

Knockdown	O
of	O
NADPH	B-geneN
oxidase	E-geneN
,	O
NOX5	B-geneY
-	I-geneY
S	E-geneY
,	O
a	O
variant	O
lacking	O
calcium	B-geneN
-	I-geneN
binding	I-geneN
domains	E-geneN
,	O
by	O
NOX5	S-geneY
siRNA	O
significantly	O
inhibited	O
acid	O
-	O
induced	O
increase	O
in	O
mPGES1	S-geneY
expression	O
,	O
thymidine	S-chem
incorporation	O
,	O
and	O
PGE2	S-chem
production	O
.	O

Overexpression	O
of	O
NOX5	B-geneY
-	I-geneY
S	E-geneY
significantly	O
increased	O
the	O
luciferase	O
activity	O
in	O
FLO	O
cells	O
transfected	O
with	O
a	O
nuclear	B-geneN
factor	I-geneN
κB	E-geneN
(	O
NF	B-geneN
-	I-geneN
κB	E-geneN
)	O
in	O
vivo	O
activation	O
reporter	O
plasmid	O
pNF	O
-	I-geneN
κB	E-geneN
-	O
Luc	O
.	O

Knockdown	O
of	O
NF	B-geneY
-	I-geneY
κB1	E-geneY
p50	S-geneY
by	O
p50	S-geneY
siRNA	O
significantly	O
decreased	O
acid	O
-	O
induced	O
increase	O
in	O
mPGES1	S-geneY
expression	O
,	O
thymidine	S-chem
incorporation	O
,	O
and	O
PGE2	S-chem
production	O
.	O

Two	O
novel	O
NF	B-geneN
-	I-geneN
κB	I-geneN
binding	I-geneN
elements	E-geneN
,	O
GGAGTCTCCC	S-geneN
and	O
CGGGACACCC	S-geneN
,	O
were	O
identified	O
in	O
the	O
mPGES1	B-geneN
gene	I-geneN
promoter	E-geneN
.	O

We	O
conclude	O
that	O
mPGES1	S-geneY
mediates	O
acid	O
-	O
induced	O
increase	O
in	O
PGE2	S-chem
production	O
and	O
cell	O
proliferation	O
.	O

Acid	O
-	O
induced	O
mPGES1	S-geneY
expression	O
depends	O
on	O
activation	O
of	O
NOX5	B-geneY
-	I-geneY
S	E-geneY
and	O
NF	B-geneY
-	I-geneY
κB1	E-geneY
p50	S-geneY
.	O

Microsomal	B-geneY
PGES1	E-geneY
may	O
be	O
a	O
potential	O
target	O
to	O
prevent	O
or	O
treat	O
EA	O
.	O

Medical	O
treatment	O
of	O
acute	O
poisoning	O
with	O
organophosphorus	S-chem
and	O
carbamate	S-chem
pesticides	O
.	O

Organophosphorus	S-chem
compounds	O
(	O
OPs	O
)	O
are	O
used	O
as	O
pesticides	O
and	O
developed	O
as	O
warfare	O
nerve	O
agents	O
such	O
as	O
tabun	S-chem
,	O
soman	S-chem
,	O
sarin	S-chem
,	O
VX	O
and	O
others	O
.	O

Exposure	O
to	O
even	O
small	O
amounts	O
of	O
an	O
OP	S-chem
can	O
be	O
fatal	O
and	O
death	O
is	O
usually	O
caused	O
by	O
respiratory	O
failure	O
.	O

The	O
mechanism	O
of	O
OP	S-chem
poisoning	O
involves	O
inhibition	O
of	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
leading	O
to	O
inactivation	O
of	O
the	O
enzyme	O
which	O
has	O
an	O
important	O
role	O
in	O
neurotransmission	O
.	O

AChE	S-geneY
inhibition	O
results	O
in	O
the	O
accumulation	O
of	O
acetylcholine	S-chem
at	O
cholinergic	O
receptor	O
sites	O
,	O
producing	O
continuous	O
stimulation	O
of	O
cholinergic	O
fibers	O
throughout	O
the	O
nervous	O
systems	O
.	O

During	O
more	O
than	O
five	O
decades	O
,	O
pyridinium	B-chem
oximes	E-chem
have	O
been	O
developed	O
as	O
therapeutic	O
agents	O
used	O
in	O
the	O
medical	O
treatment	O
of	O
poisoning	O
with	O
OP	S-chem
.	O

They	O
act	O
by	O
reactivation	O
of	O
AChE	S-geneY
inhibited	O
by	O
OP	S-chem
.	O

However	O
,	O
they	O
differ	O
in	O
their	O
activity	O
in	O
poisoning	O
with	O
pesticides	O
and	O
warfare	O
nerve	O
agents	O
and	O
there	O
is	O
still	O
no	O
universal	O
broad	O
-	O
spectrum	O
oxime	S-chem
capable	O
of	O
protecting	O
against	O
all	O
known	O
OP	S-chem
.	O

In	O
spite	O
of	O
enormous	O
efforts	O
devoted	O
to	O
development	O
of	O
new	O
pyridinium	B-chem
oximes	E-chem
as	O
potential	O
antidotes	O
against	O
poisoning	O
with	O
OP	S-chem
only	O
four	O
compounds	O
so	O
far	O
have	O
found	O
its	O
application	O
in	O
human	O
medicine	O
.	O

Presently	O
,	O
a	O
combination	O
of	O
an	O
antimuscarinic	O
agent	O
,	O
e.g	O
.	O
atropine	S-chem
,	O
AChE	S-geneY
reactivator	O
such	O
as	O
one	O
of	O
the	O
recommended	O
pyridinium	B-chem
oximes	E-chem
(	O
pralidoxime	S-chem
,	O
trimedoxime	S-chem
,	O
obidoxime	S-chem
and	O
HI	B-chem
-	I-chem
6	E-chem
)	O
and	O
diazepam	S-chem
are	O
used	O
for	O
the	O
treatment	O
of	O
OP	S-chem
poisoning	O
in	O
humans	O
.	O

In	O
this	O
article	O
the	O
available	O
data	O
related	O
to	O
medical	O
treatment	O
of	O
poisoning	O
with	O
OP	S-chem
pesticides	O
are	O
reviewed	O
and	O
the	O
current	O
recommendations	O
are	O
presented	O
.	O

Protective	O
effect	O
of	O
cinnamon	O
polyphenols	S-chem
against	O
STZ	S-chem
-	O
diabetic	O
mice	O
fed	O
high	O
-	O
sugar	O
,	O
high	O
-	O
fat	O
diet	O
and	O
its	O
underlying	O
mechanism	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
potential	O
effects	O
of	O
14days	O
'	O
intragastrically	O
given	O
of	O
cinnamon	O
polyphenols	S-chem
(	O
CPS	O
)	O
in	O
treating	O
diabetic	O
mice	O
induced	O
by	O
intraperitoneal	O
injection	O
of	O
streptozotocin	S-chem
(	O
150mgkg	O
(	O
-	O
1	O
)	O
)	O
and	O
fed	O
high	O
-	O
sugar	S-chem
,	O
high	O
-	O
fat	O
diet	O
.	O

The	O
diabetic	O
mice	O
model	O
was	O
successfully	O
established	O
through	O
determining	O
on	O
fasting	O
blood	O
-	O
glucose	S-chem
(	O
FBG	O
)	O
test	O
.	O

As	O
revealed	O
by	O
glucose	B-geneN
oxidase	E-geneN
(	O
GOD	O
)	O
and	O
radioimmunoassay	O
(	O
RIA	O
)	O
,	O
both	O
dimethyldiguanide	S-chem
(	O
DC	O
,	O
0.6gkg	O
(	O
-	O
1	O
)	O
d	O
(	O
-	O
1	O
)	O
)	O
and	O
CPS	O
(	O
0.3	O
,	O
0.6	O
,	O
1.2gkg	O
(	O
-	O
1	O
)	O
d	O
(	O
-	O
1	O
)	O
)	O
treatments	O
significantly	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
blood	O
glucose	S-chem
and	O
insulin	S-geneN
levels	O
in	O
serum	O
,	O
while	O
the	O
levels	O
of	O
oxidative	O
stress	O
markers	O
were	O
markedly	O
lowered	O
through	O
ELISA	O
assay	O
.	O

Meanwhile	O
,	O
the	O
pathological	O
damage	O
in	O
islet	O
with	O
pancreatic	O
beta	O
cells	O
was	O
ameliorated	O
by	O
treatment	O
of	O
CPS	O
at	O
different	O
doses	O
,	O
as	O
shown	O
in	O
HE	O
stain	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
treatments	O
also	O
caused	O
notable	O
reduction	O
of	O
iNOS	S-geneY
,	O
NF	B-geneN
-	I-geneN
κB	E-geneN
expressions	O
showing	O
in	O
Western	O
blot	O
analysis	O
.	O

These	O
findings	O
demonstrate	O
that	O
cinnamon	O
polyphenols	S-chem
can	O
exert	O
the	O
hypoglycemic	O
and	O
hypolipidemic	O
effects	O
through	O
the	O
mechanisms	O
that	O
may	O
be	O
associated	O
with	O
repairing	O
pancreatic	O
beta	O
cells	O
in	O
diabetic	O
mice	O
and	O
improving	O
its	O
anti	O
-	O
oxidative	O
capacity	O
,	O
as	O
well	O
as	O
attenuating	O
cytotoxicity	O
via	O
inhibition	O
of	O
iNOS	S-geneY
,	O
NF	B-geneN
-	I-geneN
κB	E-geneN
activation	O
.	O

Insulin	B-geneY
-	I-geneY
degrading	I-geneY
enzyme	E-geneY
(	O
IDE	S-geneY
)	O
:	O
a	O
novel	O
heat	B-geneN
shock	I-geneN
-	I-geneN
like	I-geneN
protein	E-geneN
.	O

Insulin	B-geneY
-	I-geneY
degrading	I-geneY
enzyme	E-geneY
(	O
IDE	S-geneY
)	O
is	O
a	O
highly	O
conserved	O
zinc	B-geneN
metallopeptidase	E-geneN
that	O
is	O
ubiquitously	O
distributed	O
in	O
human	O
tissues	O
,	O
and	O
particularly	O
abundant	O
in	O
the	O
brain	O
,	O
liver	O
,	O
and	O
muscles	O
.	O

IDE	S-geneY
activity	O
has	O
been	O
historically	O
associated	O
with	O
insulin	S-geneY
and	O
β	B-geneY
-	I-geneY
amyloid	E-geneY
catabolism	O
.	O

However	O
,	O
over	O
the	O
last	O
decade	O
,	O
several	O
experimental	O
findings	O
have	O
established	O
that	O
IDE	S-geneY
is	O
also	O
involved	O
in	O
a	O
wide	O
variety	O
of	O
physiopathological	O
processes	O
,	O
including	O
ubiquitin	S-geneN
clearance	O
and	O
Varicella	O
Zoster	O
Virus	O
infection	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
normal	O
and	O
malignant	O
cells	O
exposed	O
to	O
different	O
stresses	O
markedly	O
up	O
-	O
regulate	O
IDE	S-geneY
in	O
a	O
heat	B-geneN
shock	I-geneN
protein	E-geneN
(	O
HSP	S-geneN
)	O
-	O
like	O
fashion	O
.	O

Additionally	O
,	O
we	O
focused	O
our	O
attention	O
on	O
tumor	O
cells	O
and	O
report	O
that	O
(	O
i	O
)	O
IDE	S-geneY
is	O
overexpressed	O
in	O
vivo	O
in	O
tumors	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
;	O
(	O
ii	O
)	O
IDE	S-geneY
-	O
silencing	O
inhibits	O
neuroblastoma	O
(	O
SHSY5Y	O
)	O
cell	O
proliferation	O
and	O
triggers	O
cell	O
death	O
;	O
(	O
iii	O
)	O
IDE	S-geneY
inhibition	O
is	O
accompanied	O
by	O
a	O
decrease	O
of	O
the	O
poly	O
-	O
ubiquitinated	O
protein	O
content	O
and	O
co	O
-	O
immunoprecipitates	O
with	O
proteasome	O
and	O
ubiquitin	O
in	O
SHSY5Y	O
cells	O
.	O

In	O
this	O
work	O
,	O
we	O
propose	O
a	O
novel	O
role	O
for	O
IDE	S-geneY
as	O
a	O
heat	B-geneN
shock	I-geneN
protein	E-geneN
with	O
implications	O
in	O
cell	O
growth	O
regulation	O
and	O
cancer	O
progression	O
,	O
thus	O
opening	O
up	O
an	O
intriguing	O
hypothesis	O
of	O
IDE	S-geneY
as	O
an	O
anticancer	O
target	O
.	O

Safrole	B-chem
-	I-chem
2',3	I-chem
'	I-chem
-	I-chem
oxide	E-chem
induces	O
atherosclerotic	O
plaque	O
vulnerability	O
in	O
apolipoprotein	B-geneY
E	E-geneY
-	O
knockout	O
mice	O
.	O

Safrole	B-chem
-	I-chem
2',3	I-chem
'	I-chem
-	I-chem
oxide	E-chem
(	O
SFO	S-chem
)	O
is	O
the	O
major	O
electrophilic	O
metabolite	O
of	O
safrole	S-chem
(	O
4	B-chem
-	I-chem
allyl	I-chem
-	I-chem
1	I-chem
,	I-chem
2	I-chem
-	I-chem
methylenedioxybenzene	E-chem
)	O
,	O
a	O
natural	O
plant	O
constituent	O
found	O
in	O
essential	O
oils	O
of	O
numerous	O
edible	O
herbs	O
and	O
spices	O
and	O
in	O
food	O
containing	O
these	O
herbs	O
,	O
such	O
as	O
pesto	O
sauce	O
,	O
cola	O
beverages	O
and	O
bologna	O
sausages	O
.	O

The	O
effects	O
of	O
SFO	S-chem
in	O
mammalian	O
systems	O
,	O
especially	O
the	O
cardiovascular	O
system	O
,	O
are	O
little	O
known	O
.	O

Disruption	O
of	O
vulnerable	O
atherosclerotic	O
plaques	O
in	O
atherosclerosis	O
,	O
a	O
chronic	O
inflammatory	O
disease	O
,	O
is	O
the	O
main	O
cause	O
of	O
cardiovascular	O
events	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
SFO	S-chem
-	O
induced	O
atherosclerotic	O
plaque	O
vulnerability	O
(	O
possibility	O
of	O
rupture	O
)	O
in	O
apolipoprotein	B-geneY
E	E-geneY
-	O
knockout	O
(	O
apoE	S-geneY
(	O
-	O
/	O
-	O
)	O
)	O
mice	O
.	O

Lipid	O
area	O
in	O
vessel	O
wall	O
reached	O
59.8	O
%	O
in	O
high	O
dose	O
SFO	S-chem
(	O
SFO	S-chem
-	O
HD	O
)	O
treated	O
group	O
,	O
which	O
is	O
only	O
31.2	O
%	O
in	O
control	O
group	O
.	O

SFO	S-chem
treatment	O
changed	O
the	O
lesion	O
composition	O
to	O
an	O
unstable	O
phenotype	O
,	O
increased	O
the	O
number	O
of	O
apoptotic	O
cells	O
in	O
plaque	O
and	O
the	O
endothelium	O
in	O
plaques	O
was	O
damaged	O
after	O
SFO	S-chem
treatment	O
.	O

Furthermore	O
,	O
compared	O
with	O
control	O
groups	O
,	O
the	O
plaque	O
endothelium	O
level	O
of	O
p75	B-geneY
(	I-geneY
NTR	I-geneY
)	E-geneY
was	O
3	O
-	O
fold	O
increased	O
and	O
the	O
liver	O
level	O
of	O
p75	B-geneY
(	I-geneY
NTR	I-geneY
)	E-geneY
was	O
17.4	O
-	O
fold	O
increased	O
by	O
SFO	S-chem
-	O
HD	O
.	O

Meanwhile	O
,	O
the	O
serum	O
level	O
of	O
KC	O
(	O
a	O
functional	O
homolog	O
of	O
IL	B-geneN
-	I-geneN
8	E-geneN
and	O
the	O
main	O
proinflammatory	O
alpha	B-geneN
chemokine	E-geneN
in	O
mice	O
)	O
in	O
apoE	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
was	O
up	O
to	O
357pg	O
/	O
ml	O
in	O
SFO	S-chem
-	O
HD	O
treated	O
group	O
.	O

Thus	O
,	O
SFO	S-chem
contributes	O
to	O
the	O
instability	O
of	O
atherosclerotic	O
plaque	O
in	O
apoE	S-geneY
(	O
-	O
/	O
-	O
)	O
mice	O
through	O
activating	O
p75	B-geneY
(	I-geneY
NTR	I-geneY
)	E-geneY
and	O
IL	B-geneN
-	I-geneN
8	E-geneN
and	O
cell	O
apoptosis	O
in	O
plaque	O
.	O

Hematologic	O
and	O
hepatic	O
responses	O
of	O
the	O
freshwater	O
fish	O
Hoplias	O
malabaricus	O
after	O
saxitoxin	S-chem
exposure	O
.	O

The	O
bioaccumulation	O
of	O
saxitoxins	S-chem
(	O
STX	S-chem
)	O
in	O
the	O
trophic	O
chain	O
,	O
mainly	O
in	O
freshwater	O
,	O
are	O
not	O
completely	O
known	O
.	O

This	O
work	O
aimed	O
to	O
elucidate	O
the	O
effects	O
of	O
STX	S-chem
on	O
Hoplias	O
malabaricus	O
through	O
trophic	O
bioassay	O
.	O

The	O
fish	O
were	O
fed	O
once	O
every	O
five	O
days	O
with	O
Astyanax	O
sp	O
.	O
before	O
being	O
subjected	O
to	O
an	O
intraperitoneal	O
inoculation	O
with	O
the	O
lysate	O
of	O
Cylindrospermopsis	O
raciborskii	O
culture	O
containing	O
97	O
%	O
STX	S-chem
and	O
3	O
%	O
by	O
neosaxitoxin	S-chem
and	O
gonyautoxin	S-chem
during	O
20	O
days	O
.	O

The	O
animal	O
's	O
liver	O
was	O
assessed	O
using	O
biomarkers	O
as	O
activities	O
of	O
superoxide	B-geneN
dismutase	E-geneN
(	O
SOD	S-geneN
)	O
,	O
catalase	S-geneN
(	O
CAT	S-geneN
)	O
,	O
glutathione	B-geneN
S	I-geneN
-	I-geneN
transferase	E-geneN
(	O
GST	S-geneN
)	O
,	O
and	O
glutathione	B-geneN
peroxidase	E-geneN
(	O
GPx	S-geneN
)	O
,	O
and	O
concentrations	O
of	O
reduced	B-chem
glutathione	E-chem
(	O
GSH	S-chem
)	O
and	O
lipoperoxidation	O
(	O
LPO	O
)	O
and	O
protein	O
carbonylation	O
(	O
PCO	O
)	O
.	O

In	O
the	O
blood	O
was	O
analyzed	O
the	O
genotoxic	O
and	O
hematological	O
parameters	O
.	O

The	O
hepatosomatic	O
index	O
and	O
the	O
relative	O
condition	O
factor	O
did	O
not	O
show	O
a	O
significant	O
difference	O
between	O
the	O
exposed	O
and	O
control	O
groups	O
.	O

The	O
values	O
of	O
mean	O
corpuscular	O
hemoglobin	S-geneN
concentration	O
and	O
mean	O
corpuscular	O
hemoglobin	S-geneN
increased	O
in	O
the	O
STX	S-chem
group	O
.	O

The	O
hepatic	O
tissue	O
from	O
both	O
groups	O
exhibited	O
a	O
typical	O
pattern	O
that	O
have	O
been	O
already	O
described	O
for	O
most	O
teleost	O
fish	O
.	O

The	O
results	O
suggested	O
the	O
generation	O
of	O
reactive	O
oxygen	S-chem
species	O
,	O
with	O
increased	O
activity	O
of	O
GPx	S-geneN
and	O
concentrations	O
of	O
LPO	O
and	O
GSH	S-chem
;	O
whereas	O
the	O
specific	O
activity	O
of	O
SOD	S-geneN
decreased	O
.	O

However	O
,	O
no	O
changes	O
were	O
observed	O
in	O
the	O
CAT	S-geneN
,	O
PCO	O
,	O
and	O
DNA	O
damage	O
.	O

Although	O
the	O
STX	S-chem
effects	O
are	O
known	O
as	O
neurotoxic	O
,	O
this	O
cyanotoxin	O
caused	O
liver	O
biochemical	O
alterations	O
that	O
can	O
be	O
considered	O
ecologically	O
relevant	O
.	O

Inborn	O
errors	O
in	O
the	O
metabolism	O
of	O
glutathione	S-chem
.	O

Glutathione	S-chem
is	O
a	O
tripeptide	S-chem
composed	O
of	O
glutamate	S-chem
,	O
cysteine	S-chem
and	O
glycine	S-chem
.	O

Glutathione	S-chem
is	O
present	O
in	O
millimolar	O
concentrations	O
in	O
most	O
mammalian	O
cells	O
and	O
it	O
is	O
involved	O
in	O
several	O
fundamental	O
biological	O
functions	O
,	O
including	O
free	O
radical	O
scavenging	O
,	O
detoxification	O
of	O
xenobiotics	O
and	O
carcinogens	O
,	O
redox	O
reactions	O
,	O
biosynthesis	O
of	O
DNA	O
,	O
proteins	O
and	O
leukotrienes	S-chem
,	O
as	O
well	O
as	O
neurotransmission	O
/	O
neuromodulation	O
.	O

Glutathione	S-chem
is	O
metabolised	O
via	O
the	O
gamma	B-chem
-	I-chem
glutamyl	E-chem
cycle	O
,	O
which	O
is	O
catalyzed	O
by	O
six	O
enzymes	O
.	O

In	O
man	O
,	O
hereditary	O
deficiencies	O
have	O
been	O
found	O
in	O
five	O
of	O
the	O
six	O
enzymes	O
.	O

Glutathione	B-geneY
synthetase	E-geneY
deficiency	O
is	O
the	O
most	O
frequently	O
recognized	O
disorder	O
and	O
,	O
in	O
its	O
severe	O
form	O
,	O
it	O
is	O
associated	O
with	O
hemolytic	O
anemia	O
,	O
metabolic	O
acidosis	O
,	O
5	O
-	O
oxoprolinuria	O
,	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
damage	O
and	O
recurrent	O
bacterial	O
infections	O
.	O

Gamma	B-geneY
-	I-geneY
glutamylcysteine	I-geneY
synthetase	E-geneY
deficiency	O
is	O
also	O
associated	O
with	O
hemolytic	O
anemia	O
,	O
and	O
some	O
patients	O
with	O
this	O
disorder	O
show	O
defects	O
of	O
neuromuscular	O
function	O
and	O
generalized	O
aminoaciduria	O
.	O

Gamma	B-geneY
-	I-geneY
glutamyl	I-geneY
transpeptidase	E-geneY
deficiency	O
has	O
been	O
found	O
in	O
patients	O
with	O
CNS	O
involvement	O
and	O
glutathionuria	O
.	O

5	B-geneY
-	I-geneY
Oxoprolinase	E-geneY
deficiency	O
is	O
associated	O
with	O
5	O
-	O
oxoprolinuria	O
but	O
without	O
a	O
clear	O
association	O
with	O
other	O
symptoms	O
.	O

Dipeptidase	S-geneN
deficiency	O
has	O
been	O
described	O
in	O
one	O
patient	O
.	O

All	O
disorders	O
are	O
very	O
rare	O
and	O
inherited	O
in	O
an	O
autosomal	O
recessive	O
manner	O
.	O

Most	O
of	O
the	O
mutations	O
are	O
leaky	O
so	O
that	O
many	O
patients	O
have	O
residual	O
enzyme	O
activity	O
.	O

Diagnosis	O
is	O
made	O
by	O
measuring	O
the	O
concentration	O
of	O
different	O
metabolites	O
in	O
the	O
gamma	B-chem
-	I-chem
glutamyl	E-chem
cycle	O
,	O
enzyme	O
activity	O
and	O
in	O
glutathione	B-geneY
synthetase	E-geneY
and	O
gamma	B-geneY
-	I-geneY
glutamylcysteine	I-geneY
synthetase	E-geneY
deficiency	O
,	O
also	O
by	O
mutation	O
analysis	O
.	O

Prenatal	O
diagnosis	O
has	O
been	O
preformed	O
in	O
glutathione	S-chem
synthetase	O
deficiency	O
.	O

The	O
prognosis	O
is	O
difficult	O
to	O
predict	O
,	O
as	O
few	O
patients	O
are	O
known	O
,	O
but	O
seems	O
to	O
vary	O
significantly	O
between	O
different	O
patients	O
.	O

The	O
aims	O
of	O
the	O
treatment	O
of	O
glutathione	S-chem
synthesis	O
defects	O
are	O
to	O
avoid	O
hemolytic	O
crises	O
and	O
to	O
increase	O
the	O
defense	O
against	O
reactive	O
oxygen	S-chem
species	O
.	O

No	O
treatment	O
has	O
been	O
recommended	O
for	O
gamma	B-geneY
-	I-geneY
glutamyl	I-geneY
transpeptidase	E-geneY
,	O
5	B-geneY
-	I-geneY
oxoprolinase	E-geneY
and	O
dipeptidase	S-geneN
deficiency	O
.	O

Super	O
-	O
stable	O
ultrafine	O
beta	B-chem
-	I-chem
tungsten	E-chem
nanocrystals	O
with	O
metastable	O
phase	O
and	O
related	O
magnetism	O
.	O

Ultrafine	O
tungsten	S-chem
nanocrystals	O
(	O
average	O
size	O
of	O
3	O
nm	O
)	O
with	O
a	O
metastable	O
phase	O
(	O
beta	B-chem
-	I-chem
tungsten	E-chem
with	O
A15	O
structure	O
,	O
β	O
-	O
W	S-chem
)	O
have	O
been	O
prepared	O
by	O
laser	O
ablation	O
of	O
tungsten	S-chem
in	O
liquid	O
nitrogen	S-chem
.	O

The	O
as	O
-	O
prepared	O
metastable	O
nanocrystals	O
exhibited	O
super	O
-	O
stablity	O
,	O
and	O
can	O
keep	O
the	O
same	O
metastable	O
structure	O
over	O
a	O
period	O
of	O
6	O
months	O
at	O
room	O
temperature	O
.	O

This	O
super	O
-	O
stability	O
is	O
attributed	O
to	O
the	O
nanosized	O
confinement	O
effect	O
of	O
ultrafine	O
nanocrystals	O
.	O

The	O
magnetism	O
measurements	O
showed	O
that	O
the	O
β	O
-	O
W	S-chem
nanocrystals	O
have	O
weak	O
ferromagnetic	O
properties	O
at	O
2	O
K	O
,	O
which	O
may	O
arise	O
from	O
surface	O
defects	O
and	O
unpaired	O
electrons	O
on	O
the	O
surface	O
of	O
the	O
ultrafine	O
nanocrystals	O
.	O

These	O
findings	O
provided	O
useful	O
information	O
for	O
the	O
application	O
of	O
ultrafine	O
β	O
-	O
W	S-chem
nanocrystals	O
in	O
microelectronics	O
and	O
spintronics	O
.	O

Effects	O
of	O
nedocromil	B-chem
sodium	E-chem
on	O
the	O
binding	O
of	O
N	B-chem
-	I-chem
formyl	I-chem
-	I-chem
methionyl	I-chem
-	I-chem
leucyl	I-chem
-	I-chem
phenylalanine	E-chem
in	O
human	O
neutrophils	O
.	O

In	O
the	O
present	O
study	O
the	O
inhibition	O
by	O
nedocromil	B-chem
sodium	E-chem
of	O
the	O
specific	O
receptor	O
binding	O
of	O
FMLP	O
was	O
evaluated	O
in	O
human	O
neutrophils	O
(	O
PMNs	O
)	O
using	O
a	O
FMLP	O
-	O
(	O
3H	O
)	O
binding	O
assay	O
.	O

The	O
time	O
course	O
of	O
the	O
binding	O
was	O
markedly	O
influenced	O
by	O
nedocromil	B-chem
sodium	E-chem
used	O
at	O
a	O
concentration	O
of	O
300	O
microM	O
.	O

No	O
significant	O
inhibition	O
was	O
obtained	O
when	O
the	O
cells	O
were	O
treated	O
with	O
nedocromil	B-chem
sodium	E-chem
3	O
microM	O
or	O
with	O
sodium	S-chem
cromoglycate	O
300	O
microM	O
.	O

FMLP	O
binding	O
is	O
essentially	O
eliminated	O
by	O
the	O
highest	O
dose	O
of	O
nedocromil	B-chem
sodium	E-chem
.	O

The	O
biologic	O
meaning	O
of	O
this	O
effect	O
in	O
asthmatic	O
patients	O
should	O
be	O
further	O
evaluated	O
.	O

2	B-chem
-	I-chem
Arylpropionic	E-chem
CXC	B-geneY
chemokine	I-geneY
receptor	I-geneY
1	E-geneY
(	O
CXCR1	S-geneY
)	O
ligands	O
as	O
novel	O
noncompetitive	O
CXCL8	S-geneY
inhibitors	O
.	O

The	O
CXC	B-geneN
chemokine	E-geneN
CXCL8	S-geneY
/	O
IL	B-geneY
-	I-geneY
8	E-geneY
plays	O
a	O
major	O
role	O
in	O
the	O
activation	O
and	O
recruitment	O
of	O
polymorphonuclear	O
(	O
PMN	O
)	O
cells	O
at	O
inflammatory	O
sites	O
.	O

CXCL8	S-geneY
activates	O
PMNs	O
by	O
binding	O
the	O
seven	B-geneN
-	I-geneN
transmembrane	I-geneN
(	I-geneN
7	I-geneN
-	I-geneN
TM	I-geneN
)	I-geneN
G	I-geneN
-	I-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptors	E-geneN
CXC	B-geneY
chemokine	I-geneY
receptor	I-geneY
1	E-geneY
(	O
CXCR1	S-geneY
)	O
and	O
CXC	B-geneY
chemokine	I-geneY
receptor	I-geneY
2	E-geneY
(	O
CXCR2	S-geneY
)	O
.	O

(	B-chem
R	I-chem
)	I-chem
-	I-chem
Ketoprofen	E-chem
(	O
1	O
)	O
was	O
previously	O
reported	O
to	O
be	O
a	O
potent	O
and	O
specific	O
noncompetitive	O
inhibitor	O
of	O
CXCL8	S-geneY
-	O
induced	O
human	O
PMNs	O
chemotaxis	O
.	O

We	O
report	O
here	O
molecular	O
modeling	O
studies	O
showing	O
a	O
putative	O
interaction	O
site	O
of	O
1	O
in	O
the	O
TM	O
region	O
of	O
CXCR1	S-geneY
.	O

The	O
binding	O
model	O
was	O
confirmed	O
by	O
alanine	S-chem
scanning	O
mutagenesis	O
and	O
photoaffinity	O
labeling	O
experiments	O
.	O

The	O
molecular	O
model	O
driven	O
medicinal	O
chemistry	O
optimization	O
of	O
1	O
led	O
to	O
a	O
new	O
class	O
of	O
potent	O
and	O
specific	O
inhibitors	O
of	O
CXCL8	S-geneY
biological	O
activity	O
.	O

Among	O
these	O
,	O
repertaxin	S-chem
(	O
13	O
)	O
was	O
selected	O
as	O
a	O
clinical	O
candidate	O
drug	O
for	O
prevention	O
of	O
post	O
-	O
ischemia	O
reperfusion	O
injury	O
.	O

Beta	B-chem
-	I-chem
glucogallin	E-chem
reduces	O
the	O
expression	O
of	O
lipopolysaccharide	O
-	O
induced	O
inflammatory	O
markers	O
by	O
inhibition	O
of	O
aldose	B-geneY
reductase	E-geneY
in	O
murine	O
macrophages	O
and	O
ocular	O
tissues	O
.	O

Aldose	B-geneY
reductase	E-geneY
(	O
AR	S-geneY
)	O
catalyzes	O
the	O
reduction	O
of	O
toxic	O
lipid	O
aldehydes	S-chem
to	O
their	O
alcohol	S-chem
products	O
and	O
mediates	O
inflammatory	O
signals	O
triggered	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Beta	B-chem
-	I-chem
glucogallin	E-chem
(	O
BGG	S-chem
)	O
,	O
a	O
recently	O
described	O
AR	S-geneY
inhibitor	O
,	O
was	O
purified	O
from	O
extracts	O
of	O
the	O
Indian	O
gooseberry	O
(	O
Emblica	O
officinalis	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
BGG	S-chem
showed	O
low	O
cytotoxicity	O
in	O
Raw264.7	O
murine	O
macrophages	O
and	O
effectively	O
inhibited	O
AR	S-geneY
activity	O
as	O
measured	O
by	O
a	O
decrease	O
in	O
sorbitol	S-chem
accumulation	O
.	O

In	O
addition	O
,	O
BGG	S-chem
-	O
mediated	O
inhibition	O
of	O
AR	S-geneY
prevented	O
LPS	O
-	O
induced	O
activation	O
of	O
JNK	S-geneN
and	O
p38	S-geneN
and	O
lowered	O
ROS	O
levels	O
,	O
which	O
could	O
inhibit	O
LPS	O
-	O
induced	O
apoptosis	O
.	O

Uveitis	O
is	O
a	O
disease	O
of	O
the	O
eye	O
associated	O
with	O
chronic	O
inflammation	O
.	O

In	O
this	O
study	O
,	O
we	O
also	O
demonstrated	O
that	O
treatment	O
with	O
BGG	S-chem
decreased	O
the	O
number	O
of	O
inflammatory	O
cells	O
that	O
infiltrate	O
the	O
ocular	O
media	O
of	O
mice	O
with	O
experimental	O
uveitis	O
.	O

Accordingly	O
,	O
these	O
results	O
suggest	O
BGG	S-chem
is	O
a	O
potential	O
therapy	O
for	O
inflammatory	O
diseases	O
.	O

Spiro	O
heterocycles	O
as	O
potential	O
inhibitors	O
of	O
SIRT1	S-geneY
:	O
Pd	S-chem
/	O
C	S-chem
-	O
mediated	O
synthesis	O
of	O
novel	O
N	B-chem
-	I-chem
indolylmethyl	I-chem
spiroindoline	I-chem
-	I-chem
3,2	I-chem
'	I-chem
-	I-chem
quinazolines	E-chem
.	O

Novel	O
N	B-chem
-	I-chem
indolylmethyl	I-chem
substituted	I-chem
spiroindoline	I-chem
-	I-chem
3,2	I-chem
'	I-chem
-	I-chem
quinazolines	E-chem
were	O
designed	O
as	O
potential	O
inhibitiors	O
of	O
SIRT1	S-geneY
.	O

These	O
compounds	O
were	O
synthesized	O
in	O
good	O
yields	O
by	O
using	O
Pd	S-chem
/	O
C	B-chem
-	I-chem
Cu	E-chem
mediated	O
coupling	O
-	O
cyclization	O
strategy	O
as	O
a	O
key	O
step	O
involving	O
the	O
reaction	O
of	O
1	B-chem
-	I-chem
(	I-chem
prop	I-chem
-	I-chem
2	I-chem
-	I-chem
ynyl	I-chem
)	I-chem
-	I-chem
1'H	I-chem
-	I-chem
spiro	I-chem
[	I-chem
indoline	I-chem
-	I-chem
3,2	I-chem
'	I-chem
-	I-chem
quinazoline	I-chem
]	I-chem
-	I-chem
2,4	I-chem
'	I-chem
(	I-chem
3'H	I-chem
)	I-chem
-	I-chem
dione	E-chem
with	O
2	B-chem
-	I-chem
iodoanilides	E-chem
.	O

Some	O
of	O
the	O
compounds	O
synthesized	O
have	O
shown	O
encouraging	O
inhibition	O
of	O
Sir	B-geneY
2	E-geneY
protein	O
(	O
a	O
yeast	O
homologue	O
of	O
mammalian	B-geneN
SIRT1	E-geneN
)	O
in	O
vitro	O
and	O
three	O
of	O
them	O
showed	O
dose	O
dependent	O
inhibition	O
of	O
Sir	B-geneY
2	E-geneY
.	O

The	O
docking	O
results	O
suggested	O
that	O
the	O
benzene	S-chem
ring	O
of	O
1,2,3,4	B-chem
-	I-chem
tetrahydroquinazolin	E-chem
ring	O
system	O
of	O
these	O
molecules	O
occupied	O
the	O
deep	O
hydrophobic	O
pocket	O
of	O
the	O
protein	O
and	O
one	O
of	O
the	O
NH	S-chem
along	O
with	O
the	O
sulfonyl	S-chem
group	O
participated	O
in	O
strong	O
H	S-chem
-	O
bonding	O
interaction	O
with	O
the	O
amino	B-chem
acid	E-chem
residues	O
.	O

Glioma	O
cell	O
sensitivity	O
to	O
topotecan	S-chem
:	O
the	O
role	O
of	O
p53	S-geneY
and	O
topotecan	S-chem
-	O
induced	O
DNA	O
damage	O
.	O

Topotecan	S-chem
is	O
a	O
topoisomerase	B-geneY
I	E-geneY
inhibitor	O
which	O
is	O
currently	O
evaluated	O
as	O
an	O
adjuvant	O
agent	O
for	O
malignant	O
glioma	O
.	O

Here	O
,	O
we	O
analysed	O
the	O
effects	O
of	O
topotecan	S-chem
on	O
12	O
human	O
malignant	O
glioma	O
cell	O
lines	O
in	O
vitro	O
.	O

All	O
cell	O
lines	O
expressed	O
topoisomerase	B-geneY
I	E-geneY
mRNA	O
.	O

High	O
p53	S-geneY
protein	O
levels	O
,	O
but	O
not	O
genetic	O
or	O
functional	O
p53	S-geneY
status	O
,	O
were	O
associated	O
with	O
increased	O
topotecan	S-chem
-	O
induced	O
DNA	O
/	O
topoisomerase	B-geneY
I	E-geneY
complex	O
formation	O
.	O

Neither	O
functional	O
p53	S-geneY
status	O
,	O
nor	O
p53	S-geneY
protein	O
levels	O
,	O
nor	O
complex	O
formation	O
predicted	O
topotecan	S-chem
-	O
induced	O
growth	O
inhibition	O
.	O

We	O
thus	O
confirm	O
a	O
possible	O
role	O
for	O
p53	S-geneY
protein	O
in	O
modulating	O
topoisomerase	B-geneY
I	E-geneY
activity	O
but	O
conclude	O
that	O
the	O
major	O
molecular	O
determinants	O
of	O
topotecan	S-chem
sensitivity	O
in	O
glioma	O
cells	O
await	O
identification	O
.	O

Creb1	S-geneY
-	O
Mecp2	S-geneY
-	O
(	B-chem
m	I-chem
)	I-chem
CpG	E-chem
complex	O
transactivates	O
postnatal	O
murine	O
neuronal	O
glucose	B-geneY
transporter	I-geneY
isoform	I-geneY
3	E-geneY
expression	O
.	O

The	O
murine	O
neuronal	O
facilitative	O
glucose	B-geneY
transporter	I-geneY
isoform	I-geneY
3	E-geneY
(	O
Glut3	S-geneY
)	O
is	O
developmentally	O
regulated	O
,	O
peaking	O
in	O
expression	O
at	O
postnatal	O
day	O
(	O
PN	O
)	O
14	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
characterized	O
a	O
canonical	O
CpG	S-chem
island	O
spanning	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
glut3	S-geneY
gene	O
.	O

Methylation	O
-	O
specific	O
PCR	O
and	O
bisulfite	S-chem
sequencing	O
identified	O
methylation	O
of	O
this	O
CpG	S-chem
(	O
(	B-chem
m	I-chem
)	I-chem
CpG	E-chem
)	O
island	O
of	O
the	O
glut3	S-geneY
gene	O
,	O
frequency	O
of	O
methylation	O
increasing	O
2.5	O
-	O
fold	O
with	O
a	O
1.6	O
-	O
fold	O
increase	O
in	O
DNA	B-geneY
methyl	I-geneY
transferase	I-geneY
3a	E-geneY
concentrations	O
noted	O
with	O
advancing	O
postnatal	O
age	O
(	O
PN14	O
vs	O
PN3	O
)	O
.	O

5	O
'	O
-	O
flanking	O
region	O
of	O
glut3	S-geneY
-	O
luciferase	O
reporter	O
transient	O
transfection	O
in	O
HT22	O
hippocampal	O
neurons	O
demonstrated	O
that	O
(	B-chem
m	I-chem
)	I-chem
CpGs	E-chem
inhibit	O
glut3	S-geneY
transcription	O
.	O

Contrary	O
to	O
this	O
biological	O
function	O
,	O
glut3	S-geneY
expression	O
rises	O
synchronously	O
with	O
(	B-chem
m	I-chem
)	I-chem
CpGs	E-chem
in	O
PN14	O
vs	O
PN3	O
neurons	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
IP	O
)	O
revealed	O
that	O
methyl	B-geneY
-	I-geneY
CpG	I-geneY
binding	I-geneY
protein	I-geneY
2	E-geneY
(	O
Mecp2	S-geneY
)	O
bound	O
the	O
glut3	S-geneY
-	O
(	B-chem
m	I-chem
)	I-chem
CpGs	E-chem
.	O

Depending	O
on	O
association	O
with	O
specific	O
coregulators	O
,	O
Mecp2	S-geneY
,	O
a	O
dual	O
regulator	O
of	O
gene	O
transcription	O
,	O
may	O
repress	O
or	O
activate	O
a	O
downstream	O
gene	O
.	O

Sequential	O
chromatin	O
IP	O
uncovered	O
the	O
glut3	S-geneY
-	O
(	B-chem
m	I-chem
)	I-chem
CpGs	E-chem
to	O
bind	O
Mecp2	S-geneY
exponentially	O
upon	O
recruitment	O
of	O
Creb1	S-geneY
rather	O
than	O
histone	B-geneY
deacetylase	I-geneY
1	E-geneY
.	O

Co	O
-	O
IP	O
and	O
coimmunolocalization	O
confirmed	O
that	O
Creb1	S-geneY
associated	O
with	O
Mecp2	S-geneY
and	O
cotransfection	O
with	O
glut3	S-geneY
-	O
(	B-chem
m	I-chem
)	I-chem
CpG	E-chem
in	O
HT22	O
cells	O
enhanced	O
glut3	S-geneY
transcription	O
.	O

Separate	O
5	B-chem
-	I-chem
aza	I-chem
-	I-chem
2	I-chem
'	I-chem
-	I-chem
deoxycytidine	E-chem
pretreatment	O
or	O
in	O
combination	O
with	O
trichostatin	B-chem
A	E-chem
reduced	O
(	B-chem
m	I-chem
)	I-chem
CpG	E-chem
and	O
specific	O
small	O
interference	O
RNAs	O
targeting	O
Mecp2	S-geneY
and	O
Creb1	S-geneY
separately	O
or	O
together	O
depleting	O
Mecp2	S-geneY
and	O
/	O
or	O
Creb1	S-geneY
binding	O
of	O
glut3	S-geneY
-	O
(	B-chem
m	I-chem
)	I-chem
CpGs	E-chem
reduced	O
glut3	S-geneY
expression	O
in	O
HT22	O
cells	O
.	O

We	O
conclude	O
that	O
Glut3	S-geneY
is	O
a	O
methylation	O
-	O
sensitive	O
neuronal	O
gene	O
that	O
recruits	O
Mecp2	S-geneY
.	O

Recruitment	O
of	O
Creb1	S-geneY
-	O
Mecp2	S-geneY
by	O
glut3	S-geneY
-	O
(	B-chem
m	I-chem
)	I-chem
CpG	E-chem
contributes	O
towards	O
transactivation	O
,	O
formulating	O
an	O
escape	O
from	O
(	B-chem
m	I-chem
)	I-chem
CpG	E-chem
-	O
induced	O
gene	O
suppression	O
,	O
and	O
thereby	O
promoting	O
developmental	O
neuronal	O
glut3	S-geneY
gene	O
transcription	O
and	O
expression	O
.	O

Candesartan	B-chem
cilexetil	E-chem
-	O
-	O
a	O
review	O
of	O
effects	O
on	O
cardiovascular	O
complications	O
in	O
hypertension	O
and	O
chronic	O
heart	O
failure	O
.	O

UNLABELLED	O
:	O
Therapeutic	O
interventions	O
that	O
block	O
the	O
renin	S-geneY
-	O
angiotensin	S-geneY
-	O
aldosterone	S-chem
system	O
(	O
RAAS	O
)	O
have	O
an	O
important	O
role	O
in	O
slowing	O
the	O
progression	O
of	O
cardiovascular	O
risk	O
actors	O
to	O
established	O
cardiovascular	O
diseases	O
.	O

In	O
recent	O
years	O
,	O
angiotensin	B-geneN
receptor	E-geneN
blockers	O
(	O
ARBs	O
)	O
have	O
emerged	O
as	O
effective	O
and	O
well	O
-	O
tolerated	O
alternatives	O
to	O
an	O
angiotensin	B-geneY
-	I-geneY
converting	I-geneY
enzyme	E-geneY
inhibitor	O
(	O
ACEi	O
)	O
for	O
RAAS	O
blockade	O
.	O

The	O
ARB	O
candesartan	S-chem
was	O
initially	O
established	O
as	O
an	O
effective	O
once	O
-	O
daily	O
antihypertensive	O
treatment	O
,	O
providing	O
24	O
-	O
h	O
blood	O
pressure	O
(	O
BP	O
)	O
control	O
with	O
a	O
trough	O
:	O
peak	O
ratio	O
close	O
to	O
100	O
%	O
.	O

SCOPE	O
:	O
A	O
Medline	O
literature	O
search	O
was	O
undertaken	O
to	O
identify	O
randomised	O
,	O
controlled	O
trials	O
that	O
examined	O
the	O
efficacy	O
and	O
cardiovascular	O
outcomes	O
associated	O
with	O
candesartan	B-chem
cilexetil	E-chem
in	O
hypertension	O
and	O
chronic	O
heart	O
failure	O
(	O
CHF	O
)	O
.	O

FINDINGS	O
:	O
Compared	O
with	O
other	O
ARBs	O
,	O
candesartan	S-chem
demonstrates	O
the	O
strongest	O
binding	O
affinity	O
to	O
the	O
angiotensin	B-geneY
II	I-geneY
type	I-geneY
1	I-geneY
receptor	E-geneY
.	O

Clinical	O
trials	O
have	O
demonstrated	O
that	O
candesartan	S-chem
is	O
well	O
tolerated	O
in	O
combination	O
with	O
diuretics	O
or	O
calcium	B-geneN
channel	E-geneN
blockers	O
(	O
CCBs	O
)	O
,	O
making	O
it	O
a	O
suitable	O
treatment	O
option	O
for	O
patients	O
whose	O
hypertension	O
is	O
not	O
adequately	O
controlled	O
by	O
monotherapy	O
.	O

Subsequently	O
,	O
candesartan	S-chem
became	O
the	O
only	O
ARB	O
licensed	O
in	O
the	O
UK	O
to	O
treat	O
patients	O
with	O
CHF	O
and	O
left	O
ventricular	O
ejection	O
fraction	O
<	O
or	O
=	O
40	O
%	O
as	O
add	O
-	O
on	O
therapy	O
to	O
an	O
ACEi	O
or	O
when	O
an	O
ACEi	O
is	O
not	O
tolerated	O
.	O

Studies	O
in	O
patients	O
with	O
symptomatic	O
HF	O
have	O
indicated	O
that	O
candesartan	S-chem
treatment	O
was	O
associated	O
with	O
significant	O
relative	O
risk	O
reductions	O
in	O
cardiovascular	O
mortality	O
and	O
hospitalisation	O
due	O
to	O
CHF	O
.	O

CONCLUSIONS	O
:	O
There	O
are	O
clear	O
indications	O
that	O
the	O
clinical	O
benefits	O
of	O
candesartan	S-chem
may	O
extend	O
beyond	O
its	O
proven	O
antihypertensive	O
effects	O
to	O
a	O
wider	O
range	O
of	O
complications	O
across	O
the	O
cardiovascular	O
continuum	O
,	O
including	O
diabetes	O
,	O
left	O
ventricular	O
hypertrophy	O
,	O
atherosclerosis	O
and	O
stroke	O
.	O

Such	O
results	O
suggest	O
that	O
candesartan	S-chem
treatment	O
may	O
offer	O
significant	O
patient	O
benefits	O
as	O
well	O
as	O
practical	O
advantages	O
over	O
conventional	O
treatment	O
.	O

Phosphodiesterase	S-geneN
inhibitors	O
.	O
Part	O
5	O
:	O
hybrid	O
PDE3	B-geneN
/	I-geneN
4	E-geneN
inhibitors	O
as	O
dual	O
bronchorelaxant	O
/	O
anti	O
-	O
inflammatory	O
agents	O
for	O
inhaled	O
administration	O
.	O

(	B-chem
-	I-chem
)	I-chem
-	I-chem
6	I-chem
-	I-chem
(	I-chem
7	I-chem
-	I-chem
Methoxy	I-chem
-	I-chem
2	I-chem
-	I-chem
(	I-chem
trifluoromethyl	I-chem
)	I-chem
pyrazolo	I-chem
[	I-chem
1,5	I-chem
-	I-chem
a	I-chem
]	I-chem
pyridin	I-chem
-	I-chem
4	I-chem
-	I-chem
yl	I-chem
)	I-chem
-	I-chem
5	I-chem
-	I-chem
methyl	I-chem
-	I-chem
4,5	I-chem
-	I-chem
dihydropyridazin	I-chem
-	I-chem
3	I-chem
(	I-chem
2H	I-chem
)	I-chem
-	I-chem
one	E-chem
(	O
KCA	B-chem
-	I-chem
1490	E-chem
)	O
exhibits	O
moderate	O
dual	O
PDE3	B-geneN
/	I-geneN
4	E-geneN
-	O
inhibitory	O
activity	O
and	O
promises	O
as	O
a	O
combined	O
bronchodilatory	O
/	O
anti	O
-	O
inflammatory	O
agent	O
.	O

N	S-chem
-	O
alkylation	O
of	O
the	O
pyridazinone	S-chem
ring	O
markedly	O
enhances	O
potency	O
against	O
PDE4	S-geneN
but	O
suppresses	O
PDE3	S-geneN
inhibition	O
.	O

Addition	O
of	O
a	O
6	B-chem
-	I-chem
aryl	I-chem
-	I-chem
4,5	I-chem
-	I-chem
dihydropyridazin	I-chem
-	I-chem
3	I-chem
(	I-chem
2H	I-chem
)	I-chem
-	I-chem
one	E-chem
extension	O
to	O
the	O
N	S-chem
-	O
alkyl	O
group	O
facilitates	O
both	O
enhancement	O
of	O
PDE4	S-geneN
-	O
inhibitory	O
activity	O
and	O
restoration	O
of	O
potent	O
PDE3	S-geneN
inhibition	O
.	O

Both	O
dihydropyridazinone	S-chem
rings	O
,	O
in	O
the	O
core	O
and	O
extension	O
,	O
can	O
be	O
replaced	O
by	O
achiral	O
4,4	B-chem
-	I-chem
dimethylpyrazolone	E-chem
subunits	O
and	O
the	O
core	O
pyrazolopyridine	S-chem
by	O
isosteric	O
bicyclic	O
heteroaromatics	O
.	O

In	O
combination	O
,	O
these	O
modifications	O
afford	O
potent	O
dual	O
PDE3	B-geneN
/	I-geneN
4	E-geneN
inhibitors	O
that	O
suppress	O
histamine	S-chem
-	O
induced	O
bronchoconstriction	O
in	O
vivo	O
and	O
exhibit	O
promising	O
anti	O
-	O
inflammatory	O
activity	O
via	O
intratracheal	O
administration	O
.	O

Fetal	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
overexpression	O
programs	O
adult	O
pancreatic	O
β	O
-	O
cell	O
dysfunction	O
.	O

Adult	O
β	O
-	O
cell	O
dysfunction	O
,	O
a	O
hallmark	O
of	O
type	O
2	O
diabetes	O
,	O
can	O
be	O
programmed	O
by	O
adverse	O
fetal	O
environment	O
.	O

We	O
have	O
shown	O
that	O
fetal	O
glucocorticoids	O
(	O
GCs	O
)	O
participate	O
in	O
this	O
programming	O
through	O
inhibition	O
of	O
β	O
-	O
cell	O
development	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
this	O
regulation	O
.	O

We	O
showed	O
that	O
GCs	O
stimulate	O
the	O
expression	O
of	O
peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
-	I-geneY
γ	I-geneY
coactivator	I-geneY
-	I-geneY
1α	E-geneY
(	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
)	O
,	O
a	O
coregulator	O
of	O
the	O
GCs	B-geneY
receptor	E-geneY
(	O
GR	S-geneY
)	O
,	O
and	O
that	O
the	O
overexpression	O
of	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
represses	O
genes	O
important	O
for	O
β	O
-	O
cell	O
development	O
and	O
function	O
.	O

More	O
precisely	O
,	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
inhibited	O
the	O
expression	O
of	O
the	O
key	O
β	O
-	O
cell	O
transcription	O
factor	O
pancreatic	B-geneY
duodenal	I-geneY
homeobox	I-geneY
1	E-geneY
(	O
Pdx1	S-geneY
)	O
.	O

This	O
repression	O
required	O
the	O
GR	S-geneY
and	O
was	O
mediated	O
through	O
binding	O
of	O
a	O
GR	S-geneY
/	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
complex	O
to	O
the	O
Pdx1	B-geneN
promoter	E-geneN
.	O

To	O
explore	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
function	O
,	O
we	O
generated	O
mice	O
with	O
inducible	O
β	O
-	O
cell	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
overexpression	O
.	O

Mice	O
overexpressing	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
exhibited	O
at	O
adult	O
age	O
impaired	O
glucose	S-chem
tolerance	O
associated	O
with	O
reduced	O
insulin	O
secretion	O
,	O
decreased	O
β	O
-	O
cell	O
mass	O
,	O
and	O
β	O
-	O
cell	O
hypotrophy	O
.	O

Interestingly	O
,	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
expression	O
in	O
fetal	O
life	O
only	O
was	O
sufficient	O
to	O
impair	O
adult	O
β	O
-	O
cell	O
function	O
whereas	O
β	O
-	O
cell	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
overexpression	O
from	O
adult	O
age	O
had	O
no	O
consequence	O
on	O
β	O
-	O
cell	O
function	O
.	O

Altogether	O
,	O
our	O
results	O
demonstrate	O
that	O
the	O
GR	S-geneY
and	O
PGC	B-geneY
-	I-geneY
1α	E-geneY
participate	O
in	O
the	O
fetal	O
programming	O
of	O
adult	O
β	O
-	O
cell	O
function	O
through	O
inhibition	O
of	O
Pdx1	S-geneY
expression	O
.	O

Mazindol	S-chem
analogues	O
as	O
potential	O
inhibitors	O
of	O
the	O
cocaine	B-geneN
binding	I-geneN
site	E-geneN
at	O
the	O
dopamine	B-geneY
transporter	E-geneY
.	O

A	O
series	O
of	O
mazindol	S-chem
(	O
2	O
)	O
and	O
homomazindol	S-chem
(	O
3	O
)	O
analogues	O
with	O
a	O
variety	O
of	O
electron	O
-	O
donating	O
and	O
electron	O
-	O
withdrawing	O
groups	O
in	O
the	O
pendant	O
aryl	S-chem
group	O
and	O
the	O
benzo	S-chem
ring	O
C	O
,	O
as	O
well	O
as	O
H	O
,	O
methoxy	S-chem
,	O
and	O
alkyl	S-chem
groups	O
replacing	O
the	O
hydroxyl	S-chem
group	O
were	O
synthesized	O
,	O
and	O
their	O
binding	O
affinities	O
at	O
the	O
dopamine	B-geneN
transporter	E-geneN
(	O
DAT	S-geneN
)	O
on	O
rat	O
or	O
guinea	O
pig	O
striatal	O
membranes	O
were	O
determined	O
.	O

Several	O
active	O
analogues	O
were	O
also	O
evaluated	O
for	O
their	O
ability	O
to	O
block	O
uptake	O
of	O
DA	S-chem
,	O
5	B-chem
-	I-chem
HT	E-chem
,	O
and	O
NE	S-chem
and	O
inhibit	O
binding	O
of	O
[	B-chem
(	I-chem
125	I-chem
)	I-chem
I	I-chem
]	I-chem
RTI	I-chem
-	I-chem
55	E-chem
at	O
HEK	O
-	O
hDAT	S-geneY
,	O
HEK	O
-	O
hSERT	S-geneY
,	O
and	O
HEK	O
-	O
hNET	S-geneY
cells	O
.	O

Mazindane	S-chem
(	O
26	O
)	O
was	O
found	O
to	O
be	O
a	O
pro	O
-	O
drug	O
,	O
oxidizing	O
(	O
5	B-chem
-	I-chem
H	E-chem
-	O
-	O
>	O
5	B-chem
-	I-chem
OH	E-chem
)	O
to	O
mazindol	S-chem
on	O
rat	O
striatal	O
membranes	O
and	O
HEK	O
-	O
hDAT	S-geneY
cells	O
.	O

The	O
4',7,8	B-chem
-	I-chem
trichloro	E-chem
analogue	O
(	O
38	O
)	O
of	O
mazindol	S-chem
was	O
the	O
most	O
potent	O
and	O
selective	O
ligand	O
for	O
HEK	O
-	O
hDAT	S-geneY
cells	O
(	O
DAT	S-geneY
K	O
(	O
i	O
)	O
=	O
1.1	O
nM	O
;	O
SERT	S-geneY
/	O
DAT	S-geneY
=	O
1283	O
and	O
NET	S-geneY
/	O
DAT	S-geneY
=	O
38	O
)	O
.	O

Experimental	O
results	O
strongly	O
favor	O
the	O
cyclic	O
or	O
ol	O
tautomers	O
of	O
2	O
and	O
3	O
to	O
bind	O
more	O
tightly	O
at	O
the	O
DAT	S-geneY
than	O
the	O
corresponding	O
keto	O
tautomers	O
.	O

Pseudohypoaldosteronism	O
type	O
1	O
and	O
the	O
genes	O
encoding	O
prostasin	S-geneY
,	O
alpha	B-geneY
-	I-geneY
spectrin	E-geneY
,	O
and	O
Nedd4	S-geneY
.	O

Pseudohypoaldosteronism	O
type	O
1	O
(	O
PHA1	O
)	O
,	O
a	O
rare	O
disorder	O
of	O
infancy	O
,	O
presents	O
with	O
potential	O
life	O
-	O
threatening	O
salt	O
wasting	O
and	O
failure	O
to	O
thrive	O
.	O

Thus	O
far	O
,	O
PHA1	O
has	O
been	O
attributed	O
to	O
mutations	O
affecting	O
the	O
mineralocorticoid	B-geneY
receptor	E-geneY
or	O
any	O
of	O
the	O
three	O
subunits	O
assembling	O
the	O
amiloride	B-geneN
-	I-geneN
sensitive	I-geneN
epithelial	I-geneN
sodium	I-geneN
channel	E-geneN
(	O
ENaC	S-geneN
)	O
.	O

However	O
,	O
a	O
lot	O
of	O
patients	O
with	O
a	O
phenotype	O
resembling	O
PHA1	O
,	O
show	O
no	O
defects	O
in	O
these	O
proteins	O
,	O
making	O
it	O
likely	O
that	O
further	O
genes	O
are	O
involved	O
in	O
the	O
aetiology	O
of	O
this	O
disease	O
.	O

Recent	O
studies	O
have	O
elucidated	O
additional	O
participants	O
(	O
alpha	B-geneY
-	I-geneY
spectrin	E-geneY
and	O
members	O
of	O
the	O
families	O
of	O
transmembrane	B-geneN
serine	I-geneN
proteases	E-geneN
,	O
ubiquitin	B-geneN
-	I-geneN
protein	I-geneN
ligases	E-geneN
,	O
and	O
serum	B-geneN
-	I-geneN
and	I-geneN
glucocorticoid	I-geneN
-	I-geneN
regulated	I-geneN
kinases	E-geneN
,	O
respectively	O
)	O
regulating	O
and	O
/	O
or	O
interacting	O
in	O
the	O
complex	O
pathway	O
of	O
sodium	S-chem
retention	O
in	O
the	O
amiloride	S-chem
-	O
sensitive	O
distal	O
nephron	O
.	O

This	O
led	O
us	O
to	O
investigate	O
whether	O
PHA1	O
can	O
also	O
be	O
associated	O
with	O
mutations	O
in	O
some	O
of	O
these	O
genes	O
.	O

Our	O
data	O
suggest	O
that	O
at	O
least	O
the	O
prostasin	S-geneY
gene	O
might	O
be	O
excluded	O
as	O
a	O
causative	O
locus	O
.	O

The	O
interaction	O
between	O
mGluR1	S-geneY
and	O
the	O
calcium	B-geneN
channel	E-geneN
Cav₂.₁	S-geneY
preserves	O
coupling	O
in	O
the	O
presence	O
of	O
long	B-geneN
Homer	I-geneN
proteins	E-geneN
.	O

Group	B-geneN
I	I-geneN
metabotropic	I-geneN
glutamate	I-geneN
receptors	E-geneN
(	O
mGluR1	B-geneN
and	I-geneN
5	E-geneN
)	O
are	O
G	B-geneN
protein	I-geneN
coupled	I-geneN
receptors	E-geneN
that	O
regulate	O
neuronal	O
activity	O
in	O
a	O
number	O
of	O
ways	O
.	O

Some	O
of	O
the	O
most	O
well	O
studied	O
functions	O
of	O
group	B-geneN
I	I-geneN
mGluRs	E-geneN
,	O
such	O
as	O
initiation	O
of	O
multiple	O
forms	O
of	O
mGluR	S-geneN
-	O
dependent	O
long	O
-	O
term	O
depression	O
,	O
require	O
receptor	O
localization	O
near	O
the	O
post	O
-	O
synaptic	O
density	O
(	O
PSD	O
)	O
.	O

This	O
localization	O
is	O
in	O
turn	O
dependent	O
on	O
the	O
Homer	S-geneN
family	O
of	O
scaffolding	O
proteins	O
which	O
bind	O
to	O
a	O
small	O
motif	O
on	O
the	O
distal	O
C	S-chem
-	O
termini	O
of	O
mGluR1	B-geneN
and	I-geneN
5	E-geneN
,	O
localize	O
the	O
receptors	O
near	O
the	O
PSD	O
,	O
strengthen	O
coupling	O
to	O
post	O
-	O
synaptic	O
effectors	O
and	O
simultaneously	O
uncouple	O
the	O
mGluRs	S-geneN
from	O
extra	O
-	O
synaptic	O
effectors	O
such	O
as	O
voltage	B-geneN
dependent	I-geneN
ion	I-geneN
channels	E-geneN
.	O

Here	O
the	O
selectivity	O
of	O
this	O
uncoupling	O
process	O
was	O
examined	O
by	O
testing	O
the	O
ability	O
of	O
Homer	B-geneY
-	I-geneY
2b	E-geneY
to	O
uncouple	O
mGluR1	S-geneY
from	O
multiple	O
voltage	B-geneN
dependent	I-geneN
calcium	I-geneN
channels	E-geneN
including	O
Ca	B-geneY
(	I-geneY
V2.2	I-geneY
)	E-geneY
(	O
N	B-geneN
-	I-geneN
type	E-geneN
)	O
,	O
Ca	B-geneY
(	I-geneY
V3.2	I-geneY
)	E-geneY
(	O
T	B-geneN
-	I-geneN
type	I-geneN
)	E-geneN
,	O
and	O
Ca	B-geneY
(	I-geneY
V2.1	I-geneY
)	E-geneY
(	O
P	B-geneN
/	I-geneN
Q	I-geneN
-	I-geneN
type	E-geneN
)	O
expressed	O
in	O
rat	O
sympathetic	O
neurons	O
from	O
the	O
superior	O
cervical	O
ganglion	O
(	O
SCG	O
)	O
.	O

Of	O
these	O
,	O
only	O
the	O
mGluR1	S-geneY
-	O
Ca	B-geneY
(	I-geneY
V2.1	I-geneY
)	E-geneY
modulatory	O
pathway	O
was	O
insensitive	O
to	O
Homer	B-geneY
-	I-geneY
2b	E-geneY
expression	O
.	O

Uncoupling	O
from	O
this	O
channel	O
was	O
achieved	O
by	O
co	O
-	O
expression	O
of	O
an	O
mGluR1	S-geneY
C	S-chem
-	O
terminal	O
protein	O
designed	O
to	O
disrupt	O
a	O
previously	O
described	O
direct	O
interaction	O
between	O
these	O
two	O
proteins	O
,	O
suggesting	O
that	O
this	O
interaction	O
allows	O
incorporation	O
of	O
Ca	B-geneY
(	I-geneY
V2.1	I-geneY
)	E-geneY
into	O
the	O
mGluR1	S-geneY
/	O
Homer	S-geneN
signaling	O
complex	O
,	O
thereby	O
preserving	O
modulation	O
in	O
the	O
presence	O
of	O
scaffolding	O
Homer	B-geneN
proteins	E-geneN
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Metabotropic	B-geneN
Glutamate	I-geneN
Receptors	E-geneN
'	O
.	O

The	O
yeast	B-geneN
cap	I-geneN
binding	I-geneN
complex	E-geneN
modulates	O
transcription	O
factor	O
recruitment	O
and	O
establishes	O
proper	O
histone	B-geneN
H3K36	O
trimethylation	O
during	O
active	O
transcription	O
.	O

Recent	O
studies	O
have	O
revealed	O
a	O
close	O
relationship	O
between	O
transcription	O
,	O
histone	S-geneN
modification	O
,	O
and	O
RNA	O
processing	O
.	O

In	O
fact	O
,	O
genome	O
-	O
wide	O
analyses	O
that	O
correlate	O
histone	O
marks	O
with	O
RNA	O
processing	O
signals	O
raise	O
the	O
possibility	O
that	O
specific	O
RNA	O
processing	O
factors	O
may	O
modulate	O
transcription	O
and	O
help	O
to	O
``	O
write	O
``	O
chromatin	O
marks	O
.	O

Here	O
we	O
show	O
that	O
the	O
nuclear	B-geneN
cap	I-geneN
binding	I-geneN
complex	E-geneN
(	O
CBC	S-geneN
)	O
directs	O
recruitment	O
of	O
transcription	O
elongation	O
factors	O
and	O
establishes	O
proper	O
histone	S-geneN
marks	O
during	O
active	O
transcription	O
.	O

A	O
directed	O
genetic	O
screen	O
revealed	O
that	O
deletion	O
of	O
either	O
subunit	O
of	O
the	O
CBC	S-geneN
confers	O
a	O
synthetic	O
growth	O
defect	O
when	O
combined	O
with	O
deletion	O
of	O
genes	O
encoding	O
either	O
Ctk2	S-geneY
or	O
Bur2	S-geneY
,	O
a	O
component	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
ortholog	O
of	O
P	B-geneN
-	I-geneN
TEFb	E-geneN
.	O

The	O
CBC	S-geneN
physically	O
associates	O
with	O
these	O
complexes	O
to	O
recruit	O
them	O
during	O
transcription	O
and	O
mediates	O
phosphorylation	O
at	O
Ser	S-chem
-	O
2	O
of	O
the	O
C	S-chem
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
of	O
RNA	B-geneN
polymerase	I-geneN
II	E-geneN
.	O

To	O
understand	O
how	O
these	O
interactions	O
influence	O
downstream	O
events	O
,	O
histone	B-geneN
H3K36me3	O
was	O
examined	O
,	O
and	O
we	O
demonstrate	O
that	O
CBC	S-geneN
Δ	O
affects	O
proper	O
Set2	S-geneY
-	O
dependent	O
H3K36me3	S-geneN
.	O

Consistent	O
with	O
this	O
,	O
the	O
CBC	S-geneN
and	O
Set2	S-geneY
have	O
similar	O
effects	O
on	O
the	O
ability	O
to	O
rapidly	O
induce	O
and	O
sustain	O
activated	O
gene	O
expression	O
,	O
and	O
these	O
effects	O
are	O
distinct	O
from	O
other	O
histone	S-geneN
methyltransferases	O
.	O

This	O
work	O
provides	O
evidence	O
for	O
an	O
emerging	O
model	O
that	O
RNA	O
processing	O
factors	O
can	O
modulate	O
the	O
recruitment	O
of	O
transcription	O
factors	O
and	O
influence	O
histone	S-geneN
modification	O
during	O
elongation	O
.	O

Nitrosoureas	O
inhibit	O
the	O
stathmin	S-geneY
-	O
mediated	O
migration	O
and	O
invasion	O
of	O
malignant	O
glioma	O
cells	O
.	O

Malignant	O
gliomas	O
are	O
the	O
most	O
common	O
primary	O
intrinsic	O
brain	O
tumors	O
and	O
are	O
highly	O
lethal	O
.	O

The	O
widespread	O
migration	O
and	O
invasion	O
of	O
neoplastic	O
cells	O
from	O
the	O
initial	O
site	O
of	O
tumor	O
formation	O
into	O
the	O
surrounding	O
brain	O
render	O
these	O
lesions	O
refractory	O
to	O
definitive	O
surgical	O
treatment	O
.	O

Stathmin	S-geneY
,	O
a	O
microtubule	S-geneN
-	O
destabilizing	O
protein	O
that	O
mediates	O
cell	O
cycle	O
progression	O
,	O
can	O
also	O
regulate	O
directed	O
cell	O
movement	O
.	O

Nitrosoureas	O
,	O
traditionally	O
viewed	O
as	O
DNA	O
alkylating	O
agents	O
,	O
can	O
also	O
covalently	O
modify	O
proteins	O
such	O
as	O
stathmin	S-geneY
.	O

We	O
therefore	O
sought	O
to	O
establish	O
a	O
role	O
for	O
stathmin	S-geneY
in	O
malignant	O
glioma	O
cell	O
motility	O
,	O
migration	O
,	O
and	O
invasion	O
and	O
determine	O
the	O
effects	O
of	O
nitrosoureas	S-chem
on	O
these	O
cell	O
movement	O
-	O
related	O
processes	O
.	O

Scratch	O
wound	O
-	O
healing	O
recovery	O
,	O
Boyden	O
chamber	O
migration	O
,	O
Matrigel	O
invasion	O
,	O
and	O
organotypic	O
slice	O
invasion	O
assays	O
were	O
performed	O
before	O
and	O
after	O
the	O
down	O
-	O
regulation	O
of	O
cellular	O
stathmin	S-geneY
levels	O
and	O
in	O
the	O
absence	O
and	O
presence	O
of	O
sublethal	O
nitrosourea	S-chem
(	O
[	B-chem
1	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
chloroethyl	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
cyclohexyl	I-chem
-	I-chem
l	I-chem
-	I-chem
nitrosourea	I-chem
]	E-chem
;	O
CCNU	S-chem
)	O
concentrations	O
.	O

We	O
show	O
that	O
decreases	O
in	O
stathmin	S-geneY
expression	O
lead	O
to	O
significant	O
decreases	O
in	O
malignant	O
glioma	O
cell	O
motility	O
,	O
migration	O
,	O
and	O
invasion	O
.	O

CCNU	S-chem
,	O
at	O
a	O
concentration	O
of	O
10	O
micromol	O
/	O
L	O
,	O
causes	O
similar	O
significant	O
decreases	O
,	O
even	O
in	O
the	O
absence	O
of	O
any	O
effects	O
on	O
cell	O
viability	O
.	O

The	O
direct	O
inhibition	O
of	O
stathmin	S-geneY
by	O
CCNU	S-chem
is	O
likely	O
a	O
contributing	O
factor	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
inhibition	O
of	O
stathmin	O
expression	O
and	O
function	O
may	O
be	O
useful	O
in	O
limiting	O
the	O
spread	O
of	O
malignant	O
gliomas	O
within	O
the	O
brain	O
,	O
and	O
that	O
nitrosoureas	S-chem
may	O
have	O
therapeutic	O
benefits	O
in	O
addition	O
to	O
their	O
antiproliferative	O
effects	O
.	O

Intradialytic	O
parenteral	O
nutrition	O
:	O
comparison	O
of	O
olive	O
oil	O
versus	O
soybean	O
oil	O
-	O
based	O
lipid	O
emulsions	O
.	O

Lipid	O
,	O
oxidative	O
and	O
inflammatory	O
parameters	O
are	O
frequently	O
altered	O
in	O
dialysis	O
patients	O
and	O
may	O
be	O
worsened	O
by	O
intravenous	O
lipid	O
emulsions	O
(	O
ILE	O
)	O
.	O

We	O
assessed	O
the	O
efficacy	O
and	O
tolerance	O
of	O
olive	O
as	O
compared	O
with	O
standard	O
soybean	O
oil	O
-	O
based	O
ILE	O
during	O
intradialytic	O
parenteral	O
nutrition	O
(	O
IDPN	O
)	O
.	O

IDPN	O
mixtures	O
containing	O
amino	B-chem
acids	E-chem
,	O
glucose	S-chem
,	O
and	O
either	O
olive	O
oil	O
(	O
OO	O
group	O
,	O
n	O
17	O
)	O
or	O
soybean	O
oil	O
-	O
based	O
ILE	O
(	O
SO	O
group	O
,	O
n	O
18	O
)	O
were	O
administered	O
in	O
a	O
5	O
-	O
week	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

On	O
days	O
0	O
and	O
35	O
,	O
patients	O
'	O
nutritional	O
status	O
was	O
assessed	O
by	O
BMI	O
,	O
normalized	O
protein	O
catabolic	O
rate	O
,	O
predialytic	O
creatinine	S-chem
,	O
serum	B-geneY
albumin	E-geneY
and	O
transthyretin	S-geneY
;	O
lipid	O
metabolism	O
by	O
plasma	O
LDL	S-geneN
-	O
and	O
HDL	S-geneN
-	O
cholesterol	S-chem
,	O
triacylglycerols	S-chem
,	O
phospholipids	O
,	O
apo	B-geneN
A	I-geneN
-	I-geneN
I	I-geneN
,	I-geneN
A	I-geneN
-	I-geneN
II	I-geneN
,	I-geneN
B	I-geneN
,	I-geneN
C	I-geneN
-	I-geneN
II	I-geneN
,	I-geneN
C	I-geneN
-	I-geneN
III	I-geneN
,	I-geneN
E	E-geneN
and	O
lipoprotein	B-geneY
(	I-geneY
a	I-geneY
)	E-geneY
;	O
oxidative	O
status	O
by	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
,	O
retinol	S-chem
,	O
selenium	S-chem
,	O
glutathione	B-geneN
peroxidase	E-geneN
,	O
malondialdehyde	S-chem
and	O
advanced	O
oxidized	O
protein	O
products	O
;	O
inflammatory	O
status	O
by	O
serum	O
C	B-geneY
-	I-geneY
reactive	I-geneY
protein	E-geneY
,	O
orosomucoid	S-geneN
,	O
IL	B-geneY
-	I-geneY
2	E-geneY
and	O
IL	B-geneY
-	I-geneY
6	E-geneY
.	O

No	O
serious	O
adverse	O
event	O
was	O
observed	O
.	O

Significant	O
changes	O
were	O
observed	O
from	O
day	O
0	O
to	O
day	O
35	O
(	O
P	O
<	O
0.05	O
)	O
:	O
nutritional	O
criteria	O
improved	O
(	O
albumin	S-geneY
in	O
OO	O
;	O
albumin	S-geneY
,	O
transthyretin	S-geneY
and	O
creatinine	S-chem
in	O
SO	O
)	O
;	O
LDL	S-geneN
-	O
cholesterol	S-chem
,	O
apo	B-geneN
B	I-geneN
,	I-geneN
C	I-geneN
-	I-geneN
II	I-geneN
,	I-geneN
C	I-geneN
-	I-geneN
III	E-geneN
and	O
apo	B-geneN
A	I-geneN
-	I-geneN
I	I-geneN
/	I-geneN
A	I-geneN
-	I-geneN
II	E-geneN
ratio	O
increased	O
in	O
both	O
groups	O
.	O

HDL	S-geneN
-	O
cholesterol	S-chem
decreased	O
in	O
OO	O
;	O
apo	B-geneY
E	E-geneY
increased	O
and	O
lipoprotein	B-geneY
(	I-geneY
a	I-geneY
)	E-geneY
decreased	O
in	O
SO	O
;	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
/	O
cholesterol	S-chem
ratio	O
increased	O
in	O
OO	O
;	O
malondialdehyde	S-chem
decreased	O
in	O
both	O
groups	O
;	O
IL	B-geneY
-	I-geneY
2	E-geneY
increased	O
in	O
both	O
groups	O
.	O

The	O
between	O
-	O
group	O
comparison	O
only	O
showed	O
the	O
following	O
differences	O
:	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
/	O
cholesterol	S-chem
increased	O
in	O
OO	O
;	O
lipoprotein	B-geneY
(	I-geneY
a	I-geneY
)	E-geneY
decreased	O
in	O
SO	O
.	O

From	O
these	O
data	O
,	O
it	O
was	O
concluded	O
that	O
OO	O
-	O
and	O
SO	O
-	O
based	O
IDPNs	O
similarly	O
improved	O
nutritional	O
status	O
and	O
influenced	O
plasma	O
lipid	O
,	O
oxidative	O
,	O
inflammatory	O
and	O
immune	O
parameters	O
.	O

The	O
structure	O
and	O
properties	O
of	O
septin	B-geneY
3	E-geneY
:	O
a	O
possible	O
missing	O
link	O
in	O
septin	S-geneN
filament	O
formation	O
.	O

The	O
human	O
genome	O
codes	O
for	O
13	O
members	O
of	O
a	O
family	O
of	O
filament	O
-	O
forming	O
GTP	B-geneN
-	I-geneN
binding	I-geneN
proteins	E-geneN
known	O
as	O
septins	S-geneN
.	O

These	O
have	O
been	O
divided	O
into	O
four	O
different	O
subgroups	O
on	O
the	O
basis	O
of	O
sequence	O
similarity	O
.	O

The	O
differences	O
between	O
the	O
subgroups	O
are	O
believed	O
to	O
control	O
their	O
correct	O
assembly	O
into	O
heterofilaments	O
which	O
have	O
specific	O
roles	O
in	O
membrane	O
remodelling	O
events	O
.	O

Many	O
different	O
combinations	O
of	O
the	O
13	O
proteins	O
are	O
theoretically	O
possible	O
and	O
it	O
is	O
therefore	O
important	O
to	O
understand	O
the	O
structural	O
basis	O
of	O
specific	O
filament	O
assembly	O
.	O

However	O
,	O
three	O
-	O
dimensional	O
structures	O
are	O
currently	O
available	O
for	O
only	O
three	O
of	O
the	O
four	O
subgroups	O
.	O

In	O
the	O
present	O
study	O
we	O
describe	O
the	O
crystal	O
structure	O
of	O
a	O
construct	O
of	O
human	B-geneY
SEPT3	E-geneY
which	O
belongs	O
to	O
the	O
outstanding	O
subgroup	O
.	O

This	O
construct	O
(	O
SEPT3	S-geneY
-	O
GC	O
)	O
,	O
which	O
includes	O
the	O
GTP	B-geneN
-	I-geneN
binding	I-geneN
and	I-geneN
C	I-geneN
-	I-geneN
terminal	I-geneN
domains	E-geneN
,	O
purifies	O
as	O
a	O
nucleotide	S-chem
-	O
free	O
monomer	O
,	O
allowing	O
for	O
its	O
characterization	O
in	O
terms	O
of	O
GTP	S-chem
-	O
binding	O
and	O
hydrolysis	O
.	O

In	O
the	O
crystal	O
structure	O
,	O
SEPT3	S-geneY
-	O
GC	O
forms	O
foreshortened	O
filaments	O
which	O
employ	O
the	O
same	O
NC	O
and	O
G	O
interfaces	O
observed	O
in	O
the	O
heterotrimeric	O
complex	O
of	O
human	B-geneN
septins	I-geneN
2	I-geneN
,	I-geneN
6	I-geneN
and	I-geneN
7	E-geneN
,	O
reinforcing	O
the	O
notion	O
of	O
'	O
promiscuous	O
'	O
interactions	O
described	O
previously	O
.	O

In	O
the	O
present	O
study	O
we	O
describe	O
these	O
two	O
interfaces	O
and	O
relate	O
the	O
structure	O
to	O
its	O
tendency	O
to	O
form	O
monomers	O
and	O
its	O
efficiency	O
in	O
the	O
hydrolysis	O
of	O
GTP	S-chem
.	O

The	O
relevance	O
of	O
these	O
results	O
is	O
emphasized	O
by	O
the	O
fact	O
that	O
septins	O
from	O
the	O
SEPT3	S-geneY
subgroup	O
may	O
be	O
important	O
determinants	O
of	O
polymerization	O
by	O
occupying	O
the	O
terminal	O
position	O
in	O
octameric	O
units	O
which	O
themselves	O
form	O
the	O
building	O
blocks	O
of	O
at	O
least	O
some	O
heterofilaments	O
.	O

Efficacy	O
and	O
long	O
-	O
term	O
safety	O
of	O
alipogene	O
tiparvovec	O
(	O
AAV1	O
-	O
LPL	S-geneY
(	O
S447X	S-geneN
)	O
)	O
gene	O
therapy	O
for	O
lipoprotein	B-geneY
lipase	E-geneY
deficiency	O
:	O
an	O
open	O
-	O
label	O
trial	O
.	O

We	O
describe	O
the	O
2	O
-	O
year	O
follow	O
-	O
up	O
of	O
an	O
open	O
-	O
label	O
trial	O
(	O
CT	O
-	O
AMT	O
-	O
011	O
-	O
01	O
)	O
of	O
AAV1	O
-	O
LPL	S-geneY
(	O
S447X	S-geneN
)	O
gene	O
therapy	O
for	O
lipoprotein	B-geneY
lipase	E-geneY
(	O
LPL	S-geneY
)	O
deficiency	O
(	O
LPLD	O
)	O
,	O
an	O
orphan	O
disease	O
associated	O
with	O
chylomicronemia	O
,	O
severe	O
hypertriglyceridemia	O
,	O
metabolic	O
complications	O
and	O
potentially	O
life	O
-	O
threatening	O
pancreatitis	O
.	O

The	O
LPL	S-geneY
(	O
S447X	S-geneN
)	O
gene	O
variant	O
,	O
in	O
an	O
adeno	O
-	O
associated	O
viral	O
vector	O
of	O
serotype	O
1	O
(	O
alipogene	O
tiparvovec	O
)	O
,	O
was	O
administered	O
to	O
14	O
adult	O
LPLD	O
patients	O
with	O
a	O
prior	O
history	O
of	O
pancreatitis	O
.	O

Primary	O
objectives	O
were	O
to	O
assess	O
the	O
long	O
-	O
term	O
safety	O
of	O
alipogene	O
tiparvovec	O
and	O
achieve	O
a	O
40	O
%	O
reduction	O
in	O
fasting	O
median	O
plasma	O
triglyceride	S-chem
(	O
TG	O
)	O
at	O
3	O
-	O
12	O
weeks	O
compared	O
with	O
baseline	O
.	O

Cohorts	O
1	O
(	O
n	O
=	O
2	O
)	O
and	O
2	O
(	O
n	O
=	O
4	O
)	O
received	O
3	O
×	O
10	O
(	O
11	O
)	O
gc	O
kg	O
(	O
-	O
1	O
)	O
,	O
and	O
cohort	O
3	O
(	O
n	O
=	O
8	O
)	O
received	O
1	O
×	O
10	O
(	O
12	O
)	O
gc	O
kg	O
(	O
-	O
1	O
)	O
.	O

Cohorts	O
2	O
and	O
3	O
also	O
received	O
immunosuppressants	O
from	O
the	O
time	O
of	O
alipogene	O
tiparvovec	O
administration	O
and	O
continued	O
for	O
12	O
weeks	O
.	O

Alipogene	O
tiparvovec	O
was	O
well	O
tolerated	O
,	O
without	O
emerging	O
safety	O
concerns	O
for	O
2	O
years	O
.	O

Half	O
of	O
the	O
patients	O
demonstrated	O
a	O
40	O
%	O
reduction	O
in	O
fasting	O
TG	O
between	O
3	O
and	O
12	O
weeks	O
.	O

TG	O
subsequently	O
returned	O
to	O
baseline	O
,	O
although	O
sustained	O
LPL	S-geneY
(	O
S447X	S-geneN
)	O
expression	O
and	O
long	O
-	O
term	O
changes	O
in	O
TG	O
-	O
rich	O
lipoprotein	O
characteristics	O
were	O
noted	O
independently	O
of	O
the	O
effect	O
on	O
fasting	O
plasma	O
TG	O
.	O

Enzymatic	O
characterization	O
of	O
a	O
recombinant	O
isoform	O
hybrid	O
of	O
glutamic	B-geneN
acid	I-geneN
decarboxylase	E-geneN
(	O
rGAD67	B-geneN
/	I-geneN
65	E-geneN
)	O
expressed	O
in	O
yeast	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
Glutamic	B-geneN
acid	I-geneN
decarboxylase	E-geneN
(	O
GAD	S-geneN
,	O
EC	B-geneY
4.1.1.15	E-geneY
)	O
catalyses	O
the	O
conversion	O
of	O
glutamate	S-chem
to	O
gamma	B-chem
-	I-chem
aminobutyric	I-chem
acid	E-chem
(	O
GABA	S-chem
)	O
.	O

The	O
65	O
kDa	O
isoform	O
,	O
GAD65	S-geneY
is	O
a	O
potent	O
autoantigen	O
in	O
type	O
1	O
diabetes	O
,	O
whereas	O
GAD67	S-geneY
is	O
not	O
.	O

A	O
hybrid	O
cDNA	O
was	O
created	O
by	O
fusing	O
a	O
human	O
cDNA	O
for	O
amino	B-chem
acids	E-chem
1	O
-	O
101	O
of	O
GAD67	S-geneY
to	O
a	O
human	O
cDNA	O
for	O
amino	B-chem
acids	E-chem
96	O
-	O
585	O
of	O
GAD65	S-geneY
;	O
the	O
recombinant	O
(	O
r	O
)	O
protein	O
was	O
expressed	O
in	O
yeast	O
and	O
was	O
shown	O
to	O
have	O
equivalent	O
immunoreactivity	O
to	O
mammalian	B-geneN
brain	I-geneN
GAD	E-geneN
with	O
diabetes	O
sera	O
.	O

We	O
here	O
report	O
on	O
enzymatic	O
and	O
molecular	O
properties	O
of	O
rGAD67	B-geneN
/	I-geneN
65	E-geneN
.	O

METHODS	O
:	O
Studies	O
were	O
performed	O
on	O
enzymatic	O
activity	O
of	O
rGAD67	B-geneN
/	I-geneN
65	E-geneN
by	O
production	O
of	O
3H	B-chem
-	I-chem
GABA	E-chem
from	O
3H	B-chem
-	I-chem
glutamate	E-chem
,	O
enzyme	O
kinetics	O
,	O
binding	O
to	O
the	O
enzyme	O
cofactor	O
pyridoxal	B-chem
phosphate	E-chem
(	O
PLP	S-chem
)	O
,	O
stability	O
according	O
to	O
differences	O
in	O
pH	O
,	O
temperature	O
and	O
duration	O
of	O
storage	O
,	O
and	O
antigenic	O
reactivity	O
with	O
various	O
GAD	S-geneN
-	O
specific	O
antisera	O
.	O

RESULTS	O
:	O
The	O
properties	O
of	O
rGAD67	B-geneN
/	I-geneN
65	E-geneN
were	O
compared	O
with	O
published	O
data	O
for	O
mammalian	B-geneN
brain	I-geneN
GAD	E-geneN
(	O
brackets	O
)	O
.	O

These	O
included	O
a	O
specific	O
enzyme	O
activity	O
of	O
22.7	O
(	O
16.7	O
)	O
nKat	O
,	O
optimal	O
pH	O
for	O
enzymatic	O
activity	O
7.4	O
(	O
6.8	O
)	O
,	O
K	O
(	O
m	O
)	O
of	O
1.3	O
(	O
1.3	O
)	O
mM	O
,	O
efficient	O
non	O
-	O
covalent	O
binding	O
to	O
the	O
cofactor	O
PLP	S-chem
,	O
and	O
high	O
autoantigenic	O
potency	O
.	O

The	O
stability	O
of	O
rGAD67	B-geneN
/	I-geneN
65	E-geneN
was	O
optimal	O
over	O
3	O
months	O
at	O
-	O
80	O
degrees	O
C	O
,	O
or	O
in	O
lyophilized	O
form	O
at	O
-	O
20	O
degrees	O
C	O
.	O

CONCLUSIONS	O
:	O
Hybrid	O
rGAD67	B-geneN
/	I-geneN
65	E-geneN
has	O
enzymatic	O
and	O
other	O
properties	O
similar	O
to	O
those	O
of	O
the	O
mixed	O
isoforms	O
of	O
GAD	S-geneN
in	O
preparations	O
from	O
mammalian	O
brain	O
as	O
described	O
elsewhere	O
,	O
in	O
addition	O
to	O
its	O
previously	O
described	O
similar	O
immunoreactivity	O
.	O

Leukotriene	B-chem
D4	E-chem
induces	O
cognitive	O
impairment	O
through	O
enhancement	O
of	O
CysLT₁	B-geneY
R	E-geneY
-	O
mediated	O
amyloid	B-geneY
-	I-geneY
β	E-geneY
generation	O
in	O
mice	O
.	O

Amyloid	S-geneY
plaques	O
in	O
the	O
extracellular	O
parenchyma	O
mainly	O
consist	O
of	O
amyloid	B-geneY
-	I-geneY
β	I-geneY
peptides	E-geneY
(	O
Aβ	S-geneY
)	O
,	O
one	O
of	O
the	O
pathological	O
hallmarks	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
neuroinflammation	O
,	O
amyloidogenesis	O
,	O
and	O
memory	O
performance	O
following	O
intracerebral	O
infusions	O
of	O
leukotriene	B-chem
D4	E-chem
(	O
LTD4	S-chem
)	O
in	O
mice	O
.	O

The	O
results	O
demonstrated	O
that	O
intracerebral	O
infusions	O
of	O
LTD4	S-chem
(	O
1	O
ng	O
/	O
mouse	O
)	O
produced	O
memory	O
impairment	O
as	O
determined	O
by	O
Morris	O
water	O
maze	O
test	O
and	O
Y	O
-	O
maze	O
test	O
in	O
mice	O
,	O
and	O
caused	O
the	O
accumulation	O
of	O
Aβ1	B-geneY
-	I-geneY
40	E-geneY
and	O
Aβ1	B-geneY
-	I-geneY
42	E-geneY
in	O
the	O
hippocampus	O
and	O
cortex	O
through	O
increased	O
activity	O
of	O
β	O
-	O
and	O
γ	O
-	O
secretases	O
accompanied	O
with	O
increased	O
expression	O
of	O
amyloid	B-geneY
precursor	I-geneY
protein	E-geneY
(	O
APP	S-geneY
)	O
.	O

LTD4	S-chem
also	O
induced	O
expression	O
of	O
cysteinyl	B-geneY
leukotriene	I-geneY
receptor	I-geneY
1	E-geneY
(	O
CysLT	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
R	E-geneY
)	O
and	O
NF	B-geneN
-	I-geneN
κB	E-geneN
p65	S-geneY
in	O
the	O
hippocampus	O
and	O
cortex	O
.	O

Pretreatment	O
with	O
pranlukast	S-chem
(	O
1.5	O
ng	O
/	O
mouse	O
,	O
intracerebroventricularly	O
)	O
,	O
a	O
CysLT	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
R	E-geneY
antagonist	O
,	O
blocked	O
LTD4	S-chem
-	O
induced	O
amyloidogenesis	O
,	O
memory	O
deficits	O
.	O

Pranlukast	S-chem
(	O
0.6	O
μM	O
)	O
also	O
prevented	O
LTD4	S-chem
(	O
20	O
nM	O
)	O
-	O
induced	O
amyloidogenesis	O
in	O
the	O
cultured	O
neurons	O
in	O
vitro	O
.	O

Moreover	O
,	O
LTD4	S-chem
-	O
induced	O
increases	O
in	O
CysLT	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
R	E-geneY
and	O
NF	B-geneN
-	I-geneN
κB	E-geneN
p65	S-geneY
in	O
the	O
brain	O
were	O
also	O
attenuated	O
by	O
pranlukast	S-chem
.	O

These	O
results	O
suggest	O
that	O
LTD4	S-chem
increases	O
Aβ	B-geneY
peptide	E-geneY
burden	O
via	O
activation	O
of	O
CysLT	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
R	E-geneY
,	O
which	O
further	O
affects	O
APP	S-geneY
levels	O
and	O
activity	O
of	O
β	O
-	O
and	O
γ	O
-	O
secretases	O
via	O
the	O
NF	B-geneN
-	I-geneN
κB	E-geneN
pathway	O
.	O

Our	O
findings	O
identify	O
CysLT	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
R	E-geneY
signaling	O
as	O
a	O
novel	O
proinflammatory	O
and	O
proamyloidogenic	O
pathway	O
,	O
and	O
suggest	O
a	O
rationale	O
for	O
development	O
of	O
therapeutics	O
targeting	O
the	O
CysLT	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
R	E-geneY
in	O
neuroinflammatory	O
diseases	O
such	O
as	O
AD	O
.	O

Quantification	O
and	O
regulation	O
of	O
the	O
subcellular	O
distribution	O
of	O
bile	B-geneY
acid	I-geneY
coenzyme	I-geneY
A	I-geneY
:	I-geneY
amino	I-geneY
acid	I-geneY
N	I-geneY
-	I-geneY
acyltransferase	E-geneY
activity	O
in	O
rat	O
liver	O
.	O

Bile	B-geneY
acid	I-geneY
coenzyme	I-geneY
A	I-geneY
:	I-geneY
amino	I-geneY
acid	I-geneY
N	I-geneY
-	I-geneY
acyltransferase	E-geneY
(	O
BAT	S-geneY
)	O
is	O
responsible	O
for	O
the	O
amidation	O
of	O
bile	B-chem
acids	E-chem
with	O
the	O
amino	B-chem
acids	E-chem
glycine	S-chem
and	O
taurine	S-chem
.	O

To	O
quantify	O
total	O
BAT	S-geneY
activity	O
in	O
liver	O
subcellular	O
organelles	O
,	O
livers	O
from	O
young	O
adult	O
male	O
and	O
female	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
fractionated	O
into	O
multiple	O
subcellular	O
compartments	O
.	O

In	O
male	O
and	O
female	O
rats	O
,	O
65	O
-	O
75	O
%	O
of	O
total	O
liver	O
BAT	S-geneY
activity	O
was	O
found	O
in	O
the	O
cytosol	O
,	O
15	O
-	O
17	O
%	O
was	O
found	O
in	O
the	O
peroxisomes	O
,	O
and	O
5	O
-	O
10	O
%	O
was	O
found	O
in	O
the	O
heavy	O
mitochondrial	O
fraction	O
.	O

After	O
clofibrate	O
treatment	O
,	O
male	O
rats	O
displayed	O
an	O
increase	O
in	O
peroxisomal	O
BAT	S-geneY
specific	O
activity	O
and	O
a	O
decrease	O
in	O
cytosolic	O
BAT	S-geneY
specific	O
activity	O
,	O
whereas	O
females	O
showed	O
an	O
opposite	O
response	O
.	O

However	O
,	O
there	O
was	O
no	O
overall	O
change	O
in	O
BAT	S-geneY
specific	O
activity	O
in	O
whole	O
liver	O
homogenate	O
.	O

Treatment	O
with	O
rosiglitazone	S-chem
or	O
cholestyramine	S-chem
had	O
no	O
effect	O
on	O
BAT	S-geneY
activity	O
in	O
any	O
subcellular	O
compartment	O
.	O

These	O
experiments	O
indicate	O
that	O
the	O
majority	O
of	O
BAT	S-geneY
activity	O
in	O
the	O
rat	O
liver	O
resides	O
in	O
the	O
cytosol	O
.	O

Approximately	O
15	O
%	O
of	O
BAT	S-geneY
activity	O
is	O
present	O
in	O
the	O
peroxisomal	O
matrix	O
.	O

These	O
data	O
support	O
the	O
novel	O
finding	O
that	O
clofibrate	S-chem
treatment	O
does	O
not	O
directly	O
regulate	O
BAT	S-geneY
activity	O
but	O
does	O
alter	O
the	O
subcellular	O
localization	O
of	O
BAT	S-geneY
.	O

Differential	O
responses	O
to	O
ω	B-geneY
-	I-geneY
agatoxin	I-geneY
IVA	E-geneY
in	O
murine	O
frontal	O
cortex	O
and	O
spinal	O
cord	O
derived	O
neuronal	O
networks	O
.	O

ω	B-geneY
-	I-geneY
Agatoxin	I-geneY
-	I-geneY
IVA	E-geneY
is	O
a	O
well	O
known	O
P	B-geneN
/	I-geneN
Q	I-geneN
-	I-geneN
type	I-geneN
Ca	I-geneN
(	I-geneN
2	I-geneN
+	I-geneN
)	I-geneN
channel	E-geneN
blocker	O
and	O
has	O
been	O
shown	O
to	O
affect	O
presynaptic	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
currents	O
as	O
well	O
postsynaptic	O
potentials	O
.	O

P	B-geneN
/	I-geneN
Q	I-geneN
-	I-geneN
type	I-geneN
voltage	I-geneN
gated	I-geneN
Ca	I-geneN
(	I-geneN
2	I-geneN
+	I-geneN
)	I-geneN
channels	E-geneN
play	O
a	O
vital	O
role	O
in	O
presynaptic	O
neurotransmitter	O
release	O
and	O
thus	O
play	O
a	O
role	O
in	O
action	O
potential	O
generation	O
.	O

Monitoring	O
spontaneous	O
activity	O
of	O
neuronal	O
networks	O
on	O
microelectrode	O
arrays	O
(	O
MEAs	O
)	O
provides	O
an	O
important	O
tool	O
for	O
examining	O
this	O
neurotoxin	O
.	O

Changes	O
in	O
extracellular	O
action	O
potentials	O
are	O
readily	O
observed	O
and	O
are	O
dependent	O
on	O
synaptic	O
function	O
.	O

Given	O
the	O
efficacy	O
of	O
murine	O
frontal	O
cortex	O
and	O
spinal	O
cord	O
networks	O
to	O
detect	O
neuroactive	O
substances	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
ω	B-geneN
-	I-geneN
agatoxin	E-geneN
on	O
spontaneous	O
action	O
potential	O
firing	O
within	O
these	O
networks	O
.	O

We	O
found	O
that	O
networks	O
derived	O
from	O
spinal	O
cord	O
are	O
more	O
sensitive	O
to	O
the	O
toxin	O
than	O
those	O
from	O
frontal	O
cortex	O
;	O
a	O
concentration	O
of	O
only	O
10nM	O
produced	O
statistically	O
significant	O
effects	O
on	O
activity	O
from	O
spinal	O
cord	O
networks	O
whereas	O
50nM	O
was	O
required	O
to	O
alter	O
activity	O
in	O
frontal	O
cortex	O
networks	O
.	O

Furthermore	O
,	O
the	O
effects	O
of	O
the	O
toxin	O
on	O
frontal	O
cortex	O
are	O
more	O
complex	O
as	O
unit	O
specific	O
responses	O
were	O
observed	O
.	O

These	O
manifested	O
as	O
either	O
a	O
decrease	O
or	O
increase	O
in	O
action	O
potential	O
firing	O
rate	O
which	O
could	O
be	O
statistically	O
separated	O
as	O
unique	O
clusters	O
.	O

Administration	O
of	O
bicuculline	S-chem
,	O
a	O
GABAA	S-geneN
inhibitor	O
,	O
isolated	O
a	O
single	O
response	O
to	O
ω	B-geneN
-	I-geneN
agatoxin	E-geneN
,	O
which	O
was	O
characterized	O
by	O
a	O
reduction	O
in	O
network	O
activity	O
.	O

These	O
data	O
support	O
the	O
notion	O
that	O
the	O
two	O
clusters	O
detected	O
with	O
ω	B-geneN
-	I-geneN
agatoxin	E-geneN
exposure	O
represent	O
differential	O
responses	O
from	O
excitatory	O
and	O
inhibitory	O
neuronal	O
populations	O
.	O

Properties	O
of	O
purified	O
recombinant	O
human	B-geneN
polyamine	I-geneN
oxidase	E-geneN
,	O
PAOh1	S-geneY
/	O
SMO	S-geneY
.	O

The	O
discovery	O
of	O
an	O
inducible	O
oxidase	S-geneN
whose	O
apparent	O
substrate	O
preference	O
is	O
spermine	S-chem
indicates	O
that	O
polyamine	S-chem
catabolism	O
is	O
more	O
complex	O
than	O
that	O
originally	O
proposed	O
.	O

To	O
facilitate	O
the	O
study	O
of	O
this	O
enzyme	O
,	O
the	O
purification	O
and	O
characterization	O
of	O
the	O
recombinant	O
human	B-geneY
PAOh1	E-geneY
/	O
SMO	S-geneY
polyamine	B-geneN
oxidase	E-geneN
are	O
reported	O
.	O

Purified	O
PAOh1	S-geneY
/	O
SMO	S-geneY
oxidizes	O
both	O
spermine	S-chem
(	O
K	O
(	O
m	O
)	O
=	O
1.6	O
microM	O
)	O
and	O
N	B-chem
(	I-chem
1	I-chem
)	I-chem
-	I-chem
acetylspermine	E-chem
(	O
K	O
(	O
m	O
)	O
=	O
51	O
microM	O
)	O
,	O
but	O
does	O
not	O
oxidize	O
spermidine	S-chem
.	O

The	O
purified	O
human	O
enzyme	O
also	O
does	O
not	O
oxidize	O
eight	O
representative	O
antitumor	O
polyamine	S-chem
analogues	O
;	O
however	O
,	O
specific	O
oligamine	O
analogues	O
were	O
found	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
oxidation	O
of	O
spermine	S-chem
by	O
PAOh1	S-geneY
/	O
SMO	S-geneY
.	O

The	O
results	O
of	O
these	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
PAOh1	S-geneY
/	O
SMO	S-geneY
represents	O
a	O
new	O
addition	O
to	O
the	O
polyamine	S-chem
metabolic	O
pathway	O
that	O
may	O
represent	O
a	O
new	O
target	O
for	O
antineoplastic	O
drug	O
development	O
.	O

Ectopic	O
Thyroid	O
Tissue	O
in	O
the	O
Adrenal	O
Gland	O
:	O
Report	O
of	O
2	O
Cases	O
with	O
Pathogenetic	O
Implications	O
.	O

Background	O
:	O
Ectopic	O
thyroid	O
tissue	O
is	O
usually	O
found	O
anywhere	O
along	O
the	O
embryonic	O
descent	O
pathway	O
of	O
the	O
medial	O
thyroid	O
anlage	O
from	O
the	O
tongue	O
to	O
the	O
trachea	O
(	O
Wölfler	O
area	O
)	O
.	O

However	O
,	O
ectopic	O
thyroid	O
tissue	O
in	O
the	O
adrenal	O
gland	O
(	O
ETTAG	O
)	O
is	O
not	O
easy	O
to	O
understand	O
on	O
the	O
basis	O
of	O
thyroid	O
embryology	O
;	O
because	O
it	O
is	O
so	O
rare	O
,	O
the	O
possibility	O
of	O
metastasis	O
should	O
first	O
be	O
considered	O
.	O

Here	O
,	O
we	O
describe	O
2	O
cases	O
of	O
ETTAG	O
with	O
pathogenetic	O
implications	O
and	O
review	O
the	O
literature	O
.	O

Patient	O
findings	O
:	O
Two	O
cases	O
of	O
ETTAG	O
presented	O
as	O
incidental	O
cystic	O
adrenal	O
masses	O
in	O
adult	O
females	O
,	O
one	O
having	O
a	O
congenital	O
hernia	O
of	O
Morgagni	O
.	O

The	O
ETTAG	O
was	O
histologically	O
indistinguishable	O
from	O
normal	O
orthotopic	O
thyroid	O
tissue	O
,	O
and	O
its	O
follicular	O
nature	O
was	O
confirmed	O
by	O
immunohistochemical	O
positivity	O
for	O
thyroglobulin	S-geneY
,	O
thyroperoxidase	S-geneY
,	O
thyroid	B-geneY
transcription	I-geneY
factor	I-geneY
-	I-geneY
1	E-geneY
(	O
TTF	B-geneY
-	I-geneY
1	E-geneY
/	O
Titf	B-geneY
-	I-geneY
1	E-geneY
/	O
Nkx2.1	S-geneY
)	O
,	O
cytokeratin	S-geneN
(	O
CK	S-geneN
)	O
AE1	O
/	O
AE3	O
,	O
CK	B-geneY
7	E-geneY
,	O
pendrin	S-geneY
,	O
human	B-geneY
sodium	I-geneY
iodide	I-geneY
symporter	E-geneY
(	O
hNIS	S-geneY
)	O
,	O
paired	B-geneY
box	I-geneY
gene	I-geneY
8	E-geneY
(	O
PAX8	S-geneY
)	O
and	O
FOXE1	S-geneY
(	O
TTF	B-geneY
-	I-geneY
2	E-geneY
)	O
,	O
as	O
well	O
as	O
positivity	O
for	O
the	O
messenger	O
RNA	O
of	O
the	O
thyroglobulin	S-geneY
gene	O
by	O
in	O
situ	O
hybridization	O
analysis	O
.	O

No	O
C	O
cells	O
(	O
negativity	O
for	O
calcitonin	S-geneY
,	O
cromogranin	S-geneN
and	O
synaptophysin	S-geneY
)	O
were	O
present	O
.	O

Neither	O
BRAF	S-geneY
nor	O
KRAS	S-geneY
mutations	O
were	O
detected	O
with	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Further	O
work	O
-	O
up	O
did	O
not	O
show	O
evidence	O
of	O
thyroid	O
malignancy	O
.	O

Summary	O
:	O
ETTAG	O
is	O
a	O
rare	O
finding	O
,	O
with	O
only	O
7	O
cases	O
reported	O
;	O
women	O
are	O
much	O
more	O
frequently	O
affected	O
than	O
men	O
(	O
8	O
:	O
1	O
)	O
and	O
it	O
usually	O
clinically	O
presents	O
in	O
the	O
fifth	O
decade	O
(	O
mean	O
age	O
:	O
54	O
,	O
range	O
:	O
38	O
-	O
67	O
)	O
as	O
a	O
cystic	O
adrenal	O
mass	O
incidentally	O
discovered	O
on	O
abdominal	O
ultrasonography	O
and	O
/	O
or	O
in	O
computed	O
tomography	O
images	O
.	O

ETTAG	O
is	O
composed	O
of	O
normal	O
follicular	O
cells	O
without	O
C	O
cells	O
.	O

The	O
expression	O
of	O
some	O
transcription	O
factors	O
(	O
TTF	B-geneY
-	I-geneY
1	E-geneY
,	O
PAX8	S-geneY
and	O
FOXE1	S-geneY
)	O
involved	O
in	O
development	O
and	O
/	O
or	O
migration	O
of	O
the	O
medial	O
thyroid	O
anlage	O
is	O
preserved	O
.	O

Coexistence	O
of	O
a	O
congenital	O
hernia	O
of	O
Morgagni	O
in	O
one	O
patient	O
suggests	O
an	O
over	O
-	O
descent	O
of	O
medial	O
thyroid	O
anlage	O
derived	O
cells	O
in	O
its	O
pathogenesis	O
.	O

Conclusion	O
:	O
Although	O
ETTAG	O
pathogenesis	O
remains	O
unknown	O
,	O
the	O
lack	O
of	O
C	O
cells	O
together	O
with	O
the	O
coexistence	O
of	O
a	O
congenital	O
defect	O
of	O
the	O
anterior	O
diaphragm	O
(	O
hernia	O
of	O
Morgagni	O
)	O
in	O
one	O
of	O
our	O
patients	O
could	O
suggest	O
an	O
over	O
-	O
descent	O
of	O
medial	O
thyroid	O
anlagen	O
derived	O
cells	O
in	O
the	O
origin	O
of	O
this	O
heterotopia	O
.	O

Pharmacological	O
modulation	O
of	O
nerve	B-geneY
growth	I-geneY
factor	E-geneY
synthesis	O
:	O
a	O
mechanistic	O
comparison	O
of	O
vitamin	B-geneY
D	I-geneY
receptor	E-geneY
and	O
beta	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
agonists	O
.	O

Increasing	O
nerve	B-geneY
growth	I-geneY
factor	E-geneY
(	O
NGF	S-geneY
)	O
in	O
the	O
PNS	O
is	O
a	O
rational	O
strategy	O
for	O
treating	O
certain	O
neurodegenerative	O
disorders	O
.	O

The	O
present	O
studies	O
were	O
undertaken	O
to	O
compare	O
two	O
compounds	O
,	O
a	O
vitamin	B-chem
D	I-chem
(	I-chem
3	I-chem
)	E-chem
analogue	O
(	O
CB1093	S-chem
)	O
with	O
minimal	O
calcaemic	O
effects	O
,	O
and	O
clenbuterol	S-chem
,	O
a	O
long	O
-	O
acting	O
beta	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
agonist	O
,	O
both	O
of	O
which	O
induce	O
NGF	S-geneY
synthesis	O
in	O
vivo	O
.	O

Clenbuterol	S-chem
caused	O
significant	O
increases	O
in	O
both	O
NGF	S-geneY
mRNA	O
and	O
protein	O
in	O
3T3	O
cells	O
;	O
with	O
maxima	O
at	O
10	O
nM	O
and	O
at	O
8	O
-	O
12	O
h	O
exposure	O
.	O

Effects	O
of	O
clenbuterol	S-chem
on	O
NGF	S-geneY
mRNA	O
were	O
antagonized	O
by	O
propranolol	S-chem
.	O

Mobility	O
shift	O
assays	O
on	O
whole	O
cell	O
extracts	O
showed	O
that	O
clenbuterol	S-chem
increased	O
AP1	S-geneY
binding	O
in	O
3T3	O
cells	O
prior	O
to	O
increasing	O
NGF	S-geneY
synthesis	O
.	O

Clenbuterol	S-chem
was	O
without	O
effect	O
on	O
NGF	S-geneY
mRNA	O
levels	O
in	O
L929	O
cells	O
,	O
whereas	O
CB1093	S-chem
caused	O
significant	O
increases	O
in	O
both	O
NGF	S-geneY
mRNA	O
and	O
protein	O
levels	O
in	O
both	O
3T3	O
and	O
L929	O
cells	O
.	O

Stimulation	O
was	O
almost	O
maximal	O
at	O
24	O
h	O
exposure	O
and	O
was	O
sustained	O
for	O
at	O
least	O
72	O
h	O
.	O

The	O
magnitude	O
of	O
the	O
increase	O
was	O
much	O
greater	O
in	O
L929	O
(	O
700	O
%	O
increase	O
)	O
than	O
in	O
3T3	O
cells	O
(	O
80	O
%	O
)	O
.	O

Binding	O
to	O
the	O
vitamin	B-geneY
D	I-geneY
nuclear	I-geneY
receptor	E-geneY
(	O
VDR	S-geneY
)	O
,	O
which	O
acts	O
as	O
a	O
transcription	O
factor	O
itself	O
,	O
was	O
increased	O
as	O
early	O
as	O
30	O
min	O
after	O
exposure	O
to	O
of	O
CB1093	S-chem
and	O
maintained	O
up	O
to	O
24	O
h	O
.	O

Increased	O
VDR	S-geneY
binding	O
preceded	O
increased	O
NGF	S-geneY
mRNA	O
.	O

A	O
150	O
%	O
increase	O
in	O
AP	B-geneY
-	I-geneY
1	E-geneY
binding	O
was	O
also	O
evident	O
.	O

This	O
study	O
demonstrates	O
that	O
CB1093	S-chem
and	O
clenbuterol	S-chem
stimulate	O
NGF	S-geneY
levels	O
in	O
vitro	O
and	O
that	O
AP	B-geneY
-	I-geneY
1	E-geneY
binding	O
could	O
be	O
a	O
commonality	O
between	O
the	O
mechanism	O
of	O
NGF	S-geneY
induction	O
of	O
these	O
two	O
compounds	O
.	O

Heterogeneous	O
expression	O
and	O
polymorphic	O
genotype	O
of	O
glutathione	B-geneN
S	I-geneN
-	I-geneN
transferases	E-geneN
in	O
human	O
lung	O
.	O

BACKGROUND	O
:	O
Glutathione	B-geneN
S	I-geneN
-	I-geneN
transferases	E-geneN
(	O
GSTs	S-geneN
)	O
are	O
involved	O
in	O
the	O
detoxification	O
of	O
xenobiotics	O
by	O
conjugation	O
with	O
glutathione	S-chem
.	O

One	O
of	O
the	O
mu	O
class	O
genes	O
of	O
this	O
superfamily	O
of	O
enzymes	O
,	O
GSTM1	S-geneY
,	O
is	O
polymorphic	O
because	O
of	O
a	O
partial	O
gene	O
deletion	O
.	O

This	O
results	O
in	O
a	O
failure	O
to	O
express	O
GSTM1	S-geneY
in	O
approximately	O
50	O
%	O
of	O
individuals	O
.	O

Several	O
studies	O
have	O
linked	O
GSTM1	S-geneY
null	O
status	O
to	O
an	O
increased	O
risk	O
of	O
lung	O
carcinoma	O
.	O

This	O
study	O
investigated	O
the	O
expression	O
and	O
distribution	O
of	O
GST	S-geneN
isoenzymes	O
in	O
human	O
lung	O
,	O
and	O
developed	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
which	O
would	O
allow	O
genotyping	O
of	O
archival	O
,	O
paraffin	O
embedded	O
lung	O
tissue	O
.	O

METHODS	O
:	O
Distribution	O
was	O
examined	O
using	O
a	O
panel	O
of	O
polyclonal	O
anti	O
-	O
GST	S-geneN
antibodies	O
for	O
immunohistochemistry	O
in	O
normal	O
tissue	O
of	O
21	O
tumour	O
-	O
bearing	O
lungs	O
.	O

DNA	O
for	O
PCR	O
was	O
extracted	O
from	O
paraffin	O
blocks	O
and	O
a	O
control	O
group	O
of	O
350	O
blood	O
lysates	O
.	O

As	O
a	O
positive	O
control	O
each	O
assay	O
amplified	O
part	O
of	O
GSTM4	S-geneY
,	O
a	O
mu	O
class	O
gene	O
which	O
is	O
not	O
polymorphic	O
but	O
which	O
shows	O
strong	O
sequence	O
homology	O
to	O
GSTM1	S-geneY
.	O

The	O
presence	O
of	O
GST	S-geneN
in	O
bronchoalveolar	O
lavage	O
fluid	O
was	O
sought	O
by	O
Western	O
analysis	O
.	O

RESULTS	O
:	O
Proximal	O
airways	O
contained	O
pi	B-geneY
class	I-geneY
GST	E-geneY
,	O
alpha	B-geneN
class	I-geneN
GST	E-geneN
,	O
and	O
mu	B-geneN
class	I-geneN
GST	E-geneN
with	O
expression	O
concentrated	O
in	O
the	O
brush	O
border	O
.	O

In	O
distal	O
airspaces	O
no	O
alpha	B-geneN
GST	E-geneN
was	O
expressed	O
but	O
pi	B-geneY
GST	E-geneY
and	O
mu	B-geneN
GST	E-geneN
were	O
present	O
in	O
alveolar	O
cells	O
and	O
also	O
alveolar	O
macrophages	O
.	O

Pi	B-geneY
class	I-geneY
GST	E-geneY
was	O
present	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

The	O
PCR	O
assay	O
enabled	O
genotypic	O
determination	O
using	O
DNA	O
extracted	O
from	O
archival	O
material	O
.	O

Of	O
the	O
control	O
group	O
56	O
%	O
were	O
null	O
at	O
the	O
GSTM1	S-geneY
locus	O
.	O

CONCLUSIONS	O
:	O
The	O
distribution	O
of	O
GST	S-geneN
isoenzymes	O
in	O
the	O
lung	O
is	O
heterogeneous	O
with	O
an	O
apparent	O
decrease	O
in	O
GST	S-geneN
in	O
distal	O
lung	O
.	O

Since	O
GSTM1	S-geneY
status	O
has	O
already	O
been	O
associated	O
with	O
susceptibility	O
to	O
disease	O
,	O
the	O
PCR	O
assay	O
developed	O
will	O
allow	O
further	O
studies	O
of	O
the	O
relation	O
between	O
genotype	O
and	O
structural	O
disorders	O
in	O
the	O
lung	O
using	O
archival	O
pathological	O
material	O
.	O

Critical	O
amino	B-chem
acids	E-chem
in	O
phosphodiesterase	B-geneY
-	I-geneY
5	E-geneY
catalytic	O
site	O
that	O
provide	O
for	O
high	O
-	O
affinity	O
interaction	O
with	O
cyclic	B-chem
guanosine	I-chem
monophosphate	E-chem
and	O
inhibitors	O
.	O

The	O
molecular	O
bases	O
for	O
phosphodiesterase	B-geneY
5	E-geneY
(	O
PDE5	S-geneY
)	O
catalytic	O
-	O
site	O
affinity	O
for	O
cyclic	B-chem
guanosine	I-chem
monophosphate	E-chem
(	O
cGMP	S-chem
)	O
and	O
potency	O
of	O
inhibitors	O
are	O
poorly	O
understood	O
.	O

Cocrystal	O
structures	O
of	O
PDE5	B-geneN
catalytic	I-geneN
(	I-geneN
C	I-geneN
)	I-geneN
domain	E-geneN
with	O
inhibitors	O
reveal	O
a	O
hydrogen	S-chem
bond	O
and	O
hydrophobic	O
interactions	O
with	O
Tyr	S-chem
-	O
612	O
,	O
hydrogen	S-chem
bonds	O
with	O
Gln	S-chem
-	O
817	O
,	O
a	O
hydrophobic	O
clamp	O
formed	O
by	O
Phe	S-chem
-	O
820	O
and	O
Val	S-chem
-	O
782	O
,	O
and	O
contacts	O
with	O
His	S-chem
-	O
613	O
,	O
Leu	S-chem
-	O
765	O
,	O
and	O
Phe	S-chem
-	O
786	O
[	O
Sung	O
et	O
al	O
.	O

(	O
2003	O
)	O
Nature	O
425	O
,	O
98	O
-	O
102	O
;	O
Huai	O
et	O
al	O
.	O

(	O
2004	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

279	O
,	O
13095	O
-	O
13101	O
]	O
.	O

Present	O
results	O
of	O
point	O
mutations	O
of	O
full	O
-	O
length	O
PDE5	S-geneY
showed	O
that	O
maximum	O
catalysis	O
was	O
decreased	O
2650	O
-	O
fold	O
in	O
H613A	S-geneN
and	O
55	O
-	O
fold	O
in	O
F820A	S-geneN
.	O

Catalytic	O
-	O
site	O
affinities	O
for	O
cGMP	S-chem
,	O
vardenafil	S-chem
,	O
sildenafil	S-chem
,	O
tadalafil	S-chem
,	O
or	O
3	B-chem
-	I-chem
isobutyl	I-chem
-	I-chem
1	I-chem
-	I-chem
methylxanthine	E-chem
(	O
IBMX	S-chem
)	O
were	O
respectively	O
weakened	O
14	O
-	O
,	O
123	O
-	O
,	O
30	O
-	O
,	O
51	O
-	O
,	O
and	O
43	O
-	O
fold	O
for	O
Y612A	S-geneN
;	O
63	O
-	O
,	O
511	O
-	O
,	O
43	O
-	O
,	O
95	O
-	O
and	O
61	O
-	O
fold	O
for	O
Q817A	S-geneN
;	O
and	O
59	O
-	O
,	O
448	O
-	O
,	O
71	O
-	O
,	O
137	O
-	O
,	O
and	O
93	O
-	O
fold	O
for	O
F820A	S-geneN
.	O

The	O
data	O
indicate	O
that	O
these	O
three	O
amino	B-chem
acids	E-chem
are	O
major	O
determinants	O
of	O
affinity	O
for	O
cGMP	S-chem
and	O
potency	O
of	O
selective	O
and	O
nonselective	O
inhibitors	O
,	O
and	O
that	O
higher	O
vardenafil	S-chem
potency	O
over	O
sildenafil	S-chem
and	O
tadalafil	S-chem
results	O
from	O
stronger	O
contacts	O
with	O
Tyr	S-chem
-	O
612	O
,	O
Gln	S-chem
-	O
817	O
,	O
and	O
Phe	S-chem
-	O
820	O
.	O

Affinity	O
of	O
V782A	S-geneN
for	O
cGMP	S-chem
,	O
vardenafil	S-chem
,	O
sildenafil	S-chem
,	O
tadalafil	S-chem
,	O
or	O
IBMX	S-chem
was	O
reduced	O
5.5	O
-	O
,	O
23	O
-	O
,	O
10	O
-	O
,	O
3	O
-	O
,	O
and	O
12	O
-	O
fold	O
,	O
respectively	O
.	O

Change	O
in	O
affinity	O
for	O
cGMP	S-chem
,	O
vardenafil	S-chem
,	O
sildenafil	S-chem
,	O
or	O
IBMX	S-chem
in	O
Y612F	S-geneN
,	O
H613A	S-geneN
,	O
L765A	S-geneN
,	O
or	O
F786A	S-geneN
was	O
less	O
,	O
but	O
affinity	O
of	O
H613A	S-geneN
or	O
F786A	S-geneN
for	O
tadalafil	S-chem
was	O
weakened	O
37	O
-	O
and	O
17	O
-	O
fold	O
,	O
respectively	O
.	O

The	O
results	O
quantify	O
the	O
role	O
of	O
PDE5	S-geneY
catalytic	O
-	O
site	O
residues	O
for	O
cGMP	S-chem
and	O
inhibitors	O
,	O
indicate	O
that	O
Tyr	S-chem
-	O
612	O
,	O
Gln	S-chem
-	O
817	O
,	O
and	O
Phe	S-chem
-	O
820	O
are	O
the	O
most	O
important	O
cGMP	S-chem
or	O
inhibitor	O
contacts	O
studied	O
,	O
and	O
identify	O
residues	O
that	O
contribute	O
to	O
selectivity	O
among	O
different	O
classes	O
of	O
inhibitors	O
.	O

Inhibition	O
of	O
MCP	B-geneY
-	I-geneY
1	E-geneY
and	O
MIP	B-geneY
-	I-geneY
2	E-geneY
transcription	O
and	O
translation	O
by	O
mimosine	S-chem
in	O
muscle	O
tissue	O
infected	O
with	O
the	O
parasite	O
Trichinella	O
spiralis	O
.	O

Mimosine	S-chem
is	O
a	O
non	O
-	O
toxic	O
plant	O
aminoacid	S-chem
which	O
is	O
an	O
effective	O
inhibitor	O
of	O
DNA	O
replication	O
by	O
acting	O
at	O
the	O
S	O
-	O
phase	O
.	O

In	O
this	O
study	O
we	O
infected	O
mice	O
with	O
T.	O
spiralis	O
,	O
a	O
nematode	O
parasite	O
,	O
and	O
studied	O
the	O
inflammatory	O
response	O
through	O
the	O
determination	O
of	O
MIP	B-geneY
-	I-geneY
2	E-geneY
,	O
a	O
C	B-geneN
-	I-geneN
X	I-geneN
-	I-geneN
C	I-geneN
chemokine	E-geneN
and	O
MCP	B-geneY
-	I-geneY
1	E-geneY
,	O
a	O
C	B-geneN
-	I-geneN
C	I-geneN
chemokine	E-geneN
in	O
the	O
inflamed	O
area	O
around	O
the	O
parasitic	O
cyst	O
.	O

The	O
animals	O
were	O
infected	O
and	O
their	O
diaphragms	O
were	O
tested	O
for	O
inflammatory	O
response	O
.	O

MCP	B-geneY
-	I-geneY
1	E-geneY
and	O
MIP	B-geneY
-	I-geneY
2	E-geneY
was	O
tested	O
after	O
1	O
,	O
10	O
,	O
20	O
,	O
30	O
,	O
and	O
40	O
days	O
post	O
inoculation	O
,	O
before	O
and	O
after	O
mimosine	S-chem
treatment	O
.	O

The	O
inflammatory	O
index	O
was	O
calculated	O
by	O
counting	O
the	O
white	O
blood	O
cells	O
around	O
the	O
nematode	O
cysts	O
,	O
while	O
expression	O
of	O
MIP	B-geneY
-	I-geneY
2	E-geneY
and	O
MCP	B-geneY
-	I-geneY
1	E-geneY
was	O
calculated	O
by	O
ELISA	O
method	O
and	O
transcription	O
by	O
Northern	O
blot	O
and	O
RT	O
-	O
PCR	O
.	O

Here	O
we	O
found	O
that	O
mimosine	S-chem
strongly	O
inhibited	O
the	O
inflammatory	O
index	O
in	O
the	O
diaphragmatic	O
tissue	O
at	O
10	O
,	O
20	O
,	O
30	O
and	O
40	O
days	O
post	O
-	O
treatment	O
.	O

In	O
these	O
experiments	O
,	O
mimosine	S-chem
had	O
no	O
effect	O
on	O
the	O
number	O
of	O
cysts	O
produced	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
MCP	B-geneY
-	I-geneY
1	E-geneY
transcription	O
and	O
translation	O
was	O
completely	O
inhibited	O
by	O
mimosine	S-chem
,	O
while	O
MIP	B-geneY
-	I-geneY
2	E-geneY
transcription	O
and	O
translation	O
was	O
partially	O
inhibited	O
at	O
30	O
and	O
40	O
days	O
;	O
yet	O
it	O
was	O
totally	O
inhibited	O
after	O
10	O
and	O
20	O
days	O
in	O
encysted	O
diaphragm	O
tissue	O
infected	O
by	O
T.	O
spiralis	O
.	O

Our	O
studies	O
suggest	O
that	O
mimosine	S-chem
has	O
an	O
inhibitory	O
effect	O
through	O
the	O
inhibition	O
of	O
cytoplasmatic	O
serine	O
hydroxymethyltransferase	O
altering	O
the	O
cell	O
cycle	O
of	O
white	O
blood	O
cells	O
.	O

This	O
study	O
suggests	O
for	O
the	O
first	O
time	O
the	O
premise	O
that	O
mimosine	S-chem
acts	O
as	O
an	O
anti	O
-	O
inflammatory	O
compound	O
.	O

ATP	B-geneY
-	I-geneY
binding	I-geneY
cassette	I-geneY
transporter	I-geneY
A1	E-geneY
is	O
involved	O
in	O
hepatic	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
secretion	O
.	O

Vitamin	B-chem
E	E-chem
(	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
)	O
is	O
an	O
essential	O
fat	O
-	O
soluble	O
nutrient	O
with	O
antioxidant	O
properties	O
.	O
alpha	B-geneY
-	I-geneY
Tocopherol	I-geneY
transfer	I-geneY
protein	E-geneY
(	O
alpha	B-geneY
-	I-geneY
TTP	E-geneY
)	O
,	O
the	O
product	O
of	O
the	O
gene	O
responsible	O
for	O
familial	O
isolated	O
vitamin	B-chem
E	E-chem
deficiency	O
,	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
plasma	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
level	O
by	O
mediating	O
the	O
secretion	O
of	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
by	O
the	O
liver	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
hepatic	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
secretion	O
are	O
not	O
fully	O
understood	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
elucidate	O
the	O
mechanism	O
of	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
re	O
-	O
efflux	O
from	O
hepatocytes	O
,	O
the	O
cells	O
that	O
have	O
the	O
most	O
important	O
role	O
in	O
regulating	O
plasma	O
-	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
concentrations	O
.	O

From	O
in	O
vitro	O
experiments	O
using	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
alpha	I-chem
-	I-chem
tocopheryl	I-chem
acetate	E-chem
and	O
McARH7777	O
cells	O
that	O
stably	O
express	O
alpha	B-geneY
-	I-geneY
tocopherol	I-geneY
transfer	I-geneY
protein	E-geneY
(	O
alpha	B-geneY
-	I-geneY
TTP	E-geneY
)	O
,	O
the	O
following	O
results	O
were	O
obtained	O
.	O

First	O
,	O
addition	O
of	O
apolipoprotein	B-geneY
A	I-geneY
-	I-geneY
I	E-geneY
(	O
apoA	B-geneY
-	I-geneY
I	E-geneY
)	O
,	O
a	O
direct	O
acceptor	O
of	O
the	O
ATP	B-geneY
-	I-geneY
binding	I-geneY
cassette	I-geneY
transporter	I-geneY
A1	E-geneY
(	O
ABCA1	S-geneY
)	O
-	O
secreted	O
lipids	O
,	O
increased	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
secretion	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Second	O
,	O
probucol	S-chem
,	O
an	O
antiatherogenic	O
compound	O
reported	O
to	O
be	O
an	O
inactivator	O
of	O
ABCA1	S-geneY
reduced	O
hepatic	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
secretion	O
.	O

Third	O
,	O
ABCA1	S-geneY
-	O
RNAi	O
suppressed	O
hepatic	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
secretion	O
.	O

In	O
a	O
mouse	O
in	O
vivo	O
experiment	O
,	O
addition	O
of	O
1	O
%	O
probucol	S-chem
to	O
the	O
diet	O
decreased	O
plasma	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
concentrations	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
ABCA1	S-geneY
is	O
substantially	O
involved	O
in	O
hepatic	O
alpha	B-chem
-	I-chem
tocopherol	E-chem
secretion	O
.	O

Comparison	O
of	O
inhibitory	O
effects	O
of	O
meloxicam	S-chem
and	O
diclofenac	S-chem
on	O
human	O
thromboxane	S-chem
biosynthesis	O
after	O
single	O
doses	O
and	O
at	O
steady	O
state	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
extent	O
of	O
human	B-geneY
cyclooxygenase	I-geneY
-	I-geneY
1	E-geneY
(	O
COX	B-geneY
-	I-geneY
1	E-geneY
)	O
inhibition	O
by	O
meloxicam	S-chem
,	O
which	O
has	O
been	O
reported	O
to	O
preferentially	O
inhibit	O
cyclooxygenase	B-geneY
-	I-geneY
2	E-geneY
(	O
COX	B-geneY
-	I-geneY
2	E-geneY
)	O
.	O

The	O
effects	O
of	O
meloxicam	S-chem
were	O
compared	O
with	O
those	O
of	O
diclofenac	S-chem
,	O
a	O
nonselective	O
COX	S-geneN
inhibitor	O
.	O

METHODS	O
:	O
COX	B-geneY
-	I-geneY
1	E-geneY
inhibition	O
was	O
determined	O
by	O
measuring	O
thromboxane	B-chem
B2	E-chem
(	O
TXB2	S-chem
)	O
-	O
generation	O
from	O
clotting	O
whole	O
blood	O
ex	O
vivo	O
after	O
single	O
oral	O
doses	O
of	O
7.5	O
and	O
15	O
mg	O
meloxicam	S-chem
and	O
75	O
mg	O
diclofenac	S-chem
and	O
at	O
steady	O
state	O
(	O
15	O
mg	O
meloxicam	S-chem
daily	O
and	O
150	O
mg	O
diclofenac	S-chem
daily	O
)	O
.	O

The	O
effect	O
was	O
expressed	O
as	O
percentage	O
inhibition	O
of	O
serum	O
TXB2	S-chem
generation	O
and	O
was	O
directly	O
related	O
to	O
the	O
serum	O
drug	O
concentration	O
with	O
use	O
of	O
a	O
standard	O
sigmoidal	O
E	O
(	O
max	O
)	O
model	O
.	O

RESULTS	O
:	O
In	O
terms	O
of	O
inhibition	O
of	O
TXB2	S-chem
generation	O
,	O
diclofenac	S-chem
was	O
about	O
1	O
order	O
of	O
magnitude	O
more	O
potent	O
than	O
meloxicam	S-chem
,	O
indicated	O
by	O
a	O
diclofenac	S-chem
EC50	O
(	O
concentration	O
of	O
drug	O
required	O
to	O
cause	O
50	O
%	O
of	O
maximum	O
effect	O
)	O
that	O
was	O
about	O
10	O
times	O
lower	O
than	O
that	O
of	O
meloxicam	S-chem
(	O
EC50	O
diclofenac	S-chem
single	O
doses	O
:	O
37.50	O
+	O
/	O
-	O
29.64	O
;	O
EC50	O
meloxicam	S-chem
single	O
doses	O
:	O
677.50	O
+	O
/	O
-	O
189.08	O
)	O
.	O

However	O
,	O
serum	O
concentrations	O
of	O
meloxicam	S-chem
after	O
administration	O
of	O
15	O
mg	O
were	O
approximately	O
10	O
-	O
fold	O
higher	O
than	O
those	O
of	O
diclofenac	S-chem
.	O

Therefore	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
area	O
under	O
the	O
effect	O
time	O
curve	O
(	O
P	O
=	O
.115	O
)	O
and	O
the	O
mean	O
effect	O
(	O
P	O
=	O
.424	O
)	O
between	O
meloxicam	S-chem
and	O
diclofenac	S-chem
.	O

The	O
EC50	O
of	O
both	O
drugs	O
was	O
significantly	O
higher	O
at	O
steady	O
state	O
(	O
diclofenac	S-chem
steady	O
state	O
:	O
87.07	O
+	O
/	O
-	O
55.24	O
ng	O
/	O
mL	O
;	O
meloxicam	S-chem
steady	O
state	O
:	O
1850.12	O
+	O
/	O
-	O
829.93	O
ng	O
/	O
mL	O
)	O
than	O
after	O
a	O
single	O
dose	O
(	O
P	O
<	O
.001	O
)	O
.	O

CONCLUSION	O
:	O
These	O
data	O
show	O
that	O
meloxicam	S-chem
inhibits	O
TXB2	S-chem
generation	O
at	O
clinically	O
relevant	O
doses	O
,	O
although	O
less	O
potently	O
than	O
diclofenac	S-chem
.	O

Thus	O
our	O
data	O
suggest	O
that	O
the	O
COX	B-geneY
-	I-geneY
2	E-geneY
preference	O
of	O
meloxicam	S-chem
observed	O
in	O
vitro	O
may	O
not	O
result	O
in	O
clinical	O
advantages	O
when	O
the	O
higher	O
dose	O
of	O
15	O
mg	O
is	O
needed	O
.	O

Because	O
of	O
the	O
increase	O
in	O
EC50	O
at	O
steady	O
state	O
,	O
COX	B-geneY
-	I-geneY
1	E-geneY
is	O
relatively	O
spared	O
when	O
the	O
lower	O
dose	O
of	O
7.5	O
mg	O
is	O
administered	O
.	O

Hydrophobic	O
amino	B-chem
acids	E-chem
in	O
the	O
hinge	O
region	O
of	O
the	O
5A	B-geneY
apolipoprotein	E-geneY
mimetic	O
peptide	O
are	O
essential	O
for	O
promoting	O
cholesterol	S-chem
efflux	O
by	O
the	O
ABCA1	S-geneY
transporter	O
.	O

The	O
bihelical	O
apolipoprotein	B-geneY
mimetic	I-geneY
peptide	I-geneY
5A	E-geneY
effluxes	O
cholesterol	S-chem
from	O
cells	O
and	O
reduces	O
inflammation	O
and	O
atherosclerosis	O
in	O
animal	O
models	O
.	O

We	O
investigated	O
how	O
hydrophobic	O
residues	O
in	O
the	O
hinge	O
region	O
between	O
the	O
two	O
helices	O
are	O
important	O
in	O
the	O
structure	O
and	O
function	O
of	O
this	O
peptide	O
.	O

By	O
simulated	O
annealing	O
analysis	O
and	O
molecular	O
dynamics	O
modeling	O
,	O
two	O
hydrophobic	O
amino	B-chem
acids	E-chem
,	O
F	O
-	O
18	O
and	O
W	O
-	O
21	O
,	O
in	O
the	O
hinge	O
region	O
were	O
predicted	O
to	O
be	O
relatively	O
surface	O
-	O
exposed	O
and	O
to	O
interact	O
with	O
the	O
aqueous	O
solvent	O
.	O

Using	O
a	O
series	O
of	O
5A	O
peptide	O
analogs	O
in	O
which	O
F	O
-	O
18	O
or	O
W	O
-	O
21	O
was	O
changed	O
to	O
either	O
F	O
,	O
W	O
,	O
A	O
,	O
or	O
E	O
,	O
only	O
peptides	O
with	O
hydrophobic	O
amino	B-chem
acids	E-chem
in	O
these	O
two	O
positions	O
were	O
able	O
to	O
readily	O
bind	O
and	O
solubilize	O
phospholipid	O
vesicles	O
.	O

Compared	O
with	O
active	O
peptides	O
containing	O
F	O
or	O
W	O
,	O
peptides	O
containing	O
E	O
in	O
either	O
of	O
these	O
two	O
positions	O
were	O
more	O
than	O
10	O
-	O
fold	O
less	O
effective	O
in	O
effluxing	O
cholesterol	S-chem
by	O
the	O
ABCA1	S-geneY
transporter	O
.	O

Intravenous	O
injection	O
of	O
5A	O
in	O
C57BL	O
/	O
6	O
mice	O
increased	O
plasma	O
-	O
free	O
cholesterol	S-chem
(	O
5A	O
:	O
89.9	O
±	O
13.6	O
mg	O
/	O
dl	O
;	O
control	O
:	O
38.7	O
±	O
4.3	O
mg	O
/	O
dl	O
(	O
mean	O
±	O
S.D	O
.	O
)	O
;	O
P	O
<	O
0.05	O
)	O
and	O
triglycerides	S-chem
(	O
5A	O
:	O
887.0	O
±	O
172.0	O
mg	O
/	O
dl	O
;	O
control	O
:	O
108.9	O
±	O
9.9	O
mg	O
/	O
dl	O
;	O
P	O
<	O
0.05	O
)	O
,	O
whereas	O
the	O
EE	O
peptide	O
containing	O
E	O
in	O
both	O
positions	O
had	O
no	O
effect	O
.	O

Finally	O
,	O
5A	O
increased	O
cholesterol	S-chem
efflux	O
approximately	O
2.5	O
-	O
fold	O
in	O
vivo	O
from	O
radiolabeled	O
macrophages	O
,	O
whereas	O
the	O
EE	O
peptide	O
was	O
inactive	O
.	O

These	O
results	O
provide	O
a	O
rationale	O
for	O
future	O
design	O
of	O
therapeutic	O
apolipoprotein	S-geneN
mimetic	O
peptides	O
and	O
provide	O
new	O
insights	O
into	O
the	O
interaction	O
of	O
hydrophobic	O
residues	O
on	O
apolipoproteins	O
with	O
phospholipids	O
in	O
the	O
lipid	O
microdomain	O
created	O
by	O
the	O
ABCA1	S-geneY
transporter	O
during	O
the	O
cholesterol	S-chem
efflux	O
process	O
.	O

Biophysical	O
properties	O
,	O
pharmacology	O
,	O
and	O
modulation	O
of	O
human	O
,	O
neuronal	O
L	O
-	O
type	O
(	O
alpha	B-geneY
(	I-geneY
1D	I-geneY
)	E-geneY
,	O
Ca	B-geneY
(	I-geneY
V	I-geneY
)	I-geneY
1.3	E-geneY
)	O
voltage	O
-	O
dependent	O
calcium	S-chem
currents	O
.	O

Voltage	B-geneN
-	I-geneN
dependent	I-geneN
calcium	I-geneN
channels	E-geneN
(	O
VDCCs	O
)	O
are	O
multimeric	O
complexes	O
composed	O
of	O
a	O
pore	O
-	O
forming	O
alpha	O
(	O
1	O
)	O
subunit	O
together	O
with	O
several	O
accessory	O
subunits	O
,	O
including	O
alpha	O
(	O
2	O
)	O
delta	O
,	O
beta	O
,	O
and	O
,	O
in	O
some	O
cases	O
,	O
gamma	O
subunits	O
.	O

A	O
family	O
of	O
VDCCs	S-geneN
known	O
as	O
the	O
L	B-geneN
-	I-geneN
type	I-geneN
channels	E-geneN
are	O
formed	O
specifically	O
from	O
alpha	O
(	O
1S	O
)	O
(	O
skeletal	O
muscle	O
)	O
,	O
alpha	O
(	O
1C	O
)	O
(	O
in	O
heart	O
and	O
brain	O
)	O
,	O
alpha	O
(	O
1D	O
)	O
(	O
mainly	O
in	O
brain	O
,	O
heart	O
,	O
and	O
endocrine	O
tissue	O
)	O
,	O
and	O
alpha	O
(	O
1F	O
)	O
(	O
retina	O
)	O
.	O

Neuroendocrine	O
L	O
-	O
type	O
currents	O
have	O
a	O
significant	O
role	O
in	O
the	O
control	O
of	O
neurosecretion	O
and	O
can	O
be	O
inhibited	O
by	O
GTP	B-geneN
-	I-geneN
binding	I-geneN
(	I-geneN
G	I-geneN
-	I-geneN
)	I-geneN
proteins	E-geneN
.	O

However	O
,	O
the	O
subunit	O
composition	O
of	O
the	O
VDCCs	S-geneN
underlying	O
these	O
G	B-geneN
-	I-geneN
protein	E-geneN
-	O
regulated	O
neuroendocrine	O
L	O
-	O
type	O
currents	O
is	O
unknown	O
.	O

To	O
investigate	O
the	O
biophysical	O
and	O
pharmacological	O
properties	O
and	O
role	O
of	O
G	B-geneN
-	I-geneN
protein	E-geneN
modulation	O
of	O
alpha	B-geneY
(	I-geneY
1D	I-geneY
)	I-geneY
calcium	I-geneY
channels	E-geneY
,	O
we	O
have	O
examined	O
calcium	B-geneN
channel	E-geneN
currents	O
formed	O
by	O
the	O
human	B-geneY
neuronal	I-geneY
L	I-geneY
-	I-geneY
type	I-geneY
alpha	I-geneY
(	I-geneY
1D	I-geneY
)	E-geneY
subunit	O
,	O
co	O
-	O
expressed	O
with	O
alpha	O
(	O
2	O
)	O
delta	O
-	O
1	O
and	O
beta	O
(	O
3a	O
)	O
,	O
stably	O
expressed	O
in	O
a	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
293	O
cell	O
line	O
,	O
using	O
whole	O
cell	O
and	O
perforated	O
patch	O
-	O
clamp	O
techniques	O
.	O

The	O
alpha	O
(	O
1D	O
)	O
-	O
expressing	O
cell	O
line	O
exhibited	O
L	O
-	O
type	O
currents	O
with	O
typical	O
characteristics	O
.	O

The	O
currents	O
were	O
high	O
-	O
voltage	O
activated	O
(	O
peak	O
at	O
+	O
20	O
mV	O
in	O
20	O
mM	O
Ba2	B-chem
+	E-chem
)	O
and	O
showed	O
little	O
inactivation	O
in	O
external	O
Ba2	B-chem
+	E-chem
,	O
while	O
displaying	O
rapid	O
inactivation	O
kinetics	O
in	O
external	O
Ca2	B-chem
+	E-chem
.	O

The	O
L	O
-	O
type	O
currents	O
were	O
inhibited	O
by	O
the	O
1,4	B-chem
dihydropyridine	E-chem
(	O
DHP	S-chem
)	O
antagonists	O
nifedipine	S-chem
and	O
nicardipine	S-chem
and	O
were	O
enhanced	O
by	O
the	O
DHP	S-chem
agonist	O
BayK	B-chem
S	I-chem
-	I-chem
(	I-chem
-	I-chem
)	I-chem
8644	E-chem
.	O

However	O
,	O
alpha	B-geneY
(	I-geneY
1D	I-geneY
)	E-geneY
L	O
-	O
type	O
currents	O
were	O
not	O
modulated	O
by	O
activation	O
of	O
a	O
number	O
of	O
G	B-geneN
-	I-geneN
protein	E-geneN
pathways	O
.	O

Activation	O
of	O
endogenous	O
somatostatin	B-geneY
receptor	I-geneY
subtype	I-geneY
2	E-geneY
(	O
sst2	S-geneY
)	O
by	O
somatostatin	B-chem
-	I-chem
14	E-chem
or	O
activation	O
of	O
transiently	O
transfected	O
rat	B-geneN
D2	I-geneN
dopamine	I-geneN
receptors	E-geneN
(	O
rD2	S-geneN
(	O
long	O
)	O
)	O
by	O
quinpirole	S-chem
had	O
no	O
effect	O
.	O

Direct	O
activation	O
of	O
G	O
-	O
proteins	O
by	O
the	O
nonhydrolyzable	O
GTP	S-chem
analogue	O
,	O
guanosine	B-chem
5	I-chem
'	I-chem
-	I-chem
0	I-chem
-	I-chem
(	I-chem
3	I-chem
-	I-chem
thiotriphospate	I-chem
)	E-chem
also	O
had	O
no	O
effect	O
on	O
the	O
alpha	O
(	O
1D	O
)	O
currents	O
.	O

In	O
contrast	O
,	O
in	O
the	O
same	O
system	O
,	O
N	S-chem
-	O
type	O
currents	O
,	O
formed	O
from	O
transiently	O
transfected	O
alpha	O
(	O
1B	O
)	O
/	O
alpha	O
(	O
2	O
)	O
delta	O
-	O
1	O
/	O
beta	O
(	O
3	O
)	O
,	O
showed	O
strong	O
G	B-geneN
-	I-geneN
protein	E-geneN
-	O
mediated	O
inhibition	O
.	O

Furthermore	O
,	O
the	O
I	O
-	O
II	O
loop	O
from	O
the	O
alpha	O
(	O
1D	O
)	O
clone	O
,	O
expressed	O
as	O
a	O
glutathione	B-geneN
-	I-geneN
S	I-geneN
-	I-geneN
transferase	E-geneN
(	O
GST	S-geneN
)	O
fusion	O
protein	O
,	O
did	O
not	O
bind	O
Gbetagamma	O
,	O
unlike	O
the	O
alpha	B-geneN
(	I-geneN
1B	I-geneN
)	I-geneN
I	I-geneN
-	I-geneN
II	I-geneN
loop	E-geneN
fusion	O
protein	O
.	O

These	O
data	O
show	O
that	O
the	O
biophysical	O
and	O
pharmacological	O
properties	O
of	O
recombinant	O
human	O
alpha	O
(	O
1D	O
)	O
L	O
-	O
type	O
currents	O
are	O
similar	O
to	O
alpha	O
(	O
1C	O
)	O
currents	O
,	O
and	O
these	O
currents	O
are	O
also	O
resistant	O
to	O
modulation	O
by	O
G	B-geneN
(	I-geneN
i	I-geneN
/	I-geneN
o	I-geneN
)	E-geneN
-	O
linked	O
G	B-geneN
-	I-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptors	E-geneN
.	O

Correlations	O
of	O
receptor	O
binding	O
and	O
metabolic	O
and	O
mitogenic	O
potencies	O
of	O
insulin	S-geneY
analogs	O
designed	O
for	O
clinical	O
use	O
.	O

In	O
recent	O
years	O
,	O
analogs	O
of	O
human	B-geneY
insulin	E-geneY
have	O
been	O
engineered	O
with	O
the	O
aim	O
of	O
improving	O
therapy	O
for	O
people	O
with	O
diabetes	O
.	O

To	O
ensure	O
that	O
the	O
safety	O
profile	O
of	O
the	O
human	O
hormone	O
is	O
not	O
compromised	O
by	O
the	O
molecular	O
modifications	O
,	O
the	O
toxico	O
-	O
pharmacological	O
properties	O
of	O
insulin	S-geneY
analogs	O
should	O
be	O
carefully	O
monitored	O
.	O

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
insulin	S-geneY
and	O
IGF	B-geneY
-	I-geneY
I	I-geneY
receptor	E-geneY
binding	O
properties	O
and	O
metabolic	O
and	O
mitogenic	O
potencies	O
of	O
insulin	S-geneY
aspart	O
(	O
B28Asp	O
human	B-geneY
insulin	E-geneY
)	O
,	O
insulin	S-geneY
lispro	O
(	O
B28Lys	O
,	O
B29Pro	O
human	B-geneY
insulin	E-geneY
)	O
,	O
insulin	S-geneY
glargine	O
(	O
A21Gly	O
,	O
B31Arg	O
,	O
B32Arg	O
human	B-geneY
insulin	E-geneY
)	O
,	O
insulin	S-geneY
detemir	O
(	O
NN304	O
)	O
[	O
B29Lys	O
(	O
epsilon	B-chem
-	I-chem
tetradecanoyl	E-chem
)	O
,	O
desB30	O
human	O
insulin	S-geneY
]	O
,	O
and	O
reference	O
insulin	S-geneY
analogs	O
.	O

Receptor	O
affinities	O
were	O
measured	O
using	O
purified	O
human	O
receptors	O
,	O
insulin	B-geneY
receptor	E-geneY
dissociation	O
rates	O
were	O
determined	O
using	O
Chinese	O
hamster	O
ovary	O
cells	O
overexpressing	O
the	O
human	B-geneY
insulin	I-geneY
receptor	E-geneY
,	O
metabolic	O
potencies	O
were	O
evaluated	O
using	O
primary	O
mouse	O
adipocytes	O
,	O
and	O
mitogenic	O
potencies	O
were	O
determined	O
in	O
human	O
osteosarcoma	O
cells	O
.	O

Metabolic	O
potencies	O
correlated	O
well	O
with	O
insulin	B-geneY
receptor	E-geneY
affinities	O
.	O

Mitogenic	O
potencies	O
in	O
general	O
correlated	O
better	O
with	O
IGF	B-geneY
-	I-geneY
I	I-geneY
receptor	E-geneY
affinities	O
than	O
with	O
insulin	B-geneY
receptor	E-geneY
off	O
-	O
rates	O
.	O

The	O
2	O
rapid	O
-	O
acting	O
insulin	S-geneY
analogs	O
aspart	O
and	O
lispro	O
resembled	O
human	B-geneY
insulin	E-geneY
on	O
all	O
parameters	O
,	O
except	O
for	O
a	O
slightly	O
elevated	O
IGF	B-geneY
-	I-geneY
I	I-geneY
receptor	E-geneY
affinity	O
of	O
lispro	O
.	O

In	O
contrast	O
,	O
the	O
2	O
long	O
-	O
acting	O
insulin	S-geneY
analogs	O
,	O
glargine	O
and	O
detemir	O
,	O
differed	O
significantly	O
from	O
human	B-geneY
insulin	E-geneY
.	O

The	O
combination	O
of	O
the	O
B31B32diArg	O
and	O
A21Gly	O
substitutions	O
provided	O
insulin	S-geneY
glargine	O
with	O
a	O
6	O
-	O
to	O
8	O
-	O
fold	O
increased	O
IGF	B-geneY
-	I-geneY
I	I-geneY
receptor	E-geneY
affinity	O
and	O
mitogenic	O
potency	O
compared	O
with	O
human	B-geneY
insulin	E-geneY
.	O

The	O
attachment	O
of	O
a	O
fatty	B-chem
acid	E-chem
chain	O
to	O
LysB29	O
provided	O
insulin	S-geneY
detemir	O
with	O
reduced	O
receptor	O
affinities	O
and	O
metabolic	O
and	O
mitogenic	O
potencies	O
but	O
did	O
not	O
change	O
the	O
balance	O
between	O
mitogenic	O
and	O
metabolic	O
potencies	O
.	O

The	O
safety	O
implications	O
of	O
the	O
increased	O
growth	O
-	O
stimulating	O
potential	O
of	O
insulin	S-geneY
glargine	O
are	O
unclear	O
.	O

The	O
reduced	O
in	O
vitro	O
potency	O
of	O
insulin	S-geneY
detemir	O
might	O
explain	O
why	O
this	O
analog	O
is	O
not	O
as	O
effective	O
on	O
a	O
molar	O
basis	O
as	O
human	B-geneY
insulin	E-geneY
in	O
humans	O
.	O

Formoterol	S-chem
in	O
the	O
management	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

Bronchodilators	O
represent	O
the	O
hallmark	O
of	O
symptomatic	O
treatment	O
of	O
Chronic	O
Obstructive	O
Pulmonary	O
Disease	O
(	O
COPD	O
)	O
.	O

There	O
are	O
four	O
categories	O
of	O
bronchodilators	O
:	O
anticholinergics	O
,	O
methylxanthines	S-chem
,	O
short	O
-	O
acting	O
beta2	O
-	O
agonists	O
,	O
and	O
long	O
-	O
acting	O
beta2	O
-	O
agonists	O
such	O
as	O
formoterol	S-chem
.	O

Significant	O
research	O
has	O
been	O
performed	O
to	O
investigate	O
the	O
efficacy	O
,	O
safety	O
and	O
tolerability	O
of	O
formoterol	S-chem
in	O
the	O
therapeutic	O
field	O
of	O
COPD	O
.	O

Formoterol	S-chem
exhibits	O
a	O
rapid	O
onset	O
of	O
bronchodilation	O
similar	O
to	O
that	O
observed	O
with	O
salbutamol	S-chem
,	O
yet	O
its	O
long	O
bronchodilatory	O
duration	O
is	O
comparable	O
to	O
salmeterol	S-chem
.	O

In	O
addition	O
,	O
formoterol	S-chem
presents	O
with	O
a	O
clear	O
superiority	O
in	O
lung	O
function	O
improvement	O
compared	O
with	O
either	O
ipratropium	B-chem
bromide	E-chem
or	O
oral	O
theophylline	S-chem
,	O
while	O
its	O
efficacy	O
improves	O
when	O
administered	O
in	O
combination	O
with	O
ipratropium	S-chem
.	O

Formoterol	S-chem
has	O
been	O
shown	O
to	O
better	O
reduce	O
dynamic	O
hyperinflation	O
,	O
which	O
is	O
responsible	O
for	O
exercise	O
intolerance	O
and	O
dyspnea	O
in	O
COPD	O
patients	O
,	O
compared	O
with	O
other	O
bronchodilators	O
,	O
whereas	O
it	O
exerts	O
synergistic	O
effect	O
with	O
tiotropium	O
.	O

Moreover	O
,	O
formoterol	S-chem
reduces	O
exacerbations	O
,	O
increases	O
days	O
free	O
of	O
use	O
of	O
rescue	O
medication	O
and	O
improves	O
patients	O
'	O
quality	O
of	O
life	O
and	O
disease	O
symptoms	O
.	O

Formoterol	S-chem
has	O
a	O
favorable	O
safety	O
profile	O
and	O
is	O
better	O
tolerated	O
than	O
theophylline	S-chem
.	O

Collectively	O
,	O
data	O
extracted	O
from	O
multicenter	O
clinical	O
trials	O
support	O
formoterol	S-chem
as	O
a	O
valid	O
therapeutic	O
option	O
in	O
the	O
treatment	O
of	O
COPD	O
.	O

Suppression	O
of	O
nuclear	B-geneY
factor	I-geneY
erythroid	I-geneY
2	I-geneY
-	I-geneY
related	I-geneY
factor	I-geneY
2	E-geneY
via	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	E-geneN
contributes	O
to	O
bleomycin	S-chem
-	O
induced	O
oxidative	O
stress	O
and	O
fibrogenesis	O
.	O

Pulmonary	O
fibrosis	O
is	O
a	O
serious	O
and	O
irreversible	O
lung	O
injury	O
with	O
obscure	O
etiologic	O
mechanisms	O
and	O
no	O
effective	O
treatment	O
to	O
date	O
.	O

This	O
study	O
explored	O
a	O
crucial	O
link	O
between	O
oxidative	O
stress	O
and	O
pulmonary	O
fibrogenesis	O
,	O
focusing	O
on	O
nuclear	B-geneY
factor	I-geneY
erythroid	I-geneY
2	I-geneY
-	I-geneY
related	I-geneY
factor	I-geneY
2	E-geneY
(	O
Nrf2	S-geneY
)	O
,	O
a	O
core	O
transcription	O
factor	O
in	O
antioxidative	O
regulation	O
systems	O
.	O

Treatment	O
of	O
C57	O
BL	O
/	O
6	O
mice	O
with	O
bleomycin	S-chem
increased	O
fibroblast	O
viability	O
and	O
collagen	S-geneN
production	O
and	O
significantly	O
downregulated	O
Nrf2	S-geneN
.	O

In	O
addition	O
,	O
prominent	O
oxidative	O
stress	O
was	O
indicated	O
by	O
changes	O
in	O
superoxide	B-geneN
dismutase	E-geneN
,	O
catalase	S-geneN
activity	O
,	O
and	O
glutathione	S-chem
and	O
thiobarbituric	B-chem
acid	E-chem
-	O
reactive	O
substance	O
levels	O
.	O

In	O
a	O
cell	O
-	O
based	O
model	O
,	O
bleomycin	S-chem
suppressed	O
Nrf2	S-geneY
activation	O
via	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
related	I-geneN
kinase	E-geneN
phosphorylation	O
,	O
enhancing	O
intracellular	O
reactive	O
oxygen	S-chem
species	O
in	O
lung	O
fibroblasts	O
and	O
stimulating	O
abnormal	O
cell	O
proliferation	O
and	O
collagen	O
secretion	O
.	O

To	O
confirm	O
this	O
novel	O
mechanism	O
of	O
bleomycin	S-chem
-	O
induced	O
fibrogenesis	O
,	O
we	O
attempted	O
to	O
upregulate	O
Nrf2	S-geneY
and	O
related	O
antioxidant	O
proteins	O
in	O
bleomycin	O
-	O
treated	O
fibroblasts	O
using	O
a	O
putative	O
Nrf2	S-geneY
activator	O
,	O
caffeic	B-chem
acid	I-chem
phenethyl	I-chem
ester	E-chem
,	O
and	O
the	O
results	O
showed	O
that	O
bleomycin	S-chem
-	O
induced	O
fibroblast	O
proliferation	O
and	O
collagen	S-geneN
content	O
were	O
attenuated	O
through	O
improved	O
redox	O
balance	O
.	O

Collectively	O
,	O
these	O
results	O
disclose	O
a	O
potential	O
regulatory	O
mechanism	O
in	O
pulmonary	O
fibrosis	O
that	O
will	O
aid	O
the	O
development	O
of	O
new	O
therapies	O
.	O

Mesenchymal	O
cells	O
regulate	O
the	O
response	O
of	O
acute	O
lymphoblastic	O
leukemia	O
cells	O
to	O
asparaginase	S-geneN
.	O

Because	O
of	O
their	O
low	O
asparagine	B-geneY
synthetase	E-geneY
(	O
ASNS	S-geneY
)	O
expression	O
and	O
asparagine	S-chem
biosynthesis	O
,	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
cells	O
are	O
exquisitely	O
sensitive	O
to	O
asparagine	S-chem
depletion	O
.	O

Consequently	O
,	O
asparaginase	S-geneN
is	O
a	O
major	O
component	O
of	O
ALL	O
therapy	O
,	O
but	O
the	O
mechanisms	O
regulating	O
the	O
susceptibility	O
of	O
leukemic	O
cells	O
to	O
this	O
agent	O
are	O
unclear	O
.	O

In	O
288	O
children	O
with	O
ALL	O
,	O
cellular	O
ASNS	S-geneY
expression	O
was	O
more	O
likely	O
to	O
be	O
high	O
in	O
T	O
-	O
lineage	O
ALL	O
and	O
low	O
in	O
B	O
-	O
lineage	O
ALL	O
with	O
TEL	S-geneY
-	O
AML1	S-geneY
or	O
hyperdiploidy	O
.	O

However	O
,	O
ASNS	S-geneY
expression	O
levels	O
in	O
bone	O
marrow	O
-	O
derived	O
mesenchymal	O
cells	O
(	O
MSCs	O
)	O
,	O
which	O
form	O
the	O
microenvironment	O
where	O
leukemic	O
cells	O
grow	O
,	O
were	O
on	O
average	O
20	O
times	O
higher	O
than	O
those	O
in	O
ALL	O
cells	O
.	O

MSCs	O
protected	O
ALL	O
cells	O
from	O
asparaginase	S-geneN
cytotoxicity	O
in	O
coculture	O
experiments	O
.	O

This	O
protective	O
effect	O
correlated	O
with	O
levels	O
of	O
ASNS	S-geneY
expression	O
:	O
downregulation	O
by	O
RNA	O
interference	O
decreased	O
the	O
capacity	O
of	O
MSCs	O
to	O
protect	O
ALL	O
cells	O
from	O
asparaginase	S-geneN
,	O
whereas	O
enforced	O
ASNS	S-geneY
expression	O
conferred	O
enhanced	O
protection	O
.	O

Asparagine	S-chem
secretion	O
by	O
MSCs	O
was	O
directly	O
related	O
to	O
their	O
ASNS	S-geneY
expression	O
levels	O
,	O
suggesting	O
a	O
mechanism	O
-	O
increased	O
concentrations	O
of	O
asparagine	S-chem
in	O
the	O
leukemic	O
cell	O
microenvironment	O
-	O
for	O
the	O
protective	O
effects	O
we	O
observed	O
.	O

These	O
results	O
provide	O
what	O
we	O
believe	O
to	O
be	O
a	O
new	O
basis	O
for	O
understanding	O
asparaginase	S-geneN
resistance	O
in	O
ALL	O
and	O
indicate	O
that	O
MSC	O
niches	O
in	O
the	O
bone	O
marrow	O
can	O
form	O
a	O
safe	O
haven	O
for	O
leukemic	O
cells	O
.	O

Polymorphisms	O
in	O
dopamine	B-geneY
transporter	E-geneY
(	O
SLC6A3	S-geneY
)	O
are	O
associated	O
with	O
stimulant	O
effects	O
of	O
D	B-chem
-	I-chem
amphetamine	E-chem
:	O
an	O
exploratory	O
pharmacogenetic	O
study	O
using	O
healthy	O
volunteers	O
.	O

Individuals	O
vary	O
in	O
their	O
subjective	O
responses	O
to	O
stimulant	O
drugs	O
,	O
and	O
these	O
differences	O
are	O
believed	O
to	O
be	O
partially	O
genetic	O
in	O
origin	O
.	O

We	O
evaluated	O
associations	O
between	O
mood	O
,	O
cognitive	O
and	O
cardiovascular	O
responses	O
to	O
d	B-chem
-	I-chem
amphetamine	E-chem
and	O
four	O
polymorphisms	O
in	O
the	O
dopamine	B-geneY
transporter	E-geneY
(	O
SLC6A3	S-geneY
)	O
:	O
rs460000	O
,	O
rs3756450	O
,	O
rs37022	O
and	O
rs6869645	O
.	O

Healthy	O
Caucasian	O
male	O
and	O
female	O
volunteers	O
(	O
N	O
=	O
152	O
)	O
participated	O
in	O
a	O
double	O
-	O
blind	O
,	O
crossover	O
design	O
study	O
in	O
which	O
they	O
received	O
placebo	O
,	O
10	O
and	O
20	O
mg	O
of	O
d	B-chem
-	I-chem
amphetamine	E-chem
.	O

We	O
measured	O
self	O
-	O
reported	O
rating	O
of	O
mood	O
,	O
performance	O
on	O
the	O
Digit	O
Symbol	O
Substitution	O
Task	O
,	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

Individuals	O
with	O
the	O
C	O
/	O
C	O
genotype	O
at	O
rs460000	O
(	O
N	O
=	O
83	O
)	O
reported	O
approximately	O
twofold	O
higher	O
ratings	O
of	O
stimulation	O
and	O
euphoria	O
relative	O
to	O
the	O
A	O
/	O
A	O
+	O
A	O
/	O
C	O
(	O
N	O
=	O
69	O
)	O
genotype	O
group	O
,	O
at	O
both	O
the	O
10	O
and	O
20	O
mg	O
doses	O
.	O

No	O
other	O
responses	O
or	O
SNPs	O
showed	O
significant	O
effects	O
.	O
rs460000	O
is	O
in	O
perfect	O
LD	O
with	O
rs463379	O
(	O
CEU	O
:	O
D	O
'	O
=	O
1	O
;	O
r	O
(	O
2	O
)	O
=	O
1	O
)	O
,	O
which	O
was	O
not	O
studied	O
here	O
,	O
but	O
has	O
been	O
associated	O
with	O
etiology	O
of	O
Attention	O
Deficit	O
Hyperactivity	O
Disorder	O
(	O
ADHD	O
)	O
.	O

These	O
findings	O
suggest	O
a	O
pleiotropic	O
effect	O
of	O
this	O
polymorphic	O
locus	O
on	O
both	O
ADHD	O
and	O
sensitivity	O
to	O
the	O
subjective	O
effects	O
of	O
amphetamine	S-chem
.	O

Protective	O
effect	O
of	O
halothane	S-chem
anesthesia	O
on	O
retinal	O
light	O
damage	O
:	O
inhibition	O
of	O
metabolic	O
rhodopsin	S-geneN
regeneration	O
.	O

PURPOSE	O
:	O
To	O
determine	O
whether	O
the	O
volatile	O
anesthetic	O
halothane	S-chem
protects	O
against	O
light	O
-	O
induced	O
photoreceptor	S-geneN
degeneration	O
in	O
the	O
rodent	O
retina	O
.	O

METHODS	O
:	O
Albino	O
mice	O
and	O
rats	O
were	O
anesthetized	O
with	O
halothane	S-chem
and	O
exposed	O
to	O
high	O
levels	O
of	O
white	O
or	O
blue	O
light	O
.	O

Nonanesthetized	O
animals	O
served	O
as	O
controls	O
.	O

Retinal	O
morphology	O
was	O
assessed	O
by	O
light	O
microscopy	O
,	O
and	O
apoptosis	O
of	O
photoreceptor	S-geneN
cells	O
was	O
verified	O
by	O
detection	O
of	O
fragmented	O
genomic	O
DNA	O
and	O
in	O
situ	O
staining	O
of	O
apoptotic	O
nuclei	O
(	O
TUNEL	O
assay	O
)	O
.	O

Rhodopsin	S-geneN
regeneration	O
after	O
bleaching	O
was	O
determined	O
by	O
measuring	O
rhodopsin	S-geneN
levels	O
in	O
retinas	O
of	O
mice	O
or	O
rats	O
at	O
different	O
time	O
points	O
in	O
darkness	O
.	O

RESULTS	O
:	O
Halothane	S-chem
anesthesia	O
reversibly	O
inhibited	O
metabolic	O
rhodopsin	S-geneN
regeneration	O
and	O
thus	O
prevented	O
rhodopsin	S-geneN
from	O
absorbing	O
high	O
numbers	O
of	O
photons	O
during	O
light	O
exposure	O
.	O

Consequently	O
,	O
photoreceptors	S-geneN
of	O
mice	O
and	O
rats	O
anesthetized	O
with	O
halothane	S-chem
were	O
completely	O
protected	O
against	O
degeneration	O
induced	O
by	O
white	O
light	O
.	O

In	O
remarkable	O
contrast	O
,	O
however	O
,	O
halothane	S-chem
anesthesia	O
did	O
not	O
protect	O
against	O
blue	O
-	O
light	O
-	O
induced	O
photoreceptor	O
cell	O
death	O
.	O

CONCLUSIONS	O
:	O
After	O
the	O
initial	O
bleach	O
,	O
halothane	S-chem
impeded	O
photon	O
absorption	O
by	O
rhodopsin	S-geneN
by	O
inhibiting	O
metabolic	O
rhodopsin	S-geneN
regeneration	O
.	O

Apparently	O
,	O
the	O
rhodopsin	S-geneN
-	O
mediated	O
uptake	O
of	O
the	O
critical	O
number	O
of	O
photons	O
to	O
initiate	O
white	O
light	O
-	O
induced	O
retinal	O
degeneration	O
was	O
prevented	O
.	O

In	O
contrast	O
,	O
halothane	S-chem
did	O
not	O
protect	O
the	O
retina	O
against	O
blue	O
light	O
.	O

Blue	O
light	O
can	O
efficiently	O
restore	O
functional	O
rhodopsin	S-geneN
from	O
bleaching	O
intermediates	O
through	O
a	O
process	O
termed	O
photoreversal	O
of	O
bleaching	O
.	O

This	O
process	O
does	O
not	O
depend	O
on	O
the	O
visual	O
cycle	O
via	O
the	O
pigment	O
epithelium	O
but	O
nevertheless	O
enables	O
rhodopsin	S-geneN
molecules	O
to	O
absorb	O
the	O
critical	O
number	O
of	O
photons	O
required	O
to	O
induce	O
retinal	O
degeneration	O
.	O

Identification	O
of	O
benzofuran	S-chem
central	O
cores	O
for	O
the	O
inhibition	O
of	O
leukotriene	B-geneY
A	I-geneY
(	I-geneY
4	I-geneY
)	I-geneY
hydrolase	E-geneY
.	O

Leukotrienes	S-chem
(	O
LT	O
's	O
)	O
are	O
known	O
to	O
play	O
a	O
physiological	O
role	O
in	O
inflammatory	O
immune	O
response	O
.	O

Leukotriene	B-geneY
A	I-geneY
(	I-geneY
4	I-geneY
)	I-geneY
hydrolase	E-geneY
(	O
LTA	B-geneY
(	I-geneY
4	I-geneY
)	I-geneY
H	E-geneY
)	O
is	O
a	O
cystolic	O
enzyme	O
that	O
stereospecifically	O
catalyzes	O
the	O
transformation	O
of	O
LTA	B-chem
(	I-chem
4	I-chem
)	E-chem
to	O
LTB	B-chem
(	I-chem
4	I-chem
)	E-chem
.	O

LTB	B-chem
(	I-chem
4	I-chem
)	E-chem
is	O
a	O
known	O
pro	O
-	O
inflammatory	O
mediator	O
.	O

This	O
paper	O
describes	O
the	O
identification	O
and	O
synthesis	O
of	O
substituted	O
benzofurans	S-chem
as	O
LTH	B-geneY
(	I-geneY
4	I-geneY
)	I-geneY
H	E-geneY
inhibitors	O
.	O

The	O
benzofuran	S-chem
series	O
demonstrated	O
reduced	O
mouse	O
and	O
human	O
whole	O
blood	O
LTB	B-chem
(	I-chem
4	I-chem
)	E-chem
levels	O
in	O
vitro	O
and	O
led	O
to	O
the	O
identification	O
one	O
analog	O
for	O
advanced	O
profiling	O
.	O

Benzofuran	S-chem
28	O
showed	O
dose	O
responsive	O
target	O
engagement	O
and	O
provides	O
a	O
useful	O
tool	O
to	O
explore	O
a	O
LTA	B-geneY
(	I-geneY
4	I-geneY
)	I-geneY
H	E-geneY
inhibitor	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
,	O
such	O
as	O
asthma	O
and	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

Increased	O
muscarinic	B-geneN
receptor	E-geneN
activity	O
of	O
airway	O
smooth	O
muscle	O
isolated	O
from	O
a	O
mouse	O
model	O
of	O
allergic	O
asthma	O
.	O

The	O
mechanisms	O
leading	O
to	O
airway	O
hyper	O
-	O
responsiveness	O
(	O
AHR	O
)	O
in	O
asthma	O
are	O
still	O
not	O
fully	O
understood	O
.	O

AHR	O
could	O
be	O
produced	O
by	O
hypersensitivity	O
of	O
the	O
airway	O
smooth	O
muscle	O
or	O
hyperreactivity	O
of	O
the	O
airways	O
.	O

This	O
study	O
was	O
conducted	O
to	O
ascertain	O
whether	O
AHR	O
in	O
a	O
murine	O
model	O
of	O
asthma	O
is	O
produced	O
by	O
changes	O
at	O
the	O
level	O
of	O
the	O
airway	O
smooth	O
muscle	O
.	O

Airway	O
smooth	O
muscle	O
responses	O
were	O
characterised	O
in	O
vitro	O
in	O
isolated	O
trachea	O
spirals	O
from	O
naive	O
mice	O
and	O
from	O
an	O
acute	O
ovalbumin	S-geneY
(	O
OVA	S-geneY
)	O
challenge	O
model	O
of	O
allergic	O
asthma	O
.	O

AHR	O
was	O
investigated	O
in	O
vivo	O
in	O
conscious	O
,	O
freely	O
moving	O
mice	O
.	O

Inflammatory	O
cell	O
influx	O
into	O
the	O
lungs	O
and	O
antibody	O
responses	O
to	O
the	O
antigen	O
were	O
also	O
measured	O
.	O

In	O
vitro	O
study	O
of	O
tracheal	O
airway	O
smooth	O
muscle	O
from	O
naive	O
mice	O
demonstrated	O
concentration	O
-	O
related	O
contractions	O
to	O
methacholine	S-chem
and	O
5	B-chem
-	I-chem
HT	E-chem
,	O
but	O
no	O
responses	O
to	O
histamine	S-chem
or	O
adenosine	S-chem
or	O
its	O
stable	O
analogue	O
,	O
5	B-chem
'	I-chem
-	I-chem
N	I-chem
-	I-chem
ethyl	I-chem
-	I-chem
carboxamidoadenosine	E-chem
.	O

The	O
contractions	O
to	O
5	B-chem
-	I-chem
HT	E-chem
were	O
inhibited	O
by	O
ketanserin	S-chem
and	O
alosetron	S-chem
indicating	O
involvement	O
of	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
2A	I-geneY
)	E-geneY
and	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
3	I-geneY
)	E-geneY
receptors	O
,	O
respectively	O
.	O

In	O
an	O
acute	O
model	O
of	O
allergic	O
asthma	O
,	O
OVA	S-geneY
-	O
treated	O
mice	O
were	O
shown	O
to	O
be	O
atopic	O
by	O
inflammatory	O
cell	O
influx	O
to	O
the	O
lungs	O
after	O
OVA	S-geneY
challenge	O
,	O
increases	O
in	O
total	O
IgE	S-geneN
and	O
OVA	S-geneY
-	O
specific	O
IgG	S-geneN
levels	O
and	O
contractions	O
to	O
OVA	S-geneY
in	O
isolated	O
trachea	O
.	O

In	O
the	O
asthmatic	O
model	O
,	O
AHR	O
to	O
methacholine	S-chem
was	O
demonstrated	O
in	O
conscious	O
,	O
freely	O
moving	O
mice	O
in	O
vivo	O
and	O
in	O
isolated	O
trachea	O
in	O
vitro	O
24	O
and	O
72h	O
after	O
OVA	S-geneY
challenge	O
.	O

No	O
AHR	O
in	O
vitro	O
was	O
seen	O
for	O
5	B-chem
-	I-chem
HT	E-chem
,	O
histamine	S-chem
or	O
adenosine	S-chem
.	O

These	O
results	O
suggest	O
that	O
,	O
in	O
our	O
mouse	O
model	O
of	O
asthma	O
,	O
changes	O
occur	O
at	O
the	O
level	O
of	O
the	O
muscarinic	B-geneN
receptor	E-geneN
transduction	O
pathway	O
of	O
coupling	O
to	O
airway	O
smooth	O
muscle	O
contraction	O
.	O

These	O
changes	O
are	O
maintained	O
when	O
tissues	O
are	O
removed	O
from	O
the	O
inflammatory	O
environment	O
and	O
for	O
at	O
least	O
3	O
days	O
.	O

Acromegaly	O
:	O
molecular	O
expression	O
of	O
somatostatin	B-geneN
receptor	E-geneN
subtypes	O
and	O
treatment	O
outcome	O
.	O

About	O
a	O
third	O
of	O
acromegalic	O
patients	O
are	O
resistant	O
to	O
the	O
currently	O
commercially	O
available	O
somatostatin	S-chem
analogs	O
(	O
SA	O
)	O
octreotide	S-chem
and	O
lanreotide	S-chem
.	O

Such	O
resistance	O
is	O
related	O
to	O
an	O
overall	O
reduction	O
of	O
somatostatin	B-geneN
receptor	E-geneN
(	O
SSTR	S-geneN
)	O
density	O
or	O
to	O
a	O
differentiated	O
expression	O
of	O
SSTR	S-geneN
subtypes	O
.	O

There	O
are	O
five	O
known	O
SSTR	S-geneN
subtypes	O
.	O

SSTR2	S-geneY
and	O
SSTR5	S-geneY
are	O
usually	O
expressed	O
in	O
GH	S-geneY
-	O
secreting	O
pituitary	O
tumors	O
,	O
and	O
both	O
octreotide	S-chem
and	O
lanreotide	S-chem
bind	O
preferentially	O
to	O
SSTR2	S-geneY
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
to	O
SSTR5	S-geneY
.	O

SA	O
inhibitory	O
effects	O
on	O
GH	S-geneY
secretion	O
and	O
tumor	O
cell	O
proliferation	O
can	O
occur	O
together	O
or	O
be	O
dissociated	O
events	O
,	O
depending	O
on	O
the	O
tumor	O
expression	O
of	O
SSTR	S-geneN
subtypes	O
involved	O
in	O
each	O
mechanism	O
.	O

The	O
development	O
of	O
specific	O
somatostatin	S-chem
subtypes	O
analogs	O
,	O
mainly	O
for	O
SSTR5	S-geneY
,	O
of	O
a	O
SSTR2	S-geneY
-	O
SSTR5	S-geneY
bispecific	O
compound	O
,	O
and	O
of	O
a	O
``	O
universal	O
``	O
analog	O
with	O
high	O
affinity	O
to	B-geneN
SSTR1	I-geneN
,	I-geneN
2	I-geneN
,	I-geneN
3	I-geneN
,	I-geneN
and	O
5	O
showed	O
preliminary	O
,	O
albeit	O
promising	O
results	O
for	O
the	O
treatment	O
of	O
resistant	O
somatotropic	O
adenomas	O
.	O

Structural	O
model	O
of	O
carnitine	B-geneY
palmitoyltransferase	I-geneY
I	E-geneY
based	O
on	O
the	O
carnitine	B-geneY
acetyltransferase	E-geneY
crystal	O
.	O

CPT	B-geneY
I	E-geneY
(	O
carnitine	B-geneY
palmitoyltransferase	I-geneY
I	E-geneY
)	O
catalyses	O
the	O
conversion	O
of	O
palmitoyl	B-chem
-	I-chem
CoA	E-chem
into	O
palmitoylcarnitine	S-chem
in	O
the	O
presence	O
of	O
L	B-chem
-	I-chem
carnitine	E-chem
,	O
facilitating	O
the	O
entry	O
of	O
fatty	B-chem
acids	E-chem
into	O
mitochondria	O
.	O

We	O
propose	O
a	O
3	O
-	O
D	O
(	O
three	O
-	O
dimensional	O
)	O
structural	O
model	O
for	O
L	B-geneY
-	I-geneY
CPT	I-geneY
I	E-geneY
(	O
liver	B-geneY
CPT	I-geneY
I	E-geneY
)	O
,	O
based	O
on	O
the	O
similarity	O
of	O
this	O
enzyme	O
to	O
the	O
recently	O
crystallized	O
mouse	B-geneY
carnitine	I-geneY
acetyltransferase	E-geneY
.	O

The	O
model	O
includes	O
607	O
of	O
the	O
773	O
amino	B-chem
acids	E-chem
of	O
L	B-geneY
-	I-geneY
CPT	I-geneY
I	E-geneY
,	O
and	O
the	O
positions	O
of	O
carnitine	S-chem
,	O
CoA	S-chem
and	O
the	O
palmitoyl	S-chem
group	O
were	O
assigned	O
by	O
superposition	O
and	O
docking	O
analysis	O
.	O

Functional	O
analysis	O
of	O
this	O
3	O
-	O
D	O
model	O
included	O
the	O
mutagenesis	O
of	O
several	O
amino	B-chem
acids	E-chem
in	O
order	O
to	O
identify	O
putative	O
catalytic	O
residues	O
.	O

Mutants	O
D477A	S-geneN
,	O
D567A	S-geneN
and	O
E590D	S-geneN
showed	O
reduced	O
L	B-geneY
-	I-geneY
CPT	I-geneY
I	E-geneY
activity	O
.	O

In	O
addition	O
,	O
individual	O
mutation	O
of	O
amino	B-chem
acids	E-chem
forming	O
the	O
conserved	O
Ser685	O
-	O
Thr686	O
-	O
Ser687	O
motif	O
abolished	O
enzyme	O
activity	O
in	O
mutants	O
T686A	S-geneN
and	O
S687A	S-geneN
and	O
altered	O
K	O
(	O
m	O
)	O
and	O
the	O
catalytic	O
efficiency	O
for	O
carnitine	S-chem
in	O
mutant	O
S685A	S-geneN
.	O

We	O
conclude	O
that	O
the	O
catalytic	O
residues	O
are	O
His473	O
and	O
Asp477	O
,	O
while	O
Ser687	O
probably	O
stabilizes	O
the	O
transition	O
state	O
.	O

Several	O
conserved	O
lysines	O
,	O
i.e	O
.	O

Lys455	O
,	O
Lys505	O
,	O
Lys560	O
and	O
Lys561	O
,	O
were	O
also	O
mutated	O
.	O

Only	O
mutants	O
K455A	S-geneN
and	O
K560A	S-geneN
showed	O
decreases	O
in	O
activity	O
of	O
50	O
%	O
.	O

The	O
model	O
rationalizes	O
the	O
finding	O
of	O
nine	O
natural	O
mutations	O
in	O
patients	O
with	O
hereditary	O
L	B-geneY
-	I-geneY
CPT	I-geneY
I	E-geneY
deficiencies	O
.	O

Effect	O
of	O
blood	O
-	O
retinal	O
barrier	O
development	O
on	O
formation	O
of	O
selenite	S-chem
nuclear	O
cataract	O
in	O
rat	O
.	O

Selenite	S-chem
cataract	O
,	O
as	O
an	O
experimental	O
animal	O
model	O
of	O
nuclear	O
cataract	O
to	O
mimic	O
human	O
senile	O
cataract	O
,	O
is	O
produced	O
only	O
when	O
overdose	O
selenite	S-chem
is	O
injected	O
to	O
neonatal	O
rats	O
before	O
eyelid	O
opening	O
.	O

To	O
clarify	O
the	O
cause	O
of	O
age	O
differences	O
on	O
selenite	S-chem
cataract	O
formation	O
in	O
rats	O
,	O
mRNA	O
expression	O
of	O
GPx1	S-geneY
,	O
MsrA	S-geneY
and	O
MsrB1	S-geneY
,	O
as	O
well	O
as	O
GPx	S-geneN
activity	O
in	O
Wistar	O
rat	O
lens	O
at	O
different	O
ages	O
were	O
assayed	O
,	O
level	O
of	O
lipid	O
peroxidation	O
,	O
extent	O
of	O
lens	O
damage	O
induced	O
by	O
sodium	B-chem
selenite	E-chem
and	O
barricade	O
function	O
of	O
blood	O
-	O
retinal	O
barrier	O
(	O
BRB	O
)	O
were	O
investigated	O
.	O

The	O
results	O
showed	O
that	O
mRNA	O
expressions	O
and	O
activity	O
of	O
antioxidant	O
enzymes	O
in	O
neonatal	O
rat	O
lens	O
before	O
eyelid	O
opening	O
were	O
the	O
highest	O
and	O
then	O
decreased	O
with	O
age	O
,	O
and	O
revealed	O
by	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
using	O
lanthanum	B-chem
hydroxide	E-chem
as	O
tracer	O
that	O
higher	O
selenite	S-chem
content	O
entering	O
eyes	O
injured	O
lens	O
and	O
resulted	O
in	O
cataract	O
formation	O
for	O
immature	O
BRB	O
before	O
eyelid	O
opening	O
,	O
moreover	O
,	O
a	O
little	O
selenite	S-chem
content	O
entering	O
eyes	O
was	O
not	O
enough	O
to	O
induce	O
cataract	O
formation	O
after	O
eyelid	O
opening	O
because	O
of	O
mature	O
BRB	O
.	O

Dopamine	B-geneY
D3	I-geneY
receptor	E-geneY
-	O
preferring	O
agonists	O
increase	O
dendrite	O
arborization	O
of	O
mesencephalic	O
dopaminergic	O
neurons	O
via	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	E-geneN
phosphorylation	O
.	O

Clinical	O
improvements	O
in	O
Parkinson	O
's	O
disease	O
produced	O
by	O
dopamine	B-geneY
D3	I-geneY
receptor	E-geneY
-	O
preferring	O
agonists	O
have	O
been	O
related	O
to	O
their	O
neuroprotective	O
actions	O
and	O
,	O
more	O
recently	O
,	O
to	O
their	O
neuroregenerative	O
properties	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
dopamine	S-chem
agonists	O
produce	O
their	O
neurotrophic	O
effects	O
by	O
acting	O
directly	O
on	O
receptors	O
expressed	O
by	O
the	O
mesencephalic	O
dopaminergic	O
neurons	O
or	O
indirectly	O
on	O
receptors	O
expressed	O
by	O
astrocytes	O
,	O
via	O
release	O
of	O
neurotrophic	B-geneN
factors	E-geneN
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
the	O
dopamine	B-geneY
D3	I-geneY
receptor	E-geneY
-	O
preferring	O
agonists	O
quinpirole	S-chem
and	O
7	B-chem
-	I-chem
hydroxy	I-chem
-	I-chem
N	I-chem
,	I-chem
N	I-chem
-	I-chem
di	I-chem
-	I-chem
propyl	I-chem
-	I-chem
2	I-chem
-	I-chem
aminotetralin	E-chem
(	O
7	B-chem
-	I-chem
OH	I-chem
-	I-chem
DPAT	E-chem
)	O
,	O
as	O
well	O
as	O
of	O
the	O
indirect	O
agonist	O
amphetamine	S-chem
,	O
on	O
dopaminergic	O
neurons	O
identified	O
by	O
tyrosine	B-geneY
hydroxylase	E-geneY
immunoreactivity	O
(	O
TH	S-geneY
-	O
IR	O
)	O
.	O

Experiments	O
were	O
performed	O
on	O
neuronal	O
-	O
enriched	O
primary	O
cultures	O
containing	O
less	O
than	O
0.5	O
%	O
of	O
astrocytes	O
prepared	O
from	O
the	O
mouse	O
embryo	O
mesencephalon	O
.	O

After	O
3	O
days	O
of	O
incubation	O
,	O
both	O
quinpirole	S-chem
(	O
1	O
-	O
10	O
microm	O
)	O
and	O
7	B-chem
-	I-chem
OH	I-chem
-	I-chem
DPAT	E-chem
(	O
5	O
-	O
500	O
nm	O
)	O
dose	O
-	O
dependently	O
increased	O
the	O
maximal	O
dendrite	O
length	O
(	O
P	O
<	O
0.001	O
)	O
,	O
number	O
of	O
primary	O
dendrites	O
(	O
P	O
<	O
0.01	O
)	O
and	O
[	B-chem
3H	I-chem
]	I-chem
dopamine	E-chem
uptake	O
(	O
P	O
<	O
0.01	O
)	O
of	O
TH	S-geneY
-	O
IR	O
-	O
positive	O
mesencephalic	O
neurons	O
.	O

Similar	O
effects	O
were	O
observed	O
with	O
10	O
microm	O
amphetamine	S-chem
.	O

All	O
neurotrophic	O
effects	O
were	O
blocked	O
by	O
the	O
unselective	O
D2	B-geneN
/	I-geneN
D3	I-geneN
receptor	E-geneN
antagonist	O
sulpiride	S-chem
(	O
5	O
microm	O
)	O
and	O
by	O
the	O
selective	O
D3	B-geneY
receptor	E-geneY
antagonist	O
SB	B-chem
-	I-chem
277011	I-chem
-	I-chem
A	E-chem
at	O
a	O
low	O
dose	O
(	O
50	O
nm	O
)	O
.	O

Quinpirole	S-chem
and	O
7	B-chem
-	I-chem
OH	I-chem
-	I-chem
DPAT	E-chem
also	O
increased	O
the	O
phosphorylation	O
of	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	E-geneN
(	O
ERK	S-geneN
)	O
within	O
minutes	O
,	O
an	O
effect	O
blocked	O
by	O
pretreatment	O
with	O
SB	B-chem
-	I-chem
277011	I-chem
-	I-chem
A	E-chem
.	O

Inhibition	O
of	O
the	O
D2	B-geneN
/	I-geneN
D3	I-geneN
receptor	E-geneN
signalling	O
pathway	O
to	O
ERK	S-geneN
was	O
obtained	O
with	O
PD98059	S-chem
,	O
GF109203	S-chem
or	O
LY294002	S-chem
,	O
resulting	O
in	O
blockade	O
of	O
neurotrophic	O
effects	O
.	O

These	O
data	O
suggest	O
that	O
dopamine	S-chem
agonists	O
increase	O
dendritic	O
arborizations	O
of	O
mesencephalic	O
dopaminergic	O
neurons	O
via	O
a	O
direct	O
effect	O
on	O
D2	B-geneN
/	I-geneN
D3	I-geneN
receptors	E-geneN
,	O
preferentially	O
involving	O
D3	B-geneY
receptor	E-geneY
-	O
dependent	O
neurotransmission	O
.	O

Medroxyprogesterone	B-chem
acetate	E-chem
but	O
not	O
drospirenone	S-chem
ablates	O
the	O
protective	O
function	O
of	O
17	B-chem
beta	I-chem
-	I-chem
estradiol	E-chem
in	O
aldosterone	S-chem
salt	O
-	O
treated	O
rats	O
.	O

Controversial	O
results	O
obtained	O
from	O
human	O
and	O
animal	O
studies	O
on	O
the	O
prevention	O
of	O
heart	O
disease	O
by	O
estrogens	S-chem
and	O
progestins	S-chem
warrant	O
a	O
better	O
understanding	O
of	O
nuclear	B-geneN
hormone	I-geneN
receptor	E-geneN
function	O
and	O
interaction	O
.	O

To	O
address	O
this	O
issue	O
and	O
taking	O
into	O
account	O
that	O
effects	O
of	O
synthetic	O
progestins	S-chem
are	O
not	O
only	O
referable	O
to	O
action	O
through	O
the	O
progesterone	B-geneY
receptor	E-geneY
but	O
may	O
also	O
be	O
mediated	O
by	O
other	O
steroid	B-geneN
receptors	E-geneN
,	O
we	O
characterized	O
cardiovascular	O
function	O
and	O
inflammatory	O
gene	O
expression	O
in	O
aldosterone	S-chem
salt	O
-	O
treated	O
rats	O
on	O
long	O
-	O
term	O
administration	O
of	O
17beta	B-chem
-	I-chem
estradiol	E-chem
,	O
medroxyprogesterone	B-chem
acetate	E-chem
,	O
and	O
drospirenone	S-chem
,	O
a	O
new	O
progestogen	S-chem
exhibiting	O
antimineralocorticoid	O
activity	O
.	O

The	O
complex	O
pattern	O
of	O
cardiovascular	O
injury	O
in	O
ovariectomized	O
Wistar	O
rats	O
induced	O
by	O
chronic	O
aldosterone	S-chem
infusion	O
plus	O
a	O
high	O
-	O
salt	O
diet	O
was	O
significantly	O
attenuated	O
in	O
sham	O
-	O
ovariectomized	O
rats	O
and	O
by	O
coadministration	O
of	O
17beta	B-chem
-	I-chem
estradiol	E-chem
in	O
ovariectomized	O
animals	O
after	O
8	O
weeks	O
of	O
continuous	O
treatment	O
.	O

The	O
beneficial	O
role	O
of	O
17beta	B-chem
-	I-chem
estradiol	E-chem
on	O
blood	O
pressure	O
,	O
cardiac	O
hypertrophy	O
,	O
vascular	O
osteopontin	S-geneY
expression	O
,	O
perivascular	O
fibrosis	O
,	O
and	O
impaired	O
NO	S-chem
-	O
dependent	O
relaxation	O
of	O
isolated	O
aortic	O
rings	O
was	O
completely	O
abrogated	O
by	O
coadministration	O
of	O
medroxyprogesterone	B-chem
acetate	E-chem
.	O

In	O
contrast	O
,	O
drospirenone	S-chem
was	O
either	O
neutral	O
or	O
additive	O
to	O
17beta	B-chem
-	I-chem
estradiol	E-chem
in	O
protecting	O
against	O
aldosterone	S-chem
salt	O
-	O
induced	O
cardiovascular	O
injury	O
and	O
inflammation	O
.	O

The	O
current	O
results	O
support	O
the	O
hypothesis	O
of	O
complex	O
interactions	O
among	O
estrogen	B-geneN
,	I-geneN
progesterone	I-geneN
,	I-geneN
glucocorticoid	I-geneN
,	I-geneN
androgen	I-geneN
,	I-geneN
and	I-geneN
mineralocorticoid	I-geneN
receptor	E-geneN
signaling	O
in	O
cardiovascular	O
injury	O
and	O
inflammation	O
.	O

Novel	O
progestins	S-chem
,	O
such	O
as	O
drospirenone	S-chem
,	O
confer	O
superior	O
effects	O
compared	O
with	O
medroxyprogesterone	B-chem
acetate	E-chem
in	O
a	O
model	O
of	O
aldosterone	S-chem
-	O
induced	O
heart	O
disease	O
because	O
of	O
its	O
antimineralocorticoid	O
properties	O
.	O

Molecular	O
cloning	O
and	O
functional	O
expression	O
of	O
5	B-geneN
-	I-geneN
HT1E	E-geneN
-	O
like	O
rat	B-geneN
and	I-geneN
human	I-geneN
5	I-geneN
-	I-geneN
hydroxytryptamine	I-geneN
receptor	E-geneN
genes	O
.	O

Sequential	O
polymerase	O
chain	O
reaction	O
experiments	O
were	O
performed	O
to	O
amplify	O
a	O
unique	O
sequence	O
representing	O
a	O
guanine	B-geneN
nucleotide	I-geneN
-	I-geneN
binding	I-geneN
protein	I-geneN
(	I-geneN
G	I-geneN
-	I-geneN
protein	I-geneN
)	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
from	O
rat	O
hypothalamic	O
cDNA	O
.	O

Degenerate	O
oligonucleotides	S-chem
corresponding	O
to	O
conserved	O
amino	B-chem
acids	E-chem
from	O
transmembrane	O
domains	O
III	O
,	O
V	O
,	O
and	O
VI	O
of	O
known	O
receptors	O
[	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
,	O
5	B-geneY
-	I-geneY
HT1C	E-geneY
,	O
and	O
5	B-geneY
-	I-geneY
HT2	E-geneY
;	O
5	B-chem
-	I-chem
HT	E-chem
is	O
serotonin	S-chem
(	O
5	B-chem
-	I-chem
hydroxytryptamine	E-chem
)	O
]	O
were	O
used	O
as	O
primers	O
for	O
the	O
sequential	O
reactions	O
.	O

The	O
resulting	O
product	O
was	O
subcloned	O
and	O
used	O
to	O
screen	O
a	O
rat	O
genomic	O
library	O
to	O
identify	O
a	O
full	O
-	O
length	O
clone	O
(	O
MR77	S-geneY
)	O
containing	O
an	O
intronless	B-geneN
open	I-geneN
reading	I-geneN
frame	E-geneN
encoding	O
a	O
366	B-geneN
-	I-geneN
amino	I-geneN
acid	I-geneN
seven	I-geneN
-	I-geneN
transmembrane	I-geneN
domain	I-geneN
protein	E-geneN
.	O

The	O
human	O
homolog	O
was	O
isolated	O
,	O
and	O
its	O
encoded	O
protein	O
had	O
93	O
%	O
overall	O
amino	B-chem
acid	E-chem
identity	O
with	O
the	O
rat	O
sequence	O
.	O

Within	O
the	O
conserved	O
transmembrane	O
domains	O
,	O
the	O
sequences	O
exhibit	O
approximately	O
52	O
%	O
,	O
59	O
%	O
,	O
65	O
%	O
,	O
and	O
68	O
%	O
amino	B-chem
acid	E-chem
identity	O
with	O
the	O
known	O
rat	B-geneY
5	I-geneY
-	I-geneY
HT1A	E-geneY
,	O
rat	B-geneY
5	I-geneY
-	I-geneY
HT1B	E-geneY
,	O
rat	B-geneY
5	I-geneY
-	I-geneY
HT1D	E-geneY
,	O
and	O
human	B-geneY
5	I-geneY
-	I-geneY
HT1E	E-geneY
receptors	O
,	O
respectively	O
.	O

MR77	S-geneY
was	O
subcloned	O
into	O
a	O
eukaryotic	O
expression	O
vector	O
system	O
and	O
expressed	O
in	O
CosM6	O
cells	O
.	O

Studies	O
on	O
broken	O
cell	O
preparations	O
indicate	O
that	O
the	O
expressed	O
receptor	O
exhibits	O
125I	B-chem
-	I-chem
labeled	I-chem
d	I-chem
-	I-chem
lysergic	I-chem
acid	I-chem
diethylamide	E-chem
(	O
LSD	S-chem
)	O
binding	O
that	O
can	O
be	O
displaced	O
by	O
serotonin	S-chem
but	O
not	O
by	O
other	O
biogenic	O
amines	S-chem
.	O

The	O
specific	O
binding	O
is	O
displaced	O
by	O
the	O
selective	O
5	B-geneY
-	I-geneY
HT1D	E-geneY
agonist	O
sumatriptan	S-chem
but	O
not	O
by	O
the	O
mixed	O
5	B-geneN
-	I-geneN
HT1A	I-geneN
/	I-geneN
1D	E-geneN
agonist	O
5	B-chem
-	I-chem
carboxyamidotryptamine	E-chem
.	O

125I	B-chem
-	I-chem
labeled	I-chem
LSD	E-chem
binding	O
was	O
competitively	O
antagonized	O
by	O
the	O
ergot	O
alkaloids	O
methysergide	S-chem
and	O
ergotamine	S-chem
.	O

HeLa	O
cells	O
transfected	O
with	O
the	O
MR77	S-geneY
gene	O
exhibited	O
inhibition	O
of	O
adenylate	B-geneN
cyclase	E-geneN
in	O
response	O
to	O
serotonin	S-chem
.	O

MR77	S-geneY
is	O
expressed	O
at	O
low	O
levels	O
throughout	O
the	O
brain	O
,	O
with	O
the	O
greatest	O
expression	O
in	O
the	O
cortex	O
,	O
hippocampus	O
,	O
and	O
striatum	O
.	O

MR77	S-geneY
thus	O
represents	O
a	O
5	B-geneN
-	I-geneN
HT	I-geneN
receptor	E-geneN
of	O
the	O
5	B-geneN
-	I-geneN
HT1	E-geneN
class	O
,	O
and	O
we	O
propose	O
that	O
,	O
based	O
on	O
the	O
pharmacological	O
characterization	O
,	O
MR77	S-geneY
represents	O
an	O
additional	O
5	B-geneY
-	I-geneY
HT1E	E-geneY
-	O
like	O
receptor	O
.	O

G6PC2	S-geneY
:	O
A	O
Negative	O
Regulator	O
of	O
Basal	O
Glucose	S-chem
-	O
Stimulated	O
Insulin	S-geneY
Secretion	O
.	O

Elevated	O
fasting	O
blood	O
glucose	S-chem
(	O
FBG	O
)	O
is	O
associated	O
with	O
increased	O
risk	O
for	O
the	O
development	O
of	O
type	O
2	O
diabetes	O
and	O
cardiovascular	O
-	O
associated	O
mortality	O
.	O

Genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
have	O
linked	O
polymorphisms	O
in	O
G6PC2	S-geneY
with	O
variations	O
in	O
FBG	O
and	O
body	O
fat	O
,	O
although	O
not	O
insulin	S-geneY
sensitivity	O
or	O
glucose	S-chem
tolerance	O
.	O

G6PC2	S-geneY
encodes	O
an	O
islet	O
-	O
specific	O
,	O
endoplasmic	O
reticulum	O
-	O
resident	O
glucose	B-geneY
-	I-geneY
6	I-geneY
-	I-geneY
phosphatase	I-geneY
catalytic	I-geneY
subunit	E-geneY
.	O

A	O
combination	O
of	O
in	O
situ	O
perfused	O
pancreas	O
,	O
in	O
vitro	O
isolated	O
islet	O
,	O
and	O
in	O
vivo	O
analyses	O
were	O
used	O
to	O
explore	O
the	O
function	O
of	O
G6pc2	S-geneY
in	O
mice	O
.	O

G6pc2	S-geneY
deletion	O
had	O
little	O
effect	O
on	O
insulin	S-geneN
sensitivity	O
and	O
glucose	S-chem
tolerance	O
,	O
whereas	O
body	O
fat	O
was	O
reduced	O
in	O
female	O
G6pc2	S-geneY
knockout	O
(	O
KO	O
)	O
mice	O
on	O
both	O
a	O
chow	O
and	O
high	O
-	O
fat	O
diet	O
,	O
observations	O
that	O
are	O
all	O
consistent	O
with	O
human	O
GWAS	O
data	O
.	O

G6pc2	S-geneY
deletion	O
resulted	O
in	O
a	O
leftward	O
shift	O
in	O
the	O
dose	O
-	O
response	O
curve	O
for	O
glucose	S-chem
-	O
stimulated	O
insulin	S-geneN
secretion	O
(	O
GSIS	O
)	O
.	O

As	O
a	O
consequence	O
,	O
under	O
fasting	O
conditions	O
in	O
which	O
plasma	O
insulin	S-geneN
levels	O
were	O
identical	O
,	O
blood	O
glucose	S-chem
levels	O
were	O
reduced	O
in	O
G6pc2	S-geneY
KO	O
mice	O
,	O
again	O
consistent	O
with	O
human	O
GWAS	O
data	O
.	O

Glucose	B-geneY
-	I-geneY
6	I-geneY
-	I-geneY
phosphatase	E-geneY
activity	O
was	O
reduced	O
,	O
whereas	O
basal	O
cytoplasmic	O
calcium	S-chem
levels	O
were	O
elevated	O
in	O
islets	O
isolated	O
from	O
G6pc2	S-geneY
KO	O
mice	O
.	O

These	O
data	O
suggest	O
that	O
G6pc2	S-geneY
represents	O
a	O
novel	O
,	O
negative	O
regulator	O
of	O
basal	O
GSIS	O
that	O
acts	O
by	O
hydrolyzing	O
glucose	B-chem
-	I-chem
6	I-chem
-	I-chem
phosphate	E-chem
,	O
thereby	O
reducing	O
glycolytic	O
flux	O
.	O

Anti	O
-	O
diabetic	O
property	O
of	O
Tinospora	O
cordifolia	O
and	O
its	O
active	O
compound	O
is	O
mediated	O
through	O
the	O
expression	O
of	O
Glut	B-geneY
-	I-geneY
4	E-geneY
in	O
L6	O
myotubes	O
.	O

Tinospora	O
cordifolia	O
is	O
a	O
well	O
reported	O
plant	O
possessing	O
numerous	O
medicinal	O
values	O
including	O
anti	O
-	O
diabetic	O
property	O
.	O

Aim	O
of	O
the	O
present	O
study	O
is	O
to	O
study	O
the	O
mechanism	O
of	O
action	O
of	O
Tinospora	O
cordifolia	O
and	O
its	O
active	O
compound	O
in	O
differentiated	O
myocytes	O
,	O
L6	O
cells	O
.	O

Key	O
marker	O
of	O
diabetes	O
in	O
cells	O
is	O
the	O
insulin	B-geneY
dependent	I-geneY
glucose	I-geneY
transporter	I-geneY
-	I-geneY
4	E-geneY
(	O
Glut	B-geneY
-	I-geneY
4	E-geneY
)	O
which	O
also	O
responds	O
to	O
exogenous	O
chemicals	O
,	O
and	O
is	O
over	O
expressed	O
up	O
to	O
5	O
-	O
and	O
4	O
-	O
fold	O
,	O
by	O
Tinospora	O
cordifolia	O
and	O
palmatine	S-chem
,	O
respectively	O
.	O

Next	O
to	O
Glut	B-geneY
-	I-geneY
4	E-geneY
,	O
the	O
predominant	O
protein	O
influencing	O
glucose	S-chem
metabolism	O
is	O
PPARα	B-geneN
and	I-geneN
γ	E-geneN
whose	O
expressions	O
were	O
also	O
positively	O
modulated	O
.	O

Further	O
,	O
the	O
inhibitors	O
of	O
insulin	S-geneN
pathway	O
prevented	O
glucose	S-chem
uptake	O
mediated	O
by	O
Tinospora	O
cordifolia	O
and	O
palmatine	S-chem
which	O
shows	O
that	O
the	O
activity	O
is	O
majorly	O
mediated	O
through	O
insulin	S-geneN
pathway	O
.	O

Northern	O
contaminant	O
mixtures	O
induced	O
morphological	O
and	O
functional	O
changes	O
in	O
human	O
coronary	O
artery	O
endothelial	O
cells	O
under	O
culture	O
conditions	O
typifying	O
high	O
fat	O
/	O
sugar	S-chem
diet	O
and	O
ethanol	S-chem
exposure	O
.	O

It	O
has	O
been	O
reported	O
that	O
Northern	O
populations	O
are	O
exposed	O
to	O
mixtures	O
of	O
various	O
environmental	O
contaminants	O
unique	O
to	O
the	O
Arctic	O
(	O
Northern	O
contaminant	O
mixtures	O
-	O
NCM	O
)	O
at	O
a	O
large	O
range	O
of	O
concentrations	O
,	O
depending	O
on	O
their	O
geological	O
location	O
,	O
age	O
,	O
lifestyle	O
and	O
dietary	O
habits	O
.	O

To	O
determine	O
if	O
these	O
contaminants	O
may	O
contribute	O
to	O
a	O
cardiovascular	O
health	O
risk	O
,	O
especially	O
when	O
combined	O
with	O
a	O
high	O
fat	O
and	O
sugar	S-chem
diet	O
and	O
ethanol	S-chem
exposure	O
,	O
we	O
treated	O
human	O
coronary	O
artery	O
endothelial	O
cells	O
(	O
HCAEC	O
)	O
with	O
two	O
mixtures	O
of	O
4	O
organic	O
(	O
NCM1	O
)	O
or	O
22	O
organic	O
and	O
inorganic	O
(	O
NCM2	O
)	O
chemicals	O
detected	O
in	O
Northerners	O
'	O
blood	O
during	O
2004	O
-	O
2005	O
in	O
the	O
presence	O
or	O
absence	O
of	O
low	B-geneN
-	I-geneN
density	I-geneN
lipoprotein	E-geneN
(	O
1.5mg	O
/	O
ml	O
)	O
,	O
very	B-geneN
-	I-geneN
low	I-geneN
-	I-geneN
density	I-geneN
lipoprotein	E-geneN
(	O
1.0mg	O
/	O
ml	O
)	O
and	O
glucose	S-chem
(	O
10mmol	O
/	O
L	O
)	O
(	O
LVG	O
)	O
,	O
and	O
in	O
the	O
absence	O
or	O
presence	O
of	O
0.1	O
%	O
ethanol	S-chem
.	O

After	O
24h	O
of	O
exposure	O
,	O
cell	O
morphology	O
and	O
markers	O
of	O
cytotoxicity	O
and	O
endothelial	O
function	O
were	O
examined	O
.	O

NCM1	O
treatment	O
did	O
not	O
affect	O
cell	O
viability	O
,	O
but	O
increased	O
cell	O
size	O
,	O
disrupted	O
cell	O
membrane	O
integrity	O
,	O
and	O
decreased	O
cell	O
density	O
,	O
uptake	O
of	O
small	O
peptides	O
,	O
release	O
of	O
endothelin	B-geneY
-	I-geneY
1	E-geneY
(	O
ET	B-geneY
-	I-geneY
1	E-geneY
)	O
and	O
plasminogen	B-geneN
activator	I-geneN
inhibitor	E-geneN
(	O
PAI	S-geneN
)	O
,	O
while	O
causing	O
no	O
changes	O
in	O
endothelial	B-geneY
nitric	I-geneY
oxide	I-geneY
synthase	E-geneY
(	O
eNOS	S-geneY
)	O
protein	O
expression	O
and	O
nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
release	O
.	O

In	O
contrast	O
,	O
NCM2	O
decreased	O
cell	O
viability	O
,	O
total	O
protein	O
yield	O
,	O
uptake	O
of	O
small	O
peptides	O
,	O
eNOS	S-geneY
protein	O
expression	O
,	O
and	O
NO	S-chem
release	O
and	O
caused	O
membrane	O
damage	O
,	O
but	O
caused	O
no	O
changes	O
in	O
the	O
secretion	O
of	O
ET	B-geneY
-	I-geneY
1	E-geneY
,	O
prostacyclin	S-chem
and	O
PAI	S-geneN
.	O

The	O
presence	O
of	O
LVG	O
and	O
/	O
or	O
alcohol	S-chem
did	O
or	O
did	O
not	O
influence	O
the	O
effects	O
of	O
NCM1	O
or	O
NCM2	O
depending	O
on	O
the	O
endpoint	O
and	O
the	O
mixture	O
examined	O
.	O

These	O
results	O
suggested	O
that	O
the	O
effects	O
of	O
one	O
or	O
one	O
group	O
of	O
contaminants	O
may	O
be	O
altered	O
by	O
the	O
presence	O
of	O
other	O
contaminants	O
,	O
and	O
that	O
with	O
or	O
without	O
the	O
interaction	O
of	O
high	O
fat	O
and	O
sugar	S-chem
diet	O
and	O
/	O
or	O
ethanol	S-chem
exposure	O
,	O
NCMs	O
at	O
the	O
concentrations	O
used	O
caused	O
endothelial	O
dysfunction	O
in	O
vitro	O
.	O

It	O
remains	O
to	O
be	O
investigated	O
if	O
these	O
effects	O
of	O
NCMs	O
also	O
occur	O
in	O
vivo	O
.	O

2	B-chem
-	I-chem
[	I-chem
4	I-chem
-	I-chem
(	I-chem
3,4	I-chem
-	I-chem
Dimethylphenyl	I-chem
)	I-chem
piperazin	I-chem
-	I-chem
1	I-chem
-	I-chem
ylmethyl	I-chem
]	I-chem
-	I-chem
1H	I-chem
benzoimidazole	E-chem
(	O
A	B-chem
-	I-chem
381393	E-chem
)	O
,	O
a	O
selective	O
dopamine	B-geneY
D4	I-geneY
receptor	E-geneY
antagonist	O
.	O

2	B-chem
-	I-chem
[	I-chem
4	I-chem
-	I-chem
(	I-chem
3,4	I-chem
-	I-chem
Dimethylphenlyl	I-chem
)	I-chem
piperazin	I-chem
-	I-chem
1	I-chem
-	I-chem
ylmethyl	I-chem
]	I-chem
-	I-chem
1H	I-chem
benzoimidazole	E-chem
(	O
A	B-chem
-	I-chem
381393	E-chem
)	O
was	O
identified	O
as	O
a	O
potent	O
dopamine	B-geneY
D4	I-geneY
receptor	E-geneY
antagonist	O
with	O
excellent	O
receptor	O
selectivity	O
.	O

[	B-chem
3H	I-chem
]	I-chem
-	I-chem
spiperone	E-chem
competition	O
binding	O
assays	O
showed	O
that	O
A	B-chem
-	I-chem
381393	E-chem
potently	O
bound	O
to	O
membrane	O
from	O
cells	O
expressing	O
recombinant	O
human	B-geneN
dopamine	I-geneN
D4.4	I-geneN
receptor	E-geneN
(	O
Ki	O
=	O
1.5	O
nM	O
)	O
,	O
which	O
was	O
20	O
-	O
fold	O
higher	O
than	O
that	O
of	O
clozapine	S-chem
(	O
Ki	O
=	O
30.4	O
nM	O
)	O
.	O

A	B-chem
-	I-chem
381393	E-chem
exhibited	O
highly	O
selective	O
binding	O
for	O
the	O
dopamine	B-geneN
D4.4	I-geneN
receptor	E-geneN
(	O
>	O
2700	O
-	O
fold	O
)	O
when	O
compared	O
to	O
D1	B-geneN
,	I-geneN
D2	I-geneN
,	I-geneN
D3	I-geneN
and	I-geneN
D5	I-geneN
dopamine	I-geneN
receptors	E-geneN
.	O

Furthermore	O
,	O
in	O
comparison	O
to	O
clozapine	S-chem
and	O
L	B-chem
-	I-chem
745870	E-chem
,	O
A	B-chem
-	I-chem
381393	E-chem
exhibits	O
better	O
receptor	O
selectivity	O
,	O
showing	O
no	O
affinity	O
up	O
to	O
10	O
microM	O
for	O
a	O
panel	O
of	O
more	O
than	O
70	O
receptors	O
and	O
channels	O
,	O
with	O
the	O
exception	O
of	O
moderate	O
affinity	O
for	O
5	B-geneY
-	I-geneY
HT2A	E-geneY
(	O
Ki	O
=	O
370	O
nM	O
)	O
.	O

A	B-chem
-	I-chem
381393	E-chem
potently	O
inhibited	O
the	O
functional	O
activity	O
of	O
agonist	O
-	O
induced	O
GTP	S-chem
-	O
gamma	O
-	O
S	O
binding	O
assay	O
and	O
1	O
microM	O
dopamine	S-chem
induced	O
-	O
Ca2	B-chem
+	E-chem
flux	O
in	O
human	B-geneN
dopamine	I-geneN
D4.4	I-geneN
receptor	E-geneN
expressing	O
cells	O
,	O
but	O
not	O
in	O
human	B-geneN
dopamine	I-geneN
D2L	I-geneN
or	I-geneN
D3	I-geneN
receptor	E-geneN
cells	O
.	O

In	O
contrast	O
to	O
L	B-chem
-	I-chem
745870	E-chem
,	O
A	B-chem
-	I-chem
381393	E-chem
did	O
not	O
exhibit	O
any	O
significant	O
intrinsic	O
activity	O
in	O
a	O
D4.4	B-geneN
receptor	E-geneN
.	O

In	O
vivo	O
,	O
A	B-chem
-	I-chem
381393	E-chem
has	O
good	O
brain	O
penetration	O
after	O
subcutaneous	O
administration	O
.	O

A	B-chem
-	I-chem
381393	E-chem
inhibited	O
penile	O
erection	O
induced	O
by	O
the	O
selective	O
D4	O
agonist	O
PD168077	S-chem
in	O
conscious	O
rats	O
.	O

Thus	O
,	O
A	B-chem
-	I-chem
381393	E-chem
is	O
a	O
novel	O
selective	O
D4	O
antagonist	O
that	O
will	O
enhance	O
the	O
ability	O
to	O
study	O
dopamine	B-geneN
D4	I-geneN
receptors	E-geneN
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Formation	O
of	O
mainstream	O
cigarette	O
smoke	O
constituents	O
prioritized	O
by	O
the	O
World	O
Health	O
Organization	O
-	O
-	O
yield	O
patterns	O
observed	O
in	O
market	O
surveys	O
,	O
clustering	O
and	O
inverse	O
correlations	O
.	O

The	O
WHO	O
TobReg	O
proposed	O
mandating	O
ceilings	O
on	O
selected	O
smoke	O
constituents	O
determined	O
from	O
the	O
market	O
-	O
specific	O
median	O
of	O
nicotine	S-chem
-	O
normalized	O
yield	O
distributions	O
.	O

Data	O
validating	O
this	O
regulatory	O
concept	O
were	O
obtained	O
from	O
essentially	O
single	O
-	O
blend	O
surveys	O
.	O

This	O
process	O
is	O
strongly	O
impacted	O
by	O
inverse	O
correlations	O
among	O
yields	O
.	O

In	O
the	O
present	O
study	O
,	O
18	O
priority	O
WHO	O
smoke	O
constituent	O
yields	O
(	O
nicotine	S-chem
-	O
normalized	O
)	O
were	O
determined	O
(	O
using	O
two	O
smoking	O
regimens	O
)	O
from	O
262	O
commercial	O
brands	O
including	O
American	O
,	O
Virginia	O
and	O
local	O
blends	O
from	O
13	O
countries	O
.	O

Principal	O
Component	O
Analysis	O
was	O
used	O
to	O
identify	O
yields	O
patterns	O
,	O
clustering	O
of	O
blend	O
types	O
and	O
the	O
inverse	O
correlations	O
causing	O
these	O
clusters	O
.	O

Three	O
principal	O
components	O
explain	O
about	O
75	O
%	O
of	O
total	O
data	O
variability	O
.	O

PC1	O
was	O
sensitive	O
to	O
the	O
relative	O
levels	O
of	O
gas	O
-	O
and	O
particle	O
-	O
phase	O
compounds	O
.	O

PC2	O
and	O
PC3	O
cluster	O
American	O
-	O
and	O
Virginia	O
-	O
blends	O
,	O
revealing	O
inverse	O
correlations	O
:	O
Nitrogen	B-chem
oxides	E-chem
and	O
amino	S-chem
-	O
or	O
nitroso	S-chem
-	O
aromatic	O
compounds	O
inversely	O
correlate	O
to	O
either	O
formaldehyde	S-chem
and	O
acrolein	S-chem
,	O
or	O
benzo	B-chem
(	I-chem
a	I-chem
)	I-chem
pyrene	E-chem
and	O
di	B-chem
-	I-chem
hydroxybenzenes	E-chem
.	O

These	O
results	O
can	O
be	O
explained	O
by	O
reviewing	O
the	O
processes	O
determining	O
each	O
components	O
smoke	O
delivery	O
.	O

Regulatory	O
initiatives	O
simultaneously	O
targeting	O
selected	O
smoke	O
constituents	O
in	O
markets	O
with	O
mixed	O
blend	O
styles	O
will	O
be	O
strongly	O
impacted	O
by	O
the	O
inverse	O
correlations	O
described	O
.	O

It	O
is	O
difficult	O
to	O
predict	O
the	O
ultimate	O
impact	O
of	O
such	O
regulations	O
on	O
public	O
health	O
,	O
considering	O
the	O
complex	O
chemistry	O
of	O
cigarette	O
smoke	O
formation	O
.	O

Rivastigmine	S-chem
for	O
Alzheimer	O
's	O
disease	O
.	O

BACKGROUND	O
:	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
is	O
the	O
commonest	O
cause	O
of	O
dementia	O
affecting	O
older	O
people	O
.	O

One	O
of	O
the	O
therapeutic	O
strategies	O
aimed	O
at	O
ameliorating	O
the	O
clinical	O
manifestations	O
of	O
Alzheimer	O
's	O
disease	O
is	O
to	O
enhance	O
cholinergic	O
neurotransmission	O
in	O
relevant	O
parts	O
of	O
the	O
brain	O
by	O
the	O
use	O
of	O
cholinesterase	S-geneY
inhibitors	O
to	O
delay	O
the	O
breakdown	O
of	O
acetylcholine	S-chem
released	O
into	O
synaptic	O
clefts	O
.	O

Tacrine	S-chem
,	O
the	O
first	O
of	O
the	O
cholinesterase	S-geneY
inhibitors	O
to	O
undergo	O
extensive	O
trials	O
for	O
this	O
purpose	O
,	O
was	O
associated	O
with	O
significant	O
adverse	O
effects	O
including	O
hepatotoxicity	O
.	O

Other	O
cholinesterase	S-geneY
inhibitors	O
,	O
including	O
rivastigmine	S-chem
,	O
with	O
superior	O
properties	O
in	O
terms	O
of	O
specificity	O
of	O
action	O
and	O
low	O
risk	O
of	O
adverse	O
effects	O
,	O
have	O
now	O
been	O
introduced	O
.	O

Rivastigmine	S-chem
has	O
received	O
approval	O
for	O
use	O
in	O
60	O
countries	O
including	O
all	O
member	O
states	O
of	O
the	O
European	O
Union	O
and	O
the	O
USA	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
rivastigmine	S-chem
for	O
patients	O
with	O
dementia	O
of	O
Alzheimer	O
's	O
type	O
.	O

SEARCH	O
STRATEGY	O
:	O
The	O
Specialized	O
Register	O
of	O
the	O
Cochrane	O
Dementia	O
and	O
Cognitive	O
Improvement	O
Group	O
(	O
CDCIG	O
)	O
,	O
The	O
Cochrane	O
Library	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
PsycINFO	O
,	O
CINAHL	O
and	O
LILACS	O
were	O
searched	O
on	O
27	O
March	O
2008	O
using	O
the	O
terms	O
:	O
Rivastigmine	S-chem
OR	O
exelon	S-chem
OR	O
ENA	S-chem
OR	O
``	O
SDZ	I-chem
ENA	I-chem
713	O
``	O
.	O

The	O
CDCIG	O
Specialized	O
Register	O
contains	O
records	O
from	O
all	O
major	O
health	O
care	O
databases	O
(	O
The	O
Cochrane	O
Library	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
PsycINFO	O
,	O
CINAHL	O
,	O
LILACS	O
)	O
as	O
well	O
as	O
from	O
many	O
clinical	O
trials	O
registries	O
and	O
grey	O
literature	O
sources	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
unconfounded	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
trials	O
in	O
which	O
treatment	O
with	O
rivastigmine	S-chem
was	O
administered	O
to	O
patients	O
with	O
dementia	O
of	O
the	O
Alzheimer	O
's	O
type	O
for	O
more	O
than	O
two	O
weeks	O
and	O
its	O
effects	O
compared	O
with	O
those	O
of	O
placebo	O
in	O
a	O
parallel	O
group	O
of	O
patients	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
One	O
reviewer	O
(	O
JSB	O
)	O
applied	O
study	O
selection	O
criteria	O
,	O
assessed	O
the	O
quality	O
of	O
studies	O
and	O
extracted	O
data	O
.	O

MAIN	O
RESULTS	O
:	O
Nine	O
trials	O
,	O
involving	O
4775	O
participants	O
,	O
were	O
included	O
in	O
the	O
analyses	O
.	O

Use	O
of	O
rivastigmine	S-chem
in	O
high	O
doses	O
was	O
associated	O
with	O
statistically	O
significant	O
benefits	O
on	O
several	O
measures	O
.	O

High	O
-	O
dose	O
rivastigmine	S-chem
(	O
6	O
to	O
12	O
mg	O
daily	O
)	O
was	O
associated	O
with	O
a	O
two	O
-	O
point	O
improvement	O
in	O
cognitive	O
function	O
on	O
the	O
ADAS	O
-	O
Cog	O
score	O
compared	O
with	O
placebo	O
(	O
weighted	O
mean	O
difference	O
-	O
1.99	O
,	O
95	O
%	O
confidence	O
interval	O
-	O
2.49	O
to	O
-	O
1.50	O
,	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
)	O
and	O
a	O
2.2	O
point	O
improvement	O
in	O
activities	O
of	O
daily	O
living	O
assessed	O
on	O
the	O
Progressive	O
Deterioration	O
Scale	O
(	O
weighted	O
mean	O
difference	O
-	O
2.15	O
,	O
95	O
%	O
confidence	O
interval	O
-	O
3.16	O
to	O
-	O
1.13	O
,	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
)	O
at	O
26	O
weeks	O
.	O

At	O
lower	O
doses	O
(	O
4	O
mg	O
daily	O
or	O
lower	O
)	O
differences	O
were	O
in	O
the	O
same	O
direction	O
but	O
were	O
statistically	O
significant	O
only	O
for	O
cognitive	O
function	O
.	O

There	O
were	O
statistically	O
significantly	O
higher	O
numbers	O
of	O
events	O
of	O
nausea	O
,	O
vomiting	O
,	O
diarrhoea	O
,	O
anorexia	O
,	O
headache	O
,	O
syncope	O
,	O
abdominal	O
pain	O
and	O
dizziness	O
among	O
patients	O
taking	O
high	O
-	O
dose	O
rivastigmine	S-chem
than	O
among	O
those	O
taking	O
placebo	O
.	O

There	O
was	O
some	O
evidence	O
that	O
adverse	O
events	O
might	O
be	O
less	O
common	O
with	O
more	O
frequent	O
,	O
smaller	O
doses	O
of	O
rivastigmine	S-chem
.	O

The	O
2008	O
update	O
includes	O
a	O
new	O
study	O
testing	O
two	O
types	O
of	O
rivastigmine	S-chem
transdermal	O
patch	O
,	O
one	O
delivering	O
a	O
higher	O
dose	O
than	O
previously	O
tested	O
(	O
17.4	O
mg	O
/	O
day	O
)	O
and	O
a	O
smaller	O
patch	O
delivering	O
9.6	O
mg	O
/	O
day	O
.	O

The	O
efficacy	O
of	O
the	O
smaller	O
patch	O
was	O
not	O
significantly	O
different	O
compared	O
with	O
the	O
capsules	O
of	O
similar	O
daily	O
dose	O
,	O
but	O
was	O
associated	O
with	O
significantly	O
fewer	O
adverse	O
events	O
of	O
nausea	O
,	O
vomiting	O
,	O
dizziness	O
and	O
asthenia	O
.	O

The	O
efficacy	O
of	O
the	O
larger	O
patch	O
was	O
not	O
significantly	O
different	O
compared	O
with	O
the	O
smaller	O
patch	O
,	O
but	O
the	O
smaller	O
patch	O
was	O
associated	O
with	O
significantly	O
fewer	O
adverse	O
events	O
of	O
nausea	O
,	O
vomiting	O
,	O
weight	O
loss	O
and	O
dizziness	O
.	O

There	O
appears	O
to	O
be	O
advantages	O
associated	O
with	O
the	O
smaller	O
patch	O
compared	O
with	O
both	O
the	O
higher	O
dose	O
patch	O
and	O
the	O
6	O
-	O
12	O
mg	O
/	O
day	O
capsules	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
Rivastigmine	S-chem
appears	O
to	O
be	O
beneficial	O
for	O
people	O
with	O
mild	O
to	O
moderate	O
Alzheimer	O
's	O
disease	O
.	O

In	O
comparisons	O
with	O
placebo	O
,	O
improvements	O
were	O
seen	O
in	O
the	O
rate	O
of	O
decline	O
of	O
cognitive	O
function	O
,	O
activities	O
of	O
daily	O
living	O
,	O
and	O
severity	O
of	O
dementia	O
with	O
daily	O
doses	O
of	O
6	O
to	O
12	O
mg	O
.	O

Adverse	O
events	O
were	O
consistent	O
with	O
the	O
cholinergic	O
actions	O
of	O
the	O
drug	O
.	O

A	O
transdermal	O
patch	O
has	O
been	O
tested	O
in	O
one	O
trial	O
,	O
and	O
there	O
is	O
evidence	O
that	O
the	O
lower	O
dose	O
smaller	O
patch	O
is	O
associated	O
with	O
fewer	O
side	O
effects	O
than	O
the	O
capsules	O
or	O
the	O
higher	O
dose	O
larger	O
patch	O
and	O
has	O
comparable	O
efficacy	O
to	O
both	O
.	O

This	O
review	O
has	O
not	O
examined	O
economic	O
data	O
.	O

Design	O
,	O
synthesis	O
,	O
characterization	O
and	O
anti	O
-	O
inflammatory	O
evaluation	O
of	O
novel	O
pyrazole	S-chem
amalgamated	O
flavones	S-chem
.	O

A	O
series	O
of	O
novel	O
pyrazole	S-chem
amalgamated	O
flavones	S-chem
has	O
been	O
designed	O
and	O
synthesized	O
from	O
1	B-chem
-	I-chem
methyl	I-chem
-	I-chem
5	I-chem
-	I-chem
(	I-chem
2,4,6	I-chem
-	I-chem
trimethoxy	I-chem
-	I-chem
phenyl	I-chem
)	I-chem
-	I-chem
1H	I-chem
-	I-chem
pyrazole	E-chem
6	O
.	O

The	O
structures	O
of	O
regioisomers	O
6	O
and	O
7	O
were	O
resolved	O
by	O
2D	O
(	B-chem
1	I-chem
)	I-chem
H	E-chem
-	O
(	B-chem
1	I-chem
)	I-chem
H	E-chem
COSY	O
,	O
(	B-chem
1	I-chem
)	I-chem
H	E-chem
-	O
(	B-chem
13	I-chem
)	I-chem
C	E-chem
HSQC	O
and	O
(	B-chem
1	I-chem
)	I-chem
H	E-chem
-	O
(	B-chem
13	I-chem
)	I-chem
C	E-chem
HMBC	O
experiments	O
.	O

The	O
newly	O
synthesized	O
compounds	O
were	O
tested	O
for	O
their	O
in	O
vitro	O
COX	S-geneN
inhibition	O
and	O
in	O
vivo	O
carrageenan	O
induced	O
hind	O
paw	O
edema	O
in	O
rats	O
and	O
acetic	B-chem
acid	E-chem
induced	O
vascular	O
permeability	O
in	O
mice	O
.	O

Although	O
the	O
compounds	O
have	O
inhibitory	O
profile	O
against	O
both	O
COX	B-geneY
-	I-geneY
1	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
,	O
some	O
of	O
the	O
compounds	O
are	O
found	O
to	O
be	O
selective	O
against	O
COX	B-geneY
-	I-geneY
2	E-geneY
,	O
supported	O
by	O
inhibition	O
of	O
paw	O
edema	O
and	O
vascular	O
permeability	O
.	O

Docking	O
studies	O
were	O
also	O
carried	O
out	O
to	O
determine	O
the	O
structural	O
features	O
which	O
sway	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
the	O
tested	O
compounds	O
.	O

The	O
keto	S-chem
and	O
phenolic	S-chem
-	O
OH	S-chem
are	O
major	O
factors	O
that	O
are	O
prominently	O
involved	O
in	O
interaction	O
with	O
COX	B-geneY
-	I-geneY
2	E-geneY
active	O
site	O
.	O

Dopamine	B-geneY
D2	I-geneY
-	I-geneY
receptor	E-geneY
imaging	O
with	O
123I	B-chem
-	I-chem
iodobenzamide	E-chem
SPECT	O
in	O
migraine	O
patients	O
abusing	O
ergotamine	S-chem
:	O
does	O
ergotamine	S-chem
cross	O
the	O
blood	O
brain	O
barrier	O
?	O

Two	O
migraine	O
patients	O
were	O
studied	O
by	O
in	O
vivo	O
SPECT	O
using	O
the	O
dopamine	B-geneY
D2	I-geneY
-	I-geneY
receptor	E-geneY
specific	O
radioligand	O
123I	B-chem
-	I-chem
3	I-chem
-	I-chem
iodo	I-chem
-	I-chem
6	I-chem
-	I-chem
methoxybenzamide	E-chem
(	O
123I	B-chem
-	I-chem
IBZM	E-chem
)	O
during	O
ergotamine	S-chem
abuse	O
and	O
after	O
withdrawal	O
.	O

Results	O
were	O
compared	O
with	O
15	O
healthy	O
controls	O
.	O

Striatum	O
/	O
cerebellum	O
and	O
striatum	O
/	O
occipital	O
cortex	O
ratios	O
of	O
count	O
rate	O
density	O
were	O
calculated	O
as	O
a	O
semiquantitative	O
measurement	O
for	O
striatal	O
dopamine	B-geneY
D2	I-geneY
-	I-geneY
receptor	E-geneY
binding	O
potential	O
.	O

No	O
differences	O
were	O
found	O
in	O
striatal	O
uptake	O
of	O
123I	B-chem
-	I-chem
IBZM	E-chem
between	O
healthy	O
controls	O
and	O
the	O
patients	O
when	O
on	O
or	O
off	O
ergotamine	S-chem
.	O

Preliminary	O
evidence	O
suggests	O
that	O
ergotamine	S-chem
may	O
not	O
occupy	O
striatal	O
dopamine	B-geneY
D2	I-geneY
-	I-geneY
receptors	E-geneY
to	O
a	O
large	O
extent	O
and	O
thus	O
may	O
not	O
cross	O
the	O
blood	O
brain	O
barrier	O
in	O
large	O
quantities	O
.	O

The	O
physico	O
-	O
chemical	O
``	O
anatomy	O
``	O
of	O
the	O
tautomerization	O
through	O
the	O
DPT	O
of	O
the	O
biologically	O
important	O
pairs	O
of	B-chem
hypoxanthine	O
with	O
DNA	O
bases	O
:	O
QM	O
and	O
QTAIM	O
perspectives	O
.	O

The	O
biologically	O
important	O
tautomerization	O
of	O
the	O
Hyp	S-chem
·	O
Cyt	S-chem
,	O
Hyp	S-chem
*	O
·	O
Thy	S-chem
and	O
Hyp	S-chem
·	O
Hyp	S-chem
base	O
pairs	O
to	O
the	O
Hyp	S-chem
*	O
·	O
Cyt	S-chem
*	O
,	O
Hyp	S-chem
·	O
Thy	S-chem
*	O
and	O
Hyp	S-chem
*	O
·	O
Hyp	S-chem
*	O
base	O
pairs	O
,	O
respectively	O
,	O
by	O
the	O
double	O
proton	O
transfer	O
(	O
DPT	O
)	O
was	O
comprehensively	O
studied	O
in	O
vacuo	O
and	O
in	O
the	O
continuum	O
with	O
a	O
low	O
dielectric	O
constant	O
(	O
ε	O
=	O
4	O
)	O
corresponding	O
to	O
hydrophobic	O
interfaces	O
of	O
protein	O
-	O
nucleic	O
acid	O
interactions	O
by	O
combining	O
theoretical	O
investigations	O
at	O
the	O
B3LYP	O
/	O
6	O
-	O
311	O
+	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
level	O
of	O
QM	O
theory	O
with	O
QTAIM	O
topological	O
analysis	O
.	O

Based	O
on	O
the	O
sweeps	O
of	O
the	O
energetic	O
,	O
electron	O
-	O
topological	O
,	O
geometric	O
and	O
polar	O
parameters	O
,	O
which	O
describe	O
the	O
course	O
of	O
the	O
tautomerization	O
along	O
the	O
intrinsic	O
reaction	O
coordinate	O
(	O
IRC	O
)	O
,	O
it	O
was	O
proved	O
that	O
the	O
tautomerization	O
through	O
the	O
DPT	O
is	O
concerted	O
and	O
asynchronous	O
process	O
for	O
the	O
Hyp	S-chem
·	O
Cyt	S-chem
and	O
Hyp	S-chem
*	O
·	O
Thy	S-chem
base	O
pairs	O
,	O
while	O
concerted	O
and	O
synchronous	O
for	O
the	O
Hyp	S-chem
·	O
Hyp	S-chem
homodimer	O
.	O

The	O
continuum	O
with	O
ε	O
=	O
4	O
does	O
not	O
affect	O
qualitatively	O
the	O
course	O
of	O
the	O
tautomerization	O
reaction	O
for	O
all	O
studied	O
complexes	O
.	O

The	O
nine	O
key	O
points	O
along	O
the	O
IRC	O
of	O
the	O
Hyp	S-chem
·	O
Cyt	S-chem
↔	O
Hyp	S-chem
*	O
·	O
Cyt	S-chem
*	O
and	O
Hyp	S-chem
*	O
·	O
Thy	S-chem
↔	O
Hyp	S-chem
·	O
Thy	S-chem
*	O
tautomerizations	O
and	O
the	O
six	O
key	O
points	O
of	O
the	O
Hyp	S-chem
·	O
Hyp	S-chem
↔	O
Hyp	S-chem
*	O
·	O
Hyp	S-chem
*	O
tautomerization	O
have	O
been	O
identified	O
and	O
fully	O
characterized	O
.	O

These	O
key	O
points	O
could	O
be	O
considered	O
as	O
electron	O
-	O
topological	O
``	O
fingerprints	O
``	O
of	O
concerted	O
asynchronous	O
(	O
for	O
Hyp	O
·	I-chem
Cyt	O
and	O
Hyp	O
*	B-chem
·	I-chem
Thy	O
)	O
or	O
synchronous	O
(	O
for	O
Hyp	O
·	I-chem
Hyp	O
)	O
tautomerization	O
process	O
via	O
the	O
DPT	O
.	O

It	O
was	O
found	O
,	O
that	O
in	O
the	O
Hyp	S-chem
*	O
·	O
Cyt	S-chem
*	O
,	O
Hyp	S-chem
·	O
Thy	S-chem
*	O
,	O
Hyp	S-chem
·	O
Hyp	S-chem
and	O
Hyp	S-chem
*	O
·	O
Hyp	S-chem
*	O
base	O
pairs	O
all	O
H	S-chem
-	O
bonds	O
are	O
significantly	O
cooperative	O
and	O
mutually	O
reinforce	O
each	O
other	O
,	O
while	O
the	O
C2H	S-chem
…	O
O2	B-chem
H	E-chem
-	O
bond	O
in	O
the	O
Hyp	S-chem
·	O
Cyt	S-chem
base	O
pair	O
and	O
the	O
O6H	S-chem
…	O
O4	S-chem
H	S-chem
-	O
bond	O
in	O
the	O
Hyp	S-chem
*	O
·	O
Thy	S-chem
base	O
pair	O
behave	O
anti	O
-	O
cooperatively	O
,	O
i.e	O
.	O
,	O
they	O
become	O
weakened	O
,	O
while	O
two	O
others	O
become	O
strengthened	O
.	O

Further	O
characterization	O
of	O
alpha	O
N	B-chem
-	I-chem
acetyl	E-chem
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
regulatory	O
activity	O
,	O
I	O
:	O
Effect	O
on	O
opioid	O
-	O
and	O
alpha	O
2	O
-	O
mediated	O
supraspinal	O
antinociception	O
in	O
mice	O
.	O

Picomol	O
doses	O
of	O
the	O
acetylated	O
derivative	O
of	O
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
,	O
injected	O
intracerebroventricularly	O
(	O
icv	O
)	O
in	O
mice	O
,	O
reduced	O
the	O
analgesic	O
activity	O
of	O
morphine	S-chem
,	O
etorphine	S-chem
and	O
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
,	O
while	O
the	O
efficiency	O
of	O
DAGO	S-chem
and	O
DADLE	S-chem
in	O
producing	O
analgesia	O
was	O
enhanced	O
.	O

The	O
effects	O
of	O
the	O
delta	O
agonists	O
DPDPE	S-chem
and	O
[	B-chem
D	I-chem
-	I-chem
Ala2	I-chem
]	I-chem
-	I-chem
Deltorphin	I-chem
II	E-chem
were	O
not	O
altered	O
by	O
this	O
treatment	O
.	O

After	O
alpha	O
N	B-chem
-	I-chem
acetyl	E-chem
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
injection	O
,	O
morphine	S-chem
antagonized	O
the	O
analgesia	O
of	O
DAGO	S-chem
.	O

The	O
regulatory	O
effect	O
of	O
alpha	O
N	B-chem
-	I-chem
acetyl	E-chem
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
was	O
exhibited	O
when	O
giving	O
the	O
peptide	O
both	O
before	O
(	O
up	O
to	O
24	O
h	O
)	O
and	O
after	O
the	O
opioids	O
.	O

Naloxone	S-chem
did	O
not	O
prevent	O
or	O
reverse	O
that	O
modulatory	O
activity	O
;	O
moreover	O
,	O
pretreatment	O
with	O
the	O
acetylated	O
peptide	O
did	O
not	O
change	O
the	O
pA2	O
value	O
displayed	O
by	O
the	O
antagonist	O
at	O
the	O
mu	B-geneY
receptor	E-geneY
.	O

The	O
antinociceptive	O
activity	O
of	O
the	O
alpha	B-geneN
2	I-geneN
-	I-geneN
adrenoceptor	E-geneN
agonist	O
clonidine	S-chem
was	O
also	O
increased	O
in	O
mice	O
treated	O
with	O
alpha	O
N	B-chem
-	I-chem
acetyl	E-chem
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
.	O

The	O
reducing	O
activity	O
of	O
alpha	O
N	B-chem
-	I-chem
acetyl	E-chem
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
upon	O
morphine	S-chem
-	O
and	O
beta	O
-	O
endorphin	O
-	O
induced	O
analgesia	O
was	O
not	O
exhibited	O
in	O
mice	O
undergoing	O
treatment	O
with	O
pertussis	O
toxin	O
or	O
N	B-chem
-	I-chem
ethylmaleimide	E-chem
,	O
agents	O
known	O
to	O
impair	O
the	O
function	O
of	O
Gi	S-geneN
/	O
Go	S-geneN
transducer	O
proteins	O
.	O

However	O
,	O
the	O
enhancing	O
activity	O
displayed	O
by	O
this	O
peptide	O
upon	O
DAGO	S-chem
-	O
DADLE	S-chem
and	O
clonidine	S-chem
-	O
evoked	O
antinociception	O
was	O
still	O
manifested	O
.	O

These	O
results	O
confirm	O
and	O
strengthen	O
the	O
idea	O
of	O
alpha	O
N	B-chem
-	I-chem
acetyl	E-chem
beta	O
-	O
endorphin	O
-	O
(	O
1	O
-	O
31	O
)	O
acting	O
as	O
a	O
non	O
-	O
competitive	O
regulator	O
of	O
mu	B-geneY
opioid	E-geneY
-	O
and	O
alpha	B-geneN
2	I-geneN
-	I-geneN
adrenoceptor	E-geneN
-	O
mediated	O
supraspinal	O
antinociception	O
.	O

A	O
neural	O
substrate	O
acted	O
on	O
by	O
both	O
receptors	O
(	O
likely	O
Gi	S-geneN
/	O
Go	S-geneN
transducer	O
proteins	O
)	O
appears	O
to	O
be	O
involved	O
in	O
the	O
effects	O
of	O
that	O
neuropeptide	O
.	O

Pterostilbene	S-chem
exerts	O
antitumor	O
activity	O
against	O
human	O
osteosarcoma	O
cells	O
by	O
inhibiting	O
the	O
JAK2	S-geneY
/	O
STAT3	S-geneY
signaling	O
pathway	O
.	O

Osteosarcoma	O
is	O
a	O
high	O
-	O
grade	O
malignant	O
bone	O
tumor	O
.	O

Pterostilbene	S-chem
(	O
PTE	S-chem
)	O
is	O
a	O
natural	O
,	O
dimethylated	O
analog	O
of	O
resveratrol	S-chem
with	O
higher	O
bioavailability	O
.	O

While	O
PTE	S-chem
has	O
been	O
shown	O
to	O
have	O
potent	O
antitumor	O
activity	O
against	O
various	O
types	O
of	O
cancer	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
effects	O
of	O
PTE	S-chem
remain	O
largely	O
unknown	O
.	O

The	O
Janus	B-geneY
kinase	I-geneY
2	E-geneY
/	O
Signal	B-geneY
Transducer	I-geneY
and	I-geneY
Activator	I-geneY
of	I-geneY
Transcription	I-geneY
3	E-geneY
(	O
JAK2	S-geneY
/	O
STAT3	S-geneY
)	O
signaling	O
pathway	O
plays	O
a	O
crucial	O
role	O
in	O
tumorigenesis	O
and	O
immune	O
development	O
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
the	O
antitumor	O
activity	O
of	O
PTE	S-chem
against	O
human	O
osteosarcoma	O
cells	O
and	O
explored	O
the	O
role	O
of	O
JAK2	S-geneY
/	O
STAT3	S-geneY
and	O
apoptosis	O
-	O
related	O
signaling	O
pathways	O
on	O
the	O
activity	O
of	O
PTE	S-chem
.	O

PTE	S-chem
treatment	O
resulted	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
inhibition	O
of	O
osteosarcoma	O
cell	O
viability	O
.	O

Additionally	O
,	O
PTE	S-chem
exhibited	O
strong	O
antitumor	O
activity	O
,	O
as	O
evidenced	O
not	O
only	O
by	O
reductions	O
in	O
tumor	O
cell	O
adhesion	O
,	O
migration	O
and	O
mitochondrial	O
membrane	O
potential	O
(	O
MMP	O
)	O
but	O
also	O
by	O
increases	O
in	O
the	O
apoptotic	O
index	O
,	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
and	O
several	O
biochemical	O
parameters	O
.	O

Furthermore	O
,	O
PTE	S-chem
treatment	O
directly	O
inhibited	O
the	O
phosphorylation	O
of	O
JAK2	S-geneY
at	O
Tyr	S-chem
1007	O
and	O
the	O
downstream	O
activation	O
of	O
STAT3	S-geneY
.	O

PTE	S-chem
also	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
STAT3	S-geneY
target	O
genes	O
,	O
including	O
the	O
anti	O
-	O
apoptotic	O
proteins	O
Bcl	B-geneY
-	I-geneY
xL	E-geneY
and	O
Mcl	B-geneY
-	I-geneY
1	E-geneY
,	O
leading	O
to	O
the	O
up	O
-	O
regulation	O
of	O
mitochondrial	O
apoptosis	O
pathway	O
-	O
related	O
proteins	O
(	O
Bax	S-geneY
,	O
Bak	S-geneY
,	O
cytosolic	O
Cytochrome	B-geneY
c	E-geneY
,	O
and	O
cleaved	O
Caspase3	S-geneY
)	O
and	O
cyclin	B-geneN
-	I-geneN
dependent	I-geneN
kinase	E-geneN
inhibitors	O
such	O
as	O
p21	S-geneY
and	O
p27	S-geneY
.	O

PTE	S-chem
,	O
used	O
in	O
combination	O
with	O
a	O
known	O
JAK2	S-geneY
/	O
STAT3	S-geneY
inhibitor	O
,	O
AG490	S-chem
,	O
further	O
decreased	O
the	O
viability	O
of	O
osteosarcoma	O
cells	O
.	O

Taken	O
together	O
,	O
PTE	S-chem
is	O
a	O
potent	O
inhibitor	O
of	O
osteosarcoma	O
cell	O
growth	O
that	O
targets	O
the	O
JAK2	S-geneY
/	O
STAT3	S-geneY
signaling	O
pathway	O
.	O

These	O
data	O
suggest	O
that	O
inhibition	O
of	O
JAK2	S-geneY
/	O
STAT3	S-geneY
signaling	O
is	O
a	O
novel	O
mechanism	O
of	O
action	O
for	O
PTE	S-chem
during	O
therapeutic	O
intervention	O
in	O
osteosarcoma	O
cancers	O
.	O

Genetic	O
linkage	O
of	O
Fc	B-geneY
gamma	I-geneY
RIIa	E-geneY
and	O
Fc	B-geneY
gamma	I-geneY
RIIIa	E-geneY
and	O
implications	O
for	O
their	O
use	O
in	O
predicting	O
clinical	O
responses	O
to	O
CD20	S-geneY
-	O
directed	O
monoclonal	O
antibody	O
therapy	O
.	O

BACKGROUND	O
:	O
Polymorphisms	O
in	O
FcgammaRIIa	S-geneY
and	O
FcgammaRIIIa	S-geneY
receptors	O
are	O
associated	O
with	O
responses	O
to	O
the	O
CD20	S-geneY
-	O
directed	O
immunoglobulin	B-geneY
G1	E-geneY
(	O
IgG1	S-geneY
)	O
monoclonal	O
antibody	O
rituximab	O
among	O
patients	O
with	O
indolent	O
lymphoma	O
.	O

At	O
odds	O
with	O
the	O
aforementioned	O
clinical	O
observations	O
has	O
been	O
the	O
finding	O
that	O
IgG1	S-geneY
binding	O
is	O
impacted	O
by	O
polymorphisms	O
in	O
FcgammaRIIIa	S-geneY
but	O
not	O
FcgammaRIIa	S-geneY
.	O

One	O
possibility	O
for	O
this	O
discrepancy	O
might	O
involve	O
linkage	O
of	O
polymorphisms	O
between	O
FcgammaRIIa	S-geneY
and	O
FcgammaRIIIa	S-geneY
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
As	O
such	O
,	O
we	O
performed	O
allelespecific	O
polymerase	O
chain	O
reaction	O
and	O
directed	O
sequencing	O
of	O
the	O
genomic	O
DNA	O
coding	O
region	O
of	O
FcgammaRIIA	S-geneY
and	O
FcgammaRIIIA	S-geneY
for	O
52	O
healthy	O
individuals	O
.	O

RESULTS	O
:	O
Two	O
common	O
polymorphisms	O
were	O
observed	O
for	O
FcgammaRIIA	S-geneY
(	O
at	O
positions	O
27	O
and	O
131	O
)	O
and	O
FcgammaRIIIA	S-geneY
(	O
at	O
positions	O
48	O
and	O
158	O
)	O
.	O

Importantly	O
,	O
we	O
observed	O
linkage	O
among	O
polymorphisms	O
within	O
and	O
between	O
FcgammaRIIa	S-geneY
and	O
FcgammaRIIIa	S-geneY
,	O
including	O
the	O
expression	O
of	O
histidine	O
at	O
FcgammaRIIa	S-geneY
-	O
131	O
and	O
valine	O
at	O
FcgammaRIIIa	S-geneY
,	O
both	O
of	O
which	O
are	O
associated	O
with	O
enhanced	O
responses	O
to	O
rituximab	O
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrate	O
that	O
there	O
is	O
wide	O
linkage	O
within	O
and	O
between	O
polymorphisms	O
in	O
FcgammaRIIa	S-geneY
and	O
FcgammaRIIIa	S-geneY
and	O
might	O
provide	O
an	O
explanation	O
for	O
why	O
polymorphisms	O
at	O
FcgammaRIIa	S-geneY
are	O
associated	O
with	O
rituximab	O
responses	O
despite	O
a	O
lack	O
of	O
impact	O
on	O
IgG1	S-geneY
binding	O
.	O

CONCLUSION	O
:	O
Knowledge	O
of	O
such	O
linkages	O
could	O
facilitate	O
the	O
development	O
of	O
diagnostic	O
tests	O
aimed	O
at	O
identifying	O
patients	O
who	O
might	O
be	O
more	O
suitable	O
for	O
treatment	O
with	O
rituximab	O
and	O
possibly	O
other	O
therapeutic	O
antibodies	O
.	O

Structure	O
of	O
acetylcholinesterase	S-geneY
complexed	O
with	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
galanthamine	E-chem
at	O
2.3	O
A	O
resolution	O
.	O

(	B-chem
-	I-chem
)	I-chem
-	I-chem
Galanthamine	E-chem
(	O
GAL	S-chem
)	O
,	O
an	O
alkaloid	O
from	O
the	O
flower	O
,	O
the	O
common	O
snowdrop	O
(	O
Galanthus	O
nivalis	O
)	O
,	O
shows	O
anticholinesterase	O
activity	O
.	O

This	O
property	O
has	O
made	O
GAL	O
the	O
target	O
of	O
research	O
as	O
to	O
its	O
effectiveness	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
.	O

We	O
have	O
solved	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
GAL	O
bound	O
in	O
the	O
active	O
site	O
of	O
Torpedo	B-geneY
californica	I-geneY
acetylcholinesterase	E-geneY
(	O
TcAChE	S-geneY
)	O
to	O
2.3	O
A	O
resolution	O
.	O

The	O
inhibitor	O
binds	O
at	O
the	O
base	O
of	O
the	O
active	O
site	O
gorge	O
of	O
TcAChE	S-geneY
,	O
interacting	O
with	O
both	O
the	O
choline	B-geneN
-	I-geneN
binding	I-geneN
site	E-geneN
(	O
Trp	S-chem
-	O
84	O
)	O
and	O
the	O
acyl	B-geneN
-	I-geneN
binding	I-geneN
pocket	E-geneN
(	O
Phe	S-chem
-	O
288	O
,	O
Phe	S-chem
-	O
290	O
)	O
.	O

The	O
tertiary	B-chem
amine	E-chem
group	O
of	O
GAL	O
does	O
not	O
interact	O
closely	O
with	O
Trp	S-chem
-	O
84	O
;	O
rather	O
,	O
the	O
double	O
bond	O
of	O
its	O
cyclohexene	S-chem
ring	O
stacks	O
against	O
the	O
indole	S-chem
ring	O
.	O

The	O
tertiary	O
amine	O
appears	O
to	O
make	O
a	O
non	O
-	O
conventional	O
hydrogen	S-chem
bond	O
,	O
via	O
its	O
N	B-chem
-	I-chem
methyl	E-chem
group	O
,	O
to	O
Asp	S-chem
-	O
72	O
,	O
near	O
the	O
top	O
of	O
the	O
gorge	O
.	O

The	O
hydroxyl	S-chem
group	O
of	O
the	O
inhibitor	O
makes	O
a	O
strong	O
hydrogen	S-chem
bond	O
(	O
2.7	O
A	O
)	O
with	O
Glu	S-chem
-	O
199	O
.	O

The	O
relatively	O
tight	O
binding	O
of	O
GAL	O
to	O
TcAChE	S-geneY
appears	O
to	O
arise	O
from	O
a	O
number	O
of	O
moderate	O
to	O
weak	O
interactions	O
with	O
the	O
protein	O
,	O
coupled	O
to	O
a	O
low	O
entropy	O
cost	O
for	O
binding	O
due	O
to	O
the	O
rigid	O
nature	O
of	O
the	O
inhibitor	O
.	O

α	B-chem
-	I-chem
Amino	I-chem
-	I-chem
α´	I-chem
-	I-chem
Halomethylketones	E-chem
:	O
Synthetic	O
Methodologies	O
and	O
Pharmaceutical	O
Applications	O
as	O
Serine	B-geneN
and	I-geneN
Cysteine	I-geneN
Protease	E-geneN
Inhibitors	O
.	O

α	B-chem
-	I-chem
Amino	I-chem
-	I-chem
α´	I-chem
-	I-chem
halomethylketones	E-chem
are	O
interesting	O
scaffolds	O
bearing	O
(	O
at	O
least	O
)	O
two	O
sequential	O
electrophilic	O
carbons	S-chem
that	O
by	O
interacting	O
with	O
the	O
nucleophilic	O
moieties	O
of	O
several	O
enzymes	O
,	O
represent	O
the	O
ideal	O
candidates	O
for	O
in	O
vivo	O
and	O
in	O
vitro	O
inhibition	O
studies	O
.	O

In	O
this	O
work	O
a	O
summary	O
of	O
their	O
use	O
as	O
optimal	O
inhibitors	O
of	O
physiologically	O
relevant	O
serine	B-geneN
and	I-geneN
cysteine	I-geneN
proteases	E-geneN
is	O
given	O
with	O
a	O
particular	O
emphasis	O
on	O
recently	O
established	O
SAR	O
studies	O
.	O

A	O
brief	O
survey	O
of	O
the	O
most	O
relevant	O
synthetic	O
processes	O
for	O
their	O
obtainment	O
and	O
the	O
importance	O
they	O
possess	O
in	O
synthetic	O
medicinal	O
chemistry	O
is	O
reported	O
.	O

Gonadotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
functionally	O
antagonizes	O
testosterone	S-chem
activation	O
of	O
the	O
human	B-geneY
androgen	I-geneY
receptor	E-geneY
in	O
prostate	O
cells	O
through	O
focal	O
adhesion	O
complexes	O
involving	O
Hic	B-geneY
-	I-geneY
5	E-geneY
.	O

Gonadotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
(	O
GnRH	S-geneY
)	O
analogs	O
constitute	O
the	O
most	O
widely	O
employed	O
medical	O
treatment	O
for	O
prostatic	O
cancer	O
.	O

The	O
predominant	O
mechanism	O
of	O
action	O
is	O
presumed	O
to	O
be	O
via	O
the	O
inhibition	O
of	O
gonadotropins	O
and	O
resultant	O
decrease	O
in	O
androgen	O
.	O

However	O
,	O
GnRH	S-geneY
analogs	O
have	O
also	O
been	O
shown	O
to	O
directly	O
inhibit	O
prostate	O
cancer	O
cells	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
through	O
antiproliferative	O
cell	O
cycle	O
arrest	O
and	O
stimulation	O
of	O
apoptosis	O
.	O

Since	O
the	O
GnRH	B-geneY
receptor	E-geneY
has	O
been	O
shown	O
to	O
affect	O
sex	B-geneN
steroid	I-geneN
hormone	I-geneN
receptor	E-geneN
function	O
,	O
we	O
considered	O
that	O
part	O
of	O
GnRH	S-geneY
analog	O
actions	O
on	O
prostate	O
cells	O
may	O
be	O
mediated	O
through	O
modulation	O
of	O
the	O
human	B-geneY
androgen	I-geneY
receptor	E-geneY
.	O

Using	O
a	O
model	O
HEK293	O
cell	O
line	O
expressing	O
the	O
GnRH	B-geneY
receptor	E-geneY
,	O
we	O
demonstrated	O
a	O
novel	O
signalling	O
pathway	O
of	O
the	O
GnRH	B-geneY
receptor	E-geneY
that	O
induces	O
nuclear	O
translocation	O
of	O
the	O
androgen	B-geneY
receptor	E-geneY
that	O
renders	O
it	O
transcriptionally	O
inactive	O
.	O

This	O
mechanism	O
involves	O
the	O
calcium	S-chem
-	O
dependent	O
tyrosine	B-geneN
kinase	E-geneN
Pyk2	S-geneY
,	O
the	O
non	B-geneN
-	I-geneN
receptor	I-geneN
tyrosine	I-geneN
kinase	E-geneN
c	B-geneY
-	I-geneY
Src	E-geneY
and	O
the	O
focal	B-geneN
adhesion	I-geneN
protein	E-geneN
/	O
steroid	B-geneN
receptor	I-geneN
co	I-geneN
-	I-geneN
factor	E-geneN
,	O
Hic	B-geneY
-	I-geneY
5	E-geneY
.	O

In	O
this	O
setting	O
there	O
is	O
a	O
GnRH	S-geneY
-	O
induced	O
association	O
and	O
nuclear	O
translocation	O
of	O
the	O
androgen	B-geneY
receptor	E-geneY
with	O
Hic	B-geneY
-	I-geneY
5	E-geneY
.	O

GnRH	S-geneY
-	O
induced	O
Pyk2	S-geneY
activation	O
opposed	O
the	O
association	O
of	O
Hic	B-geneY
-	I-geneY
5	E-geneY
with	O
androgen	B-geneY
receptor	E-geneY
as	O
overexpression	O
of	O
a	O
dominant	O
negative	O
Pyk2	S-geneY
enhanced	O
the	O
GnRH	S-geneY
-	O
induced	O
nuclear	O
translocation	O
of	O
a	O
green	O
fluorescent	O
protein	O
-	O
tagged	O
human	B-geneY
androgen	I-geneY
receptor	E-geneY
.	O

GnRH	S-geneY
-	O
induced	O
c	B-geneY
-	I-geneY
Src	E-geneY
activation	O
resulted	O
in	O
the	O
phosphorylation	O
of	O
expressed	O
Hic	B-geneY
-	I-geneY
5	E-geneY
and	O
promoted	O
its	O
association	O
with	O
the	O
human	B-geneY
androgen	I-geneY
receptor	E-geneY
.	O

In	O
contrast	O
to	O
testosterone	S-chem
,	O
GnRH	S-geneY
-	O
induced	O
nuclear	O
translocation	O
did	O
not	O
transcriptionally	O
activate	O
the	O
androgen	B-geneY
receptor	E-geneY
.	O

We	O
then	O
demonstrated	O
that	O
GnRH	S-geneY
can	O
also	O
stimulate	O
androgen	B-geneY
receptor	E-geneY
mobilization	O
in	O
human	O
prostate	O
PC3	O
,	O
BPH	O
-	O
1	O
and	O
LNCaP	O
cells	O
,	O
and	O
in	O
cultured	O
rat	O
ventral	O
prostate	O
cells	O
through	O
the	O
same	O
mechanism	O
.	O

To	O
determine	O
if	O
GnRH	S-geneY
could	O
antagonize	O
androgen	O
effects	O
in	O
normal	O
tissue	O
,	O
we	O
examined	O
the	O
effect	O
of	O
GnRH	S-geneY
on	O
rat	O
ventral	O
prostate	O
organ	O
cultures	O
and	O
demonstrated	O
that	O
GnRH	S-geneY
can	O
functionally	O
antagonize	O
the	O
actions	O
of	O
testosterone	S-chem
on	O
prostate	O
cell	O
proliferation	O
and	O
tissue	O
growth	O
.	O

This	O
antagonism	O
of	O
testosterone	S-chem
action	O
by	O
GnRH	S-geneY
may	O
underlie	O
in	O
part	O
the	O
capacity	O
of	O
GnRH	B-geneY
receptor	E-geneY
activation	O
to	O
inhibit	O
prostate	O
tumor	O
growth	O
.	O

Vegfrecine	S-chem
,	O
an	O
Inhibitor	O
of	O
VEGF	B-geneN
Receptor	I-geneN
Tyrosine	I-geneN
Kinases	E-geneN
Isolated	O
from	O
the	O
Culture	O
Broth	O
of	O
Streptomyces	O
sp	O
.	O

A	O
new	O
inhibitor	O
of	O
VEGF	B-geneN
receptor	I-geneN
tyrosine	I-geneN
kinases	E-geneN
,	O
vegfrecine	S-chem
(	O
1	O
)	O
,	O
was	O
isolated	O
from	O
the	O
culture	O
broth	O
of	O
Streptomyces	O
sp	O
.	O

MK931	O
-	O
CF8	O
.	O

The	O
molecular	O
structure	O
of	O
1	O
was	O
determined	O
by	O
NMR	O
and	O
MS	O
analysis	O
combined	O
with	O
synthesis	O
.	O

Compound	O
1	O
showed	O
potent	O
inhibitory	O
activity	O
against	O
vascular	B-geneN
endothelial	I-geneN
growth	I-geneN
factor	I-geneN
receptor	E-geneN
(	O
VEGFR	S-geneN
)	O
tyrosine	B-geneN
kinases	E-geneN
in	O
in	O
vitro	O
enzyme	O
assays	O
,	O
but	O
platelet	B-geneN
-	I-geneN
derived	I-geneN
growth	I-geneN
factor	I-geneN
receptors	E-geneN
(	O
PDGFRs	S-geneN
)	O
,	O
fibroblast	B-geneN
growth	I-geneN
factor	I-geneN
receptor	E-geneN
(	O
FGFR	S-geneN
)	O
,	O
and	O
epidermal	B-geneY
growth	I-geneY
factor	I-geneY
receptor	E-geneY
(	O
EGFR	S-geneY
)	O
responded	O
only	O
weakly	O
.	O

Compound	O
1	O
is	O
a	O
promising	O
new	O
selective	O
VEGFR	S-geneN
inhibitor	O
for	O
investigating	O
new	O
treatments	O
of	O
cancer	O
and	O
inflammatory	O
diseases	O
.	O

MORAb	O
-	O
003	O
,	O
a	O
fully	O
humanized	O
monoclonal	O
antibody	O
against	O
the	O
folate	B-geneY
receptor	I-geneY
alpha	E-geneY
,	O
for	O
the	O
potential	O
treatment	O
of	O
epithelial	O
ovarian	O
cancer	O
.	O

Morphotek	O
Inc	O
is	O
developing	O
MORAb	O
-	O
003	O
,	O
a	O
humanized	O
monoclonal	O
antibody	O
directed	O
against	O
folate	B-geneY
receptor	I-geneY
alpha	E-geneY
,	O
for	O
the	O
potential	O
treatment	O
of	O
ovarian	O
cancer	O
.	O

Phase	O
II	O
clinical	O
trialsof	O
MORAb	O
-	O
003	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
platinum	S-chem
/	O
taxane	S-chem
chemotherapy	O
,	O
are	O
underway	O
in	O
ovarian	O
cancer	O
patients	O
experiencing	O
their	O
first	O
disease	O
recurrence	O
.	O

Potent	O
alpha	B-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
-	O
mediated	O
vasoconstriction	O
by	O
brimonidine	S-chem
in	O
porcine	O
ciliary	O
arteries	O
.	O

PURPOSE	O
:	O
An	O
investigation	O
into	O
whether	O
alpha	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
agonists	O
induce	O
contractions	O
in	O
the	O
porcine	O
ciliary	O
arteries	O
and	O
to	O
characterize	O
the	O
functional	O
receptor	O
subtype	O
mediating	O
these	O
responses	O
.	O

METHODS	O
:	O
Isolated	O
arteries	O
from	O
the	O
intraocular	O
part	O
of	O
the	O
porcine	O
ciliary	O
artery	O
were	O
suspended	O
in	O
microvascular	O
myographs	O
for	O
isometric	O
tension	O
recording	O
.	O

The	O
segments	O
were	O
contracted	O
with	O
the	O
alpha	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
agonists	O
brimonidine	S-chem
,	O
apraclonidine	S-chem
,	O
and	O
oxymetazoline	S-chem
.	O

To	O
determine	O
which	O
subtypes	O
of	O
the	O
alpha	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
mediate	O
this	O
contraction	O
,	O
antagonists	O
subselective	O
for	O
the	O
different	O
alpha	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
adrenoceptors	E-geneN
were	O
added	O
to	O
the	O
vessel	O
bath	O
before	O
concentration	O
-	O
response	O
curves	O
for	O
brimonidine	S-chem
were	O
obtained	O
.	O

The	O
following	O
alpha	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonists	O
were	O
applied	O
:	O
BRL44408	S-chem
(	O
alpha	B-geneY
(	I-geneY
2A	I-geneY
)	E-geneY
-	O
selective	O
)	O
,	O
ARC239	S-chem
(	O
alpha	B-geneY
(	I-geneY
2B	I-geneY
)	E-geneY
-	O
and	O
alpha	B-geneY
(	I-geneY
2C	I-geneY
)	E-geneY
-	O
selective	O
)	O
,	O
and	O
prazosin	S-chem
(	O
alpha	B-geneY
(	I-geneY
2B	I-geneY
)	E-geneY
-	O
and	O
alpha	B-geneY
(	I-geneY
2C	I-geneY
)	E-geneY
-	O
selective	O
)	O
.	O

RESULTS	O
:	O
The	O
alpha	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
agonists	O
induced	O
vasoconstriction	O
in	O
the	O
porcine	O
ciliary	O
artery	O
with	O
the	O
following	O
potency	O
order	O
(	O
EC	O
(	O
50	O
)	O
)	O
expressed	O
in	O
nanomolar	O
:	O
brimonidine	S-chem
2.11	O
,	O
oxymetazoline	S-chem
5.26	O
,	O
and	O
apraclonidine	S-chem
13.0	O
.	O

As	O
a	O
reference	O
,	O
noradrenaline	S-chem
was	O
tested	O
,	O
and	O
its	O
EC	O
(	O
50	O
)	O
was	O
determined	O
to	O
be	O
247	O
nM	O
in	O
the	O
ciliary	O
artery	O
.	O

In	O
the	O
porcine	O
ciliary	O
arteries	O
BRL44408	S-chem
,	O
ARC239	S-chem
,	O
and	O
prazosin	S-chem
caused	O
concentration	O
-	O
dependent	O
and	O
parallel	O
rightward	O
shifts	O
of	O
the	O
concentration	O
-	O
response	O
curves	O
for	O
brimonidine	S-chem
.	O

Schild	O
analyses	O
for	O
the	O
antagonists	O
against	O
brimonidine	S-chem
yielded	O
regression	O
lines	O
with	O
slopes	O
of	O
unity	O
and	O
functional	O
antagonist	O
potencies	O
(	O
pK	O
(	O
B	O
)	O
)	O
for	O
BRL44408	S-chem
(	O
7.8	O
)	O
,	O
ARC	B-chem
239	E-chem
(	O
5.8	O
)	O
and	O
for	O
prazosin	S-chem
(	O
6.0	O
)	O
suggesting	O
the	O
presence	O
of	O
functional	O
alpha	B-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptors	E-geneY
.	O

Moreover	O
,	O
there	O
was	O
a	O
good	O
correlation	O
of	O
pK	O
(	O
B	O
)	O
with	O
ligand	O
-	O
binding	O
affinity	O
(	O
pK	O
(	O
i	O
)	O
)	O
of	O
the	O
alpha	B-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
in	O
the	O
porcine	O
eye	O
tissue	O
.	O

CONCLUSIONS	O
:	O
The	O
alpha	B-geneN
(	I-geneN
2	I-geneN
)	I-geneN
-	I-geneN
adrenoceptor	E-geneN
agonists	O
brimonidine	S-chem
,	O
apraclonidine	S-chem
,	O
and	O
oxymetazoline	S-chem
are	O
potent	O
vasoconstrictors	O
in	O
the	O
porcine	O
ciliary	O
artery	O
.	O

In	O
the	O
present	O
work	O
,	O
it	O
was	O
shown	O
for	O
the	O
first	O
time	O
that	O
the	O
alpha	B-geneY
(	I-geneY
2A	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
subtype	O
mediates	O
this	O
contraction	O
.	O

Angiotensin	B-geneN
II	I-geneN
receptor	E-geneN
blockade	O
in	O
normotensive	O
subjects	O
:	O
A	O
direct	O
comparison	O
of	O
three	O
AT1	B-geneY
receptor	E-geneY
antagonists	O
.	O

Use	O
of	O
angiotensin	B-geneY
(	I-geneY
Ang	I-geneY
)	I-geneY
II	I-geneY
AT1	I-geneY
receptor	E-geneY
antagonists	O
for	O
treatment	O
of	O
hypertension	O
is	O
rapidly	O
increasing	O
,	O
yet	O
direct	O
comparisons	O
of	O
the	O
relative	O
efficacy	O
of	O
antagonists	O
to	O
block	O
the	O
renin	O
-	O
angiotensin	O
system	O
in	O
humans	O
are	O
lacking	O
.	O

In	O
this	O
study	O
,	O
the	O
Ang	B-geneN
II	I-geneN
receptor	E-geneN
blockade	O
induced	O
by	O
the	O
recommended	O
starting	O
dose	O
of	O
3	O
antagonists	O
was	O
evaluated	O
in	O
normotensive	O
subjects	O
in	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
,	O
4	O
-	O
way	O
crossover	O
study	O
.	O

At	O
1	O
-	O
week	O
intervals	O
,	O
12	O
subjects	O
received	O
a	O
single	O
dose	O
of	O
losartan	S-chem
(	O
50	O
mg	O
)	O
,	O
valsartan	S-chem
(	O
80	O
mg	O
)	O
,	O
irbesartan	S-chem
(	O
150	O
mg	O
)	O
,	O
or	O
placebo	O
.	O

Blockade	O
of	O
the	O
renin	S-geneY
-	O
angiotensin	S-geneY
system	O
was	O
assessed	O
before	O
and	O
4	O
,	O
24	O
,	O
and	O
30	O
hours	O
after	O
drug	O
intake	O
by	O
3	O
independent	O
methods	O
:	O
inhibition	O
of	O
the	O
blood	O
pressure	O
response	O
to	O
exogenous	O
Ang	B-geneY
II	E-geneY
,	O
in	O
vitro	O
Ang	B-geneN
II	I-geneN
receptor	E-geneN
assay	O
,	O
and	O
reactive	O
changes	O
in	O
plasma	O
Ang	B-geneY
II	E-geneY
levels	O
.	O

At	O
4	O
hours	O
,	O
losartan	O
blocked	O
43	O
%	O
of	O
the	O
Ang	B-geneY
II	E-geneY
-	O
induced	O
systolic	O
blood	O
pressure	O
increase	O
;	O
valsartan	S-chem
,	O
51	O
%	O
;	O
and	O
irbesartan	S-chem
,	O
88	O
%	O
(	O
P	O
<	O
0.01	O
between	O
drugs	O
)	O
.	O

The	O
effect	O
of	O
each	O
drug	O
declined	O
with	O
time	O
.	O

At	O
24	O
hours	O
,	O
a	O
residual	O
effect	O
was	O
found	O
with	O
all	O
3	O
drugs	O
,	O
but	O
at	O
30	O
hours	O
,	O
only	O
irbesartan	S-chem
induced	O
a	O
marked	O
,	O
significant	O
blockade	O
versus	O
placebo	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
Ang	B-geneN
II	I-geneN
receptor	E-geneN
blockade	O
was	O
assessed	O
with	O
an	O
in	O
vitro	O
receptor	O
assay	O
and	O
by	O
the	O
reactive	O
rise	O
in	O
plasma	O
Ang	B-geneY
II	E-geneY
levels	O
.	O

This	O
study	O
thus	O
demonstrates	O
that	O
the	O
first	O
administration	O
of	O
the	O
recommended	O
starting	O
dose	O
of	O
irbesartan	S-chem
induces	O
a	O
greater	O
and	O
longer	O
lasting	O
Ang	B-geneN
II	I-geneN
receptor	E-geneN
blockade	O
than	O
that	O
of	O
valsartan	S-chem
and	O
losartan	S-chem
in	O
normotensive	O
subjects	O
.	O

Bile	O
acids	O
induce	O
cdx2	S-geneY
expression	O
through	O
the	O
farnesoid	B-geneY
x	I-geneY
receptor	E-geneY
in	O
gastric	O
epithelial	O
cells	O
.	O

Clinical	O
and	O
experimental	O
studies	O
showed	O
that	O
the	O
reflux	O
of	O
bile	O
into	O
the	O
stomach	O
contributes	O
to	O
the	O
induction	O
of	O
intestinal	O
metaplasia	O
of	O
the	O
stomach	O
and	O
gastric	O
carcinogenesis	O
.	O

Caudal	B-geneY
-	I-geneY
type	I-geneY
homeobox	I-geneY
2	E-geneY
(	O
Cdx2	S-geneY
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
exhibition	O
of	O
intestinal	O
phenotypes	O
by	O
regulating	O
the	O
expression	O
of	O
intestine	O
-	O
specific	O
genes	O
such	O
as	O
goblet	O
-	O
specific	O
gene	O
mucin	B-geneY
2	E-geneY
(	O
MUC2	S-geneY
)	O
.	O

We	O
investigated	O
the	O
involvement	O
of	O
the	O
farnesoid	B-geneY
X	I-geneY
receptor	E-geneY
(	O
FXR	S-geneY
)	O
,	O
a	O
nuclear	B-geneN
receptor	E-geneN
for	O
bile	O
acids	O
,	O
in	O
the	O
chenodeoxycholic	B-chem
acid	E-chem
(	O
CDCA	S-chem
)	O
-	O
induced	O
expression	O
of	O
Cdx2	S-geneY
and	O
MUC2	S-geneY
in	O
normal	O
rat	O
gastric	O
epithelial	O
cells	O
(	O
RGM	O
-	O
1	O
cells	O
)	O
.	O

RGM	O
-	O
1	O
cells	O
were	O
treated	O
with	O
CDCA	S-chem
or	O
GW4064	S-chem
,	O
an	O
FXR	S-geneY
agonist	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
guggulsterone	S-chem
,	O
an	O
FXR	S-geneY
antagonist	O
.	O

CDCA	S-chem
induced	O
dose	O
-	O
dependent	O
expression	O
of	O
Cdx2	S-geneY
and	O
MUC2	S-geneY
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O

The	O
maximum	O
stimulation	O
of	O
Cdx2	S-geneY
and	O
MUC2	S-geneY
mRNA	O
induced	O
by	O
CDCA	S-chem
was	O
observed	O
at	O
3	O
h	O
and	O
by	O
6	O
h	O
,	O
respectively	O
.	O

GW4064	S-chem
also	O
induced	O
expression	O
of	O
these	O
molecules	O
.	O

The	O
effects	O
of	O
CDCA	S-chem
and	O
GW4064	S-chem
on	O
expression	O
of	O
Cdx2	S-geneY
and	O
MUC2	S-geneY
were	O
abolished	O
by	O
guggulsterone	S-chem
.	O

These	O
findings	O
suggest	O
that	O
bile	O
acids	O
may	O
induce	O
gastric	O
intestinal	O
metaplasia	O
and	O
carcinogenesis	O
through	O
the	O
FXR	S-geneY
.	O

Diverse	O
effects	O
of	O
macromolecular	O
crowding	O
on	O
the	O
sequential	O
glycan	O
-	O
processing	O
pathway	O
involved	O
in	O
glycoprotein	O
quality	O
control	O
.	O

Compared	O
with	O
in	O
vitro	O
conditions	O
,	O
the	O
intracellular	O
environment	O
is	O
highly	O
crowded	O
with	O
biomolecules	O
;	O
this	O
has	O
numerous	O
effects	O
on	O
protein	O
functions	O
,	O
including	O
enzymatic	O
activity	O
.	O

We	O
examined	O
the	O
effects	O
of	O
macromolecular	O
crowding	O
on	O
glycan	O
processing	O
of	O
N	S-chem
-	O
glycoprotein	O
in	O
the	O
endoplasmic	O
reticulum	O
as	O
a	O
model	O
sequential	O
metabolic	O
pathway	O
.	O

Experiments	O
with	O
synthetic	O
substrates	O
of	O
physiological	O
glycan	O
structure	O
clearly	O
showed	O
that	O
the	O
first	O
half	O
of	O
the	O
pathway	O
(	O
glucose	S-chem
trimming	O
)	O
was	O
accelerated	O
,	O
whereas	O
the	O
second	O
(	O
mannose	S-chem
trimming	O
)	O
was	O
decelerated	O
under	O
molecular	O
crowding	O
conditions	O
.	O

Furthermore	O
,	O
calreticulin	S-geneY
,	O
a	O
lectin	S-geneN
-	O
like	O
molecular	O
chaperone	O
,	O
bound	O
more	O
strongly	O
to	O
a	O
glycan	O
-	O
processing	O
intermediate	O
under	O
these	O
conditions	O
.	O

This	O
study	O
demonstrates	O
the	O
diverse	O
effects	O
of	O
molecular	O
crowding	O
on	O
sequential	O
enzymatic	O
processing	O
,	O
and	O
the	O
importance	O
of	O
the	O
effects	O
of	O
macromolecular	O
crowding	O
on	O
in	O
vitro	O
assays	O
for	O
understanding	O
sequential	O
metabolic	O
pathways	O
.	O

Peroxynitrite	S-chem
mediates	O
testosterone	S-chem
-	O
induced	O
vasodilation	O
of	O
microvascular	O
resistance	O
vessels	O
.	O

Our	O
knowledge	O
of	O
how	O
androgens	S-chem
influence	O
the	O
cardiovascular	O
system	O
is	O
far	O
from	O
complete	O
,	O
and	O
this	O
lack	O
of	O
understanding	O
is	O
especially	O
true	O
of	O
how	O
androgens	S-chem
affect	O
resistance	O
vessels	O
.	O

Our	O
aim	O
was	O
to	O
identify	O
the	O
signaling	O
mechanisms	O
stimulated	O
by	O
testosterone	S-chem
(	O
TES	S-chem
)	O
in	O
microvascular	O
arteries	O
and	O
to	O
understand	O
how	O
these	O
mechanisms	O
mediate	O
TES	S-chem
-	O
induced	O
vasodilation	O
.	O

Mesenteric	O
microvessels	O
were	O
isolated	O
from	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

Tension	O
studies	O
demonstrated	O
a	O
rapid	O
,	O
concentration	O
-	O
dependent	O
,	O
vasodilatory	O
response	O
to	O
TES	S-chem
that	O
did	O
not	O
involve	O
protein	O
synthesis	O
or	O
aromatization	O
to	O
17β	B-chem
-	I-chem
estradiol	E-chem
.	O

Dichlorofluorescein	S-chem
fluorescence	O
and	O
nitrotyrosine	S-chem
immunoblot	O
experiments	O
indicated	O
that	O
TES	S-chem
stimulated	O
peroxynitrite	S-chem
formation	O
in	O
microvessels	O
,	O
and	O
functional	O
studies	O
demonstrated	O
that	O
TES	S-chem
-	O
induced	O
vasodilation	O
was	O
inhibited	O
by	O
scavenging	O
peroxynitrite	S-chem
.	O

As	O
predicted	O
,	O
TES	S-chem
enhanced	O
the	O
production	O
of	O
both	O
peroxynitrite	S-chem
precursors	O
(	O
i.e	O
.	O
,	O
superoxide	S-chem
and	O
nitic	B-chem
oxide	E-chem
)	O
,	O
and	O
xanthine	B-geneY
oxidase	E-geneY
was	O
identified	O
as	O
the	O
likely	O
source	O
of	O
TES	S-chem
-	O
stimulated	O
superoxide	S-chem
production	O
.	O

Functional	O
and	O
biochemical	O
studies	O
indicated	O
that	O
TES	S-chem
signaling	O
involved	O
activity	O
of	O
the	O
phosphoinositide	B-geneN
3	I-geneN
(	I-geneN
PI3	I-geneN
)	I-geneN
kinase	E-geneN
-	O
protein	B-geneY
kinase	I-geneY
B	E-geneY
(	O
Akt	S-geneY
)	O
cascade	O
initiated	O
by	O
activation	O
of	O
the	O
androgen	B-geneY
receptor	E-geneY
and	O
culminated	O
in	O
enhanced	O
production	O
of	O
cGMP	S-chem
and	O
microvascular	O
vasodilation	O
.	O

These	O
findings	O
,	O
derived	O
from	O
a	O
variety	O
of	O
analytical	O
and	O
functional	O
approaches	O
,	O
provide	O
evidence	O
for	O
a	O
novel	O
nongenomic	O
signaling	O
mechanism	O
for	O
androgen	S-chem
action	O
in	O
the	O
microvasculature	O
:	O
TES	S-chem
-	O
stimulated	O
vasodilation	O
mediated	O
primarily	O
by	O
peroxynitrite	S-chem
formed	O
from	O
xanthine	B-geneY
oxidase	E-geneY
-	O
generated	O
superoxide	S-chem
and	O
NO	S-chem
.	O

This	O
response	O
was	O
associated	O
with	O
activation	O
of	O
the	O
PI3	B-geneN
kinase	E-geneN
-	O
Akt	S-geneY
signaling	O
cascade	O
initiated	O
by	O
activation	O
of	O
the	O
androgen	B-geneY
receptor	E-geneY
.	O

We	O
propose	O
this	O
mechanism	O
could	O
account	O
for	O
TES	S-chem
-	O
stimulated	O
cGMP	S-chem
production	O
in	O
microvessels	O
and	O
,	O
ultimately	O
,	O
vasodilation	O
.	O

Anxiolytic	O
-	O
but	O
not	O
antidepressant	O
-	O
like	O
activity	O
of	O
Lu	B-chem
AF21934	E-chem
,	O
a	O
novel	O
,	O
selective	O
positive	O
allosteric	O
modulator	O
of	O
the	O
mGlu₄	S-geneY
receptor	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
Group	B-geneN
III	I-geneN
mGlu	I-geneN
receptor	E-geneN
-	O
selective	O
orthosteric	O
agonist	O
,	O
LSP1	B-chem
-	I-chem
2111	E-chem
produced	O
anxiolytic	O
-	O
but	O
not	O
antidepressant	O
-	O
like	O
effects	O
upon	O
peripheral	O
administration	O
.	O

Herein	O
,	O
we	O
report	O
the	O
pharmacological	O
actions	O
of	O
Lu	B-chem
AF21934	E-chem
,	O
a	O
novel	O
,	O
selective	O
,	O
and	O
brain	O
-	O
penetrant	O
positive	O
allosteric	O
modulator	O
(	O
PAM	O
)	O
of	O
the	O
mGlu	B-geneY
(	I-geneY
4	I-geneY
)	E-geneY
receptor	O
in	O
the	O
stress	O
-	O
induced	O
hyperthermia	O
(	O
SIH	O
)	O
,	O
four	O
-	O
plate	O
,	O
marble	O
-	O
burying	O
and	O
Vogel	O
's	O
conflict	O
tests	O
.	O

In	O
all	O
models	O
,	O
except	O
Vogel	O
's	O
conflict	O
test	O
,	O
a	O
dose	O
-	O
dependent	O
anxiolytic	O
-	O
like	O
effect	O
was	O
seen	O
.	O

The	O
anti	O
-	O
hyperthermic	O
effect	O
of	O
Lu	B-chem
AF21934	E-chem
(	O
5	O
mg	O
/	O
kg	O
)	O
in	O
the	O
SIH	O
test	O
was	O
inhibited	O
by	O
the	O
benzodiazepine	B-geneY
receptor	E-geneY
antagonist	O
flumazenil	S-chem
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
was	O
not	O
serotonin	S-chem
-	O
dependent	O
,	O
as	O
it	O
persisted	O
in	O
serotonin	S-chem
-	O
deficient	O
mice	O
and	O
upon	O
blockade	O
of	O
either	O
5	B-geneY
-	I-geneY
HT	I-geneY
(	I-geneY
1A	I-geneY
)	E-geneY
receptors	O
by	O
WAY100635	S-chem
,	O
or	O
5	B-geneN
-	I-geneN
HT	I-geneN
(	I-geneN
2A	I-geneN
/	I-geneN
2C	I-geneN
)	E-geneN
receptors	O
by	O
ritanserin	S-chem
.	O

These	O
results	O
suggest	O
that	O
the	O
GABAergic	O
system	O
,	O
but	O
not	O
the	O
serotonergic	O
system	O
,	O
is	O
involved	O
in	O
the	O
mechanism	O
of	O
the	O
anxiolytic	O
-	O
like	O
phenotype	O
of	O
Lu	B-chem
AF21934	E-chem
in	O
rodents	O
.	O

Lu	B-chem
AF21934	E-chem
did	O
not	O
produce	O
antidepressant	O
-	O
like	O
effects	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
)	O
in	O
mice	O
;	O
however	O
,	O
it	O
decreased	O
the	O
basal	O
locomotor	O
activity	O
of	O
mice	O
that	O
were	O
not	O
habituated	O
to	O
activity	O
cages	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Metabotropic	B-geneN
Glutamate	I-geneN
Receptors	E-geneN
'	O
.	O

Transcriptome	O
alterations	O
following	O
developmental	O
atrazine	S-chem
exposure	O
in	O
zebrafish	O
are	O
associated	O
with	O
disruption	O
of	O
neuroendocrine	O
and	O
reproductive	O
system	O
function	O
,	O
cell	O
cycle	O
,	O
and	O
carcinogenesis	O
.	O

Atrazine	S-chem
,	O
a	O
herbicide	O
commonly	O
applied	O
to	O
agricultural	O
areas	O
and	O
a	O
common	O
contaminant	O
of	O
potable	O
water	O
supplies	O
,	O
is	O
implicated	O
as	O
an	O
endocrine	O
-	O
disrupting	O
chemical	O
(	O
EDC	O
)	O
and	O
potential	O
carcinogen	O
.	O

Studies	O
show	O
that	O
EDCs	O
can	O
cause	O
irreversible	O
changes	O
in	O
tissue	O
formation	O
,	O
decreased	O
reproductive	O
potential	O
,	O
obesity	O
,	O
and	O
cancer	O
.	O

The	O
U.S	O
.	O

Environmental	O
Protection	O
Agency	O
considers	O
an	O
atrazine	S-chem
concentration	O
of	O
≤	O
3	O
ppb	O
in	O
drinking	O
water	O
safe	O
for	O
consumption	O
.	O

The	O
specific	O
adverse	O
human	O
health	O
effects	O
associated	O
with	O
a	O
developmental	O
atrazine	S-chem
exposure	O
and	O
the	O
underlying	O
genetic	O
mechanisms	O
of	O
these	O
effects	O
are	O
not	O
well	O
defined	O
.	O

In	O
this	O
study	O
,	O
zebrafish	O
embryos	O
were	O
exposed	O
to	O
a	O
range	O
of	O
atrazine	S-chem
concentrations	O
to	O
establish	O
toxicity	O
.	O

Morphological	O
,	O
transcriptomic	O
,	O
and	O
protein	O
alterations	O
were	O
then	O
assessed	O
at	O
72h	O
postfertilization	O
following	O
developmental	O
atrazine	S-chem
exposure	O
at	O
0	O
,	O
0.3	O
,	O
3	O
,	O
or	O
30	O
ppb	O
.	O

A	O
significant	O
increase	O
in	O
head	O
length	O
was	O
observed	O
in	O
all	O
three	O
atrazine	S-chem
treatments	O
.	O

Transcriptomic	O
profiles	O
revealed	O
21	O
,	O
62	O
,	O
and	O
64	O
genes	O
with	O
altered	O
expression	O
in	O
the	O
0.3	O
,	O
3	O
,	O
and	O
30	O
ppb	O
atrazine	S-chem
treatments	O
,	O
respectively	O
.	O

Altered	O
genes	O
were	O
associated	O
with	O
neuroendocrine	O
and	O
reproductive	O
system	O
development	O
,	O
function	O
,	O
and	O
disease	O
;	O
cell	O
cycle	O
control	O
;	O
and	O
carcinogenesis	O
.	O

There	O
was	O
a	O
significant	O
overlap	O
(	O
42	O
genes	O
)	O
between	O
the	O
3	O
and	O
30	O
ppb	O
differentially	O
expressed	O
gene	O
lists	O
,	O
with	O
two	O
of	O
these	O
genes	O
(	O
CYP17A1	S-geneY
and	O
SAMHD1	S-geneY
)	O
present	O
in	O
all	O
three	O
atrazine	S-chem
treatments	O
.	O

Increased	O
transcript	O
levels	O
were	O
translated	O
to	O
significant	O
upregulation	O
in	O
protein	O
expression	O
.	O

Overall	O
,	O
this	O
study	O
identifies	O
genetic	O
and	O
molecular	O
targets	O
altered	O
in	O
response	O
to	O
a	O
developmental	O
atrazine	S-chem
exposure	O
to	O
further	O
define	O
the	O
biological	O
pathways	O
and	O
mechanisms	O
of	O
toxicity	O
.	O

Statins	S-chem
increase	O
p21	S-geneY
through	O
inhibition	O
of	O
histone	B-geneN
deacetylase	E-geneN
activity	O
and	O
release	O
of	O
promoter	O
-	O
associated	O
HDAC1	B-geneN
/	I-geneN
2	E-geneN
.	O

Statins	S-chem
are	O
3	B-geneY
-	I-geneY
hydroxy	I-geneY
-	I-geneY
3	I-geneY
-	I-geneY
methylglutaryl	I-geneY
-	I-geneY
CoA	I-geneY
reductase	E-geneY
inhibitors	O
broadly	O
used	O
for	O
the	O
control	O
of	O
hypercholesterolemia	O
.	O

Recently	O
,	O
they	O
are	O
reported	O
to	O
have	O
beneficial	O
effects	O
on	O
certain	O
cancers	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
statins	O
inhibited	O
the	O
histone	B-geneN
deacetylase	E-geneN
(	O
HDAC	S-geneN
)	O
activity	O
and	O
increased	O
the	O
accumulation	O
of	O
acetylated	B-geneN
histone	I-geneN
-	I-geneN
H3	E-geneN
and	O
the	O
expression	O
of	O
p21	S-geneY
(	O
WAF	S-geneY
/	O
CIP	S-geneY
)	O
in	O
human	O
cancer	O
cells	O
.	O

Computational	O
modeling	O
showed	O
the	O
direct	O
interaction	O
of	O
the	O
carboxylic	B-chem
acid	E-chem
moiety	O
of	O
statins	O
with	O
the	O
catalytic	O
site	O
of	O
HDAC2	S-geneY
.	O

In	O
the	O
subsequent	O
enzymatic	O
assay	O
,	O
it	O
was	O
shown	O
that	O
lovastatin	S-chem
inhibited	O
HDAC2	S-geneY
activity	O
competitively	O
with	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
31.6	O
micromol	O
/	O
L	O
.	O

Sp1	S-geneY
but	O
not	O
p53	S-geneY
sites	O
were	O
found	O
to	O
be	O
the	O
statins	B-geneN
-	I-geneN
responsive	I-geneN
element	E-geneN
shown	O
by	O
p21	S-geneY
luciferase	O
-	O
promoter	O
assays	O
.	O

DNA	O
affinity	O
protein	O
binding	O
assay	O
and	O
chromatin	O
immunoprecipitation	O
assay	O
showed	O
the	O
dissociation	O
of	O
HDAC1	B-geneN
/	I-geneN
2	E-geneN
and	O
association	O
of	O
CBP	S-geneY
,	O
leading	O
to	O
the	O
histone	B-geneN
-	I-geneN
H3	E-geneN
acetylation	O
on	O
the	O
Sp1	S-geneY
sites	O
of	O
p21	B-geneN
promoter	E-geneN
.	O

In	O
vitro	O
cell	O
proliferation	O
and	O
in	O
vivo	O
tumor	O
growth	O
were	O
both	O
inhibited	O
by	O
statins	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
for	O
statins	O
through	O
abrogation	O
of	O
the	O
HDAC	S-geneN
activity	O
and	O
promoter	O
histone	B-geneN
-	I-geneN
H3	E-geneN
acetylation	O
to	O
regulate	O
p21	S-geneY
expression	O
.	O

Therefore	O
,	O
statins	O
might	O
serve	O
as	O
novel	O
HDAC	S-geneN
inhibitors	O
for	O
cancer	O
therapy	O
and	O
chemoprevention	O
.	O

Cadmium	S-chem
induces	O
mitogenic	O
signaling	O
in	O
breast	O
cancer	O
cell	O
by	O
an	O
ERalpha	S-geneY
-	O
dependent	O
mechanism	O
.	O

Breast	O
cancer	O
(	O
BC	O
)	O
is	O
linked	O
to	O
estrogen	O
exposure	O
.	O

Estradiol	S-chem
(	O
E2	S-chem
)	O
stimulates	O
BC	O
cells	O
proliferation	O
by	O
binding	O
the	O
estrogen	B-geneY
receptor	E-geneY
(	O
ER	S-geneY
)	O
.	O

Hormone	O
-	O
related	O
cancers	O
have	O
been	O
linked	O
to	O
estrogenic	O
environmental	O
contaminants	O
.	O

Cadmium	S-chem
(	O
Cd	S-chem
)	O
a	O
toxic	O
pollutant	O
,	O
acts	O
as	O
estrogens	O
in	O
BC	O
cells	O
.	O

Purpose	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
whether	O
Cd	S-chem
regulates	O
MCF	O
-	O
7	O
cell	O
proliferation	O
by	O
activating	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
,	O
Akt	S-geneN
and	O
PDGFRalpha	S-geneY
kinases	S-geneN
.	O

Cd	S-chem
increased	O
cell	O
proliferation	O
and	O
the	O
ER	S-geneY
-	O
antagonist	O
ICI	O
182,780	O
blunted	O
it	O
.	O

To	O
characterize	O
an	O
ER	S-geneY
-	O
dependent	O
mechanism	O
,	O
ERalpha	B-geneN
/	I-geneN
beta	E-geneN
expression	O
was	O
evaluated	O
.	O

Cd	S-chem
decreased	O
ERalpha	S-geneY
expression	O
,	O
but	O
not	O
ERbeta	S-geneY
.	O

Cd	S-chem
also	O
increased	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
,	O
Akt	S-geneN
and	O
PDGFRalpha	S-geneY
phosphorylation	O
while	O
ICI	O
blocked	O
it	O
.	O

Since	O
stimulation	O
of	O
phosphorylation	O
was	O
slower	O
than	O
expected	O
,	O
c	B-geneY
-	I-geneY
fos	E-geneY
and	O
c	B-geneY
-	I-geneY
jun	E-geneY
proto	O
-	O
oncogenes	O
,	O
and	O
PDGFA	S-geneY
were	O
analyzed	O
.	O

Cd	S-chem
rapidly	O
increased	O
c	B-geneN
-	I-geneN
jun	E-geneN
,	O
c	B-geneN
-	I-geneN
fos	E-geneN
and	O
PDGFA	S-geneY
expression	O
.	O

Cells	O
were	O
also	O
co	O
-	O
incubated	O
with	O
the	O
Cd	S-chem
and	O
specific	O
kinases	S-geneN
inhibitors	O
,	O
which	O
blocked	O
the	O
Cd	S-chem
-	O
stimulated	O
proliferation	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
indicate	O
that	O
Cd	S-chem
increases	O
BC	O
cell	O
proliferation	O
in	O
vitro	O
by	O
stimulating	O
Akt	S-geneN
,	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
and	O
PDGFRalpha	S-geneY
kinases	S-geneN
activity	O
likely	O
by	O
activating	O
c	B-geneY
-	I-geneY
fos	E-geneY
,	O
c	B-geneY
-	I-geneY
jun	E-geneY
and	O
PDGFA	S-geneY
by	O
an	O
ERalpha	S-geneY
-	O
dependent	O
mechanism	O
.	O

A	O
fluorescent	O
polymeric	O
heparin	O
sensor	O
.	O

Linear	O
copolymers	O
have	O
been	O
developed	O
which	O
carry	O
binding	O
sites	O
tailored	O
for	O
sulfated	O
sugars	O
.	O

All	O
binding	O
monomers	O
are	O
based	O
on	O
the	O
methacrylamide	S-chem
skeleton	O
and	O
ensure	O
statistical	O
radical	O
copolymerization	O
.	O

They	O
are	O
decorated	O
with	O
o	B-chem
-	I-chem
aminomethylphenylboronates	E-chem
for	O
covalent	O
ester	O
formation	O
and	O
/	O
or	O
alkylammonium	S-chem
ions	O
for	O
noncovalent	O
Coulomb	O
attraction	O
.	O

Alcohol	S-chem
sidechains	O
maintain	O
a	O
high	O
water	O
solubility	O
;	O
a	O
dansyl	S-chem
monomer	O
was	O
constructed	O
as	O
a	O
fluorescence	O
label	O
.	O

Statistical	O
copolymerization	O
of	O
comonomer	O
mixtures	O
with	O
optimized	O
ratios	O
was	O
started	O
by	O
AIBN	S-chem
(	O
AIBN	S-chem
=	O
2,2	B-chem
'	I-chem
-	I-chem
azoisobutyronitrile	E-chem
)	O
and	O
furnished	O
water	O
-	O
soluble	O
comonomers	O
with	O
an	O
exceptionally	O
high	O
affinity	O
for	O
glucosaminoglucans	O
.	O

Heparin	O
can	O
be	O
quantitatively	O
detected	O
with	O
an	O
unprecedented	O
30	O
nM	O
sensitivity	O
,	O
and	O
a	O
neutral	O
polymer	O
without	O
any	O
ammonium	B-chem
cation	E-chem
is	O
still	O
able	O
to	O
bind	O
the	O
target	O
with	O
almost	O
micromolar	O
affinity	O
.	O

From	O
this	O
unexpected	O
result	O
,	O
we	O
propose	O
a	O
new	O
binding	O
scheme	O
between	O
the	O
boronate	S-chem
and	O
a	O
sulfated	O
ethylene	B-chem
glycol	E-chem
or	O
aminoethanol	S-chem
unit	O
.	O

Although	O
the	O
mechanism	O
of	O
heparin	O
binding	O
involves	O
covalent	O
boronate	B-chem
ester	E-chem
formation	O
,	O
it	O
can	O
be	O
completely	O
reversed	O
by	O
protamine	O
addition	O
,	O
similar	O
to	O
heparin	O
's	O
complex	O
formation	O
with	O
antithrombin	B-geneY
III	E-geneY
.	O

Sulindac	S-chem
independently	O
modulates	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
and	O
cyclic	B-geneN
GMP	I-geneN
-	I-geneN
dependent	I-geneN
protein	I-geneN
kinase	E-geneN
signaling	O
pathways	O
.	O

Colorectal	O
cancer	O
is	O
the	O
second	O
leading	O
cause	O
of	O
cancer	O
mortality	O
in	O
the	O
United	O
States	O
.	O

Substantial	O
human	O
and	O
animal	O
data	O
support	O
the	O
ability	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
to	O
cause	O
regression	O
of	O
existing	O
colon	O
tumors	O
and	O
prevent	O
new	O
tumor	O
formation	O
.	O

The	O
mechanism	O
by	O
which	O
the	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
sulindac	S-chem
prevents	O
tumor	O
growth	O
is	O
poorly	O
understood	O
and	O
seems	O
complex	O
as	O
sulindac	S-chem
can	O
modulate	O
several	O
growth	O
-	O
related	O
signaling	O
pathways	O
.	O

Sulindac	S-chem
metabolites	O
simultaneously	O
(	O
a	O
)	O
increase	O
cellular	O
cyclic	B-chem
GMP	E-chem
and	O
subsequently	O
activate	O
cyclic	B-geneN
GMP	I-geneN
-	I-geneN
dependent	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
PKG	S-geneN
)	O
;	O
(	O
b	O
)	O
activate	O
c	B-geneN
-	I-geneN
jun	I-geneN
NH2	I-geneN
-	I-geneN
terminal	I-geneN
kinase	E-geneN
(	O
JNK	S-geneN
)	O
;	O
(	O
c	O
)	O
inhibit	O
extracellular	B-geneN
signal	I-geneN
-	I-geneN
regulated	I-geneN
kinase	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
(	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
)	O
;	O
and	O
(	O
d	O
)	O
decrease	O
beta	B-geneY
-	I-geneY
catenin	E-geneY
protein	O
expression	O
at	O
times	O
and	O
doses	O
consistent	O
with	O
apoptosis	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
PKG	S-geneN
,	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
,	O
JNK	S-geneN
,	O
and	O
beta	B-geneY
-	I-geneY
catenin	E-geneY
are	O
independent	O
targets	O
for	O
sulindac	S-chem
in	O
vitro	O
.	O

Pharmacologic	O
activation	O
of	O
PKG	S-geneN
with	O
YC	B-chem
-	I-chem
1	E-chem
increases	O
JNK	S-geneN
phosphorylation	O
and	O
induces	O
apoptosis	O
in	O
colon	O
cancer	O
cells	O
without	O
modulating	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
phosphorylation	O
or	O
beta	B-geneY
-	I-geneY
catenin	E-geneY
protein	O
expression	O
.	O

Inhibition	O
of	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
with	O
U0126	S-chem
induces	O
apoptosis	O
but	O
fails	O
to	O
activate	O
JNK	S-geneN
phosphorylation	O
or	O
down	O
-	O
regulate	O
beta	B-geneY
-	I-geneY
catenin	E-geneY
protein	O
expression	O
.	O

Cotreatment	O
with	O
U0126	S-chem
and	O
YC	B-chem
-	I-chem
1	E-chem
synergistically	O
increases	O
apoptosis	O
in	O
colorectal	O
cancer	O
cells	O
and	O
recapitulates	O
the	O
effects	O
of	O
sulindac	S-chem
treatment	O
on	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
,	O
JNK	S-geneN
,	O
and	O
beta	B-geneY
-	I-geneY
catenin	E-geneY
.	O

These	O
results	O
indicate	O
that	O
sulindac	S-chem
metabolites	O
modulate	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
and	O
PKG	S-geneN
pathways	O
independently	O
in	O
colon	O
cancer	O
cells	O
and	O
suggest	O
that	O
the	O
full	O
apoptotic	O
effect	O
of	O
sulindac	S-chem
is	O
mediated	O
by	O
more	O
than	O
one	O
pathway	O
.	O

Using	O
similar	O
combinatorial	O
approaches	O
in	O
vivo	O
may	O
provide	O
more	O
effective	O
,	O
less	O
toxic	O
chemopreventive	O
and	O
chemotherapeutic	O
strategies	O
.	O

Such	O
therapies	O
could	O
dramatically	O
reduce	O
the	O
incidence	O
and	O
death	O
rate	O
from	O
colorectal	O
cancer	O
.	O

Development	O
of	O
a	O
cell	O
-	O
based	O
high	O
-	O
throughput	O
peroxisome	B-geneN
proliferator	I-geneN
-	I-geneN
activated	I-geneN
receptors	E-geneN
(	O
PPARs	S-geneN
)	O
screening	O
model	O
and	O
its	O
application	O
for	O
evaluation	O
of	O
the	O
extracts	O
from	O
Rhizoma	O
Coptis	O
.	O

To	O
date	O
,	O
peroxisome	B-geneN
proliferator	I-geneN
-	I-geneN
activated	I-geneN
receptors	E-geneN
(	O
PPARs	S-geneN
)	O
are	O
becoming	O
the	O
new	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
metabolic	O
diseases	O
,	O
such	O
as	O
Type	O
2	O
diabetes	O
,	O
obesity	O
,	O
and	O
cardiovascular	O
disease	O
.	O

In	O
this	O
study	O
,	O
a	O
cell	O
-	O
based	O
high	O
-	O
throughput	O
PPARs	S-geneN
(	O
PPARα	B-geneN
/	I-geneN
β	I-geneN
/	I-geneN
γ	E-geneN
)	O
model	O
was	O
developed	O
for	O
the	O
screening	O
of	O
PPARs	S-geneN
agonists	O
.	O

The	O
screening	O
conditions	O
were	O
evaluated	O
through	O
analyzing	O
the	O
expression	O
value	O
of	O
luciferase	O
.	O

Finally	O
,	O
24	O
h	O
of	O
drug	O
acting	O
time	O
,	O
5	O
times	O
of	O
the	O
dilution	O
factor	O
of	O
luciferase	O
zymolyte	O
,	O
and	O
about	O
2	O
×	O
10	O
(	O
4	O
)	O
cells	O
/	O
well	O
on	O
HeLa	O
cells	O
in	O
96	O
-	O
well	O
plates	O
were	O
used	O
,	O
respectively	O
.	O

Furthermore	O
,	O
the	O
quality	O
of	O
high	O
-	O
throughput	O
screening	O
(	O
HTS	O
)	O
in	O
stability	O
and	O
reliability	O
was	O
evaluated	O
by	O
the	O
Z	O
'	O
-	O
factor	O
.	O

Additionally	O
,	O
different	O
extracts	O
of	O
Rhizoma	O
Coptis	O
and	O
berberine	S-chem
were	O
tested	O
by	O
the	O
developed	O
method	O
.	O

The	O
results	O
suggested	O
that	O
both	O
the	O
EtOAc	S-chem
extract	O
and	O
berberine	S-chem
were	O
able	O
to	O
activate	O
PPARα	B-geneN
/	I-geneN
β	I-geneN
/	I-geneN
γ	E-geneN
,	O
and	O
Rhizoma	O
Coptis	O
contains	O
potential	O
natural	O
agonists	O
of	O
PPARs	S-geneN
besides	O
berberine	S-chem
.	O

In	O
conclusion	O
,	O
the	O
developed	O
HTS	O
assay	O
is	O
a	O
simple	O
,	O
rapid	O
,	O
stable	O
,	O
and	O
specific	O
method	O
for	O
the	O
screening	O
of	O
PPARs	S-geneN
natural	O
agonists	O
.	O

Dendronized	B-geneN
albumin	I-geneN
core	I-geneN
-	I-geneN
shell	I-geneN
transporters	E-geneN
with	O
high	O
drug	O
loading	O
capacity	O
.	O

We	O
describe	O
the	O
synthesis	O
of	O
a	O
core	O
-	O
shell	O
biohybrid	O
consisting	O
of	O
a	O
human	B-geneY
serum	I-geneY
albumin	E-geneY
(	O
HSA	S-geneY
)	O
core	O
that	O
serves	O
as	O
a	O
reservoir	O
for	O
lipophilic	O
molecules	O
and	O
a	O
cationized	O
shell	O
region	O
consisting	O
of	O
ethynyl	S-chem
-	O
G2.0	O
-	O
PAMAM	S-chem
or	O
ethynyl	S-chem
-	O
G3.0	O
-	O
PAMAM	S-chem
dendrons	O
.	O

The	O
binding	O
capacity	O
of	O
lipophilic	O
guests	O
was	O
quantified	O
applying	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
spectroscopy	O
,	O
and	O
five	O
to	O
six	O
out	O
of	O
seven	O
pockets	O
were	O
still	O
available	O
compared	O
with	O
HSA	S-geneY
.	O

The	O
attachment	O
of	O
ethynyl	S-chem
-	O
G2.0	O
-	O
PAMAM	S-chem
dendrons	O
to	O
HSA	S-geneY
yielded	O
a	O
nontoxic	O
core	O
-	O
shell	O
macromolecule	O
that	O
was	O
clearly	O
uptaken	O
by	O
A549	O
human	O
epithelial	O
cells	O
due	O
to	O
the	O
presence	O
of	O
the	O
dendritic	O
PAMAM	S-chem
shell	O
.	O

Significantly	O
higher	O
loading	O
of	O
doxorubicin	S-chem
was	O
observed	O
for	O
dendronized	O
G2	O
-	O
DHSA	O
compared	O
with	O
the	O
native	O
protein	O
due	O
to	O
the	O
availability	O
of	O
binding	O
pockets	O
of	O
the	O
HSA	S-geneY
core	O
,	O
and	O
interaction	O
with	O
the	O
dendritic	O
shell	O
.	O

Dendronized	O
G2	O
-	O
DHSA	O
-	O
doxorubicin	S-chem
displayed	O
significant	O
cytotoxicity	O
resulting	O
from	O
high	O
drug	O
loading	O
and	O
high	O
stability	O
under	O
different	O
conditions	O
,	O
thus	O
demonstrating	O
its	O
great	O
potential	O
as	O
a	O
transporter	O
for	O
drug	O
molecules	O
.	O

Alcohol	O
intoxications	O
during	O
adolescence	O
increase	O
motivation	O
for	O
alcohol	O
in	O
adult	O
rats	O
and	O
induce	O
neuroadaptations	O
in	O
the	O
nucleus	O
accumbens	O
.	O

Adolescent	O
alcohol	O
binge	O
drinking	O
constitutes	O
a	O
major	O
vulnerability	O
factor	O
to	O
develop	O
alcoholism	O
.	O

However	O
,	O
mechanisms	O
underlying	O
this	O
susceptibility	O
remain	O
unknown	O
.	O

We	O
evaluated	O
the	O
effect	O
of	O
adolescent	O
binge	O
-	O
like	O
ethanol	S-chem
intoxication	O
on	O
vulnerability	O
to	O
alcohol	O
abuse	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

To	O
model	O
binge	O
-	O
like	O
ethanol	S-chem
intoxication	O
,	O
every	O
2	O
days	O
,	O
rats	O
received	O
an	O
ethanol	S-chem
injection	O
(	O
3.0	O
g	O
/	O
kg	O
)	O
for	O
2	O
consecutive	O
days	O
across	O
14	O
days	O
either	O
from	O
postnatal	O
day	O
30	O
(	O
PND30	O
)	O
to	O
43	O
(	O
early	O
adolescence	O
)	O
or	O
from	O
PND	O
45	O
to	O
PND	O
58	O
(	O
late	O
adolescence	O
)	O
.	O

In	O
young	O
adult	O
animals	O
,	O
we	O
measured	O
free	O
ethanol	S-chem
consumption	O
in	O
the	O
two	O
-	O
bottle	O
choice	O
paradigm	O
,	O
motivation	O
for	O
ethanol	S-chem
in	O
the	O
operant	O
self	O
-	O
administration	O
task	O
and	O
both	O
ethanol	S-chem
's	O
rewarding	O
and	O
aversive	O
properties	O
in	O
the	O
conditioned	O
place	O
preference	O
(	O
CPP	O
)	O
and	O
taste	O
aversion	O
(	O
CTA	O
)	O
paradigms	O
.	O

While	O
intermittent	O
ethanol	S-chem
intoxications	O
(	O
IEI	O
)	O
during	O
late	O
adolescence	O
had	O
no	O
effect	O
on	O
free	O
-	O
choice	O
10	O
%	O
ethanol	S-chem
consumption	O
,	O
we	O
found	O
that	O
IEI	O
during	O
early	O
adolescence	O
promoted	O
free	O
-	O
choice	O
10	O
%	O
ethanol	S-chem
consumption	O
,	O
enhanced	O
motivation	O
for	O
ethanol	S-chem
in	O
the	O
self	O
-	O
administration	O
paradigm	O
and	O
induced	O
a	O
loss	O
of	O
both	O
ethanol	S-chem
-	O
induced	O
CPP	O
and	O
CTA	O
in	O
young	O
adults	O
.	O

No	O
modification	O
in	O
either	O
sucrose	S-chem
self	O
-	O
administration	O
or	O
amphetamine	S-chem
-	O
induced	O
CPP	O
was	O
observed	O
.	O

As	O
the	O
nucleus	O
accumbens	O
(	O
Nac	O
)	O
is	O
particularly	O
involved	O
in	O
addictive	O
behavior	O
,	O
we	O
analyzed	O
IEI	O
-	O
induced	O
long	O
-	O
term	O
neuroadaptations	O
in	O
the	O
Nac	O
using	O
c	B-geneY
-	I-geneY
Fos	E-geneY
immunohistochemistry	O
and	O
an	O
array	O
of	O
neurotransmission	O
-	O
related	O
genes	O
.	O

This	O
vulnerability	O
to	O
ethanol	S-chem
abuse	O
was	O
associated	O
with	O
a	O
lower	O
c	B-geneY
-	I-geneY
Fos	E-geneY
immunoreactivity	O
in	O
the	O
Nac	O
and	O
enduring	O
alterations	O
of	O
the	O
expression	O
of	O
Penk	S-geneY
and	O
Slc6a4	S-geneY
,	O
2	O
neurotransmission	O
-	O
related	O
genes	O
that	O
have	O
been	O
shown	O
to	O
play	O
critical	O
roles	O
in	O
the	O
behavioral	O
effects	O
of	O
ethanol	S-chem
and	O
alcoholism	O
.	O

Circulating	O
very	O
-	O
low	B-geneN
-	I-geneN
density	I-geneN
lipoprotein	E-geneN
from	O
subjects	O
with	O
impaired	O
glucose	S-chem
tolerance	O
accelerates	O
adrenocortical	O
cortisol	S-chem
and	O
aldosterone	S-chem
synthesis	O
.	O

Apart	O
from	O
their	O
role	O
in	O
cardiovascular	O
homeostasis	O
and	O
immunomodulation	O
,	O
aldosterone	S-chem
and	O
cortisol	S-chem
are	O
also	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
insulin	S-geneY
resistance	O
and	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

Furthermore	O
,	O
glycoxidative	O
modifications	O
of	O
lipoproteins	O
are	O
increasingly	O
recognized	O
as	O
an	O
etiological	O
factor	O
for	O
increased	O
cardiovascular	O
morbidity	O
and	O
mortality	O
in	O
prediabetic	O
individuals	O
.	O

The	O
causative	O
relationship	O
between	O
in	O
vivo	O
lipoprotein	O
modifications	O
and	O
steroidogenesis	O
in	O
subjects	O
with	O
impaired	O
glucose	S-chem
tolerance	O
(	O
IGT	O
)	O
,	O
however	O
,	O
is	O
not	O
well	O
defined	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
impact	O
of	O
in	O
vivo	O
modified	O
lipoproteins	O
on	O
aldosterone	S-chem
and	O
cortisol	S-chem
release	O
from	O
human	O
adrenocortical	O
H295R	O
cells	O
.	O

Following	O
an	O
oral	O
glucose	S-chem
tolerance	O
test	O
,	O
20	O
individuals	O
with	O
normal	O
glucose	S-chem
tolerance	O
(	O
NGT	O
)	O
and	O
20	O
IGT	O
subjects	O
were	O
randomly	O
selected	O
from	O
the	O
ongoing	O
PRAEDIAS	O
prevention	O
study	O
in	O
our	O
department	O
.	O

Cells	O
were	O
incubated	O
for	O
24	O
h	O
with	O
lipoproteins	O
isolated	O
from	O
NGT	O
and	O
IGT	O
individuals	O
and	O
aldosterone	S-chem
and	O
cortisol	S-chem
release	O
was	O
measured	O
in	O
the	O
supernatants	O
.	O

VLDL	S-geneN
induced	O
a	O
greater	O
stimulating	O
effect	O
on	O
adrenocortical	O
aldosterone	S-chem
and	O
cortisol	S-chem
release	O
compared	O
to	O
HDL	S-geneN
and	O
LDL	S-geneN
.	O

Moreover	O
,	O
IGT	O
-	O
VLDL	S-geneN
evoked	O
a	O
significantly	O
higher	O
effect	O
(	O
p	O
<	O
0.05	O
)	O
on	O
hormone	O
release	O
than	O
NGT	O
-	O
VLDL	S-geneN
.	O

Incubation	O
of	O
cells	O
with	O
in	O
vitro	O
modified	O
lipoproteins	O
and	O
specific	O
pharmacological	O
inhibitors	O
suggests	O
that	O
VLDL	S-geneN
presumably	O
recruits	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
as	O
one	O
of	O
the	O
downstream	O
effectors	O
of	O
Jak	B-geneY
-	I-geneY
2	E-geneY
.	O

In	O
summary	O
,	O
in	O
vivo	O
modified	O
VLDL	S-geneN
are	O
able	O
to	O
promote	O
prediabetic	O
hormonal	O
dysregulation	O
by	O
modulating	O
adrenocortical	O
steroidogenesis	O
via	O
Jak	B-geneY
-	I-geneY
2	E-geneY
-	O
ERK	S-geneN
dependent	O
pathway	O
.	O

Loss	O
of	O
a	O
primordial	O
identity	O
element	O
for	O
a	O
mammalian	O
mitochondrial	O
aminoacylation	O
system	O
.	O

In	O
mammalian	O
mitochondria	O
the	O
translational	O
machinery	O
is	O
of	O
dual	O
origin	O
with	O
tRNAs	O
encoded	O
by	O
a	O
simplified	O
and	O
rapidly	O
evolving	O
mitochondrial	O
(	O
mt	O
)	O
genome	O
and	O
aminoacyl	B-geneN
-	I-geneN
tRNA	I-geneN
synthetases	E-geneN
(	O
aaRS	S-geneN
)	O
coded	O
by	O
the	O
nuclear	O
genome	O
,	O
and	O
imported	O
.	O

Mt	O
-	O
tRNAs	O
are	O
atypical	O
with	O
biased	O
sequences	O
,	O
size	O
variations	O
in	O
loops	O
and	O
stems	O
,	O
and	O
absence	O
of	O
residues	O
forming	O
classical	O
tertiary	O
interactions	O
,	O
whereas	O
synthetases	S-geneN
appear	O
typical	O
.	O

This	O
raises	O
questions	O
about	O
identity	O
elements	O
in	O
mt	O
-	O
tRNAs	O
and	O
adaptation	O
of	O
their	O
cognate	O
mt	B-geneN
-	I-geneN
aaRSs	E-geneN
.	O

We	O
have	O
explored	O
here	O
the	O
human	O
mt	O
-	O
aspartate	S-chem
system	O
in	O
which	O
a	O
prokaryotic	B-geneN
-	I-geneN
type	I-geneN
AspRS	E-geneN
,	O
highly	O
similar	O
to	O
the	O
Escherichia	O
coli	O
enzyme	O
,	O
recognizes	O
a	O
bizarre	O
tRNA	O
(	O
Asp	O
)	O
.	O

Analysis	O
of	O
human	B-geneN
mt	I-geneN
-	I-geneN
tRNA	I-geneN
(	I-geneN
Asp	I-geneN
)	I-geneN
transcripts	E-geneN
confirms	O
the	O
identity	O
role	O
of	O
the	O
GUC	O
anticodon	O
as	O
in	O
other	O
aspartylation	O
systems	O
but	O
reveals	O
the	O
non	O
-	O
involvement	O
of	O
position	O
73	O
.	O

This	O
position	O
is	O
otherwise	O
known	O
as	O
the	O
site	O
of	O
a	O
universally	O
conserved	O
major	O
aspartate	S-chem
identity	O
element	O
,	O
G73	S-geneN
,	O
also	O
known	O
as	O
a	O
primordial	O
identity	O
signal	O
.	O

In	O
mt	O
-	O
tRNA	O
(	O
Asp	O
)	O
,	O
position	O
73	O
can	O
be	O
occupied	O
by	O
any	O
of	O
the	O
four	O
nucleotides	S-chem
without	O
affecting	O
aspartylation	O
.	O

Sequence	O
alignments	O
of	O
various	O
AspRSs	S-geneN
allowed	O
placing	O
Gly	S-chem
-	O
269	O
at	O
a	O
position	O
occupied	O
by	O
Asp	S-chem
-	O
220	O
,	O
the	O
residue	O
contacting	O
G73	S-geneN
in	O
the	O
crystallographic	O
structure	O
of	O
E.	B-geneY
coli	I-geneY
AspRS	E-geneY
-	O
tRNA	O
(	O
Asp	O
)	O
complex	O
.	O

Replacing	O
this	O
glycine	S-chem
by	O
an	O
aspartate	S-chem
renders	O
human	B-geneY
mt	I-geneY
-	I-geneY
AspRS	E-geneY
more	O
discriminative	O
to	O
G73	S-geneN
.	O

Restriction	O
in	O
the	O
aspartylation	O
identity	O
set	O
,	O
driven	O
by	O
a	O
rapid	O
mutagenic	O
rate	O
of	O
the	O
mt	O
-	O
genome	O
,	O
suggests	O
a	O
reverse	O
evolution	O
of	O
the	O
mt	O
-	O
tRNA	O
(	O
Asp	O
)	O
identity	O
elements	O
in	O
regard	O
to	O
its	O
bacterial	O
ancestor	O
.	O

Characterization	O
of	O
an	O
alpha	B-geneY
1D	I-geneY
-	I-geneY
adrenoceptor	E-geneY
mediating	O
the	O
contractile	O
response	O
of	O
rat	O
aorta	O
to	O
noradrenaline	S-chem
.	O

1	O
.	O

The	O
affinities	O
of	O
a	O
number	O
of	O
alpha	B-geneN
1	I-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonists	O
were	O
determined	O
by	O
displacement	O
of	O
[	B-chem
3H	I-chem
]	I-chem
-	I-chem
prazosin	E-chem
binding	O
from	O
cloned	O
human	B-geneY
alpha	I-geneY
1A	I-geneY
-	I-geneY
adrenoceptors	E-geneY
(	O
previously	O
designated	O
cloned	O
alpha	O
1c	O
subtype	O
)	O
,	O
alpha	O
1B	O
alpha	O
1D	O
and	O
rat	B-geneY
alpha	I-geneY
1D	I-geneY
-	I-geneY
adrenoceptors	E-geneY
,	O
stably	O
expressed	O
in	O
rat	O
-	O
1	O
fibroblasts	O
.	O

Functional	O
affinity	O
estimates	O
for	O
these	O
compounds	O
were	O
also	O
determined	O
from	O
noradrenaline	S-chem
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
.	O

2	O
.	O

BMY	B-chem
7378	E-chem
displayed	O
high	O
affinity	O
for	O
cloned	O
human	B-geneY
alpha	I-geneY
1D	I-geneY
-	I-geneY
adrenoceptors	E-geneY
(	O
pKi	O
=	O
8.2	O
+	O
/	O
-	O
0.10	O
)	O
and	O
was	O
selective	O
over	O
alpha	O
1A	O
(	O
pKi	O
=	O
6.2	O
+	O
/	O
-	O
0.10	O
)	O
and	O
alpha	O
1B	O
subtypes	O
(	O
6.7	O
+	O
/	O
-	O
0.11	O
)	O
.	O

WB	O
4101	O
,	O
benoxathian	S-chem
and	O
phentolamine	S-chem
displayed	O
high	O
affinity	O
for	O
alpha	B-geneN
1A	I-geneN
and	I-geneN
alpha	I-geneN
1D	I-geneN
adrenoceptors	E-geneN
compared	O
to	O
the	O
alpha	O
1B	O
subtype	O
.	O

Spiperone	S-chem
displayed	O
high	O
affinity	O
and	O
selectivity	O
for	O
alpha	B-geneY
1B	I-geneY
adrenoceptors	E-geneY
(	O
pKi	O
8.8	O
+	O
/	O
-	O
0.16	O
)	O
.	O

5	B-chem
-	I-chem
Methyl	I-chem
-	I-chem
urapidil	E-chem
was	O
selective	O
for	O
cloned	O
alpha	B-geneY
1A	I-geneY
adrenoceptors	E-geneY
.	O

3	O
.	O

Comparative	O
binding	O
affinities	O
(	O
pKi	O
)	O
for	O
compounds	O
at	O
cloned	O
human	B-geneN
and	I-geneN
rat1D	I-geneN
adrenoceptors	E-geneN
were	O
almost	O
identical	O
(	O
r	O
=	O
0.99	O
,	O
slope	O
=	O
1.08	O
)	O
.	O

4	O
.	O

Prazosin	S-chem
,	O
doxazosin	S-chem
and	O
5	B-chem
-	I-chem
methyl	I-chem
-	I-chem
urapidil	E-chem
were	O
potent	O
,	O
competitive	O
antagonists	O
of	O
noradrenaline	S-chem
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
(	O
pA2	O
values	O
of	O
9.8	O
,	O
8.8	O
and	O
7.8	O
respectively	O
)	O
.	O

The	O
selective	O
alpha	O
1D	O
antagonist	O
BMY	B-chem
7378	E-chem
was	O
also	O
a	O
potent	O
antagonist	O
on	O
rat	O
aorta	O
(	O
pKB	O
=	O
8.3	O
+	O
/	O
-	O
0.1	O
)	O
but	O
the	O
interaction	O
of	O
this	O
compound	O
was	O
not	O
consistent	O
with	O
competitive	O
antagonism	O
at	O
a	O
single	O
population	O
of	O
receptors	O
.	O

5	O
.	O

Functional	O
affinities	O
for	O
compounds	O
determined	O
against	O
noradrenaline	S-chem
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
correlated	O
well	O
with	O
binding	O
affinities	O
at	O
cloned	O
alpha	B-geneY
1D	I-geneY
-	I-geneY
adrenoceptors	E-geneY
(	O
r	O
=	O
0.96	O
)	O
,	O
but	O
not	O
with	O
alpha	O
1A	O
(	O
r	O
=	O
0.61	O
)	O
or	O
alpha	O
1B	O
(	O
r	O
=	O
0.46	O
)	O
subtypes	O
.	O

6	O
.	O

Noradrenaline	S-chem
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
were	O
sensitive	O
to	O
the	O
alkylating	O
effects	O
of	O
chlorethylclonidine	S-chem
(	O
CEC	S-chem
)	O
.	O

CEC	O
(	O
10	O
microM	O
)	O
caused	O
a	O
small	O
rightward	O
shift	O
in	O
the	O
noradrenaline	S-chem
concentration	O
-	O
response	O
curve	O
.	O

CEC	S-chem
at	O
100	O
microM	O
caused	O
a	O
further	O
shift	O
and	O
suppression	O
of	O
the	O
maximum	O
response	O
to	O
noradrenaline.7	S-chem
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
noradrenaline	S-chem
predominantly	O
,	O
but	O
not	O
exclusively	O
,	O
mediates	O
contraction	O
of	O
rat	O
aorta	O
through	O
the	O
activation	O
of	O
an	O
alphalD	B-geneY
-	I-geneY
adrenoceptor	E-geneY
.	O

Discovery	O
of	O
ML326	S-chem
:	O
The	O
first	O
sub	O
-	O
micromolar	O
,	O
selective	O
M5	S-geneY
PAM	O
.	O

This	O
Letter	O
describes	O
the	O
further	O
chemical	O
optimization	O
of	O
the	O
M5	S-geneY
PAM	O
MLPCN	O
probes	O
ML129	S-chem
and	O
ML172	S-chem
.	O

A	O
multi	O
-	O
dimensional	O
iterative	O
parallel	O
synthesis	O
effort	O
quickly	O
explored	O
isatin	S-chem
replacements	O
and	O
a	O
number	O
of	O
southern	O
heterobiaryl	O
variations	O
with	O
no	O
improvement	O
over	O
ML129	S-chem
and	O
ML172	S-chem
.	O

An	O
HTS	O
campaign	O
identified	O
several	O
weak	O
M5	S-geneY
PAMs	O
(	O
M5	S-geneY
EC50	O
>	O
10μM	O
)	O
with	O
a	O
structurally	O
related	O
isatin	S-chem
core	O
that	O
possessed	O
a	O
southern	O
phenethyl	B-chem
ether	E-chem
linkage	O
.	O

While	O
SAR	O
within	O
the	O
HTS	O
series	O
was	O
very	O
shallow	O
and	O
unable	O
to	O
be	O
optimized	O
,	O
grafting	O
the	O
phenethyl	B-chem
ether	E-chem
linkage	O
onto	O
the	O
ML129	S-chem
/	O
ML172	S-chem
cores	O
led	O
to	O
the	O
first	O
sub	O
-	O
micromolar	O
M5	S-geneY
PAM	O
,	O
ML326	S-chem
(	O
VU0467903	S-chem
)	O
,	O
(	O
human	O
and	O
rat	O
M5	S-geneN
EC50s	O
of	O
409nM	O
and	O
500nM	O
,	O
respectively	O
)	O
with	O
excellent	O
mAChR	S-geneN
selectivity	O
(	O
M1	O
-	O
M4	O
EC50s	O
>	O
30μM	O
)	O
and	O
a	O
robust	O
20	O
-	O
fold	O
leftward	O
shift	O
of	O
the	O
ACh	S-chem
CRC	O
.	O

The	O
vascular	O
protective	O
properties	O
of	O
kinsenoside	S-chem
isolated	O
from	O
Anoectochilus	O
roxburghii	O
under	O
high	O
glucose	S-chem
condition	O
.	O

Anoectochilus	O
roxburghii	O
is	O
a	O
traditional	O
Chinese	O
herb	O
used	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
some	O
other	O
diseases	O
.	O

The	O
vascular	O
protective	O
effect	O
of	O
its	O
major	O
active	O
ingredient	O
,	O
kinsenoside	S-chem
,	O
in	O
high	O
glucose	S-chem
conditions	O
was	O
investigated	O
in	O
in	O
vivo	O
and	O
in	O
vitro	O
experiments	O
.	O

In	O
in	O
vivo	O
tests	O
,	O
kinsenoside	S-chem
(	O
50	O
and	O
100mg	O
/	O
kg	O
)	O
efficiently	O
lowered	O
blood	O
glucose	S-chem
and	O
cholesterol	S-chem
levels	O
and	O
it	O
enhanced	O
the	O
oxidation	O
resistance	O
of	O
diabetic	O
mice	O
induced	O
by	O
streptozotocin	S-chem
.	O

In	O
the	O
in	O
vitro	O
assay	O
,	O
kinsenoside	S-chem
(	O
20	O
and	O
50μg	O
/	O
mL	O
)	O
markedly	O
inhibited	O
changes	O
in	O
various	O
biochemical	O
substances	O
(	O
nitric	B-chem
oxide	E-chem
(	O
NO	S-chem
)	O
,	O
lactic	B-geneN
dehydrogenase	E-geneN
(	O
LDH	S-geneN
)	O
,	O
superoxide	B-geneN
dismutase	E-geneN
(	O
SOD	S-geneN
)	O
,	O
and	O
catalase	S-geneY
(	O
CAT	S-geneY
)	O
)	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
damaged	O
by	O
high	O
glucose	S-chem
(	O
35mM	O
)	O
and	O
restored	O
vascular	O
endothelial	O
structure	O
by	O
balancing	O
the	O
matrix	B-geneN
metalloproteinases	E-geneN
-	O
the	O
tissue	B-geneN
inhibitors	I-geneN
of	I-geneN
matrix	I-geneN
metalloproteinases	E-geneN
(	O
MMP	S-geneN
-	O
TIMP	S-geneN
)	O
system	O
.	O

The	O
vascular	O
protective	O
effects	O
of	O
kinsenoside	S-chem
were	O
speculated	O
to	O
be	O
attributed	O
to	O
oxidative	O
stress	O
inhibition	O
and	O
the	O
reduction	O
of	O
nuclear	B-geneN
factor	I-geneN
kappa	I-geneN
B	E-geneN
(	O
NF	B-geneN
-	I-geneN
κB	E-geneN
)	O
mRNA	O
expression	O
levels	O
in	O
high	O
glucose	S-chem
conditions	O
.	O

Moreover	O
,	O
histological	O
examination	O
,	O
including	O
hematoxylin	S-chem
-	O
eosin	S-chem
(	O
H	O
&	O
E	O
)	O
staining	O
,	O
masson	O
trichrome	O
(	O
Masson	O
)	O
staining	O
,	O
and	O
periodic	O
Schiff	O
-	O
methenamine	S-chem
(	O
PASM	O
)	O
staining	O
,	O
greatly	O
supported	O
the	O
morphological	O
and	O
functional	O
amelioration	O
of	O
diabetes	O
-	O
related	O
changes	O
in	O
mice	O
aortas	O
after	O
kinsenoside	S-chem
(	O
20	O
and	O
50μg	O
/	O
mL	O
)	O
treatment	O
.	O

These	O
results	O
indicated	O
that	O
kinsenoside	S-chem
might	O
be	O
a	O
promising	O
agent	O
for	O
the	O
treatment	O
of	O
diabetic	O
vascular	O
disease	O
.	O

Highly	O
selective	O
phosphodiesterase	B-geneN
4	E-geneN
inhibitors	O
for	O
the	O
treatment	O
of	O
allergic	O
skin	O
diseases	O
and	O
psoriasis	O
.	O

The	O
phosphodiesterase	B-geneN
(	I-geneN
PDE	I-geneN
)	I-geneN
4	E-geneN
is	O
the	O
predominant	O
cyclic	B-chem
AMP	E-chem
degrading	O
enzyme	O
in	O
a	O
variety	O
of	O
inflammatory	O
cells	O
including	O
eosinophils	O
,	O
neutrophils	O
,	O
macrophages	O
,	O
T	O
cells	O
and	O
monocytes	O
.	O

In	O
addition	O
,	O
this	O
enzyme	O
is	O
expressed	O
in	O
non	O
-	O
immune	O
cells	O
such	O
as	O
keratinocytes	O
and	O
fibroblasts	O
.	O

Highly	O
selective	O
PDE4	S-geneN
inhibitors	O
are	O
currently	O
under	O
evaluation	O
for	O
the	O
treatment	O
of	O
asthma	O
and	O
/	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

Due	O
to	O
the	O
broad	O
anti	O
-	O
inflammatory	O
/	O
immuno	O
-	O
modulatory	O
action	O
of	O
PDE4	S-geneN
inhibitors	O
,	O
it	O
has	O
been	O
proposed	O
that	O
PDE4	S-geneN
inhibitors	O
might	O
also	O
be	O
efficacious	O
for	O
skin	O
disorders	O
such	O
as	O
atopic	O
dermatitis	O
.	O

Consequently	O
,	O
PDE4	S-geneN
inhibitors	O
including	O
cilomilast	S-chem
and	O
AWD	B-chem
12	I-chem
-	I-chem
281	E-chem
have	O
been	O
tested	O
in	O
several	O
models	O
of	O
allergic	O
and	O
irritant	O
skin	O
inflammation	O
.	O

These	O
PDE4	S-geneN
inhibitors	O
displayed	O
strong	O
anti	O
-	O
inflammatory	O
action	O
in	O
models	O
of	O
allergic	O
contact	O
dermatitis	O
in	O
mice	O
,	O
in	O
the	O
arachidonic	B-chem
acid	E-chem
induced	O
skin	O
inflammation	O
in	O
mice	O
and	O
in	O
ovalbumin	S-geneY
sensitised	O
guinea	O
pigs	O
.	O

The	O
determination	O
of	O
cytokines	S-geneN
in	O
skin	O
homogenates	O
revealed	O
that	O
both	O
Th1	O
as	O
well	O
as	O
Th2	O
cytokines	S-geneN
are	O
suppressed	O
by	O
PDE4	S-geneN
inhibitors	O
,	O
indicating	O
an	O
anti	O
-	O
inflammatory	O
activity	O
in	O
both	O
the	O
Th2	O
dominated	O
acute	O
phase	O
as	O
well	O
as	O
the	O
Th1	O
dominated	O
chronic	O
phase	O
of	O
atopic	O
dermatitis	O
.	O

Due	O
to	O
the	O
suppression	O
of	O
Th1	O
cytokines	S-geneN
,	O
activity	O
can	O
also	O
be	O
expected	O
in	O
psoriasis	O
.	O

Results	O
of	O
early	O
clinical	O
trials	O
with	O
both	O
topically	O
(	O
cipamfylline	S-chem
,	O
CP80,633	S-chem
)	O
and	O
systemically	O
(	O
CC	O
-	O
10004	O
)	O
active	O
PDE4	S-geneN
inhibitors	O
demonstrated	O
efficacy	O
in	O
atopic	O
dermatitis	O
and	O
in	O
the	O
case	O
of	O
CC	O
-	O
10004	O
,	O
also	O
in	O
psoriasis	O
.	O

AWD	B-chem
12	I-chem
-	I-chem
281	E-chem
(	O
GW	B-chem
842470	E-chem
)	O
is	O
currently	O
under	O
clinical	O
evaluation	O
for	O
the	O
topical	O
treatment	O
of	O
atopic	O
dermatitis	O
.	O

Results	O
concerning	O
clinical	O
efficacy	O
of	O
this	O
potent	O
and	O
selective	O
PDE4	S-geneN
inhibitor	O
are	O
anxiously	O
awaited	O
.	O

GPR109A	S-geneY
(	O
PUMA	B-geneY
-	I-geneY
G	E-geneY
/	O
HM74A	S-geneY
)	O
mediates	O
nicotinic	B-chem
acid	E-chem
-	O
induced	O
flushing	O
.	O

Nicotinic	B-chem
acid	E-chem
(	O
niacin	S-chem
)	O
has	O
long	O
been	O
used	O
as	O
an	O
antidyslipidemic	O
drug	O
.	O

Its	O
special	O
profile	O
of	O
actions	O
,	O
especially	O
the	O
rise	O
in	O
HDL	S-geneN
-	O
cholesterol	S-chem
levels	O
induced	O
by	O
nicotinic	B-chem
acid	E-chem
,	O
is	O
unique	O
among	O
the	O
currently	O
available	O
pharmacological	O
tools	O
to	O
treat	O
lipid	O
disorders	O
.	O

Recently	O
,	O
a	O
G	B-geneN
-	I-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
,	O
termed	O
GPR109A	S-geneY
(	O
HM74A	S-geneY
in	O
humans	O
,	O
PUMA	B-geneY
-	I-geneY
G	E-geneY
in	O
mice	O
)	O
,	O
was	O
described	O
and	O
shown	O
to	O
mediate	O
the	O
nicotinic	B-chem
acid	E-chem
-	O
induced	O
antilipolytic	O
effects	O
in	O
adipocytes	O
.	O

One	O
of	O
the	O
major	O
problems	O
of	O
the	O
pharmacotherapeutical	O
use	O
of	O
nicotinic	B-chem
acid	E-chem
is	O
a	O
strong	O
flushing	O
response	O
.	O

This	O
side	O
effect	O
,	O
although	O
harmless	O
,	O
strongly	O
affects	O
patient	O
compliance	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
mice	O
lacking	O
PUMA	B-geneY
-	I-geneY
G	E-geneY
did	O
not	O
show	O
nicotinic	B-chem
acid	E-chem
-	O
induced	O
flushing	O
.	O

In	O
addition	O
,	O
flushing	O
in	O
response	O
to	O
nicotinic	B-chem
acid	E-chem
was	O
also	O
abrogated	O
in	O
the	O
absence	O
of	O
cyclooxygenase	B-geneY
type	I-geneY
1	E-geneY
,	O
and	O
mice	O
lacking	O
prostaglandin	B-geneN
D	I-geneN
(	I-geneN
2	I-geneN
)	I-geneN
(	I-geneN
PGD	I-geneN
(	I-geneN
2	I-geneN
)	I-geneN
)	I-geneN
and	I-geneN
prostaglandin	I-geneN
E	I-geneN
(	I-geneN
2	I-geneN
)	I-geneN
(	I-geneN
PGE	I-geneN
(	I-geneN
2	I-geneN
)	I-geneN
)	I-geneN
receptors	E-geneN
had	O
reduced	O
flushing	O
responses	O
.	O

The	O
mouse	O
orthologue	O
of	O
GPR109A	S-geneY
,	O
PUMA	B-geneY
-	I-geneY
G	E-geneY
,	O
is	O
highly	O
expressed	O
in	O
macrophages	O
and	O
other	O
immune	O
cells	O
,	O
and	O
transplantation	O
of	O
wild	O
-	O
type	O
bone	O
marrow	O
into	O
irradiated	O
PUMA	B-geneY
-	I-geneY
G	E-geneY
-	O
deficient	O
mice	O
restored	O
the	O
nicotinic	B-chem
acid	E-chem
-	O
induced	O
flushing	O
response	O
.	O

Our	O
data	O
clearly	O
indicate	O
that	O
GPR109A	S-geneY
mediates	O
nicotinic	B-chem
acid	E-chem
-	O
induced	O
flushing	O
and	O
that	O
this	O
effect	O
involves	O
release	O
of	O
PGE	B-chem
(	I-chem
2	I-chem
)	E-chem
and	O
PGD	B-chem
(	I-chem
2	I-chem
)	E-chem
,	O
most	O
likely	O
from	O
immune	O
cells	O
of	O
the	O
skin	O
.	O

Locally	O
administered	O
prostaglandin	B-chem
E2	E-chem
prevents	O
aeroallergen	O
-	O
induced	O
airway	O
sensitization	O
in	O
mice	O
through	O
immunomodulatory	O
mechanisms	O
.	O

Prostaglandin	B-chem
E2	E-chem
attenuates	O
airway	O
pathology	O
in	O
asthmatic	O
patients	O
and	O
exerts	O
a	O
protective	O
effect	O
in	O
antigen	O
-	O
sensitized	O
mice	O
when	O
administered	O
systemically	O
.	O

We	O
aimed	O
to	O
establish	O
the	O
consequences	O
of	O
intranasal	O
PGE2	S-chem
administration	O
on	O
airway	O
reactivity	O
to	O
aeroallergens	O
in	O
mice	O
and	O
reveal	O
the	O
underlying	O
immunoinflammatory	O
mechanisms	O
.	O

PGE2	S-chem
was	O
administered	O
either	O
daily	O
during	O
a	O
10	O
-	O
day	O
exposure	O
to	O
house	O
dust	O
mite	O
(	O
HDM	O
)	O
extracts	O
or	O
for	O
limited	O
intervals	O
.	O

Airway	O
hyperreactivity	O
was	O
measured	O
by	O
whole	O
-	O
body	O
and	O
invasive	O
plethysmography	O
.	O

The	O
phenotypes	O
of	O
lung	O
immune	O
cells	O
and	O
cytokine	S-geneN
production	O
were	O
analysed	O
by	O
flow	O
cytometry	O
and	O
ELISA	O
,	O
respectively	O
.	O

Airway	O
hyperreactivity	O
was	O
sustainably	O
reduced	O
only	O
when	O
PGE2	S-chem
administration	O
was	O
restricted	O
to	O
the	O
initial	O
5	O
days	O
of	O
exposure	O
to	O
HDM	O
.	O

Lung	O
inflammation	O
,	O
IL	B-geneY
-	I-geneY
4	E-geneY
production	O
,	O
and	O
airway	O
mast	O
cell	O
activity	O
were	O
also	O
prevented	O
under	O
this	O
early	O
short	O
-	O
term	O
treatment	O
with	O
PGE2	S-chem
.	O

Interestingly	O
,	O
a	O
Th2	O
response	O
was	O
already	O
committed	O
on	O
day	O
5	O
of	O
exposure	O
to	O
HDM	O
.	O

This	O
was	O
paralleled	O
by	O
GM	B-geneY
-	I-geneY
CSF	E-geneY
and	O
osteopontin	S-geneY
upregulation	O
and	O
a	O
decreased	O
number	O
of	O
plasmacytoid	O
dendritic	O
and	O
T	O
regulatory	O
cells	O
,	O
as	O
well	O
as	O
a	O
trend	O
towards	O
reduced	O
IL	B-geneY
-	I-geneY
10	E-geneY
expression	O
.	O

Local	O
PGE2	S-chem
administration	O
prevented	O
the	O
increase	O
of	O
airway	O
IL	B-geneY
-	I-geneY
13	E-geneY
and	O
osteopontin	S-geneY
and	O
kept	O
lung	O
plasmacytoid	O
dendritic	O
cell	O
counts	O
close	O
to	O
baseline	O
.	O

GM	B-geneY
-	I-geneY
CSF	E-geneY
and	O
Tregs	O
were	O
unaffected	O
by	O
the	O
treatment	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
protection	O
provided	O
by	O
PGE2	S-chem
is	O
a	O
result	O
of	O
the	O
modulation	O
of	O
early	O
lung	O
immunomodulatory	O
mechanisms	O
,	O
and	O
possibly	O
a	O
shift	O
in	O
the	O
balance	O
of	O
dendritic	O
cells	O
towards	O
a	O
tolerogenic	O
profile	O
.	O

Lowering	O
interleukin	B-geneN
-	I-geneN
1	E-geneN
activity	O
with	O
anakinra	O
improves	O
myocardial	O
deformation	O
in	O
rheumatoid	O
arthritis	O
.	O

OBJECTIVE	O
:	O
Inhibition	O
of	O
interleukin	B-geneN
-	I-geneN
1	E-geneN
activity	O
improves	O
nitro	S-chem
-	O
oxidative	O
stress	O
,	O
endothelial	O
and	O
coronary	O
function	O
.	O

The	O
authors	O
investigated	O
(	O
a	O
)	O
the	O
association	O
of	O
nitro	S-chem
-	O
oxidative	O
stress	O
and	O
endothelial	O
function	O
with	O
myocardial	O
deformation	O
,	O
(	O
b	O
)	O
the	O
effects	O
of	O
anakinra	O
,	O
an	O
interleukin	B-geneY
-	I-geneY
1a	I-geneY
receptor	E-geneY
antagonist	O
on	O
myocardial	O
deformation	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

METHODS	O
:	O
The	O
authors	O
compared	O
46	O
RA	O
patients	O
to	O
23	O
normal	O
controls	O
.	O

23	O
patients	O
received	O
anakinra	O
(	O
150	O
mg	O
subcutaneously	O
once	O
daily	O
)	O
and	O
23	O
patients	O
a	O
5	O
-	O
mg	O
increase	O
of	O
prednisolone	S-chem
dose	O
for	O
30	O
days	O
.	O

At	O
baseline	O
and	O
post	O
-	O
treatment	O
this	O
study	O
assessed	O
(	O
a	O
)	O
the	O
left	O
ventricular	O
(	O
LV	O
)	O
longitudinal	O
,	O
circumferential	O
and	O
radial	O
strain	O
and	O
strain	O
rate	O
,	O
using	O
speckle	O
tracking	O
echocardiography	O
,	O
(	O
b	O
)	O
the	O
coronary	O
flow	O
reserve	O
(	O
CFR	O
)	O
,	O
(	O
c	O
)	O
the	O
flow	O
-	O
mediated	O
endothelial	O
-	O
dependent	O
dilation	O
of	O
the	O
brachial	O
artery	O
(	O
FMD	O
)	O
and	O
(	O
d	O
)	O
nitrotyrosine	S-chem
(	O
NT	S-chem
)	O
and	O
malondialdehyde	S-chem
blood	O
levels	O
.	O

RESULTS	O
:	O
Patients	O
had	O
impaired	O
baseline	O
myocardial	O
deformation	O
indices	O
compared	O
to	O
controls	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CFR	O
and	O
NT	S-chem
levels	O
were	O
related	O
to	O
longitudinal	O
strain	O
,	O
systolic	O
and	O
diastolic	O
strain	O
rate	O
,	O
circumferential	O
strain	O
and	O
systolic	O
strain	O
rate	O
(	O
p	O
<	O
0.05	O
)	O
.	O

FMD	O
was	O
related	O
to	O
longitudinal	O
and	O
circumferential	O
diastolic	O
strain	O
rate	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Compared	O
to	O
baseline	O
,	O
anakinra	O
-	O
treated	O
patients	O
increased	O
the	O
longitudinal	O
strain	O
(	O
-	O
17.8	O
%	O
(	O
3.7	O
%	O
)	O
vs	O
-	O
22.1	O
%	O
(	O
3.5	O
%	O
)	O
)	O
,	O
systolic	O
(	O
-	O
1.02	O
(	O
0.23	O
)	O
l	O
/	O
s	O
vs	O
-	O
1.25	O
(	O
0.23	O
)	O
l	O
/	O
s	O
)	O
and	O
diastolic	O
(	O
0.96	O
(	O
0.37	O
)	O
l	O
/	O
s	O
vs	O
1.20	O
(	O
0.39	O
)	O
l	O
/	O
s	O
)	O
longitudinal	O
strain	O
rate	O
,	O
circumferential	O
strain	O
and	O
strain	O
rate	O
(	O
p	O
<	O
0.05	O
for	O
all	O
comparisons	O
)	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
among	O
prednisolone	S-chem
-	O
treated	O
patients	O
CONCLUSIONS	O
:	O
Myocardial	O
deformation	O
is	O
impaired	O
in	O
RA	O
patients	O
and	O
is	O
related	O
to	O
nitro	S-chem
-	O
oxidative	O
stress	O
and	O
endothelial	O
dysfunction	O
.	O

Chronic	O
inhibition	O
of	O
IL	B-geneN
-	I-geneN
1	E-geneN
improves	O
LV	O
deformation	O
in	O
parallel	O
with	O
endothelial	O
function	O
and	O
nitro	S-chem
-	O
oxidative	O
stress	O
.	O

Nicotine	S-chem
receptor	O
gene	O
CHRNA4	S-geneY
modulates	O
early	O
event	O
-	O
related	O
potentials	O
in	O
auditory	O
and	O
visual	O
oddball	O
target	O
detection	O
tasks	O
.	O

The	O
present	O
study	O
seeks	O
to	O
identify	O
effects	O
of	O
a	O
common	O
genetic	O
polymorphism	O
in	O
the	O
human	B-geneN
nicotinic	I-geneN
alpha4beta2	I-geneN
receptor	E-geneN
on	O
components	O
of	O
the	O
cognitive	O
event	O
-	O
related	O
potentials	O
in	O
auditory	O
and	O
visual	O
modalities	O
.	O

The	O
same	O
sense	O
thymine	S-chem
-	O
to	O
-	O
cytosine	S-chem
polymorphism	O
(	O
c.1629T	O
-	I-geneN
C	E-geneN
;	O
Ser543Ser	S-geneN
)	O
was	O
shown	O
to	O
preferentially	O
modulate	O
early	O
components	O
in	O
both	O
modalities	O
.	O

Specifically	O
,	O
the	O
auditory	O
N1	O
component	O
amplitude	O
was	O
higher	O
for	O
T	O
allele	O
homozygotes	O
than	O
for	O
C	O
allele	O
carriers	O
.	O

The	O
visual	O
P1	O
component	O
revealed	O
the	O
same	O
pattern	O
of	O
significant	O
polymorphic	O
modulation	O
,	O
but	O
the	O
later	O
N1	O
amplitude	O
differences	O
were	O
only	O
marginally	O
significant	O
.	O

There	O
was	O
no	O
reliable	O
indication	O
of	O
interactions	O
between	O
genotype	O
and	O
task	O
factors	O
.	O

Parallel	O
modulation	O
of	O
early	O
latency	O
modality	O
-	O
specific	O
event	O
-	O
related	O
potential	O
(	O
ERP	O
)	O
components	O
in	O
vision	O
and	O
audition	O
may	O
indicate	O
that	O
the	O
CHRNA4	S-geneY
polymorphism	O
affects	O
factors	O
that	O
are	O
common	O
to	O
top	O
-	O
down	O
modulation	O
of	O
sensory	O
processing	O
across	O
modalities	O
.	O

Identification	O
and	O
synthesis	O
of	O
N	B-chem
-	I-chem
(	I-chem
thiophen	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
)	I-chem
benzamide	E-chem
derivatives	O
as	O
BRAF	S-geneY
(	O
V600E	S-geneN
)	O
inhibitors	O
.	O

The	O
V600E	S-geneN
BRAF	S-geneY
kinase	S-geneN
mutation	O
,	O
which	O
activates	O
the	O
downstream	O
MAPK	S-geneN
signaling	O
pathway	O
,	O
commonly	O
occurs	O
in	O
about	O
8	O
%	O
of	O
all	O
human	O
malignancies	O
and	O
about	O
50	O
%	O
of	O
all	O
melanomas	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
virtual	O
screening	O
and	O
chemical	O
synthesis	O
to	O
identify	O
a	O
series	O
of	O
N	B-chem
-	I-chem
(	I-chem
thiophen	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
)	I-chem
benzamide	E-chem
derivatives	O
as	O
potent	O
BRAF	S-geneY
(	O
V600E	S-geneN
)	O
inhibitors	O
.	O

Structure	O
-	O
activity	O
relationship	O
studies	O
of	O
these	O
derivatives	O
revealed	O
that	O
compounds	O
b40	O
and	O
b47	O
are	O
the	O
two	O
most	O
potent	O
BRAF	S-geneY
(	O
V600E	S-geneN
)	O
inhibitors	O
in	O
this	O
series	O
.	O

Clinical	O
effects	O
of	O
pranlukast	S-chem
,	O
an	O
oral	O
leukotriene	B-geneN
receptor	E-geneN
antagonist	O
,	O
in	O
mild	O
-	O
to	O
-	O
moderate	O
asthma	O
:	O
a	O
4	O
week	O
randomized	O
multicentre	O
controlled	O
trial	O
.	O

OBJECTIVE	O
:	O
Leukotriene	S-chem
antagonists	O
are	O
increasingly	O
used	O
in	O
asthma	O
management	O
.	O

Pranlukast	S-chem
is	O
a	O
new	O
,	O
orally	O
active	O
,	O
selective	O
inhibitor	O
of	O
CysLt1	S-geneY
leukotriene	B-geneN
receptor	E-geneN
.	O

The	O
present	O
clinical	O
trial	O
was	O
performed	O
to	O
study	O
the	O
effect	O
and	O
safety	O
of	O
pranlukast	S-chem
in	O
mild	O
-	O
to	O
-	O
moderate	O
asthma	O
.	O

METHODOLOGY	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
group	O
study	O
was	O
performed	O
in	O
eight	O
medical	O
centres	O
in	O
Korea	O
.	O

Mild	O
-	O
to	O
-	O
moderate	O
asthma	O
patients	O
who	O
had	O
been	O
treated	O
with	O
beta2	O
-	O
agonists	O
and	O
/	O
or	O
inhaled	O
corticosteroids	S-chem
were	O
studied	O
.	O

The	O
patients	O
'	O
symptoms	O
were	O
evaluated	O
by	O
asthma	O
diary	O
and	O
twice	O
-	O
daily	O
peak	O
flow	O
monitoring	O
.	O

RESULTS	O
:	O
Of	O
the	O
206	O
patients	O
enrolled	O
,	O
197	O
were	O
eligible	O
for	O
analysis	O
.	O

The	O
pranlukast	S-chem
group	O
(	O
n	O
=	O
98	O
)	O
showed	O
statistically	O
significant	O
improvement	O
in	O
asthma	O
symptoms	O
,	O
including	O
asthma	O
attack	O
rate	O
,	O
daily	O
living	O
score	O
,	O
and	O
morning	O
and	O
evening	O
asthma	O
scores	O
.	O

Pranlukast	S-chem
significantly	O
reduced	O
the	O
consumption	O
of	O
beta2	O
-	O
agonist	O
.	O

Compared	O
with	O
the	O
placebo	O
group	O
,	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
and	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV1	O
)	O
were	O
not	O
significantly	O
higher	O
in	O
the	O
pranlukast	S-chem
group	O
.	O

Morning	O
and	O
evening	O
peak	O
expiratory	O
flow	O
(	O
PEF	O
)	O
were	O
significantly	O
increased	O
after	O
pranlukast	S-chem
treatment	O
at	O
weeks	O
2	O
and	O
4	O
(	O
380.8	O
+	O
/	O
-	O
10.1	O
L	O
/	O
min	O
at	O
baseline	O
,	O
394.5	O
+	O
/	O
-	O
10.1	O
at	O
week	O
2	O
,	O
396.3	O
+	O
/	O
-	O
10.4	O
at	O
week	O
4	O
)	O
.	O

There	O
were	O
no	O
serious	O
adverse	O
reactions	O
.	O

CONCLUSION	O
:	O
Pranlukast	S-chem
,	O
an	O
oral	O
leukotriene	S-chem
antagonist	O
,	O
was	O
well	O
tolerated	O
and	O
was	O
effective	O
for	O
the	O
management	O
of	O
mild	O
-	O
to	O
-	O
moderate	O
asthma	O
.	O

Inactivation	O
of	O
factor	B-geneY
XII	E-geneY
active	O
fragment	O
in	O
normal	O
plasma	O
.	O
Predominant	O
role	O
of	O
C	B-geneY
-	I-geneY
1	I-geneY
-	I-geneY
inhibitor	E-geneY
.	O

To	O
define	O
the	O
factors	O
responsible	O
for	O
the	O
inactivation	O
of	O
the	O
active	O
fragment	O
derived	O
from	O
Factor	B-geneY
XII	E-geneY
(	O
Factor	B-geneY
XIIf	E-geneY
)	O
in	O
plasma	O
,	O
we	O
studied	O
the	O
inactivation	O
kinetics	O
of	O
Factor	B-geneY
XIIf	E-geneY
in	O
various	O
purified	O
and	O
plasma	O
mixtures	O
.	O

We	O
also	O
analyzed	O
the	O
formation	O
of	O
125I	S-chem
-	O
Factor	B-geneY
XIIf	E-geneY
-	O
inhibitor	O
complexes	O
by	O
sodium	B-chem
dodecyl	I-chem
sulfate	E-chem
polyacrylamide	S-chem
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
.	O

In	O
purified	O
systems	O
,	O
the	O
bimolecular	O
rate	O
constants	O
for	O
the	O
reactions	O
of	O
Factor	B-geneY
XIIf	E-geneY
with	O
C	B-geneY
-	I-geneY
1	I-geneY
-	I-geneY
inhibitor	E-geneY
,	O
alpha	B-geneY
2	I-geneY
-	I-geneY
antiplasmin	E-geneY
,	O
and	O
antithrombin	B-geneY
III	E-geneY
were	O
18.5	O
,	O
0.91	O
,	O
and	O
0.32	O
X	O
10	O
(	O
4	O
)	O
M	O
-	O
1	O
min	O
-	O
1	O
,	O
respectively	O
.	O

Furthermore	O
,	O
SDS	O
-	O
PAGE	O
analysis	O
revealed	O
that	O
1	O
:	O
1	O
stoichiometric	O
complexes	O
were	O
formed	O
between	O
125I	S-chem
-	O
Factor	B-geneY
XIIf	E-geneY
and	O
each	O
of	O
these	O
three	O
inhibitors	O
.	O

In	O
contrast	O
,	O
kinetic	O
and	O
SDS	O
-	O
PAGE	O
studies	O
indicated	O
that	O
Factor	B-geneY
XIIf	E-geneY
did	O
not	O
react	O
with	O
alpha	B-geneY
1	I-geneY
-	I-geneY
antitrypsin	E-geneY
or	O
alpha	B-geneY
2	I-geneY
-	I-geneY
macroglobulin	E-geneY
.	O

The	O
inactivation	O
rate	O
constant	O
of	O
Factor	B-geneY
XIIf	E-geneY
by	O
prekallikrein	S-geneY
-	O
deficient	O
plasma	O
was	O
14.4	O
X	O
10	O
(	O
-	O
2	O
)	O
min	O
-	O
1	O
,	O
a	O
value	O
that	O
was	O
essentially	O
identical	O
to	O
the	O
value	O
predicted	O
from	O
the	O
studies	O
in	O
purified	O
systems	O
(	O
15.5	O
X	O
10	O
(	O
-	O
2	O
)	O
min	O
-	O
1	O
)	O
.	O

This	O
constant	O
was	O
reduced	O
to	O
1.8	O
X	O
10	O
(	O
-	O
2	O
)	O
min	O
-	O
1	O
when	O
Factor	B-geneY
XIIf	E-geneY
was	O
inactivated	O
by	O
prekallikrein	S-geneY
-	O
deficient	O
plasma	O
that	O
had	O
been	O
immunodepleted	O
(	O
less	O
than	O
5	O
%	O
)	O
of	O
C	B-geneY
-	I-geneY
1	I-geneY
-	I-geneY
inhibitor	E-geneY
.	O

In	O
addition	O
,	O
after	O
inactivation	O
in	O
normal	O
plasma	O
,	O
74	O
%	O
of	O
the	O
active	O
125I	S-chem
-	O
Factor	B-geneY
XIIf	E-geneY
was	O
found	O
to	O
form	O
a	O
complex	O
with	O
C	B-geneY
-	I-geneY
1	I-geneY
-	I-geneY
inhibitor	E-geneY
,	O
whereas	O
26	O
%	O
of	O
the	O
enzyme	O
formed	O
complexes	O
with	O
alpha	B-geneY
2	I-geneY
-	I-geneY
antiplasmin	E-geneY
and	O
antithrombin	B-geneY
III	E-geneY
.	O

Furthermore	O
,	O
42	O
%	O
of	O
the	O
labeled	O
enzyme	O
was	O
still	O
complexed	O
with	O
C	B-geneY
-	I-geneY
1	I-geneY
-	I-geneY
inhibitor	E-geneY
when	O
125I	S-chem
-	O
Factor	B-geneY
XII	E-geneY
was	O
inactivated	O
in	O
hereditary	O
angioedema	O
plasma	O
that	O
contained	O
32	O
%	O
of	O
functional	O
C	B-geneY
-	I-geneY
1	I-geneY
-	I-geneY
inhibitor	E-geneY
.	O

This	O
study	O
quantitatively	O
demonstrates	O
the	O
dominant	O
role	O
of	O
C	B-geneY
-	I-geneY
1	I-geneY
-	I-geneY
inhibitor	E-geneY
in	O
the	O
inactivation	O
of	O
Factor	B-geneY
XIIf	E-geneY
in	O
the	O
plasma	O
milieu	O
.	O

Pyrrolopyrazines	S-chem
as	O
Selective	O
Spleen	B-geneY
Tyrosine	I-geneY
Kinase	E-geneY
Inhibitors	O
.	O

We	O
describe	O
the	O
discovery	O
of	O
several	O
pyrrolopyrazines	S-chem
as	O
potent	O
and	O
selective	O
Syk	S-geneY
inhibitors	O
and	O
the	O
efforts	O
that	O
eventually	O
led	O
to	O
the	O
desired	O
improvements	O
in	O
physicochemical	O
properties	O
and	O
human	O
whole	O
blood	O
potencies	O
.	O

Ultimately	O
,	O
our	O
mouse	O
model	O
revealed	O
unexpected	O
toxicity	O
that	O
precluded	O
us	O
from	O
further	O
advancing	O
this	O
series	O
.	O

Cavity	O
Ringdown	O
Spectroscopy	O
of	O
the	O
Hydroxy	B-chem
-	I-chem
Methyl	I-chem
-	I-chem
Peroxy	E-chem
Radical	O
.	O

We	O
report	O
vibrational	O
and	O
electronic	O
spectra	O
of	O
the	O
hydroxyl	B-chem
-	I-chem
methyl	I-chem
-	I-chem
peroxy	E-chem
radical	O
(	O
HOCH2OO	S-chem
,	O
or	O
HMP	S-chem
)	O
,	O
the	O
primary	O
product	O
of	O
the	O
reaction	O
of	O
the	O
hydroperoxy	S-chem
radical	O
,	O
HO2	S-chem
,	O
and	O
formaldehyde	S-chem
,	O
HCHO	S-chem
.	O

The	O
ν1	O
vibrational	O
(	O
OH	S-chem
stretch	O
)	O
spectrum	O
and	O
the	O
Ã	O
-	O
X	O
electronic	O
spectrum	O
of	O
HMP	S-chem
were	O
detected	O
by	O
Infrared	O
Cavity	O
Ringdown	O
Spectroscopy	O
(	O
IR	O
-	O
CRDS	O
)	O
,	O
and	O
assignments	O
were	O
verified	O
with	O
density	O
functional	O
calculations	O
.	O

The	O
HMP	S-chem
radical	O
was	O
generated	O
in	O
reactions	O
of	O
HCHO	S-chem
with	O
HO2	S-chem
.	O

Free	O
radical	O
reactions	O
were	O
initiated	O
by	O
pulsed	O
laser	O
photolysis	O
(	O
PLP	O
)	O
of	O
Cl2	S-chem
in	O
the	O
presence	O
of	O
HCHO	S-chem
and	O
O2	S-chem
in	O
a	O
flow	O
reactor	O
at	O
300	O
-	O
330	O
Torr	O
and	O
295K	O
.	O

IR	O
-	O
CRDS	O
spectra	O
were	O
measured	O
in	O
mid	O
-	O
IR	O
and	O
near	O
-	O
IR	O
regions	O
over	O
the	O
ranges	O
3525	O
-	O
3700	O
cm	O
(	O
-	O
1	O
)	O
(	O
ν1	O
)	O
and	O
7250	O
-	O
7800	O
cm	O
(	O
-	O
1	O
)	O
(	O
Ã	O
-	O
X	O
)	O
(	O
respectively	O
,	O
at	O
a	O
delay	O
time	O
100	O
µs	O
after	O
photolysis	O
.	O

The	O
ν1	O
spectrum	O
had	O
an	O
origin	O
at	O
3622	O
cm	O
(	O
-	O
1	O
)	O
and	O
exhibited	O
partially	O
resolved	O
P	O
-	O
and	O
R	O
-	O
branch	O
contours	O
and	O
a	O
small	O
Q	O
branch	O
.	O

At	O
these	O
short	O
delay	O
times	O
,	O
spectral	O
interference	O
from	O
HOOH	S-chem
and	O
HCOOH	S-chem
was	O
minimal	O
,	O
and	O
could	O
be	O
subtracted	O
.	O

From	O
B3LYP	O
/	O
6	O
-	O
31G	O
+	O
(	O
d	O
,	O
p	O
)	O
calculations	O
,	O
we	O
found	O
that	O
the	O
anharmonic	O
vibrational	O
frequency	O
and	O
band	O
contour	O
predicted	O
for	O
the	O
lowest	O
energy	O
conformer	O
,	O
HMP	S-chem
-	O
A	O
,	O
The	O
calculated	O
anharmonic	O
vibrational	O
frequency	O
and	O
band	O
contour	O
computed	O
using	O
B3LYP	O
/	O
63	O
-	O
1G	O
(	O
d	O
,	O
p	O
)	O
level	O
were	O
in	O
good	O
agreement	O
with	O
the	O
observed	O
spectrum	O
.	O

In	O
the	O
near	O
-	O
IR	O
,	O
we	O
observed	O
four	O
well	O
spaced	O
vibronic	O
bands	O
,	O
each	O
with	O
partially	O
resolved	O
rotational	O
contours	O
.	O

We	O
assigned	O
the	O
apparent	O
origin	O
of	O
the	O
electronic	O
spectrum	O
of	O
HMP	S-chem
at	O
7392	O
cm	O
(	O
-	O
1	O
)	O
and	O
two	O
bands	O
to	O
the	O
blue	O
to	O
a	O
progression	O
in	O
ν15	O
'	O
,	O
the	O
lowest	O
torsional	O
mode	O
of	O
the	O
state	O
(	O
ν15	O
'	O
=	O
171	O
cm	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
band	O
furthest	O
to	O
the	O
red	O
was	O
assigned	O
as	O
a	O
hot	O
band	O
in	O
ν15	O
``	O
,	O
leading	O
to	O
a	O
ground	O
state	O
torsional	O
frequency	O
of	O
(	O
ν15	O
``	O
=	O
122	O
cm	O
(	O
-	O
1	O
)	O
)	O
.	O

We	O
simulated	O
the	O
spectrum	O
using	O
second	O
order	O
vibrational	O
perturbation	O
theory	O
(	O
VPT2	O
)	O
with	O
B3LYP	O
/	O
6	O
-	O
31	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
calculations	O
at	O
the	O
minimum	O
energy	O
geometries	O
of	O
the	O
HMP	S-chem
-	O
A	O
conformer	O
on	O
the	O
X	O
̃	O
and	O
A	O
̃	O
states	O
.	O

The	O
predictions	O
of	O
the	O
electronic	O
origin	O
frequency	O
,	O
torsional	O
frequencies	O
,	O
anharmonicities	O
and	O
rotational	O
band	O
contours	O
matched	O
the	O
observed	O
spectrum	O
.	O

We	O
investigated	O
the	O
torsional	O
modes	O
more	O
explicitly	O
by	O
computing	O
potential	O
energy	O
surfaces	O
of	O
HMP	S-chem
as	O
a	O
function	O
of	O
the	O
two	O
dihedral	O
angles	O
τOCOH	O
and	O
τOOCO	O
.	O

Wave	O
functions	O
and	O
energy	O
levels	O
were	O
calculated	O
based	O
on	O
this	O
potential	O
surface	O
;	O
these	O
results	O
were	O
used	O
to	O
calculate	O
the	O
Franck	O
-	O
Condon	O
factors	O
,	O
which	O
reproduced	O
the	O
vibronic	O
band	O
intensities	O
in	O
the	O
observed	O
electronic	O
spectrum	O
.	O

The	O
transitions	O
that	O
we	O
observed	O
all	O
involved	O
states	O
with	O
wave	O
functions	O
localized	O
on	O
the	O
minimum	O
energy	O
conformer	O
,	O
HMP	S-chem
-	O
A	O
.	O

Our	O
calculations	O
indicated	O
that	O
the	O
observed	O
near	O
-	O
IR	O
spectrum	O
was	O
that	O
of	O
the	O
minimum	O
energy	O
conformer	O
HMP	S-chem
-	O
A	O
,	O
but	O
that	O
this	O
conformer	O
is	O
not	O
the	O
lowest	O
energy	O
conformer	O
in	O
the	O
state	O
,	O
which	O
remains	O
unobserved	O
.	O

We	O
estimated	O
that	O
the	O
energy	O
of	O
this	O
lowest	O
conformer	O
(	O
HMP	S-chem
-	O
B	O
)	O
of	O
the	O
Ã	O
state	O
to	O
be	O
T0	O
(	O
Ã	O
)	O
≈	O
7200	O
cm	O
(	O
-	O
1	O
)	O
,	O
based	O
on	O
the	O
energy	O
difference	O
E0	O
(	O
HMP	S-chem
-	O
B	O
)	O
-	O
E0	O
(	O
HMP	S-chem
-	O
A	O
)	O
on	O
the	O
Ã	O
state	O
computed	O
at	O
the	O
B3LYP	O
/	O
6	O
-	O
31	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
level	O
.	O

Fluticasone	B-chem
propionate	E-chem
:	O
safety	O
profile	O
.	O

Fluticasone	B-chem
propionate	E-chem
is	O
a	O
potent	O
fluorinated	O
corticosteroid	O
used	O
for	O
the	O
topical	O
therapy	O
of	O
dermatoses	O
and	O
as	O
inhalation	O
therapy	O
for	O
bronchial	O
asthma	O
and	O
allergic	O
rhinitis	O
.	O

This	O
agent	O
has	O
a	O
good	O
safety	O
profile	O
with	O
a	O
low	O
propensity	O
for	O
systemic	O
side	O
effects	O
,	O
such	O
as	O
suppression	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
,	O
and	O
a	O
low	O
incidence	O
of	O
local	O
side	O
effects	O
such	O
as	O
pruritus	O
,	O
burning	O
,	O
or	O
skin	O
atrophy	O
.	O

The	O
pharmacologic	O
properties	O
of	O
fluticasone	B-chem
propionate	E-chem
-	O
including	O
high	O
lipophilicity	O
,	O
high	O
selectivity	O
and	O
affinity	O
for	O
the	O
glucocorticoid	B-geneY
receptor	E-geneY
,	O
low	O
systemic	O
absorption	O
,	O
and	O
rapid	O
metabolism	O
and	O
clearance	O
-	O
combine	O
to	O
give	O
fluticasone	B-chem
propionate	E-chem
a	O
high	O
therapeutic	O
index	O
.	O

Phα1β	O
toxin	O
prevents	O
capsaicin	S-chem
-	O
induced	O
nociceptive	O
behavior	O
and	O
mechanical	O
hypersensitivity	O
without	O
acting	O
on	O
TRPV1	S-geneY
channels	O
.	O

Phα1β	O
toxin	O
is	O
a	O
peptide	O
purified	O
from	O
the	O
venom	O
of	O
the	O
armed	O
spider	O
Phoneutria	O
nigriventer	O
,	O
with	O
markedly	O
antinociceptive	O
action	O
in	O
models	O
of	O
acute	O
and	O
persistent	O
pain	O
in	O
rats	O
.	O

Similarly	O
to	O
ziconotide	O
,	O
its	O
analgesic	O
action	O
is	O
related	O
to	O
inhibition	O
of	O
high	O
voltage	O
activated	O
calcium	S-chem
channels	O
with	O
more	O
selectivity	O
for	O
N	O
-	O
type	O
.	O

In	O
this	O
study	O
we	O
evaluated	O
the	O
effect	O
of	O
Phα1β	O
when	O
injected	O
peripherally	O
or	O
intrathecally	O
in	O
a	O
rat	O
model	O
of	O
spontaneous	O
pain	O
induced	O
by	O
capsaicin	S-chem
.	O

We	O
also	O
investigated	O
the	O
effect	O
of	O
Phα1β	O
on	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
transients	O
in	O
cultured	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
neurons	O
and	O
HEK293	O
cells	O
expressing	O
the	O
TRPV1	S-geneY
receptor	O
.	O

Intraplantar	O
or	O
intrathecal	O
administered	O
Phα1β	O
reduced	O
both	O
nocifensive	O
behavior	O
and	O
mechanical	O
hypersensitivity	O
induced	O
by	O
capsaicin	S-chem
similarly	O
to	O
that	O
observed	O
with	O
SB366791	S-chem
,	O
a	O
specific	O
TRPV1	S-geneY
antagonist	O
.	O

Peripheral	O
nifedipine	S-chem
and	O
mibefradil	S-chem
did	O
also	O
decrease	O
nociceptive	O
behavior	O
induced	O
by	O
intraplantar	O
capsaicin	S-chem
.	O

In	O
contrast	O
,	O
ω	O
-	O
conotoxin	O
MVIIA	O
(	O
a	O
selective	O
N	B-geneN
-	I-geneN
type	I-geneN
Ca	I-geneN
(	I-geneN
2	I-geneN
+	I-geneN
)	I-geneN
channel	E-geneN
blocker	O
)	O
was	O
effective	O
only	O
when	O
administered	O
intrathecally	O
.	O

Phα1β	O
,	O
MVIIA	O
and	O
SB366791	S-chem
inhibited	O
,	O
with	O
similar	O
potency	O
,	O
the	O
capsaicin	S-chem
-	O
induced	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
transients	O
in	O
DRG	O
neurons	O
.	O

The	O
simultaneous	O
administration	O
of	O
Phα1β	O
and	O
SB366791	S-chem
inhibited	O
the	O
capsaicin	S-chem
-	O
induced	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
transients	O
that	O
were	O
additive	O
suggesting	O
that	O
they	O
act	O
through	O
different	O
targets	O
.	O

Moreover	O
,	O
Phα1β	O
did	O
not	O
inhibit	O
capsaicin	S-chem
-	O
activated	O
currents	O
in	O
patch	O
-	O
clamp	O
recordings	O
of	O
HEK293	O
cells	O
that	O
expressed	O
TRPV1	S-geneY
receptors	O
.	O

Our	O
results	O
show	O
that	O
Phα1β	O
may	O
be	O
effective	O
as	O
a	O
therapeutic	O
strategy	O
for	O
pain	O
and	O
this	O
effect	O
is	O
not	O
related	O
to	O
the	O
inhibition	O
of	O
TRPV1	S-geneY
receptors	O
.	O

RNA	O
interference	O
-	O
triggered	O
reversal	O
of	O
ABCC2	S-geneY
-	O
dependent	O
cisplatin	S-chem
resistance	O
in	O
human	O
cancer	O
cells	O
.	O

The	O
adenosine	B-geneN
triphosphate	I-geneN
binding	I-geneN
cassette	I-geneN
(	I-geneN
ABC	I-geneN
)	I-geneN
-	I-geneN
transporter	E-geneN
ABCC2	S-geneY
(	O
MRP2	S-geneY
/	O
cMOAT	S-geneY
)	O
can	O
mediate	O
resistance	O
against	O
the	O
commonly	O
used	O
anticancer	O
drugs	O
cisplatin	S-chem
and	O
paclitaxel	S-chem
.	O

To	O
overcome	O
the	O
ABCC2	S-geneY
-	O
depending	O
drug	O
resistance	O
,	O
two	O
specific	O
anti	O
-	O
ABCC2	S-geneY
small	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
were	O
designed	O
for	O
transient	O
triggering	O
of	O
the	O
gene	O
-	O
silencing	O
RNA	O
interference	O
(	O
RNAi	O
)	O
pathway	O
in	O
the	O
cisplatin	S-chem
-	O
resistant	O
human	O
ovarian	O
carcinoma	O
cell	O
line	O
A2780RCIS	O
.	O

Since	O
both	O
siRNAs	O
showed	O
biological	O
activity	O
,	O
for	O
stable	O
inhibition	O
of	O
ABCC2	S-geneY
a	O
corresponding	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
-	O
encoding	O
expression	O
vector	O
was	O
designed	O
.	O

By	O
treatment	O
of	O
A2780RCIS	O
cells	O
with	O
this	O
construct	O
,	O
the	O
expressions	O
of	O
the	O
targeted	O
ABCC2	S-geneY
encoding	O
mRNA	O
and	O
transport	O
protein	O
were	O
inhibited	O
.	O

These	O
effects	O
were	O
accompanied	O
by	O
reversal	O
of	O
resistance	O
against	O
cisplatin	S-chem
and	O
paclitaxel	S-chem
.	O

Thus	O
,	O
the	O
data	O
demonstrate	O
the	O
utility	O
of	O
the	O
analyzed	O
RNAs	O
as	O
powerful	O
laboratory	O
tools	O
and	O
indicate	O
that	O
siRNA	O
-	O
and	O
shRNA	O
-	O
mediated	O
RNAi	O
-	O
based	O
gene	O
therapeutic	O
approaches	O
may	O
be	O
applicable	O
in	O
preventing	O
and	O
reversing	O
ABCC2	S-geneY
-	O
depending	O
drug	O
resistance	O
.	O

Dual	O
inhibitor	O
of	O
PDE7	S-geneN
and	O
GSK	B-geneN
-	I-geneN
3	E-geneN
-	O
VP1.15	O
acts	O
as	O
antipsychotic	O
and	O
cognitive	O
enhancer	O
in	O
C57BL	O
/	O
6J	O
mice	O
.	O

Cognitive	O
deficit	O
is	O
a	O
core	O
of	O
schizophrenia	O
and	O
it	O
is	O
not	O
effectively	O
treated	O
by	O
the	O
available	O
antipsychotic	O
drugs	O
,	O
hence	O
new	O
and	O
more	O
effective	O
therapy	O
is	O
needed	O
.	O

Schizophrenia	O
is	O
considered	O
as	O
a	O
pathway	O
disorder	O
where	O
Disrupted	B-geneY
-	I-geneY
In	I-geneY
-	I-geneY
Schizophrenia	I-geneY
-	I-geneY
1	E-geneY
(	O
DISC1	S-geneY
)	O
is	O
important	O
molecular	O
player	O
that	O
regulates	O
multiple	O
cellular	O
cascades	O
.	O

We	O
recently	O
reported	O
synergistic	O
action	O
between	O
phosphodiesterase	B-geneN
-	I-geneN
4	E-geneN
(	O
PDE4	S-geneN
)	O
and	O
glycogen	B-geneN
synthase	I-geneN
kinase	I-geneN
-	I-geneN
3	E-geneN
(	O
GSK	B-geneN
-	I-geneN
3	E-geneN
)	O
as	O
DISC1	S-geneY
interacting	O
proteins	O
.	O

In	O
the	O
current	O
study	O
we	O
characterized	O
behavioural	O
effects	O
of	O
a	O
newly	O
developed	O
compound	O
,	O
VP1.15	O
that	O
inhibits	O
both	O
PDE7	S-geneN
and	O
GSK	B-geneN
-	I-geneN
3	E-geneN
with	O
main	O
focus	O
on	O
its	O
antipsychotic	O
and	O
cognitive	O
capacities	O
.	O

VP1.15	O
reduced	O
ambulation	O
in	O
C57BL	O
/	O
6J	O
mice	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
7.5	O
mg	O
/	O
kg	O
and	O
3	O
mg	O
/	O
kg	O
,	O
respectively	O
)	O
and	O
,	O
hence	O
,	O
lower	O
dose	O
was	O
chosen	O
for	O
the	O
further	O
analysis	O
.	O

VP1.1.5	O
facilitated	O
pre	O
-	O
pulse	O
inhibition	O
(	O
PPI	O
)	O
,	O
reversed	O
amphetamine	S-chem
-	O
but	O
not	O
MK	B-chem
-	I-chem
801	E-chem
-	O
induced	O
PPI	O
deficit	O
.	O

The	O
drug	O
was	O
able	O
to	O
ameliorate	O
the	O
disrupted	O
latent	O
inhibition	O
(	O
LI	O
)	O
induced	O
by	O
the	O
increased	O
number	O
of	O
conditioning	O
trials	O
and	O
reversed	O
amphetamine	S-chem
-	O
induced	O
LI	O
deficit	O
,	O
supporting	O
further	O
its	O
antipsychotic	O
effects	O
.	O

The	O
drug	O
also	O
significantly	O
improved	O
episodic	O
memory	O
in	O
the	O
spatial	O
object	O
recognition	O
test	O
,	O
facilitated	O
working	O
memory	O
in	O
Y	O
-	O
maze	O
and	O
enhanced	O
cued	O
fear	O
memory	O
,	O
but	O
had	O
no	O
effect	O
on	O
executive	O
function	O
in	O
the	O
Puzzle	O
box	O
and	O
contextual	O
fear	O
conditioning	O
.	O

Taken	O
together	O
,	O
VP1.15	O
elicited	O
antipsychotic	O
effects	O
and	O
also	O
facilitated	O
cognitive	O
domains	O
in	O
mice	O
,	O
suggesting	O
that	O
multitarget	O
drugs	O
,	O
affecting	O
molecular	O
substrates	O
from	O
the	O
same	O
pathway	O
,	O
perhaps	O
could	O
be	O
antipsychotics	O
of	O
new	O
-	O
generation	O
that	O
open	O
a	O
new	O
possibilities	O
in	O
drug	O
discoveries	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Cognitive	O
Enhancers	O
'	O
.	O

Neostigmine	S-chem
:	O
safe	O
and	O
effective	O
treatment	O
for	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
.	O

BACKGROUND	O
:	O
Ogilvie	O
's	O
syndrome	O
,	O
or	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
,	O
is	O
a	O
common	O
and	O
relatively	O
dangerous	O
condition	O
.	O

If	O
left	O
untreated	O
,	O
it	O
may	O
cause	O
ischemic	O
necrosis	O
and	O
colonic	O
perforation	O
,	O
with	O
a	O
mortality	O
rate	O
as	O
high	O
as	O
50	O
percent	O
.	O

Neostigmine	S-chem
enhances	O
excitatory	O
parasympathetic	O
activity	O
by	O
competing	O
with	O
acetylcholine	S-chem
for	O
attachment	O
to	O
acetylcholinesterase	S-geneY
at	O
sites	O
of	O
cholinergic	O
transmission	O
and	O
enhancing	O
cholinergic	O
action	O
.	O

We	O
hypothesized	O
that	O
neostigmine	S-chem
would	O
restore	O
peristalsis	O
in	O
patients	O
with	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
.	O

METHODS	O
:	O
Twenty	O
-	O
eight	O
patients	O
at	O
Fletcher	O
Allen	O
Health	O
Care	O
and	O
The	O
Cleveland	O
Clinic	O
Foundation	O
were	O
treated	O
for	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
with	O
neostigmine	S-chem
2.5	O
mg	O
IV	O
over	O
3	O
minutes	O
while	O
being	O
monitored	O
with	O
telemetry	O
.	O

Mechanical	O
obstruction	O
had	O
been	O
excluded	O
.	O

RESULTS	O
:	O
Complete	O
clinical	O
resolution	O
of	O
large	O
bowel	O
distention	O
occurred	O
in	O
26	O
of	O
the	O
28	O
patients	O
.	O

Time	O
to	O
pass	O
flatus	O
varied	O
from	O
30	O
seconds	O
to	O
10	O
minutes	O
after	O
administration	O
of	O
neostigmine	S-chem
.	O

No	O
adverse	O
effects	O
or	O
complications	O
were	O
noted	O
.	O

Of	O
the	O
two	O
patients	O
who	O
did	O
not	O
resolve	O
,	O
one	O
had	O
a	O
sigmoid	O
cancer	O
that	O
required	O
resection	O
and	O
one	O
patient	O
died	O
from	O
multiorgan	O
failure	O
.	O

CONCLUSION	O
:	O
This	O
study	O
supports	O
the	O
theory	O
that	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
is	O
the	O
result	O
of	O
excessive	O
parasympathetic	O
suppression	O
rather	O
than	O
sympathetic	O
overactivity	O
.	O

We	O
have	O
shown	O
that	O
neostigmine	S-chem
is	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
.	O

The	O
microsomal	B-geneY
/	I-geneY
peroxidase	I-geneY
antigen	E-geneY
:	O
modulation	O
of	O
its	O
expression	O
in	O
thyroid	O
cells	O
.	O

Evidence	O
has	O
accumulated	O
in	O
the	O
last	O
few	O
years	O
that	O
the	O
expression	O
of	O
the	O
microsomal	B-geneY
/	I-geneY
peroxidase	I-geneY
antigen	E-geneY
(	O
M	B-geneY
/	I-geneY
TPO	I-geneY
-	I-geneY
Ag	E-geneY
)	O
in	O
thyroid	O
cells	O
is	O
induced	O
by	O
TSH	S-geneN
,	O
through	O
pathways	O
which	O
involve	O
intracellular	O
cAMP	S-chem
accumulation	O
and	O
protein	O
synthesis	O
.	O

These	O
data	O
have	O
been	O
found	O
true	O
in	O
any	O
thyroid	O
system	O
studied	O
so	O
far	O
,	O
both	O
in	O
terms	O
of	O
immunologic	O
and	O
enzymatic	O
activity	O
of	O
TPO	S-geneY
.	O

TSH	S-geneN
and	O
cAMP	S-chem
also	O
increase	O
the	O
levels	O
of	O
the	O
specific	O
mRNA	O
for	O
TPO	S-geneY
in	O
thyroid	O
cells	O
from	O
different	O
species	O
.	O

Whether	O
this	O
phenomenon	O
is	O
due	O
to	O
a	O
direct	O
transcriptional	O
regulation	O
of	O
the	O
TPO	S-geneY
gene	O
,	O
as	O
shown	O
in	O
dog	O
thyroid	O
cells	O
,	O
or	O
to	O
posttranscriptional	O
effects	O
,	O
as	O
it	O
would	O
appear	O
in	O
FRTL	O
-	O
5	O
cells	O
,	O
remains	O
to	O
be	O
clarified	O
by	O
future	O
experiments	O
.	O

Thyroid	B-geneN
stimulating	I-geneN
antibody	E-geneN
(	O
TSAb	S-geneN
)	O
of	O
Graves	O
'	O
disease	O
also	O
stimulates	O
the	O
expression	O
of	O
M	B-geneY
/	I-geneY
TPO	I-geneY
-	I-geneY
Ag	E-geneY
.	O

This	O
finding	O
gives	O
further	O
support	O
to	O
the	O
relevance	O
of	O
TSAb	S-geneN
in	O
the	O
pathogenesis	O
of	O
hyperthyroidism	O
and	O
explains	O
the	O
well	O
known	O
observation	O
that	O
the	O
``	O
microsomal	O
``	O
antigen	O
is	O
particularly	O
abundant	O
in	O
glands	O
of	O
Graves	O
'	O
patients	O
.	O

The	O
modulation	O
of	O
M	B-geneY
/	I-geneY
TPO	I-geneY
-	I-geneY
Ag	E-geneY
surface	O
expression	O
by	O
TSH	S-geneN
can	O
explain	O
the	O
decrease	O
of	O
circulating	O
anti	O
-	O
MAb	O
observed	O
during	O
L	B-chem
-	I-chem
thyroxine	E-chem
therapy	O
in	O
hypothyroid	O
patients	O
with	O
Hashimoto	O
's	O
thyroiditis	O
.	O

Other	O
agents	O
,	O
such	O
as	O
methimazole	S-chem
and	O
sodium	B-chem
iodide	E-chem
,	O
which	O
influence	O
thyroid	O
cell	O
function	O
,	O
do	O
not	O
directly	O
interfere	O
with	O
the	O
expression	O
of	O
M	B-geneY
/	I-geneY
TPO	I-geneY
-	I-geneY
Ag	E-geneY
.	O

Cytokines	S-geneN
,	O
such	O
as	O
gamma	B-geneY
-	I-geneY
interferon	E-geneY
,	O
interleukin	B-geneN
-	I-geneN
1	E-geneN
,	O
and	O
interleukin	B-geneY
-	I-geneY
6	E-geneY
have	O
been	O
shown	O
to	O
inhibit	O
the	O
TSH	S-geneN
-	O
induced	O
increase	O
of	O
TPO	S-geneY
mRNA	O
,	O
but	O
further	O
investigations	O
are	O
required	O
to	O
elucidate	O
the	O
exact	O
role	O
of	O
cytokines	S-geneN
in	O
the	O
regulation	O
of	O
M	B-geneY
/	I-geneY
TPO	I-geneY
-	I-geneY
Ag	E-geneY
expression	O
.	O

Entacapone	S-chem
.	O
A	O
review	O
of	O
its	O
use	O
in	O
Parkinson	O
's	O
disease	O
.	O

UNLABELLED	O
:	O
Entacapone	S-chem
is	O
a	O
potent	O
and	O
specific	O
peripheral	O
catechol	B-geneY
-	I-geneY
O	I-geneY
-	I-geneY
methyltransferase	E-geneY
(	O
COMT	S-geneY
)	O
inhibitor	O
.	O

It	O
has	O
been	O
shown	O
to	O
improve	O
the	O
clinical	O
benefits	O
of	O
levodopa	S-chem
plus	O
an	O
aromatic	B-geneY
L	I-geneY
-	I-geneY
amino	I-geneY
acid	I-geneY
decarboxylase	E-geneY
inhibitor	O
(	O
AADC	S-geneY
)	O
when	O
given	O
to	O
patients	O
with	O
Parkinson	O
's	O
disease	O
and	O
end	O
-	O
of	O
-	O
dose	O
deterioration	O
in	O
the	O
response	O
to	O
levodopa	S-chem
(	O
the	O
'	O
wearing	O
off	O
'	O
phenomenon	O
)	O
.	O

The	O
efficacy	O
of	O
entacapone	S-chem
is	O
currently	O
being	O
assessed	O
in	O
patients	O
with	O
stable	O
Parkinson	O
's	O
disease	O
.	O

In	O
2	O
well	O
conducted	O
trials	O
of	O
6	O
months	O
'	O
duration	O
and	O
smaller	O
short	O
term	O
studies	O
,	O
treatment	O
with	O
entacapone	S-chem
(	O
200	O
mg	O
with	O
each	O
dose	O
of	O
levodopa	S-chem
/	O
AADC	S-geneY
inhibitor	O
)	O
was	O
associated	O
with	O
significant	O
increases	O
in	O
daily	O
'	O
on	O
'	O
time	O
and	O
decreases	O
in	O
'	O
off	O
'	O
time	O
.	O

Changes	O
in	O
Unified	O
Parkinson	O
's	O
Disease	O
Rating	O
Scale	O
(	O
UPDRS	O
)	O
scores	O
concurred	O
with	O
changes	O
in	O
'	O
on	O
'	O
and	O
'	O
off	O
'	O
times	O
:	O
entacapone	S-chem
improved	O
total	O
,	O
activities	O
of	O
daily	O
living	O
and	O
motor	O
function	O
scores	O
,	O
but	O
it	O
had	O
no	O
effect	O
on	O
mentation	O
scores	O
.	O

Entacapone	S-chem
also	O
provided	O
benefits	O
when	O
given	O
with	O
controlled	O
release	O
levodopa	S-chem
/	O
AADC	S-geneY
inhibitor	O
or	O
with	O
standard	O
levodopa	S-chem
/	O
AADC	S-geneY
inhibitor	O
and	O
selegiline	S-chem
in	O
small	O
trials	O
.	O

Dopaminergic	O
events	O
,	O
including	O
dyskinesia	O
and	O
nausea	O
,	O
are	O
among	O
the	O
most	O
common	O
events	O
with	O
entacapone	S-chem
,	O
and	O
are	O
related	O
to	O
the	O
drug	O
's	O
ability	O
to	O
potentiate	O
the	O
effects	O
of	O
levodopa	S-chem
.	O

Diarrhoea	O
,	O
abdominal	O
pain	O
,	O
constipation	O
and	O
urine	O
discolouration	O
are	O
the	O
most	O
common	O
nondopaminergic	O
events	O
,	O
although	O
the	O
latter	O
event	O
is	O
the	O
only	O
one	O
to	O
occur	O
consistently	O
more	O
frequently	O
with	O
entacapone	O
than	O
with	O
placebo	O
.	O

However	O
,	O
adverse	O
events	O
of	O
any	O
type	O
infrequently	O
led	O
to	O
study	O
discontinuation	O
.	O

CONCLUSIONS	O
:	O
The	O
efficacy	O
and	O
tolerability	O
of	O
entacapone	O
administered	O
with	O
levodopa	S-chem
/	O
AADC	S-geneY
inhibitor	O
have	O
not	O
yet	O
been	O
compared	O
with	O
those	O
of	O
other	O
strategies	O
for	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
.	O

However	O
,	O
once	O
the	O
decision	O
to	O
initiate	O
levodopa	S-chem
therapy	O
has	O
been	O
made	O
,	O
studies	O
generally	O
support	O
the	O
use	O
of	O
entacapone	O
as	O
an	O
adjunct	O
to	O
levodopa	S-chem
in	O
patients	O
with	O
Parkinson	O
's	O
disease	O
and	O
the	O
'	O
wearing	O
off	O
'	O
phenomenon	O
.	O

Glutathione	S-chem
conjugation	O
attenuates	O
biological	O
activities	O
of	O
6	B-chem
-	I-chem
dehydroshogaol	E-chem
from	O
ginger	O
.	O

6	B-chem
-	I-chem
Dehydroshogaol	E-chem
(	O
6	B-chem
-	I-chem
DHSG	E-chem
)	O
is	O
a	O
bioactive	O
α	B-chem
,	I-chem
β	I-chem
-	I-chem
unsaturated	I-chem
carbonyl	E-chem
compound	O
isolated	O
from	O
fresh	O
ginger	O
with	O
anti	O
-	O
inflammatory	O
and	O
phase	O
II	O
enzyme	O
inducing	O
activities	O
.	O

Here	O
we	O
describe	O
the	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
-	O
dependent	O
metabolism	O
and	O
the	O
effect	O
of	O
this	O
metabolic	O
transformation	O
on	O
the	O
biological	O
activities	O
of	O
6	B-chem
-	I-chem
DHSG	E-chem
.	O

Compared	O
with	O
other	O
ginger	O
compounds	O
,	O
such	O
as	O
6	B-chem
-	I-chem
gingerol	E-chem
and	O
6	B-chem
-	I-chem
shogaol	E-chem
,	O
6	B-chem
-	I-chem
DHSG	E-chem
showed	O
the	O
most	O
potent	O
anti	O
-	O
inflammatory	O
effect	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
RAW	O
264.7	O
cells	O
.	O

The	O
biological	O
activities	O
of	O
6	B-chem
-	I-chem
DHSG	E-chem
were	O
attenuated	O
by	O
sulfhydryl	S-chem
antioxidants	O
such	O
as	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
or	O
N	B-chem
-	I-chem
acetyl	I-chem
cysteine	E-chem
(	O
NAC	S-chem
)	O
,	O
but	O
not	O
ascorbic	B-chem
acid	E-chem
(	O
ASC	S-chem
)	O
.	O

6	B-chem
-	I-chem
DHSG	E-chem
was	O
metabolised	O
by	O
GSH	S-chem
to	O
form	O
a	O
GSH	S-chem
conjugate	O
(	O
GS	B-chem
-	I-chem
6	I-chem
-	I-chem
DHSG	E-chem
)	O
in	O
RAW	O
264.7	O
cells	O
,	O
via	O
a	O
potential	O
mechanism	O
involving	O
the	O
catalytic	O
activity	O
of	O
glutathione	B-geneN
-	I-geneN
S	I-geneN
-	I-geneN
transferase	E-geneN
(	O
GST	S-geneN
)	O
.	O

GS	B-chem
-	I-chem
6	I-chem
-	I-chem
DHSG	E-chem
showed	O
reduced	O
biological	O
activities	O
compared	O
with	O
6	B-chem
-	I-chem
DHSG	E-chem
in	O
multiple	O
biological	O
assays	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
GSH	S-chem
conjugation	O
attenuates	O
the	O
biological	O
activities	O
of	O
6	B-chem
-	I-chem
DHSG	E-chem
and	O
other	O
α	B-chem
,	I-chem
β	I-chem
-	I-chem
unsaturated	I-chem
carbonyl	E-chem
compounds	O
.	O

Cellular	O
and	O
pharmacogenetics	O
foundation	O
of	O
synergistic	O
interaction	O
of	O
pemetrexed	S-chem
and	O
gemcitabine	S-chem
in	O
human	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
cells	O
.	O

Gemcitabine	S-chem
and	O
pemetrexed	S-chem
are	O
effective	O
agents	O
in	O
the	O
treatment	O
of	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
,	O
and	O
the	O
present	O
study	O
investigates	O
cellular	O
and	O
genetic	O
aspects	O
of	O
their	O
interaction	O
against	O
A549	O
,	O
Calu	O
-	O
1	O
,	O
and	O
Calu	O
-	O
6	O
cells	O
.	O

Cells	O
were	O
treated	O
with	O
pemetrexed	S-chem
and	O
gemcitabine	S-chem
,	O
and	O
their	O
interaction	O
was	O
assessed	O
using	O
the	O
combination	O
index	O
.	O

The	O
role	O
of	O
drug	O
metabolism	O
in	O
gemcitabine	S-chem
cytotoxicity	O
was	O
examined	O
with	O
inhibitors	O
of	O
deoxycytidine	B-geneY
kinase	E-geneY
(	O
dCK	S-geneY
)	O
,	O
5	B-geneY
'	I-geneY
-	I-geneY
nucleotidase	E-geneY
,	O
and	O
cytidine	B-geneY
deaminase	E-geneY
,	O
whereas	O
the	O
role	O
of	O
pemetrexed	O
targets	O
,	O
thymidylate	B-geneY
synthase	E-geneY
(	O
TS	S-geneY
)	O
,	O
dihydrofolate	B-geneY
reductase	E-geneY
(	O
DHFR	S-geneY
)	O
,	O
and	O
glycinamide	B-geneY
ribonucleotide	I-geneY
formyltransferase	E-geneY
(	O
GARFT	S-geneY
)	O
in	O
drug	O
chemosensitivity	O
was	O
analyzed	O
in	O
cytotoxicity	O
rescue	O
studies	O
.	O

The	O
effect	O
of	O
gemcitabine	S-chem
and	O
pemetrexed	O
on	O
Akt	S-geneN
phosphorylation	O
was	O
investigated	O
with	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
whereas	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
used	O
to	O
study	O
target	O
gene	O
-	O
expression	O
profiles	O
and	O
its	O
modulation	O
by	O
each	O
drug	O
.	O

Synergistic	O
cytotoxicity	O
was	O
demonstrated	O
,	O
and	O
pemetrexed	S-chem
significantly	O
decreased	O
the	O
amount	O
of	O
phosphorylated	B-geneN
Akt	E-geneN
,	O
enhanced	O
apoptosis	O
,	O
and	O
increased	O
the	O
expression	O
of	O
dCK	S-geneY
in	O
A549	O
and	O
Calu	O
-	O
6	O
cells	O
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
the	O
human	B-geneY
nucleoside	I-geneY
equilibrative	I-geneY
transporter	I-geneY
1	E-geneY
(	O
hENT1	S-geneY
)	O
in	O
all	O
cell	O
lines	O
.	O

PCR	O
demonstrated	O
a	O
correlation	O
between	O
dCK	S-geneY
expression	O
and	O
gemcitabine	S-chem
sensitivity	O
,	O
whereas	O
expression	O
of	O
TS	S-geneY
,	O
DHFR	S-geneY
,	O
and	O
GARFT	S-geneY
was	O
predictive	O
of	O
pemetrexed	S-chem
chemosensitivity	O
.	O

These	O
data	O
demonstrated	O
that	O
1	O
)	O
gemcitabine	S-chem
and	O
pemetrexed	S-chem
synergistically	O
interact	O
against	O
NSCLC	O
cells	O
through	O
the	O
suppression	O
of	O
Akt	S-geneN
phosphorylation	O
and	O
induction	O
of	O
apoptosis	O
;	O
2	O
)	O
the	O
gene	O
expression	O
profile	O
of	O
critical	O
genes	O
may	O
predict	O
for	O
drug	O
chemosensitivity	O
;	O
and	O
3	O
)	O
pemetrexed	S-chem
enhances	O
dCK	S-geneY
and	O
hENT1	S-geneY
expression	O
,	O
thus	O
suggesting	O
the	O
role	O
of	O
gene	O
-	O
expression	O
modulation	O
for	O
rational	O
development	O
of	O
chemotherapy	O
combinations	O
.	O

Systemic	O
administration	O
of	O
beta2	B-geneY
-	I-geneY
adrenoceptor	E-geneY
agonists	O
,	O
formoterol	S-chem
and	O
salmeterol	S-chem
,	O
elicit	O
skeletal	O
muscle	O
hypertrophy	O
in	O
rats	O
at	O
micromolar	O
doses	O
.	O

beta	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
-	I-geneY
Adrenoceptor	E-geneY
agonists	O
provide	O
a	O
potential	O
therapy	O
for	O
muscle	O
wasting	O
and	O
weakness	O
,	O
but	O
their	O
use	O
may	O
be	O
limited	O
by	O
adverse	O
effects	O
on	O
the	O
heart	O
,	O
mediated	O
in	O
part	O
,	O
by	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
activation	O
.	O

Two	O
beta	O
(	O
2	O
)	O
-	O
agonists	O
,	O
formoterol	S-chem
and	O
salmeterol	S-chem
,	O
are	O
approved	O
for	O
treating	O
asthma	O
and	O
have	O
an	O
extended	O
duration	O
of	O
action	O
and	O
increased	O
safety	O
,	O
associated	O
with	O
greater	O
beta	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
selectivity	O
.	O

The	O
pharmacological	O
profiles	O
of	O
formoterol	S-chem
and	O
salmeterol	S-chem
and	O
their	O
effects	O
on	O
skeletal	O
and	O
cardiac	O
muscle	O
mass	O
were	O
investigated	O
in	O
12	O
-	O
week	O
-	O
old	O
,	O
male	O
F344	O
rats	O
.	O

Formoterol	S-chem
and	O
salmeterol	S-chem
were	O
each	O
administered	O
via	O
daily	O
i.p	O
.	O
injection	O
at	O
one	O
of	O
seven	O
doses	O
(	O
ranging	O
from	O
1	O
to	O
2,000	O
microg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
)	O
,	O
for	O
4	O
weeks	O
.	O

Rats	O
were	O
anaesthetised	O
and	O
the	O
EDL	O
and	O
soleus	O
muscles	O
and	O
the	O
heart	O
were	O
excised	O
and	O
weighed	O
.	O

Dose	O
-	O
response	O
curves	O
were	O
constructed	O
based	O
on	O
skeletal	O
and	O
cardiac	O
muscle	O
hypertrophy	O
.	O

Formoterol	S-chem
was	O
more	O
potent	O
than	O
salmeterol	S-chem
,	O
with	O
a	O
significantly	O
lower	O
ED	O
(	O
50	O
)	O
in	O
EDL	O
muscles	O
(	O
1	O
and	O
130	O
microg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
,	O
P	O
<	O
0.05	O
)	O
,	O
whereas	O
salmeterol	S-chem
had	O
greater	O
intrinsic	O
activity	O
than	O
formoterol	S-chem
in	O
both	O
EDL	O
and	O
soleus	O
muscles	O
(	O
12	O
%	O
greater	O
hypertrophy	O
than	O
formoterol	S-chem
)	O
.	O

The	O
drugs	O
had	O
similar	O
potency	O
and	O
intrinsic	O
activity	O
in	O
the	O
heart	O
,	O
with	O
a	O
smaller	O
leftward	O
shift	O
for	O
formoterol	S-chem
than	O
seen	O
in	O
skeletal	O
muscle	O
.	O

A	O
dose	O
of	O
25	O
microg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
of	O
formoterol	S-chem
elicited	O
greater	O
EDL	O
and	O
soleus	O
hypertrophy	O
than	O
salmeterol	S-chem
,	O
but	O
resulted	O
in	O
similar	O
beta	B-geneN
-	I-geneN
adrenoceptor	E-geneN
downregulation	O
.	O

These	O
results	O
show	O
that	O
doses	O
as	O
low	O
as	O
1	O
microg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
of	O
formoterol	S-chem
can	O
elicit	O
significant	O
muscle	O
hypertrophy	O
with	O
minimal	O
cardiac	O
hypertrophy	O
and	O
provide	O
important	O
information	O
regarding	O
the	O
potential	O
therapeutic	O
use	O
of	O
formoterol	S-chem
and	O
salmeterol	S-chem
for	O
muscle	O
wasting	O
.	O

Nuclear	O
diacylglycerol	B-geneY
kinase	I-geneY
-	I-geneY
theta	E-geneY
is	O
activated	O
in	O
response	O
to	O
alpha	B-geneY
-	I-geneY
thrombin	E-geneY
.	O

Currently	O
,	O
there	O
is	O
substantial	O
evidence	O
that	O
nuclear	O
lipid	O
metabolism	O
plays	O
a	O
critical	O
role	O
in	O
a	O
number	O
of	O
signal	O
transduction	O
cascades	O
.	O

Previous	O
work	O
from	O
our	O
laboratory	O
showed	O
that	O
stimulation	O
of	O
quiescent	O
fibroblasts	O
with	O
alpha	B-geneY
-	I-geneY
thrombin	E-geneY
leads	O
to	O
the	O
production	O
of	O
two	O
lipid	O
second	O
messengers	O
in	O
the	O
nucleus	O
:	O
an	O
increase	O
in	O
nuclear	O
diacylglycerol	S-chem
mass	O
and	O
an	O
activation	O
of	O
phospholipase	O
D	O
,	O
which	O
catalyzes	O
the	O
hydrolysis	O
of	O
phosphatidylcholine	S-chem
to	O
generate	O
phosphatidic	B-chem
acid	E-chem
.	O

Diacylglycerol	B-geneN
kinase	E-geneN
(	O
DGK	S-geneN
)	O
catalyzes	O
the	O
conversion	O
of	O
diacylglycerol	S-chem
to	O
phosphatidic	B-chem
acid	E-chem
,	O
making	O
it	O
an	O
attractive	O
candidate	O
for	O
a	O
signal	O
transduction	O
component	O
.	O

There	O
is	O
substantial	O
evidence	O
that	O
this	O
activity	O
is	O
indeed	O
regulated	O
in	O
a	O
number	O
of	O
signaling	O
cascades	O
(	O
reviewed	O
by	O
van	O
Blitterswijk	O
,	O
W	O
.	O

J.	O
,	O
and	O
Houssa	O
,	O
B	O
.	O

(	O
1999	O
)	O
Chem	O
.	O

Phys	O
.	O

Lipids	O
98	O
,	O
95	O
-	O
108	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
addition	O
of	O
alpha	B-geneY
-	I-geneY
thrombin	E-geneY
to	O
quiescent	O
IIC9	O
fibroblasts	O
results	O
in	O
an	O
increase	O
in	O
nuclear	O
DGK	S-geneN
activity	O
.	O

The	O
examination	O
of	O
nuclei	O
isolated	O
from	O
quiescent	O
IIC9	O
cells	O
indicates	O
that	O
DGK	B-geneY
-	I-geneY
theta	E-geneY
and	O
DGK	B-geneY
-	I-geneY
delta	E-geneY
are	O
both	O
present	O
.	O

We	O
took	O
advantage	O
of	O
the	O
previous	O
observations	O
that	O
phosphatidylserine	S-chem
inhibits	O
DGK	B-geneY
-	I-geneY
delta	E-geneY
(	O
reviewed	O
by	O
Sakane	O
,	O
F.	O
,	O
Imai	O
,	O
S.	O
,	O
Kai	O
,	O
M.	O
,	O
Wada	O
,	O
I.	O
,	O
and	O
Kanoh	O
,	O
H	O
.	O

(	O
1996	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

271	O
,	O
8394	O
-	O
8401	O
)	O
,	O
and	O
constitutively	O
active	O
RhoA	S-geneY
inhibits	O
DGK	B-geneY
-	I-geneY
theta	E-geneY
(	O
reviewed	O
by	O
Houssa	O
,	O
B.	O
,	O
de	O
Widt	O
,	O
J.	O
,	O
Kranenburg	O
,	O
O.	O
,	O
Moolenaar	O
,	O
W	O
.	O

H.	O
,	O
and	O
van	O
Blitterswijk	O
,	O
W	O
.	O

J	O
.	O

(	O
1999	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

274	O
,	O
6820	O
-	O
6822	O
)	O
to	O
identify	O
the	O
activity	O
induced	O
by	O
alpha	B-geneY
-	I-geneY
thrombin	E-geneY
.	O

Constitutively	O
active	O
RhoA	S-geneY
inhibited	O
the	O
nuclear	O
stimulated	O
activity	O
,	O
whereas	O
phosphatidylserine	S-chem
did	O
not	O
have	O
an	O
inhibitory	O
effect	O
.	O

In	O
addition	O
,	O
a	O
monoclonal	O
anti	O
-	O
DGK	B-geneY
-	I-geneY
theta	E-geneY
antibody	O
inhibited	O
the	O
alpha	B-geneY
-	I-geneY
thrombin	E-geneY
-	O
stimulated	O
nuclear	O
activity	O
in	O
vitro	O
.	O

These	O
results	O
demonstrate	O
that	O
DGK	B-geneY
-	I-geneY
theta	E-geneY
is	O
the	O
isoform	O
responsive	O
to	O
alpha	B-geneY
-	I-geneY
thrombin	E-geneY
stimulation	O
.	O

Western	O
blot	O
and	O
immunofluorescence	O
microscopy	O
analyses	O
showed	O
that	O
alpha	B-geneY
-	I-geneY
thrombin	E-geneY
induced	O
the	O
translocation	O
of	O
DGK	B-geneY
-	I-geneY
theta	E-geneY
to	O
the	O
nucleus	O
,	O
implicating	O
that	O
this	O
translocation	O
is	O
at	O
least	O
partly	O
responsible	O
for	O
the	O
increased	O
nuclear	O
activity	O
.	O

Taken	O
together	O
,	O
these	O
data	O
are	O
the	O
first	O
to	O
demonstrate	O
an	O
agonist	O
-	O
induced	O
activity	O
of	O
nuclear	O
DGK	B-geneY
-	I-geneY
theta	E-geneY
activity	O
and	O
a	O
nuclear	O
localization	O
of	O
DGK	B-geneY
-	I-geneY
delta	E-geneY
.	O

A	O
combination	O
of	O
[	B-chem
+	I-chem
]	I-chem
and	I-chem
[	I-chem
-	I-chem
]	I-chem
-	I-chem
Huperzine	I-chem
A	E-chem
improves	O
protection	O
against	O
soman	O
toxicity	O
compared	O
to	O
[	B-chem
+	I-chem
]	I-chem
-	I-chem
Huperzine	I-chem
A	E-chem
in	O
guinea	O
pigs	O
.	O

The	O
neuropathologic	O
mechanisms	O
after	O
exposure	O
to	O
lethal	O
doses	O
of	O
nerve	O
agent	O
are	O
complex	O
and	O
involve	O
multiple	O
biochemical	O
pathways	O
.	O

Effective	O
treatment	O
requires	O
drugs	O
that	O
can	O
simultaneously	O
protect	O
by	O
reversible	O
binding	O
to	O
the	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
and	O
blocking	O
cascades	O
of	O
seizure	O
related	O
brain	O
damage	O
,	O
inflammation	O
,	O
neuronal	O
degeneration	O
as	O
well	O
as	O
promoting	O
induction	O
of	O
neuroregeneration	O
.	O

[	B-chem
-	I-chem
]	I-chem
-	I-chem
Huperzine	I-chem
A	E-chem
(	O
[	B-chem
-	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
)	O
,	O
is	O
a	O
naturally	O
occurring	O
potent	O
reversible	O
AChE	S-geneY
inhibitor	O
that	O
penetrates	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

It	O
also	O
has	O
several	O
neuroprotective	O
effects	O
including	O
modification	O
of	O
beta	B-geneY
-	I-geneY
amyloid	I-geneY
peptide	E-geneY
,	O
reduction	O
of	O
oxidative	O
stress	O
,	O
anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
apoptotic	O
and	O
induction	O
and	O
regulation	O
of	O
nerve	B-geneY
growth	I-geneY
factor	E-geneY
.	O

Toxicities	O
at	O
higher	O
doses	O
restrict	O
the	O
neuroporotective	O
ability	O
of	O
[	B-chem
-	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
for	O
treatment	O
.	O

The	O
synthetic	O
stereoisomer	O
,	O
[	B-chem
+	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
,	O
is	O
less	O
toxic	O
due	O
to	O
poor	O
AChE	S-geneY
inhibition	O
and	O
is	O
suitable	O
for	O
both	O
pre	O
-	O
/	O
post	O
-	O
exposure	O
treatments	O
of	O
nerve	O
agent	O
toxicity	O
.	O

[	B-chem
+	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
block	O
the	O
N	B-chem
-	I-chem
methyl	I-chem
-	I-chem
d	I-chem
-	I-chem
aspartate	E-chem
(	O
NMDA	S-chem
)	O
-	O
induced	O
seizure	O
in	O
rats	O
,	O
reduce	O
excitatory	O
amino	B-chem
acid	E-chem
induced	O
neurotoxicity	O
and	O
also	O
prevent	O
soman	O
induced	O
toxicity	O
with	O
minimum	O
performance	O
decrement	O
.	O

Unique	O
combinations	O
of	O
two	O
stereo	O
-	O
isomers	O
of	O
Hup	B-chem
A	E-chem
may	O
provide	O
an	O
excellent	O
pre	O
/	O
post	O
-	O
treatment	O
drug	O
for	O
the	O
nerve	O
agent	O
induced	O
seizure	O
/	O
status	O
epilepticus	O
.	O

We	O
investigated	O
a	O
combination	O
of	O
[	B-chem
+	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
with	O
a	O
small	O
dose	O
of	O
[	B-chem
-	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
(	O
[	B-chem
+	I-chem
]	I-chem
and	I-chem
[	I-chem
-	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
)	O
against	O
soman	S-chem
toxicity	O
.	O

Our	O
data	O
showed	O
that	O
pretreatment	O
with	O
a	O
combination	O
[	B-chem
+	I-chem
]	I-chem
and	I-chem
[	I-chem
-	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
significantly	O
increased	O
the	O
survival	O
rate	O
and	O
reduced	O
behavioral	O
abnormalities	O
after	O
exposure	O
to	O
1.2×LD50	O
soman	O
compared	O
to	O
[	B-chem
+	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
in	O
guinea	O
pigs	O
.	O

In	O
addition	O
,	O
[	B-chem
+	I-chem
]	I-chem
and	I-chem
[	I-chem
-	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
pretreatment	O
inhibited	O
the	O
development	O
of	O
high	O
power	O
of	O
EEG	O
better	O
than	O
[	B-chem
+	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
pretreatment	O
alone	O
.	O

These	O
data	O
suggest	O
that	O
a	O
combination	O
of	O
[	B-chem
+	I-chem
]	I-chem
and	I-chem
[	I-chem
-	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
offers	O
better	O
protection	O
than	O
[	B-chem
+	I-chem
]	I-chem
-	I-chem
Hup	I-chem
A	E-chem
and	O
serves	O
as	O
a	O
potent	O
medical	O
countermeasure	O
against	O
lethal	O
dose	O
nerve	O
agent	O
toxicity	O
in	O
guinea	O
pigs	O
.	O

Probing	O
for	O
a	O
hydrophobic	O
a	O
binding	O
register	O
in	O
prostate	B-geneY
-	I-geneY
specific	I-geneY
membrane	I-geneY
antigen	E-geneY
with	O
phenylalkylphosphonamidates	S-chem
.	O

To	O
explore	O
for	O
the	O
existence	O
of	O
an	O
auxiliary	O
hydrophobic	O
binding	O
register	O
remote	O
from	O
the	O
active	O
site	O
of	O
PSMA	S-geneY
a	O
series	O
of	O
phenylalkylphosphonamidate	S-chem
derivatives	O
of	O
glutamic	B-chem
acid	E-chem
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
inhibitory	O
potencies	O
against	O
PSMA	S-geneY
.	O

Both	O
the	O
phenyl	B-chem
-	I-chem
and	I-chem
benzylphosphonamidates	E-chem
(	O
1a	O
and	O
1b	O
)	O
exhibited	O
only	O
modest	O
inhibitory	O
potency	O
against	O
.	O

The	O
phenethyl	S-chem
analog	O
1c	O
was	O
intermediate	O
in	O
inhibitory	O
potency	O
while	O
inhibitors	O
possessing	O
a	O
longer	O
alkyl	S-chem
tether	O
from	O
the	O
phenyl	O
ring	O
,	O
resulted	O
in	O
markedly	O
improved	O
K	O
(	O
i	O
)	O
values	O
.	O

The	O
greatest	O
inhibitory	O
potency	O
was	O
obtained	O
for	O
the	O
inhibitors	O
in	O
which	O
the	O
phenyl	O
ring	O
was	O
extended	O
furthest	O
from	O
the	O
central	O
phosphorus	S-chem
(	O
1f	O
,	O
n	O
=	O
5	O
and	O
1g	O
,	O
n	O
=	O
6	O
)	O
.	O

The	O
slightly	O
serrated	O
pattern	O
that	O
emerged	O
as	O
the	O
alkyl	S-chem
tether	O
increased	O
from	O
three	O
to	O
six	O
methylene	O
units	O
suggests	O
that	O
inhibitory	O
potency	O
is	O
not	O
simply	O
correlated	O
to	O
increased	O
hydrophobicity	O
imparted	O
by	O
the	O
phenylalkyl	S-chem
chain	O
,	O
but	O
rather	O
that	O
one	O
or	O
more	O
hydrophobic	O
binding	O
registers	O
may	O
exist	O
remote	O
from	O
the	O
substrate	O
recognition	O
architecture	O
in	O
the	O
active	O
site	O
of	O
PSMA	S-geneY
.	O

The	O
neuropharmacological	O
basis	O
for	O
the	O
use	O
of	O
memantine	S-chem
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Memantine	S-chem
has	O
been	O
demonstrated	O
to	O
be	O
safe	O
and	O
effective	O
in	O
the	O
symptomatic	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

While	O
the	O
neurobiological	O
basis	O
for	O
the	O
therapeutic	O
activity	O
of	O
memantine	S-chem
is	O
not	O
fully	O
understood	O
,	O
the	O
drug	O
is	O
not	O
a	O
cholinesterase	S-geneY
inhibitor	O
and	O
,	O
therefore	O
,	O
acts	O
differently	O
from	O
current	O
AD	O
therapies	O
.	O

Memantine	S-chem
can	O
interact	O
with	O
a	O
variety	O
of	O
ligand	B-geneN
-	I-geneN
gated	I-geneN
ion	I-geneN
channels	E-geneN
.	O

However	O
,	O
NMDA	B-geneN
receptors	E-geneN
appear	O
to	O
be	O
a	O
key	O
target	O
of	O
memantine	S-chem
at	O
therapeutic	O
concentrations	O
.	O

Memantine	S-chem
is	O
an	O
uncompetitive	O
(	O
channel	O
blocking	O
)	O
NMDA	B-geneN
receptor	E-geneN
antagonist	O
.	O

Like	O
other	O
NMDA	B-geneN
receptor	E-geneN
antagonists	O
,	O
memantine	S-chem
at	O
high	O
concentrations	O
can	O
inhibit	O
mechanisms	O
of	O
synaptic	O
plasticity	O
that	O
are	O
believed	O
to	O
underlie	O
learning	O
and	O
memory	O
.	O

However	O
,	O
at	O
lower	O
,	O
clinically	O
relevant	O
concentrations	O
memantine	S-chem
can	O
under	O
some	O
circumstances	O
promote	O
synaptic	O
plasticity	O
and	O
preserve	O
or	O
enhance	O
memory	O
in	O
animal	O
models	O
of	O
AD	O
.	O

In	O
addition	O
,	O
memantine	S-chem
can	O
protect	O
against	O
the	O
excitotoxic	O
destruction	O
of	O
cholinergic	O
neurons	O
.	O

Blockade	O
of	O
NMDA	B-geneN
receptors	E-geneN
by	O
memantine	S-chem
could	O
theoretically	O
confer	O
disease	O
-	O
modifying	O
activity	O
in	O
AD	O
by	O
inhibiting	O
the	O
``	O
weak	O
``	B-geneN
NMDA	I-geneN
receptor	O
-	O
dependent	O
excitotoxicity	O
that	O
has	O
been	O
hypothesized	O
to	O
play	O
a	O
role	O
in	O
the	O
progressive	O
neuronal	O
loss	O
that	O
underlies	O
the	O
evolving	O
dementia	O
.	O

Moreover	O
,	O
recent	O
in	O
vitro	O
studies	O
suggest	O
that	O
memantine	S-chem
abrogates	O
beta	B-geneY
-	I-geneY
amyloid	E-geneY
(	O
Abeta	S-geneY
)	O
toxicity	O
and	O
possibly	O
inhibits	O
Abeta	S-geneY
production	O
.	O

Considerable	O
attention	O
has	O
focused	O
on	O
the	O
investigation	O
of	O
theories	O
to	O
explain	O
the	O
better	O
tolerability	O
of	O
memantine	S-chem
over	O
other	O
NMDA	B-geneN
receptor	E-geneN
antagonists	O
,	O
particularly	O
those	O
that	O
act	O
by	O
a	O
similar	O
channel	O
blocking	O
mechanism	O
such	O
as	O
dissociative	O
anesthetic	O
-	O
like	O
agents	O
(	O
phencyclidine	S-chem
,	O
ketamine	S-chem
,	O
MK	B-chem
-	I-chem
801	E-chem
)	O
.	O

A	O
variety	O
of	O
channel	O
-	O
level	O
factors	O
could	O
be	O
relevant	O
,	O
including	O
fast	O
channel	O
-	O
blocking	O
kinetics	O
and	O
strong	O
voltage	O
-	O
dependence	O
(	O
allowing	O
rapid	O
relief	O
of	O
block	O
during	O
synaptic	O
activity	O
)	O
,	O
as	O
well	O
as	O
reduced	O
trapping	O
(	O
permitting	O
egress	O
from	O
closed	O
channels	O
)	O
.	O

These	O
factors	O
may	O
allow	O
memantine	S-chem
to	O
block	O
channel	O
activity	O
induced	O
by	O
low	O
,	O
tonic	O
levels	O
of	O
glutamate	S-chem
-	O
-	O
an	O
action	O
that	O
might	O
contribute	O
to	O
symptomatic	O
improvement	O
and	O
could	O
theoretically	O
protect	O
against	O
weak	O
excitotoxicity	O
-	O
-	O
while	O
sparing	O
synaptic	O
responses	O
required	O
for	O
normal	O
behavioral	O
functioning	O
,	O
cognition	O
and	O
memory	O
.	O

Diclofenac	S-chem
inhibits	O
proliferation	O
and	O
differentiation	O
of	O
neural	O
stem	O
cells	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
widely	O
used	O
in	O
clinical	O
situations	O
as	O
anti	O
-	O
inflammatory	O
,	O
analgesic	O
and	O
antipyretic	O
drugs	O
.	O

However	O
,	O
it	O
is	O
still	O
unknown	O
whether	O
NSAIDs	O
have	O
effects	O
on	O
the	O
development	O
of	O
the	O
central	O
nervous	O
system	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
NSAIDs	O
on	O
neural	O
stem	O
cell	O
(	O
NSC	O
)	O
proliferation	O
and	O
differentiation	O
into	O
neurons	O
.	O

In	O
contrast	O
to	O
aspirin	S-chem
,	O
naproxen	S-chem
,	O
indomethacin	S-chem
and	O
ibuprofen	S-chem
,	O
treatment	O
with	O
diclofenac	S-chem
(	O
10	O
microM	O
)	O
for	O
2	O
days	O
induced	O
the	O
death	O
of	O
NSCs	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Diclofenac	S-chem
also	O
inhibited	O
the	O
proliferation	O
of	O
NSCs	O
and	O
their	O
differentiation	O
into	O
neurons	O
.	O

Treatment	O
with	O
diclofenac	S-chem
resulted	O
in	O
nuclear	O
condensation	O
(	O
a	O
morphological	O
change	O
due	O
to	O
apoptosis	O
of	O
NSCs	O
)	O
24hr	O
after	O
the	O
treatment	O
and	O
activated	O
caspase	B-geneY
-	I-geneY
3	E-geneY
after	O
6	O
hr	O
,	O
indicating	O
that	O
diclofenac	S-chem
may	O
cause	O
apoptosis	O
of	O
neuronal	O
cells	O
via	O
activation	O
of	O
the	O
caspase	S-geneN
cascade	O
.	O

These	O
results	O
suggest	O
that	O
diclofenac	S-chem
may	O
affect	O
the	O
development	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Control	O
of	O
hypercholesterolemia	O
and	O
atherosclerosis	O
using	O
the	O
cholesterol	S-chem
recognition	O
/	O
interaction	O
amino	B-chem
acid	E-chem
sequence	O
of	O
the	O
translocator	B-geneY
protein	I-geneY
TSPO	E-geneY
.	O

The	O
translocator	B-geneY
protein	I-geneY
(	I-geneY
18	I-geneY
-	I-geneY
kDa	I-geneY
)	I-geneY
TSPO	E-geneY
is	O
an	O
ubiquitous	O
high	O
affinity	O
cholesterol	S-chem
-	O
binding	O
protein	O
reported	O
to	O
be	O
present	O
in	O
the	O
endothelial	O
and	O
smooth	O
muscle	O
cells	O
of	O
the	O
blood	O
vessels	O
;	O
its	O
expression	O
dramatically	O
increased	O
in	O
macrophages	O
found	O
in	O
atherosclerotic	O
plaques	O
.	O

A	O
domain	O
in	O
the	O
carboxy	S-chem
-	O
terminus	O
of	O
TSPO	S-geneY
was	O
identified	O
and	O
characterized	O
as	O
the	O
cholesterol	S-chem
recognition	O
/	O
interaction	O
amino	B-chem
acid	E-chem
consensus	O
(	O
CRAC	O
)	O
.	O

The	O
ability	O
of	O
the	O
CRAC	O
domain	O
to	O
bind	O
to	O
cholesterol	S-chem
led	O
us	O
to	O
hypothesize	O
that	O
this	O
peptide	O
could	O
be	O
used	O
as	O
an	O
hypocholesterolemic	O
,	O
with	O
potential	O
anti	O
-	O
atherogenic	O
properties	O
,	O
agent	O
.	O

We	O
report	O
herein	O
the	O
therapeutic	O
benefit	O
that	O
resulted	O
for	O
the	O
administration	O
of	O
the	O
VLNYYVWR	O
human	O
CRAC	O
sequence	O
to	O
guinea	O
pigs	O
fed	O
with	O
a	O
high	O
cholesterol	S-chem
diet	O
and	O
ApoE	S-geneY
knock	O
-	O
out	O
B6.129P2	O
-	O
Apoetm1Unc	O
/	O
J	O
mice	O
.	O

CRAC	O
treatment	O
(	O
3	O
and	O
30mg	O
/	O
kg	O
once	O
daily	O
for	O
6	O
weeks	O
)	O
resulted	O
in	O
reduced	O
circulating	O
cholesterol	S-chem
levels	O
in	O
guinea	O
pigs	O
fed	O
with	O
2	O
%	O
high	O
cholesterol	S-chem
diet	O
and	O
ApoE	S-geneY
knock	O
-	O
out	O
B6.129P2	O
-	O
Apoetm1Unc	O
/	O
J	O
mice	O
.	O

In	O
high	O
cholesterol	S-chem
fed	O
guinea	O
pigs	O
,	O
CRAC	O
treatment	O
administered	O
once	O
daily	O
induced	O
an	O
increase	O
in	O
circulating	O
HDL	O
,	O
decreased	O
total	O
,	O
free	O
and	O
LDL	O
cholesterol	S-chem
,	O
and	O
removed	O
atheroma	O
deposits	O
in	O
the	O
aorta	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
treatment	O
also	O
prevented	O
the	O
high	O
cholesterol	S-chem
diet	O
-	O
induced	O
increase	O
in	O
serum	O
creatine	B-geneN
kinase	E-geneN
,	O
total	O
and	O
isoforms	O
,	O
markers	O
of	O
neurological	O
,	O
cardiac	O
and	O
muscular	O
damage	O
.	O

No	O
toxicity	O
was	O
observed	O
.	O

Taken	O
together	O
these	O
results	O
support	O
a	O
role	O
of	O
TSPO	S-geneY
in	O
lipid	O
homeostasis	O
and	O
atherosclerosis	O
and	O
indicate	O
that	O
CRAC	O
may	O
constitute	O
a	O
novel	O
and	O
safe	O
treatment	O
of	O
hypercholesterolemia	O
and	O
atherosclerosis	O
.	O

Gene	O
expression	O
profiling	O
and	O
pathway	O
analysis	O
of	O
hepatotoxicity	O
induced	O
by	O
triptolide	S-chem
in	O
Wistar	O
rats	O
.	O

Triptolide	S-chem
(	O
TP	O
)	O
,	O
a	O
major	O
component	O
of	O
TWHF	O
,	O
is	O
widely	O
used	O
to	O
treat	O
rheumatoid	O
arthritis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
nephritis	O
and	O
leprosy	O
.	O

However	O
,	O
its	O
clinical	O
use	O
is	O
limited	O
by	O
hepatotoxicity	O
.	O

To	O
further	O
elucidate	O
the	O
underlying	O
mechanism	O
of	O
its	O
hepatotoxic	O
effects	O
,	O
hepatic	O
gene	O
expression	O
profiles	O
were	O
analyzed	O
.	O

TP	O
(	O
1000	O
and	O
300μg	O
/	O
kg	O
)	O
was	O
orally	O
administered	O
to	O
Wistar	O
rats	O
for	O
14days	O
.	O

Current	O
study	O
indicated	O
that	O
female	O
rats	O
were	O
more	O
sensitive	O
to	O
TP	O
-	O
induced	O
hepatotoxicity	O
than	O
males	O
.	O

Genome	O
-	O
wide	O
microarray	O
analyses	O
identified	O
3329	O
differentially	O
expressed	O
genes	O
in	O
liver	O
of	O
female	O
rats	O
.	O

Analyses	O
of	O
these	O
genes	O
identified	O
over	O
-	O
represented	O
functions	O
associated	O
with	O
insulin	S-geneN
signaling	O
pathway	O
,	O
glucose	S-chem
metabolism	O
,	O
cell	O
cycle	O
,	O
oxidative	O
stress	O
and	O
apoptosis	O
,	O
which	O
were	O
consistent	O
with	O
the	O
results	O
of	O
significant	O
increase	O
of	O
Caspase	B-geneY
-	I-geneY
3	E-geneY
activity	O
and	O
reduction	O
of	O
serum	O
glucose	S-chem
,	O
GSH	S-chem
/	O
GSSG	S-chem
ratio	O
,	O
glucose	B-geneY
-	I-geneY
6	I-geneY
-	I-geneY
phosphatase	E-geneY
and	O
phosphoenolpyruvate	B-geneY
carboxykinase	E-geneY
activities	O
,	O
liver	O
glycogen	O
.	O

In	O
addition	O
,	O
it	O
was	O
observed	O
for	O
the	O
first	O
time	O
that	O
glucocorticoids	O
and	O
IGF1	S-geneY
might	O
get	O
involved	O
in	O
TP	O
-	O
induced	O
hepatotoxicity	O
.	O

These	O
data	O
suggest	O
that	O
TP	O
treatment	O
could	O
alter	O
the	O
hepatic	O
redox	O
status	O
,	O
reduce	O
serum	O
glucose	S-chem
and	O
induce	O
hepatocyte	O
apoptosis	O
,	O
consistent	O
with	O
the	O
differential	O
expression	O
of	O
genes	O
involved	O
in	O
insulin	S-geneN
signaling	O
pathway	O
,	O
glucose	S-chem
metabolism	O
pathway	O
and	O
cell	O
stress	O
pathway	O
,	O
all	O
of	O
which	O
might	O
contribute	O
to	O
the	O
overall	O
TP	O
-	O
induced	O
hepatotoxicity	O
.	O

MAPK	S-geneN
signaling	O
pathways	O
regulate	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
induced	O
by	O
isoorientin	S-chem
in	O
human	O
hepatoblastoma	O
cancer	O
cells	O
.	O

Isoorientin	S-chem
(	O
ISO	S-chem
)	O
(	O
CAS	O
RN	O
:	O
4261	B-chem
-	I-chem
42	I-chem
-	I-chem
1	E-chem
)	O
is	O
a	O
flavonoid	S-chem
compound	O
that	O
can	O
be	O
extracted	O
from	O
several	O
plant	O
species	O
,	O
such	O
as	O
Phyllostachys	O
pubescens	O
,	O
Patrinia	O
,	O
and	O
Drosophyllum	O
lusitanicum	O
.	O

ISO	S-chem
is	O
able	O
to	O
induce	O
apoptosis	O
through	O
mitochondrial	O
dysfunction	O
and	O
inhibition	O
of	O
PI3K	S-geneN
/	O
Akt	S-geneN
signaling	O
pathway	O
in	O
HepG2	O
cells	O
,	O
however	O
,	O
the	O
effects	O
of	O
ISO	S-chem
on	O
MAPK	S-geneN
signaling	O
pathways	O
remain	O
unknown	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
ISO	S-chem
on	O
this	O
pathway	O
,	O
and	O
the	O
roles	O
of	O
MAPK	S-geneN
kinases	S-geneN
on	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
in	O
HepG2	O
cells	O
.	O

The	O
results	O
showed	O
that	O
ISO	S-chem
induced	O
cell	O
death	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
,	O
and	O
induction	O
apoptosis	O
is	O
main	O
cause	O
for	O
ISO	S-chem
-	O
induced	O
cytotoxicity	O
in	O
HepG2	O
cells	O
.	O

ISO	S-chem
significantly	O
inhibited	O
the	O
levels	O
of	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
kinase	O
and	O
increased	O
the	O
expression	O
of	O
JNK	S-geneN
and	O
p38	S-geneN
kinases	S-geneN
.	O

Furthermore	O
,	O
U0126	S-chem
(	O
an	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
inhibitor	O
)	O
significantly	O
enhanced	O
the	O
ISO	S-chem
-	O
induced	O
the	O
Bax	S-geneY
/	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
ratio	O
,	O
the	O
release	O
of	O
cytochrome	B-geneY
c	E-geneY
to	O
the	O
cytosol	O
fraction	O
,	O
and	O
the	O
levels	O
of	O
cleaved	O
caspase	B-geneY
-	I-geneY
3	E-geneY
.	O

While	O
SP600125	S-chem
(	O
a	O
JNK	S-geneN
inhibitor	O
)	O
and	O
SB203580	S-chem
(	O
a	O
p38	S-geneN
inhibitor	O
)	O
markedly	O
prevented	O
the	O
expression	O
of	O
these	O
proteins	O
induced	O
by	O
ISO	S-chem
.	O

Furthermore	O
,	O
the	O
ROS	O
inhibitor	O
(	O
NAC	S-chem
)	O
notably	O
promoted	O
the	O
inhibited	O
effect	O
of	O
ISO	S-chem
on	O
the	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
kinase	O
.	O

NAC	S-chem
also	O
suppressed	O
the	O
p	O
-	O
JNK	S-geneN
and	O
p	B-geneN
-	I-geneN
p38	E-geneN
,	O
but	O
failed	O
to	O
reverse	O
the	O
effects	O
of	O
ISO	S-chem
.	O

These	O
results	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
ISO	S-chem
induces	O
apoptosis	O
in	O
HepG2	O
cells	O
through	O
inactivating	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
kinase	O
and	O
activating	O
JNK	S-geneN
and	O
p38	S-geneN
kinases	S-geneN
,	O
and	O
ROS	O
stimulated	O
by	O
ISO	S-chem
is	O
able	O
to	O
activate	O
the	O
MAPK	S-geneN
singaling	O
pathway	O
as	O
the	O
upstream	O
signaling	O
molecules	O
.	O

Initiating	O
event	O
of	O
the	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
induced	O
by	O
ISO	S-chem
is	O
MAPK	S-geneN
signals	O
.	O

Cyclopenta	B-chem
[	I-chem
c	I-chem
]	I-chem
phenanthrenes	E-chem
-	O
Chemistry	O
and	O
biological	O
activity	O
.	O

Despite	O
cyclopenta	B-chem
-	I-chem
fused	I-chem
polycyclic	I-chem
aromatic	I-chem
hydrocarbons	E-chem
(	O
CP	B-chem
-	I-chem
PAHs	E-chem
)	O
having	O
been	O
detected	O
in	O
the	O
environment	O
,	O
the	O
ability	O
of	O
these	O
compounds	O
to	O
induce	O
cellular	O
and	O
tissue	O
responses	O
remains	O
poorly	O
characterized	O
.	O

In	O
this	O
review	O
,	O
we	O
look	O
at	O
the	O
chemistry	O
and	O
biological	O
activity	O
of	O
the	O
cyclopenta	B-chem
[	I-chem
c	I-chem
]	I-chem
phenanthrenes	E-chem
(	O
CP	B-chem
[	I-chem
c	I-chem
]	I-chem
Ph	E-chem
)	O
as	O
potential	O
chemicals	O
of	O
concern	O
in	O
the	O
process	O
of	O
risk	O
assessment	O
.	O

The	O
first	O
part	O
of	O
the	O
review	O
deals	O
with	O
the	O
environmental	O
occurrence	O
and	O
chemistry	O
of	O
CP	B-chem
-	I-chem
PAHs	E-chem
,	O
focusing	O
on	O
available	O
methods	O
of	O
CP	B-chem
[	I-chem
c	I-chem
]	I-chem
Ph	E-chem
chemical	O
synthesis	O
.	O

The	O
most	O
interesting	O
structural	O
feature	O
of	O
the	O
CP	B-chem
[	I-chem
c	I-chem
]	I-chem
Ph	E-chem
is	O
the	O
presence	O
of	O
a	O
pseudo	O
fjord	O
-	O
region	O
constructed	O
by	O
the	O
cyclopentane	S-chem
ring	O
.	O

This	O
compound	O
can	O
be	O
treated	O
either	O
as	O
a	O
structurally	O
similar	O
one	O
to	O
B	B-chem
[	I-chem
c	I-chem
]	I-chem
Ph	E-chem
,	O
or	O
as	O
a	O
phenanthrene	S-chem
skeleton	O
with	O
an	O
electrodonating	O
alkyl	S-chem
substituent	O
in	O
the	O
bay	O
-	O
region	O
of	O
the	O
molecule	O
.	O

The	O
second	O
thread	O
,	O
providing	O
available	O
data	O
on	O
the	O
adverse	O
effects	O
of	O
CP	B-chem
[	I-chem
c	I-chem
]	I-chem
Ph	E-chem
compounds	O
on	O
cells	O
and	O
tissues	O
of	O
living	O
organisms	O
,	O
mainly	O
fish	O
,	O
improves	O
our	O
understanding	O
of	O
these	O
possible	O
environmental	O
hazards	O
.	O

The	O
data	O
show	O
that	O
CP	B-chem
[	I-chem
c	I-chem
]	I-chem
Ph	E-chem
is	O
less	O
potent	O
at	O
inducing	O
CYP1A	S-geneN
gene	O
expression	O
in	O
rainbow	O
trout	O
than	O
benzo	B-chem
[	I-chem
a	I-chem
]	I-chem
pyrene	E-chem
(	O
B	B-chem
[	I-chem
a	I-chem
]	I-chem
P	E-chem
)	O
,	O
a	O
well	O
-	O
known	O
Ah	O
-	O
receptor	O
agonist	O
.	O

Interestingly	O
,	O
the	O
CP	B-chem
[	I-chem
c	I-chem
]	I-chem
Ph	E-chem
dependent	O
up	O
-	O
regulation	O
of	O
CYP1A	S-geneN
mRNA	O
is	O
positively	O
correlated	O
with	O
the	O
incidences	O
of	O
clastogenic	O
changes	O
in	O
rainbow	O
trout	O
erythrocytes	O
.	O

CP	B-chem
[	I-chem
c	I-chem
]	I-chem
Ph	E-chem
has	O
,	O
comparably	O
to	O
B	B-chem
[	I-chem
a	I-chem
]	I-chem
P	E-chem
,	O
a	O
potential	O
to	O
repress	O
expression	O
of	O
tumor	B-geneY
suppressor	I-geneY
p53	E-geneY
,	O
in	O
the	O
head	O
kidney	O
of	O
rainbow	O
trout	O
.	O

Furthermore	O
,	O
estrogen	S-chem
responsive	O
genes	O
in	O
fish	O
liver	O
,	O
ERα	S-geneY
and	O
VTG	S-geneY
,	O
are	O
not	O
induced	O
by	O
CP	B-chem
[	I-chem
c	I-chem
]	I-chem
Ph	E-chem
,	O
suggesting	O
that	O
the	O
compound	O
has	O
no	O
endocrine	O
disrupting	O
potential	O
.	O

However	O
,	O
some	O
CP	B-chem
[	I-chem
c	I-chem
]	I-chem
Phs	E-chem
show	O
mutagenic	O
activity	O
when	O
investigated	O
in	O
the	O
Ames	O
test	O
,	O
and	O
exhibit	O
genotoxic	O
properties	O
in	O
in	O
vitro	O
micronucleus	O
assay	O
.	O

The	O
above	O
characteristics	O
suggest	O
that	O
CP	B-chem
-	I-chem
PAHs	E-chem
are	O
chemicals	O
of	O
concern	O
for	O
which	O
potential	O
pathways	O
of	O
exposure	O
should	O
be	O
further	O
identified	O
.	O

Low	O
-	O
Dose	O
Dexamethasone	S-chem
Treatment	O
Promotes	O
Pro	O
-	O
Survival	O
Signalling	O
Pathway	O
In	O
Adult	O
Rat	O
Prefrontal	O
Cortex	O
.	O

Synthetic	O
glucocorticoid	O
dexamethasone	S-chem
(	O
DEX	S-chem
)	O
,	O
a	O
highly	O
potent	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
agent	O
,	O
is	O
widely	O
used	O
in	O
treatments	O
of	O
brain	O
cancer	O
,	O
inflammatory	O
and	O
autoimmune	O
diseases	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
whether	O
a	O
low	O
-	O
dose	O
subchronic	O
DEX	S-chem
treatment	O
(	O
100	O
μg	O
/	O
kg	O
for	O
8	O
consecutive	O
days	O
)	O
exerts	O
long	O
-	O
term	O
effects	O
on	O
apoptosis	O
in	O
the	O
adult	O
rat	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
by	O
examining	O
the	O
expression	O
of	O
cell	O
death	O
-	O
promoting	O
molecules	O
(	O
poly	B-geneN
(	I-geneN
ADP	I-geneN
-	I-geneN
ribose	I-geneN
)	I-geneN
polymerase	E-geneN
(	O
PARP	S-geneN
)	O
,	O
p53	S-geneY
,	O
procaspase	B-geneY
3	E-geneY
,	O
cleaved	O
caspase	B-geneY
3	E-geneY
,	O
Bax	S-geneY
)	O
and	O
cell	O
-	O
survival	O
molecules	O
(	O
AKT	S-geneN
,	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
)	O
.	O

Our	O
results	O
revealed	O
that	O
body	O
,	O
thymus	O
and	O
adrenal	O
weight	O
as	O
well	O
corticosterone	S-chem
level	O
in	O
the	O
serum	O
and	O
PFC	O
were	O
reduced	O
a	O
day	O
following	O
last	O
DEX	S-chem
injection	O
.	O

In	O
PFC	O
,	O
DEX	S-chem
caused	O
activation	O
of	O
AKT	S-geneN
,	O
augmentation	O
of	O
pro	O
-	O
survival	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
protein	O
and	O
enhanced	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
/	O
Bax	S-geneY
protein	O
ratio	O
,	O
as	O
well	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
translocation	O
to	O
mitochondria	O
.	O

The	O
unaltered	O
profile	O
in	O
the	O
protein	O
expression	O
of	O
apoptotic	O
molecules	O
PARP	S-geneN
,	O
procaspase	B-geneY
3	E-geneY
and	O
Bax	S-geneY
was	O
detected	O
,	O
while	O
the	O
p53	S-geneY
protein	O
was	O
decreased	O
.	O

Results	O
of	O
RT	O
-	O
PCR	O
analysis	O
showed	O
decrease	O
of	O
p53	S-geneY
mRNA	O
level	O
and	O
no	O
significant	O
difference	O
in	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
and	O
Bax	S-geneY
mRNA	O
expressions	O
in	O
DEX	S-chem
-	O
treated	O
rats	O
.	O

Finally	O
,	O
the	O
DNA	O
fragmentation	O
assay	O
and	O
Fluoro	O
-	O
Jade	O
staining	O
demonstrated	O
no	O
considerable	O
changes	O
in	O
the	O
apoptosis	O
in	O
rat	O
PFC	O
.	O

Our	O
findings	O
support	O
the	O
concept	O
that	O
a	O
low	O
-	O
dose	O
DEX	S-chem
creates	O
the	O
hypocorticoid	O
state	O
in	O
the	O
brain	O
and	O
indicate	O
that	O
subchronic	O
DEX	S-chem
treatment	O
activates	O
pro	O
-	O
survival	O
signalling	O
pathway	O
but	O
does	O
not	O
change	O
apoptotic	O
markers	O
in	O
rat	O
PFC	O
.	O

This	O
mechanism	O
might	O
be	O
relevant	O
for	O
DEX	S-chem
-	O
induced	O
apoptosis	O
resistance	O
observed	O
during	O
and	O
after	O
chemotherapy	O
of	O
patients	O
with	O
brain	O
tumours	O
.	O

©	O
2013	O
British	O
Society	O
for	O
Neuroendocrinology	O
.	O

P2Y	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
receptor	E-geneY
agonist	O
INS37217	S-chem
enhances	O
functional	O
recovery	O
after	O
detachment	O
caused	O
by	O
subretinal	O
injection	O
in	O
normal	O
and	O
rds	O
mice	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
effects	O
of	O
INS37217	S-chem
on	O
the	O
recovery	O
of	O
retinal	S-chem
function	O
after	O
experimental	O
retinal	S-chem
detachment	O
induced	O
by	O
subretinal	O
injection	O
.	O

METHODS	O
:	O
Subretinal	O
injections	O
of	O
1	O
micro	O
L	O
of	O
fluorescent	O
microbeads	O
,	O
saline	O
,	O
or	O
INS37217	S-chem
(	O
1	O
-	O
200	O
micro	O
M	O
)	O
were	O
made	O
by	O
the	O
transvitreal	O
method	O
in	O
normal	O
(	O
C57BL	O
/	O
6	O
)	O
mice	O
and	O
in	O
mice	O
heterozygous	O
for	O
the	O
retinal	S-chem
degeneration	O
slow	O
(	O
rds	O
)	O
gene	O
.	O

Control	O
,	O
mock	O
-	O
injected	O
animals	O
underwent	O
corneal	O
puncture	O
without	O
injection	O
.	O

Histologic	O
and	O
ERG	O
evaluations	O
were	O
made	O
at	O
0	O
to	O
1	O
and	O
8	O
hours	O
,	O
and	O
1	O
,	O
3	O
,	O
7	O
,	O
10	O
,	O
14	O
,	O
and	O
60	O
days	O
post	O
injection	O
(	O
PI	O
)	O
.	O

DNA	O
fragmentation	O
was	O
evaluated	O
by	O
terminal	O
deoxynucleotidyl	S-chem
transferase	O
-	O
mediated	O
uridine	B-chem
5	I-chem
'	I-chem
-	I-chem
triphosphate	I-chem
-	I-chem
biotin	E-chem
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
.	O

RESULTS	O
:	O
A	O
single	O
subretinal	O
injection	O
of	O
saline	O
solution	O
containing	O
fluorescent	O
beads	O
caused	O
a	O
histologically	O
evident	O
retinal	O
detachment	O
and	O
distributed	O
the	O
microbeads	O
to	O
almost	O
all	O
the	O
subretinal	O
space	O
.	O

Spontaneous	O
reattachment	O
occurred	O
within	O
24	O
hours	O
after	O
injection	O
and	O
was	O
accompanied	O
by	O
evident	O
retinal	S-chem
folding	O
that	O
appeared	O
largely	O
resolved	O
by	O
6	O
days	O
later	O
.	O

Relative	O
to	O
controls	O
,	O
injection	O
of	O
saline	O
resulted	O
in	O
approximately	O
40	O
%	O
recovery	O
of	O
dark	O
-	O
adapted	O
a	O
-	O
wave	O
amplitude	O
at	O
24	O
hours	O
PI	O
and	O
gradually	O
improved	O
to	O
approximately	O
90	O
%	O
of	O
controls	O
at	O
2	O
months	O
PI	O
.	O

Subretinal	O
injection	O
of	O
saline	O
containing	O
INS37217	S-chem
(	O
10	O
micro	O
M	O
)	O
significantly	O
increased	O
rod	O
and	O
cone	O
ERG	O
of	O
normal	O
and	O
rds	O
(	O
+	O
/	O
-	O
)	O
mice	O
at	O
1	O
and	O
10	O
days	O
PI	O
,	O
when	O
compared	O
with	O
injection	O
of	O
saline	O
alone	O
.	O

Additionally	O
,	O
INS37217	S-chem
reduced	O
the	O
number	O
of	O
TUNEL	O
-	O
positive	O
photoreceptors	O
and	O
the	O
enhanced	O
rate	O
of	O
reattachment	O
.	O

CONCLUSIONS	O
:	O
Enhancement	O
of	O
ERG	O
recovery	O
by	O
INS37217	S-chem
is	O
likely	O
due	O
to	O
reduced	O
retinal	S-chem
folding	O
and	O
cell	O
death	O
associated	O
with	O
detachment	O
.	O

These	O
results	O
support	O
the	O
use	O
of	O
INS37217	S-chem
to	O
help	O
restore	O
function	O
after	O
therapies	O
that	O
involve	O
subretinal	O
administration	O
of	O
drugs	O
in	O
animal	O
models	O
of	O
retinal	S-chem
diseases	O
.	O

The	O
calponin	B-geneN
homology	I-geneN
domain	E-geneN
of	O
Vav1	S-geneY
associates	O
with	O
calmodulin	S-geneY
and	O
is	O
prerequisite	O
to	O
T	B-geneN
cell	I-geneN
antigen	I-geneN
receptor	E-geneN
-	O
induced	O
calcium	S-chem
release	O
in	O
Jurkat	O
T	O
lymphocytes	O
.	O

Vav1	S-geneY
is	O
a	O
guanine	B-geneN
nucleotide	I-geneN
exchange	I-geneN
factor	E-geneN
that	O
is	O
expressed	O
specifically	O
in	O
hematopoietic	O
cells	O
and	O
plays	O
important	O
roles	O
in	O
T	O
cell	O
development	O
and	O
activation	O
.	O

Vav1	S-geneY
consists	O
of	O
multiple	O
structural	O
domains	O
so	O
as	O
to	O
facilitate	O
both	O
its	O
guanine	B-chem
nucleotide	E-chem
exchange	O
activity	O
and	O
scaffold	O
function	O
following	O
T	B-geneN
cell	I-geneN
antigen	I-geneN
receptor	E-geneN
(	O
TCR	S-geneN
)	O
engagement	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
calponin	B-geneN
homology	I-geneN
(	I-geneN
CH	I-geneN
)	I-geneN
domain	E-geneN
of	O
Vav1	S-geneY
is	O
required	O
for	O
TCR	S-geneY
-	O
stimulated	O
calcium	S-chem
mobilization	O
and	O
thus	O
downstream	O
activation	O
of	O
nuclear	B-geneN
factor	I-geneN
of	I-geneN
activated	I-geneN
T	I-geneN
cells	E-geneN
.	O

However	O
,	O
it	O
remained	O
obscure	O
how	O
Vav1	S-geneY
functions	O
in	O
regulating	O
calcium	S-chem
flux	O
.	O

In	O
an	O
effort	O
to	O
explore	O
molecules	O
interacting	O
with	O
Vav1	S-geneY
,	O
we	O
found	O
that	O
calmodulin	S-geneY
bound	O
to	O
Vav1	S-geneY
in	O
a	O
calcium	S-chem
-	O
dependent	O
and	O
TCR	S-geneN
activation	O
-	O
independent	O
manner	O
.	O

The	O
binding	O
site	O
was	O
mapped	O
to	O
the	O
CH	B-geneN
domain	E-geneN
of	O
Vav1	S-geneY
.	O

Reconstitution	O
of	O
vav1	S-geneY
-	O
null	O
Jurkat	O
T	O
cells	O
(	O
J.Vav1	O
)	O
with	O
CH	S-geneN
-	O
deleted	O
Vav1	S-geneY
exhibited	O
a	O
severe	O
deficiency	O
in	O
calcium	S-chem
release	O
to	O
the	O
same	O
extent	O
as	O
that	O
of	O
Jurkat	O
cells	O
treated	O
with	O
the	O
calmodulin	S-geneY
inhibitor	O
or	O
J.Vav1	O
cells	O
.	O

The	O
defect	O
persisted	O
even	O
when	O
phospholipase	B-geneY
-	I-geneY
Cgamma1	E-geneY
was	O
fully	O
activated	O
,	O
indicating	O
a	O
prerequisite	O
role	O
of	O
Vav1	B-geneN
CH	I-geneN
domain	E-geneN
in	O
calcium	S-chem
signaling	O
.	O

The	O
results	O
suggest	O
that	O
Vav1	S-geneY
and	O
calmodulin	S-geneY
function	O
cooperatively	O
to	O
potentiate	O
TCR	S-geneN
-	O
induced	O
calcium	S-chem
release	O
.	O

This	O
study	O
unveiled	O
a	O
mechanism	O
by	O
which	O
the	O
Vav1	B-geneN
CH	I-geneN
domain	E-geneN
is	O
involved	O
in	O
calcium	S-chem
signaling	O
and	O
provides	O
insight	O
into	O
our	O
understanding	O
of	O
the	O
role	O
of	O
Vav1	S-geneY
in	O
T	O
cell	O
activation	O
.	O

A	O
molecular	O
mechanism	O
of	O
pyruvate	S-chem
protection	O
against	O
cytotoxicity	O
of	O
reactive	O
oxygen	S-chem
species	O
in	O
osteoblasts	O
.	O

We	O
demonstrated	O
previously	O
that	O
exogenous	O
pyruvate	S-chem
has	O
a	O
protective	O
action	O
against	O
cell	O
death	O
by	O
hydrogen	B-chem
peroxide	E-chem
in	O
cultured	O
osteoblasts	O
through	O
a	O
mechanism	O
associated	O
with	O
its	O
antioxidative	O
property	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
evaluated	O
possible	O
participation	O
of	O
monocarboxylate	B-geneN
transporters	E-geneN
(	O
MCTs	S-geneN
)	O
responsible	O
for	O
the	O
bidirectional	O
membrane	O
transport	O
of	O
pyruvate	S-chem
in	O
the	O
cytoprotective	O
property	O
in	O
osteoblasts	O
.	O

Expression	O
of	O
the	O
MCT2	S-geneY
isoform	O
was	O
found	O
in	O
cultured	O
rat	O
calvarial	O
osteoblasts	O
and	O
in	O
osteoblasts	O
located	O
on	O
mouse	O
tibia	O
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
.	O

The	O
accumulation	O
of	O
[	B-chem
14C	I-chem
]	I-chem
pyruvate	E-chem
occurred	O
in	O
a	O
temperature	O
-	O
and	O
pH	O
-	O
dependent	O
manner	O
in	O
osteoblasts	O
cultured	O
for	O
7	O
days	O
with	O
high	O
sensitivity	O
to	O
a	O
specific	O
MCT	S-geneN
inhibitor	O
,	O
whereas	O
pyruvate	S-chem
was	O
released	O
into	O
extracellular	O
spaces	O
from	O
cultured	O
osteoblasts	O
in	O
a	O
fashion	O
sensitive	O
to	O
the	O
MCT	S-geneN
inhibitor	O
.	O

Transient	O
overexpression	O
of	O
the	O
MCT2	S-geneY
isoform	O
led	O
to	O
reduced	O
vulnerability	O
to	O
the	O
cytotoxicity	O
of	O
hydrogen	B-chem
peroxide	E-chem
with	O
an	O
increased	O
activity	O
of	O
[	B-chem
14C	I-chem
]	I-chem
pyruvate	E-chem
accumulation	O
in	O
murine	O
osteoblastic	O
MC3T3	O
-	O
E1	O
cells	O
.	O

Ovariectomy	O
significantly	O
decreased	O
the	O
content	O
of	O
pyruvate	S-chem
in	O
femoral	O
bone	O
marrows	O
in	O
mice	O
in	O
vivo	O
,	O
whereas	O
daily	O
i.p	O
.	O
administration	O
of	O
pyruvate	S-chem
at	O
0.25	O
g	O
/	O
kg	O
significantly	O
prevented	O
alterations	O
of	O
several	O
histomorphometric	O
parameters	O
as	O
well	O
as	O
cancellous	O
bone	O
loss	O
in	O
femurs	O
by	O
ovariectomy	O
on	O
28	O
days	O
after	O
the	O
operation	O
.	O

These	O
results	O
suggest	O
that	O
MCTs	S-geneN
may	O
be	O
functionally	O
expressed	O
by	O
osteoblasts	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
mechanisms	O
related	O
to	O
the	O
cytoprotective	O
property	O
of	O
pyruvate	S-chem
.	O

Toxicity	O
of	O
the	O
flame	O
-	O
retardant	O
BDE	B-chem
-	I-chem
49	E-chem
on	O
brain	O
mitochondria	O
and	O
neuronal	O
progenitor	O
striatal	O
cells	O
enhanced	O
by	O
a	O
PTEN	S-geneY
-	O
deficient	O
background	O
.	O

Polybrominated	B-chem
diphenyl	I-chem
ethers	E-chem
(	O
PBDEs	S-chem
)	O
represent	O
an	O
important	O
group	O
of	O
flame	O
retardants	O
extensively	O
used	O
,	O
tonnage	O
of	O
which	O
in	O
the	O
environment	O
has	O
been	O
steadily	O
increasing	O
over	O
the	O
past	O
25	O
years	O
.	O

PBDEs	S-chem
or	O
metabolites	O
can	O
induce	O
neurotoxicity	O
and	O
mitochondrial	O
dysfunction	O
(	O
MD	O
)	O
through	O
a	O
variety	O
of	O
mechanisms	O
.	O

Recently	O
,	O
PBDEs	S-chem
with	O
<	O
5	O
Br	S-chem
substitutions	O
(	O
i.e	O
.	O
,	O
2,2',4,4	B-chem
'	I-chem
-	I-chem
tetrabromodiphenyl	I-chem
ether	E-chem
[	O
BDE	B-chem
-	I-chem
47	E-chem
]	O
and	O
2,2',4,5	B-chem
'	I-chem
-	I-chem
tetrabromodiphenyl	I-chem
ether	E-chem
[	O
BDE	B-chem
-	I-chem
49	E-chem
]	O
)	O
have	O
gained	O
interest	O
because	O
of	O
their	O
high	O
bioaccumulation	O
.	O

In	O
particular	O
,	O
congeners	O
such	O
as	O
BDE	B-chem
-	I-chem
49	E-chem
arise	O
as	O
one	O
of	O
the	O
most	O
biologically	O
active	O
,	O
with	O
concentrations	O
typically	O
lower	O
than	O
those	O
observed	O
for	O
BDE	B-chem
-	I-chem
47	E-chem
in	O
biological	O
tissues	O
;	O
however	O
,	O
its	O
potential	O
to	O
cause	O
MD	O
at	O
biologically	O
relevant	O
concentrations	O
is	O
unknown	O
.	O

To	O
this	O
end	O
,	O
the	O
effect	O
of	O
BDE	B-chem
-	I-chem
49	E-chem
was	O
studied	O
in	O
brain	O
mitochondria	O
and	O
neuronal	O
progenitor	O
striatal	O
cells	O
(	O
NPC	O
)	O
.	O

BDE	B-chem
-	I-chem
49	E-chem
uncoupled	O
mitochondria	O
at	O
concentrations	O
<	O
0.1	O
nM	O
,	O
whereas	O
at	O
>	O
1	O
nM	O
,	O
it	O
inhibited	O
the	O
electron	O
transport	O
at	O
Complex	O
V	O
(	O
mixed	O
type	O
inhibition	O
;	O
IC	O
(	O
50	O
)	O
=	O
6	O
nM	O
)	O
and	O
Complex	O
IV	O
(	O
noncompetitive	O
inhibition	O
;	O
IC	O
(	O
50	O
)	O
=	O
40	O
nM	O
)	O
.	O

These	O
concentrations	O
are	O
easily	O
achieved	O
in	O
plasma	O
concentrations	O
considering	O
that	O
BDE	B-chem
-	I-chem
49	E-chem
(	O
this	O
study	O
,	O
400	O
-	O
fold	O
)	O
and	O
other	O
PBDEs	S-chem
accumulate	O
1	O
-	O
3	O
orders	O
of	O
magnitude	O
in	O
the	O
cells	O
,	O
particularly	O
in	O
mitochondria	O
and	O
microsomes	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
NPC	O
and	O
exacerbated	O
with	O
PTEN	S-geneY
(	O
negative	O
modulator	O
of	O
the	O
PI3K	S-geneN
/	O
Akt	S-geneN
pathway	O
)	O
deficiency	O
,	O
background	O
associated	O
with	O
autism	O
-	O
like	O
behavior	O
,	O
schizophrenia	O
,	O
and	O
epilepsy	O
.	O

PBDE	S-chem
-	O
mediated	O
MD	O
per	O
se	O
or	O
enhanced	O
by	O
a	O
background	O
that	O
confers	O
susceptibility	O
to	O
this	O
exposure	O
may	O
have	O
profound	O
implications	O
in	O
the	O
energy	O
balance	O
of	O
brain	O
.	O

Developmental	O
changes	O
in	O
lactate	B-geneY
dehydrogenase	I-geneY
-	I-geneY
X	E-geneY
activity	O
in	O
young	O
jaundiced	O
male	O
rats	O
.	O

This	O
study	O
was	O
designed	O
to	O
examine	O
the	O
testicular	O
maturation	O
in	O
both	O
jaundiced	O
(	O
jj	O
)	O
and	O
nonjaundiced	O
(	O
Jj	O
)	O
male	O
Gunn	O
rats	O
as	O
indicated	O
by	O
the	O
activity	O
of	O
a	O
testis	O
and	O
sperm	O
-	O
specific	O
enzyme	O
,	O
lactate	B-geneY
dehydrogenase	I-geneY
-	I-geneY
X	E-geneY
(	O
LDH	B-geneY
-	I-geneY
X	E-geneY
)	O
,	O
and	O
serum	O
testosterone	S-chem
levels	O
.	O

Testicular	O
cytosolic	O
LDH	B-geneY
-	I-geneY
X	E-geneY
activity	O
was	O
determined	O
by	O
oxidation	O
of	O
reduced	O
nicotinamide	B-chem
adenine	I-chem
dinucleotide	E-chem
(	O
NADH	S-chem
)	O
.	O

Serum	O
testosterone	S-chem
levels	O
were	O
measured	O
by	O
radioimmunoassay	O
(	O
RIA	O
)	O
.	O

Testicular	O
LDH	B-geneY
-	I-geneY
X	E-geneY
activity	O
increased	O
rapidly	O
between	O
30	O
and	O
50	O
days	O
of	O
age	O
in	O
both	O
Jj	O
and	O
jj	O
Gunn	O
rats	O
.	O

LDH	B-geneY
-	I-geneY
X	E-geneY
activity	O
was	O
significantly	O
lower	O
in	O
the	O
jj	O
Gunn	O
rats	O
at	O
50	O
and	O
60	O
days	O
of	O
age	O
.	O

Testosterone	S-chem
level	O
was	O
significantly	O
lower	O
in	O
the	O
jj	O
Gunn	O
rats	O
at	O
50	O
days	O
of	O
age	O
.	O

LDH	B-geneY
-	I-geneY
X	E-geneY
activity	O
and	O
serum	O
testosterone	S-chem
levels	O
were	O
similar	O
for	O
both	O
genotypes	O
at	O
180	O
days	O
of	O
age	O
.	O

The	O
delay	O
of	O
testicular	O
maturation	O
in	O
the	O
jaundiced	O
males	O
seems	O
to	O
be	O
due	O
to	O
lower	O
LDH	B-geneY
-	I-geneY
X	E-geneY
activity	O
and	O
serum	O
testosterone	S-chem
levels	O
.	O

Grb10	S-geneY
-	O
mediated	O
Negative	O
Regulation	O
of	O
IGF1R	S-geneY
-	O
Activated	O
Signalling	O
Pathway	O
Results	O
in	O
Cognitive	O
Disorder	O
in	O
Diabetic	O
Rats	O
.	O

Growth	B-geneY
factor	I-geneY
receptor	I-geneY
-	I-geneY
bound	I-geneY
protein	I-geneY
10	E-geneY
(	O
Grb10	S-geneY
)	O
is	O
a	O
Src	B-geneN
homology	I-geneN
2	I-geneN
(	I-geneN
SH2	I-geneN
)	I-geneN
domain	E-geneN
-	O
containing	O
protein	O
and	O
one	O
of	O
the	O
binding	O
partners	O
for	O
several	O
trans	O
-	O
membrane	O
tyrosine	B-geneN
-	I-geneN
kinase	I-geneN
receptors	E-geneN
,	O
including	O
insulin	B-geneY
receptor	E-geneY
(	O
IR	S-geneY
)	O
and	O
insulin	B-geneY
-	I-geneY
like	I-geneY
growth	I-geneY
factor	I-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
(	O
IGF1	B-geneY
-	I-geneY
R	E-geneY
)	O
.	O

The	O
hippocampus	O
,	O
which	O
is	O
critical	O
for	O
cognitive	O
functions	O
,	O
is	O
one	O
of	O
the	O
main	O
distribution	O
areas	O
of	O
Grb10	S-geneY
in	O
the	O
central	O
nervous	O
system	O
.	O

In	O
recent	O
years	O
,	O
diabetic	O
encephalopathy	O
has	O
been	O
defined	O
as	O
a	O
third	O
type	O
of	O
diabetes	O
and	O
the	O
IGF1	B-geneY
-	I-geneY
IR	E-geneY
pathway	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
the	O
neuropathogenic	O
process	O
of	O
cognitive	O
disorder	O
in	O
diabetes	O
.	O

However	O
,	O
the	O
role	O
of	O
endogenous	O
Grb10	S-geneY
in	O
regulating	O
the	O
IGF1	B-geneY
-	I-geneY
IR	E-geneY
pathway	O
and	O
neurobehavioral	O
changes	O
is	O
not	O
explicit	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
in	O
vivo	O
function	O
of	O
endogenous	O
Grb10	S-geneY
in	O
diabetic	O
encephalopathy	O
and	O
the	O
underlying	O
mechanisms	O
.	O

Using	O
stereotaxic	O
surgical	O
techniques	O
and	O
lentiviral	O
vectors	O
expressing	O
specific	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
,	O
we	O
could	O
steadily	O
knock	O
down	O
Grb10	S-geneY
expression	O
in	O
the	O
hippocampus	O
.	O

More	O
importantly	O
,	O
we	O
demonstrated	O
that	O
hippocampus	O
-	O
specific	O
modulation	O
of	O
Grb10	S-geneY
protein	O
levels	O
led	O
to	O
a	O
prominent	O
remission	O
of	O
cognitive	O
disorder	O
,	O
including	O
improvements	O
in	O
both	O
ultrastructural	O
pathology	O
and	O
abnormal	O
neurobehavioural	O
changes	O
.	O

Our	O
findings	O
indicate	O
that	O
endogenous	O
overexpression	O
of	O
Grb10	S-geneY
functions	O
as	O
a	O
suppressor	O
of	O
the	O
IGF1	B-geneY
-	I-geneY
IR	E-geneY
pathway	O
,	O
which	O
may	O
represent	O
an	O
important	O
mechanism	O
that	O
regulates	O
cognitive	O
disorder	O
in	O
diabetes	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Adrenocortical	O
reserves	O
in	O
hyperthyroidism	O
.	O

Explicit	O
data	O
regarding	O
the	O
changes	O
in	O
adrenocortical	O
reserves	O
during	O
hyperthyroidism	O
do	O
not	O
exist	O
.	O

We	O
aimed	O
to	O
document	O
the	O
capability	O
(	O
response	O
)	O
of	O
adrenal	O
gland	O
to	O
secrete	O
cortisol	S-chem
and	O
DHEA	S-chem
-	O
S	O
during	O
hyperthyroidism	O
compared	O
to	O
euthyroidism	O
,	O
and	O
to	O
describe	O
factors	O
associated	O
with	O
these	O
responses	O
.	O

A	O
standard	O
-	O
dose	O
(	O
0.25	O
mg	O
/	O
i.v	O
.	O
)	O
ACTH	O
stimulation	O
test	O
was	O
performed	O
to	O
the	O
same	O
patients	O
before	O
hyperthyroidism	O
treatment	O
,	O
and	O
after	O
attainment	O
of	O
euthyroidism	O
.	O

Baseline	O
cortisol	S-chem
(	O
Cor0	O
)	O
,	O
DHEA	S-chem
-	O
S	O
(	O
DHEA	S-chem
-	O
S0	O
)	O
,	O
cortisol	B-geneY
binding	I-geneY
globulin	E-geneY
(	O
CBG	S-geneY
)	O
,	O
ACTH	S-geneY
,	O
calculated	O
free	O
cortisol	S-chem
(	O
by	O
Coolen	O
's	O
equation	O
=	O
CFC	O
)	O
,	O
free	O
cortisol	O
index	O
(	O
FCI	O
)	O
,	O
60	O
-	O
min	O
cortisol	O
(	I-chem
Cor60	O
)	O
,	O
and	O
DHEA	O
-	I-chem
S	E-chem
(	O
DHEA	O
-	I-chem
S60	O
)	O
,	O
delta	O
cortisol	I-chem
(	I-chem
Δ	E-chem
Cor	O
)	I-chem
,	E-chem
delta	O
DHEA	I-chem
-	I-chem
S	E-chem
(	O
Δ	O
DHEA	O
-	I-chem
S	E-chem
)	O
responses	O
were	O
evaluated	O
.	O

Forty	O
-	O
one	O
patients	O
[	O
22	O
females	O
,	O
49.5	O
±	O
15.2	O
years	O
old	O
,	O
32	O
Graves	O
disease	O
,	O
nine	O
toxic	O
nodular	O
goiter	O
]	O
had	O
similar	O
Cor0	O
,	O
DHEA	O
-	I-chem
S0	E-chem
,	O
CFC	O
,	O
FCI	O
,	O
and	O
DHEA	O
-	I-chem
S60	O
in	O
hyperthyroid	O
and	O
euthyroid	O
states	O
.	O

Cor60	O
,	O
Δ	B-chem
Cor	E-chem
,	O
and	O
Δ	B-chem
DHEA	E-chem
-	O
S	O
were	O
lower	O
in	O
hyperthyroidism	O
.	O

In	O
four	O
(	O
10	O
%	O
)	O
patients	O
the	O
peak	O
ACTH	O
-	E-geneY
stimulated	O
cortisol	O
values	O
were	O
lower	O
than	O
18	O
μg	O
/	O
dL	O
.	O

When	O
the	O
test	O
repeated	O
after	O
attainment	O
of	O
euthyroidism	O
,	O
all	O
of	O
the	O
patients	O
had	O
normal	O
cortisol	S-chem
response	O
.	O

Regression	O
analysis	O
demonstrated	O
an	O
independent	O
association	O
of	O
Cor60	O
with	O
free	O
T3	O
in	O
hyperthyroidism	O
.	O

However	O
,	O
the	O
predictors	O
of	O
CFC	O
,	O
FCI	O
,	O
and	O
DHEA	S-chem
-	O
S	O
levels	O
were	O
serum	O
creatinine	S-chem
levels	O
in	O
hyperthyroidism	O
,	O
and	O
both	O
creatinine	S-chem
and	O
transaminase	S-geneN
levels	O
in	O
euthyroidism	O
.	O

ACTH	S-geneY
-	O
stimulated	O
peak	O
cortisol	S-chem
,	O
delta	B-chem
cortisol	E-chem
,	O
and	O
delta	B-chem
DHEA	E-chem
-	O
S	O
levels	O
are	O
decreased	O
during	O
hyperthyroidism	O
,	O
probably	O
due	O
to	O
increased	O
turnover	O
.	O

Since	O
about	O
10	O
%	O
of	O
the	O
subjects	O
with	O
hyperthyroidism	O
are	O
at	O
risk	O
for	O
adrenal	O
insufficiency	O
,	O
clinicians	O
dealing	O
with	O
Graves	O
'	O
disease	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
adrenal	O
insufficiency	O
during	O
hyperthyroid	O
stage	O
.	O

Aldosterone	S-chem
-	O
induced	O
ENaC	S-geneN
and	O
basal	O
Na	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
/	I-geneN
K	I-geneN
(	I-geneN
+	I-geneN
)	I-geneN
-	I-geneN
ATPase	E-geneN
trafficking	O
via	O
protein	B-geneY
kinase	I-geneY
D1	E-geneY
-	O
phosphatidylinositol	B-geneY
4	I-geneY
-	I-geneY
kinaseIIIβ	E-geneY
trans	O
Golgi	O
signalling	O
in	O
M1	O
cortical	O
collecting	O
duct	O
cells	O
.	O

Aldosterone	S-chem
regulates	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
transport	O
in	O
the	O
distal	O
nephron	O
through	O
multiple	O
mechanisms	O
that	O
include	O
the	O
transcriptional	O
control	O
of	O
epithelial	O
sodium	B-geneN
channel	E-geneN
(	O
ENaC	S-geneN
)	O
and	O
Na	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
/	I-geneN
K	I-geneN
(	I-geneN
+	I-geneN
)	I-geneN
-	I-geneN
ATPase	E-geneN
subunits	O
.	O

Aldosterone	S-chem
also	O
induces	O
the	O
rapid	O
phosphorylation	O
of	O
Protein	B-geneY
Kinase	I-geneY
D1	E-geneY
(	O
PKD1	S-geneY
)	O
.	O

PKD	S-geneY
isoforms	O
regulate	O
protein	O
trafficking	O
,	O
by	O
the	O
control	O
of	O
vesicle	O
fission	O
from	O
the	O
trans	O
Golgi	O
network	O
(	O
TGN	O
)	O
through	O
activation	O
of	O
phosphatidylinositol	B-geneY
4	I-geneY
-	I-geneY
kinaseIIIβ	E-geneY
(	O
PI4KIIIβ	S-geneY
)	O
.	O

We	O
report	O
rapid	O
ENaCγ	S-geneY
translocation	O
to	O
the	O
plasma	O
membrane	O
after	O
30min	O
aldosterone	O
treatment	O
in	O
polarized	O
M1	O
cortical	O
collecting	O
duct	O
cells	O
,	O
which	O
was	O
significantly	O
impaired	O
in	O
PKD1	S-geneY
shRNA	O
-	O
mediated	O
knockdown	O
cells	O
.	O

In	O
PKD1	S-geneY
-	O
deficient	O
cells	O
,	O
the	O
ouabain	S-chem
-	O
sensitive	O
current	O
was	O
significantly	O
reduced	O
and	O
Na	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
/	I-geneN
K	I-geneN
(	I-geneN
+	I-geneN
)	I-geneN
-	I-geneN
ATPase	I-geneN
α	I-geneN
and	I-geneN
β	E-geneN
subunits	O
showed	O
aberrant	O
localization	O
.	O

PKD1	S-geneY
and	O
PI4KIIIβ	S-geneY
localize	O
to	O
the	O
TGN	O
,	O
and	O
aldosterone	S-chem
induced	O
an	O
interaction	O
between	O
PKD1	S-geneY
and	O
PI4KIIIβ	S-geneY
following	O
aldosterone	S-chem
treatment	O
.	O

This	O
study	O
reveals	O
a	O
novel	O
mechanism	O
for	O
rapid	O
regulation	O
of	O
ENaC	S-geneN
and	O
the	O
Na	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
/	I-geneN
K	I-geneN
(	I-geneN
+	I-geneN
)	I-geneN
-	I-geneN
ATPase	E-geneN
,	O
via	O
directed	O
trafficking	O
through	O
PKD1	S-geneY
-	O
PI4KIIIβ	S-geneY
signalling	O
at	O
the	O
level	O
of	O
the	O
TGN	O
.	O

The	O
Interaction	O
of	O
Adrenomedullin	S-geneY
and	O
Macrophages	O
Induces	O
Ovarian	O
Cancer	O
Cell	O
Migration	O
via	O
Activation	O
of	O
RhoA	S-geneY
Signaling	O
Pathway	O
.	O

Tumor	O
-	O
associated	O
macrophages	O
(	O
TAMs	O
)	O
are	O
correlated	O
with	O
poor	O
prognosis	O
in	O
many	O
human	O
cancers	O
;	O
however	O
,	O
the	O
mechanism	O
by	O
which	O
TAMs	O
facilitate	O
ovarian	O
cancer	O
cell	O
migration	O
and	O
invasion	O
remains	O
unknown	O
.	O

This	O
study	O
was	O
aimed	O
to	O
examine	O
the	O
function	O
of	O
adrenomedullin	S-geneY
(	O
ADM	S-geneY
)	O
in	O
macrophage	O
polarization	O
and	O
their	O
further	O
effects	O
on	O
the	O
migration	O
of	O
ovarian	O
cancer	O
cells	O
.	O

Exogenous	O
ADM	S-geneY
antagonist	O
and	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
specific	O
for	O
ADM	S-geneY
expression	O
were	O
treated	O
to	O
macrophages	O
and	O
EOC	O
cell	O
line	O
HO8910	O
,	O
respectively	O
.	O

Then	O
macrophages	O
were	O
cocultured	O
with	O
HO8910	O
cells	O
without	O
direct	O
contact	O
.	O

Flow	O
cytometry	O
,	O
Western	O
blot	O
and	O
real	O
-	O
time	O
PCR	O
were	O
used	O
to	O
detect	O
macrophage	O
phenotype	O
and	O
cytokine	S-geneN
production	O
.	O

The	O
migration	O
ability	O
and	O
cytoskeleton	O
rearrangement	O
of	O
ovarian	O
cancer	O
cells	O
were	O
determined	O
by	O
Transwell	O
migration	O
assay	O
and	O
phalloidin	S-chem
staining	O
.	O

Western	O
blot	O
was	O
performed	O
to	O
evaluate	O
the	O
activity	O
status	O
of	O
signaling	O
molecules	O
in	O
the	O
process	O
of	O
ovarian	O
cancer	O
cell	O
migration	O
.	O

The	O
results	O
showed	O
that	O
ADM	S-geneY
induced	O
macrophage	O
phenotype	O
and	O
cytokine	S-geneN
production	O
similar	O
to	O
TAMs	O
.	O

Macrophages	O
polarized	O
by	O
ADM	S-geneY
promoted	O
the	O
migration	O
and	O
cytoskeleton	O
rearrangement	O
of	O
HO8910	O
cells	O
.	O

The	O
expression	O
of	O
RhoA	S-geneY
and	O
its	O
downstream	O
effector	O
,	O
cofilin	S-geneN
,	O
were	O
upregulated	O
in	O
macrophage	O
-	O
induced	O
migration	O
of	O
HO8910	O
cells	O
.	O

In	O
conclusion	O
,	O
ADM	S-geneY
could	O
polarize	O
macrophages	O
similar	O
to	O
TAMs	O
,	O
and	O
then	O
polarized	O
macrophages	O
promote	O
the	O
migration	O
of	O
ovarian	O
cancer	O
cells	O
via	O
activation	O
of	O
RhoA	S-geneY
signaling	O
pathway	O
in	O
vitro	O
.	O

Impaired	O
antibody	O
synthesis	O
after	O
spinal	O
cord	O
injury	O
is	O
level	O
dependent	O
and	O
is	O
due	O
to	O
sympathetic	O
nervous	O
system	O
dysregulation	O
.	O

Individuals	O
with	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
are	O
highly	O
susceptible	O
to	O
infection	O
.	O

This	O
post	O
-	O
traumatic	O
immune	O
suppression	O
is	O
thought	O
to	O
occur	O
via	O
alterations	O
in	O
sympathetic	O
nervous	O
system	O
(	O
SNS	O
)	O
or	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
function	O
.	O

Normally	O
,	O
the	O
HPA	O
axis	O
and	O
SNS	O
help	O
coordinate	O
proper	O
immune	O
function	O
.	O

After	O
SCI	O
,	O
the	O
HPA	O
axis	O
becomes	O
activated	O
and	O
descending	O
input	O
to	O
sympathetic	O
preganglionic	O
neurons	O
(	O
SPNs	O
)	O
is	O
impaired	O
.	O

Because	O
lymphoid	O
organs	O
are	O
innervated	O
by	O
SPNs	O
distributed	O
throughout	O
the	O
thoracolumbar	O
spinal	O
cord	O
,	O
we	O
predicted	O
level	O
-	O
dependent	O
immune	O
suppression	O
after	O
SCI	O
due	O
to	O
activation	O
of	O
the	O
HPA	O
axis	O
and	O
loss	O
of	O
descending	O
input	O
to	O
SPNs	O
.	O

We	O
tested	O
this	O
hypothesis	O
by	O
measuring	O
indices	O
of	O
HPA	O
(	O
circulating	O
corticosterone	S-chem
;	O
CORT	S-chem
)	O
and	O
SNS	O
function	O
(	O
norepinephrine	S-chem
(	O
NE	S-chem
)	O
in	O
spleen	O
)	O
as	O
well	O
as	O
antigen	O
-	O
specific	O
antibody	O
synthesis	O
against	O
an	O
exogenous	O
non	O
-	O
self	O
protein	O
following	O
high	O
-	O
or	O
low	O
-	O
level	O
SCI	O
.	O

Using	O
a	O
mid	O
-	O
thoracic	O
(	O
T9	O
)	O
spinal	O
contusion	O
injury	O
model	O
,	O
we	O
found	O
that	O
CORT	S-chem
was	O
elevated	O
after	O
SCI	O
with	O
aberrant	O
patterns	O
of	O
diurnal	O
CORT	S-chem
synthesis	O
evident	O
through	O
at	O
least	O
the	O
first	O
24	O
h	O
post	O
-	O
injury	O
.	O

However	O
,	O
splenic	O
NE	S-chem
and	O
antibody	O
synthesis	O
were	O
similar	O
to	O
uninjured	O
controls	O
.	O

Injury	O
severity	O
did	O
not	O
change	O
these	O
parameters	O
.	O

Indeed	O
,	O
CORT	S-chem
,	O
NE	S-chem
and	O
antibody	O
synthesis	O
were	O
similar	O
after	O
T9	O
contusion	O
or	O
transection	O
SCI	O
.	O

In	O
contrast	O
,	O
high	O
-	O
level	O
SCI	O
(	O
T3	O
)	O
caused	O
sustained	O
increases	O
in	O
CORT	S-chem
and	O
splenic	O
NE	S-chem
along	O
with	O
impaired	O
antibody	O
synthesis	O
and	O
elevated	O
splenocyte	O
apoptosis	O
.	O

The	O
immunosuppressive	O
effects	O
of	O
T3	O
SCI	O
were	O
caused	O
by	O
NE	S-chem
acting	O
at	O
beta2	B-geneY
-	I-geneY
adrenergic	I-geneY
receptors	E-geneY
(	O
beta2AR	S-geneY
)	O
and	O
could	O
be	O
reversed	O
using	O
beta2AR	S-geneY
blockers	O
.	O

Interestingly	O
,	O
impaired	O
antibody	O
after	O
T3	O
SCI	O
could	O
be	O
mimicked	O
after	O
T9	O
SCI	O
with	O
a	O
beta2AR	S-geneY
agonist	O
.	O

These	O
data	O
illustrate	O
the	O
immunosuppressive	O
effects	O
of	O
the	O
SNS	O
after	O
high	O
-	O
level	O
SCI	O
and	O
indicate	O
that	O
immune	O
deficits	O
may	O
be	O
overcome	O
using	O
beta	O
-	O
blockers	O
.	O

The	O
effect	O
of	O
manganese	S-chem
on	O
dopamine	S-chem
toxicity	O
and	O
dopamine	B-geneY
transporter	E-geneY
(	O
DAT	S-geneY
)	O
in	O
control	O
and	O
DAT	S-geneY
transfected	O
HEK	O
cells	O
.	O

Chronic	O
exposure	O
to	O
Mn	S-chem
results	O
in	O
the	O
development	O
of	O
a	O
neurological	O
disorder	O
known	O
as	O
manganism	O
characterized	O
by	O
neurological	O
deficits	O
resembling	O
that	O
seen	O
in	O
Parkinsonism	O
.	O

Although	O
dopaminergic	O
neurons	O
within	O
the	O
nigrostriatal	O
pathway	O
appear	O
intact	O
,	O
Mn	S-chem
-	O
induced	O
irregularities	O
in	O
DA	O
transmission	O
have	O
been	O
observed	O
including	O
decreased	O
amphetamine	S-chem
-	O
induced	O
DA	O
release	O
and	O
loss	O
of	O
the	O
dopamine	B-geneY
transporter	E-geneY
(	O
DAT	S-geneY
)	O
.	O

Results	O
of	O
studies	O
to	O
evaluate	O
the	O
effect	O
of	O
Mn	S-chem
and	O
DA	O
on	O
cell	O
viability	O
in	O
control	O
and	O
DAT	S-geneY
-	O
transfected	O
HEK	O
cells	O
reveal	O
that	O
Mn	S-chem
is	O
equally	O
toxic	O
to	O
both	O
cell	O
lines	O
whereas	O
DA	O
was	O
only	O
toxic	O
to	O
cells	O
containing	O
DAT	S-geneY
.	O

DA	O
toxicity	O
was	O
saturable	O
suggesting	O
that	O
transport	O
may	O
be	O
rate	O
limiting	O
.	O

When	O
Mn	S-chem
and	O
DA	O
were	O
added	O
simultaneously	O
to	O
the	O
media	O
,	O
cell	O
toxicity	O
was	O
similar	O
to	O
that	O
produced	O
by	O
Mn	S-chem
alone	O
suggesting	O
that	O
Mn	S-chem
may	O
suppress	O
DA	O
uptake	O
in	O
the	O
DAT	S-geneY
containing	O
cells	O
.	O

Preincubation	O
of	O
DA	O
prior	O
to	O
the	O
addition	O
of	O
Mn	S-chem
resulted	O
in	O
cell	O
death	O
which	O
was	O
essentially	O
additive	O
with	O
that	O
produced	O
independently	O
by	O
the	O
two	O
agents	O
.	O

Mn	S-chem
was	O
also	O
shown	O
to	O
decrease	O
DA	O
uptake	O
and	O
amphetamine	S-chem
-	O
induced	O
DA	O
efflux	O
in	O
DAT	S-geneY
containing	O
cells	O
.	O

Time	O
-	O
lapsed	O
confocal	O
microscopy	O
indicates	O
that	O
Mn	S-chem
can	O
promote	O
trafficking	O
of	O
cell	O
surface	O
DAT	S-geneY
into	O
intracellular	O
compartments	O
which	O
may	O
account	O
for	O
the	O
decrease	O
in	O
DA	O
uptake	O
and	O
DA	O
efflux	O
in	O
these	O
cells	O
.	O

Mn	S-chem
-	O
induced	O
internalization	O
of	O
DAT	S-geneY
may	O
provide	O
an	O
explanation	O
for	O
disruption	O
in	O
DA	O
transmission	O
previously	O
reported	O
in	O
the	O
striatum	O
.	O

Universal	O
rule	O
on	O
chirality	O
-	O
dependent	O
bandgaps	O
in	O
graphene	S-chem
antidot	O
lattices	O
.	O

Graphene	S-chem
with	O
periodically	O
patterned	O
antidots	O
has	O
attracted	O
intense	O
research	O
attention	O
as	O
it	O
represents	O
a	O
facile	O
route	O
to	O
open	O
a	O
bandgap	O
for	O
graphene	S-chem
electronics	O
.	O

However	O
,	O
not	O
all	O
graphene	S-chem
antidot	O
lattices	O
(	O
GALs	O
)	O
can	O
open	O
a	O
bandgap	O
and	O
a	O
guiding	O
rule	O
is	O
missing	O
.	O

Here	O
,	O
through	O
systematic	O
first	O
-	O
principles	O
calculations	O
,	O
it	O
is	O
found	O
that	O
bandgaps	O
in	O
triangular	O
GALs	O
are	O
surprisingly	O
well	O
defined	O
by	O
a	O
chirality	O
vector	O
R	O
=	O
n	O
a1	O
+	O
ma2	O
connecting	O
two	O
neighboring	O
antidots	O
,	O
where	O
a1	O
and	O
a2	O
are	O
the	O
basis	O
vectors	O
of	O
graphene	S-chem
.	O

The	O
bandgap	O
opens	O
in	O
the	O
GALs	O
with	O
(	O
n	O
-	O
m	O
)	O
mod3	O
=	O
0	O
but	O
remains	O
closed	O
in	O
those	O
with	O
(	O
n	O
-	O
m	O
)	O
mod3	O
=	O
±1	O
,	O
reminiscent	O
of	O
the	O
gap	O
-	O
chirality	O
rule	O
in	O
carbon	S-chem
nanotubes	O
.	O

Remarkably	O
,	O
the	O
gap	O
value	O
in	O
GALs	O
allows	O
ample	O
modulation	O
by	O
adjusting	O
the	O
length	O
of	O
chirality	O
vectors	O
,	O
shape	O
and	O
size	O
of	O
the	O
antidots	O
.	O

The	O
gap	O
-	O
chirality	O
relation	O
in	O
GALs	O
stems	O
from	O
the	O
chirality	O
-	O
dependent	O
atomic	O
structures	O
of	O
GALs	O
as	O
revealed	O
by	O
a	O
super	O
-	O
atom	O
model	O
as	O
well	O
as	O
Clar	O
sextet	O
analyses	O
.	O

This	O
chirality	O
-	O
dependent	O
bandgap	O
is	O
further	O
shown	O
to	O
be	O
a	O
generic	O
behavior	O
in	O
any	O
parallelogram	O
GAL	O
and	O
thus	O
serves	O
as	O
an	O
essential	O
stepping	O
stone	O
for	O
experimenters	O
to	O
realize	O
graphene	S-chem
devices	O
by	O
antidot	O
engineering	O
.	O

Profile	O
of	O
certolizumab	O
and	O
its	O
potential	O
in	O
the	O
treatment	O
of	O
psoriatic	O
arthritis	O
.	O

Psoriatic	O
arthritis	O
(	O
PsA	O
)	O
is	O
a	O
chronic	O
inflammatory	O
arthropathy	O
associated	O
with	O
psoriasis	O
(	O
PsO	O
)	O
.	O

PsA	O
could	O
be	O
considered	O
an	O
enthesal	O
disease	O
because	O
of	O
the	O
link	O
between	O
mechanical	O
stress	O
(	O
entheses	O
)	O
and	O
immunologically	O
active	O
tissue	O
(	O
synovium	O
)	O
.	O

Evidence	O
of	O
efficacy	O
of	O
anti	O
-	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
alpha	E-geneY
(	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
)	O
is	O
supported	O
by	O
reduction	O
of	O
histological	O
vascularity	O
and	O
immune	O
cell	O
infiltrates	O
in	O
synovial	O
tissue	O
after	O
treatment	O
.	O

Certolizumab	O
pegol	O
(	O
CZP	O
)	O
is	O
a	O
polyethylene	O
glycolylated	O
(	O
PEGylated	O
)	O
Fab	S-geneN
'	O
fragment	O
of	O
a	O
humanized	O
monoclonal	O
antibody	O
that	O
binds	O
and	O
neutralizes	O
human	B-geneY
TNF	I-geneY
-	I-geneY
alpha	E-geneY
.	O

The	O
PEG	S-chem
moiety	O
of	O
the	O
Fab	S-geneN
fragment	O
,	O
markedly	O
increases	O
the	O
half	O
-	O
life	O
of	O
CZP	O
and	O
confers	O
to	O
the	O
drug	O
a	O
unique	O
structure	O
that	O
differs	O
from	O
the	O
other	O
anti	O
-	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
agents	O
tested	O
for	O
the	O
treatment	O
of	O
Crohn	O
's	O
disease	O
,	O
rheumatoid	O
arthritis	O
,	O
ankylosing	O
spondylitis	O
,	O
axial	O
spondyloarthritis	O
,	O
nonradiographic	O
spondyloarthritis	O
,	O
PsO	O
,	O
and	O
PsA	O
.	O

In	O
contrast	O
to	O
other	O
anti	O
-	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
agents	O
,	O
CZP	O
did	O
not	O
mediate	O
increased	O
levels	O
of	O
apoptosis	O
,	O
suggesting	O
that	O
these	O
mechanisms	O
are	O
not	O
essential	O
for	O
the	O
anti	O
-	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
efficacy	O
in	O
Crohn	O
's	O
disease	O
.	O

As	O
CZP	O
,	O
infliximab	O
,	O
and	O
adalimumab	O
,	O
but	O
not	O
etanercept	O
,	O
almost	O
completely	O
inhibited	O
lipopolysaccharide	O
-	O
induced	O
interleukin	B-geneY
-	I-geneY
1	I-geneY
beta	E-geneY
release	O
from	O
monocytes	O
,	O
this	O
cytokine	S-geneN
-	O
production	O
inhibition	O
may	O
be	O
relevant	O
for	O
drug	O
efficacy	O
.	O

Due	O
to	O
these	O
characteristics	O
,	O
it	O
has	O
been	O
demonstrated	O
in	O
clinical	O
studies	O
that	O
CZP	O
effectively	O
improves	O
signs	O
and	O
symptoms	O
of	O
arthritis	O
and	O
physical	O
function	O
and	O
skin	O
manifestations	O
of	O
PsO	O
,	O
with	O
a	O
safety	O
profile	O
similar	O
to	O
rheumatoid	O
arthritis	O
.	O

This	O
drug	O
can	O
be	O
considered	O
as	O
a	O
valid	O
treatment	O
in	O
patients	O
affected	O
by	O
PsA	O
.	O

The	O
efficacy	O
and	O
tolerability	O
profiles	O
suggest	O
CZP	O
as	O
a	O
suitable	O
antipsoriatic	O
drug	O
in	O
the	O
treatment	O
of	O
PsA	O
.	O

Copper	S-chem
induced	O
upregulation	O
of	O
apoptosis	O
related	O
genes	O
in	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
gill	O
.	O

Copper	S-chem
(	O
Cu	S-chem
)	O
is	O
an	O
essential	O
micronutrient	O
that	O
,	O
when	O
present	O
in	O
high	O
concentrations	O
,	O
becomes	O
toxic	O
to	O
aquatic	O
organisms	O
.	O

It	O
is	O
known	O
that	O
Cu	S-chem
toxicity	O
may	O
induce	O
apoptotic	O
cell	O
death	O
.	O

However	O
,	O
the	O
precise	O
mechanism	O
and	O
the	O
pathways	O
that	O
are	O
activated	O
,	O
in	O
fish	O
,	O
are	O
still	O
unclear	O
.	O

Thus	O
,	O
this	O
study	O
aimed	O
to	O
assess	O
which	O
apoptotic	O
pathways	O
are	O
triggered	O
by	O
Cu	S-chem
,	O
in	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
gill	O
,	O
the	O
main	O
target	O
of	O
waterborne	O
pollutants	O
.	O

Fish	O
where	O
exposed	O
to	O
12.5	O
and	O
100	O
μg	O
/	O
L	O
of	O
Cu	S-chem
during	O
6	O
,	O
12	O
,	O
24	O
and	O
48	O
h	O
.	O

Fish	O
gills	O
were	O
collected	O
to	O
TUNEL	O
assay	O
and	O
mRNA	O
expression	O
analysis	O
of	O
selected	O
genes	O
by	O
real	O
time	O
PCR	O
.	O

An	O
approach	O
to	O
different	O
apoptosis	O
pathways	O
was	O
done	O
selecting	O
p53	S-geneY
,	O
caspase	B-geneY
-	I-geneY
8	E-geneY
,	O
caspase	B-geneY
-	I-geneY
9	E-geneY
and	O
apoptosis	B-geneY
inducing	I-geneY
factor	E-geneY
(	O
AIF	S-geneY
)	O
genes	O
.	O

The	O
higher	O
incidence	O
of	O
TUNEL	O
-	O
positive	O
cells	O
,	O
in	O
gill	O
epithelia	O
of	O
the	O
exposed	O
fish	O
,	O
proved	O
that	O
Cu	S-chem
induced	O
apoptosis	O
.	O

The	O
results	O
suggest	O
that	O
different	O
apoptosis	O
pathways	O
are	O
triggered	O
by	O
Cu	S-chem
at	O
different	O
time	O
points	O
of	O
the	O
exposure	O
period	O
,	O
as	O
the	O
increase	O
in	O
transcripts	O
was	O
sequential	O
,	O
instead	O
of	O
simultaneous	O
.	O

Apoptosis	O
seems	O
to	O
be	O
initiated	O
via	O
intrinsic	O
pathway	O
(	O
caspase	B-geneY
-	I-geneY
9	E-geneY
)	O
,	O
through	O
p53	S-geneY
activation	O
;	O
then	O
followed	O
by	O
the	O
extrinsic	O
pathway	O
(	O
caspase	B-geneY
-	I-geneY
8	E-geneY
)	O
and	O
finally	O
by	O
the	O
caspase	S-geneN
-	O
independent	O
pathway	O
(	O
AIF	S-geneY
)	O
.	O

A	O
possible	O
model	O
for	O
Cu	S-chem
-	O
induce	O
apoptosis	O
pathways	O
is	O
proposed	O
.	O

Rutin	S-chem
-	O
and	O
Selenium	S-chem
-	O
attenuated	O
cadmium	S-chem
-	O
induced	O
testicular	O
pathophysiology	O
in	O
rats	O
.	O

Cadmium	S-chem
(	O
Cd	S-chem
)	O
is	O
known	O
to	O
cause	O
oxidative	O
damage	O
in	O
the	O
testes	O
of	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
role	O
of	O
rutin	S-chem
(	O
RUT	S-chem
,	O
30	O
mg	O
/	O
kg	O
)	O
and	O
selenium	S-chem
(	O
Se	S-chem
,	O
0.15	O
ppm	O
)	O
alone	O
or	O
in	O
combination	O
against	O
Cd	S-chem
(	O
200	O
ppm	O
)	O
-	O
induced	O
lipid	O
peroxidation	O
,	O
steroidogenesis	O
and	O
changes	O
in	O
antioxidant	O
defence	O
system	O
in	O
the	O
rat	O
testes	O
.	O

The	O
obtained	O
results	O
showed	O
that	O
Cd	S-chem
increased	O
lipid	O
peroxidation	O
and	O
abnormal	O
sperm	O
count	O
and	O
decreased	O
plasma	O
testosterone	S-chem
,	O
lactate	B-geneN
dehydrogenase	E-geneN
,	O
acid	B-geneN
phosphatase	E-geneN
,	O
alkaline	B-geneN
phosphatase	E-geneN
and	O
testicular	B-geneN
steroidogenic	I-geneN
enzymes	E-geneN
:	O
3β	B-geneN
-	I-geneN
hydroxysteroid	I-geneN
dehydrogenase	E-geneN
(	O
HSD	S-geneN
)	O
,	O
17β	B-geneN
-	I-geneN
HSD	E-geneN
activities	O
as	O
well	O
as	O
epididymal	O
sperm	O
counts	O
and	O
motility	O
,	O
while	O
RUT	S-chem
and	O
Se	S-chem
treatment	O
reversed	O
this	O
change	O
to	O
control	O
values	O
.	O

Acute	O
intoxication	O
with	O
Cd	S-chem
was	O
also	O
followed	O
by	O
significantly	O
decreased	O
activity	O
of	O
the	O
antioxidant	O
defence	O
system	O
(	O
superoxide	B-geneN
dismutase	E-geneN
(	O
SOD	S-geneN
)	O
,	O
catalase	S-geneY
(	O
CAT	S-geneY
)	O
,	O
glutathione	B-geneN
peroxidase	E-geneN
(	O
GSH	B-geneN
-	I-geneN
Px	E-geneN
)	O
,	O
glutathione	B-geneY
reductase	E-geneY
(	O
GR	S-geneY
)	O
,	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
,	O
and	O
glutathione	B-geneN
-	I-geneN
S	I-geneN
-	I-geneN
transferase	E-geneN
(	O
GST	S-geneN
)	O
)	O
.	O

Treatment	O
with	O
RUT	S-chem
and	O
Se	S-chem
reversed	O
Cd	S-chem
-	O
induced	O
alterations	O
of	O
antioxidant	O
defence	O
system	O
and	O
significantly	O
prevented	O
Cd	S-chem
-	O
induced	O
testes	O
damage	O
and	O
depletion	O
of	O
plasma	O
and	O
testicular	O
Se	S-chem
levels	O
.	O

RUT	S-chem
and	O
Se	S-chem
appear	O
not	O
to	O
have	O
more	O
profound	O
effects	O
than	O
their	O
separate	O
effects	O
against	O
Cd	S-chem
-	O
induced	O
testicular	O
toxicity	O
,	O
although	O
Se	S-chem
was	O
more	O
potent	O
than	O
RUT	S-chem
in	O
the	O
recovery	O
of	O
testosterone	S-chem
levels	O
.	O

These	O
results	O
suggest	O
that	O
both	O
RUT	S-chem
and	O
Se	S-chem
do	O
not	O
have	O
synergistic	O
role	O
against	O
Cd	S-chem
-	O
induced	O
testicular	O
injury	O
.	O

Selective	O
inhibitors	O
and	O
tailored	O
activity	O
probes	O
for	O
lipoprotein	B-geneY
-	I-geneY
associated	I-geneY
phospholipase	I-geneY
A	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
.	O

Lipoprotein	B-geneY
-	I-geneY
associated	I-geneY
phospholipase	I-geneY
A	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
(	O
Lp	B-geneY
-	I-geneY
PLA	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
or	O
PLA	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
G7	I-geneY
)	E-geneY
binds	O
to	O
low	B-geneN
-	I-geneN
density	I-geneN
lipoprotein	E-geneN
(	O
LDL	S-geneN
)	O
particles	O
,	O
where	O
it	O
is	O
thought	O
to	O
hydrolyze	O
oxidatively	O
truncated	O
phospholipids	O
.	O

Lp	B-geneY
-	I-geneY
PLA	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
has	O
also	O
been	O
implicated	O
as	O
a	O
pro	O
-	O
tumorigenic	O
enzyme	O
in	O
human	O
prostate	O
cancer	O
.	O

Several	O
inhibitors	O
of	O
Lp	B-geneY
-	I-geneY
PLA	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
have	O
been	O
described	O
,	O
including	O
darapladib	S-chem
,	O
which	O
is	O
currently	O
in	O
phase	O
3	O
clinical	O
development	O
for	O
the	O
treatment	O
of	O
atherosclerosis	O
.	O

The	O
selectivity	O
that	O
darapladib	S-chem
and	O
other	O
Lp	B-geneY
-	I-geneY
PLA	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
inhibitors	O
display	O
across	O
the	O
larger	O
serine	B-geneN
hydrolase	E-geneN
family	O
has	O
not	O
,	O
however	O
,	O
been	O
reported	O
.	O

Here	O
,	O
we	O
describe	O
the	O
use	O
of	O
both	O
general	O
and	O
tailored	O
activity	O
-	O
based	O
probes	O
for	O
profiling	O
Lp	B-geneY
-	I-geneY
PLA	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
and	O
inhibitors	O
of	O
this	O
enzyme	O
in	O
native	O
biological	O
systems	O
.	O

We	O
show	O
that	O
both	O
darapladib	S-chem
and	O
a	O
novel	O
class	O
of	O
structurally	O
distinct	O
carbamate	S-chem
inhibitors	O
inactivate	O
Lp	B-geneY
-	I-geneY
PLA	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
in	O
mouse	O
tissues	O
and	O
human	O
cell	O
lines	O
with	O
high	O
selectivity	O
.	O

Our	O
findings	O
thus	O
identify	O
both	O
inhibitors	O
and	O
chemoproteomic	O
probes	O
that	O
are	O
suitable	O
for	O
investigating	O
Lp	B-geneY
-	I-geneY
PLA	I-geneY
(	I-geneY
2	I-geneY
)	E-geneY
function	O
in	O
biological	O
systems	O
.	O

Selective	O
Bisubstrate	O
Inhibitors	O
with	O
Sub	O
-	O
nanomolar	O
Affinity	O
for	O
Protein	B-geneN
Kinase	E-geneN
Pim	B-geneY
-	I-geneY
1	E-geneY
.	O

Potent	O
and	O
selective	O
:	O
The	O
unique	O
nature	O
of	O
the	O
ATP	S-chem
binding	O
pocket	O
structure	O
of	O
Pim	S-geneN
family	O
protein	B-geneN
kinases	E-geneN
(	O
PKs	S-geneN
)	O
was	O
used	O
for	O
the	O
development	O
of	O
bisubstrate	O
inhibitors	O
and	O
a	O
fluorescent	O
probe	O
with	O
sub	O
-	O
nanomolar	O
affinity	O
.	O

Conjugates	O
of	O
arginine	S-chem
-	O
rich	O
peptides	O
with	O
two	O
ATP	S-chem
mimetic	O
scaffolds	O
were	O
synthesized	O
and	O
tested	O
as	O
inhibitors	O
of	O
Pim	B-geneY
-	I-geneY
1	E-geneY
.	O

Against	O
a	O
panel	O
of	O
124	O
protein	B-geneN
kinases	E-geneN
,	O
a	O
novel	O
ARC	O
-	O
PIM	S-geneN
conjugate	O
selectively	O
inhibited	O
PKs	S-geneN
of	O
the	O
Pim	S-geneN
family	O
.	O

Identification	O
of	O
a	O
SIRT1	S-geneY
mutation	O
in	O
a	O
family	O
with	O
type	O
1	O
diabetes	O
.	O

Type	O
1	O
diabetes	O
is	O
caused	O
by	O
autoimmune	O
-	O
mediated	O
β	O
cell	O
destruction	O
leading	O
to	O
insulin	S-geneY
deficiency	O
.	O

The	O
histone	B-geneN
deacetylase	E-geneN
SIRT1	S-geneY
plays	O
an	O
essential	O
role	O
in	O
modulating	O
several	O
age	O
-	O
related	O
diseases	O
.	O

Here	O
we	O
describe	O
a	O
family	O
carrying	O
a	O
mutation	O
in	O
the	O
SIRT1	S-geneY
gene	O
,	O
in	O
which	O
all	O
five	O
affected	O
members	O
developed	O
an	O
autoimmune	O
disorder	O
:	O
four	O
developed	O
type	O
1	O
diabetes	O
,	O
and	O
one	O
developed	O
ulcerative	O
colitis	O
.	O

Initially	O
,	O
a	O
26	O
-	O
year	O
-	O
old	O
man	O
was	O
diagnosed	O
with	O
the	O
typical	O
features	O
of	O
type	O
1	O
diabetes	O
,	O
including	O
lean	O
body	O
mass	O
,	O
autoantibodies	O
,	O
T	O
cell	O
reactivity	O
to	O
β	O
cell	O
antigens	O
,	O
and	O
a	O
rapid	O
dependence	O
on	O
insulin	S-geneY
.	O

Direct	O
and	O
exome	O
sequencing	O
identified	O
the	O
presence	O
of	O
a	O
T	O
-	O
to	O
-	O
C	O
exchange	O
in	O
exon	O
1	O
of	O
SIRT1	S-geneY
,	O
corresponding	O
to	O
a	O
leucine	B-geneN
-	I-geneN
to	I-geneN
-	I-geneN
proline	I-geneN
mutation	I-geneN
at	I-geneN
residue	I-geneN
107	E-geneN
.	O

Expression	O
of	O
SIRT1	S-geneY
-	O
L107P	S-geneN
in	O
insulin	S-geneY
-	O
producing	O
cells	O
resulted	O
in	O
overproduction	O
of	O
nitric	B-chem
oxide	E-chem
,	O
cytokines	S-geneN
,	O
and	O
chemokines	S-geneN
.	O

These	O
observations	O
identify	O
a	O
role	O
for	O
SIRT1	S-geneY
in	O
human	O
autoimmunity	O
and	O
unveil	O
a	O
monogenic	O
form	O
of	O
type	O
1	O
diabetes	O
.	O

Extracts	O
of	O
Scutellaria	O
baicalensis	O
reduced	O
body	O
weight	O
and	O
blood	O
triglyceride	S-chem
in	O
db	O
/	O
db	O
Mice	O
.	O

Scutellaria	O
baicalensis	O
has	O
been	O
extensively	O
employed	O
for	O
the	O
clinical	O
treatment	O
of	O
hyperlipidemia	O
,	O
atherosclerosis	O
,	O
hypertension	O
,	O
dysentery	O
,	O
inflammatory	O
diseases	O
,	O
and	O
the	O
common	O
cold	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
anti	O
-	O
obesity	O
and	O
anti	O
-	O
dyslipidemia	O
effect	O
of	O
Scutellaria	O
baicalensis	O
extracts	O
(	O
SBE	O
)	O
in	O
type	O
2	O
diabetic	O
db	O
/	O
db	O
mice	O
.	O

Male	O
db	O
/	O
db	O
mice	O
were	O
divided	O
into	O
three	O
groups	O
(	O
n	O
=	O
5	O
)	O
and	O
orally	O
administrated	O
vehicle	O
(	O
control	O
)	O
,	O
SBE	O
10	O
,	O
and	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
day	O
for	O
4	O
weeks	O
everyday	O
.	O

Administration	O
of	O
SBE	O
improves	O
weight	O
gain	O
,	O
hypertriglyceridemia	O
,	O
and	O
hyperinsulinemia	O
in	O
db	O
/	O
db	O
mice	O
.	O

In	O
obese	O
db	O
/	O
db	O
mice	O
,	O
SBE	O
treatment	O
also	O
reduced	O
plasma	O
alanine	B-geneN
aminotransferase	E-geneN
levels	O
.	O

In	O
the	O
livers	O
of	O
db	O
/	O
db	O
mice	O
,	O
SBE	O
promoted	O
5	B-geneN
'	I-geneN
AMP	I-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
activity	O
and	O
restored	O
metabolic	O
process	O
and	O
insulin	S-geneN
signaling	O
pathways	O
.	O

Our	O
data	O
demonstrate	O
that	O
SBE	O
exerts	O
potent	O
anti	O
-	O
obesity	O
and	O
anti	O
-	O
hypertriglyceride	O
effects	O
suggesting	O
its	O
useful	O
potential	O
function	O
as	O
adjuvant	O
therapeutic	O
agent	O
for	O
the	O
treatment	O
of	O
weight	O
gain	O
and	O
hypertriglyceridemia	O
.	O

Association	O
of	O
ATP	B-geneN
-	I-geneN
binding	I-geneN
cassette	I-geneN
transporter	E-geneN
variants	O
with	O
the	O
risk	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Aim	O
:	O
A	O
number	O
of	O
studies	O
have	O
demonstrated	O
that	O
ABCB1	S-geneY
and	O
BCRP	S-geneY
(	O
ABCG2	S-geneY
)	O
actively	O
transport	O
Aβ	S-geneY
.	O

We	O
aimed	O
to	O
investigate	O
the	O
association	O
of	O
genetic	O
variants	O
of	O
selected	O
multidrug	B-geneN
transporters	E-geneN
with	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
in	O
histopathologically	O
confirmed	O
AD	O
cases	O
and	O
controls	O
.	O

Materials	O
&	O
methods	O
:	O
DNA	O
from	O
brain	O
tissue	O
of	O
71	O
AD	O
cases	O
with	O
Consortium	O
to	O
Establish	O
a	O
Registry	O
for	O
Alzheimer	O
's	O
Disease	O
(	O
CERAD	O
)	O
neuropathological	O
stages	O
B	O
/	O
C	O
and	O
81	O
controls	O
was	O
genotyped	O
for	O
selected	O
variants	O
in	O
ABCA1	S-geneY
,	O
ABCA7	S-geneY
,	O
ABCB1	S-geneY
,	O
ABCC2	S-geneY
and	O
ABCG2	S-geneY
.	O

In	O
addition	O
,	O
the	O
APOE4	S-geneY
status	O
was	O
analyzed	O
.	O

Results	O
:	O
The	O
novel	O
ABCA7	S-geneY
SNP	O
,	O
rs3752246	O
,	O
tended	O
to	O
be	O
associated	O
with	O
AD	O
in	O
our	O
study	O
.	O

Variants	O
in	O
ABCB1	S-geneY
were	O
significantly	O
less	O
frequent	O
in	O
AD	O
cases	O
older	O
than	O
65	O
years	O
of	O
age	O
and	O
among	O
females	O
.	O

This	O
association	O
of	O
ABCB1	S-geneY
2677G	B-geneN
>	I-geneN
T	E-geneN
(	O
rs2032582	O
)	O
was	O
more	O
pronounced	O
in	O
APOE4	S-geneY
-	O
negative	O
cases	O
(	O
p	O
=	O
0.005	O
)	O
.	O

However	O
,	O
only	O
ABCC2	S-geneY
3972C	B-geneN
>	I-geneN
T	E-geneN
(	O
rs3740066	O
)	O
was	O
significantly	O
associated	O
with	O
AD	O
risk	O
after	O
logistic	O
regression	O
analysis	O
including	O
all	O
variants	O
.	O

Other	O
transporters	O
showed	O
a	O
lack	O
of	O
association	O
.	O

Conclusion	O
:	O
Our	O
results	O
support	O
the	O
hypothesis	O
that	O
ABCB1	S-geneY
and	O
possibly	O
other	O
ABC	B-geneN
-	I-geneN
transporters	E-geneN
are	O
involved	O
in	O
the	O
process	O
of	O
Aβ	S-geneY
accumulation	O
in	O
the	O
aging	O
brain	O
and	O
may	O
modulate	O
the	O
risk	O
for	O
AD	O
in	O
an	O
allele	O
-	O
specific	O
manner	O
,	O
and	O
thus	O
might	O
represent	O
a	O
new	O
target	O
for	O
prevention	O
and	O
treatment	O
of	O
AD	O
.	O

Original	O
submitted	O
8	O
October	O
2012	O
;	O
Revision	O
submitted	O
22	O
January	O
2013	O
.	O

Efficient	O
MRI	O
labeling	O
of	O
endothelial	O
progenitor	O
cells	O
:	O
Design	O
of	O
thiolated	O
surface	O
stabilized	O
superparamagnetic	O
iron	B-chem
oxide	E-chem
nanoparticles	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
design	O
thiolated	O
surface	O
stabilized	O
superparamagnetic	O
iron	B-chem
oxide	E-chem
nanoparticles	O
(	O
TSS	O
-	O
SPIONs	O
)	O
for	O
efficient	O
internalization	O
with	O
high	O
MRI	O
sensitivity	O
.	O

TSS	O
-	O
SPIONs	O
were	O
developed	O
by	O
chelation	O
between	O
thiolated	O
chitosan	O
-	O
thioglycolic	B-chem
acid	E-chem
(	O
chitosan	O
-	O
TGA	S-chem
)	O
hydrogel	O
and	O
iron	S-chem
ions	O
(	O
Fe	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
/	O
Fe	B-chem
(	I-chem
3	I-chem
+	I-chem
)	E-chem
)	O
.	O

Likely	O
,	O
unmodified	O
chitosan	O
hydrogel	O
SPIONs	O
(	O
UC	O
-	O
SPIONs	O
)	O
and	O
uncoated	O
SPIONs	O
were	O
used	O
as	O
control	O
.	O

Moreover	O
,	O
TSS	O
-	O
SPIONs	O
were	O
investigated	O
regarding	O
to	O
their	O
iron	S-chem
core	O
size	O
,	O
hydrodynamic	O
diameter	O
,	O
zeta	O
potential	O
,	O
iron	S-chem
contents	O
,	O
molar	O
relaxivities	O
(	O
r1	O
and	O
r2	O
)	O
,	O
and	O
cellular	O
internalization	O
.	O

TSS	O
-	O
SPIONs	O
demonstrated	O
an	O
iron	B-chem
oxide	E-chem
core	O
diameter	O
(	O
crystallite	O
size	O
by	O
XRD	O
)	O
of	O
3.1±0.02nm	O
,	O
a	O
hydrodynamic	O
diameter	O
of	O
94±20nm	O
,	O
a	O
zeta	O
potential	O
of	O
+	O
21±5mV	O
,	O
and	O
an	O
iron	S-chem
content	O
of	O
3.6±0.9mg	O
/	O
mL	O
.	O

In	O
addition	O
,	O
internalization	O
of	O
TSS	O
-	O
SPIONs	O
into	O
human	O
endothelial	O
progenitor	O
cells	O
(	O
EPC	O
)	O
from	O
umbilical	O
cord	O
blood	O
was	O
more	O
than	O
threefold	O
and	O
17	O
-	O
fold	O
higher	O
in	O
contrast	O
to	O
UC	O
-	O
SPIONs	O
and	O
SPIONs	O
,	O
respectively	O
.	O

With	O
twofold	O
lower	O
incubation	O
iron	S-chem
concentration	O
of	O
TSS	O
-	O
SPIONs	O
,	O
more	O
than	O
threefold	O
higher	O
internalization	O
was	O
achieved	O
as	O
compared	O
to	O
Resovist	O
®	O
.	O

Also	O
,	O
cell	O
viability	O
of	O
more	O
than	O
90	O
%	O
was	O
observed	O
in	O
the	O
presence	O
of	O
TSS	O
-	O
SPIONs	O
after	O
24h	O
.	O

The	O
molar	O
MR	O
relaxivities	O
(	O
r2	O
)	O
value	O
at	O
1.5T	O
was	O
threefold	O
higher	O
than	O
that	O
of	O
Resovist	O
®	O
and	O
demonstrated	O
that	O
TSS	O
-	O
SPIONs	O
have	O
the	O
potential	O
as	O
very	O
effective	O
T2	O
contrast	O
-	O
enhancement	O
agent	O
.	O

According	O
to	O
these	O
findings	O
,	O
TSS	O
-	O
SPIONs	O
with	O
efficient	O
internalization	O
,	O
lower	O
cytotoxicity	O
,	O
and	O
high	O
MRI	O
sensitivity	O
seem	O
to	O
be	O
promising	O
for	O
cell	O
tracking	O
.	O

SB365	S-chem
,	O
Pulsatilla	B-chem
saponin	I-chem
D	E-chem
suppresses	O
the	O
proliferation	O
of	O
human	O
colon	O
cancer	O
cells	O
and	O
induces	O
apoptosis	O
by	O
modulating	O
the	O
AKT	S-geneN
/	O
mTOR	S-geneY
signalling	O
pathway	O
.	O

Pulsatilla	O
koreana	O
has	O
been	O
used	O
as	O
a	O
traditional	O
medicine	O
for	O
the	O
treatment	O
of	O
several	O
diseases	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
SB365	S-chem
,	O
Pulsatilla	B-chem
saponin	I-chem
D	E-chem
isolated	O
from	O
the	O
root	O
of	O
P.	O
koreana	O
inhibits	O
the	O
progression	O
of	O
colon	O
cancer	O
.	O

We	O
found	O
that	O
SB365	S-chem
strongly	O
suppressed	O
the	O
growth	O
and	O
proliferation	O
of	O
colon	O
cancer	O
cells	O
and	O
induced	O
their	O
apoptosis	O
.	O

Also	O
,	O
SB365	S-chem
showed	O
anti	O
-	O
angiogenic	O
activity	O
by	O
decreasing	O
the	O
expression	O
of	O
HIF	B-geneY
-	I-geneY
1α	E-geneY
and	O
VEGF	S-geneY
.	O

These	O
results	O
were	O
confirmed	O
by	O
an	O
in	O
vivo	O
study	O
showing	O
that	O
SB365	S-chem
significantly	O
inhibited	O
tumor	O
growth	O
by	O
the	O
induction	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
angiogenesis	O
with	O
stronger	O
anticancer	O
activity	O
than	O
5	B-chem
-	I-chem
FU	E-chem
.	O

When	O
further	O
examined	O
for	O
its	O
anticancer	O
mechanism	O
,	O
SB365	S-chem
effectively	O
suppressed	O
the	O
AKT	S-geneN
/	O
mTOR	S-geneY
pathway	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Taken	O
together	O
,	O
our	O
study	O
demonstrated	O
that	O
SB365	S-chem
inhibits	O
the	O
AKT	S-geneN
/	O
mTOR	S-geneY
pathway	O
,	O
leading	O
to	O
the	O
suppression	O
of	O
tumor	O
growth	O
and	O
angiogenesis	O
together	O
with	O
induction	O
of	O
apoptosis	O
.	O

Therefore	O
,	O
SB365	S-chem
is	O
a	O
good	O
candidate	O
as	O
a	O
natural	O
product	O
for	O
use	O
in	O
the	O
treatment	O
of	O
colon	O
cancer	O
.	O

[	O
Effect	O
of	O
mifepristone	S-chem
on	O
the	O
expression	O
of	O
progesterone	B-geneY
receptor	E-geneY
messenger	O
RNA	O
and	O
protein	O
in	O
uterine	O
leiomyomata	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
expression	O
of	O
progesterone	B-geneY
receptor	E-geneY
(	O
PR	S-geneY
)	O
mRNA	O
and	O
PR	B-geneY
protein	E-geneY
levels	O
in	O
the	O
myometrium	O
and	O
leiomyomata	O
from	O
untreated	O
and	O
mifepristone	S-chem
pretreated	O
women	O
with	O
leiomyoma	O
and	O
to	O
examine	O
the	O
mechanism	O
of	O
mifepristone	S-chem
treatment	O
on	O
uterine	O
leiomyomata	O
.	O

METHODS	O
:	O
Expression	O
of	O
PR	B-geneN
mRNA	E-geneN
and	O
PR	B-geneY
protein	E-geneY
were	O
determined	O
by	O
Northern	O
blot	O
and	O
HAP	O
of	O
single	O
-	O
dose	O
saturated	O
analysis	O
in	O
myometrium	O
and	O
leiomyomata	O
(	O
center	O
and	O
marginal	O
area	O
)	O
from	O
27	O
untreated	O
and	O
6	O
mifepristone	S-chem
pretreated	O
women	O
with	O
leiomyomata	O
.	O

RESULTS	O
:	O
PR	B-geneN
mRNA	E-geneN
abundance	O
and	O
PR	B-geneY
protein	E-geneY
levels	O
in	O
both	O
myomatous	O
center	O
and	O
marginal	O
area	O
were	O
significantly	O
greater	O
than	O
those	O
in	O
corporal	O
myometrium	O
(	O
P	O
<	O
0.01	O
)	O
in	O
both	O
follicular	O
and	O
luteal	O
phases	O
,	O
but	O
similar	O
between	O
myomatous	O
center	O
and	O
marginal	O
area	O
(	O
P	O
>	O
0.05	O
)	O
.	O

6	O
cases	O
pretreated	O
with	O
mifepristone	S-chem
25	O
mg	O
/	O
day	O
for	O
3	O
months	O
were	O
operated	O
,	O
all	O
but	O
one	O
patient	O
displayed	O
a	O
decrease	O
in	O
leiomyomata	O
volume	O
.	O

PR	B-geneN
mRNA	E-geneN
abundance	O
in	O
both	O
myometruim	O
and	O
leiomyomata	O
(	O
center	O
and	O
marginal	O
area	O
)	O
was	O
significantly	O
decreased	O
in	O
4	O
patients	O
continuing	O
mifepristone	S-chem
treatment	O
before	O
the	O
operation	O
but	O
not	O
in	O
the	O
other	O
2	O
patients	O
stopping	O
RU486	S-chem
1	O
month	O
before	O
operation	O
.	O

PR	B-geneY
protein	E-geneY
levels	O
in	O
these	O
tissues	O
showed	O
significant	O
decrease	O
in	O
all	O
6	O
cases	O
.	O

CONCLUSION	O
:	O
There	O
are	O
overexpression	O
of	O
PRmRNA	S-geneN
and	O
PR	B-geneY
protein	E-geneY
in	O
leiomyomata	O
.	O

One	O
of	O
the	O
mechanism	O
of	O
mifepristone	S-chem
action	O
on	O
decreasing	O
leiomyomata	O
volume	O
may	O
be	O
related	O
to	O
suppression	O
on	O
expression	O
of	O
PR	B-geneY
gene	E-geneY
.	O

It	O
seems	O
that	O
suppression	O
on	O
transcription	O
of	O
PR	B-geneY
gene	E-geneY
is	O
reversible	O
,	O
but	O
on	O
translation	O
of	O
PR	B-geneY
gene	E-geneY
may	O
maintain	O
in	O
a	O
relatively	O
longer	O
period	O
.	O

Assessment	O
of	O
effects	O
of	O
IR	O
and	O
IPC	O
on	O
activities	O
of	O
cytochrome	B-geneN
P450	E-geneN
isozymes	O
in	O
rats	O
by	O
a	O
five	O
-	O
drug	O
cocktail	O
approach	O
.	O

Abstract	O
Background	O
and	O
objective	O
:	O
To	O
evaluate	O
the	O
effects	O
of	O
ischemia	O
and	O
reperfusion	O
(	O
IR	O
)	O
and	O
ischemic	O
preconditioning	O
(	O
IPC	O
)	O
on	O
the	O
metabolic	O
activities	O
of	O
cytochrome	B-geneN
P450	E-geneN
(	O
CYP	S-geneN
)	O
isozymes	O
in	O
rats	O
by	O
a	O
five	O
-	O
drug	O
cocktail	O
approach	O
.	O

Methods	O
:	O
Cocktail	O
approach	O
was	O
used	O
to	O
evaluate	O
the	O
influence	O
of	O
IR	O
and	O
IPC	O
on	O
the	O
activities	O
of	O
CYP1A2	S-geneY
,	O
CYP2C9	S-geneY
,	O
CYP2E1	S-geneY
,	O
CYP2D6	S-geneY
and	O
CYP3A4	S-geneY
,	O
which	O
were	O
reflected	O
by	O
the	O
changes	O
of	O
pharmacokinetic	O
parameters	O
of	O
five	O
specific	O
probe	O
drugs	O
:	O
caffeine	S-chem
,	O
chlorzoxazone	S-chem
,	O
tolbutamide	S-chem
,	O
metoprolol	S-chem
and	O
midazolam	S-chem
,	O
respectively	O
.	O

Rats	O
were	O
randomly	O
divided	O
into	O
IR	O
,	O
IPC	O
and	O
sham	O
groups	O
,	O
and	O
then	O
injected	O
the	O
mixture	O
of	O
five	O
probe	O
drugs	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
a	O
series	O
of	O
time	O
-	O
points	O
and	O
the	O
concentrations	O
of	O
probe	O
drugs	O
in	O
plasma	O
were	O
determined	O
by	O
a	O
HPLC	O
method	O
with	O
UV	O
detection	O
.	O

The	O
pharmacokinetic	O
parameters	O
were	O
calculated	O
by	O
the	O
software	O
of	O
DAS	O
2.0	O
.	O

Results	O
:	O
The	O
parameters	O
including	O
t	O
(	O
1	O
/	O
2β	O
)	O
,	O
CLs	O
,	O
AUC	O
,	O
MRT	O
and	O
K	O
(	O
10	O
)	O
exhibited	O
a	O
similar	O
tendency	O
for	O
both	O
IR	O
and	O
IPC	O
groups	O
.	O

Compared	O
with	O
sham	O
group	O
,	O
CLs	O
and	O
K	O
(	O
10	O
)	O
of	O
five	O
probe	O
drugs	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0.05	O
)	O
,	O
AUC	O
and	O
t	O
(	O
1	O
/	O
2β	O
)	O
of	O
five	O
or	O
some	O
probe	O
drugs	O
were	O
significantly	O
increased	O
in	O
IR	O
and	O
IPC	O
groups	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Compared	O
with	O
IPC	O
group	O
,	O
CLs	O
of	O
five	O
probe	O
drugs	O
were	O
decreased	O
and	O
AUC	O
were	O
significantly	O
increased	O
in	O
the	O
IR	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Conclusion	O
:	O
IR	O
can	O
variably	O
decrease	O
the	O
activities	O
of	O
CYP	B-geneN
isozymes	E-geneN
in	O
rats	O
and	O
this	O
decrease	O
can	O
be	O
attenuated	O
by	O
IPC	O
.	O

New	O
progestagens	S-chem
for	O
contraceptive	O
use	O
.	O

The	O
progestins	S-chem
have	O
different	O
pharmacologic	O
properties	O
depending	O
upon	O
the	O
parent	O
molecule	O
,	O
usually	O
testosterone	S-chem
or	O
progesterone	S-chem
(	O
P	O
)	O
,	O
from	O
which	O
they	O
are	O
derived	O
.	O

Very	O
small	O
structural	O
changes	O
in	O
the	O
parent	O
molecule	O
may	O
induce	O
considerable	O
differences	O
in	O
the	O
activity	O
of	O
the	O
derivative	O
.	O

In	O
hormonal	O
contraceptives	O
,	O
progestins	O
represent	O
the	O
major	O
agent	O
designed	O
for	O
suppressing	O
ovulation	O
and	O
are	O
used	O
in	O
combination	O
with	O
estrogen	S-chem
(	O
E	O
)	O
usually	O
ethinyl	B-chem
-	I-chem
estradiol	E-chem
(	O
EE	S-chem
)	O
.	O

The	O
development	O
of	O
new	O
generations	O
of	O
progestins	S-chem
with	O
improved	O
selectivity	O
profiles	O
has	O
been	O
a	O
great	O
challenge	O
.	O

Steroidal	S-chem
and	O
nonsteroidal	O
progesterone	B-geneY
receptor	E-geneY
(	O
PR	S-geneY
)	O
agonists	O
have	O
been	O
synthesized	O
as	O
well	O
,	O
although	O
the	O
latter	O
are	O
still	O
in	O
a	O
very	O
early	O
stage	O
of	O
development	O
.	O

Several	O
new	O
progestins	S-chem
,	O
have	O
been	O
synthesized	O
in	O
the	O
last	O
two	O
decades	O
.	O

These	O
include	O
dienogest	S-chem
(	O
DNG	S-chem
)	O
,	O
drospirenone	S-chem
(	O
DRSP	S-chem
)	O
,	O
Nestorone	S-chem
(	O
NES	S-chem
)	O
,	O
nomegestrol	B-chem
acetate	E-chem
(	O
NOMAc	S-chem
)	O
and	O
trimegestone	S-chem
(	O
TMG	S-chem
)	O
.	O

These	O
new	O
progestins	S-chem
have	O
been	O
designed	O
to	O
have	O
no	O
androgenic	O
or	O
estrogenic	O
actions	O
and	O
to	O
be	O
closer	O
in	O
activity	O
to	O
the	O
physiological	O
hormone	O
P	O
.	O

DRSP	S-chem
differs	O
from	O
the	O
classic	O
progestins	S-chem
as	O
it	O
is	O
derived	O
from	O
spirolactone	S-chem
.	O

It	O
is	O
essentially	O
an	O
antimineralocorticoid	O
steroid	S-chem
with	O
no	O
androgenic	O
effect	O
but	O
a	O
partial	O
antiandrogenic	O
effect	O
.	O

The	O
antiovulatory	O
potency	O
of	O
the	O
different	O
progestins	S-chem
varies	O
.	O

TMG	S-chem
and	O
NES	S-chem
are	O
the	O
most	O
potent	O
progestins	S-chem
synthesized	O
to	O
date	O
,	O
followed	O
by	O
two	O
of	O
the	O
older	O
progestins	S-chem
,	O
keto	B-chem
-	I-chem
desogestrel	E-chem
(	O
keto	B-chem
-	I-chem
DSG	E-chem
)	O
and	O
levonorgestrel	S-chem
(	O
LNG	S-chem
)	O
.	O

The	O
new	O
molecules	O
TMG	S-chem
,	O
DRSP	S-chem
and	O
DNG	S-chem
also	O
have	O
antiandrogenic	O
activity	O
.	O

Striking	O
differences	O
exist	O
regarding	O
the	O
side	O
effects	O
among	O
the	O
progestins	S-chem
and	O
the	O
combination	O
with	O
EE	S-chem
leads	O
to	O
other	O
reactions	O
related	O
to	O
the	O
E	O
itself	O
and	O
whether	O
the	O
associated	O
progestin	S-chem
counterbalances	O
,	O
more	O
or	O
less	O
,	O
the	O
estrogenic	O
action	O
.	O

The	O
19	B-chem
-	I-chem
norprogesterone	E-chem
molecules	O
and	O
the	O
new	O
molecules	O
DRSP	S-chem
and	O
DNG	S-chem
are	O
not	O
androgenic	O
and	O
,	O
therefore	O
,	O
have	O
no	O
negative	O
effect	O
on	O
the	O
lipid	O
profile	O
.	O

Given	O
their	O
pharmacological	O
properties	O
,	O
it	O
is	O
likely	O
that	O
the	O
new	O
progestins	S-chem
may	O
have	O
neutral	O
effects	O
on	O
metabolic	O
or	O
vascular	O
risks	O
.	O

However	O
,	O
this	O
hypothesis	O
must	O
be	O
confirmed	O
in	O
large	O
clinical	O
trials	O
.	O

HOW	O
GOOD	O
IS	O
THE	O
LEVOTHYROXINE	S-chem
REPLACEMENT	O
IN	O
PRIMARY	O
HYPOTHYROIDISM	O
PATIENTS	O
IN	O
BRAZIL	O
?	O
-	O
DATA	O
OF	O
A	O
MULTICENTRE	O
STUDY	O
.	O

Background	O
:	O
Studies	O
done	O
in	O
every	O
continent	O
has	O
shown	O
that	O
only	O
around	O
50	O
%	O
of	O
the	O
patients	O
subjected	O
to	O
thyroid	O
hormone	O
replacement	O
have	O
TSH	S-geneN
in	O
the	O
normal	O
range	O
.	O

However	O
,	O
until	O
to	O
date	O
,	O
there	O
are	O
no	O
consistent	O
data	O
about	O
Brazil	O
.	O

Objectives	O
:	O
To	O
evaluate	O
levothyroxine	S-chem
(	O
LT4	S-chem
)	O
replacement	O
treatment	O
in	O
patients	O
with	O
primary	O
hypothyroidism	O
followed	O
in	O
referral	O
centers	O
in	O
Brazil	O
.	O

Methods	O
:	O
Patients	O
with	O
primary	O
hypothyroidism	O
followed	O
in	O
referral	O
centers	O
(	O
University	O
Hospitals	O
from	O
Universidade	O
Federal	O
do	O
Rio	O
de	O
Janeiro	O
-	O
UFRJ	O
,	O
Unicamp	O
,	O
Universidade	O
Federal	O
do	O
Paraná	O
-	O
UFPR	O
and	O
Universidade	O
Federal	O
do	O
Ceará	O
-	O
UFC	O
)	O
answered	O
a	O
questionnairethat	O
inquired	O
about	O
clinical	O
and	O
biochemical	O
conditions	O
,	O
social	O
-	O
economic	O
status	O
,	O
life	O
quality	O
and	O
clinicians	O
'	O
orientations	O
as	O
well	O
as	O
their	O
understanding	O
about	O
the	O
information	O
given	O
.	O

Serum	O
TSH	S-geneN
was	O
checked	O
close	O
to	O
the	O
interview	O
.	O

Results	O
:	O
2292	O
consecutive	O
patients	O
met	O
the	O
inclusion	O
criteria	O
.	O

Mean	O
age	O
51.2	O
years	O
and	O
TSH	S-geneN
values	O
between	O
0.4	O
and	O
4.0	O
mUI	O
/	O
l	O
were	O
considered	O
to	O
be	O
within	O
the	O
reference	O
range	O
.	O

Among	O
all	O
patients	O
taking	O
thyroid	O
medication	O
,	O
42.7	O
%	O
%	O
had	O
an	O
abnormal	O
serum	O
TSH	S-geneN
(	O
28.3	O
%	O
were	O
undertreated	O
and	O
14.4	O
%	O
were	O
over	O
treated	O
)	O
.	O

Approximately	O
all	O
patients	O
(	O
99	O
%	O
)	O
took	O
LT4	S-chem
in	O
the	O
morning	O
but	O
less	O
than	O
30	O
minutes	O
before	O
breakfast	O
(	O
85.4	O
%	O
)	O
.	O

Regarding	O
the	O
clinicians´	O
orientations	O
:	O
97.5	O
%	O
of	O
the	O
patients	O
were	O
instructed	O
to	O
take	O
the	O
medication	O
daily	O
,	O
and	O
92.6	O
%	O
to	O
take	O
30	O
minutes	O
before	O
breakfast	O
(	O
92.6	O
%	O
)	O
.	O

However	O
,	O
only	O
52.1	O
%	O
were	O
told	O
that	O
not	O
to	O
take	O
LT4	S-chem
along	O
with	O
other	O
medication	O
.	O

Conclusions	O
:	O
Our	O
study	O
found	O
that	O
there	O
was	O
a	O
significant	O
number	O
of	O
patients	O
taking	O
thyroid	O
hormones	O
were	O
not	O
in	O
the	O
therapeutic	O
range	O
.	O

Clinicians	O
should	O
,	O
therefore	O
,	O
consider	O
monitoring	O
patients	O
on	O
thyroid	O
replacement	O
more	O
frequently	O
and	O
being	O
more	O
precise	O
on	O
giving	O
recommendations	O
about	O
the	O
correct	O
use	O
of	O
LT4	S-chem
.	O

Oxysterols	S-chem
in	O
cancer	O
cell	O
proliferation	O
and	O
death	O
.	O

Oxysterols	S-chem
have	O
been	O
shown	O
to	O
interfere	O
with	O
proliferation	O
and	O
cause	O
the	O
death	O
of	O
many	O
cancer	O
cell	O
types	O
,	O
such	O
as	O
leukaemia	O
,	O
glioblastoma	O
,	O
colon	O
,	O
breast	O
and	O
prostate	O
cancer	O
cells	O
,	O
while	O
they	O
have	O
little	O
or	O
no	O
effect	O
on	O
senescent	O
cells	O
.	O

The	O
mechanisms	O
by	O
which	O
oxysterols	S-chem
may	O
influence	O
proliferation	O
are	O
manifold	O
:	O
they	O
control	O
the	O
transcription	O
and	O
the	O
turnover	O
of	O
the	O
key	O
enzyme	O
in	O
cholesterol	S-chem
synthesis	O
,	O
3	B-geneY
-	I-geneY
hydroxy	I-geneY
-	I-geneY
3	I-geneY
-	I-geneY
methylglutaryl	I-geneY
CoA	I-geneY
reductase	E-geneY
,	O
by	O
binding	O
to	O
Insig	B-geneY
-	I-geneY
1	E-geneY
,	O
Insig	B-geneY
-	I-geneY
2	E-geneY
and	O
liver	B-geneN
X	I-geneN
receptors	E-geneN
.	O

Oxysterols	S-chem
are	O
thought	O
to	O
be	O
generated	O
in	O
proportion	O
to	O
the	O
rate	O
of	O
cholesterol	S-chem
synthesis	O
.	O

Although	O
there	O
is	O
no	O
consensus	O
about	O
the	O
mechanism	O
by	O
which	O
these	O
oxysterols	S-chem
are	O
generated	O
in	O
vivo	O
,	O
it	O
clearly	O
has	O
to	O
be	O
ubiquitous	O
.	O

The	O
25	B-geneN
-	I-geneN
and	I-geneN
the	I-geneN
27	I-geneN
-	I-geneN
cholesterol	I-geneN
hydroxylases	E-geneN
,	O
present	O
in	O
almost	O
all	O
tissues	O
,	O
are	O
possible	O
candidates	O
.	O

Cholesterol	S-chem
uptake	O
from	O
lipoproteins	S-geneN
,	O
intracellular	O
vesicle	O
transport	O
and	O
lipid	O
transfer	O
are	O
also	O
modified	O
by	O
oxysterols	S-chem
.	O

Oxysterols	S-chem
interfere	O
with	O
ERK	S-geneN
,	O
hedgehog	S-geneN
and	O
wnt	S-geneN
pathways	O
of	O
proliferation	O
and	O
differentiation	O
.	O

When	O
administered	O
in	O
vitro	O
to	O
cancer	O
cell	O
lines	O
,	O
oxysterols	S-chem
invariably	O
both	O
slow	O
down	O
proliferation	O
and	O
provoke	O
cell	O
death	O
.	O

Perhaps	O
is	O
it	O
sufficient	O
to	O
stop	O
proliferation	O
of	O
a	O
cancer	O
to	O
provoke	O
its	O
eradication	O
.	O

Therefore	O
,	O
the	O
two	O
facets	O
of	O
oxysterol	S-chem
action	O
that	O
seem	O
important	O
for	O
cancer	O
treatment	O
,	O
cytostaticity	O
and	O
cytotoxicity	O
,	O
will	O
be	O
discussed	O
.	O

Pharmacokinetic	O
analysis	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
of	O
intravenous	O
nordihydroguaiaretic	B-chem
acid	E-chem
in	O
the	O
mouse	O
.	O

Nordihydroguaiaretic	B-chem
acid	E-chem
(	O
NDGA	S-chem
)	O
has	O
been	O
shown	O
to	O
inhibit	O
both	O
5	B-geneY
-	I-geneY
lipoxygenase	E-geneY
and	O
ornithine	B-geneY
decarboxylase	E-geneY
and	O
is	O
active	O
against	O
several	O
cancer	O
cell	O
lines	O
and	O
at	O
least	O
one	O
mouse	O
tumor	O
model	O
.	O

Despite	O
these	O
findings	O
,	O
there	O
have	O
been	O
no	O
reports	O
on	O
the	O
pharmacokinetics	O
of	O
NDGA	S-chem
.	O

A	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
method	O
was	O
developed	O
to	O
detect	O
NDGA	S-chem
in	O
mouse	O
plasma	O
.	O

The	O
limit	O
of	O
detection	O
of	O
this	O
method	O
was	O
0.5	O
microg	O
/	O
ml	O
.	O

Administration	O
of	O
NDGA	S-chem
(	O
50	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
to	O
mice	O
resulted	O
in	O
a	O
peak	O
plasma	O
concentration	O
of	O
14.7	O
microg	O
/	O
ml	O
.	O

The	O
terminal	O
half	O
-	O
life	O
of	O
NDGA	S-chem
was	O
135.0	O
min	O
with	O
a	O
clearance	O
of	O
201.9	O
ml	O
/	O
min	O
x	O
kg	O
.	O

Neuroprotective	O
effect	O
of	O
nimesulide	S-chem
,	O
a	O
preferential	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
,	O
against	O
pentylenetetrazol	S-chem
(	O
PTZ	S-chem
)	O
-	O
induced	O
chemical	O
kindling	O
and	O
associated	O
biochemical	O
parameters	O
in	O
mice	O
.	O

Brain	O
cyclooxygenases	S-geneN
(	O
COX	S-geneN
)	O
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
prostaglandin	S-chem
synthesis	O
,	O
is	O
rapidly	O
and	O
transiently	O
induced	O
by	O
convulsions	O
in	O
hippocampal	O
and	O
cortical	O
neurons	O
.	O

Previous	O
studies	O
have	O
explored	O
the	O
protective	O
effect	O
of	O
naproxen	S-chem
(	O
non	O
-	O
selective	O
COX	S-geneN
-	O
inhibitor	O
)	O
or	O
rofecoxib	S-chem
(	O
selective	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
)	O
against	O
chemical	O
kindling	O
in	O
mice	O
.	O

With	O
this	O
background	O
,	O
the	O
present	O
study	O
was	O
designed	O
to	O
explore	O
the	O
possible	O
effect	O
of	O
nimesulide	S-chem
(	O
a	O
preferential	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
)	O
against	O
pentylenetetrazol	S-chem
(	O
PTZ	S-chem
)	O
-	O
induced	O
kindling	O
epilepsy	O
in	O
mice	O
.	O

To	O
induce	O
kindling	O
,	O
PTZ	S-chem
was	O
injected	O
in	O
a	O
subconvulsive	O
dose	O
(	O
40	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
every	O
other	O
day	O
for	O
15	O
days	O
.	O

Nimesulide	S-chem
(	O
2.5	O
or	O
5	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
was	O
administered	O
each	O
day	O
45	O
min	O
before	O
either	O
PTZ	S-chem
or	O
vehicle	O
challenge	O
.	O

The	O
intensity	O
of	O
kindling	O
was	O
assessed	O
immediately	O
after	O
PTZ	S-chem
administration	O
according	O
to	O
a	O
prevalidated	O
scoring	O
scale	O
.	O

On	O
16th	O
day	O
i.e	O
.	O

24	O
h	O
after	O
the	O
last	O
dose	O
of	O
PTZ	S-chem
,	O
animals	O
were	O
sacrificed	O
and	O
various	O
biochemical	O
parameters	O
were	O
assessed	O
in	O
the	O
whole	O
brain	O
.	O

Compared	O
with	O
normal	O
control	O
group	O
,	O
PTZ	S-chem
-	O
kindled	O
mice	O
had	O
significantly	O
higher	O
levels	O
of	O
malondialdehyde	S-chem
,	O
nitrite	S-chem
,	O
myeloperoxidase	S-geneY
but	O
had	O
lower	O
levels	O
of	O
reduced	O
glutathione	S-chem
in	O
the	O
whole	O
brain	O
homogenate	O
.	O

Chronic	O
treatment	O
with	O
nimesulide	S-chem
(	O
2.5	O
or	O
5	O
mg	O
/	O
kg	O
,	O
p.o	O
.	O
)	O
for	O
15	O
days	O
showed	O
significant	O
decrease	O
in	O
kindling	O
score	O
and	O
could	O
play	O
a	O
role	O
in	O
controlling	O
the	O
accompanying	O
biochemical	O
alterations	O
due	O
to	O
PTZ	S-chem
.	O

These	O
results	O
suggested	O
that	O
nimesulide	S-chem
,	O
a	O
preferential	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
offered	O
neuroprotection	O
against	O
PTZ	S-chem
-	O
induced	O
kindling	O
in	O
mice	O
.	O

Fingolimod	S-chem
protects	O
cultured	O
cortical	O
neurons	O
against	O
excitotoxic	O
death	O
.	O

Fingolimod	S-chem
(	O
FTY720	S-chem
)	O
,	O
a	O
novel	O
drug	O
approved	O
for	O
the	O
treatment	O
of	O
relapsing	O
-	O
remitting	O
multiple	O
sclerosis	O
,	O
activates	O
different	O
sphingosine	B-geneN
-	I-geneN
1	I-geneN
-	I-geneN
phosphate	I-geneN
receptor	E-geneN
(	O
S1PR	S-geneN
)	O
subtypes	O
.	O

Its	O
primary	O
mechanism	O
of	O
action	O
is	O
to	O
reduce	O
the	O
egress	O
of	O
T	O
lymphocytes	O
from	O
secondary	O
lymphoid	O
organs	O
,	O
thus	O
restraining	O
neuroinflammation	O
and	O
autoimmunity	O
.	O

However	O
,	O
recent	O
evidence	O
suggests	O
that	O
the	O
action	O
of	O
FTY720	S-chem
involves	O
S1PRs	S-geneN
expressed	O
by	O
cells	O
resident	O
in	O
the	O
CNS	O
,	O
including	O
neurons	O
.	O

Here	O
,	O
we	O
examined	O
the	O
effect	O
of	O
FTY720	S-chem
,	O
its	O
active	O
metabolite	O
,	O
FTY720	B-chem
-	I-chem
P	E-chem
,	O
and	O
sphingosine	B-chem
-	I-chem
1	I-chem
-	I-chem
phosphate	E-chem
(	O
S1P	S-chem
)	O
on	O
neuronal	O
viability	O
using	O
a	O
classical	O
in	O
vitro	O
model	O
of	O
excitotoxic	O
neuronal	O
death	O
.	O

Mixed	O
cultures	O
of	O
mouse	O
cortical	O
cells	O
were	O
challenged	O
with	O
toxic	O
concentrations	O
of	O
N	B-chem
-	I-chem
methyl	I-chem
-	I-chem
d	I-chem
-	I-chem
aspartate	E-chem
(	O
NMDA	S-chem
)	O
for	O
10	O
min	O
,	O
and	O
neuronal	O
death	O
was	O
assessed	O
20	O
h	O
later	O
.	O

FTY720	S-chem
,	O
FTY720	B-chem
-	I-chem
P	E-chem
,	O
and	O
S1P	S-chem
were	O
all	O
neuroprotective	O
when	O
applied	O
18	O
-	O
20	O
h	O
prior	O
to	O
the	O
NMDA	S-chem
pulse	O
.	O

Neuroprotection	O
was	O
attenuated	O
by	O
pertussis	B-geneN
toxin	E-geneN
,	O
and	O
inhibited	O
by	O
the	O
selective	O
type	B-geneY
-	I-geneY
1	I-geneY
S1PR	E-geneY
(	O
S1P1R	S-geneY
)	O
antagonist	O
,	O
W146	S-chem
,	O
and	O
by	O
inhibitors	O
of	O
the	O
mitogen	B-geneN
associated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
MAPK	S-geneN
)	O
and	O
the	O
phosphatidylinositol	B-geneN
-	I-geneN
3	I-geneN
-	I-geneN
kinase	E-geneN
(	O
PtdIns	B-geneN
-	I-geneN
3	I-geneN
-	I-geneN
K	E-geneN
)	O
pathways	O
.	O

Both	O
FTY720	S-chem
and	O
FTY720	B-chem
-	I-chem
P	E-chem
retained	O
their	O
protective	O
activity	O
in	O
pure	O
cultures	O
of	O
mouse	O
or	O
rat	O
cortical	O
neurons	O
.	O

These	O
data	O
offer	O
the	O
first	O
direct	O
demonstration	O
that	O
FTY720	S-chem
and	O
its	O
active	O
metabolite	O
protect	O
neurons	O
against	O
excitotoxic	O
death	O
.	O

Inhibition	O
of	O
angiogenesis	O
and	O
invasion	O
by	O
DMBT	S-chem
is	O
mediated	O
by	O
downregulation	O
of	O
VEGF	S-geneN
and	O
MMP	B-geneY
-	I-geneY
9	E-geneY
through	O
Akt	S-geneN
pathway	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
breast	O
cancer	O
cells	O
.	O

Invasion	O
,	O
either	O
directly	O
or	O
via	O
metastasis	O
formation	O
,	O
is	O
the	O
main	O
cause	O
of	O
death	O
in	O
cancer	O
patients	O
,	O
development	O
of	O
efficient	O
anti	O
-	O
invasive	O
agents	O
is	O
an	O
important	O
research	O
challenge	O
.	O

In	O
order	O
to	O
obtain	O
more	O
potent	O
inhibitors	O
,	O
a	O
series	O
of	O
brartemicin	S-chem
analogs	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
inhibitory	O
activity	O
against	O
invasion	O
.	O

Among	O
the	O
synthetic	O
analogs	O
tested	O
,	O
DMBT	S-chem
,	O
6,6	B-chem
'	I-chem
-	I-chem
bis	I-chem
(	I-chem
2,3	I-chem
-	I-chem
dimethoxybenzoyl	I-chem
)	I-chem
-	I-chem
a	I-chem
,	I-chem
a	I-chem
-	I-chem
d	I-chem
-	I-chem
trehalose	E-chem
,	O
was	O
found	O
to	O
be	O
the	O
most	O
potent	O
anti	O
-	O
invasive	O
agent	O
.	O

But	O
the	O
effects	O
of	O
DMBT	S-chem
on	O
breast	O
cancer	O
cells	O
were	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
DMBT	S-chem
on	O
invasion	O
and	O
metastasis	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
were	O
investigated	O
.	O

MTT	S-chem
assay	O
showed	O
that	O
no	O
obvious	O
inhibitory	O
or	O
cytotoxic	O
effect	O
of	O
DMBT	S-chem
was	O
found	O
.	O

DMBT	S-chem
could	O
inhibit	O
invasion	O
,	O
migration	O
and	O
tube	O
formation	O
of	O
HUVECs	O
.	O

Gelatin	O
zymography	O
showed	O
that	O
DMBT	S-chem
inhibited	O
secretion	O
and	O
activity	O
of	O
MMP	B-geneY
-	I-geneY
9	E-geneY
.	O

Western	O
blotting	O
demonstrated	O
that	O
DMBT	S-chem
effectively	O
suppressed	O
the	O
expression	O
of	O
VEGF	S-geneN
,	O
p	B-geneY
-	I-geneY
VEGFR	I-geneY
-	I-geneY
2	E-geneY
,	O
p	B-geneY
-	I-geneY
EGFR	E-geneY
,	O
and	O
p	B-geneN
-	I-geneN
Akt	E-geneN
.	O

These	O
results	O
suggested	O
that	O
DMBT	S-chem
could	O
inhibit	O
invasion	O
and	O
angiogenesis	O
by	O
downregulation	O
of	O
VEGFand	S-geneN
MMP	B-geneY
-	I-geneY
9	E-geneY
,	O
resulting	O
from	O
the	O
inhibition	O
of	O
Akt	S-geneN
pathway	O
.	O

DMBT	S-chem
might	O
be	O
a	O
promising	O
lead	O
molecule	O
for	O
the	O
anti	O
-	O
metastasis	O
and	O
serve	O
as	O
a	O
therapeutic	O
agent	O
to	O
inhibit	O
breast	O
cancer	O
cell	O
invasion	O
and	O
metastasis	O
.	O

Effects	O
of	O
amlodipine	S-chem
on	O
the	O
oral	O
bioavailability	O
of	O
cephalexin	S-chem
and	O
cefuroxime	B-chem
axetil	E-chem
in	O
healthy	O
volunteers	O
.	O

In	O
this	O
study	O
,	O
the	O
authors	O
compared	O
the	O
effects	O
of	O
amlodipine	S-chem
(	O
AML	S-chem
)	O
on	O
the	O
bioavailability	O
of	O
cephalexin	S-chem
(	O
LEX	S-chem
)	O
and	O
cefuroxime	B-chem
axetil	E-chem
(	O
CXM	S-chem
)	O
.	O

Twenty	O
-	O
four	O
healthy	O
men	O
were	O
randomized	O
to	O
4	O
treatments	O
according	O
to	O
a	O
crossover	O
design	O
with	O
a	O
14	O
-	O
day	O
washout	O
.	O

After	O
an	O
overnight	O
fast	O
,	O
they	O
were	O
administered	O
orally	O
LEX	S-chem
500	O
mg	O
alone	O
,	O
LEX	S-chem
500	O
mg	O
2	O
hours	O
after	O
oral	O
administration	O
of	O
AML	S-chem
5	O
mg	O
,	O
CXM	S-chem
500	O
mg	O
alone	O
,	O
and	O
CXM	S-chem
500	O
mg	O
2	O
hours	O
after	O
oral	O
administration	O
of	O
AML	S-chem
5	O
mg	O
.	O

All	O
participants	O
completed	O
the	O
whole	O
study	O
without	O
side	O
effects	O
being	O
observed	O
.	O

Pharmacokinetic	O
data	O
were	O
analyzed	O
by	O
noncompartmental	O
modeling	O
with	O
WinNonlin	O
software	O
.	O

The	O
geometric	O
mean	O
(	O
GM	O
)	O
ratios	O
were	O
1.38	O
(	O
90	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1.32	O
-	O
1.45	O
)	O
for	O
the	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
for	O
LEX	S-chem
and	O
1.27	O
(	O
1.18	O
-	O
1.36	O
)	O
for	O
the	O
maximum	O
concentration	O
of	O
drug	O
in	O
serum	O
(	O
C	O
(	O
max	O
)	O
)	O
for	O
LEX	S-chem
followed	O
by	O
AML	S-chem
versus	O
alone	O
.	O

In	O
contrast	O
,	O
no	O
significant	O
differences	O
were	O
found	O
in	O
the	O
pharmacokinetic	O
parameters	O
of	O
CXM	S-chem
between	O
treatments	O
(	O
P	O
<	O
.05	O
)	O
.	O

They	O
authors	O
conclude	O
that	O
AML	S-chem
possesses	O
an	O
enhancement	O
effect	O
in	O
β	B-chem
-	I-chem
lactam	E-chem
antibiotic	O
bioavailability	O
(	O
in	O
this	O
case	O
,	O
LEX	S-chem
)	O
,	O
and	O
this	O
interaction	O
may	O
be	O
specific	O
to	O
the	O
peptidomimetic	O
β	B-chem
-	I-chem
lactam	E-chem
antibiotics	O
.	O

Regulation	O
of	O
pancreatic	O
endocrine	O
cell	O
differentiation	O
by	O
sulphated	O
proteoglycans	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Epithelium	O
-	O
mesenchyme	O
interactions	O
play	O
a	O
major	O
role	O
in	O
pancreas	O
development	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
embryonic	O
pancreatic	O
mesenchyme	O
enhanced	O
progenitor	O
cell	O
proliferation	O
but	O
inhibited	O
endocrine	O
cell	O
differentiation	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
played	O
by	O
sulphated	O
proteoglycans	O
,	O
which	O
are	O
known	O
to	O
be	O
essential	O
to	O
embryonic	O
development	O
,	O
in	O
this	O
inhibitory	O
effect	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
first	O
determined	O
the	O
expression	O
of	O
the	O
genes	O
encoding	O
glypicans	S-geneN
,	O
syndecans	S-geneN
and	O
the	O
main	O
glycosaminoglycan	O
chain	O
-	O
modifying	O
enzymes	O
in	O
immature	O
embryonic	O
day	O
(	O
E	O
)	O
13.5	O
and	O
more	O
differentiated	O
E17.5	O
rat	O
pancreases	O
.	O

Next	O
,	O
using	O
an	O
in	O
vitro	O
model	O
of	O
pancreas	O
development	O
,	O
we	O
blocked	O
the	O
action	O
of	O
endogenous	O
sulphated	O
proteoglycans	O
by	O
treating	O
embryonic	O
pancreases	O
in	O
culture	O
with	O
chlorate	S-chem
,	O
an	O
inhibitor	O
of	O
proteoglycan	O
sulphation	O
,	O
and	O
examined	O
the	O
effects	O
on	O
pancreatic	O
endocrine	O
cell	O
differentiation	O
.	O

RESULTS	O
:	O
We	O
first	O
showed	O
that	O
expression	O
of	O
the	O
genes	O
encoding	O
glypicans	B-geneN
1	I-geneN
,	I-geneN
2	I-geneN
,	I-geneN
3	I-geneN
and	I-geneN
5	E-geneN
and	O
heparan	B-geneY
sulphate	I-geneY
2	I-geneY
-	I-geneY
sulfotransferase	E-geneY
decreased	O
between	O
E13.5	O
and	O
E17.5	O
.	O

We	O
next	O
found	O
that	O
alteration	O
of	O
proteoglycan	O
action	O
by	O
chlorate	S-chem
blocked	O
the	O
inhibitory	O
effect	O
of	O
the	O
mesenchyme	O
on	O
endocrine	O
differentiation	O
.	O

Chlorate	S-chem
-	O
treated	O
pancreases	O
exhibited	O
a	O
dramatic	O
increase	O
in	O
beta	O
cell	O
number	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
169	O
-	O
and	O
375	O
-	O
fold	O
increase	O
with	O
30	O
mmol	O
/	O
l	O
and	O
40	O
mmol	O
/	O
l	O
chlorate	S-chem
,	O
respectively	O
)	O
and	O
in	O
alpha	O
cell	O
development	O
.	O

Insulin	S-geneN
-	O
positive	O
cells	O
that	O
developed	O
in	O
the	O
presence	O
of	O
chlorate	S-chem
exhibited	O
a	O
phenotype	O
of	O
mature	O
cells	O
with	O
regard	O
to	O
the	O
expression	O
of	O
the	O
following	O
genes	O
:	O
pancreatic	B-geneY
and	I-geneY
duodenal	I-geneY
homeobox	I-geneY
gene	I-geneY
1	E-geneY
(	O
Pdx1	S-geneY
)	O
,	O
proprotein	B-geneY
convertase	I-geneY
subtilisin	I-geneY
/	I-geneY
kexin	I-geneY
type	I-geneY
1	E-geneY
(	O
Pcsk1	S-geneY
;	O
previously	O
known	O
as	O
pro	B-geneY
-	I-geneY
hormone	I-geneY
convertase	I-geneY
1	I-geneY
/	I-geneY
3	E-geneY
)	O
,	O
proprotein	B-geneY
convertase	I-geneY
subtilisin	I-geneY
/	I-geneY
kexin	I-geneY
type	I-geneY
2	E-geneY
(	O
Pcsk2	S-geneY
;	O
previously	O
known	O
as	O
pro	B-geneY
-	I-geneY
hormone	I-geneY
convertase	I-geneY
2	E-geneY
)	O
and	O
solute	B-geneY
carrier	I-geneY
family	I-geneY
2	I-geneY
(	I-geneY
facilitated	I-geneY
glucose	I-geneY
transporter	I-geneY
)	I-geneY
,	I-geneY
member	I-geneY
2	E-geneY
(	O
Slc2a1	S-geneY
;	O
previously	O
known	O
as	O
glucose	B-geneY
transporter	I-geneY
2	E-geneY
)	O
.	O

Finally	O
,	O
we	O
showed	O
that	O
chlorate	S-chem
activated	O
endocrine	O
cell	O
development	O
by	O
inducing	O
neurogenin	B-geneY
3	E-geneY
(	O
Neurog3	S-geneY
)	O
expression	O
in	O
early	O
endocrine	O
progenitor	O
cells	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
We	O
demonstrated	O
that	O
sulphated	O
proteoglycans	O
control	O
pancreatic	O
endocrine	O
cell	O
differentiation	O
.	O

Understanding	O
the	O
mechanism	O
by	O
which	O
sulphated	O
proteoglycans	O
affect	O
beta	O
cell	O
development	O
could	O
be	O
useful	O
in	O
the	O
generation	O
of	O
beta	O
cells	O
from	O
embryonic	O
stem	O
cells	O
.	O

Antithrombotic	O
activity	O
of	O
a	O
newly	O
synthesized	O
coumarin	S-chem
derivative	O
3	B-chem
-	I-chem
(	I-chem
5	I-chem
-	I-chem
hydroxy	I-chem
-	I-chem
2,2	I-chem
-	I-chem
dimethyl	I-chem
-	I-chem
chroman	I-chem
-	I-chem
6	I-chem
-	I-chem
yl	I-chem
)	I-chem
-	I-chem
N	I-chem
-	I-chem
{	I-chem
2	I-chem
-	I-chem
[	I-chem
3	I-chem
-	I-chem
(	I-chem
5	I-chem
-	I-chem
hydroxy	I-chem
-	I-chem
2,2	I-chem
-	I-chem
dimethyl	I-chem
-	I-chem
chroman	I-chem
-	I-chem
6	I-chem
-	I-chem
yl	I-chem
)	I-chem
-	I-chem
propionylamino	I-chem
]	I-chem
-	I-chem
ethyl	I-chem
}	I-chem
-	I-chem
propionamide	E-chem
.	O

Anti	O
-	O
platelet	O
therapy	O
is	O
a	O
useful	O
strategy	O
to	O
prevent	O
acute	O
thromboembolic	O
artery	O
occlusions	O
.	O

This	O
study	O
was	O
designed	O
to	O
assess	O
the	O
efficacy	O
of	O
seselin	S-chem
derivatives	O
against	O
murine	O
pulmonary	O
thromboembolism	O
,	O
bleeding	O
time	O
,	O
platelet	O
activation	O
and	O
thrombosis	O
.	O

Administration	O
of	O
C3	O
(	O
16	O
mg	O
/	O
kg	O
)	O
offered	O
70	O
%	O
protection	O
against	O
collagen	S-geneN
-	O
and	O
epinephrine	S-chem
-	O
induced	O
pulmonary	O
thromboembolism	O
and	O
30	O
%	O
protection	O
against	O
arachidonic	B-chem
acid	E-chem
-	O
induced	O
death	O
in	O
mice	O
,	O
without	O
adversely	O
affecting	O
bleeding	O
time	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
by	O
C3	O
in	O
ferric	B-chem
chloride	E-chem
-	O
induced	O
arterial	O
thrombosis	O
in	O
rats	O
.	O

Significant	O
reduction	O
in	O
thrombus	O
weight	O
was	O
observed	O
in	O
arteriovenous	O
shunt	O
model	O
.	O

In	O
rat	O
PRP	O
,	O
C3	O
reduced	O
ADP	S-chem
and	O
collagen	S-geneN
-	O
induced	O
platelet	O
aggregation	O
.	O

In	O
chronic	O
hamster	O
model	O
of	O
dyslipidemia	O
,	O
administration	O
of	O
C3	O
(	O
16	O
mg	O
/	O
kg	O
p.o	O
.	O
for	O
90	O
days	O
)	O
had	O
no	O
effect	O
on	O
plasma	O
lipids	O
,	O
vasoreactivity	O
and	O
platelet	O
adhesion	O
.	O

C3	O
fed	O
hamsters	O
showed	O
reduced	O
whole	O
-	O
blood	O
aggregation	O
response	O
to	O
ADP	S-chem
and	O
collagen	S-geneN
compared	O
to	O
HC	O
-	O
fed	O
hamsters	O
.	O

In	O
addition	O
,	O
C3	O
augmented	O
thrombin	O
time	O
;	O
however	O
,	O
time	O
to	O
occlusion	O
was	O
not	O
increased	O
.	O

These	O
results	O
convincingly	O
demonstrated	O
that	O
C3	O
is	O
a	O
novel	O
molecule	O
that	O
reduces	O
the	O
risk	O
of	O
thrombosis	O
and	O
alleviates	O
prothrombotic	O
state	O
associated	O
with	O
hyperlipidemia	O
without	O
any	O
adverse	O
effect	O
on	O
bleeding	O
time	O
.	O

The	O
high	O
benefit	O
/	O
risk	O
ratio	O
of	O
this	O
compound	O
makes	O
it	O
a	O
suitable	O
candidate	O
for	O
future	O
valid	O
studies	O
.	O

Influence	O
of	O
the	O
Green	O
Tea	O
Leaf	O
Extract	O
on	O
Neurotoxicity	O
of	O
Aluminium	B-chem
Chloride	E-chem
in	O
Rats	O
.	O

Aluminium	S-chem
may	O
have	O
an	O
important	O
role	O
in	O
the	O
aetiology	O
/	O
pathogenesis	O
/	O
precipitation	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Because	O
green	O
tea	O
(	O
Camellia	O
sinensis	O
L.	O
)	O
reportedly	O
has	O
health	O
-	O
promoting	O
effects	O
in	O
the	O
central	O
nervous	O
system	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
green	O
tea	O
leaf	O
extract	O
(	O
GTLE	O
)	O
on	O
aluminium	B-chem
chloride	E-chem
(	O
AlCl3	S-chem
)	O
neurotoxicity	O
in	O
rats	O
.	O

All	O
solutions	O
were	O
injected	O
into	O
the	O
cornu	O
ammonis	O
region	O
1	O
hippocampal	O
region	O
.	O

We	O
measured	O
the	O
performance	O
of	O
active	O
avoidance	O
(	O
AA	O
)	O
tasks	O
,	O
various	O
enzyme	O
activities	O
and	O
total	O
glutathione	S-chem
content	O
(	O
TGC	O
)	O
in	O
the	O
forebrain	O
cortex	O
(	O
FbC	O
)	O
,	O
striatum	O
,	O
basal	O
forebrain	O
(	O
BFb	O
)	O
,	O
hippocampus	O
,	O
brain	O
stem	O
and	O
cerebellum	O
.	O

AlCl3	S-chem
markedly	O
reduced	O
AA	O
performance	O
and	O
activities	O
of	O
cytochrome	B-geneN
c	I-geneN
oxidase	E-geneN
(	O
COX	S-geneN
)	O
and	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
in	O
all	O
regions	O
.	O

It	O
decreased	O
TGC	O
in	O
the	O
FbC	O
,	O
striatum	O
,	O
BFb	O
,	O
hippocampus	O
,	O
brain	O
stem	O
and	O
cerebellum	O
,	O
and	O
increased	O
superoxide	S-chem
dismutase	O
activity	O
in	O
the	O
FbC	O
,	O
cerebellum	O
and	O
BFb	O
.	O

GTLE	O
pretreatment	O
completely	O
reversed	O
the	O
damaging	O
effects	O
of	O
AlCl3	S-chem
on	O
AA	O
and	O
superoxide	B-geneN
dismutase	E-geneN
activity	O
,	O
markedly	O
corrected	O
COX	S-geneN
and	O
AChE	S-geneY
activities	O
,	O
and	O
moderately	O
improved	O
TGC	O
.	O

GTLE	O
alone	O
increased	O
COX	S-geneN
and	O
AChE	S-geneY
activities	O
in	O
almost	O
all	O
regions	O
.	O

GTLE	O
reduces	O
AlCl3	S-chem
neurotoxicity	O
probably	O
via	O
antioxidative	O
effects	O
and	O
improves	O
mitochondrial	O
and	O
cholinergic	O
synaptic	O
functions	O
through	O
the	O
actions	O
of	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
epigallocatechin	I-chem
gallate	E-chem
and	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
epicatechin	E-chem
,	O
compounds	O
most	O
abundantly	O
found	O
in	O
GTLE	O
.	O

Our	O
results	O
suggest	O
that	O
green	O
tea	O
might	O
be	O
beneficial	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

3	B-chem
'	I-chem
-	I-chem
R	I-chem
/	I-chem
S	I-chem
-	I-chem
Hydroxyvoacamine	E-chem
,	O
a	O
potent	O
acetylcholinesterase	S-geneY
inhibitor	O
from	O
Tabernaemontana	O
divaricata	O
.	O

Guided	O
by	O
the	O
acetylcholinesterase	S-geneY
inhibiting	O
activity	O
,	O
the	O
bisindole	B-chem
alkaloid	E-chem
3	B-chem
'	I-chem
-	I-chem
R	I-chem
/	I-chem
S	I-chem
-	I-chem
hydroxyvoacamine	E-chem
was	O
isolated	O
from	O
a	O
stem	O
extract	O
of	O
Tabernaemontana	O
divaricata	O
,	O
a	O
plant	O
used	O
in	O
Thailand	O
in	O
traditional	O
rejuvenation	O
remedies	O
for	O
improving	O
the	O
memory	O
.	O

The	O
structure	O
of	O
the	O
alkaloid	O
was	O
elucidated	O
by	O
extensive	O
use	O
of	O
NMR	O
spectroscopy	O
and	O
the	O
complete	O
assignment	O
of	O
the	O
(	B-chem
1	I-chem
)	I-chem
H	E-chem
and	O
(	B-chem
13	I-chem
)	I-chem
C	E-chem
NMR	O
spectra	O
is	O
reported	O
.	O

The	O
alkaloid	O
acted	O
as	O
a	O
non	O
-	O
competitive	O
inhibitor	O
against	O
AChE	S-geneY
with	O
an	O
IC50	O
value	O
of	O
7.00±1.99μM	O
.	O

An	O
HPLC	O
method	O
was	O
developed	O
for	O
the	O
quantitative	O
analysis	O
of	O
the	O
AChE	S-geneY
inhibitor	O
.	O

It	O
suggested	O
that	O
there	O
was	O
12.4	O
%	O
(	O
w	O
/	O
w	O
)	O
of	O
3	B-chem
'	I-chem
-	I-chem
R	I-chem
/	I-chem
S	I-chem
-	I-chem
hydroxyvoacamine	E-chem
in	O
the	O
alkaloid	O
enriched	O
fraction	O
of	O
T.	O
divaricata	O
stem	O
.	O

Hospitalized	O
osteoporotic	O
vertebral	O
fracture	O
increases	O
the	O
risk	O
of	O
stroke	O
:	O
a	O
population	O
-	O
based	O
cohort	O
study	O
.	O

The	O
association	O
between	O
osteoporosis	O
and	O
cardiovascular	O
diseases	O
has	O
been	O
demonstrated	O
.	O

Higher	O
cardiovascular	O
risk	O
has	O
also	O
been	O
correlated	O
with	O
vertebral	O
fractures	O
.	O

However	O
,	O
the	O
association	O
between	O
osteoporotic	O
vertebral	O
fracture	O
and	O
the	O
possibly	O
higher	O
risk	O
of	O
stroke	O
remains	O
uncertain	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
incidence	O
,	O
risk	O
,	O
and	O
type	O
of	O
stroke	O
in	O
patients	O
with	O
osteoporotic	O
vertebral	O
fracture	O
.	O

Patients	O
with	O
osteoporotic	O
vertebral	O
fracture	O
were	O
identified	O
(	O
n	O
=	O
380	O
)	O
and	O
10	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
per	O
case	O
(	O
comparison	O
group	O
,	O
n	O
=	O
3795	O
)	O
were	O
chosen	O
from	O
a	O
nationwide	O
representative	O
cohort	O
of	O
999,997	O
people	O
from	O
1998	O
to	O
2005	O
.	O

Both	O
groups	O
were	O
followed	O
-	O
up	O
for	O
stroke	O
events	O
for	O
3	O
years	O
,	O
matched	O
by	O
propensity	O
scores	O
with	O
adjustments	O
for	O
covariates	O
such	O
as	O
comorbidities	O
(	O
ie	O
,	O
hypertension	O
,	O
diabetes	O
,	O
arrhythmia	O
,	O
or	O
coronary	O
heart	O
diseases	O
)	O
and	O
exposure	O
to	O
medications	O
(	O
ie	O
,	O
aspirin	S-chem
,	O
lipid	O
lowering	O
drug	O
,	O
or	O
nitrates	S-chem
)	O
,	O
and	O
assessed	O
by	O
Kaplan	O
-	O
Meier	O
and	O
Cox	O
regression	O
analyses	O
.	O

The	O
incidence	O
rate	O
of	O
stroke	O
in	O
the	O
osteoporotic	O
vertebral	O
fracture	O
group	O
(	O
37.5	O
per	O
1000	O
person	O
-	O
years	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
27.5	O
-	O
51.2	O
)	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
comparison	O
group	O
(	O
14.0	O
per	O
1000	O
person	O
-	O
years	O
;	O
95	O
%	O
CI	O
,	O
12.0	O
-	O
16.4	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Stroke	O
was	O
more	O
likely	O
to	O
occur	O
in	O
the	O
osteoporotic	O
vertebral	O
fracture	O
patients	O
than	O
in	O
the	O
normal	O
controls	O
(	O
crude	O
hazard	O
ratio	O
[	O
HR	O
]	O
2.68	O
,	O
95	O
%	O
CI	O
1.89	O
-	O
3.79	O
,	O
p	O
<	O
0.001	O
;	O
adjusted	O
HR	O
2.71	O
,	O
95	O
%	O
CI	O
1.90	O
-	O
3.86	O
,	O
p	O
<	O
0.001	O
)	O
.	O

In	O
conclusion	O
,	O
patients	O
with	O
osteoporotic	O
vertebral	O
fracture	O
have	O
a	O
higher	O
risk	O
of	O
stroke	O
(	O
ie	O
,	O
both	O
ischemic	O
and	O
hemorrhagic	O
)	O
and	O
require	O
stroke	O
prevention	O
strategies	O
.	O

Two	O
distinct	O
mechanisms	O
of	O
Topoisomerase	B-geneY
1	E-geneY
-	O
dependent	O
mutagenesis	O
in	O
yeast	O
.	O

Topoisomerase	B-geneY
1	E-geneY
(	O
Top1	S-geneY
)	O
resolves	O
transcription	O
-	O
associated	O
supercoils	O
by	O
generating	O
transient	O
single	O
-	O
strand	O
breaks	O
in	O
DNA	O
.	O

Top1	S-geneY
activity	O
in	O
yeast	O
is	O
a	O
major	O
source	O
of	O
transcription	O
-	O
associated	O
mutagenesis	O
,	O
generating	O
a	O
distinctive	O
mutation	O
signature	O
characterized	O
by	O
deletions	O
in	O
short	O
,	O
tandem	O
repeats	O
.	O

A	O
similar	O
signature	O
is	O
associated	O
with	O
the	O
persistence	O
of	O
ribonucleoside	B-chem
monophosphates	E-chem
(	O
rNMPs	S-chem
)	O
in	O
DNA	O
,	O
and	O
it	O
also	O
depends	O
on	O
Top1	S-geneY
activity	O
.	O

There	O
is	O
only	O
partial	O
overlap	O
,	O
however	O
,	O
between	O
Top1	S-geneY
-	O
dependent	O
deletion	O
hotspots	O
identified	O
in	O
highly	O
transcribed	O
DNA	O
and	O
those	O
associated	O
with	O
rNMPs	S-chem
,	O
suggesting	O
the	O
existence	O
of	O
both	O
rNMP	S-chem
-	O
dependent	O
and	O
rNMP	S-chem
-	O
independent	O
events	O
.	O

Here	O
,	O
we	O
present	O
genetic	O
studies	O
confirming	O
that	O
there	O
are	O
two	O
distinct	O
types	O
of	O
hotspots	O
.	O

Data	O
suggest	O
a	O
novel	O
model	O
in	O
which	O
rNMP	S-chem
-	O
dependent	O
hotspots	O
are	O
generated	O
by	O
sequential	O
Top1	S-geneY
reactions	O
and	O
are	O
consistent	O
with	O
rNMP	S-chem
-	O
independent	O
hotspots	O
reflecting	O
processing	O
of	O
a	O
trapped	O
Top1	S-geneY
cleavage	O
complex	O
.	O

A	O
case	O
of	O
adult	O
-	O
onset	O
type	O
II	O
citrullinemia	O
-	O
-	O
deterioration	O
of	O
clinical	O
course	O
after	O
infusion	O
of	O
hyperosmotic	O
and	O
high	O
sugar	O
solutions	O
.	O

BACKGROUND	O
:	O
Adult	O
-	O
onset	O
type	O
II	O
citrullinemia	O
(	O
CTLN2	O
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
mutations	O
of	O
SLC25A13	S-geneY
gene	O
encoding	O
citrin	S-geneY
and	O
is	O
characterized	O
by	O
recurrent	O
encephalopathy	O
with	O
hyperammonemia	O
.	O

Factors	O
affecting	O
disease	O
progression	O
remain	O
unknown	O
.	O

We	O
report	O
a	O
case	O
with	O
CTLN2	O
,	O
whose	O
clinical	O
course	O
was	O
rapidly	O
worsened	O
by	O
the	O
administration	O
of	O
Glyceol	O
,	O
a	O
hyperosmotic	O
diuretic	O
solution	O
consisting	O
of	O
10	O
%	O
glycerol	S-chem
and	O
5	O
%	O
fructose	S-chem
in	O
saline	O
.	O

CASE	O
REPORT	O
:	O
A	O
34	O
-	O
year	O
-	O
old	O
man	O
was	O
admitted	O
in	O
coma	O
after	O
repeated	O
episodes	O
of	O
altered	O
consciousness	O
.	O

His	O
plasma	O
ammonia	S-chem
level	O
was	O
markedly	O
elevated	O
without	O
any	O
evidence	O
of	O
liver	O
diseases	O
.	O

Brain	O
MRI	O
revealed	O
high	O
signal	O
intensities	O
at	O
the	O
bilateral	O
cingulate	O
gyri	O
and	O
insular	O
cortices	O
,	O
suggesting	O
hepatic	O
encephalopathy	O
.	O

We	O
administered	O
Glyceol	O
.	O
intravenously	O
to	O
alleviate	O
brain	O
edema	O
,	O
however	O
,	O
he	O
developed	O
intractable	O
seizures	O
along	O
with	O
steep	O
increase	O
in	O
plasma	O
ammonia	S-chem
levels	O
(	O
from	O
808	O
to	O
2210	O
microg	O
/	O
dL	O
)	O
and	O
died	O
.	O

The	O
diagnosis	O
of	O
CTLN2	O
was	O
confirmed	O
by	O
elevations	O
of	O
plasma	O
citrulline	S-chem
level	O
(	O
384.3	O
nmol	O
/	O
mL	O
;	O
normal	O
17	O
-	O
43	O
nmol	O
/	O
mL	O
)	O
and	O
serum	O
pancreatic	B-geneY
secretory	I-geneY
trypsin	I-geneY
inhibitor	E-geneY
(	O
PSTI	S-geneY
)	O
(	O
110	O
ng	O
/	O
mL	O
;	O
normal	O
4.6	O
-	O
12.2	O
ng	O
/	O
mL	O
)	O
,	O
decrease	O
in	O
hepatic	O
argininosuccinate	B-geneY
synthetase	E-geneY
activity	O
(	O
5.5	O
%	O
of	O
control	O
)	O
,	O
lack	O
of	O
hepatic	O
citrin	S-geneY
protein	O
expression	O
and	O
mutations	O
in	O
SLC25A13	S-geneY
gene	O
(	O
compound	O
heterozygote	O
with	O
S225X	S-geneN
and	O
Ex1	B-geneN
-	I-geneN
1G	I-geneN
>	I-geneN
A	E-geneN
)	O
.	O

CONCLUSIONS	O
:	O
Physicians	O
should	O
take	O
CTLN2	O
into	O
consideration	O
as	O
a	O
differential	O
diagnosis	O
in	O
Asian	O
patients	O
with	O
a	O
history	O
of	O
repeated	O
unconsciousness	O
with	O
hyperammonemia	O
and	O
use	O
D	B-chem
-	I-chem
mannitol	E-chem
but	O
not	O
glycerol	S-chem
to	O
treat	O
brain	O
edema	O
in	O
patients	O
with	O
CTLN2	O
.	O

A	O
single	O
residue	O
in	O
leucyl	B-geneY
-	I-geneY
tRNA	I-geneY
synthetase	E-geneY
affecting	O
amino	B-chem
acid	E-chem
specificity	O
and	O
tRNA	O
aminoacylation	O
.	O

Human	B-geneY
mitochondrial	I-geneY
leucyl	I-geneY
-	I-geneY
tRNA	I-geneY
synthetase	E-geneY
(	O
hs	B-geneY
mt	I-geneY
LeuRS	E-geneY
)	O
achieves	O
high	O
aminoacylation	O
fidelity	O
without	O
a	O
functional	O
editing	O
active	O
site	O
,	O
representing	O
a	O
rare	O
example	O
of	O
a	O
class	B-geneN
I	I-geneN
aminoacyl	I-geneN
-	I-geneN
tRNA	I-geneN
synthetase	E-geneN
(	O
aaRS	S-geneN
)	O
that	O
does	O
not	O
proofread	O
its	O
products	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
enzyme	O
achieves	O
high	O
selectivity	O
by	O
using	O
a	O
more	O
specific	O
synthetic	O
active	O
site	O
that	O
is	O
not	O
prone	O
to	O
errors	O
under	O
physiological	O
conditions	O
.	O

Interestingly	O
,	O
the	O
synthetic	O
active	O
site	O
of	O
hs	B-geneY
mt	I-geneY
LeuRS	E-geneY
displays	O
a	O
high	O
degree	O
of	O
homology	O
with	O
prokaryotic	O
,	O
lower	O
eukaryotic	O
,	O
and	O
other	O
mitochondrial	O
LeuRSs	S-geneY
that	O
are	O
less	O
specific	O
.	O

However	O
,	O
there	O
is	O
one	O
residue	O
that	O
differs	O
between	O
hs	B-geneN
mt	I-geneN
and	I-geneN
Escherichia	I-geneN
coli	I-geneN
LeuRSs	E-geneN
located	O
on	O
a	O
flexible	O
closing	O
loop	O
near	O
the	O
signature	O
KMSKS	B-geneN
motif	E-geneN
.	O

Here	O
we	O
describe	O
studies	O
indicating	O
that	O
this	O
particular	O
residue	O
(	O
K600	O
in	O
hs	B-geneY
mt	I-geneY
LeuRS	E-geneY
and	O
L570	O
in	O
E.	B-geneY
coli	I-geneY
LeuRS	E-geneY
)	O
strongly	O
impacts	O
aminoacylation	O
in	O
two	O
ways	O
:	O
it	O
affects	O
both	O
amino	B-chem
acid	E-chem
discrimination	O
and	O
transfer	O
RNA	O
(	O
tRNA	O
)	O
binding	O
.	O

While	O
this	O
residue	O
may	O
not	O
be	O
in	O
direct	O
contact	O
with	O
the	O
amino	B-chem
acid	E-chem
or	O
tRNA	O
substrate	O
,	O
substitutions	O
of	O
this	O
position	O
in	O
both	O
enzymes	O
lead	O
to	O
altered	O
catalytic	O
efficiency	O
and	O
perturbations	O
to	O
the	O
discrimination	O
of	O
leucine	S-chem
and	O
isoleucine	S-chem
.	O

In	O
addition	O
,	O
tRNA	O
recognition	O
and	O
aminoacylation	O
is	O
affected	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
conformation	O
of	O
the	O
synthetic	O
active	O
site	O
,	O
modulated	O
by	O
this	O
residue	O
,	O
may	O
be	O
coupled	O
to	O
specificity	O
and	O
provide	O
new	O
insights	O
into	O
the	O
origins	O
of	O
selectivity	O
without	O
editing	O
.	O

Loperamide	S-chem
modifies	O
but	O
does	O
not	O
block	O
the	O
corticotropin	B-geneY
-	I-geneY
releasing	I-geneY
hormone	E-geneY
-	O
induced	O
ACTH	S-geneY
response	O
in	O
patients	O
with	O
Addison	O
's	O
disease	O
.	O

The	O
effect	O
of	O
loperamide	S-chem
-	O
a	O
peripheral	O
opiate	O
agonist	O
-	O
on	O
plasma	O
ACTH	S-geneY
response	O
to	O
Corticotropin	B-geneY
-	I-geneY
releasing	I-geneY
Hormone	E-geneY
(	O
CRH	S-geneY
)	O
has	O
been	O
investigated	O
in	O
6	O
patients	O
with	O
Addison	O
's	O
disease	O
.	O

After	O
placebo	O
administration	O
CRH	S-geneY
induced	O
a	O
marked	O
ACTH	S-geneY
increase	O
.	O

After	O
loperamide	S-chem
administration	O
ACTH	S-geneY
levels	O
fell	O
to	O
a	O
nadir	O
of	O
135	O
+	O
/	O
-	O
76	O
pg	O
/	O
ml	O
,	O
and	O
then	O
CRH	S-geneY
was	O
still	O
able	O
to	O
induce	O
an	O
ACTH	S-geneY
increase	O
;	O
the	O
pattern	O
of	O
ACTH	S-geneY
response	O
to	O
CRH	S-geneY
was	O
slightly	O
delayed	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
the	O
two	O
ACTH	S-geneY
curves	O
after	O
CRH	S-geneY
only	O
in	O
the	O
early	O
phase	O
of	O
the	O
response	O
.	O

These	O
data	O
suggest	O
that	O
the	O
inhibitory	O
role	O
of	O
loperamide	O
on	O
ACTH	S-geneY
secretion	O
is	O
exerted	O
at	O
supra	O
-	O
pituitary	O
level	O
,	O
although	O
a	O
pituitary	O
site	O
of	O
action	O
can	O
not	O
be	O
excluded	O
.	O

Almorexant	S-chem
effects	O
on	O
CYP3A4	S-geneY
activity	O
studied	O
by	O
its	O
simultaneous	O
and	O
time	O
-	O
separated	O
administration	O
with	O
simvastatin	S-chem
and	O
atorvastatin	S-chem
.	O

PURPOSE	O
:	O
To	O
characterise	O
further	O
the	O
previously	O
observed	O
cytochrome	B-geneY
P450	I-geneY
3A4	E-geneY
(	O
CYP3A4	S-geneY
)	O
interaction	O
of	O
the	O
dual	O
orexin	B-geneN
receptor	E-geneN
antagonist	O
almorexant	S-chem
.	O

METHODS	O
:	O
Pharmacokinetic	O
interactions	O
were	O
investigated	O
(	O
n	O
=	O
14	O
healthy	O
male	O
subjects	O
in	O
two	O
treatment	O
groups	O
)	O
between	O
almorexant	O
at	E-chem
steady	O
-	O
state	O
when	O
administered	O
either	O
concomitantly	O
or	O
2	O
h	O
after	O
administration	O
of	O
single	O
doses	O
of	O
simvastatin	O
(	I-chem
40	E-chem
mg	O
)	O
or	O
atorvastatin	O
(	I-chem
40	I-chem
mg	O
)	O
.	O

RESULTS	O
:	O
Almorexant	S-chem
dose	O
-	O
dependently	O
increased	O
simvastatin	S-chem
exposure	O
(	O
AUC	O
(	O
0	O
-	O
∞	O
)	O
)	O
when	O
administered	O
concomitantly	O
[	O
geometric	O
mean	O
ratios	O
(	O
90	O
%	O
CI	O
)	O
:	O
2.5	O
(	O
2.1	O
,	O
2.9	O
)	O
(	O
100	O
mg	O
)	O
,	O
3.9	O
(	O
3.3	O
,	O
4.6	O
)	O
(	O
200	O
mg	O
)	O
]	O
,	O
but	O
not	O
C	O
(	O
max	O
)	O
[	O
3.7	O
(	O
3.0	O
,	O
4.5	O
)	O
for	O
both	O
doses	O
]	O
.	O

Time	O
-	O
separated	O
administration	O
resulted	O
in	O
relevant	O
reductions	O
of	O
the	O
interaction	O
[	O
AUC	O
(	O
0	O
-	O
∞	O
)	O
:	O
1.4	O
(	O
1.2	O
,	O
1.7	O
)	O
(	O
100	O
mg	O
)	O
,	O
1.7	O
(	O
1.5	O
,	O
2.0	O
)	O
(	O
200	O
mg	O
)	O
;	O
C	O
(	O
max	O
)	O
:	O
1.5	O
(	O
1.3	O
,	O
1.9	O
)	O
(	O
100	O
mg	O
)	O
,	O
1.9	O
(	O
1.6	O
,	O
2.4	O
)	O
(	O
200	O
mg	O
)	O
]	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
hydroxyacid	B-chem
simvastatin	E-chem
.	O

Independent	O
of	O
almorexant	S-chem
dose	O
and	O
relative	O
time	O
of	O
administration	O
,	O
AUC	O
(	O
0	O
-	O
∞	O
)	O
and	O
C	O
(	O
max	O
)	O
of	O
atorvastatin	S-chem
increased	O
(	O
ratios	O
ranged	O
from	O
1.1	O
to	O
1.5	O
)	O
.	O

AUC	O
(	O
0	O
-	O
∞	O
)	O
and	O
C	O
(	O
max	O
)	O
of	O
o	B-chem
-	I-chem
hydroxy	I-chem
atorvastatin	E-chem
decreased	O
dose	O
-	O
independently	O
[	O
AUC	O
(	O
0	O
-	O
∞	O
)	O
:	O
0.8	O
(	O
0.8	O
,	O
0.9	O
)	O
(	O
100	O
mg	O
)	O
,	O
0.6	O
(	O
0.5	O
,	O
0.6	O
)	O
(	O
200	O
mg	O
)	O
;	O
C	O
(	O
max	O
)	O
:	O
0.3	O
(	O
0.3	O
,	O
0.4	O
)	O
(	O
100	O
mg	O
)	O
,	O
0.2	O
(	O
0.2	O
,	O
0.3	O
)	O
(	O
200	O
mg	O
)	O
]	O
when	O
atorvastatin	O
was	I-chem
concomitantly	O
administered	O
.	O

C	O
(	O
max	O
)	O
of	O
o	B-chem
-	I-chem
hydroxy	I-chem
atorvastatin	E-chem
slightly	O
decreased	O
(	O
0.8	O
for	O
both	O
doses	O
)	O
following	O
time	O
-	O
separated	O
administration	O
;	O
AUC	O
(	O
0	O
-	O
∞	O
)	O
was	O
unchanged	O
.	O

CONCLUSIONS	O
:	O
Whereas	O
almorexant	S-chem
increased	O
simvastatin	S-chem
exposure	O
dose	O
-	O
and	O
relative	O
time	O
of	O
administration	O
-	O
dependently	O
,	O
atorvastatin	S-chem
exposure	O
increased	O
to	O
a	O
smaller	O
extent	O
and	O
irrespective	O
of	O
dose	O
and	O
time	O
.	O

This	O
suggests	O
that	O
the	O
observed	O
interaction	O
of	O
almorexant	S-chem
with	O
simvastatin	S-chem
is	O
mainly	O
caused	O
by	O
intestinal	O
CYP3A4	S-geneY
inhibition	O
,	O
whereas	O
the	O
interaction	O
with	O
atorvastatin	S-chem
is	O
more	O
due	O
to	O
hepatic	O
CYP3A4	S-geneY
inhibition	O
.	O

Evaluation	O
of	O
the	O
pharmacological	O
selectivity	O
profile	O
of	O
alpha	B-geneN
1	I-geneN
adrenoceptor	E-geneN
antagonists	O
at	O
prostatic	O
alpha	B-geneN
1	I-geneN
adrenoceptors	E-geneN
:	O
binding	O
,	O
functional	O
and	O
in	O
vivo	O
studies	O
.	O

1	O
.	O

The	O
profile	O
of	O
a	O
range	O
of	O
alpha	B-geneN
1	I-geneN
adrenoceptor	E-geneN
antagonists	O
was	O
determined	O
in	O
vitro	O
against	O
cloned	O
human	B-geneN
alpha	I-geneN
1A	I-geneN
,	I-geneN
alpha	I-geneN
1B	I-geneN
and	I-geneN
alpha	I-geneN
1D	I-geneN
adrenoceptors	E-geneN
and	O
against	O
noradrenaline	S-chem
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
and	O
human	O
prostate	O
.	O

The	O
in	O
vivo	O
profile	O
of	O
compounds	O
was	O
determined	O
in	O
an	O
anaesthetized	O
dog	O
model	O
which	O
allowed	O
the	O
simultaneous	O
assessment	O
of	O
antagonist	O
potency	O
against	O
phenylephrine	S-chem
-	O
mediated	O
increases	O
in	O
blood	O
pressure	O
and	O
prostatic	O
pressure	O
.	O

2	O
.	O

The	O
quinazoline	S-chem
antagonists	O
,	O
prazosin	S-chem
,	O
doxazosin	S-chem
and	O
alfuzosin	S-chem
displayed	O
high	O
affinity	O
but	O
were	O
non	O
selective	O
for	O
the	O
three	O
cloned	O
human	B-geneN
alpha	I-geneN
1	I-geneN
adrenoceptors	E-geneN
.	O

Indoramin	S-chem
and	O
SNAP	B-chem
1069	E-chem
showed	O
selectivity	O
for	O
alpha	B-geneN
1A	I-geneN
and	I-geneN
alpha	I-geneN
1B	I-geneN
adrenoceptors	E-geneN
relative	O
to	O
the	O
alpha	B-geneY
1D	I-geneY
subtype	E-geneY
.	O

Rec	B-chem
15	I-chem
/	I-chem
2739	E-chem
,	O
WB	B-chem
4101	E-chem
,	O
SL	B-chem
89,0591	E-chem
,	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
and	I-chem
(	I-chem
-	I-chem
)	I-chem
-	I-chem
tamsulosin	E-chem
showed	O
selectivity	O
for	O
alpha	B-geneN
1A	I-geneN
and	I-geneN
alpha	I-geneN
1D	I-geneN
adrenoceptors	E-geneN
relative	O
to	O
the	O
alpha	B-geneY
1B	I-geneY
subtype	E-geneY
.	O

RS	B-chem
17053	E-chem
showed	O
high	O
affinity	O
and	O
selectivity	O
for	O
alpha	B-geneY
1A	I-geneY
adrenoceptors	E-geneY
(	O
pKi	O
8.6	O
)	O
relative	O
to	O
alpha	B-geneY
1B	E-geneY
(	O
pKi	O
=	O
7.3	O
)	O
and	O
alpha	B-geneY
1D	E-geneY
(	O
pKi	O
=	O
7.1	O
)	O
subtypes	O
.	O

3	O
.	O

(	B-chem
+	I-chem
)	I-chem
-	I-chem
Tamsulosin	E-chem
,	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
tamsulosin	E-chem
,	O
SL	B-chem
89,0591	E-chem
,	O
Rec	B-chem
15	I-chem
/	I-chem
2739	E-chem
,	O
SNAP	B-chem
1069	E-chem
and	O
RS	B-chem
17053	E-chem
appeared	O
to	O
act	O
as	O
competitive	O
antagonists	O
of	O
noradrenaline	S-chem
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
yielding	O
pA2	O
affinity	O
estimates	O
which	O
were	O
similar	O
to	O
binding	O
affinities	O
at	O
cloned	O
human	B-geneY
alpha	I-geneY
1D	I-geneY
adrenoceptors	E-geneY
.	O

The	O
following	O
rank	O
order	O
was	O
obtained	O
:	O
prazosin	S-chem
=	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
tamsulosin	E-chem
>	O
doxazosin	S-chem
>	O
SL	B-chem
89,0591	E-chem
=	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
tamsulosin	E-chem
>	O
Rec	B-chem
15	I-chem
/	I-chem
2739	E-chem
>	O
RS	B-chem
17053	E-chem
=	O
SNAP	B-chem
1069	E-chem
.	O

4	O
.	O

(	B-chem
-	I-chem
)	I-chem
-	I-chem
Tamsulosin	E-chem
was	O
a	O
very	O
potent	O
,	O
insurmountable	O
antagonist	O
of	O
noradrenaline	S-chem
-	O
mediated	O
contractions	O
of	O
human	O
prostate	O
,	O
yielding	O
an	O
approximate	O
pA2	O
estimate	O
of	O
9.8	O
at	O
1	O
nM	O
.	O

The	O
corresponding	O
(	O
+	O
)	O
-	O
enantiomer	O
was	O
30	O
fold	O
weaker	O
.	O

SL	O
89,0591	O
,	O
SNAP	O
1069	O
and	O
Rec	O
15	O
/	O
2739	O
yielded	O
pA2	O
estimates	O
which	O
compared	O
well	O
with	O
their	O
alpha	B-geneY
1A	E-geneY
binding	O
affinities	O
.	O

The	O
affinity	O
estimate	O
for	O
prazosin	S-chem
on	O
human	O
prostate	O
was	O
lower	O
than	O
the	O
corresponding	O
binding	O
affinity	O
determined	O
at	O
alpha	B-geneY
1A	I-geneY
adrenoceptors	E-geneY
and	O
RS	B-chem
17053	E-chem
was	O
a	O
very	O
weak	O
antagonist	O
on	O
human	O
prostate	O
(	O
pA2	O
=	O
6.0	O
)	O
relative	O
to	O
the	O
high	O
affinity	O
(	O
pKi	O
=	O
8.6	O
)	O
determined	O
at	O
cloned	O
human	B-geneY
alpha	I-geneY
1A	I-geneY
adrenoceptors	E-geneY
.	O

5	O
.	O

In	O
the	O
anaesthetized	O
dog	O
,	O
in	O
vivo	O
pseudo	O
``	O
pA2	O
'	O
values	O
showed	O
that	O
doxazosin	O
,	B-chem
(	I-chem
+	I-chem
)	I-chem
-	I-chem
and	I-chem
(	I-chem
-	I-chem
)	I-chem
-	I-chem
tamsulosin	O
inhibited	O
phenylephrine	O
-	O
induced	O
increases	O
in	O
prostatic	O
and	O
blood	O
pressure	O
with	O
similar	O
affinity	O
,	O
implying	O
that	O
these	O
agents	O
show	O
little	O
or	O
no	O
selectivity	O
for	O
prostatic	O
responses	O
in	O
this	O
model	O
.	O

SL	O
89,0591	O
and	O
SNAP	O
1069	O
were	O
moderately	O
selective	O
(	O
3	O
and	O
6	O
fold	O
respectively	O
)	O
for	O
prostatic	O
pressure	O
relative	O
to	O
blood	O
pressure	O
.	O

Rec	B-chem
15	I-chem
/	I-chem
2739	E-chem
was	O
a	O
more	O
potent	O
antagonist	O
of	O
phenylephrine	S-chem
-	O
mediated	O
increases	O
in	O
prostatic	O
pressure	O
(	O
``	O
pA2	O
'	O
=	O
8.74	O
)	O
compared	O
to	O
blood	O
pressure	O
(	O
``	O
pA2	O
'	O
=	O
7.51	O
)	O
.	O

6	O
.	O

Data	O
in	O
this	O
study	O
suggest	O
that	O
the	O
alpha	B-geneN
1	I-geneN
adrenoceptor	E-geneN
mediating	O
noradrenaline	S-chem
-	O
induced	O
contractions	O
of	O
human	O
prostate	O
,	O
whilst	O
having	O
some	O
of	O
the	O
characteristics	O
of	O
an	O
alpha	B-geneY
1A	I-geneY
adrenoceptor	E-geneY
,	O
can	O
not	O
be	O
satisfactorily	O
aligned	O
with	O
cloned	O
alpha	B-geneN
1A	I-geneN
,	I-geneN
alpha	I-geneN
1B	I-geneN
or	I-geneN
alpha	I-geneN
1D	I-geneN
adrenoceptors	E-geneN
.	O

In	O
addition	O
,	O
studies	O
in	O
the	O
anaesthetized	O
dog	O
have	O
shown	O
that	O
agents	O
having	O
high	O
affinity	O
and	O
selectivity	O
for	O
prostatic	O
alpha	B-geneN
1	I-geneN
adrenoceptors	E-geneN
,	O
particularly	O
over	O
the	O
alpha	B-geneY
1D	I-geneY
subtype	E-geneY
,	O
appear	O
to	O
inhibit	O
phenylephrine	S-chem
-	O
induced	O
increases	O
in	O
prostatic	O
pressure	O
selectively	O
compared	O
to	O
blood	O
pressure	O
.	O

IFNα	S-geneN
converts	O
IL	B-geneY
-	I-geneY
22	E-geneY
into	O
a	O
cytokine	S-geneN
efficiently	O
activating	O
STAT1	S-geneY
and	O
its	O
downstream	O
targets	O
.	O

Besides	O
their	O
antiviral	O
activity	O
,	O
type	B-geneN
I	I-geneN
Interferons	E-geneN
(	O
IFN	S-geneN
)	O
display	O
context	O
-	O
specific	O
immunomodulation	O
.	O

In	O
contrast	O
to	O
long	O
-	O
known	O
IFNα	B-geneN
/	I-geneN
β	E-geneN
,	O
Interleukin	B-geneY
(	I-geneY
IL	I-geneY
)	I-geneY
-	I-geneY
22	E-geneY
is	O
an	O
anti	O
-	O
bacterial	O
,	O
largely	O
tissue	O
protective	O
cytokine	S-geneN
that	O
recently	O
gained	O
attention	O
.	O

Herein	O
,	O
cellular	O
IFNα	S-geneN
/	O
IL	B-geneY
-	I-geneY
22	E-geneY
interactions	O
are	O
investigated	O
.	O

We	O
report	O
that	O
pre	O
-	O
conditioning	O
of	O
epithelial	O
cells	O
with	O
IFNα	S-geneN
initiated	O
dramatic	O
changes	O
in	O
IL	B-geneY
-	I-geneY
22	E-geneY
signaling	O
normally	O
dominated	O
by	O
signal	B-geneY
transducer	I-geneY
and	I-geneY
activator	I-geneY
of	I-geneY
transcription	I-geneY
(	I-geneY
STAT	I-geneY
)	I-geneY
-	I-geneY
3	E-geneY
.	O

Specifically	O
,	O
by	O
using	O
human	O
DLD1	O
colon	O
epithelial	O
/	O
carcinoma	O
cells	O
we	O
demonstrate	O
that	O
,	O
upon	O
IFNα	S-geneN
,	O
IL	B-geneY
-	I-geneY
22	E-geneY
converts	O
into	O
a	O
cytokine	S-geneN
robustly	O
activating	O
STAT1	S-geneY
and	O
its	O
downstream	O
pro	O
-	O
inflammatory	O
targets	O
CXCL9	S-geneY
,	O
CXCL10	S-geneY
,	O
and	O
inducible	B-geneY
nitric	I-geneY
oxide	I-geneY
synthase	E-geneY
(	O
iNOS	S-geneY
)	O
.	O

Accordingly	O
,	O
only	O
after	O
IFNα	S-geneN
pre	O
-	O
incubation	O
was	O
IL	B-geneY
-	I-geneY
22	E-geneY
-	O
induced	O
STAT1	S-geneY
binding	O
to	O
the	O
CXCL10	B-geneN
promoter	E-geneN
detectable	O
.	O

Using	O
the	O
viral	O
mimic	O
polyinosinic	B-chem
:	I-chem
polycytidylic	I-chem
acid	E-chem
and	O
the	O
IFNα	B-geneN
/	I-geneN
β	E-geneN
antagonist	O
B18R	O
we	O
furthermore	O
demonstrate	O
the	O
capability	O
of	O
endogenous	O
IFN	S-geneN
to	O
promote	O
IL	B-geneY
-	I-geneY
22	E-geneY
-	O
induced	O
STAT1	S-geneY
activation	O
and	O
expression	O
of	O
CXCL10	S-geneY
.	O

IL	B-geneY
-	I-geneY
22	E-geneY
-	O
induced	O
STAT1	S-geneY
activation	O
subsequent	O
to	O
IFNα	S-geneN
priming	O
became	O
likewise	O
apparent	O
in	O
human	O
Caco2	O
colon	O
epithelial	O
/	O
carcinoma	O
cells	O
,	O
HepG2	O
hepatoma	O
cells	O
,	O
and	O
primary	O
keratinocytes	O
.	O

Current	O
observations	O
may	O
relate	O
to	O
characteristics	O
of	O
IFNα	B-geneN
/	I-geneN
β	E-geneN
in	O
clinical	O
therapy	O
and	O
expose	O
margins	O
of	O
tissue	O
protection	O
by	O
IL	B-geneY
-	I-geneY
22	E-geneY
application	O
.	O

Accumulation	O
of	O
cystathionine	S-chem
,	O
cystathionine	B-chem
ketimine	E-chem
,	O
and	O
perhydro	B-chem
-	I-chem
1,4	I-chem
-	I-chem
thiazepine	I-chem
-	I-chem
3,5	I-chem
-	I-chem
dicarboxylic	I-chem
acid	E-chem
in	O
whole	O
brain	O
and	O
various	O
regions	O
of	O
the	O
brain	O
of	O
D	B-chem
,	I-chem
L	I-chem
-	I-chem
propargylglycine	E-chem
-	O
treated	O
rats	O
.	O

Experimental	O
cystathioninuria	O
was	O
induced	O
in	O
rats	O
by	O
administration	O
of	O
the	O
cystathionine	B-geneY
gamma	I-geneY
-	I-geneY
lyase	E-geneY
inhibitor	O
,	O
D	B-chem
,	I-chem
L	I-chem
-	I-chem
propargylglycine	E-chem
.	O

The	O
cystathionine	S-chem
metabolites	O
,	O
cystathionine	B-chem
ketimine	E-chem
(	O
CK	S-chem
)	O
and	O
perhydro	B-chem
-	I-chem
1,4	I-chem
-	I-chem
thiazepine	I-chem
-	I-chem
3,5	I-chem
-	I-chem
dicarboxylic	I-chem
acid	E-chem
(	O
PHTZDC	S-chem
)	O
,	O
were	O
identified	O
in	O
whole	O
brain	O
and	O
various	O
regions	O
of	O
the	O
brain	O
in	O
D	B-chem
,	I-chem
L	I-chem
-	I-chem
propargylglycine	E-chem
-	O
treated	O
rats	O
.	O

The	O
concentration	O
of	O
CK	S-chem
and	O
PHTZDC	S-chem
in	O
whole	O
brain	O
and	O
various	O
regions	O
of	O
the	O
brain	O
increased	O
gradually	O
after	O
administration	O
of	O
D	B-chem
,	I-chem
L	I-chem
-	I-chem
propargylglycine	E-chem
,	O
and	O
reached	O
the	O
highest	O
value	O
at	O
about	O
20	O
hours	O
.	O

CK	S-chem
and	O
PHTZDC	S-chem
accumulated	O
in	O
whole	O
brain	O
and	O
various	O
regions	O
of	O
the	O
brain	O
in	O
proportion	O
to	O
the	O
amount	O
of	O
accumulated	O
cystathionine	O
after	O
D	B-chem
,	I-chem
L	I-chem
-	I-chem
propargylglycine	E-chem
administration	O
.	O

The	O
concentration	O
of	O
these	O
compounds	O
in	O
the	O
cerebellum	O
was	O
higher	O
versus	O
the	O
other	O
regions	O
of	O
the	O
rat	O
brain	O
.	O

Improving	O
the	O
tolerability	O
of	O
anticholinergic	O
agents	O
in	O
the	O
treatment	O
of	O
overactive	O
bladder	O
.	O

Pharmacological	O
treatment	O
for	O
overactive	O
bladder	O
has	O
centred	O
around	O
the	O
interruption	O
of	O
the	O
detrusor	O
activity	O
that	O
is	O
central	O
to	O
urge	O
and	O
incontinence	O
symptoms	O
.	O

The	O
majority	O
of	O
patients	O
with	O
this	O
disorder	O
are	O
treated	O
with	O
antimuscarinic	O
agents	O
.	O

These	O
drugs	O
have	O
been	O
demonstrated	O
to	O
improve	O
urgency	O
,	O
frequency	O
of	O
micturition	O
and	O
urge	O
incontinence	O
,	O
all	O
of	O
which	O
are	O
primary	O
symptoms	O
of	O
overactive	O
bladder	O
;	O
however	O
,	O
they	O
are	O
also	O
commonly	O
associated	O
with	O
anticholinergic	O
adverse	O
effects	O
,	O
most	O
notably	O
dry	O
mouth	O
.	O

Attempts	O
to	O
increase	O
tolerability	O
have	O
included	O
the	O
development	O
of	O
advanced	O
formulations	O
that	O
regulate	O
release	O
of	O
the	O
active	O
ingredient	O
and	O
the	O
development	O
of	O
pharmacological	O
agents	O
that	O
target	O
the	O
desired	O
bladder	O
receptors	O
more	O
specifically	O
and	O
accurately	O
.	O

Although	O
all	O
agents	O
provide	O
good	O
efficacy	O
,	O
tolerability	O
is	O
greatly	O
affected	O
by	O
the	O
formulation	O
used	O
to	O
deliver	O
the	O
active	O
pharmacological	O
agent	O
,	O
as	O
well	O
as	O
the	O
specificity	O
of	O
the	O
targeted	O
receptors	O
.	O

Clinical	O
trials	O
involving	O
a	O
transdermal	O
formulation	O
of	O
oxybutynin	S-chem
have	O
shown	O
that	O
this	O
delivery	O
method	O
may	O
be	O
associated	O
with	O
a	O
lower	O
incidence	O
of	O
anticholinergic	O
adverse	O
events	O
compared	O
with	O
both	O
the	O
immediate	O
-	O
release	O
and	O
the	O
extended	O
-	O
release	O
oral	O
formulations	O
of	O
traditional	O
agents	O
,	O
as	O
well	O
as	O
the	O
most	O
recently	O
approved	O
agents	O
-	O
trospium	B-chem
chloride	E-chem
,	O
solifenacin	S-chem
and	O
darifenacin	S-chem
.	O

Much	O
is	O
still	O
being	O
learned	O
about	O
the	O
function	O
and	O
specificity	O
of	O
muscarinic	B-geneN
receptors	E-geneN
,	O
which	O
will	O
support	O
the	O
development	O
of	O
agents	O
with	O
sustained	O
efficacy	O
and	O
enhanced	O
tolerability	O
compared	O
with	O
the	O
available	O
formulations	O
to	O
date	O
.	O

These	O
include	O
the	O
S	B-chem
-	I-chem
isomer	I-chem
of	I-chem
oxybutynin	E-chem
,	O
as	O
well	O
as	O
selective	O
muscarinic	B-geneY
M2	I-geneY
receptor	E-geneY
antagonists	O
.	O

Binding	O
between	O
proteins	O
and	O
cationic	O
spherical	O
polyelectrolyte	O
brushes	O
:	O
effect	O
of	O
pH	O
,	O
ionic	O
strength	O
,	O
and	O
stoichiometry	O
.	O

Cationic	O
spherical	O
polyelectrolyte	O
brushes	O
(	O
SPBs	O
)	O
were	O
synthesized	O
by	O
photoemulsion	O
polymerization	O
,	O
consisting	O
of	O
a	O
polystyrene	S-chem
core	O
with	O
a	O
diameter	O
around	O
80	O
nm	O
and	O
a	O
poly	B-chem
(	I-chem
2	I-chem
-	I-chem
aminoethylmethacrylate	I-chem
hydrochloride	I-chem
)	E-chem
(	O
PAEMH	S-chem
)	O
shell	O
with	O
a	O
thickness	O
from	O
10	O
to	O
50	O
nm	O
densely	O
grafted	O
on	O
the	O
core	O
surface	O
.	O

The	O
binding	O
of	O
various	O
proteins	O
onto	O
SPBs	O
was	O
observed	O
by	O
turbidimetric	O
titration	O
,	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
,	O
zeta	O
potential	O
,	O
and	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
.	O

The	O
binding	O
,	O
aggregation	O
,	O
and	O
releasing	O
of	O
proteins	O
by	O
SPB	O
can	O
be	O
tuned	O
by	O
modulating	O
pH	O
.	O

The	O
pH	O
regions	O
of	O
binding	O
for	O
bovine	B-geneY
serum	I-geneY
albumin	E-geneY
(	O
BSA	S-geneY
)	O
,	O
β	B-geneY
-	I-geneY
lactoglobulin	E-geneY
(	O
BLG	S-geneY
)	O
,	O
and	O
papain	S-geneY
onto	O
SPBs	O
are	O
markedly	O
different	O
and	O
tunable	O
by	O
ionic	O
strength	O
and	O
stoichiometry	O
between	O
protein	O
and	O
SPB	O
.	O

Binding	O
energetics	O
,	O
affinity	O
,	O
and	O
amount	O
of	O
various	O
proteins	O
onto	O
cationic	O
SPBs	O
were	O
determined	O
by	O
ITC	O
.	O

These	O
findings	O
lay	O
the	O
foundation	O
for	O
SPB	O
applications	O
in	O
the	O
protein	O
purification	O
and	O
selective	O
immobilization	O
of	O
different	O
proteins	O
,	O
enzymes	O
,	O
and	O
antibodies	O
.	O

Modulation	O
of	O
cellular	O
insulin	S-geneN
signaling	O
and	O
PTP1B	S-geneY
effects	O
by	O
lipid	O
metabolites	O
in	O
skeletal	O
muscle	O
cells	O
.	O

Normal	O
glucose	S-chem
regulation	O
is	O
achieved	O
by	O
having	O
adequate	O
insulin	S-geneY
secretion	O
and	O
effective	O
glucose	S-chem
uptake	O
/	O
disposal	O
.	O

Excess	O
lipids	O
in	O
peripheral	O
tissues	O
-	O
skeletal	O
muscle	O
,	O
liver	O
and	O
adipose	O
tissue	O
-	O
may	O
attenuate	O
insulin	S-geneY
signaling	O
through	O
the	O
protein	B-geneN
kinase	I-geneN
B	E-geneN
(	O
AKt	S-geneN
)	O
pathway	O
and	O
up	O
-	O
regulate	O
protein	B-geneY
tyrosine	I-geneY
phosphatase	I-geneY
1B	E-geneY
(	O
PTP1B	S-geneY
)	O
,	O
a	O
negative	O
regulator	O
of	O
insulin	S-geneY
signaling	O
.	O

We	O
studied	O
accumulation	O
of	O
lipid	O
metabolites	O
[	O
triglycerides	S-chem
(	O
TAGs	S-chem
)	O
,	O
diglycerides	S-chem
(	O
DAGs	S-chem
)	O
]	O
and	O
ceramides	S-chem
in	O
relation	O
to	O
insulin	S-geneN
signaling	O
and	O
expression	O
and	O
phosphorylation	O
of	O
PTP1B	S-geneY
by	O
preincubating	O
rat	O
skeletal	O
muscle	O
cells	O
(	O
L6	O
myotubes	O
)	O
with	O
three	O
saturated	O
and	O
three	O
unsaturated	O
free	O
fatty	B-chem
acids	E-chem
(	O
FFAs	O
)	O
(	O
200	O
μM	O
)	O
.	O

Cells	O
were	O
also	O
evaluated	O
in	O
the	O
presence	O
of	O
wortmannin	S-chem
,	O
an	O
inhibitor	O
of	O
phosphatidylinositol	B-geneN
3	I-geneN
-	I-geneN
kinases	E-geneN
and	O
thus	O
AKt	S-geneN
(	O
0	O
-	O
100	O
nM	O
)	O
.	O

Unsaturated	O
FFAs	O
increased	O
DAGs	S-chem
,	O
TAGs	S-chem
and	O
PTP1B	S-geneY
expression	O
significantly	O
,	O
but	O
cells	O
remained	O
insulin	S-geneN
sensitive	O
as	O
assessed	O
by	O
robust	O
AKt	S-geneN
and	O
PTP1B	S-geneY
phosphorylation	O
at	O
serine	S-chem
(	O
Ser	S-chem
)	O
50	O
,	O
Ser	S-chem
398	O
and	O
tyrosine	S-chem
152	O
.	O

Saturated	O
palmitic	B-chem
and	I-chem
stearic	I-chem
acids	E-chem
increased	O
ceramides	S-chem
,	O
up	O
-	O
regulated	O
PTP1B	S-geneY
,	O
and	O
had	O
AKt	S-geneN
and	O
PTP1B	S-geneY
phosphorylation	O
at	O
Ser	S-chem
50	O
impaired	O
.	O

We	O
show	O
a	O
significant	O
correlation	O
between	O
phosphorylation	O
levels	O
of	O
AKt	S-geneN
and	O
of	O
PTP1B	S-geneY
at	O
Ser	O
50	O
(	O
R	O
(	O
2	O
)	O
=	O
0.84	O
,	O
P	O
<	O
.05	O
)	O
.	O

The	O
same	O
was	O
observed	O
with	O
increasing	O
wortmannin	S-chem
dose	O
(	O
R	O
(	O
2	O
)	O
=	O
0.73	O
,	O
P	O
<	O
.05	O
)	O
.	O

Only	O
FFAs	O
that	O
increased	O
ceramides	S-chem
caused	O
impairment	O
of	O
AKt	S-geneN
and	O
PTP1B	S-geneY
phosphorylation	O
at	O
Ser	S-chem
50	O
.	O

PTP1B	S-geneY
overexpression	O
in	O
the	O
presence	O
of	O
excess	O
lipids	O
may	O
not	O
directly	O
cause	O
insulin	S-geneN
resistance	O
unless	O
it	O
is	O
accompanied	O
by	O
decreased	O
PTP1B	S-geneY
phosphorylation	O
.	O

A	O
clear	O
relationship	O
between	O
PTP1B	S-geneY
phosphorylation	O
levels	O
at	O
Ser	S-chem
50	O
and	O
its	O
negative	O
effect	O
on	O
insulin	S-geneN
signaling	O
is	O
shown	O
.	O

Passive	O
stiffness	O
of	O
airway	O
smooth	O
muscle	O
:	O
the	O
next	O
target	O
for	O
improving	O
airway	O
distensibility	O
and	O
treatment	O
for	O
asthma	O
?	O

Reduced	O
airway	O
distensibility	O
due	O
to	O
increased	O
airway	O
stiffness	O
is	O
a	O
characteristic	O
of	O
asthma	O
.	O

Airway	O
stiffness	O
is	O
determined	O
by	O
the	O
property	O
and	O
structural	O
organization	O
of	O
the	O
various	O
elements	O
of	O
the	O
airway	O
wall	O
,	O
and	O
is	O
often	O
divided	O
into	O
active	O
and	O
passive	O
components	O
.	O

Active	O
stiffness	O
is	O
thought	O
to	O
be	O
associated	O
with	O
activation	O
of	O
muscle	O
cells	O
in	O
the	O
airway	O
wall	O
.	O

This	O
component	O
of	O
stiffness	O
can	O
be	O
inhibited	O
when	O
active	O
force	O
produced	O
by	O
the	O
muscle	O
is	O
abolished	O
.	O

Passive	O
stiffness	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
thought	O
to	O
stem	O
from	O
non	O
-	O
muscle	O
component	O
of	O
the	O
airway	O
wall	O
,	O
especially	O
the	O
collagen	S-geneN
/	O
elastin	S-geneY
fibrous	O
network	O
of	O
the	O
extracellular	O
matrix	O
within	O
which	O
the	O
muscle	O
cells	O
are	O
embedded	O
.	O

In	O
this	O
brief	O
review	O
,	O
the	O
notion	O
that	O
passive	O
stiffness	O
is	O
exclusively	O
extracellular	O
in	O
origin	O
is	O
challenged	O
.	O

Recent	O
evidence	O
suggests	O
that	O
a	O
substantial	O
portion	O
of	O
the	O
passive	O
stiffness	O
of	O
an	O
in	O
vitro	O
preparation	O
of	O
tracheal	O
smooth	O
muscle	O
is	O
calcium	S-chem
sensitive	O
and	O
is	O
regulated	O
by	O
Rho	B-geneN
-	I-geneN
kinase	E-geneN
,	O
although	O
the	O
underlying	O
mechanism	O
and	O
the	O
details	O
of	O
regulation	O
for	O
the	O
development	O
of	O
this	O
intracellular	O
passive	O
stiffness	O
are	O
still	O
largely	O
unknown	O
.	O

To	O
reduce	O
airway	O
stiffness	O
different	O
lines	O
of	O
attack	O
must	O
be	O
tailored	O
to	O
different	O
components	O
of	O
the	O
stiffness	O
.	O

The	O
regulatable	O
passive	O
stiffness	O
is	O
distinct	O
from	O
the	O
relatively	O
permanent	O
stiffness	O
of	O
the	O
extracellular	O
matrix	O
and	O
the	O
stiffness	O
associated	O
with	O
active	O
muscle	O
contraction	O
.	O

To	O
improve	O
airway	O
distensibility	O
during	O
asthma	O
exacerbation	O
,	O
a	O
comprehensive	O
approach	O
to	O
reduce	O
overall	O
airway	O
stiffness	O
should	O
therefore	O
include	O
a	O
strategy	O
for	O
targeting	O
the	O
regulatable	O
passive	O
stiffness	O
.	O

A	O
human	O
hemi	O
-	O
cornea	O
model	O
for	O
eye	O
irritation	O
testing	O
:	O
quality	O
control	O
of	O
production	O
,	O
reliability	O
and	O
predictive	O
capacity	O
.	O

We	O
have	O
developed	O
a	O
3	O
-	O
dimensional	O
human	O
hemi	O
-	O
cornea	O
which	O
comprises	O
an	O
immortalized	O
epithelial	O
cell	O
line	O
and	O
keratocytes	O
embedded	O
in	O
a	O
collagen	S-geneN
stroma	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
used	O
MTT	S-chem
reduction	O
of	O
the	O
whole	O
tissue	O
to	O
clarify	O
whether	O
the	O
production	O
of	O
this	O
complex	O
3	O
-	O
D	O
-	O
model	O
is	O
transferable	O
into	O
other	O
laboratories	O
and	O
whether	O
these	O
tissues	O
can	O
be	O
constructed	O
reproducibly	O
.	O

Our	O
results	O
demonstrate	O
the	O
reproducible	O
production	O
of	O
the	O
hemi	O
-	O
cornea	O
model	O
according	O
to	O
standard	O
operation	O
procedures	O
using	O
15	O
independent	O
batches	O
of	O
reconstructed	O
hemi	O
-	O
cornea	O
models	O
in	O
two	O
independent	O
laboratories	O
each	O
.	O

Furthermore	O
,	O
the	O
hemi	O
-	O
cornea	O
tissues	O
have	O
been	O
treated	O
with	O
20	O
chemicals	O
of	O
different	O
eye	O
-	O
irritating	O
potential	O
under	O
blind	O
conditions	O
to	O
assess	O
the	O
performance	O
and	O
limitations	O
of	O
our	O
test	O
system	O
comparing	O
three	O
different	O
prediction	O
models	O
.	O

The	O
most	O
suitable	O
prediction	O
model	O
revealed	O
an	O
overall	O
in	O
vitro	O
-	O
in	O
vivo	O
concordance	O
of	O
80	O
%	O
and	O
70	O
%	O
in	O
the	O
participating	O
laboratories	O
,	O
respectively	O
,	O
and	O
an	O
inter	O
-	O
laboratory	O
concordance	O
of	O
80	O
%	O
.	O

Sensitivity	O
of	O
the	O
test	O
was	O
77	O
%	O
and	O
specificity	O
was	O
between	O
57	O
%	O
and	O
86	O
%	O
to	O
discriminate	O
classified	O
from	O
non	O
-	O
classified	O
chemicals	O
.	O

We	O
conclude	O
that	O
additional	O
physiologically	O
relevant	O
endpoints	O
in	O
both	O
epithelium	O
and	O
stroma	O
have	O
to	O
be	O
developed	O
for	O
the	O
reliable	O
prediction	O
of	O
all	O
GHS	O
classes	O
of	O
eye	O
irritation	O
in	O
one	O
stand	O
alone	O
test	O
system	O
.	O

Common	O
resistance	O
mechanisms	O
to	O
deoxynucleoside	O
analogues	O
in	O
variants	O
of	O
the	O
human	O
erythroleukaemic	O
line	O
K562	O
.	O

Resistant	O
variants	O
of	O
the	O
human	O
leukaemic	O
line	O
K562	O
were	O
developed	O
using	O
selection	O
with	O
the	O
deoxynucleoside	O
analogues	O
cytosine	B-chem
arabinoside	E-chem
,	O
2	B-chem
-	I-chem
chlorodeoxyadenosine	E-chem
,	O
fludarabine	S-chem
and	O
gemcitabine	S-chem
.	O

The	O
resistant	O
lines	O
displayed	O
a	O
high	O
degree	O
of	O
cross	O
resistance	O
to	O
all	O
deoxynucleoside	O
analogues	O
,	O
with	O
little	O
or	O
no	O
cross	O
resistance	O
to	O
other	O
agents	O
.	O

There	O
was	O
a	O
profound	O
accumulation	O
defect	O
of	O
all	O
nucleoside	O
analogues	O
in	O
the	O
resistant	O
variants	O
but	O
no	O
significant	O
defect	O
in	O
nucleoside	O
transport	O
in	O
any	O
of	O
the	O
variants	O
.	O

5	B-geneY
'	I-geneY
nucleotidase	E-geneY
activity	O
was	O
strongly	O
increased	O
and	O
deoxycytidine	B-geneY
kinase	E-geneY
activity	O
was	O
moderately	O
reduced	O
in	O
all	O
of	O
the	O
resistant	O
variants	O
,	O
resulting	O
in	O
reduced	O
accumulation	O
of	O
triphosphate	S-chem
analogues	O
.	O

In	O
addition	O
a	O
deletion	O
in	O
one	O
of	O
the	O
alleles	O
of	O
the	O
deoxycytidine	B-geneY
kinase	E-geneY
was	O
detected	O
in	O
the	O
fludarabine	S-chem
-	O
resistant	O
line	O
.	O

Ribonucleotide	B-geneN
reductase	E-geneN
activity	O
was	O
found	O
to	O
be	O
strongly	O
increased	O
in	O
the	O
gemcitabine	S-chem
-	O
selected	O
line	O
and	O
purine	B-geneY
nucleoside	I-geneY
phosphorylase	E-geneY
was	O
increased	O
in	O
the	O
2	B-chem
-	I-chem
chlorodeoxyadenosine	E-chem
-	O
selected	O
line	O
.	O

Free	O
nucleotide	S-chem
pools	O
were	O
increased	O
in	O
the	O
2	B-chem
-	I-chem
chlorodeoxyadenosine	E-chem
-	O
selected	O
line	O
.	O

There	O
was	O
no	O
expression	O
of	O
the	O
mdr1	S-geneY
gene	O
by	O
the	O
resistant	O
lines	O
.	O

Karyotypic	O
analysis	O
and	O
FISH	O
experiments	O
using	O
a	O
6q21	O
specific	O
probe	O
showed	O
alterations	O
in	O
the	O
6	O
(	O
q16	O
-	O
q22	O
)	O
region	O
which	O
contains	O
the	O
5	B-geneY
'	I-geneY
-	I-geneY
nucleotidase	E-geneY
gene	O
.	O

Early	O
events	O
in	O
the	O
activation	O
and	O
degradation	O
of	O
deoxynucleoside	O
analogues	O
appear	O
to	O
constitute	O
common	O
mechanisms	O
of	O
resistance	O
to	O
these	O
compounds	O
.	O

Glycosylation	O
enhances	O
the	O
anti	O
-	O
migratory	O
activities	O
of	O
isomalyngamide	O
A	I-chem
analogs	O
.	O

Three	O
,	O
new	O
,	O
fully	O
synthetic	O
glycosylated	B-chem
isomalyngamide	I-chem
A	E-chem
analogs	O
4	O
-	O
6	O
were	O
prepared	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
migratory	O
activities	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O

The	O
results	O
of	O
the	O
study	O
show	O
that	O
two	O
glycosylated	O
derivatives	O
4	O
and	O
5	O
,	O
containing	O
mannose	S-chem
and	O
galactose	S-chem
appendages	O
,	O
suppress	O
metastatic	O
events	O
(	O
e.g	O
.	O
,	O
migration	O
,	O
invasion	O
and	O
adhesion	O
)	O
in	O
human	O
breast	O
adenocarcinoma	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
at	O
``	O
nontoxic	O
``	O
concentration	O
levels	O
.	O

In	O
contrast	O
,	O
derivative	O
6	O
that	O
contains	O
a	O
lactose	S-chem
moiety	O
,	O
displays	O
a	O
less	O
potent	O
activity	O
.	O

The	O
findings	O
show	O
that	O
monosaccharide	S-chem
rather	O
than	O
disaccharide	S-chem
appendages	O
to	O
the	O
isomalyngamide	B-chem
A	E-chem
backbone	O
more	O
greatly	O
influence	O
cell	O
migration	O
and	O
invasive	O
ability	O
.	O

Evidence	O
has	O
been	O
gained	O
for	O
a	O
mechanism	O
for	O
inhibition	O
of	O
metastatic	O
activities	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
by	O
4	O
and	O
5	O
,	O
involving	O
inactivation	O
of	O
the	O
expression	O
of	O
p	B-geneY
-	I-geneY
FAK	E-geneY
and	O
paxillin	S-geneY
through	O
the	O
integrin	O
-	O
mediated	O
antimetastatic	O
pathway	O
.	O

Age	O
-	O
Related	O
Macular	O
Degeneration	O
-	O
Associated	O
Silent	O
Polymorphisms	O
in	O
HtrA1	S-geneY
Impair	O
Its	O
Ability	O
To	O
Antagonize	O
Insulin	B-geneY
-	I-geneY
Like	I-geneY
Growth	I-geneY
Factor	I-geneY
1	E-geneY
.	O

Synonymous	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
within	O
a	O
transcript	O
's	O
coding	O
region	O
produce	O
no	O
change	O
in	O
the	O
amino	B-chem
acid	E-chem
sequence	O
of	O
the	O
protein	O
product	O
and	O
are	O
therefore	O
intuitively	O
assumed	O
to	O
have	O
a	O
neutral	O
effect	O
on	O
protein	O
function	O
.	O

We	O
report	O
that	O
two	O
common	O
variants	O
of	O
high	B-geneY
-	I-geneY
temperature	I-geneY
requirement	I-geneY
A1	E-geneY
(	O
HTRA1	S-geneY
)	O
that	O
increase	O
the	O
inherited	O
risk	O
of	O
neovascular	O
age	O
-	O
related	O
macular	O
degeneration	O
(	O
NvAMD	O
)	O
harbor	O
synonymous	O
SNPs	O
within	O
exon	O
1	O
of	O
HTRA1	S-geneY
that	O
convert	O
common	O
codons	O
for	O
Ala34	S-chem
and	O
Gly36	S-chem
to	O
less	O
frequently	O
used	O
codons	O
.	O

The	O
frequent	O
-	O
to	O
-	O
rare	O
codon	O
conversion	O
reduced	O
the	O
mRNA	O
translation	O
rate	O
and	O
appeared	O
to	O
compromise	O
HtrA1	B-geneY
's	E-geneY
conformation	O
and	O
function	O
.	O

The	O
protein	O
product	O
generated	O
from	O
the	O
SNP	O
-	O
containing	O
cDNA	O
displayed	O
enhanced	O
susceptibility	O
to	O
proteolysis	O
and	O
a	O
reduced	O
affinity	O
for	O
an	O
anti	O
-	O
HtrA1	S-geneY
antibody	O
.	O

The	O
NvAMD	O
-	O
associated	O
synonymous	O
polymorphisms	O
lie	O
within	O
HtrA1	B-geneN
's	I-geneN
putative	I-geneN
insulin	I-geneN
-	I-geneN
like	I-geneN
growth	I-geneN
factor	I-geneN
1	I-geneN
(	I-geneN
IGF	I-geneN
-	I-geneN
1	I-geneN
)	I-geneN
binding	I-geneN
domain	E-geneN
.	O

They	O
reduced	O
HtrA1	B-geneY
's	E-geneY
abilities	O
to	O
associate	O
with	O
IGF	B-geneY
-	I-geneY
1	E-geneY
and	O
to	O
ameliorate	O
IGF	B-geneY
-	I-geneY
1	E-geneY
-	O
stimulated	O
signaling	O
events	O
and	O
cellular	O
responses	O
.	O

These	O
observations	O
highlight	O
the	O
relevance	O
of	O
synonymous	O
codon	O
usage	O
to	O
protein	O
function	O
and	O
implicate	O
homeostatic	O
protein	O
quality	O
control	O
mechanisms	O
that	O
may	O
go	O
awry	O
in	O
NvAMD	O
.	O

Butein	S-chem
protects	O
human	O
dental	O
pulp	O
cells	O
from	O
hydrogen	B-chem
peroxide	E-chem
-	O
induced	O
oxidative	O
toxicity	O
via	O
Nrf2	S-geneY
pathway	O
-	O
dependent	O
heme	B-geneY
oxygenase	I-geneY
-	I-geneY
1	E-geneY
expressions	O
.	O

Rhus	O
verniciflua	O
Stokes	O
is	O
a	O
plant	O
that	O
is	O
native	O
to	O
East	O
Asian	O
countries	O
,	O
such	O
as	O
Korea	O
,	O
China	O
,	O
and	O
Japan	O
.	O

Butein	S-chem
,	O
a	O
plant	O
polyphenol	S-chem
,	O
is	O
one	O
of	O
the	O
major	O
active	O
components	O
of	O
R.	O
verniciflua	O
.	O

Reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
,	O
produced	O
via	O
dental	O
adhesive	O
bleaching	O
agents	O
and	O
pulpal	O
disease	O
,	O
can	O
cause	O
oxidative	O
stress	O
.	O

Here	O
,	O
we	O
found	O
that	O
butein	S-chem
possesses	O
cytoprotective	O
effects	O
on	O
hydrogen	B-chem
peroxide	E-chem
(	O
H2O2	S-chem
)	O
-	O
induced	O
dental	O
cell	O
death	O
.	O

H2O2	S-chem
is	O
a	O
representative	O
ROS	O
and	O
causes	O
cell	O
death	O
through	O
necrosis	O
in	O
human	O
dental	O
pulp	O
(	O
HDP	O
)	O
cells	O
.	O

H2O2	S-chem
-	O
induced	O
cytotoxicity	O
and	O
production	O
of	O
ROS	O
were	O
blocked	O
in	O
the	O
presence	O
of	O
butein	S-chem
,	O
and	O
these	O
effects	O
were	O
dose	O
dependent	O
.	O

Butein	S-chem
also	O
increased	O
heme	B-geneY
oxygenase	I-geneY
-	I-geneY
1	E-geneY
(	O
HO	B-geneY
-	I-geneY
1	E-geneY
)	O
protein	O
expression	O
and	O
HO	S-geneY
activity	O
.	O

In	O
addition	O
,	O
butein	S-chem
-	O
dependent	O
HO	B-geneY
-	I-geneY
1	E-geneY
expression	O
was	O
required	O
for	O
the	O
inhibition	O
of	O
H2O2	S-chem
-	O
induced	O
cell	O
death	O
and	O
ROS	O
generation	O
.	O

Furthermore	O
,	O
butein	S-chem
treatment	O
caused	O
nuclear	O
accumulation	O
of	O
nuclear	B-geneY
factor	I-geneY
-	I-geneY
E2	I-geneY
-	I-geneY
related	I-geneY
factor	I-geneY
2	E-geneY
(	O
Nrf2	S-geneY
)	O
and	O
increased	O
the	O
promoter	O
activity	O
of	O
antioxidant	B-geneN
response	I-geneN
elements	E-geneN
(	O
AREs	S-geneN
)	O
.	O

Treatment	O
of	O
HDP	O
cells	O
with	O
a	O
c	B-geneN
-	I-geneN
Jun	I-geneN
NH2	I-geneN
-	I-geneN
terminal	I-geneN
kinase	E-geneN
(	O
JNK	S-geneN
)	O
inhibitor	O
also	O
reduced	O
butein	S-chem
-	O
induced	O
HO	B-geneY
-	I-geneY
1	E-geneY
expression	O
,	O
and	O
butein	S-chem
treatment	O
led	O
to	O
increased	O
JNK	S-geneN
phosphorylation	O
.	O

These	O
results	O
indicate	O
that	O
butein	S-chem
may	O
be	O
used	O
to	O
prevent	O
functional	O
dental	O
cell	O
death	O
and	O
thus	O
may	O
be	O
useful	O
as	O
a	O
pulpal	O
disease	O
agent	O
.	O

Successful	O
liver	O
transplantation	O
for	O
Budd	O
-	O
Chiari	O
syndrome	O
in	O
a	O
patient	O
with	O
paroxysmal	O
nocturnal	O
hemoglobinuria	O
treated	O
with	O
the	O
anti	O
-	O
complement	O
antibody	O
eculizumab	O
.	O

Paroxysmal	O
nocturnal	O
hemoglobinuria	O
(	O
PNH	O
)	O
is	O
a	O
rare	O
,	O
acquired	O
hemolytic	O
anemia	O
caused	O
by	O
somatic	O
mutations	O
in	O
the	O
phosphatidylinositol	B-geneY
glycan	I-geneY
-	I-geneY
complementation	I-geneY
class	I-geneY
A	E-geneY
gene	O
and	O
the	O
resulting	O
absence	O
of	O
a	O
key	O
complement	O
regulatory	O
protein	O
,	O
CD59	S-geneY
.	O

Affected	O
red	O
blood	O
cells	O
in	O
patients	O
with	O
PNH	O
undergo	O
intravascular	O
complement	O
-	O
mediated	O
lysis	O
with	O
resulting	O
anemia	O
,	O
hemoglobinuria	O
,	O
and	O
venous	O
thromboses	O
.	O

Hepatic	O
venous	O
outflow	O
thrombosis	O
[	O
Budd	O
-	O
Chiari	O
syndrome	O
(	O
BCS	O
)	O
]	O
is	O
especially	O
common	O
in	O
PNH	O
patients	O
and	O
often	O
fatal	O
.	O

The	O
few	O
case	O
reports	O
of	O
outcomes	O
in	O
patients	O
undergoing	O
liver	O
transplant	O
for	O
BCS	O
secondary	O
to	O
PNH	O
detail	O
instances	O
of	O
recurrent	O
BCS	O
as	O
well	O
as	O
early	O
thrombotic	O
portal	O
vein	O
occlusion	O
and	O
hepatic	O
artery	O
thrombosis	O
requiring	O
retransplantation	O
.	O

PNH	O
is	O
therefore	O
generally	O
considered	O
a	O
contraindication	O
to	O
liver	O
transplantation	O
.	O

Here	O
we	O
present	O
the	O
first	O
report	O
of	O
a	O
patient	O
with	O
PNH	O
and	O
BCS	O
undergoing	O
successful	O
liver	O
transplantation	O
while	O
receiving	O
eculizumab	O
,	O
a	O
humanized	O
monoclonal	O
antibody	O
that	O
blocks	O
the	O
activation	O
of	O
the	O
terminal	O
complement	O
at	O
C5	S-geneY
.	O

Pyridoxal	B-chem
5	I-chem
'	I-chem
-	I-chem
phosphate	E-chem
may	O
be	O
curative	O
in	O
early	O
-	O
onset	O
epileptic	O
encephalopathy	O
.	O

Neonatal	O
epileptic	O
encephalopathy	O
can	O
be	O
caused	O
by	O
inborn	O
errors	O
of	O
metabolism	O
.	O

These	O
conditions	O
are	O
often	O
unresponsive	O
to	O
treatment	O
with	O
conventional	O
antiepileptic	O
drugs	O
.	O

Six	O
children	O
with	O
pyridox	B-geneY
(	I-geneY
am	I-geneY
)	I-geneY
ine	I-geneY
-	I-geneY
5	I-geneY
'	I-geneY
-	I-geneY
phosphate	I-geneY
oxidase	E-geneY
(	O
PNPO	S-geneY
)	O
deficiency	O
presented	O
with	O
neonatal	O
epileptic	O
encephalopathy	O
.	O

Two	O
were	O
treated	O
with	O
pyridoxal	B-chem
5	I-chem
'	I-chem
-	I-chem
phosphate	E-chem
(	O
PLP	S-chem
)	O
within	O
the	O
first	O
month	O
of	O
life	O
and	O
showed	O
normal	O
development	O
or	O
moderate	O
psychomotor	O
retardation	O
thereafter	O
.	O

Four	O
children	O
with	O
late	O
or	O
no	O
treatment	O
died	O
or	O
showed	O
severe	O
mental	O
handicap	O
.	O

All	O
of	O
the	O
children	O
showed	O
atypical	O
biochemical	O
findings	O
.	O

Prompt	O
treatment	O
with	O
PLP	S-chem
in	O
all	O
neonates	O
and	O
infants	O
with	O
epileptic	O
encephalopathy	O
should	O
become	O
mandatory	O
,	O
permitting	O
normal	O
development	O
in	O
at	O
least	O
some	O
of	O
those	O
affected	O
with	O
PNPO	S-geneY
deficiency	O
.	O

Iron	S-chem
and	O
diabetes	O
risk	O
.	O

Iron	S-chem
overload	O
is	O
a	O
risk	O
factor	O
for	O
diabetes	O
.	O

The	O
link	O
between	O
iron	S-chem
and	O
diabetes	O
was	O
first	O
recognized	O
in	O
pathologic	O
conditions	O
-	O
hereditary	O
hemochromatosis	O
and	O
thalassemia	O
-	O
but	O
high	O
levels	O
of	O
dietary	O
iron	S-chem
also	O
impart	O
diabetes	O
risk	O
.	O

Iron	S-chem
plays	O
a	O
direct	O
and	O
causal	O
role	O
in	O
diabetes	O
pathogenesis	O
mediated	O
both	O
by	O
β	O
cell	O
failure	O
and	O
insulin	S-geneY
resistance	O
.	O

Iron	S-chem
also	O
regulates	O
metabolism	O
in	O
most	O
tissues	O
involved	O
in	O
fuel	O
homeostasis	O
,	O
with	O
the	O
adipocyte	O
in	O
particular	O
serving	O
an	O
iron	S-chem
-	O
sensing	O
role	O
.	O

The	O
underlying	O
molecular	O
mechanisms	O
mediating	O
these	O
effects	O
are	O
numerous	O
and	O
incompletely	O
understood	O
but	O
include	O
oxidant	O
stress	O
and	O
modulation	O
of	O
adipokines	S-geneN
and	O
intracellular	O
signal	O
transduction	O
pathways	O
.	O

The	O
influence	O
of	O
Goishi	O
tea	O
on	O
adipocytokines	S-geneN
in	O
obese	O
mice	O
.	O

This	O
study	O
investigated	O
the	O
influence	O
of	O
Goishi	O
-	O
tea	O
on	O
visceral	O
fat	O
weight	O
in	O
induced	O
obese	O
mice	O
.	O

Mice	O
were	O
divided	O
into	O
two	O
main	O
groups	O
,	O
normal	O
and	O
obesity	O
.	O

In	O
obesity	O
group	O
,	O
mice	O
were	O
fed	O
with	O
high	O
-	O
fat	O
diet	O
.	O

Goishi	O
-	O
tea	O
including	O
its	O
fractions	O
(	O
ethyl	B-chem
-	I-chem
acetate	E-chem
layer	O
and	O
water	O
layer	O
)	O
was	O
administrated	O
in	O
normal	O
and	O
obesity	O
three	O
sub	O
-	O
groups	O
.	O

Results	O
showed	O
no	O
influence	O
of	O
Goishi	O
-	O
tea	O
in	O
normal	O
group	O
.	O

However	O
,	O
visceral	O
fat	O
weight	O
,	O
size	O
of	O
adipose	O
cell	O
and	O
cholesterol	S-chem
level	O
were	O
significantly	O
decreased	O
in	O
obesity	O
group	O
fed	O
Goishi	O
-	O
tea	O
compared	O
to	O
control	O
group	O
.	O

Moreover	O
,	O
adiponectin	S-geneY
levels	O
tended	O
to	O
increase	O
and	O
adipocytokines	S-geneN
has	O
significant	O
values	O
lower	O
in	O
obesity	O
group	O
fed	O
Goishi	O
-	O
tea	O
compared	O
to	O
control	O
group	O
.	O

Interestingly	O
,	O
Goishi	O
tea	O
involved	O
in	O
the	O
high	O
-	O
fat	O
diet	O
induced	O
-	O
obese	O
mice	O
can	O
inhibit	O
fat	O
accumulation	O
and	O
maintain	O
adiponectins	S-geneY
without	O
increasing	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
alpha	E-geneY
and	O
interleukin	B-geneY
-	I-geneY
6	E-geneY
.	O

It	O
would	O
be	O
beneficial	O
for	O
the	O
prevention	O
of	O
metabolic	O
syndrome	O
and	O
obesity	O
-	O
related	O
disorder	O
.	O

Validation	O
of	O
an	O
in	O
vitro	O
exposure	O
system	O
for	O
toxicity	O
assessment	O
of	O
air	O
-	O
delivered	O
nanomaterials	O
.	O

To	O
overcome	O
the	O
limitations	O
of	O
in	O
vitro	O
exposure	O
of	O
submerged	O
lung	O
cells	O
to	O
nanoparticles	O
(	O
NPs	O
)	O
,	O
we	O
validated	O
an	O
integrated	O
low	O
flow	O
system	O
capable	O
of	O
generating	O
and	O
depositing	O
airborne	O
NPs	O
directly	O
onto	O
cells	O
at	O
an	O
air	O
-	O
liquid	O
interface	O
(	O
ALI	O
)	O
.	O

The	O
in	O
vitro	O
exposure	O
system	O
was	O
shown	O
to	O
provide	O
uniform	O
and	O
controlled	O
dosing	O
of	O
particles	O
with	O
70.3	O
%	O
efficiency	O
to	O
epithelial	O
cells	O
grown	O
on	O
transwells	O
.	O

This	O
system	O
delivered	O
a	O
continuous	O
airborne	O
exposure	O
of	O
NPs	O
to	O
lung	O
cells	O
without	O
loss	O
of	O
cell	O
viability	O
in	O
repeated	O
4h	O
exposure	O
periods	O
.	O

We	O
sequentially	O
exposed	O
cells	O
to	O
air	O
-	O
delivered	O
copper	S-chem
(	O
Cu	S-chem
)	O
NPs	O
in	O
vitro	O
to	O
compare	O
toxicity	O
results	O
to	O
our	O
prior	O
in	O
vivo	O
inhalation	O
studies	O
.	O

The	O
evaluation	O
of	O
cellular	O
dosimetry	O
indicated	O
that	O
a	O
large	O
amount	O
of	O
Cu	S-chem
was	O
taken	O
up	O
,	O
dissolved	O
and	O
released	O
into	O
the	O
basolateral	O
medium	O
(	O
62	O
%	O
of	O
total	O
mass	O
)	O
.	O

Exposure	O
to	O
Cu	S-chem
NPs	O
decreased	O
cell	O
viability	O
to	O
73	O
%	O
(	O
p	O
<	O
0.01	O
)	O
and	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
elevated	O
levels	O
of	O
lactate	B-geneN
dehydrogenase	E-geneN
,	O
intracellular	O
reactive	O
oxygen	S-chem
species	O
and	O
interleukin	B-geneY
-	I-geneY
8	E-geneY
that	O
mirrored	O
our	O
findings	O
from	O
subacute	O
in	O
vivo	O
inhalation	O
studies	O
in	O
mice	O
.	O

Our	O
results	O
show	O
that	O
this	O
exposure	O
system	O
is	O
useful	O
for	O
screening	O
of	O
NP	O
toxicity	O
in	O
a	O
manner	O
that	O
represents	O
cellular	O
responses	O
of	O
the	O
pulmonary	O
epithelium	O
in	O
vivo	O
.	O

Purification	O
,	O
physicochemical	O
characterisation	O
and	O
anticancer	O
activity	O
of	O
a	O
polysaccharide	O
from	O
Cyclocarya	O
paliurus	O
leaves	O
.	O

A	O
Cyclocarya	O
paliurus	O
(	O
Batal	O
.	O
)	O
Iljinskaja	O
polysaccharide	O
(	O
CPP	O
)	O
was	O
isolated	O
and	O
purified	O
by	O
hot	O
water	O
extraction	O
,	O
ethanol	S-chem
precipitation	O
,	O
deproteinisation	O
and	O
anion	O
-	O
exchange	O
chromatography	O
.	O

Its	O
physicochemical	O
properties	O
were	O
characterised	O
by	O
gel	O
permeation	O
chromatography	O
(	O
GPC	O
)	O
,	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
)	O
,	O
thermal	O
gravimetric	O
analysis	O
(	O
TGA	O
)	O
,	O
Fourier	O
transform	O
infrared	O
spectrometry	O
(	O
FTIR	O
)	O
,	O
UV	O
-	O
visible	O
spectrophotometry	O
,	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
and	O
viscometry	O
analysis	O
.	O

The	O
anticancer	O
effect	O
of	O
CPP	O
in	O
human	O
gastric	O
cancer	O
HeLa	O
cells	O
was	O
also	O
evaluated	O
by	O
3	B-chem
-	I-chem
(	I-chem
4,5	I-chem
-	I-chem
dimethylthiazol	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
)	I-chem
-	I-chem
2,5	I-chem
-	I-chem
diphenyltetrazolium	I-chem
bromide	E-chem
(	O
MTT	S-chem
)	O
assay	O
.	O

The	O
results	O
showed	O
that	O
the	O
molecular	O
weight	O
of	O
CPP	O
was	O
900	O
kDa	O
,	O
and	O
it	O
contained	O
64.8	O
%	O
total	O
sugar	O
,	O
23.5	O
%	O
uronic	B-chem
acid	E-chem
,	O
9.26	O
%	O
protein	O
,	O
and	O
six	O
kinds	O
of	O
monosaccharides	S-chem
,	O
including	O
glucose	S-chem
,	O
rhamnose	S-chem
,	O
arabinose	S-chem
,	O
xylose	S-chem
,	O
mannose	S-chem
and	O
galactose	S-chem
,	O
with	O
molar	O
percentages	O
of	O
32.7	O
%	O
,	O
9.33	O
%	O
,	O
30.6	O
%	O
,	O
3.48	O
%	O
,	O
10.4	O
%	O
,	O
and	O
13.5	O
%	O
,	O
respectively	O
.	O

Furthermore	O
,	O
the	O
results	O
showed	O
that	O
CPP	O
exhibited	O
a	O
strong	O
inhibition	O
effect	O
on	O
the	O
growth	O
of	O
human	O
gastric	O
cancer	O
HeLa	O
cells	O
.	O

Systematic	O
evaluation	O
of	O
640	O
FDA	O
drugs	O
for	O
their	O
effect	O
on	O
CD4	O
(	O
+	O
)	O
Foxp3	S-geneY
(	O
+	O
)	O
regulatory	O
T	O
cells	O
using	O
a	O
novel	O
cell	O
-	O
based	O
high	O
throughput	O
screening	O
assay	O
.	O

Regulatory	O
T	O
cells	O
(	O
Treg	O
)	O
,	O
which	O
play	O
a	O
pivotal	O
role	O
in	O
maintaining	O
immune	O
homeostasis	O
by	O
suppressing	O
the	O
proliferation	O
of	O
effector	O
T	O
cells	O
,	O
have	O
great	O
therapeutic	O
potential	O
for	O
autoimmune	O
diseases	O
and	O
transplantation	O
.	O

However	O
,	O
progress	O
on	O
their	O
clinical	O
application	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
high	O
throughput	O
screening	O
(	O
HTS	O
)	O
strategies	O
for	O
the	O
systematic	O
and	O
rapid	O
evaluation	O
of	O
existing	O
drugs	O
and	O
the	O
identification	O
of	O
novel	O
drug	O
candidates	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
an	O
innovative	O
in	O
vitro	O
HTS	O
assay	O
using	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
from	O
Foxp3	S-geneY
-	O
GFP	O
transgenic	O
mice	O
that	O
specifically	O
express	O
the	O
GFP	O
signal	O
in	O
Foxp3	S-geneY
(	O
+	O
)	O
Treg	O
cells	O
detectable	O
by	O
FACS	O
analysis	O
in	O
a	O
high	O
throughput	O
manner	O
.	O

Systematic	O
evaluation	O
of	O
640	O
FDA	O
-	O
approved	O
drugs	O
revealed	O
that	O
70	O
drugs	O
increased	O
the	O
number	O
of	O
Treg	O
cells	O
with	O
suppression	O
function	O
only	O
in	O
the	O
presence	O
of	O
TGFβ	S-geneY
,	O
75	O
drugs	O
increased	O
Treg	O
numbers	O
even	O
in	O
the	O
absence	O
of	O
TGFβ	S-geneY
,	O
and	O
32	O
drugs	O
increased	O
Treg	O
numbers	O
synergistically	O
with	O
TGFβ	S-geneY
.	O

The	O
identified	O
Treg	O
-	O
promoting	O
drugs	O
include	O
those	O
previously	O
known	O
to	O
induce	O
Treg	O
(	O
rapamycin	S-chem
and	O
retinoic	B-chem
acid	I-chem
)	E-chem
,	O
statins	O
,	O
glucocorticoids	O
and	O
drugs	O
in	O
many	O
other	O
categories	O
.	O

Furthermore	O
,	O
Treg	O
cells	O
cultured	O
with	O
the	O
identified	O
drugs	O
possess	O
surface	O
and	O
intracellular	O
markers	O
characteristic	O
of	O
natural	O
Treg	O
cells	O
and	O
possess	O
suppressive	O
function	O
.	O

These	O
results	O
suggest	O
that	O
this	O
Treg	O
HTS	O
assay	O
can	O
be	O
used	O
to	O
screen	O
compound	O
libraries	O
to	O
identify	O
novel	O
chemical	O
entities	O
for	O
Treg	O
-	O
based	O
immune	O
therapies	O
.	O

Computationally	O
assisted	O
assignment	O
of	O
kahalalide	B-chem
Y	E-chem
configuration	O
using	O
an	O
NMR	O
-	O
constrained	O
conformational	O
search	O
.	O

Assignment	O
of	O
the	O
absolute	O
configuration	O
of	O
cyclic	O
peptides	O
frequently	O
yields	O
challenges	O
,	O
leaving	O
one	O
or	O
more	O
stereogenic	O
centers	O
unassigned	O
due	O
to	O
small	O
quantities	O
of	O
sample	O
and	O
the	O
limited	O
utility	O
of	O
Marfey	O
's	O
or	O
other	O
methods	O
for	O
assigning	O
amino	B-chem
or	I-chem
hydroxy	I-chem
acids	E-chem
.	O

Here	O
,	O
we	O
report	O
isolation	O
of	O
kahalalide	B-chem
Y	E-chem
(	O
1	O
)	O
from	O
Bryopsis	O
pennata	O
for	O
the	O
first	O
time	O
;	O
in	O
addition	O
,	O
the	O
application	O
of	O
a	O
combination	O
of	O
molecular	O
modeling	O
and	O
NOE	O
distance	O
constraint	O
calculations	O
was	O
utilized	O
to	O
determine	O
the	O
conformation	O
of	O
1	O
and	O
the	O
absolute	O
configuration	O
of	O
the	O
final	O
stereogenic	O
center	O
of	O
1	O
.	O

Using	O
the	O
Schrödinger	O
suite	O
,	O
the	O
structure	O
of	O
1	O
was	O
sketched	O
in	O
Maestro	O
and	O
minimized	O
using	O
the	O
OPLS2005	O
force	O
field	O
in	O
Macromodel	O
.	O

A	O
conformational	O
search	O
was	O
performed	O
separately	O
for	O
structures	O
having	O
an	O
R	O
or	O
S	O
configuration	O
at	O
C	O
-	O
3	O
of	O
the	O
beta	B-chem
-	I-chem
hydroxy	I-chem
fatty	I-chem
acid	E-chem
subunit	O
that	O
completes	O
the	O
cyclic	O
scaffold	O
of	O
1	O
,	O
after	O
which	O
multiple	O
minimizations	O
for	O
all	O
generated	O
conformers	O
were	O
carried	O
out	O
.	O

The	O
lowest	O
energy	O
conformers	O
of	O
R	O
and	O
S	O
stereoisomers	O
were	O
then	O
subjected	O
to	O
B3LYP	O
geometry	O
optimizations	O
including	O
solvent	O
effects	O
.	O

The	O
S	O
stereoisomer	O
was	O
shown	O
to	O
be	O
in	O
excellent	O
agreement	O
with	O
the	O
NOE	O
-	O
derived	O
distance	O
constraints	O
and	O
hydrogen	S-chem
-	O
bonding	O
stability	O
studies	O
.	O

The	O
clinical	O
profile	O
of	O
the	O
angiotensin	B-geneN
II	I-geneN
receptor	E-geneN
blocker	O
eprosartan	S-chem
.	O

Angiotensin	B-geneN
II	I-geneN
receptor	E-geneN
antagonists	O
block	O
angiotensin	B-geneY
II	I-geneY
type	I-geneY
1	I-geneY
(	I-geneY
AT1	I-geneY
)	I-geneY
receptors	E-geneY
and	O
reduce	O
the	O
pressor	O
effects	O
of	O
angiotensin	S-geneY
in	O
the	O
vasculature	O
.	O

By	O
this	O
mechanism	O
,	O
they	O
induce	O
similar	O
pharmacological	O
effects	O
to	O
angiotensin	B-geneY
-	I-geneY
converting	I-geneY
enzyme	E-geneY
(	O
ACE	S-geneY
)	O
inhibitors	O
,	O
resulting	O
in	O
a	O
lowering	O
of	O
blood	O
pressure	O
(	O
BP	O
)	O
.	O

However	O
,	O
AT1	S-geneY
antagonists	O
differ	O
from	O
ACE	S-geneY
inhibitors	O
with	O
respect	O
to	O
side	O
effects	O
,	O
and	O
induce	O
less	O
cough	O
,	O
which	O
is	O
related	O
to	O
bradykinin	S-geneY
activation	O
.	O

Within	O
the	O
class	O
of	O
angiotensin	B-geneY
II	E-geneY
antagonists	O
,	O
eprosartan	O
differs	O
from	O
other	O
currently	O
clinically	O
available	O
agents	O
in	O
terms	O
of	O
its	O
chemical	O
structure	O
and	O
its	O
dual	O
pharmacological	O
mode	O
of	O
action	O
.	O

Eprosartan	S-chem
acts	O
not	O
only	O
at	O
vascular	O
AT1	S-geneY
receptors	O
but	O
also	O
at	O
presynaptic	O
AT1	S-geneY
receptors	O
,	O
causing	O
inhibition	O
of	O
sympathetically	O
stimulated	O
noradrenaline	S-chem
release	O
.	O

Eprosartan	S-chem
is	O
not	O
metabolized	O
by	O
cytochrome	B-geneN
P450	E-geneN
enzymes	O
and	O
therefore	O
has	O
a	O
low	O
potential	O
for	O
metabolic	O
drug	O
interactions	O
,	O
which	O
may	O
be	O
of	O
importance	O
when	O
treating	O
the	O
elderly	O
and	O
patients	O
on	O
multiple	O
drugs	O
.	O

In	O
clinical	O
trials	O
eprosartan	S-chem
has	O
proven	O
to	O
be	O
at	O
least	O
as	O
effective	O
as	O
the	O
ACE	S-geneY
inhibitor	O
enalapril	O
in	O
reducing	O
BP	O
,	O
but	O
with	O
a	O
significantly	O
lower	O
incidence	O
of	O
side	O
effects	O
.	O

Eprosartan	S-chem
is	O
safe	O
,	O
effective	O
and	O
well	O
tolerated	O
in	O
long	O
-	O
term	O
treatment	O
,	O
either	O
as	O
monotherapy	O
or	O
in	O
combination	O
with	O
other	O
antihypertensive	O
drugs	O
such	O
as	O
hydrochlorothiazide	S-chem
.	O

Platelet	O
-	O
derived	O
microparticles	O
in	O
overweight	O
/	O
obese	O
women	O
with	O
the	O
polycystic	O
ovary	O
syndrome	O
.	O

A	O
substantial	O
proportion	O
of	O
women	O
with	O
the	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
are	O
obese	O
and	O
obesity	O
is	O
considered	O
as	O
a	O
prothrombotic	O
state	O
.	O

Platelet	O
-	O
derived	O
microparticles	O
(	O
PMPs	O
)	O
might	O
be	O
implicated	O
in	O
the	O
activation	O
of	O
the	O
coagulation	O
cascade	O
.	O

We	O
aimed	O
to	O
assess	O
plasma	O
PMPs	O
in	O
overweight	O
/	O
obese	O
women	O
with	O
PCOS	O
.	O

We	O
measured	O
plasma	O
PMPs	O
and	O
determined	O
anthropometric	O
,	O
metabolic	O
,	O
hormonal	O
and	O
ultrasonographic	O
features	O
of	O
PCOS	O
in	O
67	O
overweight	O
/	O
obese	O
women	O
with	O
PCOS	O
(	O
with	O
body	O
mass	O
index	O
[	O
BMI	O
]	O
>	O
25.0	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
in	O
21	O
BMI	O
-	O
matched	O
healthy	O
women	O
.	O

Circulating	O
androgens	S-chem
and	O
markers	O
of	O
insulin	S-geneY
resistance	O
(	O
IR	O
)	O
were	O
higher	O
in	O
women	O
with	O
PCOS	O
than	O
in	O
controls	O
.	O

Plasma	O
PMPs	O
were	O
also	O
higher	O
in	O
women	O
with	O
PCOS	O
than	O
in	O
controls	O
(	O
p	O
=	O
0.046	O
)	O
.	O

In	O
women	O
with	O
PCOS	O
,	O
plasma	O
PMPs	O
correlated	O
with	O
the	O
mean	O
number	O
of	O
follicles	O
in	O
the	O
ovaries	O
(	O
r	O
=	O
0.343	O
;	O
p	O
=	O
0.006	O
)	O
.	O

In	O
controls	O
,	O
plasma	O
PMPs	O
did	O
not	O
correlate	O
with	O
any	O
of	O
the	O
studied	O
parameters	O
.	O

In	O
conclusion	O
,	O
plasma	O
PMPs	O
are	O
elevated	O
in	O
overweight	O
/	O
obese	O
women	O
with	O
PCOS	O
compared	O
with	O
BMI	O
-	O
matched	O
controls	O
.	O

The	O
cause	O
of	O
this	O
increase	O
is	O
unclear	O
but	O
both	O
IR	O
and	O
hyperandrogenemia	O
might	O
be	O
implicated	O
.	O

More	O
studies	O
are	O
required	O
to	O
elucidate	O
the	O
pathogenesis	O
of	O
the	O
elevation	O
of	O
PMPs	O
in	O
PCOS	O
and	O
to	O
assess	O
its	O
implications	O
on	O
the	O
cardiovascular	O
risk	O
of	O
these	O
patients	O
.	O

Acute	O
and	O
chronic	O
interference	O
with	O
BDNF	S-geneY
/	O
TrkB	S-geneY
-	O
signaling	O
impair	O
LTP	O
selectively	O
at	O
mossy	O
fiber	O
synapses	O
in	O
the	O
CA3	O
region	O
of	O
mouse	O
hippocampus	O
.	O

Brain	B-geneY
-	I-geneY
derived	I-geneY
neurotrophic	I-geneY
factor	E-geneY
(	O
BDNF	S-geneY
)	O
signaling	O
via	O
TrkB	S-geneY
crucially	O
regulates	O
synaptic	O
plasticity	O
in	O
the	O
brain	O
.	O

Although	O
BDNF	S-geneY
is	O
abundant	O
at	O
hippocampal	O
mossy	O
fiber	O
(	O
MF	O
)	O
synapses	O
,	O
which	O
critically	O
contribute	O
to	O
hippocampus	O
dependent	O
memory	O
,	O
its	O
role	O
in	O
MF	O
synaptic	O
plasticity	O
(	O
long	O
-	O
term	O
potentiation	O
,	O
LTP	O
)	O
remained	O
largely	O
unclear	O
.	O

Using	O
field	O
potential	O
recordings	O
in	O
CA3	O
of	O
adult	O
heterozygous	O
BDNF	S-geneY
knockout	O
(	O
ko	O
,	O
BDNF	S-geneY
+	O
/	O
-	O
)	O
mice	O
we	O
observed	O
impaired	O
(	O
∼	O
50	O
%	O
)	O
NMDAR	S-geneN
-	O
independent	O
MF	O
-	O
LTP	O
.	O

In	O
contrast	O
to	O
MF	O
synapses	O
,	O
LTP	O
at	O
neighboring	O
associative	O
/	O
commissural	O
(	O
A	O
/	O
C	O
)	O
fiber	O
synapses	O
remained	O
unaffected	O
.	O

To	O
exclude	O
that	O
impaired	O
MF	O
-	O
LTP	O
in	O
BDNF	S-geneY
+	O
/	O
-	O
mice	O
was	O
due	O
to	O
developmental	O
changes	O
in	O
response	O
to	O
chronically	O
reduced	O
BDNF	S-geneY
levels	O
,	O
and	O
to	O
prove	O
the	O
importance	O
of	O
acute	O
availability	O
of	O
BDNF	S-geneY
in	O
MF	O
-	O
LTP	O
,	O
we	O
also	O
tested	O
effects	O
of	O
acute	O
interference	O
with	O
BDNF	S-geneY
/	O
TrkB	S-geneY
signaling	O
.	O

Inhibition	O
of	O
TrkB	S-geneY
tyrosine	B-geneN
kinase	E-geneN
signaling	O
with	O
k252a	O
,	O
or	O
with	O
the	O
selective	O
BDNF	S-geneY
scavenger	O
TrkB	S-geneY
-	O
Fc	O
,	O
both	O
inhibited	O
MF	O
-	O
LTP	O
to	O
the	O
same	O
extent	O
as	O
observed	O
in	O
BDNF	S-geneY
+	O
/	O
-	O
mice	O
.	O

Basal	O
synaptic	O
transmission	O
,	O
short	O
-	O
term	O
plasticity	O
,	O
and	O
synaptic	O
fatigue	O
during	O
LTP	O
induction	O
were	O
not	O
significantly	O
altered	O
by	O
treatment	O
with	O
k252a	O
or	O
TrkB	S-geneY
-	O
Fc	O
,	O
or	O
by	O
chronic	O
BDNF	S-geneY
reduction	O
in	O
BDNF	S-geneY
+	O
/	O
-	O
mice	O
.	O

Since	O
the	O
acute	O
interference	O
with	O
BDNF	S-geneY
-	O
signaling	O
did	O
not	O
completely	O
block	O
MF	O
-	O
LTP	O
,	O
our	O
results	O
provide	O
evidence	O
that	O
an	O
additional	O
mechanism	O
besides	O
BDNF	S-geneY
induced	O
TrkB	S-geneY
signaling	O
contributes	O
to	O
this	O
type	O
of	O
LTP	O
.	O

Our	O
results	O
prove	O
for	O
the	O
first	O
time	O
a	O
mechanistic	O
action	O
of	O
acute	O
BDNF	S-geneY
/	O
TrkB	S-geneY
signaling	O
in	O
presynaptic	O
expression	O
of	O
MF	O
-	O
LTP	O
in	O
adult	O
hippocampus	O
.	O

Impact	O
of	O
ketorolac	S-chem
administration	O
around	O
ovarian	O
stimulation	O
on	O
in	O
vivo	O
and	O
in	O
vitro	O
fertilization	O
and	O
subsequent	O
embryo	O
development	O
.	O

Abstract	O
We	O
performed	O
this	O
study	O
to	O
investigate	O
the	O
effect	O
of	O
ketorolac	S-chem
(	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
)	O
administration	O
around	O
ovarian	O
stimulation	O
on	O
in	O
vivo	O
and	O
in	O
vitro	O
fertilization	O
process	O
.	O

Sixty	O
-	O
four	O
female	O
mice	O
(	O
ICR	O
)	O
were	O
injected	O
with	O
ketorolac	S-chem
(	O
0	O
,	O
7.5	O
,	O
15	O
and	O
30	O
µg	O
/	O
d	O
)	O
for	O
3	O
d	O
starting	O
from	O
the	O
day	O
of	O
eCG	O
treatment	O
.	O

In	O
experiment	O
1	O
,	O
41	O
mice	O
were	O
triggered	O
by	O
hCG	S-geneN
and	O
then	O
mated	O
;	O
two	O
-	O
cell	O
embryos	O
were	O
obtained	O
and	O
in	O
vitro	O
development	O
up	O
to	O
blastocyst	O
was	O
observed	O
.	O

In	O
experiment	O
2	O
,	O
23	O
mice	O
were	O
triggered	O
by	O
hCG	S-geneN
and	O
mature	O
oocytes	O
were	O
collected	O
;	O
in	O
vitro	O
fertilization	O
rate	O
and	O
subsequent	O
embryo	O
development	O
up	O
to	O
blastocyst	O
was	O
recorded	O
.	O

In	O
experiment	O
1	O
,	O
the	O
blastocyst	O
-	O
forming	O
rates	O
per	O
in	O
vivo	O
fertilized	O
two	O
-	O
cell	O
embryo	O
showed	O
an	O
inverse	O
relationship	O
with	O
a	O
dosage	O
of	O
ketorolac	S-chem
(	O
97.6	O
%	O
,	O
64.2	O
%	O
,	O
35.4	O
%	O
and	O
25.9	O
%	O
)	O
.	O

In	O
experiment	O
2	O
,	O
degenerated	O
oocytes	O
were	O
frequently	O
observed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
4.3	O
%	O
,	O
22.9	O
%	O
,	O
22.4	O
%	O
and	O
75.0	O
%	O
)	O
.	O

Lower	O
fertilization	O
rates	O
were	O
noted	O
in	O
all	O
the	O
three	O
ketorolac	S-chem
-	O
treating	O
groups	O
;	O
blastocyst	O
-	O
forming	O
rate	O
was	O
significantly	O
lower	O
in	O
30	O
-	O
µg	O
-	O
treating	O
group	O
when	O
compared	O
with	O
the	O
control	O
group	O
.	O

Administration	O
of	O
ketorolac	S-chem
around	O
ovarian	O
stimulation	O
significantly	O
affects	O
the	O
development	O
of	O
in	O
vivo	O
fertilized	O
embryo	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

High	O
-	O
dose	O
ketorolac	S-chem
could	O
result	O
in	O
a	O
poor	O
oocyte	O
quality	O
and	O
decreased	O
embryo	O
developmental	O
competence	O
.	O

Colon	O
cancer	O
cells	O
with	O
high	O
invasive	O
potential	O
are	O
susceptible	O
to	O
induction	O
of	O
apoptosis	O
by	O
a	O
selective	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
.	O

Cyclooxygenase	B-geneY
-	I-geneY
2	E-geneY
(	O
COX	B-geneY
-	I-geneY
2	E-geneY
)	O
expression	O
has	O
been	O
shown	O
to	O
correlate	O
with	O
the	O
invasiveness	O
of	O
colon	O
cancer	O
cells	O
.	O

To	O
further	O
investigate	O
this	O
positive	O
correlation	O
and	O
its	O
possible	O
therapeutic	O
implications	O
,	O
a	O
selective	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
,	O
etodolac	S-chem
,	O
was	O
tested	O
on	O
three	O
variants	O
of	O
HT	O
-	O
29	O
colon	O
cancer	O
cell	O
lines	O
,	O
HT	O
-	O
29	O
/	O
Inv1	O
,	O
HT	O
-	O
29	O
/	O
Inv2	O
and	O
HT	O
-	O
29	O
/	O
Inv3	O
,	O
with	O
graded	O
increases	O
of	O
in	O
vitro	O
Matrigel	O
invasive	O
potential	O
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
expression	O
levels	O
.	O

HT	O
-	O
29	O
variants	O
with	O
higher	O
invasive	O
potential	O
were	O
found	O
to	O
be	O
more	O
sensitive	O
to	O
etodolac	S-chem
by	O
in	O
vitro	O
growth	O
inhibition	O
assays	O
,	O
the	O
estimated	O
LD	O
(	O
50	O
)	O
being	O
0.5	O
mM	O
for	O
highly	O
invasive	O
HT	O
-	O
29	O
/	O
Inv2	O
and	O
HT	O
-	O
29	O
/	O
Inv3	O
cells	O
,	O
0.6	O
mM	O
for	O
slightly	O
less	O
invasive	O
HT	O
-	O
29	O
/	O
Inv1	O
,	O
and	O
1.8	O
mM	O
for	O
the	O
parental	O
HT	O
-	O
29	O
.	O

Treatment	O
of	O
the	O
highly	O
invasive	O
HT	O
-	O
29	O
/	O
Inv2	O
and	O
Inv3	O
variants	O
with	O
as	O
little	O
as	O
0.1	O
mM	O
etodolac	S-chem
in	O
the	O
growth	O
medium	O
produced	O
signs	O
of	O
apoptosis	O
,	O
as	O
detected	O
by	O
DNA	O
fragmentation	O
and	O
TUNEL	O
(	O
terminal	O
deoxynucleotidyl	O
transferase	O
dUTP	S-chem
-	O
biotin	S-chem
nick	O
end	O
labeling	O
)	O
assay	O
.	O

In	O
vivo	O
experiments	O
in	O
SCID	O
mice	O
showed	O
that	O
etolodac	S-chem
inhibited	O
the	O
growth	O
of	O
subcutaneous	O
tumors	O
induced	O
by	O
HT	O
-	O
29	O
/	O
Inv3	O
cells	O
significantly	O
more	O
than	O
those	O
by	O
the	O
parental	O
HT	O
-	O
29	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitors	O
have	O
a	O
potential	O
role	O
in	O
prevention	O
of	O
tumor	O
invasion	O
in	O
colon	O
cancer	O
patients	O
.	O

A	O
comparison	O
of	O
the	O
effects	O
of	O
nabumetone	S-chem
vs	O
meloxicam	S-chem
on	O
serum	O
thromboxane	B-chem
B2	E-chem
and	O
platelet	O
function	O
in	O
healthy	O
volunteers	O
.	O

AIMS	O
:	O
To	O
compare	O
the	O
effects	O
of	O
nabumetone	S-chem
and	O
meloxicam	S-chem
,	O
two	O
cyclo	B-geneY
-	I-geneY
oxygenase	I-geneY
-	I-geneY
2	E-geneY
(	O
COX	B-geneY
-	I-geneY
2	E-geneY
)	O
preferential	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
on	O
platelet	O
COX	B-geneY
-	I-geneY
1	E-geneY
activity	O
and	O
platelet	O
function	O
.	O

METHODS	O
:	O
Twelve	O
healthy	O
volunteers	O
(	O
3	O
male	O
,	O
9	O
female	O
,	O
median	O
age	O
22	O
years	O
)	O
participated	O
in	O
an	O
open	O
,	O
randomized	O
,	O
cross	O
-	O
over	O
trial	O
of	O
nabumetone	S-chem
1000	O
mg	O
twice	O
daily	O
vs	O
meloxicam	S-chem
7.5	O
mg	O
twice	O
daily	O
during	O
1	O
week	O
with	O
2	O
weeks	O
wash	O
-	O
out	O
.	O

After	O
a	O
second	O
2	O
week	O
wash	O
-	O
out	O
period	O
,	O
one	O
dose	O
of	O
indomethacin	S-chem
50	O
mg	O
was	O
given	O
as	O
a	O
positive	O
control	O
to	O
check	O
for	O
NSAID	O
induced	O
inhibition	O
of	O
platelet	O
function	O
.	O

COX	B-geneY
-	I-geneY
1	E-geneY
inhibition	O
was	O
measured	O
as	O
percentage	O
inhibition	O
of	O
serum	O
TXB2	S-chem
generation	O
in	O
clotting	O
whole	O
blood	O
,	O
and	O
as	O
closure	O
time	O
with	O
use	O
of	O
the	O
platelet	O
function	O
analyser	O
PFA	O
-	O
100	O
.	O

Data	O
are	O
reported	O
as	O
median	O
with	O
range	O
.	O

Paired	O
variables	O
were	O
analysed	O
using	O
Wilcoxons	O
signed	O
rank	O
test	O
.	O

RESULTS	O
:	O
TXB2	S-chem
levels	O
decreased	O
significantly	O
after	O
all	O
three	O
medications	O
,	O
but	O
percentage	O
inhibition	O
after	O
nabumetone	S-chem
and	O
indomethacin	S-chem
(	O
88	O
%	O
and	O
97	O
%	O
,	O
respectively	O
)	O
was	O
significantly	O
higher	O
than	O
after	O
meloxicam	S-chem
(	O
63	O
%	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Closure	O
times	O
increased	O
significantly	O
after	O
administration	O
of	O
all	O
three	O
medications	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Increases	O
in	O
closure	O
time	O
after	O
administration	O
did	O
not	O
differ	O
between	O
nabumetone	S-chem
and	O
meloxicam	S-chem
(	O
24	O
%	O
and	O
14	O
%	O
,	O
respectively	O
)	O
,	O
but	O
were	O
significantly	O
larger	O
after	O
indomethacin	S-chem
administration	O
(	O
63	O
%	O
)	O
(	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
the	O
maximum	O
registered	O
dosage	O
,	O
nabumetone	S-chem
inhibits	O
thromboxane	S-chem
production	O
much	O
more	O
than	O
meloxicam	O
,	O
signifying	O
less	O
COX	B-geneY
-	I-geneY
2	E-geneY
selectivity	O
of	O
the	O
former	O
.	O

However	O
,	O
both	O
nabumetone	S-chem
and	O
meloxicam	S-chem
cause	O
only	O
minor	O
impairment	O
in	O
platelet	O
function	O
in	O
comparison	O
with	O
indomethacin	S-chem
and	O
the	O
difference	O
between	O
them	O
is	O
not	O
significant	O
.	O

Effect	O
of	O
protein	O
malnutrition	O
on	O
the	O
metabolism	O
and	O
toxicity	O
of	O
cisplatin	S-chem
,	O
5	B-chem
-	I-chem
fluorouracil	E-chem
and	O
mitomycin	B-chem
C	E-chem
in	O
rat	O
stomach	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
protein	O
malnutrition	O
on	O
metabolism	O
and	O
toxicity	O
of	O
cisplatin	S-chem
(	O
CP	O
)	O
,	O
5	B-chem
-	I-chem
fluorouracil	E-chem
(	O
FU	O
)	O
and	O
mitomycin	B-chem
C	E-chem
(	O
MMC	S-chem
)	O
in	O
rat	O
stomach	O
.	O

Weanling	O
male	O
Wistar	O
rats	O
received	O
a	O
normal	O
(	O
24	O
%	O
)	O
or	O
low	O
(	O
2.5	O
%	O
)	O
protein	O
diet	O
for	O
28days	O
and	O
were	O
allocated	O
into	O
:	O
normally	O
-	O
fed	O
control	O
,	O
protein	O
-	O
malnourished	O
control	O
(	O
PM	O
)	O
,	O
3	O
normally	O
-	O
fed	O
drug	O
-	O
treated	O
groups	O
and	O
3	O
protein	O
-	O
malnourished	O
drug	O
-	O
treated	O
groups	O
(	O
PM	O
-	O
CP	O
,	O
PM	O
-	O
FU	O
and	O
PM	O
-	O
MMC	S-chem
)	O
.	O

Cisplatin	S-chem
and	O
MMC	S-chem
were	O
injected	O
intraperitoneally	O
(	O
8mg	O
/	O
kg	O
on	O
day	O
26	O
and	O
1mg	O
/	O
kg	O
/	O
day	O
for	O
7days	O
,	O
respectively	O
)	O
.	O

5	B-chem
-	I-chem
Fluorouracil	E-chem
was	O
given	O
orally	O
(	O
50mg	O
/	O
kg	O
/	O
day	O
for	O
5days	O
)	O
.	O

Compared	O
with	O
normally	O
-	O
fed	O
counterparts	O
,	O
PM	O
-	O
CP	O
rats	O
exhibited	O
higher	O
glutathione	B-geneN
S	I-geneN
-	I-geneN
transferase	E-geneN
,	O
aminopeptidase	B-geneY
N	E-geneY
and	O
cysteine	B-geneY
S	I-geneY
-	I-geneY
conjugate	I-geneY
beta	I-geneY
-	I-geneY
lyase	E-geneY
(	O
CCBL	S-geneY
)	O
and	O
lower	O
gamma	B-geneY
-	I-geneY
glutamyltransferase	E-geneY
activities	O
,	O
PM	O
-	O
FU	O
rats	O
exhibited	O
decreased	O
dihydropyrimidine	B-geneY
dehydrogenase	E-geneY
and	O
cytochrome	B-geneN
P450	I-geneN
1A1	I-geneN
/	I-geneN
2	E-geneN
activities	O
and	O
PM	O
-	O
MMC	S-chem
rats	O
showed	O
higher	O
quinone	B-geneN
reductase	E-geneN
and	O
depleted	O
xanthine	B-geneY
oxidase	E-geneY
activities	O
.	O

Protein	O
-	O
malnourished	O
drug	O
-	O
treated	O
groups	O
exhibited	O
exacerbated	O
gastrotoxicity	O
,	O
relative	O
to	O
normally	O
-	O
fed	O
counterparts	O
,	O
manifested	O
by	O
lower	O
mucus	O
levels	O
,	O
higher	O
permeability	O
and	O
histopathological	O
deterioration	O
,	O
along	O
with	O
increased	O
oxidative	O
stress	O
in	O
PM	O
-	O
CP	O
rats	O
and	O
exaggerated	O
prostaglandin	B-chem
E2	E-chem
production	O
in	O
PM	O
-	O
MMC	S-chem
rats	O
.	O

Conclusively	O
,	O
protein	O
malnutrition	O
alters	O
CP	O
,	O
FU	O
and	O
MMC	S-chem
metabolism	O
in	O
rat	O
stomach	O
by	O
enhancing	O
CCBL	S-geneY
pathway	O
for	O
CP	O
activation	O
,	O
delaying	O
FU	O
elimination	O
and	O
activating	O
two	O
-	O
electron	O
reduction	O
of	O
MMC	S-chem
,	O
potentiating	O
their	O
gastrotoxicity	O
.	O

Density	O
of	O
GM1	O
in	O
nanoclusters	O
is	O
a	O
critical	O
factor	O
in	O
the	O
formation	O
of	O
a	O
spherical	O
assembly	O
of	O
amyloid	B-geneY
β	I-geneY
-	I-geneY
protein	E-geneY
on	O
synaptic	O
plasma	O
membranes	O
.	O

The	O
deposition	O
of	O
amyloid	B-geneY
β	I-geneY
-	I-geneY
protein	E-geneY
(	O
Aβ	S-geneY
)	O
is	O
a	O
pathological	O
hallmark	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

We	O
previously	O
found	O
that	O
the	O
ganglioside	S-chem
-	O
enriched	O
microdomains	O
(	O
ganglioside	S-chem
clusters	O
)	O
in	O
presynaptic	O
neuronal	O
membranes	O
play	O
a	O
key	O
role	O
in	O
the	O
initiation	O
of	O
the	O
Aβ	S-geneY
assembly	O
process	O
.	O

However	O
,	O
not	O
all	O
ganglioside	S-chem
clusters	O
accelerate	O
Aβ	S-geneY
assembly	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
directly	O
observed	O
a	O
spherical	O
Aβ	S-geneY
in	O
an	O
atomic	O
force	O
microscopic	O
study	O
on	O
the	O
morphology	O
of	O
a	O
reconstituted	O
lipid	O
bilayer	O
composed	O
of	O
lipids	O
that	O
were	O
extracted	O
from	O
a	O
detergent	O
-	O
resistant	O
membrane	O
microdomain	O
(	O
DRM	O
)	O
fraction	O
of	O
synaptosomes	O
prepared	O
from	O
aged	O
mouse	O
brain	O
.	O

The	O
Aβ	S-geneY
assembly	O
was	O
generated	O
on	O
a	O
distinctive	O
GM1	B-geneN
domain	E-geneN
,	O
which	O
was	O
characterized	O
as	O
the	O
Aβ	S-geneY
-	O
sensitive	O
ganglioside	S-chem
nanocluster	O
(	O
ASIGN	O
)	O
.	O

By	O
using	O
an	O
artificial	O
GM1	O
cluster	O
-	O
binding	O
peptide	O
,	O
ASIGN	O
was	O
found	O
to	O
have	O
a	O
high	O
density	O
of	O
GM1	O
;	O
therefore	O
,	O
there	O
would	O
be	O
a	O
critical	O
density	O
of	O
GM1	O
in	O
nanoclusters	O
to	O
induce	O
Aβ	S-geneY
binding	O
and	O
assembly	O
.	O

These	O
results	O
suggest	O
that	O
ganglioside	S-chem
-	O
bound	O
Aβ	S-geneY
(	O
GAβ	O
)	O
,	O
which	O
acts	O
as	O
an	O
endogenous	O
seed	O
for	O
Aβ	S-geneY
fibril	O
formation	O
in	O
AD	O
brains	O
,	O
is	O
generated	O
on	O
ASIGN	O
on	O
synaptosomal	O
membranes	O
.	O

Gemcitabine	S-chem
and	O
pemetrexed	B-chem
disodium	E-chem
combinations	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Pemetrexed	B-chem
disodium	E-chem
(	O
ALIMTA	S-chem
)	O
is	O
a	O
novel	O
antimetabolite	O
that	O
inhibits	O
at	O
least	O
three	O
folate	S-chem
-	O
dependent	O
enzymes	O
,	O
thymidylate	B-geneY
synthase	E-geneY
,	O
dihydrofolate	B-geneY
reductase	E-geneY
,	O
and	O
glycinamide	B-geneY
ribonucleotide	I-geneY
formyltransferase	E-geneY
.	O

Pemetrexed	B-chem
disodium	E-chem
is	O
broadly	O
active	O
in	O
a	O
wide	O
variety	O
of	O
solid	O
tumours	O
,	O
including	O
non	O
-	O
small	O
cell	O
lung	O
,	O
breast	O
,	O
bladder	O
,	O
head	O
and	O
neck	O
and	O
ovarian	O
cancers	O
.	O

Gemcitabine	S-chem
is	O
a	O
broadly	O
active	O
pyrimidine	B-chem
nucleoside	E-chem
antimetabolite	O
,	O
which	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
pancreatic	O
and	O
non	O
-	O
small	O
cell	O
lung	O
cancers	O
.	O

Three	O
preclinical	O
studies	O
have	O
been	O
reported	O
that	O
show	O
cytotoxic	O
synergy	O
between	O
gemcitabine	S-chem
and	O
pemetrexed	S-chem
.	O

Clinical	O
activity	O
with	O
this	O
combination	O
has	O
been	O
observed	O
in	O
a	O
phase	O
I	O
study	O
,	O
with	O
partial	O
responses	O
in	O
three	O
of	O
five	O
patients	O
previously	O
treated	O
for	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

An	O
international	O
phase	O
II	O
study	O
of	O
this	O
combination	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
is	O
ongoing	O
.	O

Astemizole	S-chem
,	O
a	O
potent	O
histamine	B-geneY
H1	I-geneY
-	I-geneY
receptor	E-geneY
antagonist	O
:	O
effect	O
in	O
allergic	O
rhinoconjunctivitis	O
,	O
on	O
antigen	O
and	O
histamine	S-chem
induced	O
skin	O
weal	O
responses	O
and	O
relationship	O
to	O
serum	O
levels	O
.	O

The	O
efficacy	O
of	O
astemizole	S-chem
,	O
a	O
new	O
,	O
long	O
acting	O
,	O
oral	O
histamine	B-geneY
H1	I-geneY
-	I-geneY
receptor	E-geneY
antagonist	O
was	O
compared	O
to	O
placebo	O
for	O
the	O
treatment	O
of	O
allergic	O
rhinitis	O
and	O
conjunctivitis	O
during	O
the	O
grass	O
pollen	O
season	O
of	O
1982	O
.	O

Sixty	O
-	O
three	O
patients	O
with	O
a	O
positive	O
skin	O
prick	O
test	O
to	O
grass	O
pollen	O
and	O
current	O
symptoms	O
participated	O
in	O
an	O
8	O
week	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
study	O
.	O

Astemizole	S-chem
,	O
10	O
mg	O
,	O
was	O
significantly	O
better	O
than	O
placebo	O
in	O
alleviating	O
both	O
nose	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
eye	O
(	O
P	O
less	O
than	O
0.01	O
)	O
symptoms	O
despite	O
significantly	O
greater	O
use	O
of	O
the	O
reserve	O
medication	O
,	O
clemastine	S-chem
,	O
by	O
the	O
placebo	O
group	O
(	O
P	O
less	O
than	O
0.003	O
)	O
.	O

There	O
was	O
a	O
lag	O
period	O
of	O
5	O
days	O
after	O
initiation	O
of	O
therapy	O
before	O
treatment	O
benefit	O
became	O
manifest	O
.	O

Subdivision	O
of	O
nasal	O
symptoms	O
indicated	O
significant	O
improvement	O
compared	O
to	O
placebo	O
over	O
the	O
8	O
weeks	O
for	O
sneezing	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
runny	O
nose	O
(	O
P	O
less	O
than	O
0.05	O
)	O
but	O
not	O
blocked	O
nose	O
.	O

The	O
absence	O
of	O
effect	O
on	O
nasal	O
blockage	O
was	O
confirmed	O
by	O
parallel	O
measurement	O
of	O
nasal	O
calibre	O
by	O
body	O
plethysmography	O
.	O

The	O
antihistaminic	O
potency	O
of	O
astemizole	S-chem
was	O
indicated	O
by	O
an	O
80	O
%	O
inhibition	O
of	O
the	O
histamine	S-chem
induced	O
skin	O
weal	O
response	O
after	O
8	O
weeks	O
therapy	O
.	O

A	O
positive	O
correlation	O
was	O
found	O
between	O
serum	O
drug	O
levels	O
and	O
%	O
inhibition	O
of	O
histamine	S-chem
skin	O
weal	O
(	O
r	O
=	O
0.64	O
,	O
P	O
less	O
than	O
0.001	O
)	O
.	O

Astemizole	S-chem
was	O
free	O
from	O
adverse	O
sedative	O
or	O
anticholinergic	O
effects	O
but	O
did	O
cause	O
a	O
mean	O
increase	O
in	O
weight	O
of	O
1.3	O
kg	O
(	O
P	O
less	O
than	O
0.01	O
)	O
after	O
8	O
weeks	O
therapy	O
,	O
not	O
found	O
with	O
placebo	O
.	O

Preclinical	O
efficacy	O
of	O
emedastine	S-chem
,	O
a	O
potent	O
,	O
selective	O
histamine	B-geneY
H1	E-geneY
antagonist	O
for	O
topical	O
ocular	O
use	O
.	O

Emedastine	S-chem
[	O
1	B-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
ethoxyethyl	I-chem
)	I-chem
-	I-chem
2	I-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
methyl	I-chem
-	I-chem
1	I-chem
-	I-chem
homopiperazinyl	I-chem
)	I-chem
-	I-chem
benzimidazole	I-chem
difumarate	E-chem
]	O
was	O
evaluated	O
for	O
topical	O
ocular	O
anti	O
-	O
histaminic	O
activity	O
in	O
histamine	S-chem
and	O
antigen	O
stimulated	O
conjunctivitis	O
models	O
.	O

Concentration	O
-	O
dependent	O
inhibition	O
of	O
histamine	S-chem
induced	O
vascular	O
permeability	O
changes	O
occurring	O
in	O
the	O
conjunctiva	O
was	O
observed	O
when	O
the	O
time	O
interval	O
between	O
topical	O
ocular	O
administration	O
and	O
histamine	S-chem
challenge	O
ranged	O
from	O
1	O
min	O
to	O
8	O
hr	O
.	O

The	O
calculated	O
ED50	O
values	O
obtained	O
using	O
intervals	O
of	O
1	O
min	O
,	O
30	O
min	O
,	O
2	O
,	O
4	O
and	O
8	O
hr	O
were	O
0.0002	O
%	O
,	O
0.000035	O
%	O
,	O
0.0029	O
%	O
,	O
0.019	O
%	O
and	O
0.19	O
%	O
,	O
w	O
/	O
v	O
,	O
respectively	O
.	O

Comparisons	O
of	O
relative	O
potency	O
30	O
min	O
post	O
dosing	O
between	O
emedastine	O
and	O
other	O
anti	O
-	O
histamines	S-chem
demonstrated	O
that	O
emedastine	S-chem
is	O
equipotent	O
to	O
ketotifen	S-chem
,	O
and	O
7	O
,	O
7	O
,	O
10	O
,	O
10	O
,	O
100	O
,	O
357	O
,	O
3333	O
,	O
and	O
5813	O
times	O
more	O
potent	O
than	O
brompheniramine	S-chem
,	O
chlorpheniramine	S-chem
,	O
clemastine	S-chem
,	O
pyrilamine	S-chem
,	O
levocabastine	S-chem
,	O
pheniramine	S-chem
,	O
diphenhydramine	S-chem
,	O
and	O
antazoline	S-chem
,	O
respectively	O
.	O

Emedastine	S-chem
(	O
0.1	O
%	O
)	O
failed	O
to	O
significantly	O
attenuate	O
either	O
serotonin	O
or	O
platelet	O
-	O
activating	O
-	O
factor	O
induced	O
vascular	O
permeability	O
changes	O
indicating	O
high	O
selectivity	O
for	O
the	O
histamine	B-geneY
H1	I-geneY
receptor	E-geneY
.	O

In	O
a	O
passive	O
conjunctival	O
anaphylaxis	O
model	O
in	O
guinea	O
pigs	O
,	O
significant	O
inhibition	O
of	O
the	O
allergic	O
response	O
was	O
observed	O
following	O
topical	O
ocular	O
administration	O
of	O
emedastine	S-chem
5	O
min	O
or	O
30	O
min	O
prior	O
to	O
antigen	O
challenge	O
(	O
ED50s	O
0.0046	O
%	O
and	O
0.00022	O
%	O
,	O
respectively	O
)	O
.	O

These	O
data	O
clearly	O
indicate	O
that	O
emedastine	S-chem
has	O
potential	O
as	O
a	O
topical	O
ocular	O
anti	O
-	O
histamine	S-chem
for	O
treating	O
allergic	O
conjunctivitis	O
.	O

Amino	B-chem
acid	E-chem
derived	O
quinazolines	S-chem
as	O
Rock	S-geneN
/	O
PKA	S-geneN
inhibitors	O
.	O

SAR	O
and	O
lead	O
optimization	O
studies	O
for	O
Rock	S-geneN
inhibitors	O
based	O
on	O
amino	B-chem
acid	E-chem
-	O
derived	O
quinazolines	S-chem
are	O
described	O
.	O

Studies	O
demonstrated	O
that	O
these	O
amino	B-chem
acid	E-chem
derived	O
quinazolinones	S-chem
were	O
mainly	O
pan	O
-	O
Rock	B-geneN
(	I-geneN
I	I-geneN
&	I-geneN
II	I-geneN
)	E-geneN
inhibitors	O
.	O

While	O
selectivity	O
against	O
other	O
kinases	S-geneN
could	O
be	O
achieved	O
,	O
selectivity	O
for	O
most	O
of	O
these	O
compounds	O
against	O
PKA	S-geneN
was	O
not	O
achieved	O
.	O

This	O
is	O
distinct	O
from	O
Rock	S-geneN
inhibitors	O
based	O
on	O
non	O
-	O
amino	B-chem
acid	E-chem
derived	O
quinazolinones	S-chem
,	O
where	O
high	O
selectivity	O
against	O
PKA	S-geneN
could	O
be	O
obtained	O
.	O
(	O
22	O
)	O
The	O
inhibitors	O
presented	O
here	O
in	O
some	O
cases	O
possessed	O
sub	O
-	O
nanomolar	O
inhibition	O
of	O
Rock	S-geneN
,	O
nanomolar	O
potency	O
in	O
ppMLC	O
cell	O
based	O
assays	O
,	O
low	O
to	O
fair	O
cytochrome	B-geneN
P	I-geneN
-	I-geneN
450	E-geneN
inhibition	O
,	O
and	O
good	O
human	O
microsomal	O
stability	O
.	O

Molecular	O
analysis	O
of	O
PCCB	S-geneY
gene	O
in	O
Korean	O
patients	O
with	O
propionic	S-chem
acidemia	O
.	O

Propionic	O
acidemia	O
(	O
PA	O
)	O
is	O
an	O
autosomal	O
recessive	O
inborn	O
error	O
in	O
the	O
catabolism	O
of	O
methionine	S-chem
,	O
isoleucine	S-chem
,	O
threonine	S-chem
,	O
and	O
valine	S-chem
,	O
odd	B-chem
-	I-chem
numbered	I-chem
chain	I-chem
length	I-chem
fatty	I-chem
acids	E-chem
and	O
cholesterol	S-chem
.	O

Clinical	O
symptoms	O
are	O
very	O
heterogeneous	O
and	O
present	O
as	O
a	O
severe	O
neonatal	O
-	O
onset	O
or	O
a	O
late	O
-	O
onset	O
form	O
.	O

It	O
is	O
caused	O
by	O
a	O
deficiency	O
of	O
propionyl	B-geneN
-	I-geneN
CoA	I-geneN
carboxylase	E-geneN
(	O
PCC	S-geneN
,	O
EC	B-geneY
6.4.1.3	E-geneY
)	O
,	O
a	O
biotin	S-chem
-	O
dependent	O
enzyme	O
that	O
catalyzes	O
the	O
carboxylation	O
of	O
propionyl	B-chem
-	I-chem
CoA	E-chem
to	O
D	B-chem
-	I-chem
methylmalonyl	I-chem
-	I-chem
CoA	E-chem
.	O

PCC	S-geneN
is	O
a	O
heteropolymeric	O
enzyme	O
composed	O
of	O
alpha	O
-	O
and	O
beta	O
-	O
subunits	O
.	O

A	O
greater	O
heterogeneity	O
is	O
observed	O
in	O
the	O
PCCA	S-geneY
gene	O
,	O
while	O
for	O
the	O
PCCB	S-geneY
gene	O
,	O
a	O
limited	O
number	O
of	O
mutations	O
is	O
responsible	O
for	O
the	O
majority	O
of	O
the	O
alleles	O
characterized	O
in	O
both	O
Caucasian	O
and	O
Oriental	O
populations	O
.	O

We	O
identified	O
eight	O
Korean	O
patients	O
with	O
PA	O
by	O
organic	O
acid	O
analysis	O
confirmed	O
in	O
five	O
patients	O
by	O
the	O
PCC	S-geneN
enzyme	O
assay	O
in	O
the	O
lymphoblasts	O
.	O

Two	O
neonatal	O
-	O
onset	O
patients	O
showed	O
undetectable	O
PCC	S-geneN
activities	O
while	O
three	O
cases	O
with	O
residual	O
enzyme	O
activities	O
had	O
relatively	O
late	O
manifestations	O
.	O

In	O
the	O
molecular	O
analysis	O
,	O
we	O
identified	O
five	O
novel	O
mutations	O
,	O
Y439C	S-geneN
,	O
1527del3	O
,	O
1357insT	O
,	O
IVS12	B-geneN
-	I-geneN
8T	I-geneN
-	I-geneN
-	I-geneN
>	I-geneN
A	E-geneN
,	O
and	O
31del10	O
,	O
and	O
one	O
known	O
mutation	O
,	O
T428I	S-geneN
in	O
PCCB	S-geneY
gene	O
.	O

Alleleic	O
frequency	O
of	O
T428I	S-geneN
in	O
Korean	O
patients	O
with	O
PA	O
was	O
56.3	O
%	O
in	O
this	O
study	O
.	O

Two	O
neonatal	O
-	O
onset	O
patients	O
with	O
null	O
enzyme	O
activities	O
were	O
homozygotes	O
with	O
1527del3	O
and	O
T428I	S-geneN
,	O
respectively	O
.	O

This	O
finding	O
implies	O
that	O
T428I	S-geneN
and	O
1527del3	O
mutation	O
could	O
be	O
responsible	O
for	O
their	O
severe	O
clinical	O
courses	O
and	O
null	O
enzyme	O
activities	O
.	O

The	O
mRNA	O
of	O
PCCB	S-geneY
gene	O
in	O
T428I	S-geneN
and	O
1527del3	O
homozygotes	O
were	O
normal	O
but	O
in	O
Western	O
blot	O
analysis	O
,	O
the	O
betaPCC	S-geneY
-	O
subunit	O
was	O
only	O
absent	O
in	O
1527del3	O
homozygote	O
patient	O
suggesting	O
different	O
molecular	O
pathology	O
.	O

Activity	O
of	O
XL184	S-chem
(	O
Cabozantinib	S-chem
)	O
,	O
an	O
oral	O
tyrosine	B-geneN
kinase	E-geneN
inhibitor	O
,	O
in	O
patients	O
with	O
medullary	O
thyroid	O
cancer	O
.	O

PURPOSE	O
:	O
XL184	S-chem
(	O
cabozantinib	S-chem
)	O
is	O
a	O
potent	O
inhibitor	O
of	O
MET	S-geneY
,	O
vascular	B-geneY
endothelial	I-geneY
growth	I-geneY
factor	I-geneY
receptor	I-geneY
2	E-geneY
(	O
VEGFR2	S-geneY
)	O
,	O
and	O
RET	S-geneY
,	O
with	O
robust	O
antiangiogenic	O
,	O
antitumor	O
,	O
and	O
anti	O
-	O
invasive	O
effects	O
in	O
preclinical	O
models	O
.	O

Early	O
observations	O
of	O
clinical	O
benefit	O
in	O
a	O
phase	O
I	O
study	O
of	O
cabozantinib	S-chem
,	O
which	O
included	O
patients	O
with	O
medullary	O
thyroid	O
cancer	O
(	O
MTC	O
)	O
,	O
led	O
to	O
expansion	O
of	O
an	O
MTC	O
-	O
enriched	O
cohort	O
,	O
which	O
is	O
the	O
focus	O
of	O
this	O
article	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
phase	O
I	O
dose	O
-	O
escalation	O
study	O
of	O
oral	O
cabozantinib	S-chem
was	O
conducted	O
in	O
patients	O
with	O
advanced	O
solid	O
tumors	O
.	O

Primary	O
end	O
points	O
included	O
evaluation	O
of	O
safety	O
,	O
pharmacokinetics	O
,	O
and	O
maximum	O
-	O
tolerated	O
dose	O
(	O
MTD	O
)	O
determination	O
.	O

Additional	O
end	O
points	O
included	O
RECIST	O
(	O
Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
)	O
response	O
,	O
pharmacodynamics	O
,	O
RET	S-geneY
mutational	O
status	O
,	O
and	O
biomarker	O
analyses	O
.	O

RESULTS	O
:	O
Eighty	O
-	O
five	O
patients	O
were	O
enrolled	O
,	O
including	O
37	O
with	O
MTC	O
.	O

The	O
MTD	O
was	O
175	O
mg	O
daily	O
.	O

Dose	O
-	O
limiting	O
toxicities	O
were	O
grade	O
3	O
palmar	O
plantar	O
erythrodysesthesia	O
(	O
PPE	O
)	O
,	O
mucositis	O
,	O
and	O
AST	S-geneN
,	O
ALT	S-geneN
,	O
and	O
lipase	S-geneN
elevations	O
and	O
grade	O
2	O
mucositis	O
that	O
resulted	O
in	O
dose	O
interruption	O
and	O
reduction	O
.	O

Ten	O
(	O
29	O
%	O
)	O
of	O
35	O
patients	O
with	O
MTC	O
with	O
measurable	O
disease	O
had	O
a	O
confirmed	O
partial	O
response	O
.	O

Overall	O
,	O
18	O
patients	O
experienced	O
tumor	O
shrinkage	O
of	O
30	O
%	O
or	O
more	O
,	O
including	O
17	O
(	O
49	O
%	O
)	O
of	O
35	O
patients	O
with	O
MTC	O
with	O
measurable	O
disease	O
.	O

Additionally	O
,	O
15	O
(	O
41	O
%	O
)	O
of	O
37	O
patients	O
with	O
MTC	O
had	O
stable	O
disease	O
(	O
SD	O
)	O
for	O
at	O
least	O
6	O
months	O
,	O
resulting	O
in	O
SD	O
for	O
6	O
months	O
or	O
longer	O
or	O
confirmed	O
partial	O
response	O
in	O
68	O
%	O
of	O
patients	O
with	O
MTC	O
.	O

CONCLUSION	O
:	O
Cabozantinib	S-chem
has	O
an	O
acceptable	O
safety	O
profile	O
and	O
is	O
active	O
in	O
MTC	O
.	O

Cabozantinib	S-chem
may	O
provide	O
clinical	O
benefit	O
by	O
simultaneously	O
targeting	O
multiple	O
pathways	O
of	O
importance	O
in	O
MTC	O
,	O
including	O
MET	S-geneY
,	O
VEGFR2	S-geneY
,	O
and	O
RET	S-geneY
.	O

A	O
global	O
phase	O
III	O
pivotal	O
study	O
in	O
MTC	O
is	O
ongoing	O
(	O
ClinicalTrials.gov	O
number	O
NCT00215605	O
)	O
.	O

Cloning	O
and	O
expression	O
of	O
a	O
novel	O
serotonin	B-geneN
receptor	E-geneN
with	O
high	O
affinity	O
for	O
tricyclic	S-chem
psychotropic	O
drugs	O
.	O

We	O
have	O
used	O
the	O
polymerase	O
chain	O
reaction	O
technique	O
to	O
selectively	O
amplify	O
a	O
guanine	B-geneN
nucleotide	I-geneN
-	I-geneN
binding	I-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
cDNA	O
sequence	O
from	O
rat	O
striatal	O
mRNA	O
that	O
exhibits	O
high	O
homology	O
to	O
previously	O
cloned	O
serotonin	B-geneN
receptors	E-geneN
.	O

Sequencing	O
of	O
a	O
full	O
length	O
clone	O
isolated	O
from	O
a	O
rat	O
striatal	O
cDNA	O
library	O
revealed	O
an	O
open	O
reading	O
frame	O
of	O
1311	O
base	O
pairs	O
,	O
encoding	O
a	O
437	O
-	O
residue	O
protein	O
with	O
seven	O
hydrophobic	O
regions	O
.	O

Within	O
these	O
hydrophobic	O
regions	O
,	O
this	O
receptor	O
was	O
found	O
to	O
be	O
41	O
-	O
36	O
%	O
identical	O
to	O
the	O
following	O
serotonin	B-geneN
[	I-geneN
5	I-geneN
-	I-geneN
hydroxytryptamine	I-geneN
(	I-geneN
5	I-geneN
-	I-geneN
HT	I-geneN
)	I-geneN
]	I-geneN
receptors	E-geneN
:	O
5	B-geneY
-	I-geneY
HT2	E-geneY
>	O
5	B-geneY
-	I-geneY
HT1D	E-geneY
>	O
5	B-geneY
-	I-geneY
HT1C	E-geneY
>	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
>	O
5	B-geneY
-	I-geneY
HT1A	E-geneY
>	O
5	B-geneY
-	I-geneY
HT1E	E-geneY
.	O

Northern	O
blots	O
revealed	O
a	O
approximately	O
4.2	O
-	O
kilobase	O
transcript	O
localized	O
in	O
various	O
brain	O
regions	O
,	O
with	O
the	O
following	O
rank	O
order	O
of	O
abundance	O
:	O
striatum	O
>	O
>	O
olfactory	O
tubercle	O
>	O
cerebral	O
cortex	O
>	O
hippocampus	O
.	O

Expression	O
of	O
this	O
clone	O
in	O
COS	O
-	O
7	O
cells	O
resulted	O
in	O
the	O
appearance	O
of	O
high	O
affinity	O
,	O
saturable	O
binding	O
of	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
[	I-chem
2	I-chem
-	I-chem
125I	I-chem
]	I-chem
iodolysergic	I-chem
acid	I-chem
diethylamide	E-chem
(	O
[	B-chem
125I	I-chem
]	I-chem
LSD	E-chem
)	O
with	O
a	O
Kd	O
of	O
1.26	O
nM	O
.	O

Among	O
endogenous	O
biogenic	O
amines	O
,	O
only	O
5	B-chem
-	I-chem
HT	E-chem
completely	O
inhibited	O
[	B-chem
125I	I-chem
]	I-chem
LSD	E-chem
binding	O
(	O
Ki	O
=	O
150	O
nM	O
)	O
.	O

The	O
inhibition	O
of	O
[	B-chem
125I	I-chem
]	I-chem
LSD	E-chem
binding	O
by	O
other	O
serotonergic	O
agonists	O
and	O
antagonists	O
revealed	O
a	O
pharmacological	O
profile	O
that	O
does	O
not	O
correlate	O
with	O
that	O
of	O
any	O
previously	O
described	O
serotonin	B-geneN
receptor	E-geneN
subtype	O
.	O

In	O
addition	O
,	O
this	O
receptor	O
exhibits	O
high	O
affinity	O
for	O
a	O
number	O
of	O
tricyclic	S-chem
antipsychotic	O
and	O
antidepressant	O
drugs	O
,	O
including	O
clozapine	S-chem
,	O
amoxipine	S-chem
,	O
and	O
amitriptyline	S-chem
.	O

In	O
HEK	O
-	O
293	O
cells	O
stably	O
transfected	O
with	O
this	O
receptor	O
,	O
serotonin	S-chem
elicits	O
a	O
potent	O
stimulation	O
of	O
adenylyl	B-geneN
cyclase	E-geneN
activity	O
,	O
which	O
is	O
blocked	O
by	O
antipsychotic	O
and	O
antidepressant	O
drugs	O
.	O

The	O
distinct	O
structural	O
and	O
pharmacological	O
properties	O
of	O
this	O
receptor	O
site	O
indicate	O
that	O
it	O
represents	O
a	O
completely	O
novel	O
subtype	O
of	O
serotonin	B-geneN
receptor	E-geneN
.	O

Based	O
on	O
its	O
affinity	O
for	O
tricyclic	S-chem
psychotropic	O
drugs	O
and	O
its	O
localization	O
to	O
limbic	O
and	O
cortical	O
regions	O
of	O
the	O
brain	O
,	O
it	O
is	O
likely	O
that	O
this	O
receptor	O
may	O
play	O
a	O
role	O
in	O
several	O
neuropsychiatric	O
disorders	O
that	O
involve	O
serotonergic	O
systems	O
.	O

Effect	O
of	O
ketoconazole	S-chem
on	O
the	O
pharmacokinetic	O
profile	O
of	O
ambrisentan	S-chem
.	O

Ambrisentan	S-chem
is	O
an	O
endothelin	B-geneY
type	I-geneY
A	I-geneY
(	I-geneY
ET	I-geneY
(	I-geneY
A	I-geneY
)	I-geneY
)	I-geneY
-	I-geneY
selective	I-geneY
receptor	E-geneY
antagonist	O
that	O
is	O
metabolized	O
primarily	O
by	O
glucuronidation	O
but	O
also	O
undergoes	O
oxidative	O
metabolism	O
by	O
CYP3A4	S-geneY
.	O

The	O
potential	O
for	O
ketoconazole	S-chem
,	O
the	O
archetypal	O
strong	O
inhibitor	O
of	O
CYP3A4	S-geneY
,	O
to	O
alter	O
the	O
pharmacokinetic	O
profile	O
of	O
ambrisentan	S-chem
and	O
its	O
oxidative	O
metabolite	O
,	O
4	B-chem
-	I-chem
hydroxymethyl	I-chem
ambrisentan	E-chem
,	O
was	O
assessed	O
in	O
an	O
open	O
-	O
label	O
,	O
nonrandomized	O
,	O
2	O
-	O
period	O
,	O
single	O
-	O
sequence	O
study	O
in	O
16	O
healthy	O
men	O
.	O

Participants	O
received	O
a	O
single	O
dose	O
of	O
ambrisentan	S-chem
10	O
mg	O
alone	O
and	O
after	O
4	O
days	O
of	O
ketoconazole	S-chem
400	O
mg	O
administered	O
once	O
daily	O
.	O

In	O
the	O
presence	O
of	O
multiple	O
doses	O
of	O
ketoconazole	S-chem
,	O
single	O
-	O
dose	O
ambrisentan	S-chem
AUC	O
(	O
0	O
-	O
infinity	O
)	O
estimate	O
was	O
increased	O
by	O
35.3	O
%	O
,	O
whereas	O
C	O
(	O
max	O
)	O
was	O
increased	O
by	O
20.0	O
%	O
.	O

For	O
the	O
4	B-chem
-	I-chem
hydroxymethyl	I-chem
ambrisentan	E-chem
metabolite	O
,	O
AUC	O
(	O
0	O
-	O
infinity	O
)	O
estimate	O
was	O
decreased	O
by	O
4.0	O
%	O
,	O
whereas	O
C	O
(	O
max	O
)	O
was	O
decreased	O
by	O
16.5	O
%	O
.	O

Concomitant	O
administration	O
of	O
ambrisentan	S-chem
and	O
ketoconazole	S-chem
was	O
well	O
tolerated	O
.	O

In	O
summary	O
,	O
ketoconazole	S-chem
had	O
no	O
clinically	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
or	O
safety	O
profile	O
of	O
ambrisentan	S-chem
;	O
therefore	O
,	O
no	O
changes	O
in	O
ambrisentan	S-chem
dose	O
should	O
be	O
necessary	O
when	O
the	O
drug	O
is	O
administered	O
concomitantly	O
with	O
known	O
CYP3A4	S-geneY
inhibitors	O
.	O

Effect	O
of	O
the	O
Potent	O
Antiviral	O
1	B-chem
-	I-chem
Cinnamoyl	I-chem
-	I-chem
3,11	I-chem
-	I-chem
Dihydroxymeliacarpin	E-chem
on	O
Cytokine	S-geneN
Production	O
by	O
Murine	O
Macrophages	O
Stimulated	O
with	O
HSV	O
-	O
2	O
.	O

The	O
limonoid	O
1	B-chem
-	I-chem
cinnamoyl	I-chem
-	I-chem
3,11	I-chem
-	I-chem
dihydroxymeliacarpin	E-chem
(	O
CDM	S-chem
)	O
isolated	O
from	O
leaf	O
extracts	O
of	O
Melia	O
azedarach	O
L	O
,	O
has	O
potent	O
antiherpetic	O
effect	O
in	O
epithelial	O
cells	O
.	O

Since	O
Meliacine	O
,	O
the	O
partially	O
purified	O
extract	O
source	O
of	O
CDM	S-chem
,	O
has	O
therapeutic	O
effect	O
on	O
murine	O
genital	O
herpes	O
,	O
the	O
potential	O
use	O
of	O
CDM	S-chem
as	O
microbicide	O
against	O
herpetic	O
infections	O
was	O
studied	O
here	O
.	O

To	O
determine	O
the	O
cytotoxic	O
effect	O
of	O
CDM	S-chem
,	O
the	O
MTT	S-chem
assay	O
and	O
acridine	O
orange	O
staining	O
of	O
living	O
cells	O
were	O
performed	O
.	O

The	O
antiherpetic	O
action	O
of	O
CDM	S-chem
was	O
measured	O
by	O
plaque	O
reduction	O
assay	O
,	O
and	O
the	O
immunomodulatory	O
effect	O
was	O
determined	O
by	O
measuring	O
the	O
cytokine	S-geneN
production	O
using	O
a	O
bioassay	O
and	O
ELISA	O
method	O
.	O

The	O
results	O
presented	O
here	O
showed	O
that	O
CDM	S-chem
inhibited	O
Herpes	O
Simplex	O
Virus	O
type	O
2	O
(	O
HSV	O
-	O
2	O
)	O
multiplication	O
in	O
Vero	O
cells	O
but	O
did	O
not	O
affect	O
its	O
replication	O
in	O
macrophages	O
which	O
were	O
not	O
permissive	O
to	O
HSV	O
infection	O
.	O

In	O
macrophages	O
,	O
levels	O
of	O
TNF	B-geneY
-	I-geneY
α	E-geneY
,	O
IFN	B-geneY
-	I-geneY
γ	E-geneY
,	O
NO	O
,	O
IL	B-geneY
-	I-geneY
6	E-geneY
and	O
IL	B-geneY
-	I-geneY
10	E-geneY
were	O
increased	O
by	O
CDM	S-chem
used	O
alone	O
or	O
in	O
combination	O
with	O
HSV	O
-	O
2	O
.	O

Besides	O
,	O
CDM	S-chem
not	O
only	O
synergized	O
TNF	B-geneY
-	I-geneY
α	E-geneY
production	O
combined	O
with	O
IFN	B-geneY
-	I-geneY
γ	E-geneY
,	O
but	O
also	O
prolonged	O
its	O
expression	O
in	O
time	O
.	O

Results	O
indicate	O
that	O
CDM	S-chem
inhibits	O
HSV	O
-	O
2	O
multiplication	O
in	O
epithelial	O
cells	O
and	O
also	O
increases	O
cytokine	S-geneN
production	O
in	O
macrophages	O
,	O
both	O
important	O
actions	O
to	O
the	O
clearance	O
of	O
infecting	O
virus	O
in	O
the	O
mouse	O
vagina	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

5	B-chem
-	I-chem
Amino	I-chem
-	I-chem
2	I-chem
-	I-chem
hydroxybenzoic	I-chem
acid	E-chem
4	B-chem
-	I-chem
(	I-chem
5	I-chem
-	I-chem
thioxo	I-chem
-	I-chem
5H	I-chem
-	I-chem
[	I-chem
1,2	I-chem
]	I-chem
dithiol	I-chem
-	I-chem
3yl	I-chem
)	I-chem
-	I-chem
phenyl	I-chem
ester	E-chem
(	O
ATB	B-chem
-	I-chem
429	E-chem
)	O
,	O
a	O
hydrogen	B-chem
sulfide	E-chem
-	O
releasing	O
derivative	O
of	O
mesalamine	S-chem
,	O
exerts	O
antinociceptive	O
effects	O
in	O
a	O
model	O
of	O
postinflammatory	O
hypersensitivity	O
.	O

H	B-chem
(	I-chem
2	I-chem
)	I-chem
S	E-chem
functions	O
as	O
a	O
neuromodulator	O
and	O
exerts	O
anti	O
-	O
inflammatory	O
activities	O
.	O

Recent	O
data	O
indicate	O
that	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
is	O
linked	O
to	O
inflammation	O
of	O
the	O
gastrointestinal	O
tract	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
a	O
novel	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
S	E-chem
-	O
releasing	O
derivative	O
of	O
mesalamine	S-chem
(	O
5	B-chem
-	I-chem
amino	I-chem
-	I-chem
2	I-chem
-	I-chem
hydroxybenzoic	I-chem
acid	I-chem
4	I-chem
-	I-chem
(	I-chem
5	I-chem
-	I-chem
thioxo	I-chem
-	I-chem
5H	I-chem
-	I-chem
[	I-chem
1,2	I-chem
]	I-chem
dithiol	I-chem
-	I-chem
3yl	I-chem
)	I-chem
-	I-chem
phenyl	I-chem
ester	E-chem
,	O
ATB	B-chem
-	I-chem
429	E-chem
)	O
in	O
modulating	O
nociception	O
to	O
colorectal	O
distension	O
(	O
CRD	O
)	O
,	O
a	O
model	O
that	O
mimics	O
some	O
features	O
of	O
IBS	O
,	O
in	O
healthy	O
and	O
postcolitic	O
rats	O
.	O

Four	O
graded	O
(	O
0.4	O
-	O
1.6	O
ml	O
of	O
water	O
)	O
CRDs	O
were	O
produced	O
in	O
conscious	O
rats	O
,	O
and	O
colorectal	O
sensitivity	O
and	O
pain	O
were	O
assessed	O
by	O
measuring	O
the	O
abdominal	O
withdrawal	O
response	O
and	O
spinal	O
c	B-geneY
-	I-geneY
Fos	E-geneY
expression	O
.	O

In	O
healthy	O
rats	O
,	O
ATB	B-chem
-	I-chem
429	E-chem
dose	O
dependently	O
(	O
25	O
,	O
50	O
,	O
or	O
100	O
mg	O
/	O
kg	O
)	O
attenuated	O
CRD	O
-	O
induced	O
hypersensitivity	O
and	O
significantly	O
inhibited	O
CRD	O
-	O
induced	O
overexpression	O
of	O
spinal	O
c	B-geneY
-	I-geneY
FOS	E-geneY
mRNA	O
,	O
whereas	O
mesalamine	S-chem
had	O
no	O
effect	O
.	O

ATB	B-chem
-	I-chem
429	E-chem
-	O
induced	O
antinociception	O
was	O
reversed	O
by	O
glibenclamide	S-chem
,	O
a	O
ATP	B-geneN
-	I-geneN
sensitive	I-geneN
K	I-geneN
(	I-geneN
+	I-geneN
)	I-geneN
(	I-geneN
K	I-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
)	I-geneN
channel	E-geneN
inhibitor	O
.	O

The	O
antinociceptive	O
effect	O
of	O
ATB	B-chem
-	I-chem
429	E-chem
was	O
maintained	O
in	O
a	O
rodent	O
model	O
of	O
postinflammatory	O
hypersensitivity	O
(	O
4	O
weeks	O
after	O
colitis	O
induction	O
)	O
.	O

At	O
a	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
,	O
ATB	B-chem
-	I-chem
429	E-chem
reversed	O
the	O
allodynic	O
response	O
caused	O
by	O
CRD	O
in	O
postcolitic	O
rats	O
.	O

Colonic	O
cyclooxygenase	B-geneY
-	I-geneY
2	E-geneY
and	O
interkeukin	B-geneY
-	I-geneY
1beta	E-geneY
mRNA	O
and	O
spinal	O
c	B-geneY
-	I-geneY
FOS	E-geneY
mRNA	O
expression	O
were	O
significantly	O
down	O
-	O
regulated	O
by	O
ATB	B-chem
-	I-chem
429	E-chem
,	O
but	O
not	O
by	O
mesalamine	S-chem
.	O

ATB	B-chem
-	I-chem
429	E-chem
,	O
but	O
not	O
mesalamine	S-chem
,	O
increased	O
blood	O
concentrations	O
of	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
S	E-chem
in	O
both	O
healthy	O
and	O
postcolitic	O
rats	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
ATB	B-chem
-	I-chem
429	E-chem
inhibits	O
hypersensitivity	O
induced	O
by	O
CRD	O
in	O
both	O
healthy	O
and	O
postcolitic	O
,	O
allodynic	O
rats	O
by	O
a	O
K	B-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
channel	E-geneN
-	O
mediated	O
mechanism	O
.	O

This	O
study	O
provides	O
evidence	O
that	O
H	B-chem
(	I-chem
2	I-chem
)	I-chem
S	E-chem
-	O
releasing	O
drugs	O
might	O
have	O
beneficial	O
effects	O
in	O
the	O
treatment	O
of	O
painful	O
intestinal	O
disorders	O
.	O

Sulindac	B-chem
sulfide	E-chem
inhibits	O
epidermal	B-geneY
growth	I-geneY
factor	E-geneY
-	O
induced	O
phosphorylation	O
of	O
extracellular	B-geneN
-	I-geneN
regulated	I-geneN
kinase	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
and	O
Bad	S-geneY
in	O
human	O
colon	O
cancer	O
cells	O
.	O

Colorectal	O
cancer	O
is	O
the	O
second	O
leading	O
cause	O
of	O
cancer	O
death	O
in	O
the	O
United	O
States	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
including	O
sulindac	S-chem
are	O
promising	O
chemopreventive	O
agents	O
for	O
colorectal	O
cancer	O
.	O

Sulindac	S-chem
and	O
selective	O
cyclooxygenase	B-geneY
(	I-geneY
COX	I-geneY
)	I-geneY
-	I-geneY
2	E-geneY
inhibitors	O
cause	O
regression	O
of	O
colonic	O
polyps	O
in	O
familial	O
polyposis	O
patients	O
.	O

Sulindac	S-chem
induces	O
apoptotic	O
cell	O
death	O
in	O
cancer	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
tumor	O
cells	O
,	O
activation	O
of	O
extracellular	B-geneN
-	I-geneN
regulated	I-geneN
kinase	I-geneN
(	I-geneN
ERK	I-geneN
)	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
results	O
in	O
phosphorylation	O
of	O
several	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
effectors	O
,	O
including	O
the	O
proapoptotic	O
protein	O
Bad	S-geneY
.	O

Phosphorylation	O
of	O
Ser112	S-chem
by	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
inactivates	O
Bad	S-geneY
and	O
protects	O
the	O
tumor	O
cell	O
from	O
apoptosis	O
.	O

Sulindac	S-chem
metabolites	O
and	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
selectively	O
inhibit	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
phosphorylation	O
in	O
human	O
colon	O
cancer	O
cells	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
epidermal	B-geneY
growth	I-geneY
factor	E-geneY
(	O
EGF	S-geneY
)	O
strongly	O
induces	O
phosphorylation	O
of	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
and	O
Bad	S-geneY
in	O
HT29	O
colon	O
cancer	O
cells	O
.	O

EGF	S-geneY
-	O
stimulated	O
phosphorylation	O
of	O
ERK	S-geneN
and	O
Bad	S-geneY
is	O
blocked	O
by	O
pretreatment	O
with	O
U0126	S-chem
,	O
a	O
selective	O
MAP	B-geneN
kinase	I-geneN
kinase	I-geneN
(	I-geneN
MKK	I-geneN
)	I-geneN
1	I-geneN
/	I-geneN
2	E-geneN
inhibitor	O
.	O

Similarly	O
,	O
pretreatment	O
with	O
sulindac	B-chem
sulfide	E-chem
blocks	O
the	O
ability	O
of	O
EGF	S-geneY
to	O
induce	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
and	O
Bad	S-geneY
phosphorylation	O
,	O
but	O
also	O
down	O
-	O
regulates	O
total	O
Bad	S-geneY
but	O
not	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
protein	O
levels	O
.	O

The	O
ability	O
of	O
sulindac	S-chem
to	O
block	O
ERK1	B-geneN
/	I-geneN
2	E-geneN
signaling	O
by	O
the	O
EGF	B-geneY
receptor	E-geneY
may	O
account	O
for	O
at	O
least	O
part	O
of	O
its	O
potent	O
growth	O
-	O
inhibitory	O
effects	O
against	O
cancer	O
cells	O
.	O

Tipping	O
the	O
energy	O
balance	O
toward	O
longevity	O
.	O

AMPK	S-geneY
is	O
a	O
cellular	O
energy	O
sensor	O
conserved	O
across	O
eukaryotes	O
that	O
in	O
C.	O
elegans	O
prolongs	O
life	O
span	O
and	O
mimics	O
dietary	O
restriction	O
.	O

Stenesen	O
and	O
colleagues	O
(	O
2012	O
)	O
activate	O
AMPK	S-geneN
both	O
directly	O
and	O
indirectly	O
by	O
altering	O
AMP	S-chem
biosynthesis	O
to	O
slow	O
aging	O
in	O
Drosophila	O
,	O
highlighting	O
AMPK	S-geneN
as	O
a	O
conserved	O
life	O
span	O
modulator	O
that	O
links	O
energy	O
sensing	O
to	O
longevity	O
.	O

Organization	O
and	O
expression	O
of	O
the	O
SLC36	B-geneN
cluster	I-geneN
of	I-geneN
amino	I-geneN
acid	I-geneN
transporter	E-geneN
genes	O
.	O

Three	O
closely	O
related	O
genes	O
encoding	O
amino	B-chem
acid	E-chem
transport	O
proteins	O
are	O
clustered	O
on	O
5q32	O
in	O
humans	O
,	O
and	O
Chromosome	O
(	O
Chr	O
)	O
11	O
in	O
mice	O
.	O

The	O
human	B-geneY
SLC36A1	E-geneY
gene	O
,	O
which	O
encodes	O
the	O
lysosomal	B-geneY
amino	I-geneY
acid	I-geneY
transporter	I-geneY
LYAAT1	E-geneY
/	O
PAT1	S-geneY
,	O
generates	O
multiple	O
alternative	O
mRNAs	O
,	O
some	O
of	O
which	O
encode	O
truncated	O
proteins	O
.	O

SLC36A1	S-geneY
is	O
expressed	O
in	O
numerous	O
tissues	O
,	O
whereas	O
expression	O
of	O
SLC36A2	S-geneY
,	O
which	O
encodes	O
the	O
glycine	B-geneN
transporter	E-geneN
tramdorinl	S-geneY
/	O
PAT2	S-geneY
,	O
is	O
most	O
abundant	O
in	O
kidney	O
and	O
muscle	O
.	O

Expression	O
of	O
a	O
third	O
gene	O
,	O
SLC36A3	S-geneY
,	O
is	O
restricted	O
to	O
testis	O
.	O

Mouse	B-geneY
Slc36a2	E-geneY
also	O
is	O
expressed	O
in	O
bone	O
and	O
fat	O
tissue	O
.	O

Polymorphisms	O
in	O
human	B-geneY
SLC36A2	E-geneY
exclude	O
it	O
as	O
a	O
candidate	O
locus	O
for	O
a	O
peripheral	O
neuropathy	O
that	O
has	O
been	O
mapped	O
to	O
5q31	O
-	O
33	O
.	O

SLC36A2	S-geneY
is	O
a	O
candidate	O
gene	O
for	O
5q	O
-	O
myelodysplastic	O
syndrome	O
,	O
on	O
the	O
basis	O
of	O
its	O
chromosomal	O
location	O
and	O
its	O
expression	O
in	O
bone	O
.	O

Analysis	O
of	O
plasmin	S-geneY
binding	O
and	O
urokinase	S-geneY
activation	O
of	O
plasminogen	S-geneY
bound	O
to	O
the	O
Heymann	B-geneY
nephritis	I-geneY
autoantigen	E-geneY
,	O
gp330	S-geneY
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
the	O
Heymann	B-geneY
nephritis	I-geneY
autoantigen	E-geneY
,	O
gp330	S-geneY
,	O
can	O
serve	O
as	O
a	O
receptor	O
site	O
for	O
plasminogen	S-geneY
.	O

This	O
binding	O
was	O
not	O
significantly	O
inhibited	O
by	O
the	O
lysine	S-chem
analogue	O
epsilon	B-chem
-	I-chem
amino	I-chem
caproic	I-chem
acid	E-chem
(	O
EACA	S-chem
)	O
,	O
indicating	O
that	O
plasminogen	S-geneY
binding	O
was	O
not	O
just	O
through	O
lysine	S-chem
binding	O
sites	O
as	O
suggested	O
for	O
other	O
plasminogen	S-geneY
binding	O
sites	O
.	O

We	O
now	O
report	O
that	O
once	O
plasminogen	S-geneY
is	O
bound	O
to	O
gp330	S-geneY
,	O
it	O
can	O
be	O
converted	O
to	O
its	O
active	O
form	O
of	O
plasmin	S-geneY
by	O
urokinase	S-geneY
.	O

This	O
conversion	O
of	O
plasminogen	S-geneY
to	O
plasmin	S-geneY
proceeds	O
at	O
a	O
faster	O
rate	O
when	O
plasminogen	S-geneY
is	O
first	O
prebound	O
to	O
gp330	S-geneY
.	O

Although	O
there	O
is	O
a	O
proportional	O
increase	O
in	O
the	O
Vmax	O
of	O
the	O
urokinase	S-geneY
-	O
catalyzed	O
reaction	O
with	O
increasing	O
gp330	S-geneY
concentrations	O
,	O
no	O
change	O
in	O
Km	O
was	O
observed	O
.	O

Once	O
activated	O
,	O
plasmin	S-geneY
remains	O
bound	O
to	O
gp330	S-geneY
in	O
an	O
active	O
state	O
capable	O
of	O
cleaving	O
the	O
chromogenic	O
tripeptide	O
,	O
S	O
-	O
2251	O
.	O

The	O
binding	O
of	O
plasmin	S-geneY
to	O
gp330	S-geneY
did	O
not	O
significantly	O
change	O
its	O
enzymatic	O
activity	O
;	O
however	O
,	O
gp330	S-geneY
did	O
have	O
a	O
stabilizing	O
effect	O
on	O
plasmin	S-geneY
activity	O
at	O
37	O
degrees	O
C	O
.	O

While	O
bound	O
to	O
gp330	S-geneY
,	O
plasmin	S-geneY
is	O
protected	O
from	O
inactivation	O
by	O
its	O
natural	O
inhibitor	O
alpha	B-geneY
2	I-geneY
-	I-geneY
antiplasmin	E-geneY
.	O

The	O
binding	O
of	O
plasmin	S-geneY
to	O
gp330	S-geneY
as	O
analyzed	O
by	O
ELISA	O
was	O
shown	O
to	O
be	O
time	O
dependent	O
,	O
reversible	O
,	O
saturable	O
,	O
and	O
specific	O
for	O
gp330	S-geneY
.	O

Inhibition	O
of	O
binding	O
of	O
both	O
plasminogen	S-geneY
and	O
plasmin	S-geneY
to	O
gp330	S-geneY
by	O
benzamidine	S-chem
was	O
similar	O
,	O
although	O
EACA	S-chem
inhibited	O
the	O
binding	O
of	O
plasmin	S-geneY
to	O
gp330	S-geneY
slightly	O
more	O
than	O
the	O
binding	O
of	O
plasminogen	S-geneY
to	O
gp330	S-geneY
.	O

These	O
results	O
indicate	O
that	O
the	O
binding	O
of	O
plasminogen	S-geneY
to	O
gp330	S-geneY
serves	O
as	O
an	O
effective	O
means	O
of	O
increasing	O
the	O
rate	O
of	O
plasmin	S-geneY
production	O
on	O
the	O
glomerular	O
and	O
tubular	O
epithelial	O
cell	O
surface	O
while	O
protecting	O
the	O
active	O
plasmin	S-geneY
from	O
natural	O
inhibitors	O
.	O

Androgen	B-geneY
receptor	E-geneY
CAG	B-geneN
repeat	E-geneN
length	O
modifies	O
the	O
effect	O
of	O
2,3,7,8	B-chem
-	I-chem
tetrachlorodibenzo	I-chem
-	I-chem
p	I-chem
-	I-chem
dioxin	E-chem
on	O
receptor	O
activity	O
in	O
human	O
prostate	O
cells	O
.	O

Increased	O
incidence	O
of	O
prostate	O
cancer	O
has	O
been	O
reported	O
in	O
men	O
exposed	O
to	O
2,3,7,8	B-chem
-	I-chem
tetrachlorodibenzo	I-chem
-	I-chem
p	I-chem
-	I-chem
dioxin	E-chem
(	O
TCDD	S-chem
)	O
.	O

TCDD	S-chem
acts	O
through	O
the	O
aryl	B-geneY
hydrocarbon	I-geneY
receptor	E-geneY
(	O
AhR	S-geneY
)	O
,	O
which	O
interacts	O
with	O
the	O
androgen	B-geneY
receptor	E-geneY
(	O
AR	S-geneY
)	O
.	O

The	O
AR	S-geneY
gene	O
contains	O
a	O
polymorphic	O
CAG	B-geneN
repeat	E-geneN
that	O
influences	O
its	O
transcriptional	O
activity	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
TCDD	S-chem
on	O
prostate	O
cancer	O
cells	O
(	O
PC	O
-	O
3	O
)	O
and	O
non	O
-	O
tumor	O
prostate	O
cells	O
(	O
PNT1A	O
)	O
on	O
5α	B-chem
-	I-chem
dihydrotestosterone	E-chem
-	O
activated	O
ARs	S-geneY
containing	O
CAG	B-geneN
repeats	E-geneN
within	O
normal	O
length	O
range	O
(	O
16	O
,	O
22	O
,	O
and	O
28	O
)	O
.	O

The	O
AhR	S-geneY
target	O
gene	O
CYP1A1	S-geneY
mRNA	O
expression	O
was	O
induced	O
by	O
TCDD	S-chem
,	O
but	O
was	O
not	O
affected	O
by	O
the	O
AR	S-geneY
CAG	S-geneN
length	O
.	O

TCDD	S-chem
had	O
no	O
effect	O
on	O
AR	S-geneY
activity	O
in	O
PC	O
-	O
3	O
cells	O
,	O
whereas	O
the	O
shortest	O
AR	S-geneY
variant	O
was	O
induced	O
by	O
TCDD	S-chem
in	O
PNT1A	O
cells	O
.	O

In	O
conclusion	O
,	O
the	O
CAG	S-geneN
length	O
dependent	O
effect	O
of	O
TCDD	S-chem
on	O
AR	S-geneY
activity	O
in	O
PNT1A	O
,	O
but	O
not	O
in	O
PC	O
-	O
3	O
cells	O
,	O
indicates	O
as	O
a	O
cell	O
-	O
specific	O
effect	O
of	O
TCDD	S-chem
on	O
AR	S-geneY
activity	O
.	O

Inhibition	O
of	O
monoamine	B-geneN
oxidase	E-geneN
by	O
phthalide	S-chem
analogues	O
.	O

Based	O
on	O
recent	O
reports	O
that	O
the	O
small	O
molecules	O
,	O
isatin	S-chem
and	O
phthalimide	S-chem
,	O
are	O
suitable	O
scaffolds	O
for	O
the	O
design	O
of	O
high	O
potency	O
monoamine	B-geneN
oxidase	E-geneN
(	O
MAO	S-geneN
)	O
inhibitors	O
,	O
the	O
present	O
study	O
examines	O
the	O
MAO	S-geneN
inhibitory	O
properties	O
of	O
a	O
series	O
of	O
phthalide	S-chem
[	O
2	B-chem
-	I-chem
benzofuran	I-chem
-	I-chem
1	I-chem
(	I-chem
3H	I-chem
)	I-chem
-	I-chem
one	E-chem
]	O
analogues	O
.	O

Phthalide	S-chem
is	O
structurally	O
related	O
to	O
isatin	S-chem
and	O
phthalimide	S-chem
and	O
it	O
is	O
demonstrated	O
here	O
that	O
substitution	O
at	O
C6	O
of	O
the	O
phthalide	S-chem
moiety	O
yields	O
compounds	O
endowed	O
with	O
high	O
binding	O
affinities	O
to	O
both	O
human	B-geneN
MAO	E-geneN
isoforms	O
.	O

Among	O
the	O
nineteen	O
homologues	O
evaluated	O
,	O
the	O
lowest	O
IC	O
(	O
50	O
)	O
values	O
recorded	O
for	O
the	O
inhibition	O
of	O
MAO	B-geneN
-	I-geneN
A	I-geneN
and	I-geneN
-	I-geneN
B	E-geneN
were	O
0.096	O
and	O
0.0014	O
μM	O
,	O
respectively	O
.	O

In	O
most	O
instances	O
,	O
C6	O
-	O
substituted	O
phthalides	S-chem
exhibit	O
MAO	B-geneY
-	I-geneY
B	E-geneY
specific	O
inhibition	O
.	O

Among	O
a	O
series	O
of	O
6	B-chem
-	I-chem
benzyloxyphthalides	E-chem
bearing	O
substituents	O
on	O
the	O
para	O
position	O
of	O
the	O
phenyl	S-chem
ring	O
the	O
general	O
order	O
of	O
potency	O
was	O
CF	B-chem
(	I-chem
3	I-chem
)	E-chem
>	O
I	S-chem
>	O
Br	S-chem
>	O
Cl	S-chem
>	O
F	S-chem
>	O
CH	B-chem
(	I-chem
3	I-chem
)	E-chem
>	O
H	S-chem
.	O

The	O
results	O
also	O
show	O
that	O
the	O
binding	O
modes	O
of	O
representative	O
phthalides	S-chem
are	O
reversible	O
and	O
competitive	O
at	O
both	O
MAO	S-geneN
isoforms	O
.	O

Based	O
on	O
these	O
data	O
,	O
C6	S-chem
-	O
substituted	O
phthalides	S-chem
may	O
serve	O
as	O
leads	O
for	O
the	O
development	O
of	O
therapies	O
for	O
neurodegenerative	O
disorders	O
such	O
as	O
Parkinson	O
's	O
disease	O
.	O

Plants	O
as	O
a	O
source	O
of	O
butyrylcholinesterase	S-geneY
variants	O
designed	O
for	O
enhanced	O
cocaine	B-geneN
hydrolase	E-geneN
activity	O
.	O

Cocaine	S-chem
addiction	O
affects	O
millions	O
of	O
people	O
with	O
disastrous	O
personal	O
and	O
social	O
consequences	O
.	O

Cocaine	S-chem
is	O
one	O
of	O
the	O
most	O
reinforcing	O
of	O
all	O
drugs	O
of	O
abuse	O
,	O
and	O
even	O
those	O
who	O
undergo	O
rehabilitation	O
and	O
experience	O
long	O
periods	O
of	O
abstinence	O
have	O
more	O
than	O
80	O
%	O
chance	O
of	O
relapse	O
.	O

Yet	O
there	O
is	O
no	O
FDA	O
-	O
approved	O
treatment	O
to	O
decrease	O
the	O
likelihood	O
of	O
relapse	O
in	O
rehabilitated	O
addicts	O
.	O

Recent	O
studies	O
,	O
however	O
,	O
have	O
demonstrated	O
a	O
promising	O
potential	O
treatment	O
option	O
with	O
the	O
help	O
of	O
the	O
serum	O
enzyme	O
butyrylcholinesterase	S-geneY
(	O
BChE	S-geneY
)	O
,	O
which	O
is	O
capable	O
of	O
breaking	O
down	O
naturally	O
occurring	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
cocaine	E-chem
before	O
the	O
drug	O
can	O
influence	O
the	O
reward	O
centers	O
of	O
the	O
brain	O
or	O
affect	O
other	O
areas	O
of	O
the	O
body	O
.	O

This	O
activity	O
of	O
wild	O
-	O
type	O
(	O
WT	O
)	O
BChE	S-geneY
,	O
however	O
,	O
is	O
relatively	O
low	O
.	O

This	O
prompted	O
the	O
design	O
of	O
variants	O
of	O
BChE	S-geneY
which	O
exhibit	O
significantly	O
improved	O
catalytic	O
activity	O
against	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
cocaine	E-chem
.	O

Plants	O
are	O
a	O
promising	O
means	O
to	O
produce	O
large	O
amounts	O
of	O
these	O
cocaine	B-geneN
hydrolase	E-geneN
variants	O
of	O
BChE	S-geneN
,	O
cheaply	O
,	O
safely	O
with	O
no	O
concerns	O
regarding	O
human	O
pathogens	O
and	O
functionally	O
equivalent	O
to	O
enzymes	O
derived	O
from	O
other	O
sources	O
.	O

Here	O
,	O
in	O
expressing	O
cocaine	S-chem
-	O
hydrolyzing	O
mutants	O
of	O
BChE	S-geneN
in	O
Nicotiana	O
benthamiana	O
using	O
the	O
MagnICON	O
virus	O
-	O
assisted	O
transient	O
expression	O
system	O
,	O
and	O
in	O
reporting	O
their	O
initial	O
biochemical	O
analysis	O
,	O
we	O
provide	O
proof	O
-	O
of	O
-	O
principle	O
that	O
plants	O
can	O
express	O
engineered	O
BChE	S-geneN
proteins	O
with	O
desired	O
properties	O
.	O

Inhibition	O
of	O
gelatinase	B-geneY
A	E-geneY
(	O
MMP	B-geneY
-	I-geneY
2	E-geneY
)	O
by	O
batimastat	S-chem
and	O
captopril	S-chem
reduces	O
tumor	O
growth	O
and	O
lung	O
metastases	O
in	O
mice	O
bearing	O
Lewis	O
lung	O
carcinoma	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
the	O
synthetic	O
matrix	B-geneN
metalloproteinase	E-geneN
inhibitor	O
,	O
batimastat	S-chem
(	O
BB	B-chem
-	I-chem
94	E-chem
)	O
and	O
the	O
angiotensin	B-geneY
-	I-geneY
converting	I-geneY
enzyme	E-geneY
inhibitor	O
,	O
captopril	S-chem
,	O
on	O
metalloproteinase	S-geneN
activity	O
of	O
murine	O
Lewis	O
-	O
lung	O
-	O
carcinoma	O
cells	O
(	O
3LL	O
)	O
in	O
vitro	O
,	O
and	O
on	O
local	O
growth	O
and	O
lung	O
metastasis	O
of	O
the	O
same	O
tumor	O
implanted	O
intramuscularly	O
in	O
syngeneic	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
effect	O
of	O
BB	B-chem
-	I-chem
94	E-chem
and	O
captopril	S-chem
on	O
the	O
survival	O
of	O
the	O
3LL	O
-	O
tumor	O
-	O
bearing	O
mice	O
was	O
also	O
examined	O
.	O

Here	O
we	O
report	O
that	O
captopril	S-chem
treatment	O
resulted	O
in	O
decreased	O
transcription	O
and	O
protein	O
levels	O
of	O
gelatinase	B-geneY
A	E-geneY
by	O
3LL	O
cells	O
.	O

Both	O
BB	B-chem
-	I-chem
94	E-chem
and	O
captopril	O
also	O
prevented	O
substrate	O
degradation	O
by	O
gelatinase	B-geneN
A	I-geneN
and	I-geneN
B	E-geneN
released	O
in	O
conditioned	O
medium	O
by	O
cultured	O
cells	O
.	O

Treatment	O
of	O
tumor	O
-	O
bearing	O
animals	O
with	O
BB	B-chem
-	I-chem
94	E-chem
(	O
i.p	O
.	O
)	O
or	O
captopril	S-chem
(	O
in	O
drinking	O
water	O
)	O
resulted	O
in	O
significant	O
inhibition	O
of	O
the	O
mean	O
tumor	O
volume	O
(	O
25	O
and	O
33	O
%	O
respectively	O
)	O
and	O
of	O
the	O
mean	O
lung	O
metastasis	O
number	O
(	O
26	O
and	O
29	O
%	O
respectively	O
)	O
.	O

When	O
both	O
agents	O
were	O
given	O
,	O
they	O
acted	O
in	O
synergy	O
,	O
resulting	O
in	O
51	O
and	O
80	O
%	O
inhibition	O
of	O
tumor	O
growth	O
and	O
metastasis	O
.	O

The	O
survival	O
time	O
of	O
the	O
mice	O
treated	O
with	O
both	O
BB	B-chem
-	I-chem
94	E-chem
and	O
captopril	S-chem
was	O
also	O
significantly	O
longer	O
compared	O
with	O
the	O
groups	O
treated	O
with	O
each	O
agent	O
alone	O
or	O
with	O
the	O
vehicle	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
of	O
an	O
essential	O
role	O
of	O
metalloproteinase	B-geneN
(	I-geneN
s	I-geneN
)	E-geneN
in	O
the	O
metastatic	O
process	O
.	O

Moreover	O
,	O
blockade	O
of	O
invasion	O
,	O
angiogenesis	O
and	O
other	O
processes	O
mediated	O
by	O
metalloproteinases	S-geneN
may	O
underlie	O
the	O
anti	O
-	O
tumor	O
and	O
anti	O
-	O
metastatic	O
effect	O
of	O
BB	B-chem
-	I-chem
94	E-chem
and	O
captopril	S-chem
and	O
their	O
combination	O
.	O

It	O
is	O
conceivable	O
that	O
this	O
combination	O
could	O
be	O
tested	O
in	O
selected	O
clinical	O
conditions	O
as	O
an	O
adjuvant	O
modality	O
to	O
cytotoxic	O
therapy	O
.	O

Cholinesterase	S-geneY
inhibitors	O
for	O
Alzheimer	O
's	O
disease	O
.	O

BACKGROUND	O
:	O
Since	O
the	O
introduction	O
of	O
the	O
first	O
cholinesterase	S-geneY
inhibitor	O
(	O
ChEI	O
)	O
in	O
1997	O
,	O
most	O
clinicians	O
and	O
probably	O
most	O
patients	O
would	O
consider	O
the	O
cholinergic	O
drugs	O
,	O
donepezil	S-chem
,	O
galantamine	S-chem
and	O
rivastigmine	S-chem
,	O
to	O
be	O
the	O
first	O
line	O
pharmacotherapy	O
for	O
mild	O
to	O
moderate	O
Alzheimer	O
's	O
disease.The	O
drugs	O
have	O
slightly	O
different	O
pharmacological	O
properties	O
,	O
but	O
they	O
all	O
work	O
by	O
inhibiting	O
the	O
breakdown	O
of	O
acetylcholine	S-chem
,	O
an	O
important	O
neurotransmitter	O
associated	O
with	O
memory	O
,	O
by	O
blocking	O
the	O
enzyme	O
acetylcholinesterase	S-geneY
.	O

The	O
most	O
that	O
these	O
drugs	O
could	O
achieve	O
is	O
to	O
modify	O
the	O
manifestations	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Cochrane	O
reviews	O
of	O
each	O
ChEI	O
for	O
Alzheimer	O
's	O
disease	O
have	O
been	O
completed	O
(	O
Birks	O
2005	O
,	O
Birks	O
2005b	O
and	O
Loy	O
2005	O
)	O
.	O

Despite	O
the	O
evidence	O
from	O
the	O
clinical	O
studies	O
and	O
the	O
intervening	O
clinical	O
experience	O
the	O
debate	O
on	O
whether	O
ChEIs	O
are	O
effective	O
continues	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
effects	O
of	O
donepezil	S-chem
,	O
galantamine	S-chem
and	O
rivastigmine	S-chem
in	O
people	O
with	O
mild	O
,	O
moderate	O
or	O
severe	O
dementia	O
due	O
to	O
Alzheimer	O
's	O
disease	O
.	O

SEARCH	O
STRATEGY	O
:	O
The	O
Cochrane	O
Dementia	O
and	O
Cognitive	O
Improvement	O
Group	O
's	O
Specialized	O
Register	O
was	O
searched	O
using	O
the	O
terms	O
'	O
donepezil	S-chem
'	O
,	O
'	O
E2020	S-chem
'	O
,	O
'	O
Aricept	S-chem
'	O
,	O
galanthamin	S-chem
*	O
galantamin	S-chem
*	O
reminyl	S-chem
,	O
rivastigmine	S-chem
,	O
exelon	S-chem
,	O
``	O
ENA	I-chem
713	O
``	O
and	O
ENA	I-chem
-	I-chem
713	O
on	O
12	O
June	O
2005	O
.	O

This	O
Register	O
contains	O
up	O
-	O
to	O
-	O
date	O
records	O
of	O
all	O
major	O
health	O
care	O
databases	O
and	O
many	O
ongoing	O
trial	O
databases	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
unconfounded	O
,	O
blinded	O
,	O
randomized	O
trials	O
in	O
which	O
treatment	O
with	O
a	O
ChEI	O
was	O
compared	O
with	O
placebo	O
or	O
another	O
ChEI	O
for	O
patients	O
with	O
mild	O
,	O
moderate	O
or	O
severe	O
dementia	O
due	O
to	O
Alzheimer	O
's	O
disease	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Data	O
were	O
extracted	O
by	O
one	O
reviewer	O
(	O
JSB	O
)	O
,	O
pooled	O
where	O
appropriate	O
and	O
possible	O
,	O
and	O
the	O
pooled	O
treatment	O
effects	O
,	O
or	O
the	O
risks	O
and	O
benefits	O
of	O
treatment	O
estimated	O
.	O

MAIN	O
RESULTS	O
:	O
The	O
results	O
of	O
13	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	O
controlled	O
trials	O
demonstrate	O
that	O
treatment	O
for	O
periods	O
of	O
6	O
months	O
and	O
one	O
year	O
,	O
with	O
donepezil	S-chem
,	O
galantamine	S-chem
or	O
rivastigmine	S-chem
at	O
the	O
recommended	O
dose	O
for	O
people	O
with	O
mild	O
,	O
moderate	O
or	O
severe	O
dementia	O
due	O
to	O
Alzheimer	O
's	O
disease	O
produced	O
improvements	O
in	O
cognitive	O
function	O
,	O
on	O
average	O
-	O
2.7	O
points	O
(	O
95	O
%	O
CI	O
-	O
3.0	O
to	O
-	O
2.3	O
)	O
,	O
in	O
the	O
midrange	O
of	O
the	O
70	O
point	O
ADAS	O
-	O
Cog	O
Scale	O
.	O

Study	O
clinicians	O
blind	O
to	O
other	O
measures	O
rated	O
global	O
clinical	O
state	O
more	O
positively	O
in	O
treated	O
patients	O
.	O

Benefits	O
of	O
treatment	O
were	O
also	O
seen	O
on	O
measures	O
of	O
activities	O
of	O
daily	O
living	O
and	O
behaviour	O
.	O

None	O
of	O
these	O
treatment	O
effects	O
are	O
large	O
.	O

There	O
is	O
nothing	O
to	O
suggest	O
the	O
effects	O
are	O
less	O
for	O
patients	O
with	O
severe	O
dementia	O
or	O
mild	O
dementia	O
,	O
although	O
there	O
is	O
very	O
little	O
evidence	O
for	O
other	O
than	O
mild	O
to	O
moderate	O
dementia.More	O
patients	O
leave	O
ChEI	O
treatment	O
groups	O
,	O
approximately	O
29	O
%	O
,	O
on	O
account	O
of	O
adverse	O
events	O
than	O
leave	O
the	O
placebo	O
groups	O
(	O
18	O
%	O
)	O
.	O

There	O
is	O
evidence	O
of	O
more	O
adverse	O
events	O
in	O
total	O
in	O
the	O
patients	O
treated	O
with	O
a	O
ChEI	O
than	O
with	O
placebo	O
.	O

Although	O
many	O
types	O
of	O
adverse	O
event	O
were	O
reported	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhoea	O
,	O
were	O
significantly	O
more	O
frequent	O
in	O
the	O
ChEI	O
groups	O
than	O
in	O
placebo	O
.	O

There	O
are	O
four	O
studies	O
,	O
all	O
supported	O
by	O
one	O
of	O
the	O
pharmaceutical	O
companies	O
,	O
in	O
which	O
two	O
ChEIs	O
were	O
compared	O
,	O
two	O
studies	O
of	O
donepezil	S-chem
compared	O
with	O
galantamine	S-chem
,	O
and	O
two	O
of	O
donepezil	S-chem
compared	O
with	O
rivastigmine	S-chem
.	O

In	O
three	O
studies	O
the	O
patients	O
were	O
not	O
blinded	O
to	O
treatment	O
,	O
only	O
the	O
fourth	O
,	O
DON	O
vs	O
RIV	O
/	O
Bullock	O
is	O
double	O
blind	O
.	O

Two	O
of	O
the	O
studies	O
provide	O
little	O
evidence	O
,	O
they	O
are	O
of	O
12	O
weeks	O
duration	O
,	O
which	O
is	O
barely	O
long	O
enough	O
to	O
complete	O
the	O
drug	O
titration	O
.	O

There	O
is	O
no	O
evidence	O
from	O
DON	O
vs	O
GAL	O
/	O
Wilcock	O
of	O
a	O
treatment	O
difference	O
between	O
donepezil	S-chem
and	O
galantamine	S-chem
at	O
52	O
weeks	O
for	O
cognition	O
,	O
activities	O
of	O
daily	O
living	O
,	O
the	O
numbers	O
who	O
leave	O
the	O
trial	O
before	O
the	O
end	O
of	O
treatment	O
,	O
the	O
number	O
who	O
suffer	O
any	O
adverse	O
event	O
,	O
or	O
any	O
specific	O
adverse	O
event	O
.	O

There	O
is	O
no	O
evidence	O
from	O
DON	O
vs	O
RIV	O
/	O
Bullock	O
of	O
a	O
difference	O
between	O
donepezil	S-chem
and	O
rivastigmine	S-chem
for	O
cognitive	O
function	O
,	O
activities	O
of	O
daily	O
living	O
and	O
behavioural	O
disturbance	O
at	O
two	O
years	O
.	O

Fewer	O
patients	O
suffer	O
adverse	O
events	O
on	O
donepezil	S-chem
than	O
rivastigmine	S-chem
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
The	O
three	O
cholinesterase	S-geneY
inhibitors	O
are	O
efficacious	O
for	O
mild	O
to	O
moderate	O
Alzheimer	O
's	O
disease	O
.	O

It	O
is	O
not	O
possible	O
to	O
identify	O
those	O
who	O
will	O
respond	O
to	O
treatment	O
prior	O
to	O
treatment	O
.	O

There	O
is	O
no	O
evidence	O
that	O
treatment	O
with	O
a	O
ChEI	O
is	O
not	O
cost	O
effective	O
.	O

Despite	O
the	O
slight	O
variations	O
in	O
the	O
mode	O
of	O
action	O
of	O
the	O
three	O
cholinesterase	S-geneY
inhibitors	O
there	O
is	O
no	O
evidence	O
of	O
any	O
differences	O
between	O
them	O
with	O
respect	O
to	O
efficacy	O
.	O

There	O
appears	O
to	O
be	O
less	O
adverse	O
effects	O
associated	O
with	O
donepezil	S-chem
compared	O
with	O
rivastigmine	S-chem
.	O

It	O
may	O
be	O
that	O
galantamine	S-chem
and	O
rivastigmine	S-chem
match	O
donepezil	S-chem
in	O
tolerability	O
if	O
a	O
careful	O
and	O
gradual	O
titration	O
routine	O
over	O
more	O
than	O
three	O
months	O
is	O
used	O
.	O

Titration	O
with	O
donepezil	S-chem
is	O
more	O
straightforward	O
and	O
the	O
lower	O
dose	O
may	O
be	O
worth	O
consideration	O
.	O

Differential	O
binding	O
of	O
fibroblast	B-geneN
growth	I-geneN
factor	I-geneN
-	I-geneN
2	I-geneN
and	I-geneN
-	I-geneN
7	E-geneN
to	O
basement	O
membrane	O
heparan	O
sulfate	S-chem
:	O
comparison	O
of	O
normal	O
and	O
abnormal	O
human	O
tissues	O
.	O

Fibroblast	B-geneN
growth	I-geneN
factors	E-geneN
(	O
FGFs	S-geneN
)	O
play	O
multiple	O
roles	O
during	O
development	O
and	O
in	O
adult	O
tissues	O
as	O
paracrine	O
regulators	O
of	O
growth	O
and	O
differentiation	O
.	O

FGFs	S-geneN
signal	O
through	O
transmembrane	B-geneN
receptor	I-geneN
tyrosine	I-geneN
kinases	E-geneN
,	O
but	O
heparan	O
sulfate	S-chem
is	O
also	O
required	O
for	O
signaling	O
by	O
members	O
of	O
the	O
FGF	S-geneN
family	O
.	O

In	O
addition	O
,	O
heparan	O
sulfate	O
may	O
be	O
involved	O
in	O
determining	O
tissue	O
distribution	O
of	O
FGFs	S-geneN
.	O

Using	O
biotinylated	O
FGF	B-geneY
-	I-geneY
2	E-geneY
and	O
FGF	B-geneY
-	I-geneY
7	E-geneY
(	O
KGF	S-geneY
)	O
as	O
probes	O
,	O
we	O
have	O
identified	O
specific	O
interactions	O
between	O
FGFs	S-geneN
and	O
heparan	O
sulfates	S-chem
in	O
human	O
tissues	O
.	O

Both	O
FGF	S-geneN
species	O
bind	O
to	O
tissue	O
mast	O
cells	O
and	O
to	O
epithelial	O
cell	O
membranes	O
.	O

Binding	O
to	O
basement	O
membrane	O
heparan	O
sulfate	S-chem
is	O
tissue	O
source	O
dependent	O
and	O
specific	O
.	O

Although	O
FGF	B-geneY
-	I-geneY
2	E-geneY
strongly	O
binds	O
to	O
basement	O
membrane	O
heparan	O
sulfate	S-chem
in	O
skin	O
and	O
most	O
other	O
tissue	O
sites	O
examined	O
,	O
FGF	B-geneY
-	I-geneY
7	E-geneY
fails	O
to	O
bind	O
to	O
basement	O
membrane	O
heparan	O
sulfate	S-chem
in	O
most	O
locations	O
.	O

However	O
,	O
in	O
subendothelial	O
matrix	O
in	O
blood	O
vessels	O
and	O
in	O
the	O
basement	O
membrane	O
of	O
a	O
papillary	O
renal	O
cell	O
carcinoma	O
,	O
strong	O
FGF	B-geneY
-	I-geneY
7	E-geneY
binding	O
is	O
seen	O
.	O

In	O
summary	O
,	O
distinct	O
and	O
specific	O
affinities	O
of	O
heparan	O
sulfates	S-chem
for	O
different	O
FGFs	S-geneN
were	O
identified	O
that	O
may	O
affect	O
growth	O
factor	O
activation	O
and	O
local	O
distribution	O
.	O

Heparan	O
sulfate	S-chem
may	O
have	O
a	O
gatekeeper	O
function	O
to	O
either	O
restrict	O
or	O
permit	O
diffusion	O
of	O
heparin	O
-	O
binding	O
growth	O
factors	O
across	O
the	O
basement	O
membrane	O
.	O

Pioglitazone	S-chem
protects	O
against	O
cisplatin	S-chem
induced	O
nephrotoxicity	O
in	O
rats	O
and	O
potentiates	O
its	O
anticancer	O
activity	O
against	O
human	O
renal	O
adenocarcinoma	O
cell	O
lines	O
.	O

Cisplatin	S-chem
-	O
induced	O
nephrotoxicity	O
is	O
a	O
serious	O
problem	O
that	O
limits	O
its	O
use	O
in	O
cancer	O
treatment	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
renal	O
protective	O
capacity	O
of	O
pioglitazone	S-chem
to	O
reduce	O
the	O
cisplatin	S-chem
-	O
induced	O
nephrotoxicity	O
.	O

The	O
underlying	O
suggested	O
mechanism	O
(	O
s	O
)	O
and	O
whether	O
this	O
nephroprotective	O
effect	O
(	O
if	O
any	O
)	O
interferes	O
with	O
the	O
cytotoxic	O
effect	O
of	O
cisplatin	S-chem
on	O
cancer	O
cells	O
were	O
also	O
investigated	O
.	O

Pioglitazone	S-chem
,	O
Bisphenol	B-chem
A	I-chem
diglycidyl	I-chem
ether	E-chem
,	O
BADGE	S-chem
,	O
IP	O
injected	O
(	O
Peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
gamma	E-geneY
(	O
PPAR	B-geneY
-	I-geneY
γ	E-geneY
)	O
antagonist	O
)	O
,	O
or	O
their	O
combination	O
were	O
administered	O
to	O
rats	O
one	O
hour	O
before	O
cisplatin	S-chem
injection	O
.	O

Moreover	O
,	O
their	O
effects	O
on	O
the	O
cell	O
viability	O
of	O
human	O
renal	O
adenocarcinoma	O
cell	O
models	O
(	O
ACHN	O
)	O
were	O
studied	O
.	O

The	O
obtained	O
results	O
showed	O
that	O
pioglitazone	S-chem
improved	O
the	O
renal	O
function	O
,	O
structural	O
changes	O
,	O
renal	O
malondialdehyde	S-chem
(	O
MDA	S-chem
)	O
,	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
alpha	E-geneY
(	O
TNF	B-geneY
-	I-geneY
α	E-geneY
)	O
,	O
nuclear	B-geneN
factor	I-geneN
kappa	I-geneN
B	E-geneN
(	O
NF	B-geneN
-	I-geneN
κB	E-geneN
)	O
genes	O
expression	O
in	O
cisplatin	S-chem
injected	O
rats	O
.	O

It	O
increased	O
both	O
renal	O
reduced	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
content	O
and	O
PPAR	B-geneY
-	I-geneY
γ	E-geneY
gene	O
expression	O
.	O

In	O
contrast	O
to	O
the	O
data	O
obtained	O
by	O
prior	O
administration	O
of	O
BADGE	S-chem
.	O

Pioglitazone	S-chem
also	O
potentiated	O
the	O
cytotoxic	O
effect	O
of	O
cisplatin	S-chem
on	O
human	O
renal	O
adenocarcinoma	O
cells	O
and	O
this	O
effect	O
was	O
abolished	O
by	O
BADGE	S-chem
co	O
administration	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
suggested	O
that	O
pioglitazone	S-chem
protected	O
against	O
cisplatin	S-chem
-	O
induced	O
nephrotoxicity	O
through	O
its	O
interaction	O
with	O
PPAR	B-geneY
-	I-geneY
γ	E-geneY
receptors	O
and	O
antioxidant	O
effects	O
.	O

Furthermore	O
,	O
pioglitazone	S-chem
did	O
not	O
interfere	O
but	O
rather	O
potentiated	O
the	O
cytotoxic	O
effects	O
of	O
cisplatin	S-chem
on	O
human	O
renal	O
adenocarcinoma	O
cells	O
.	O

IL	B-geneY
-	I-geneY
4	E-geneY
stimulates	O
the	O
expression	O
of	O
CXCL	B-geneY
-	I-geneY
8	E-geneY
,	O
E	B-geneY
-	I-geneY
selectin	E-geneY
,	O
VEGF	S-geneY
,	O
and	O
inducible	B-geneY
nitric	I-geneY
oxide	I-geneY
synthase	E-geneY
mRNA	O
by	O
equine	O
pulmonary	O
artery	O
endothelial	O
cells	O
.	O

Little	O
is	O
known	O
concerning	O
the	O
possible	O
contribution	O
of	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
-	O
type	O
cytokines	S-geneN
to	O
the	O
recruitment	O
of	O
neutrophils	O
into	O
the	O
lung	O
tissue	O
.	O

In	O
the	O
present	O
study	O
,	O
endothelial	O
cells	O
from	O
equine	O
pulmonary	O
arteries	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
recombinant	O
equine	B-geneY
(	I-geneY
re	I-geneY
)	I-geneY
IL	I-geneY
-	I-geneY
4	E-geneY
and	O
reIL	B-geneY
-	I-geneY
5	E-geneY
,	O
and	O
the	O
cytokine	S-geneN
mRNA	O
expression	O
of	O
molecules	O
implicated	O
in	O
the	O
chemotaxis	O
and	O
migration	O
of	O
neutrophils	O
was	O
studied	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

The	O
functional	O
response	O
of	O
reIL	B-geneY
-	I-geneY
4	E-geneY
-	O
induced	O
endothelial	O
cell	O
stimulation	O
on	O
neutrophil	O
migration	O
was	O
also	O
studied	O
using	O
a	O
chemotaxis	O
chamber	O
.	O

ReIL	B-geneY
-	I-geneY
4	E-geneY
either	O
increased	O
the	O
expression	O
of	O
CXCL	B-geneY
-	I-geneY
8	E-geneY
,	O
E	B-geneY
-	I-geneY
selectin	E-geneY
,	O
vascular	B-geneY
endothelial	I-geneY
growth	I-geneY
factor	E-geneY
(	O
VEGF	S-geneY
)	O
,	O
and	O
inducible	B-geneY
nitric	I-geneY
oxide	I-geneY
synthase	E-geneY
(	O
iNOS	S-geneY
)	O
,	O
or	O
potentiated	O
the	O
coeffects	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
alpha	E-geneY
(	O
TNF	B-geneY
-	I-geneY
alpha	E-geneY
)	O
on	O
CXCL	B-geneY
-	I-geneY
8	E-geneY
.	O

Supernatants	O
collected	O
from	O
cultured	O
endothelial	O
cells	O
stimulated	O
with	O
reIL	B-geneY
-	I-geneY
4	E-geneY
significantly	O
promoted	O
neutrophil	O
migration	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Dexamethasone	S-chem
(	O
DXM	S-chem
)	O
decreased	O
the	O
expression	O
of	O
CXCL	B-geneY
-	I-geneY
8	E-geneY
,	O
VEGF	S-geneY
,	O
and	O
iNOS	S-geneY
induced	O
by	O
reIL	B-geneY
-	I-geneY
4	E-geneY
,	O
while	O
1400W	B-chem
dihydrochloride	E-chem
(	O
1400W	S-chem
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
iNOS	S-geneY
,	O
decreased	O
the	O
expression	O
of	O
E	B-geneY
-	I-geneY
selectin	E-geneY
,	O
VEGF	S-geneY
,	O
and	O
iNOS	S-geneY
.	O

DXM	S-chem
and	O
1400W	S-chem
attenuated	O
the	O
mRNA	O
expression	O
of	O
E	B-geneY
-	I-geneY
selectin	E-geneY
and	O
iNOS	S-geneY
induced	O
by	O
the	O
costimulation	O
of	O
reIL	B-geneY
-	I-geneY
4	E-geneY
,	O
reTNF	B-geneY
-	I-geneY
alpha	E-geneY
,	O
and	O
LPS	O
.	O

Neither	O
equine	B-geneN
nor	I-geneN
human	I-geneN
recombinant	I-geneN
IL	I-geneN
-	I-geneN
5	E-geneN
influenced	O
the	O
mRNA	O
expression	O
of	O
CXCL	B-geneY
-	I-geneY
8	E-geneY
,	O
E	B-geneY
-	I-geneY
selectin	E-geneY
,	O
or	O
VEGF	S-geneY
.	O

These	O
findings	O
suggest	O
that	O
Th2	O
-	O
type	O
cytokines	S-geneN
may	O
contribute	O
to	O
pulmonary	O
neutrophilia	O
during	O
allergic	O
inflammation	O
by	O
the	O
increased	O
expression	O
of	O
neutrophil	O
chemokines	S-geneN
and	O
adhesion	B-geneN
molecules	E-geneN
by	O
endothelial	O
cells	O
.	O

DXM	S-chem
and	O
the	O
iNOS	S-geneY
inhibitors	O
may	O
decrease	O
pulmonary	O
neutrophilia	O
due	O
,	O
in	O
part	O
,	O
to	O
a	O
direct	O
inhibition	O
of	O
some	O
of	O
these	O
factors	O
.	O

Solubility	O
-	O
driven	O
optimization	O
of	O
(	B-chem
pyridin	I-chem
-	I-chem
3	I-chem
-	I-chem
yl	I-chem
)	I-chem
benzoxazinyl	I-chem
-	I-chem
oxazolidinones	E-chem
leading	O
to	O
a	O
promising	O
antibacterial	O
agent	O
.	O

The	O
solubility	O
-	O
driven	O
structural	O
modification	O
of	O
(	B-chem
pyridin	I-chem
-	I-chem
3	I-chem
-	I-chem
yl	I-chem
)	I-chem
benzoxazinyl	I-chem
-	I-chem
oxazolidinones	E-chem
is	O
described	O
,	O
which	O
resulted	O
in	O
the	O
development	O
of	O
a	O
new	O
series	O
of	O
benzoxazinyl	B-chem
-	I-chem
oxazolidinone	E-chem
analogues	O
with	O
high	O
antibacterial	O
activity	O
against	O
Gram	O
-	O
positive	O
pathogens	O
,	O
including	O
that	O
against	O
linezolid	S-chem
-	O
resistant	O
strains	O
and	O
low	O
hERG	S-geneY
inhibition	O
.	O

With	O
regard	O
to	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
trends	O
among	O
the	O
various	O
substituents	O
on	O
the	O
pyridyl	S-chem
ring	O
,	O
relatively	O
small	O
and	O
nonbasic	O
substituents	O
were	O
preferable	O
to	O
sterically	O
demanding	O
or	O
basic	O
substituents	O
.	O

Oxazolidinone	S-chem
ring	O
substitution	O
on	O
the	O
pyridyl	S-chem
ring	O
generated	O
analogues	O
with	O
antibacterial	O
activity	O
superior	O
to	O
imidazolidinone	S-chem
ring	O
.	O

Solubility	O
was	O
enhanced	O
by	O
the	O
incorporation	O
of	O
polar	O
groups	O
,	O
especially	O
when	O
compounds	O
were	O
converted	O
to	O
their	O
prodrugs	O
.	O

Among	O
the	O
prodrugs	O
,	O
compound	O
85	O
exhibited	O
excellent	O
solubility	O
and	O
a	O
good	O
pharmacokinetic	O
profile	O
.	O

In	O
a	O
MRSA	O
systemic	O
infection	O
model	O
,	O
compound	O
85	O
displayed	O
an	O
ED50	O
=	O
5.00	O
mg	O
/	O
kg	O
,	O
a	O
potency	O
that	O
is	O
2	O
-	O
fold	O
better	O
than	O
that	O
of	O
linezolid	S-chem
.	O

Gene	O
deletion	O
reveals	O
roles	O
for	O
annexin	B-geneY
A1	E-geneY
in	O
the	O
regulation	O
of	O
lipolysis	O
and	O
IL	B-geneY
-	I-geneY
6	E-geneY
release	O
in	O
epididymal	O
adipose	O
tissue	O
.	O

In	O
this	O
study	O
,	O
epididymal	O
adipose	O
tissue	O
from	O
male	O
annexin	B-geneY
1	E-geneY
(	O
ANXA1	S-geneY
)	O
-	O
null	O
and	O
wild	O
-	O
type	O
control	O
mice	O
were	O
used	O
to	O
explore	O
the	O
potential	O
role	O
of	O
ANXA1	S-geneY
in	O
adipocyte	O
biology	O
.	O

ANXA1	S-geneY
was	O
detected	O
by	O
Western	O
blot	O
analysis	O
in	O
wild	O
-	O
type	O
tissue	O
and	O
localized	O
predominantly	O
to	O
the	O
stromal	O
-	O
vascular	O
compartment	O
.	O

Epididymal	O
fat	O
pad	O
mass	O
was	O
reduced	O
by	O
ANXA1	S-geneY
gene	O
deletion	O
,	O
but	O
adipocyte	O
size	O
was	O
unchanged	O
,	O
suggesting	O
that	O
ANXA1	S-geneY
is	O
required	O
for	O
the	O
maintenance	O
of	O
adipocyte	O
and	O
/	O
or	O
preadipocyte	O
cell	O
number	O
.	O

Epididymal	O
tissue	O
from	O
wild	O
-	O
type	O
mice	O
responded	O
in	O
vitro	O
to	O
noradrenaline	S-chem
and	O
isoprenaline	S-chem
with	O
increased	O
glycerol	S-chem
release	O
,	O
reduced	O
IL	B-geneY
-	I-geneY
6	E-geneY
release	O
,	O
and	O
increased	O
cAMP	S-chem
accumulation	O
.	O

Qualitatively	O
similar	O
but	O
significantly	O
attenuated	O
responses	O
to	O
the	O
catecholamines	S-chem
were	O
observed	O
in	O
tissue	O
from	O
ANXA1	S-geneY
-	O
null	O
mice	O
,	O
an	O
effect	O
that	O
was	O
not	O
associated	O
with	O
changes	O
in	O
beta	B-geneN
-	I-geneN
adrenoceptor	E-geneN
mRNA	O
expression	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
also	O
stimulated	O
lipolysis	O
in	O
vitro	O
,	O
but	O
its	O
effects	O
were	O
muted	O
by	O
ANXA1	S-geneY
gene	O
deletion	O
.	O

By	O
contrast	O
,	O
LPS	O
failed	O
to	O
influence	O
IL	B-geneY
-	I-geneY
6	E-geneY
release	O
from	O
wild	O
-	O
type	O
tissue	O
but	O
stimulated	O
the	O
release	O
of	O
the	O
cytokine	S-geneN
from	O
tissue	O
from	O
ANXA1	S-geneY
-	O
null	O
mice	O
.	O

ANXA1	S-geneY
gene	O
deletion	O
did	O
not	O
affect	O
glucocorticoid	B-geneY
receptor	E-geneY
expression	O
or	O
the	O
ability	O
of	O
dexamethasone	S-chem
to	O
suppress	O
catecholamine	S-chem
-	O
induced	O
lipolysis	O
.	O

It	O
did	O
,	O
however	O
,	O
augment	O
IL	B-geneY
-	I-geneY
6	E-geneY
expression	O
and	O
modify	O
the	O
inhibitory	O
effects	O
of	O
glucocorticoids	O
on	O
IL	B-geneY
-	I-geneY
6	E-geneY
release	O
.	O

Collectively	O
,	O
these	O
studies	O
suggest	O
that	O
ANXA1	S-geneY
supports	O
aspects	O
of	O
adipose	O
tissue	O
mass	O
and	O
alters	O
the	O
sensitivity	O
of	O
epididymal	O
adipose	O
tissue	O
to	O
catecholamines	S-chem
,	O
glucocorticoids	O
,	O
and	O
LPS	O
,	O
thereby	O
modulating	O
lipolysis	O
and	O
IL	B-geneY
-	I-geneY
6	E-geneY
release	O
.	O

Transcriptional	O
regulation	O
of	O
human	B-geneY
ferredoxin	I-geneY
1	E-geneY
in	O
ovarian	O
granulosa	O
cells	O
.	O

Ferredoxin	B-geneY
1	E-geneY
(	O
FDX1	S-geneY
;	O
adrenodoxin	S-geneY
)	O
is	O
an	O
iron	S-chem
-	O
sulfur	S-chem
protein	O
that	O
is	O
involved	O
in	O
various	O
metabolic	O
processes	O
,	O
including	O
steroid	B-chem
hormone	E-chem
synthesis	O
in	O
mammalian	O
tissues	O
.	O

We	O
investigated	O
the	O
transcriptional	O
regulation	O
of	O
FDX1	S-geneY
in	O
ovarian	O
granulosa	O
cells	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
the	O
NR5A	S-geneN
family	O
,	O
including	O
steroidogenic	B-geneY
factor	I-geneY
-	I-geneY
1	E-geneY
(	O
SF	B-geneY
-	I-geneY
1	E-geneY
)	O
and	O
liver	B-geneY
receptor	I-geneY
homolog	I-geneY
-	I-geneY
1	E-geneY
could	O
induce	O
differentiation	O
of	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
hMSCs	O
)	O
into	O
steroidogenic	O
cells	O
.	O

A	O
ChIP	O
assay	O
showed	O
that	O
SF	B-geneY
-	I-geneY
1	E-geneY
could	O
bind	O
to	O
the	O
FDX1	B-geneN
promoter	E-geneN
in	O
differentiated	O
hMSCs	O
.	O

Luciferase	O
reporter	O
assays	O
showed	O
that	O
transcription	O
of	O
FDX1	S-geneY
was	O
synergistically	O
activated	O
by	O
the	O
NR5A	S-geneN
family	O
and	O
8Br	B-chem
-	I-chem
cAMP	E-chem
treatment	O
through	O
two	O
SF	B-geneY
-	I-geneY
1	E-geneY
binding	O
sites	O
and	O
a	O
CRE	S-geneN
-	O
like	O
sequence	O
in	O
a	O
human	O
ovarian	O
granulosa	O
cell	O
line	O
,	O
KGN	O
.	O

Knockdown	O
of	O
FDX1	S-geneY
attenuated	O
progesterone	S-chem
production	O
in	O
KGN	O
cells	O
.	O

These	O
results	O
indicate	O
transcription	O
of	O
FDX1	S-geneY
is	O
regulated	O
by	O
the	O
NR5A	S-geneN
family	O
and	O
cAMP	S-chem
signaling	O
,	O
and	O
participates	O
in	O
steroid	S-chem
hormone	O
production	O
in	O
ovarian	O
granulosa	O
cells	O
.	O

Autoradiographic	O
study	O
of	O
serotonin	B-geneY
transporter	E-geneY
during	O
memory	O
formation	O
.	O

Serotonin	B-geneY
transporter	E-geneY
(	O
SERT	S-geneY
)	O
has	O
been	O
associated	O
with	O
drugs	O
of	O
abuse	O
like	O
d	B-chem
-	I-chem
methamphetamine	E-chem
(	O
METH	S-chem
)	O
.	O

METH	S-chem
is	O
well	O
known	O
to	O
produce	O
effects	O
on	O
the	O
monoamine	S-chem
systems	O
but	O
it	O
is	O
unclear	O
how	O
METH	S-chem
affects	O
SERT	S-geneY
and	O
memory	O
.	O

Here	O
the	O
effects	O
of	O
METH	S-chem
and	O
the	O
serotonin	S-chem
reuptake	O
inhibitor	O
fluoxetine	S-chem
(	O
FLX	S-chem
)	O
on	O
autoshaping	O
and	O
novel	O
object	O
recognition	O
(	O
NOR	O
)	O
were	O
investigated	O
.	O

Notably	O
,	O
both	O
memory	O
tasks	O
recruit	O
different	O
behavioral	O
,	O
neural	O
and	O
cognitive	O
demand	O
.	O

In	O
autoshaping	O
task	O
a	O
dose	O
-	O
response	O
curve	O
for	O
METH	S-chem
was	O
determined	O
.	O

METH	S-chem
(	O
1.0mg	O
/	O
kg	O
)	O
impaired	O
short	O
-	O
term	O
memory	O
(	O
STM	O
;	O
lasting	O
less	O
of	O
90min	O
)	O
in	O
NOR	O
and	O
impaired	O
both	O
STM	O
and	O
long	O
-	O
term	O
memory	O
(	O
LTM	O
;	O
lasting	O
24	O
and	O
48h	O
)	O
in	O
autoshaping	O
,	O
indicating	O
that	O
METH	S-chem
had	O
long	O
-	O
lasting	O
effects	O
in	O
the	O
latter	O
task	O
.	O

A	O
comparative	O
autoradiography	O
study	O
of	O
the	O
relationship	O
between	O
the	O
binding	O
pattern	O
of	O
SERT	S-geneY
in	O
autoshaping	O
new	O
untrained	O
vs.	O
trained	O
treated	O
(	O
METH	S-chem
,	O
FLX	S-chem
,	O
or	O
both	O
)	O
animals	O
was	O
made	O
.	O

Considering	O
that	O
hemispheric	O
dominance	O
is	O
important	O
for	O
LTM	O
,	O
hence	O
right	O
vs.	O
left	O
hemisphere	O
of	O
the	O
brain	O
was	O
compared	O
.	O

Results	O
showed	O
that	O
trained	O
animals	O
decreased	O
cortical	O
SERT	S-geneY
binding	O
relative	O
to	O
untrained	O
ones	O
.	O

In	O
untrained	O
and	O
trained	O
treated	O
animals	O
with	O
the	O
amnesic	O
dose	O
(	O
1.0mg	O
/	O
kg	O
)	O
of	O
METH	S-chem
SERT	S-geneY
binding	O
in	O
several	O
areas	O
including	O
hippocampus	O
and	O
cortex	O
decreased	O
,	O
more	O
remarkably	O
in	O
the	O
trained	O
animals	O
.	O

In	O
contrast	O
,	O
FLX	O
improved	O
memory	O
,	O
increased	O
SERT	S-geneY
binding	O
,	O
prevented	O
the	O
METH	S-chem
amnesic	O
effect	O
and	O
re	O
-	O
established	O
the	O
SERT	S-geneY
binding	O
.	O

In	O
general	O
,	O
memory	O
and	O
amnesia	O
seemed	O
to	O
make	O
SERT	S-geneY
more	O
vulnerable	O
to	O
drugs	O
effects	O
.	O

Brugada	O
syndrome	O
.	O

A	O
novel	O
clinical	O
entity	O
characterized	O
by	O
ST	O
segment	O
elevation	O
in	O
right	O
precordial	O
leads	O
(	O
V1	O
to	O
V3	O
)	O
,	O
incomplete	O
or	O
complete	O
right	O
bundle	O
branch	O
block	O
,	O
and	O
susceptibility	O
to	O
ventricular	O
tachyarrhythmia	O
and	O
sudden	O
cardiac	O
death	O
has	O
been	O
described	O
by	O
Brugada	O
et	O
al	O
.	O
in	O
1992	O
.	O

This	O
disease	O
is	O
now	O
frequently	O
called	O
``	O
Brugada	O
syndrome	O
``	O
(	O
BrS	O
)	O
.	O

The	O
prevalence	O
of	O
BrS	O
in	O
the	O
general	O
population	O
is	O
unknown	O
.	O

The	O
suggested	O
prevalence	O
ranges	O
from	O
5	O
/	O
1,000	O
(	O
Caucasians	O
)	O
to	O
14	O
/	O
1,000	O
(	O
Japanese	O
)	O
.	O

Syncope	O
,	O
typically	O
occurring	O
at	O
rest	O
or	O
during	O
sleep	O
(	O
in	O
individuals	O
in	O
their	O
third	O
or	O
fourth	O
decades	O
of	O
life	O
)	O
is	O
a	O
common	O
presentation	O
of	O
BrS	O
.	O

In	O
some	O
cases	O
,	O
tachycardia	O
does	O
not	O
terminate	O
spontaneously	O
and	O
it	O
may	O
degenerate	O
into	O
ventricular	O
fibrillation	O
and	O
lead	O
to	O
sudden	O
death	O
.	O

Both	O
sporadic	O
and	O
familial	O
cases	O
have	O
been	O
reported	O
and	O
pedigree	O
analysis	O
suggests	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
inheritance	O
.	O

In	O
approximately	O
20	O
%	O
of	O
the	O
cases	O
BrS	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
SCN5A	S-geneY
gene	O
on	O
chromosome	O
3p21	O
-	O
23	O
,	O
encoding	O
the	O
cardiac	O
sodium	B-geneN
channel	E-geneN
,	O
a	O
protein	O
involved	O
in	O
the	O
control	O
of	O
myocardial	O
excitability	O
.	O

Since	O
the	O
use	O
of	O
the	O
implantable	O
cardioverter	O
defibrillator	O
(	O
ICD	O
)	O
is	O
the	O
only	O
therapeutic	O
option	O
of	O
proven	O
efficacy	O
for	O
primary	O
and	O
secondary	O
prophylaxis	O
of	O
cardiac	O
arrest	O
,	O
the	O
identification	O
of	O
high	O
-	O
risk	O
subjects	O
is	O
one	O
of	O
the	O
major	O
goals	O
in	O
the	O
clinical	O
decision	O
-	O
making	O
process	O
.	O

Quinidine	S-chem
may	O
be	O
regarded	O
as	O
an	O
adjunctive	O
therapy	O
for	O
patients	O
at	O
higher	O
risk	O
and	O
may	O
reduce	O
the	O
number	O
of	O
cases	O
of	O
ICD	O
shock	O
in	O
patients	O
with	O
multiple	O
recurrences	O
.	O

The	O
factor	B-geneY
VII	I-geneY
-	I-geneY
activating	I-geneY
protease	E-geneY
(	O
FSAP	S-geneY
)	O
enhances	O
the	O
activity	O
of	O
bone	B-geneY
morphogenetic	I-geneY
protein	I-geneY
-	I-geneY
2	E-geneY
(	O
BMP	B-geneY
-	I-geneY
2	E-geneY
)	O
.	O

Factor	B-geneY
VII	I-geneY
-	I-geneY
activating	I-geneY
protease	E-geneY
(	O
FSAP	S-geneY
)	O
is	O
a	O
circulating	O
protease	S-geneN
involved	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
,	O
calcification	O
,	O
and	O
fibrotic	O
processes	O
.	O

To	O
understand	O
how	O
FSAP	S-geneY
controls	O
the	O
balance	O
of	O
local	O
growth	O
factors	O
,	O
we	O
have	O
investigated	O
its	O
effect	O
on	O
the	O
regulation	O
of	O
bone	B-geneN
morphogenetic	I-geneN
proteins	E-geneN
(	O
BMPs	S-geneN
)	O
.	O

BMP	B-geneY
-	I-geneY
2	E-geneY
is	O
produced	O
as	O
a	O
large	O
pro	O
-	O
form	O
and	O
secreted	O
as	O
a	O
mature	O
heparin	B-geneY
-	I-geneY
binding	I-geneY
growth	I-geneY
factor	E-geneY
after	O
intracellular	O
processing	O
by	O
pro	B-geneN
-	I-geneN
protein	I-geneN
convertases	E-geneN
(	O
PCs	S-geneN
)	O
.	O

In	O
this	O
study	O
,	O
we	O
discovered	O
that	O
FSAP	S-geneY
enhances	O
the	O
biological	O
activity	O
of	O
mature	O
BMP	B-geneY
-	I-geneY
2	E-geneY
as	O
well	O
as	O
its	O
pro	O
-	O
form	O
,	O
as	O
shown	O
by	O
osteogenic	O
differentiation	O
of	O
C2C12	O
myoblasts	O
.	O

These	O
findings	O
were	O
complemented	O
by	O
knockdown	O
of	O
FSAP	S-geneY
in	O
hepatocytes	O
,	O
which	O
revealed	O
BMP	B-geneY
-	I-geneY
2	E-geneY
processing	O
by	O
endogenous	O
FSAP	S-geneY
.	O

N	S-chem
-	O
terminal	O
sequencing	O
indicated	O
that	O
pro	B-geneY
-	I-geneY
BMP	I-geneY
-	I-geneY
2	E-geneY
was	O
cleaved	O
by	O
FSAP	S-geneY
at	O
the	O
canonical	O
PC	B-geneN
cleavage	I-geneN
site	E-geneN
,	O
giving	O
rise	O
to	O
mature	O
BMP	B-geneY
-	I-geneY
2	E-geneY
(	O
Arg	S-chem
(	O
282	O
)	O
↓	O
Gln	S-chem
(	O
283	O
)	O
)	O
,	O
as	O
well	O
as	O
in	O
the	O
N	B-geneN
-	I-geneN
terminal	I-geneN
heparin	I-geneN
binding	I-geneN
region	E-geneN
of	O
mature	O
BMP	B-geneY
-	I-geneY
2	E-geneY
,	O
generating	O
a	O
truncated	O
mature	O
BMP	B-geneY
-	I-geneY
2	E-geneY
peptide	O
(	O
Arg	S-chem
(	O
289	O
)	O
↓	O
Lys	S-chem
(	O
290	O
)	O
)	O
.	O

Similarly	O
,	O
mature	O
BMP	B-geneY
-	I-geneY
2	E-geneY
was	O
also	O
cleaved	O
to	O
a	O
truncated	O
peptide	O
within	O
its	O
N	S-chem
-	O
terminal	O
region	O
(	O
Arg	S-chem
(	O
289	O
)	O
↓	O
Lys	S-chem
(	O
290	O
)	O
)	O
.	O

Plasmin	S-geneY
exhibited	O
a	O
similar	O
activity	O
,	O
but	O
it	O
was	O
weaker	O
compared	O
with	O
FSAP	S-geneY
.	O

Thrombin	S-geneY
,	O
Factor	B-geneY
VIIa	E-geneY
,	O
Factor	B-geneY
Xa	E-geneY
,	O
and	O
activated	B-geneY
protein	I-geneY
C	E-geneY
were	O
not	O
effective	O
.	O

These	O
results	O
were	O
further	O
supported	O
by	O
the	O
observation	O
that	O
the	O
mutation	O
of	O
the	O
heparin	B-geneN
binding	I-geneN
region	E-geneN
of	O
BMP	B-geneY
-	I-geneY
2	E-geneY
inhibited	O
the	O
processing	O
by	O
FSAP	S-geneY
but	O
not	O
by	O
PC	S-geneN
.	O

Thus	O
,	O
the	O
proteolysis	O
and	O
activation	O
of	O
pro	B-geneY
-	I-geneY
BMP	I-geneY
-	I-geneY
2	E-geneY
and	O
mature	O
BMP	B-geneY
-	I-geneY
2	E-geneY
by	O
FSAP	S-geneY
can	O
regulate	O
cell	O
differentiation	O
and	O
calcification	O
in	O
vasculature	O
and	O
may	O
explain	O
why	O
polymorphisms	O
in	O
the	O
gene	O
encoding	O
for	O
FSAP	S-geneY
are	O
related	O
to	O
vascular	O
diseases	O
.	O

From	O
traditional	O
European	O
medicine	O
to	O
discovery	O
of	O
new	O
drug	O
candidates	O
for	O
the	O
treatment	O
of	O
dementia	O
and	O
Alzheimer	O
's	O
disease	O
:	O
acetylcholinesterase	S-geneY
inhibitors	O
.	O

The	O
leading	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
therapeutics	O
to	O
date	O
involves	O
inhibitors	O
of	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
,	O
which	O
should	O
,	O
in	O
principle	O
,	O
elevate	O
cholinergic	O
signaling	O
and	O
limit	O
inflammation	O
.	O

In	O
spite	O
of	O
the	O
effectiveness	O
in	O
20	O
%	O
-	O
30	O
%	O
of	O
AD	O
patients	O
,	O
more	O
attention	O
has	O
been	O
paid	O
to	O
find	O
new	O
anti	O
-	O
AChE	S-geneY
agents	O
from	O
medicinal	O
plants	O
.	O

Galanthamine	S-chem
,	O
contained	O
in	O
the	O
bulbs	O
and	O
flowers	O
of	O
Galanthus	O
and	O
related	O
genera	O
like	O
Narcissus	O
,	O
represents	O
a	O
good	O
example	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
review	O
the	O
role	O
of	O
possible	O
AChE	S-geneY
inhibitors	O
(	O
AChEI	O
)	O
present	O
in	O
plants	O
traditionally	O
used	O
in	O
European	O
medicine	O
for	O
improving	O
memory	O
.	O

Starting	O
from	O
Galanthamine	S-chem
,	O
properties	O
of	O
Melissa	O
species	O
,	O
Salvia	O
officinalis	O
,	O
Arnica	O
chamissonis	O
and	O
Ruta	O
graveolens	O
are	O
discussed	O
to	O
point	O
to	O
the	O
role	O
of	O
these	O
plants	O
as	O
potential	O
sources	O
for	O
the	O
development	O
of	O
therapeutic	O
agents	O
for	O
AD	O
.	O

Update	O
on	O
rivastigmine	S-chem
.	O

BACKGROUND	O
:	O
Rivastigmine	S-chem
is	O
a	O
carbamate	S-chem
drug	O
designed	O
to	O
inhibit	O
both	O
acetylcholinesterase	S-geneY
and	O
butyrylcholinesterase	S-geneY
by	O
reversibly	O
covalently	O
bonding	O
to	O
these	O
enzymes	O
.	O

Butyrylcholinesterase	S-geneY
in	O
-	O
creases	O
as	O
Alzheimer	O
disease	O
progresses	O
,	O
so	O
its	O
inhibition	O
may	O
become	O
more	O
important	O
as	O
the	O
disease	O
worsens	O
.	O

Metabolism	O
of	O
rivastigmine	S-chem
occurs	O
at	O
the	O
synapse	O
rather	O
than	O
at	O
the	O
liver	O
and	O
previous	O
studies	O
have	O
demonstrated	O
no	O
drug	O
-	O
drug	O
interactions	O
.	O

Rivastigmine	S-chem
has	O
a	O
half	O
-	O
life	O
at	O
the	O
synapse	O
of	O
9	O
hours	O
allowing	O
for	O
bid	O
dosing	O
.	O

REVIEW	O
SUMMARY	O
:	O
Effective	O
therapy	O
requires	O
up	O
-	O
titration	O
from	O
initial	O
dosage	O
of	O
3	O
mg	O
/	O
d	O
to	O
6	O
mg	O
/	O
d	O
with	O
additional	O
increases	O
to	O
9	O
mg	O
or	O
12	O
mg	O
/	O
d	O
giving	O
additional	O
benefits	O
in	O
some	O
patients	O
.	O

Beneficial	O
effects	O
with	O
rivastigmine	S-chem
therapy	O
in	O
the	O
functioning	O
of	O
activities	O
of	O
daily	O
living	O
,	O
behavior	O
,	O
cognition	O
,	O
and	O
global	O
functioning	O
have	O
been	O
demonstrated	O
in	O
patients	O
with	O
mild	O
to	O
moderate	O
Alzheimer	O
disease	O
in	O
4	O
large	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
multicenter	O
clinical	O
trials	O
.	O

Potential	O
adverse	O
effects	O
of	O
nausea	O
,	O
vomiting	O
,	O
or	O
diarrhea	O
in	O
these	O
original	O
Alzheimer	O
trials	O
with	O
rapid	O
(	O
every	O
week	O
)	O
dosage	O
increases	O
occurred	O
in	O
up	O
to	O
34	O
%	O
of	O
patients	O
and	O
can	O
be	O
minimized	O
by	O
slower	O
monthly	O
up	O
-	O
titrations	O
.	O

Rivastigmine	S-chem
also	O
was	O
proven	O
effective	O
in	O
decreasing	O
psychiatric	O
symptoms	O
and	O
cognitive	O
deficits	O
in	O
a	O
large	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
in	O
patients	O
with	O
diffuse	O
Lewy	O
body	O
disease	O
.	O

Other	O
studies	O
have	O
suggested	O
that	O
rivastigmine	S-chem
improves	O
symptoms	O
in	O
nursing	O
home	O
patients	O
with	O
more	O
severe	O
stage	O
Alzheimer	O
disease	O
,	O
Parkinson	O
dementia	O
,	O
and	O
subcortical	O
dementia	O
.	O

Follow	O
-	O
up	O
studies	O
have	O
suggested	O
that	O
rivastigmine	S-chem
may	O
delay	O
disease	O
progression	O
and	O
,	O
in	O
patients	O
discontinuing	O
the	O
drug	O
,	O
no	O
withdrawal	O
effects	O
were	O
seen	O
.	O

CONCLUSION	O
:	O
Rivastigmine	S-chem
is	O
an	O
effective	O
therapeutic	O
agent	O
for	O
treating	O
cognitive	O
and	O
behavioral	O
symptoms	O
in	O
Alzheimer	O
disease	O
and	O
diffuse	O
Lewy	O
body	O
disease	O
and	O
may	O
also	O
have	O
beneficial	O
effects	O
in	O
vascular	O
and	O
Parkinson	O
dementias	O
.	O

Pharmacological	O
activators	O
of	O
AMP	B-geneY
-	I-geneY
activated	I-geneY
protein	I-geneY
kinase	E-geneY
have	O
different	O
effects	O
on	O
Na	B-chem
+	E-chem
transport	O
processes	O
across	O
human	O
lung	O
epithelial	O
cells	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
AMP	B-geneY
-	I-geneY
activated	I-geneY
protein	I-geneY
kinase	E-geneY
(	O
AMPK	S-geneY
)	O
is	O
activated	O
by	O
metformin	S-chem
,	O
phenformin	S-chem
,	O
and	O
the	O
AMP	S-chem
mimetic	O
,	O
5	B-chem
-	I-chem
aminoimidazole	I-chem
-	I-chem
4	I-chem
-	I-chem
carboxamide	I-chem
-	I-chem
1	I-chem
-	I-chem
beta	I-chem
-	I-chem
D	I-chem
-	I-chem
ribofuranoside	E-chem
(	O
AICAR	S-chem
)	O
.	O

We	O
have	O
completed	O
an	O
extensive	O
study	O
of	O
the	O
pharmacological	O
effects	O
of	O
these	O
drugs	O
on	O
AMPK	S-geneY
activation	O
,	O
adenine	B-chem
nucleotide	E-chem
concentration	O
,	O
transepithelial	O
amiloride	S-chem
-	O
sensitive	O
(	O
I	O
(	O
amiloride	S-chem
)	O
)	O
and	O
ouabain	S-chem
-	O
sensitive	O
basolateral	O
(	O
I	O
(	O
ouabain	S-chem
)	O
)	O
short	O
circuit	O
current	O
in	O
H441	O
lung	O
epithelial	O
cells	O
.	O

EXPERIMENTAL	O
APPROACH	O
:	O
H441	O
cells	O
were	O
grown	O
on	O
permeable	O
filters	O
at	O
air	O
interface	O
.	O

I	O
(	O
amiloride	S-chem
)	O
,	O
I	O
(	O
ouabain	S-chem
)	O
and	O
transepithelial	O
resistance	O
were	O
measured	O
in	O
Ussing	O
chambers	O
.	O

AMPK	S-geneY
activity	O
was	O
measured	O
as	O
the	O
amount	O
of	O
radiolabelled	O
phosphate	S-chem
transferred	O
to	O
the	O
SAMS	O
peptide	O
.	O

Adenine	B-chem
nucleotide	E-chem
concentration	O
was	O
analysed	O
by	O
reverse	O
phase	O
HPLC	O
and	O
NAD	B-chem
(	I-chem
P	I-chem
)	I-chem
H	E-chem
autofluorescence	O
was	O
measured	O
using	O
confocal	O
microscopy	O
.	O

KEY	O
RESULTS	O
:	O
Phenformin	S-chem
,	O
AICAR	S-chem
and	O
metformin	S-chem
increased	O
AMPK	B-geneY
(	I-geneY
alpha1	I-geneY
)	E-geneY
activity	O
and	O
decreased	O
I	O
(	O
amiloride	S-chem
)	O
.	O

The	O
AMPK	S-geneY
inhibitor	O
Compound	O
C	O
prevented	O
the	O
action	O
of	O
metformin	S-chem
and	O
AICAR	S-chem
but	O
not	O
phenformin	S-chem
.	O

Phenformin	S-chem
and	O
AICAR	S-chem
decreased	O
I	O
(	O
ouabain	S-chem
)	O
across	O
H441	O
monolayers	O
and	O
decreased	O
monolayer	O
resistance	O
.	O

The	O
decrease	O
in	O
I	O
(	O
amiloride	S-chem
)	O
was	O
closely	O
related	O
to	O
I	O
(	O
ouabain	S-chem
)	O
with	O
phenformin	S-chem
,	O
but	O
not	O
in	O
AICAR	S-chem
treated	O
monolayers	O
.	O

Metformin	S-chem
and	O
phenformin	S-chem
increased	O
the	O
cellular	O
AMP	S-chem
:	O
ATP	S-chem
ratio	O
but	O
only	O
phenformin	S-chem
and	O
AICAR	S-chem
decreased	O
cellular	O
ATP	S-chem
.	O

CONCLUSIONS	O
AND	O
IMPLICATIONS	O
:	O
Activation	O
of	O
alpha1	B-geneY
-	I-geneY
AMPK	E-geneY
is	O
associated	O
with	O
inhibition	O
of	O
apical	O
amiloride	B-geneN
-	I-geneN
sensitive	I-geneN
Na	I-geneN
(	I-geneN
+	I-geneN
)	I-geneN
channels	E-geneN
(	O
ENaC	S-geneN
)	O
,	O
which	O
has	O
important	O
implications	O
for	O
the	O
clinical	O
use	O
of	O
metformin	S-chem
.	O

Additional	O
pharmacological	O
effects	O
evoked	O
by	O
AICAR	S-chem
and	O
phenformin	S-chem
on	O
I	O
(	O
ouabain	S-chem
)	O
,	O
with	O
potential	O
secondary	O
effects	O
on	O
apical	O
Na	B-chem
+	E-chem
conductance	O
,	O
ENaC	S-geneN
activity	O
and	O
monolayer	O
resistance	O
,	O
have	O
important	O
consequences	O
for	O
their	O
use	O
as	O
pharmacological	O
activators	O
of	O
AMPK	S-geneY
in	O
cell	O
systems	O
where	O
Na	B-geneN
+	I-geneN
K	I-geneN
+	I-geneN
ATPase	E-geneN
is	O
an	O
important	O
component	O
.	O

Induction	O
of	O
the	O
liver	O
cancer	O
-	O
down	O
-	O
regulated	O
long	O
noncoding	O
RNA	O
uc002mbe.2	S-geneY
mediates	O
trichostatin	S-chem
-	O
induced	O
apoptosis	O
of	O
liver	O
cancer	O
cells	O
.	O

Differential	O
expression	O
of	O
long	O
non	O
-	O
coding	O
RNAs	O
(	O
lncRNAs	O
)	O
plays	O
critical	O
roles	O
in	O
hepatocarcinogenesis	O
.	O

Considerable	O
attention	O
has	O
focused	O
on	O
the	O
antitumor	O
effect	O
of	O
histone	B-geneN
deacetylase	E-geneN
inhibitor	O
(	O
Trichostatin	B-chem
A	E-chem
,	O
TSA	S-chem
)	O
as	O
well	O
as	O
the	O
coding	O
gene	O
expression	O
-	O
induced	O
apoptosis	O
of	O
cancer	O
cells	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
whether	O
lncRNA	O
has	O
a	O
role	O
in	O
TSA	S-chem
-	O
induced	O
apoptosis	O
of	O
human	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
cells	O
.	O

The	O
global	O
expression	O
of	O
lncRNAs	O
and	O
coding	O
genes	O
was	O
analyzed	O
with	O
the	O
Human	O
LncRNA	O
Array	O
V2.0	O
after	O
24h	O
treatment	O
.	O

Expression	O
was	O
verified	O
in	O
cell	O
lines	O
and	O
tissues	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

The	O
data	O
showed	O
that	O
4.8	O
%	O
(	O
959	O
)	O
of	O
lncRNA	O
and	O
6.1	O
%	O
(	O
1849	O
)	O
of	O
protein	O
coding	O
gene	O
were	O
significantly	O
differentially	O
expressed	O
.	O

The	O
differential	O
expressions	O
of	O
lncRNA	O
and	O
protein	O
coding	O
genes	O
had	O
distinguishable	O
hierarchical	O
clustering	O
expression	O
profiling	O
pattern	O
.	O

Among	O
these	O
differentially	O
expressed	O
lncRNAs	O
,	O
the	O
greatest	O
change	O
was	O
noted	O
for	O
uc002mbe.2	S-geneY
,	O
which	O
had	O
more	O
than	O
300	O
folds	O
induction	O
upon	O
TSA	S-chem
treatment	O
.	O

TSA	S-chem
selectively	O
induced	O
uc002mbe.2	S-geneY
in	O
four	O
studied	O
HCC	O
cell	O
lines	O
.	O

Compared	O
with	O
normal	O
human	O
hepatocytes	O
and	O
adjacent	O
noncancerous	O
tissues	O
,	O
uc002mbe.2	S-geneY
expression	O
level	O
was	O
significantly	O
lower	O
in	O
the	O
HCC	O
cell	O
lines	O
and	O
liver	O
cancer	O
tissues	O
.	O

The	O
TSA	S-chem
-	O
induced	O
uc002mbe.2	S-geneY
expression	O
was	O
positively	O
correlated	O
with	O
the	O
apoptotic	O
effect	O
of	O
TSA	S-chem
in	O
HCC	O
cells	O
.	O

In	O
addition	O
,	O
knockdown	O
the	O
expression	O
of	O
uc002mbe.2	S-geneY
significantly	O
reduced	O
TSA	S-chem
-	O
induced	O
apoptosis	O
of	O
Huh7cells	O
.	O

Therefore	O
,	O
TSA	S-chem
-	O
induced	O
apoptosis	O
of	O
HCC	O
cells	O
is	O
uc002mbe.2	S-geneY
dependent	O
and	O
reduced	O
expression	O
of	O
uc002mbe.2	S-geneY
may	O
be	O
associated	O
with	O
liver	O
carcinogenesis	O
.	O

Cellular	O
mechanisms	O
of	O
insulin	S-geneY
resistance	O
:	O
role	O
of	O
stress	B-geneN
-	I-geneN
regulated	I-geneN
serine	I-geneN
kinases	E-geneN
and	O
insulin	B-geneN
receptor	I-geneN
substrates	E-geneN
(	O
IRS	S-geneN
)	O
serine	S-chem
phosphorylation	O
.	O

Insulin	B-geneN
receptor	I-geneN
substrates	E-geneN
(	O
IRS	S-geneN
)	O
serine	S-chem
phosphorylation	O
is	O
a	O
time	O
-	O
controlled	O
physiological	O
feedback	O
mechanism	O
in	O
insulin	S-geneY
signaling	O
that	O
is	O
hijacked	O
by	O
metabolic	O
and	O
inflammatory	O
stresses	O
to	O
promote	O
insulin	S-geneY
resistance	O
.	O

Kinases	S-geneN
,	O
including	O
IKKbeta	S-geneY
,	O
JNK	S-geneN
,	O
ERK	S-geneN
,	O
mTOR	S-geneY
,	O
and	O
S6K	S-geneN
,	O
activated	O
by	O
the	O
inducers	O
of	O
insulin	S-geneY
resistance	O
induce	O
uncontrolled	O
IRS	S-geneN
serine	S-chem
phosphorylation	O
.	O

Studies	O
with	O
genetically	O
modified	O
mice	O
reveal	O
that	O
these	O
kinases	S-geneN
integrate	O
signals	O
from	O
metabolic	O
and	O
inflammatory	O
stresses	O
in	O
adipose	O
tissue	O
,	O
liver	O
,	O
and	O
hypothalamus	O
leading	O
to	O
peripheral	O
and	O
central	O
insulin	S-geneN
resistance	O
.	O

Moreover	O
,	O
IKKbeta	S-geneY
/	O
NF	B-geneN
-	I-geneN
kappaB	E-geneN
and	O
JNK1	S-geneY
pathways	O
in	O
myeloid	O
cells	O
represent	O
a	O
core	O
mechanism	O
involved	O
in	O
inflammation	O
linked	O
to	O
obesity	O
.	O

These	O
kinases	S-geneN
are	O
thus	O
potential	O
drug	O
targets	O
against	O
insulin	S-geneN
resistance	O
and	O
the	O
targeting	O
of	O
the	O
IKKbeta	S-geneY
/	O
NF	B-geneN
-	I-geneN
kappaB	E-geneN
or	O
the	O
JNK	S-geneN
pathway	O
may	O
evolve	O
into	O
future	O
diabetes	O
medication	O
.	O

G	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptors	E-geneN
as	O
direct	O
targets	O
of	O
inhaled	O
anesthetics	O
.	O

The	O
molecular	O
pharmacology	O
of	O
inhalational	O
anesthetics	O
remains	O
poorly	O
understood	O
.	O

Despite	O
accumulating	O
evidence	O
suggesting	O
that	O
neuronal	O
membrane	O
proteins	O
are	O
potential	O
targets	O
of	O
inhaled	O
anesthetics	O
,	O
most	O
currently	O
favored	O
membrane	O
protein	O
targets	O
lack	O
any	O
direct	O
evidence	O
for	O
anesthetic	O
binding	O
.	O

We	O
report	O
herein	O
the	O
location	O
of	O
the	O
binding	O
site	O
for	O
the	O
inhaled	O
anesthetic	O
halothane	S-chem
at	O
the	O
amino	B-chem
acid	E-chem
residue	O
level	O
of	O
resolution	O
in	O
the	O
ligand	O
binding	O
cavity	O
in	O
a	O
prototypical	O
G	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
,	O
bovine	B-geneY
rhodopsin	E-geneY
.	O

Tryptophan	S-chem
fluorescence	O
quenching	O
and	O
direct	O
photoaffinity	O
labeling	O
with	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
halothane	E-chem
suggested	O
an	O
interhelical	O
location	O
of	O
halothane	S-chem
with	O
a	O
stoichiometry	O
of	O
1	O
(	O
halothane	S-chem
/	O
rhodopsin	O
molar	O
ratio	O
)	O
.	O

Radiosequence	O
analysis	O
of	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
halothane	E-chem
-	O
labeled	O
rhodopsin	S-geneY
revealed	O
that	O
halothane	S-chem
contacts	O
an	O
amino	B-chem
acid	E-chem
residue	O
(	O
Trp265	O
)	O
lining	O
the	O
ligand	O
binding	O
cavity	O
in	O
the	O
transmembrane	O
core	O
of	O
the	O
receptor	O
.	O

The	O
predicted	O
functional	O
consequence	O
,	O
competition	O
between	O
halothane	S-chem
and	O
the	O
ligand	O
retinal	O
,	O
was	O
shown	O
here	O
by	O
spectroscopy	O
and	O
is	O
known	O
to	O
exist	O
in	O
vivo	O
.	O

These	O
data	O
suggest	O
that	O
competition	O
with	O
endogenous	O
ligands	O
may	O
be	O
a	O
general	O
mechanism	O
of	O
the	O
action	O
of	O
halothane	S-chem
at	O
this	O
large	O
family	O
of	O
signaling	O
proteins	O
.	O

Block	O
of	O
human	B-geneY
NaV1.5	E-geneY
sodium	B-geneN
channels	E-geneN
by	O
novel	O
alpha	B-chem
-	I-chem
hydroxyphenylamide	E-chem
analogues	O
of	O
phenytoin	S-chem
.	O

Voltage	B-geneN
-	I-geneN
gated	I-geneN
sodium	I-geneN
(	I-geneN
Na	I-geneN
)	I-geneN
channels	E-geneN
are	O
a	O
critical	O
component	O
of	O
electrically	O
excitable	O
cells	O
.	O

Phenytoin	S-chem
(	O
diphenylhydantoin	S-chem
,	O
DPH	S-chem
)	O
is	O
an	O
established	O
sodium	B-geneN
channel	E-geneN
blocker	O
and	O
is	O
a	O
useful	O
anticonvulsant	O
and	O
class	O
1b	O
antiarrhythmic	O
,	O
and	O
has	O
been	O
effectively	O
used	O
in	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
synthesized	O
novel	O
alpha	B-chem
-	I-chem
hydroxyphenylamide	E-chem
analogues	O
of	O
diphenylhydantoin	S-chem
and	O
examined	O
their	O
ability	O
to	O
inhibit	O
human	B-geneY
Na	I-geneY
(	I-geneY
V	I-geneY
)	I-geneY
1.5	E-geneY
sodium	B-geneN
channels	E-geneN
expressed	O
in	O
Chinese	O
Hamster	O
Ovary	O
(	O
CHO	O
-	O
K1	O
)	O
cells	O
.	O

Phenyl	S-chem
ring	O
substitutions	O
were	O
examined	O
including	O
para	B-chem
-	I-chem
methyl	E-chem
,	O
para	B-chem
-	I-chem
fluoro	E-chem
,	O
para	B-chem
-	I-chem
chloro	E-chem
,	O
ortho	B-chem
-	I-chem
chloro	E-chem
and	O
meta	B-chem
-	I-chem
chloro	E-chem
.	O

We	O
have	O
found	O
that	O
phenyl	S-chem
ring	O
substitutions	O
with	O
electron	O
withdrawing	O
properties	O
resulted	O
in	O
compounds	O
with	O
greater	O
activity	O
.	O

In	O
comparison	O
to	O
diphenylhydantoin	S-chem
,	O
the	O
novel	O
chloro	S-chem
-	O
substituted	O
alpha	B-chem
-	I-chem
hydroxyphenylamide	E-chem
compounds	O
produced	O
as	O
much	O
as	O
a	O
20	O
-	O
fold	O
greater	O
tonic	O
and	O
frequency	O
-	O
dependent	O
blockade	O
of	O
Na	B-geneY
(	I-geneY
V	I-geneY
)	I-geneY
1.5	E-geneY
channels	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
14.5	O
microM	O
.	O

In	O
addition	O
,	O
the	O
chloro	S-chem
-	O
substitutions	O
have	O
position	O
specific	O
state	O
dependent	O
blocking	O
properties	O
.	O

The	O
ortho	B-chem
-	I-chem
,	I-chem
meta	I-chem
-	I-chem
and	I-chem
para	I-chem
-	I-chem
chloro	E-chem
substitutions	O
have	O
an	O
8	O
-	O
,	O
13	O
-	O
and	O
3	O
-	O
fold	O
increased	O
affinity	O
for	O
the	O
inactivated	O
state	O
,	O
respectively	O
.	O

Molecular	O
modeling	O
suggests	O
that	O
these	O
differences	O
in	O
affinity	O
are	O
due	O
to	O
a	O
direct	O
interaction	O
with	O
the	O
receptor	O
.	O

Comparing	O
models	O
of	O
diphenylhydantoin	S-chem
to	O
the	O
novel	O
alpha	B-chem
-	I-chem
hydroxyphenlyamide	E-chem
compound	O
suggests	O
that	O
the	O
increased	O
activity	O
may	O
be	O
due	O
to	O
an	O
optimized	O
phenyl	S-chem
ring	O
position	O
and	O
increased	O
molecular	O
volume	O
.	O

This	O
information	O
may	O
be	O
useful	O
in	O
the	O
development	O
of	O
more	O
potent	O
sodium	B-geneN
channel	E-geneN
blockers	O
.	O

Overexpression	O
of	O
H1	B-geneY
calponin	E-geneY
in	O
osteoblast	O
lineage	O
cells	O
leads	O
to	O
a	O
decrease	O
in	O
bone	O
mass	O
by	O
disrupting	O
osteoblast	O
function	O
and	O
promoting	O
osteoclast	O
formation	O
.	O

H1	B-geneY
calponin	E-geneY
(	O
CNN1	S-geneY
)	O
is	O
known	O
as	O
a	O
smooth	O
muscle	O
-	O
specific	O
,	O
actin	S-geneN
-	O
binding	O
protein	O
which	O
regulates	O
smooth	O
muscle	O
contractive	O
activity	O
.	O

Although	O
previous	O
studies	O
have	O
shown	O
that	O
CNN1	S-geneY
has	O
effect	O
on	O
bone	O
,	O
the	O
mechanism	O
is	O
not	O
well	O
defined	O
.	O

To	O
investigate	O
the	O
role	O
of	O
CNN1	S-geneY
in	O
maintaining	O
bone	O
homeostasis	O
,	O
we	O
generated	O
transgenic	O
mice	O
overexpressing	O
Cnn1	S-geneY
under	O
the	O
control	O
of	O
the	O
osteoblast	O
-	O
specific	O
3.6	O
-	O
kb	O
Col1a1	B-geneN
promoter	E-geneN
.	O

Col1a1	S-geneY
-	O
Cnn1	S-geneY
transgenic	O
mice	O
showed	O
delayed	O
bone	O
formation	O
at	O
embryonic	O
stage	O
and	O
decreased	O
bone	O
mass	O
at	O
adult	O
stage	O
.	O

Morphology	O
analyses	O
showed	O
reduced	O
trabecular	O
number	O
,	O
thickness	O
and	O
defects	O
in	O
bone	O
formation	O
.	O

The	O
proliferation	O
and	O
migration	O
of	O
osteoblasts	O
were	O
decreased	O
in	O
Col1a1	S-geneY
-	O
Cnn1	S-geneY
mice	O
due	O
to	O
alterations	O
in	O
cytoskeleton	O
.	O

The	O
early	O
osteoblast	O
differentiation	O
of	O
Col1a1	S-geneY
-	O
Cnn1	S-geneY
mice	O
was	O
increased	O
,	O
but	O
the	O
late	O
stage	O
differentiation	O
and	O
mineralization	O
of	O
osteoblasts	O
derived	O
from	O
Col1a1	S-geneY
-	O
Cnn1	S-geneY
mice	O
were	O
significantly	O
decreased	O
.	O

In	O
addition	O
to	O
impaired	O
bone	O
formation	O
,	O
the	O
decreased	O
bone	O
mass	O
was	O
also	O
associated	O
with	O
enhanced	O
osteoclastogenesis	O
.	O

Tartrate	B-geneY
-	I-geneY
resistant	I-geneY
acid	I-geneY
phosphatase	E-geneY
(	O
TRAP	S-geneY
)	O
staining	O
revealed	O
increased	O
osteoclast	O
numbers	O
in	O
tibias	O
of	O
2	O
-	O
month	O
-	O
old	O
Col1a1	S-geneY
-	O
Cnn1	S-geneY
mice	O
,	O
and	O
increased	O
numbers	O
of	O
osteoclasts	O
co	O
-	O
cultured	O
with	O
Col1a1	S-geneY
-	O
Cnn1	S-geneY
osteoblasts	O
.	O

The	O
ratio	O
of	O
RANKL	S-geneY
to	O
OPG	S-geneY
was	O
significantly	O
increased	O
in	O
Col1a1	S-geneY
-	O
Cnn1	S-geneY
osteoblasts	O
.	O

These	O
findings	O
reveal	O
a	O
novel	O
function	O
of	O
CNN1	S-geneY
in	O
maintaining	O
bone	O
homeostasis	O
by	O
coupling	O
bone	O
formation	O
to	O
bone	O
resorption	O
.	O

AMP	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
underlying	O
in	O
vitro	O
antiglioma	O
action	O
of	O
compound	O
C	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
compound	O
C	O
,	O
a	O
well	O
-	O
known	O
inhibitor	O
of	O
the	O
intracellular	O
energy	O
sensor	O
AMP	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
AMPK	S-geneN
)	O
,	O
on	O
proliferation	O
and	O
viability	O
of	O
human	O
U251	O
and	O
rat	O
C6	O
glioma	O
cell	O
lines	O
.	O

Compound	O
C	O
caused	O
G	O
(	O
2	O
)	O
/	O
M	O
cell	O
cycle	O
block	O
,	O
accompanied	O
by	O
apoptotic	O
glioma	O
cell	O
death	O
characterized	O
by	O
caspase	S-geneN
activation	O
,	O
phosphatidylserine	S-chem
exposure	O
and	O
DNA	O
fragmentation	O
.	O

The	O
mechanisms	O
underlying	O
the	O
pro	O
-	O
apoptotic	O
action	O
of	O
compound	O
C	O
involved	O
induction	O
of	O
oxidative	O
stress	O
and	O
downregulation	O
of	O
antiapoptotic	O
molecule	O
Bcl	B-geneN
-	I-geneN
2	E-geneN
,	O
while	O
no	O
alteration	O
of	O
pro	O
-	O
apoptotic	O
Bax	S-geneN
was	O
observed	O
.	O

Compound	O
C	O
diminished	O
AMPK	S-geneN
phosphorylation	O
and	O
enzymatic	O
activity	O
,	O
resulting	O
in	O
reduced	O
phosphorylation	O
of	O
its	O
target	O
acetyl	B-geneN
CoA	I-geneN
carboxylase	E-geneN
.	O

AMPK	S-geneN
activators	O
metformin	S-chem
and	O
AICAR	S-chem
partly	O
prevented	O
the	O
cell	O
cycle	O
block	O
,	O
oxidative	O
stress	O
and	O
apoptosis	O
induced	O
by	O
compound	O
C	O
.	O

The	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
targeting	O
of	O
human	B-geneY
AMPK	E-geneY
mimicked	O
compound	O
C	O
-	O
induced	O
G	O
(	O
2	O
)	O
/	O
M	O
cell	O
cycle	O
arrest	O
,	O
but	O
failed	O
to	O
induce	O
oxidative	O
stress	O
and	O
apoptosis	O
in	O
U251	O
glioma	O
cells	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
indicate	O
that	O
AMPK	S-geneN
inhibition	O
is	O
required	O
,	O
but	O
not	O
sufficient	O
for	O
compound	O
C	O
-	O
mediated	O
apoptotic	O
death	O
of	O
glioma	O
cells	O
.	O

Enhanced	O
mGlu5	B-geneY
-	I-geneY
receptor	E-geneY
dependent	O
long	O
-	O
term	O
depression	O
at	O
the	O
Schaffer	O
collateral	O
-	O
CA1	O
synapse	O
of	O
congenitally	O
learned	O
helpless	O
rats	O
.	O

Alterations	O
of	O
the	O
glutamatergic	O
system	O
have	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
and	O
treatment	O
of	O
major	O
depression	O
.	O

In	O
order	O
to	O
investigate	O
the	O
expression	O
and	O
function	O
of	O
mGlu5	B-geneY
receptors	E-geneY
in	O
an	O
animal	O
model	O
for	O
treatment	O
-	O
resistant	O
depression	O
we	O
used	O
rats	O
bred	O
for	O
congenital	O
learned	O
helplessness	O
(	O
cLH	O
)	O
and	O
the	O
control	O
strain	O
,	O
bred	O
for	O
resistance	O
against	O
inescapable	O
stress	O
,	O
congenitally	O
.	O
not	O
learned	O
helpless	O
rats	O
(	O
cNLH	O
)	O
.	O

Western	O
blot	O
analysis	O
showed	O
an	O
increased	O
expression	O
of	O
mGlu5	S-geneY
(	O
but	O
not	O
mGlu1a	S-geneY
)	O
receptors	O
in	O
the	O
hippocampus	O
of	O
cLH	O
rats	O
,	O
as	O
compared	O
with	O
control	O
cNLH	O
rats	O
.	O

We	O
also	O
examined	O
mGlu1	B-geneN
/	I-geneN
5	E-geneN
receptor	O
signaling	O
by	O
in	O
vivo	O
measurement	O
of	O
DHPG	S-chem
-	O
stimulated	O
polyphosphoinositides	S-chem
hydrolysis	O
.	O

Stimulation	O
of	O
(	B-chem
3	I-chem
)	I-chem
H	I-chem
-	I-chem
inositolmonophosphate	E-chem
formation	O
induced	O
by	O
i.c.v	O
.	O
injection	O
of	O
DHPG	S-chem
was	O
enhanced	O
by	O
about	O
50	O
%	O
in	O
the	O
hippocampus	O
of	O
cLH	O
rats	O
.	O

Correspondingly	O
,	O
DHPG	S-chem
-	O
induced	O
long	O
-	O
term	O
depression	O
(	O
LTD	O
)	O
at	O
Schaffer	O
collateral	O
/	O
CA1	O
pyramidal	O
cell	O
synapses	O
was	O
amplified	O
in	O
hippocampal	O
slices	O
of	O
cLH	O
rats	O
,	O
whereas	O
LTD	O
induced	O
by	O
low	O
frequency	O
stimulation	O
of	O
the	O
Schaffer	O
collaterals	O
did	O
not	O
change	O
.	O

Moreover	O
,	O
these	O
effects	O
were	O
associated	O
with	O
decreased	O
basal	O
dendritic	O
spine	O
density	O
of	O
CA1	O
pyramidal	O
cell	O
in	O
cLH	O
rats	O
.	O

These	O
data	O
raise	O
the	O
attractive	O
possibility	O
that	O
changes	O
in	O
the	O
expression	O
and	O
function	O
of	O
mGlu5	B-geneY
receptors	E-geneY
in	O
the	O
hippocampus	O
might	O
underlie	O
the	O
changes	O
in	O
synaptic	O
plasticity	O
associated	O
with	O
the	O
depressive	O
-	O
like	O
phenotype	O
of	O
cLH	O
rats	O
.	O

However	O
,	O
chronic	O
treatment	O
of	O
cLH	O
rats	O
with	O
MPEP	S-chem
did	O
not	O
reverse	O
learned	O
helplessness	O
,	O
indicating	O
that	O
the	O
enhanced	O
mGlu5	B-geneY
receptor	E-geneY
function	O
is	O
not	O
the	O
only	O
player	O
in	O
the	O
behavioral	O
phenotype	O
of	O
this	O
genetic	O
model	O
of	O
depression	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Metabotropic	B-geneN
Glutamate	I-geneN
Receptors	E-geneN
'	O
.	O

Characterisation	O
of	O
acetylcholinesterase	S-geneN
release	O
from	O
neuronal	O
cells	O
.	O

Although	O
acetylcholinesterase	S-geneY
(	O
AChE	S-geneY
)	O
is	O
primarily	O
a	O
hydrolytic	O
enzyme	O
,	O
metabolising	O
the	O
neurotransmitter	O
acetylcholine	S-chem
in	O
cholinergic	O
synapses	O
,	O
it	O
also	O
has	O
some	O
non	O
-	O
catalytic	O
functions	O
in	O
the	O
brain	O
which	O
are	O
far	O
less	O
well	O
characterised	O
.	O

AChE	S-geneY
was	O
shown	O
to	O
be	O
secreted	O
or	O
shed	O
from	O
the	O
neuronal	O
cell	O
surface	O
like	O
several	O
other	O
membrane	O
proteins	O
,	O
such	O
as	O
the	O
amyloid	B-geneY
precursor	I-geneY
protein	E-geneY
(	O
APP	S-geneY
)	O
.	O

Since	O
AChE	S-geneY
does	O
not	O
possess	O
a	O
transmembrane	B-geneN
domain	E-geneN
,	O
its	O
anchorage	O
in	O
the	O
membrane	O
is	O
established	O
via	O
the	O
Proline	B-geneY
Rich	I-geneY
Membrane	I-geneY
Anchor	E-geneY
(	O
PRiMA	S-geneY
)	O
,	O
a	O
transmembrane	O
protein	O
.	O

Both	O
the	O
subunit	O
oligomerisation	O
and	O
membrane	O
anchor	O
of	O
AChE	S-geneY
are	O
shared	O
by	O
a	O
related	O
enzyme	O
,	O
butyrylcholinesterase	S-geneY
(	O
BChE	S-geneY
)	O
,	O
the	O
physiological	O
function	O
of	O
which	O
in	O
the	O
brain	O
is	O
unclear	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
assayed	O
the	O
relative	O
activities	O
of	O
AChE	S-geneY
and	O
BChE	S-geneY
in	O
membrane	O
fractions	O
and	O
culture	O
medium	O
of	O
three	O
different	O
neuronal	O
cell	O
lines	O
,	O
namely	O
the	O
neuroblastoma	O
cell	O
lines	O
SH	O
-	O
SY5Y	O
and	O
NB7	O
and	O
the	O
mouse	O
basal	O
forebrain	O
cell	O
line	O
SN56	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
shedding	O
process	O
of	O
AChE	S-geneY
,	O
we	O
have	O
used	O
several	O
pharmacological	O
treatments	O
,	O
which	O
showed	O
that	O
it	O
is	O
likely	O
to	O
be	O
mediated	O
in	O
part	O
by	O
an	O
EDTA	S-chem
-	O
and	O
batimastat	S-chem
-	O
sensitive	O
,	O
but	O
GM6001	S-chem
-	O
insensitive	O
metalloprotease	S-geneN
,	O
with	O
the	O
possible	O
additional	O
involvement	O
of	O
a	O
thiol	B-geneN
isomerase	E-geneN
.	O

Cellular	O
release	O
of	O
AChE	S-geneY
by	O
SH	O
-	O
SY5Y	O
is	O
significantly	O
enhanced	O
by	O
the	O
muscarinic	B-geneN
acetylcholine	I-geneN
receptor	E-geneN
(	O
mAChR	S-geneN
)	O
agonists	O
carbachol	S-chem
or	O
muscarine	S-chem
,	O
with	O
the	O
effect	O
of	O
carbachol	S-chem
blocked	O
by	O
the	O
mAChR	S-geneN
antagonist	O
atropine	S-chem
.	O

AChE	S-geneY
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	O
disease	O
and	O
it	O
has	O
been	O
shown	O
that	O
it	O
accelerates	O
formation	O
and	O
increases	O
toxicity	O
of	O
amyloid	B-geneY
fibrils	E-geneY
,	O
which	O
have	O
been	O
closely	O
linked	O
to	O
the	O
pathology	O
of	O
AD	O
.	O

In	O
light	O
of	O
this	O
,	O
greater	O
understanding	O
of	O
AChE	S-geneY
and	O
BChE	S-geneY
physiology	O
may	O
also	O
benefit	O
AD	O
research	O
.	O

NHE3	S-geneY
inhibition	O
activates	O
duodenal	O
bicarbonate	O
secretion	O
in	O
the	O
rat	O
.	O

We	O
examined	O
the	O
effect	O
of	O
inhibition	O
of	O
Na	B-geneN
+	I-geneN
/	I-geneN
H	I-geneN
+	I-geneN
exchange	E-geneN
(	O
NHE	S-geneN
)	O
on	O
duodenal	O
bicarbonate	O
secretion	O
(	O
DBS	O
)	O
in	O
rats	O
to	O
further	O
understand	O
DBS	O
regulation	O
.	O

DBS	O
was	O
measured	O
by	O
using	O
the	O
pH	O
-	O
stat	O
method	O
and	O
by	O
using	O
CO2	S-chem
-	O
sensitive	O
electrodes	O
.	O

5	B-chem
-	I-chem
(	I-chem
N	I-chem
,	I-chem
N	I-chem
-	I-chem
dimethyl	I-chem
)	I-chem
-	I-chem
amiloride	E-chem
(	O
50	O
microM	O
;	O
DMA	S-chem
)	O
,	O
a	O
concentration	O
that	O
selectively	O
inhibits	O
the	O
NHE	S-geneN
isoforms	O
NHE1	S-geneY
and	O
NHE2	S-geneY
,	O
but	O
not	O
NHE3	S-geneY
,	O
did	O
not	O
affect	O
DBS	O
.	O

Nevertheless	O
,	O
3	O
mM	O
DMA	S-chem
,	O
a	O
higher	O
concentration	O
that	O
inhibits	O
NHE1	S-geneY
,	O
NHE2	S-geneY
,	O
and	O
NHE3	S-geneY
,	O
significantly	O
increased	O
DBS	O
.	O

Moreover	O
,	O
S1611	S-chem
and	O
S3226	S-chem
,	O
both	O
specific	O
inhibitors	O
of	O
NHE3	S-geneY
only	O
,	O
or	O
perfusion	O
with	O
Na	B-chem
+	E-chem
-	O
free	O
solutions	O
,	O
dose	O
dependently	O
increased	O
DBS	O
,	O
as	O
measured	O
by	O
pH	O
-	O
stat	O
and	O
CO2	S-chem
-	O
sensitive	O
electrode	O
,	O
without	O
affecting	O
intracellular	O
pH	O
.	O

Coperfusion	O
with	O
0.1	O
microM	O
indomethacin	S-chem
,	O
0.5	O
mM	O
DIDS	O
,	O
or	O
1	O
mM	O
methazolamide	S-chem
did	O
not	O
affect	O
S3226	S-chem
-	O
induced	O
DBS	O
.	O

Nevertheless	O
,	O
coperfusion	O
with	O
0.1	O
and	O
0.3	O
mM	O
5	B-chem
-	I-chem
nitro	I-chem
-	I-chem
2	I-chem
-	I-chem
(	I-chem
3	I-chem
-	I-chem
phenylpropylamino	I-chem
)	I-chem
benzoic	I-chem
acid	E-chem
,	O
which	O
inhibits	O
the	O
cystic	B-geneY
fibrosis	I-geneY
transmembrane	I-geneY
conductor	I-geneY
regulator	E-geneY
(	O
CFTR	S-geneY
)	O
,	O
dose	O
dependently	O
inhibited	O
S3226	S-chem
-	O
induced	O
DBS	O
.	O

In	O
conclusion	O
,	O
only	O
specific	O
apical	O
NHE3	S-geneY
inhibition	O
increased	O
DBS	O
,	O
whereas	O
prostaglandin	S-chem
synthesis	O
,	O
Na	B-geneY
+	I-geneY
-	I-geneY
HCO3	I-geneY
-	I-geneY
cotransporter	E-geneY
activation	O
,	O
or	O
intracellular	O
HCO3	S-chem
-	O
formation	O
by	O
carbonic	B-geneN
anhydrase	E-geneN
was	O
not	O
involved	O
.	O

Because	O
NHE3	S-geneY
inhibition	O
-	O
increased	O
DBS	O
was	O
inhibited	O
by	O
an	O
anion	B-geneN
channel	E-geneN
inhibitor	O
and	O
because	O
reciprocal	O
CFTR	S-geneY
regulation	O
has	O
been	O
previously	O
shown	O
between	O
NHE3	S-geneY
and	O
apical	B-geneN
membrane	I-geneN
anion	I-geneN
transporters	E-geneN
,	O
we	O
speculate	O
that	O
NHE3	S-geneY
inhibition	O
increased	O
DBS	O
by	O
altering	O
anion	O
transporter	E-geneN
function	O
.	O

Phosphodiesterase	B-geneN
4	E-geneN
inhibitors	O
delay	O
human	O
eosinophil	O
and	O
neutrophil	O
apoptosis	O
in	O
the	O
absence	O
and	O
presence	O
of	O
salbutamol	S-chem
.	O

In	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
the	O
number	O
of	O
eosinophils	O
and	O
neutrophils	O
in	O
the	O
lung	O
is	O
increased	O
.	O

One	O
described	O
mechanism	O
leading	O
to	O
the	O
impaired	O
clearance	O
of	O
these	O
cells	O
from	O
the	O
lung	O
is	O
the	O
delay	O
in	O
their	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
.	O

Selective	O
inhibitors	O
of	O
phosphodiesterases	S-geneN
(	O
PDEs	S-geneN
)	O
are	O
under	O
development	O
for	O
the	O
treatment	O
of	O
lung	O
diseases	O
because	O
of	O
their	O
anti	O
-	O
inflammatory	O
and	O
bronchodilator	O
activity	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
establish	O
whether	O
inhibitors	O
of	O
PDE3	S-geneN
,	O
PDE4	S-geneN
and	O
PDE5	S-geneY
modulate	O
human	O
eosinophil	O
or	O
neutrophil	O
apoptosis	O
or	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenoceptor	E-geneY
agonist	O
-	O
or	O
cytokine	S-geneN
-	O
afforded	O
survival	O
.	O

We	O
also	O
evaluated	O
whether	O
a	O
PDE4	S-geneN
inhibitor	O
could	O
modulate	O
the	O
effect	O
of	O
a	O
corticosteroid	S-chem
on	O
eosinophil	O
and	O
neutrophil	O
apoptosis	O
.	O

Apoptosis	O
was	O
measured	O
by	O
using	O
the	O
relative	O
DNA	O
fragmentation	O
assay	O
and	O
Annexin	O
-	O
V	O
binding	O
.	O

Inhibitors	O
of	O
PDE4	S-geneN
(	O
rolipram	S-chem
;	O
0.1	O
-	O
10	O
microM	O
)	O
and	O
PDE3	S-geneN
(	O
cilostazol	S-chem
;	O
0.1	O
-	O
10	O
microM	O
)	O
delayed	O
spontaneous	O
eosinophil	O
apoptosis	O
maximally	O
by	O
25	O
%	O
and	O
15	O
%	O
,	O
respectively	O
.	O

A	O
combination	O
of	O
a	O
PDE4	S-geneN
or	O
PDE3	S-geneN
inhibitor	O
(	O
10	O
microM	O
)	O
with	O
salbutamol	S-chem
(	O
100	O
nM	O
)	O
further	O
delayed	O
eosinophil	O
apoptosis	O
maximally	O
by	O
42	O
-	O
49	O
%	O
.	O

In	O
neutrophils	O
,	O
rolipram	S-chem
(	O
10	O
microM	O
)	O
also	O
decreased	O
apoptosis	O
with	O
a	O
maximal	O
inhibition	O
of	O
13	O
%	O
.	O

The	O
combination	O
of	O
rolipram	S-chem
(	O
10	O
microM	O
)	O
and	O
salbutamol	S-chem
(	O
100	O
nM	O
)	O
produced	O
a	O
27	O
%	O
inhibition	O
of	O
neutrophil	O
apoptosis	O
.	O

Inhibitor	O
of	O
cGMP	B-geneY
-	I-geneY
specific	I-geneY
PDE5	E-geneY
(	O
zaprinast	S-chem
;	O
0.1	O
-	O
10	O
microM	O
)	O
did	O
not	O
affect	O
eosinophil	O
apoptosis	O
and	O
only	O
slightly	O
increased	O
spontaneous	O
neutrophil	O
apoptosis	O
.	O

The	O
effect	O
of	O
budesonide	S-chem
on	O
apoptosis	O
was	O
not	O
significantly	O
modulated	O
by	O
a	O
PDE4	S-geneN
inhibitor	O
in	O
eosinophils	O
or	O
neutrophils	O
.	O

The	O
present	O
results	O
show	O
that	O
selective	O
inhibitors	O
of	O
cAMP	B-geneN
-	I-geneN
hydrolyzing	I-geneN
PDEs	E-geneN
(	O
PDE3	S-geneN
and	O
PDE4	S-geneN
)	O
delay	O
eosinophil	O
apoptosis	O
and	O
,	O
thus	O
,	O
increase	O
their	O
survival	O
in	O
vitro	O
.	O

Furthermore	O
,	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenoceptor	E-geneY
agonists	O
enhance	O
the	O
anti	O
-	O
apoptotic	O
effects	O
of	O
PDE3	S-geneN
and	O
PDE4	S-geneN
inhibitors	O
,	O
suggesting	O
that	O
such	O
drug	O
combinations	O
may	O
prolong	O
eosinophil	O
and	O
neutrophil	O
longevity	O
in	O
the	O
lung	O
.	O

Diuretic	O
effects	O
of	O
cannabinoids	O
.	O

In	O
vivo	O
effects	O
of	O
cannabinoid	O
(	O
CB	O
)	O
agonists	O
are	O
often	O
assessed	O
using	O
four	O
well	O
-	O
established	O
measures	O
:	O
locomotor	O
activity	O
,	O
hypothermia	O
,	O
cataleptic	O
-	O
like	O
effects	O
,	O
and	O
analgesia	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
doses	O
of	O
CB	O
agonists	O
that	O
produce	O
these	O
effects	O
also	O
reliably	O
increase	O
diuresis	O
.	O

Diuretic	O
effects	O
of	O
several	O
CB	O
agonists	O
were	O
measured	O
in	O
female	O
rats	O
over	O
2	O
hours	O
immediately	O
after	O
drug	O
injection	O
,	O
and	O
results	O
were	O
compared	O
with	O
hypothermic	O
effects	O
.	O

Direct	O
-	O
acting	O
CB1	S-geneY
agonists	O
,	O
including	O
Δ	B-chem
(	I-chem
9	I-chem
)	I-chem
-	I-chem
tetrahydrocannabinol	E-chem
,	O
WIN	B-chem
55,212	E-chem
[	O
R	B-chem
-	I-chem
(	I-chem
1	I-chem
)	I-chem
-	I-chem
[	I-chem
2,3	I-chem
-	I-chem
dihydro	I-chem
-	I-chem
5	I-chem
-	I-chem
methyl	I-chem
-	I-chem
3	I-chem
-	I-chem
[	I-chem
(	I-chem
morpholinyl	I-chem
)	I-chem
methyl	I-chem
]	I-chem
pyrrolo	I-chem
[	I-chem
1,2,3	I-chem
-	I-chem
de	I-chem
]	I-chem
-	I-chem
1,4	I-chem
-	I-chem
benzoxazinyl	I-chem
]	I-chem
-	I-chem
(	I-chem
1	I-chem
-	I-chem
naphthalenyl	I-chem
)	I-chem
methanone	I-chem
mesylate	E-chem
]	O
,	O
AM2389	S-chem
[	O
9β	B-chem
-	I-chem
hydroxy	I-chem
-	I-chem
3	I-chem
-	I-chem
(	I-chem
1	I-chem
-	I-chem
hexyl	I-chem
-	I-chem
cyclobut	I-chem
-	I-chem
1	I-chem
-	I-chem
yl	I-chem
)	I-chem
-	I-chem
hexahydrocannabinol	E-chem
]	O
,	O
and	O
AM4054	S-chem
[	O
9β	B-chem
-	I-chem
(	I-chem
hydroxymethyl	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
(	I-chem
1	I-chem
-	I-chem
adamantyl	I-chem
)	I-chem
-	I-chem
hexahydrocannabinol	E-chem
]	O
,	O
produced	O
dose	O
-	O
dependent	O
increases	O
in	O
diuresis	O
and	O
decreases	O
in	O
colonic	O
temperature	O
,	O
with	O
slightly	O
lower	O
ED	O
(	O
50	O
)	O
values	O
for	O
diuresis	O
than	O
for	O
hypothermia	O
.	O

The	O
highest	O
doses	O
of	O
cannabinoid	O
drugs	O
yielded	O
,	O
on	O
average	O
,	O
26	O
-	O
32	O
g	O
/	O
kg	O
urine	O
;	O
comparable	O
effects	O
were	O
obtained	O
with	O
10	O
mg	O
/	O
kg	O
furosemide	S-chem
and	O
3.0	O
mg	O
/	O
kg	O
trans	B-chem
-	I-chem
(	I-chem
-	I-chem
)	I-chem
-	I-chem
3,4	I-chem
-	I-chem
dichloro	I-chem
-	I-chem
N	I-chem
-	I-chem
methyl	I-chem
-	I-chem
N	I-chem
-	I-chem
[	I-chem
2	I-chem
-	I-chem
(	I-chem
1	I-chem
-	I-chem
pyrrolidinyl	I-chem
)	I-chem
cyclohexyl	I-chem
]	I-chem
benzeneacetamide	E-chem
(	O
U50	B-chem
-	I-chem
488	E-chem
)	O
.	O

Methanandamide	S-chem
(	O
10.0	O
mg	O
/	O
kg	O
)	O
had	O
lesser	O
effect	O
than	O
other	O
CB	O
agonists	O
,	O
and	O
the	O
CB2	S-geneY
agonist	O
AM1241	S-chem
[	O
1	B-chem
-	I-chem
(	I-chem
methylpiperidin	I-chem
-	I-chem
2	I-chem
-	I-chem
ylmethyl	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
iodo	I-chem
-	I-chem
5	I-chem
-	I-chem
nitrobenzoyl	I-chem
)	I-chem
indole	E-chem
]	O
,	O
the	O
anandamide	S-chem
transport	O
inhibitor	O
AM404	S-chem
,	O
and	O
the	O
CB	O
antagonist	O
rimonabant	S-chem
did	O
not	O
have	O
diuretic	O
effects	O
.	O

In	O
further	O
studies	O
,	O
the	O
diuretic	O
effects	O
of	O
the	O
CB1	S-geneY
agonist	O
AM4054	S-chem
were	O
similar	O
in	O
male	O
and	O
female	O
rats	O
,	O
displayed	O
a	O
relatively	O
rapid	O
onset	O
to	O
action	O
,	O
and	O
were	O
dose	O
-	O
dependently	O
antagonized	O
by	O
30	O
minutes	O
pretreatment	O
with	O
rimonabant	S-chem
,	O
but	O
not	O
by	O
the	O
vanilloid	B-geneY
receptor	I-geneY
type	I-geneY
I	E-geneY
antagonist	O
capsazepine	S-chem
,	O
nor	O
were	O
the	O
effects	O
of	O
WIN	B-chem
55,212	E-chem
antagonized	O
by	O
the	O
CB2	S-geneY
antagonist	O
AM630	S-chem
[	O
(	B-chem
6	I-chem
-	I-chem
iodo	I-chem
-	I-chem
2	I-chem
-	I-chem
methyl	I-chem
-	I-chem
1	I-chem
-	I-chem
[	I-chem
2	I-chem
-	I-chem
(	I-chem
4	I-chem
-	I-chem
morpholinyl	I-chem
)	I-chem
ethyl	I-chem
]	I-chem
-	I-chem
1H	I-chem
-	I-chem
indol	I-chem
-	I-chem
3	I-chem
-	I-chem
yl	I-chem
]	I-chem
(	I-chem
4	I-chem
-	I-chem
methoxyphenyl	I-chem
)	I-chem
methanone	I-chem
)	E-chem
]	O
.	O

These	O
data	O
indicate	O
that	O
cannabinoids	O
have	O
robust	O
diuretic	O
effects	O
in	O
rats	O
that	O
are	O
mediated	O
via	O
CB1	S-geneY
receptor	O
mechanisms	O
.	O

Tandem	O
Assays	O
of	O
Protein	O
and	O
Glucose	S-chem
with	O
Functionalized	O
Core	O
/	O
Shell	O
Particles	O
Based	O
on	O
Magnetic	O
Separation	O
and	O
Surface	O
-	O
Enhanced	O
Raman	O
Scattering	O
.	O

Tandem	O
assays	O
of	O
protein	O
and	O
glucose	S-chem
in	O
combination	O
with	O
mannose	S-chem
-	O
functionalized	O
Fe3	B-chem
O4	E-chem
@	O
SiO2	S-chem
and	O
Ag	S-chem
@	O
SiO2	S-chem
tag	O
particles	O
have	O
promising	O
potential	O
in	O
effective	O
magnetic	O
separation	O
and	O
highly	O
sensitive	O
and	O
selective	O
SERS	O
assays	O
of	O
biomaterials	O
.	O

It	O
is	O
for	O
the	O
first	O
time	O
that	O
tandem	O
assay	O
of	O
glucose	S-chem
is	O
developed	O
using	O
SERS	O
based	O
on	O
the	O
Con	O
A	O
-	O
sandwiched	O
microstructures	O
between	O
the	O
functionalized	O
magnetic	O
and	O
tag	O
particles	O
.	O

Mechanism	O
of	O
specific	O
membrane	O
targeting	O
by	O
C2	B-geneN
domains	E-geneN
:	O
localized	O
pools	O
of	O
target	O
lipids	O
enhance	O
Ca2	B-chem
+	E-chem
affinity	O
.	O

The	O
C2	B-geneN
domain	E-geneN
is	O
a	O
ubiquitous	O
,	O
conserved	O
protein	B-geneN
signaling	I-geneN
motif	E-geneN
widely	O
found	O
in	O
eukaryotic	O
signaling	O
proteins	O
.	O

Although	O
considerable	O
functional	O
diversity	O
exists	O
,	O
most	O
C2	B-geneN
domains	E-geneN
are	O
activated	O
by	O
Ca2	B-chem
+	E-chem
binding	O
and	O
then	O
dock	O
to	O
a	O
specific	O
cellular	O
membrane	O
.	O

The	O
C2	B-geneN
domains	E-geneN
of	O
protein	B-geneY
kinase	I-geneY
Calpha	E-geneY
(	O
PKCalpha	S-geneY
)	O
and	O
cytosolic	B-geneY
phospholipase	I-geneY
A2alpha	E-geneY
(	O
cPLA2alpha	S-geneY
)	O
,	O
for	O
example	O
,	O
are	O
known	O
to	O
dock	O
to	O
different	O
membrane	O
surfaces	O
during	O
an	O
intracellular	O
Ca2	B-chem
+	E-chem
signal	O
.	O

Ca2	B-chem
+	E-chem
activation	O
targets	O
the	O
PKCalpha	B-geneN
C2	I-geneN
domain	E-geneN
to	O
the	O
plasma	O
membrane	O
and	O
the	O
cPLA2alpha	B-geneN
C2	I-geneN
domain	E-geneN
to	O
the	O
internal	O
membranes	O
,	O
with	O
no	O
detectable	O
spatial	O
overlap	O
.	O

It	O
is	O
crucial	O
to	O
determine	O
how	O
such	O
targeting	O
specificity	O
is	O
achieved	O
at	O
physiological	O
bulk	O
Ca2	B-chem
+	E-chem
concentrations	O
that	O
during	O
a	O
typical	O
signaling	O
event	O
rarely	O
exceed	O
1	O
muM	O
.	O

For	O
the	O
isolated	O
PKCalpha	B-geneN
C2	I-geneN
domain	E-geneN
in	O
the	O
presence	O
of	O
physiological	O
Ca2	B-chem
+	E-chem
levels	O
,	O
the	O
target	O
lipids	O
phosphatidylserine	S-chem
(	O
PS	S-chem
)	O
and	O
phosphatidylinositol	B-chem
-	I-chem
4,5	I-chem
-	I-chem
bisphosphate	E-chem
(	O
PIP2	S-chem
)	O
are	O
together	O
sufficient	O
to	O
recruit	O
the	O
PKCalpha	B-geneN
C2	I-geneN
domain	O
to	O
a	O
lipid	O
mixture	O
mimicking	O
the	O
plasma	O
membrane	O
inner	O
leaflet	O
.	O

For	O
the	O
cPLA2alpha	B-geneN
C2	I-geneN
domain	E-geneN
,	O
the	O
target	O
lipid	O
phosphatidylcholine	S-chem
(	O
PC	S-chem
)	O
appears	O
to	O
be	O
sufficient	O
to	O
drive	O
membrane	O
targeting	O
to	O
an	O
internal	O
membrane	O
mimic	O
at	O
physiological	O
Ca2	B-chem
+	E-chem
levels	O
,	O
although	O
the	O
results	O
do	O
not	O
rule	O
out	O
a	O
second	O
,	O
unknown	O
target	O
molecule	O
.	O

Stopped	O
-	O
flow	O
kinetic	O
studies	O
provide	O
additional	O
information	O
about	O
the	O
fundamental	O
molecular	O
events	O
that	O
occur	O
during	O
Ca2	B-chem
+	E-chem
-	O
activated	O
membrane	O
docking	O
.	O

In	O
principle	O
,	O
C2	B-geneN
domain	E-geneN
-	O
directed	O
intracellular	O
targeting	O
,	O
which	O
requires	O
coincidence	O
detection	O
of	O
multiple	O
signals	O
(	O
Ca2	B-chem
+	E-chem
and	O
one	O
or	O
more	O
target	O
lipids	O
)	O
,	O
can	O
exhibit	O
two	O
different	O
mechanisms	O
:	O
messenger	O
-	O
activated	O
target	O
affinity	O
(	O
MATA	O
)	O
and	O
target	O
-	O
activated	O
messenger	O
affinity	O
(	O
TAMA	O
)	O
.	O

The	O
C2	B-geneN
domains	E-geneN
studied	O
here	O
both	O
utilize	O
the	O
TAMA	O
mechanism	O
,	O
in	O
which	O
the	O
C2	B-geneN
domain	E-geneN
Ca2	B-chem
+	E-chem
affinity	O
is	O
too	O
low	O
to	O
be	O
activated	O
by	O
physiological	O
Ca2	B-chem
+	E-chem
signals	O
in	O
most	O
regions	O
of	O
the	O
cell	O
.	O

Only	O
when	O
the	O
C2	B-geneN
domain	E-geneN
nears	O
its	O
target	O
membrane	O
,	O
which	O
provides	O
a	O
high	O
local	O
concentration	O
of	O
target	O
lipid	O
,	O
is	O
the	O
effective	O
Ca2	B-chem
+	E-chem
affinity	O
increased	O
by	O
the	O
coupled	O
binding	O
equilibrium	O
to	O
a	O
level	O
that	O
enables	O
substantial	O
Ca2	B-chem
+	E-chem
activation	O
and	O
target	O
docking	O
.	O

Overall	O
,	O
the	O
findings	O
emphasize	O
the	O
importance	O
of	O
using	O
physiological	O
ligand	O
concentrations	O
in	O
targeting	O
studies	O
because	O
super	O
-	O
physiological	O
concentrations	O
can	O
drive	O
docking	O
interactions	O
even	O
when	O
an	O
important	O
targeting	O
molecule	O
is	O
missing	O
.	O

Failure	O
of	O
ritodrine	S-chem
to	O
prevent	O
preterm	O
labor	O
in	O
the	O
sheep	O
.	O

OBJECTIVES	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
continuous	O
infusion	O
of	O
ritodrine	S-chem
could	O
prevent	O
preterm	O
delivery	O
in	O
sheep	O
.	O

STUDY	O
DESIGN	O
:	O
Sheep	O
in	O
preterm	O
labor	O
induced	O
by	O
RU	B-chem
486	E-chem
(	O
mifepristone	S-chem
)	O
received	O
infusions	O
of	O
either	O
ritodrine	S-chem
(	O
n	O
=	O
5	O
)	O
or	O
saline	O
solution	O
(	O
n	O
=	O
5	O
)	O
,	O
and	O
the	O
progress	O
of	O
labor	O
was	O
monitored	O
.	O
beta	B-geneY
2	I-geneY
-	I-geneY
Adrenergic	I-geneY
receptor	E-geneY
density	O
and	O
function	O
(	O
agonist	O
-	O
induced	O
cyclic	B-chem
adenosine	I-chem
monophosphate	E-chem
production	O
)	O
was	O
measured	O
in	O
myometrial	O
samples	O
from	O
both	O
groups	O
.	O

RESULTS	O
:	O
Ritodrine	S-chem
initially	O
inhibited	O
labor	O
contractions	O
.	O

This	O
inhibition	O
was	O
only	O
maintained	O
for	O
16	O
hours	O
,	O
after	O
which	O
both	O
the	O
amplitude	O
and	O
frequency	O
of	O
electromyographic	O
bursts	O
and	O
contractions	O
returned	O
.	O

The	O
failure	O
of	O
the	O
myometrium	O
to	O
respond	O
to	O
ritodrine	S-chem
(	O
desensitization	O
)	O
was	O
associated	O
with	O
significant	O
reductions	O
in	O
agonist	O
-	O
induced	O
cyclic	B-chem
adenosine	I-chem
monophosphate	E-chem
production	O
and	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenergic	I-geneY
receptor	E-geneY
concentration	O
in	O
myometrial	O
tissue	O
collected	O
from	O
these	O
animals	O
compared	O
with	O
the	O
saline	O
solution	O
-	O
treated	O
controls	O
.	O

CONCLUSIONS	O
:	O
Continuous	O
infusion	O
of	O
ritodrine	S-chem
to	O
sheep	O
in	O
preterm	O
labor	O
produces	O
only	O
a	O
transient	O
inhibition	O
of	O
contractions	O
.	O

This	O
desensitization	O
is	O
caused	O
by	O
a	O
down	O
-	O
regulation	O
of	O
myometrial	O
beta	B-geneY
2	I-geneY
-	I-geneY
adrenergic	I-geneY
receptors	E-geneY
.	O

Effects	O
of	O
monoamine	B-geneN
oxidase	E-geneN
inhibitors	O
on	O
levels	O
of	O
catechols	S-chem
and	O
homovanillic	B-chem
acid	E-chem
in	O
striatum	O
and	O
plasma	O
.	O

Levels	O
of	O
homovanillic	B-chem
acid	E-chem
(	O
HVA	S-chem
)	O
,	O
dihydroxyphenylacetic	B-chem
acid	E-chem
(	O
DOPAC	S-chem
)	O
and	O
dihydroxyphenylglycol	S-chem
(	O
DHPG	S-chem
)	O
in	O
plasma	O
and	O
the	O
striatium	O
were	O
measured	O
after	O
inhibition	O
of	O
monoamine	B-geneY
oxidase	I-geneY
type	I-geneY
A	E-geneY
(	O
MAO	B-geneY
-	I-geneY
A	E-geneY
)	O
by	O
clorgyline	S-chem
(	O
4	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
,	O
MAO	B-geneY
-	I-geneY
B	E-geneY
by	O
(	B-chem
-	I-chem
)	I-chem
deprenyl	E-chem
(	O
1	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
,	O
both	O
MAO	B-geneY
-	I-geneY
A	E-geneY
and	O
MAO	B-geneY
-	I-geneY
B	E-geneY
by	O
nialamide	S-chem
(	O
75	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
or	O
peripheral	O
neuronal	O
MAO	S-geneN
by	O
debrisoquin	S-chem
(	O
40	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

Levels	O
of	O
HVA	S-chem
in	O
plasma	O
decreased	O
by	O
about	O
60	O
%	O
after	O
single	O
doses	O
of	O
nialamide	S-chem
or	O
clorgyline	S-chem
,	O
by	O
about	O
80	O
%	O
after	O
repeated	O
doses	O
of	O
nialamide	S-chem
,	O
by	O
about	O
40	O
%	O
after	O
a	O
single	O
dose	O
of	O
debrisoquin	S-chem
and	O
by	O
about	O
50	O
%	O
after	O
repeated	O
doses	O
of	O
debrisoquin	S-chem
.	O

The	O
administration	O
of	O
clorgyline	S-chem
,	O
nialamide	S-chem
or	O
debrisoquin	S-chem
significantly	O
decreased	O
concentrations	O
of	O
DOPAC	S-chem
and	O
DHPG	S-chem
in	O
plasma	O
,	O
whereas	O
(	B-chem
-	I-chem
)	I-chem
deprenyl	E-chem
did	O
not	O
affect	O
levels	O
of	O
DHPG	S-chem
or	O
HVA	S-chem
.	O

None	O
of	O
the	O
MAO	S-geneN
inhibitors	O
produced	O
more	O
than	O
about	O
80	O
%	O
depression	O
of	O
levels	O
of	O
any	O
of	O
the	O
deaminated	O
metabolites	O
.	O

The	O
results	O
suggest	O
that	O
most	O
of	O
the	O
HVA	S-chem
in	O
plasma	O
is	O
derived	O
from	O
deamination	O
of	O
DA	S-chem
by	O
MAO	B-geneY
-	I-geneY
A	E-geneY
in	O
peripheral	O
neurons	O
;	O
that	O
DOPAC	S-chem
in	O
plasma	O
is	O
derived	O
from	O
cells	O
outside	O
the	O
central	O
nervous	O
system	O
;	O
that	O
DHPG	S-chem
in	O
plasma	O
is	O
derived	O
virtually	O
exclusively	O
from	O
the	O
metabolism	O
of	O
norepinephrine	S-chem
in	O
sympathetic	O
nerve	O
endings	O
and	O
that	O
residual	O
levels	O
of	O
HVA	S-chem
after	O
treatment	O
with	O
debrisoquin	S-chem
provide	O
an	O
improved	O
but	O
limited	O
indication	O
of	O
central	O
dopaminergic	O
activity	O
.	O

Structure	O
of	O
human	B-geneY
microsomal	I-geneY
cytochrome	I-geneY
P450	I-geneY
2C8	E-geneY
.	O
Evidence	O
for	O
a	O
peripheral	B-geneN
fatty	I-geneN
acid	I-geneN
binding	I-geneN
site	E-geneN
.	O

A	O
2.7	O
-	O
Angstrom	O
molecular	O
structure	O
of	O
human	B-geneY
microsomal	I-geneY
cytochrome	I-geneY
P450	I-geneY
2C8	E-geneY
(	O
CYP2C8	S-geneY
)	O
was	O
determined	O
by	O
x	O
-	O
ray	O
crystallography	O
.	O

The	O
membrane	O
protein	O
was	O
modified	O
for	O
crystallization	O
by	O
replacement	O
of	O
the	O
hydrophobic	O
N	O
-	O
terminal	O
transmembrane	O
domain	O
with	O
a	O
short	O
hydrophilic	O
sequence	O
before	O
residue	O
28	O
.	O

The	O
structure	O
of	O
the	O
native	O
sequence	O
is	O
complete	O
from	O
residue	O
28	O
to	O
the	O
beginning	O
of	O
a	O
C	S-chem
-	O
terminal	O
histidine	S-chem
tag	O
used	O
for	O
purification	O
.	O

CYP2C8	S-geneY
is	O
one	O
of	O
the	O
principal	O
hepatic	O
drug	O
-	O
metabolizing	O
enzymes	O
that	O
oxidizes	O
therapeutic	O
drugs	O
such	O
as	O
taxol	O
and	O
cerivastatin	O
and	O
endobiotics	O
such	O
as	O
retinoic	O
acid	O
and	O
arachidonic	O
acid	O
.	O

Consistent	O
with	O
the	O
relatively	O
large	O
size	O
of	O
its	O
preferred	O
substrates	O
,	O
the	O
active	O
site	O
volume	O
is	O
twice	O
that	O
observed	O
for	O
the	O
structure	O
of	O
CYP2C5	S-geneY
.	O

The	O
extended	O
active	O
site	O
cavity	O
is	O
bounded	O
by	O
the	O
beta1	B-geneN
sheet	E-geneN
and	O
helix	B-geneN
F	I-geneN
'	E-geneN
that	O
have	O
not	O
previously	O
been	O
implicated	O
in	O
substrate	O
recognition	O
by	O
mammalian	B-geneN
P450s	E-geneN
.	O

CYP2C8	S-geneY
crystallized	O
as	O
a	O
symmetric	O
dimer	O
formed	O
by	O
the	O
interaction	O
of	O
helices	O
F	I-geneN
,	I-geneN
F	I-geneN
'	I-geneN
,	I-geneN
G	I-geneN
'	I-geneN
,	I-geneN
and	I-geneN
G	E-geneN
.	O

Two	O
molecules	O
of	O
palmitic	B-chem
acid	E-chem
are	O
bound	O
in	O
the	O
dimer	O
interface	O
.	O

The	O
dimer	O
is	O
observed	O
in	O
solution	O
,	O
and	O
mass	O
spectrometry	O
confirmed	O
the	O
association	O
of	O
palmitic	B-chem
acid	E-chem
with	O
the	O
enzyme	O
.	O

This	O
novel	O
finding	O
identifies	O
a	O
peripheral	O
binding	O
site	O
in	O
P450s	S-geneN
that	O
may	O
contribute	O
to	O
drug	O
-	O
drug	O
interactions	O
in	O
P450	S-geneN
metabolism	O
.	O

Differentiating	O
the	O
roles	O
of	O
mGlu2	S-geneY
and	O
mGlu3	S-geneY
receptors	O
using	O
LY541850	S-chem
,	O
an	O
mGlu2	S-geneY
agonist	O
/	O
mGlu3	S-geneY
antagonist	O
.	O

Despite	O
the	O
potential	O
therapeutic	O
relevance	O
of	O
group	B-geneN
II	I-geneN
metabotropic	I-geneN
glutamate	I-geneN
(	I-geneN
mGlu	I-geneN
)	I-geneN
receptors	E-geneN
,	O
there	O
has	O
been	O
a	O
lack	O
of	O
pharmacological	O
tools	O
for	O
separating	O
the	O
roles	O
of	O
mGlu2	S-geneY
and	O
mGlu3	S-geneY
receptor	O
subtypes	O
.	O

LY541850	S-chem
was	O
claimed	O
from	O
human	B-geneN
mGlu	I-geneN
receptors	E-geneN
expressed	O
in	O
non	O
-	O
neuronal	O
cells	O
to	O
be	O
a	O
selective	O
orthosteric	O
mGlu2	S-geneY
agonist	O
and	O
mGlu3	S-geneY
antagonist	O
.	O

We	O
have	O
verified	O
this	O
pharmacological	O
profile	O
of	O
LY541850	S-chem
in	O
hippocampal	O
slices	O
.	O

Field	O
excitatory	O
post	O
-	O
synaptic	O
potentials	O
(	O
fEPSPs	O
)	O
evoked	O
by	O
stimulation	O
of	O
the	O
temporo	O
-	O
ammonic	O
path	O
(	O
TAP	O
)	O
input	O
to	O
CA1	O
stratum	O
lacunosum	O
moleculare	O
(	O
SLM	O
)	O
were	O
inhibited	O
by	O
LY541850	S-chem
in	O
mGlu3	S-geneY
-	O
/	O
-	O
mice	O
(	O
EC	O
(	O
50	O
)	O
38	O
nM	O
)	O
and	O
wild	O
-	O
type	O
littermates	O
(	O
EC	O
(	O
50	O
)	O
42	O
nM	O
)	O
to	O
a	O
similar	O
extent	O
but	O
were	O
not	O
significantly	O
affected	O
in	O
mGlu2	S-geneY
-	O
/	O
-	O
mice	O
.	O

The	O
group	O
II	O
agonist	O
,	O
DCG	O
-	O
IV	O
,	O
inhibited	O
the	O
fEPSP	O
in	O
all	O
three	O
genotypes	O
.	O

Co	O
-	O
application	O
of	O
DCG	O
-	O
IV	O
and	O
LY541850	S-chem
in	O
mGlu3	S-geneY
-	O
/	O
-	O
and	O
wild	O
-	O
type	O
littermates	O
resulted	O
in	O
an	O
additive	O
effect	O
,	O
whereas	O
in	O
mGlu2	S-geneY
-	O
/	O
-	O
mice	O
,	O
LY541850	S-chem
reversed	O
the	O
inhibitory	O
action	O
of	O
DCG	O
-	O
IV	O
.	O

These	O
results	O
confirm	O
the	O
selective	O
mGlu2	S-geneY
agonist	O
and	O
mGlu3	S-geneY
antagonist	O
actions	O
of	O
LY541850	S-chem
.	O

A	O
similar	O
profile	O
of	O
activity	O
was	O
seen	O
in	O
medial	O
perforant	O
path	O
synapse	O
to	O
the	O
dentate	O
gyrus	O
.	O

Systemic	O
administration	O
of	O
LY541850	S-chem
to	O
wild	O
-	O
type	O
mice	O
,	O
reduced	O
the	O
increase	O
in	O
locomotor	O
activity	O
following	O
both	O
phencyclidine	S-chem
and	O
amphetamine	S-chem
administration	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
mGlu2	S-geneY
receptors	O
mediate	O
the	O
antipsychotic	O
effects	O
of	O
mixed	O
group	O
II	O
agonists	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Metabotropic	B-geneN
Glutamate	I-geneN
Receptors	E-geneN
'	O
.	O

Identification	O
of	O
N	S-chem
-	O
terminal	O
receptor	O
activity	O
-	O
modifying	O
protein	O
residues	O
important	O
for	O
calcitonin	B-geneN
gene	I-geneN
-	I-geneN
related	I-geneN
peptide	E-geneN
,	O
adrenomedullin	S-geneY
,	O
and	O
amylin	B-geneN
receptor	E-geneN
function	O
.	O

Calcitonin	B-geneN
-	I-geneN
family	I-geneN
receptors	E-geneN
comprise	O
calcitonin	B-geneY
receptor	I-geneY
-	I-geneY
like	I-geneY
receptor	E-geneY
(	O
CL	S-geneY
)	O
or	O
calcitonin	B-geneY
receptor	E-geneY
and	O
receptor	B-geneN
activity	I-geneN
-	I-geneN
modifying	I-geneN
protein	E-geneN
(	O
RAMP	S-geneN
)	O
pairings	O
.	O

Calcitonin	B-geneY
gene	I-geneY
-	I-geneY
related	I-geneY
peptide	I-geneY
(	I-geneY
CGRP	I-geneY
)	I-geneY
receptors	E-geneY
are	O
CL	S-geneY
/	O
RAMP1	S-geneY
,	O
whereas	O
adrenomedullin	B-geneN
(	I-geneN
AM	I-geneN
)	I-geneN
receptors	E-geneN
are	O
CL	S-geneY
/	O
RAMP2	S-geneY
(	O
AM1	B-geneY
receptor	E-geneY
)	O
or	O
CL	S-geneY
/	O
RAMP3	S-geneY
(	O
AM2	B-geneY
receptor	E-geneY
)	O
.	O

Amylin	B-geneN
(	I-geneN
Amy	I-geneN
)	I-geneN
receptors	E-geneN
are	O
RAMP	S-geneN
hetero	O
-	O
oligomers	O
with	O
the	O
calcitonin	B-geneY
receptor	E-geneY
(	O
AMY1	S-geneY
,	O
AMY2	S-geneY
,	O
and	O
AMY3	S-geneY
,	O
respectively	O
)	O
.	O

How	O
RAMPs	S-geneN
change	O
G	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
pharmacology	O
is	O
not	O
fully	O
understood	O
.	O

We	O
exploited	O
sequence	O
differences	O
between	O
RAMP1	S-geneY
and	O
RAMP3	S-geneY
to	O
identify	O
individual	O
residues	O
capable	O
of	O
altering	O
receptor	O
pharmacology	O
.	O

Alignment	O
of	O
human	B-geneN
RAMPs	E-geneN
revealed	O
eight	O
residues	O
that	O
are	O
conserved	O
in	O
RAMP2	S-geneY
and	O
RAMP3	S-geneY
but	O
are	O
different	O
in	O
RAMP1	S-geneY
.	O

We	O
hypothesized	O
that	O
residues	O
in	O
RAMP2	S-geneY
and	O
RAMP3	S-geneY
,	O
but	O
not	O
RAMP1	S-geneY
,	O
are	O
responsible	O
for	O
making	O
CL	S-geneY
/	O
RAMP2	S-geneY
and	O
CL	S-geneY
/	O
RAMP3	S-geneY
AM	B-geneN
receptors	E-geneN
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
,	O
we	O
introduced	O
individual	O
RAMP3	S-geneY
residues	O
into	O
RAMP1	S-geneY
and	O
vice	O
versa	O
in	O
these	O
eight	O
positions	O
.	O

Mutant	O
or	O
wild	O
-	O
type	O
RAMPs	S-geneN
were	O
transfected	O
into	O
Cos7	O
cells	O
with	O
CL	S-geneY
or	O
the	O
insert	O
-	O
negative	O
form	O
of	O
the	O
calcitonin	B-geneY
receptor	E-geneY
[	O
CT	B-geneY
(	I-geneY
a	I-geneY
)	E-geneY
]	O
.	O

Agonist	O
-	O
stimulated	O
cAMP	O
production	O
and	O
cell	O
-	O
surface	O
expression	O
of	O
constructs	O
were	O
measured	O
.	O

Position	O
74	O
in	O
RAMP1	S-geneY
and	O
RAMP3	S-geneY
was	O
critical	O
for	O
determining	O
AM	S-geneY
potency	O
and	O
affinity	O
,	O
and	O
Phe93	O
in	O
RAMP1	S-geneY
was	O
an	O
important	O
contributor	O
to	O
alphaCGRP	S-geneY
potency	O
at	O
CGRP	B-geneY
receptors	E-geneY
.	O

Mutant	O
RAMP	S-geneN
/	O
CT	B-geneY
(	I-geneY
a	I-geneY
)	I-geneY
receptor	E-geneY
complexes	O
displayed	O
different	O
phenotypes	O
.	O

It	O
is	O
noteworthy	O
that	O
RAMP1	S-geneY
S103N	S-geneN
and	O
W74E	S-geneN
mutations	O
led	O
to	O
enhanced	O
rAmy	S-geneY
potency	O
,	O
probably	O
related	O
to	O
increased	O
cell	O
-	O
surface	O
expression	O
of	O
these	O
complexes	O
.	O

This	O
differs	O
from	O
the	O
effect	O
on	O
CL	S-geneY
-	O
based	O
receptors	O
where	O
expression	O
was	O
unchanged	O
.	O

Targeted	O
substitution	O
has	O
emphasized	O
the	O
importance	O
of	O
position	O
74	O
in	O
RAMP1	S-geneY
/	O
RAMP3	S-geneY
as	O
a	O
key	O
determinant	O
of	O
AM	S-geneY
pharmacology	O
.	O

Kinetic	O
and	O
stereochemical	O
studies	O
on	O
novel	O
inactivators	O
of	O
C	S-chem
-	O
terminal	O
amidation	O
.	O

C	S-chem
-	O
terminal	O
amidation	O
,	O
a	O
required	O
post	O
-	O
translational	O
modification	O
for	O
the	O
bioactivation	O
of	O
many	O
neuropeptides	O
,	O
entails	O
sequential	O
enzymic	O
action	O
by	O
peptidylglycine	B-geneY
alpha	I-geneY
-	I-geneY
mono	I-geneY
-	I-geneY
oxygenase	E-geneY
(	O
PAM	S-geneY
,	O
EC	B-geneY
1.14.17.3	E-geneY
)	O
and	O
peptidylamidoglycolate	B-geneY
lyase	E-geneY
(	O
PGL	S-geneY
,	O
EC	B-geneY
4.3.2.5	E-geneY
)	O
.	O

Here	O
we	O
introduce	O
novel	O
compounds	O
in	O
which	O
an	O
olefinic	O
functionality	O
is	O
incorporated	O
into	O
peptide	O
analogues	O
as	O
the	O
most	O
potent	O
turnover	O
-	O
dependent	O
inactivators	O
of	O
PAM	S-geneY
.	O

Kinetic	O
parameters	O
for	O
PAM	S-geneY
inactivation	O
by	O
4	B-chem
-	I-chem
oxo	I-chem
-	I-chem
5	I-chem
-	I-chem
acetamido	I-chem
-	I-chem
6	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
hex	I-chem
-	I-chem
2	I-chem
-	I-chem
enoic	I-chem
acid	I-chem
and	I-chem
4	I-chem
-	I-chem
oxo	I-chem
-	I-chem
5	I-chem
-	I-chem
acetamido	I-chem
-	I-chem
6	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
thienyl	I-chem
)	I-chem
-	I-chem
hex	I-chem
-	I-chem
2	I-chem
-	I-chem
enoic	I-chem
acid	E-chem
were	O
obtained	O
by	O
using	O
both	O
the	O
conventional	O
dilution	O
assay	O
method	O
and	O
the	O
more	O
complex	O
progress	O
curve	O
method	O
.	O

The	O
results	O
obtained	O
from	O
the	O
progress	O
curve	O
method	O
establish	O
that	O
these	O
compounds	O
exhibit	O
the	O
kinetic	O
characteristics	O
of	O
pure	O
competitive	O
inactivators	O
(	O
i.e	O
.	O
no	O
ESI	O
complex	O
forms	O
during	O
inactivation	O
)	O
.	O

On	O
the	O
basis	O
of	O
k	O
(	O
inact	O
)	O
/	O
K	O
(	O
i	O
)	O
values	O
,	O
4	B-chem
-	I-chem
oxo	I-chem
-	I-chem
5	I-chem
-	I-chem
acetamido	I-chem
-	I-chem
6	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
thienyl	I-chem
)	I-chem
-	I-chem
hex	I-chem
-	I-chem
2	I-chem
-	I-chem
enoic	I-chem
acid	E-chem
is	O
almost	O
two	O
orders	O
of	O
magnitude	O
more	O
potent	O
than	O
benzoylacrylate	S-chem
,	O
a	O
chemically	O
analogous	O
olefinic	O
inactivator	O
that	O
lacks	O
the	O
peptide	O
moiety	O
.	O

Stereochemical	O
studies	O
established	O
that	O
PAM	S-geneY
inactivation	O
by	O
4	B-chem
-	I-chem
oxo	I-chem
-	I-chem
5	I-chem
-	I-chem
acetamido	I-chem
-	I-chem
6	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
thienyl	I-chem
)	I-chem
-	I-chem
hex	I-chem
-	I-chem
2	I-chem
-	I-chem
enoic	I-chem
acid	E-chem
is	O
stereospecific	O
with	O
respect	O
to	O
the	O
moiety	O
at	O
the	O
P	O
(	O
2	O
)	O
position	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
results	O
with	O
substrates	O
and	O
reversible	O
inhibitors	O
.	O

In	O
contrast	O
,	O
2	B-chem
,	I-chem
4	I-chem
-	I-chem
dioxo	I-chem
-	I-chem
5	I-chem
-	I-chem
acetamido	I-chem
-	I-chem
6	I-chem
-	I-chem
phenylhexanoic	I-chem
acid	E-chem
,	O
which	O
is	O
a	O
competitive	O
inhibitor	O
with	O
respect	O
to	O
ascorbate	S-chem
,	O
exhibits	O
a	O
low	O
degree	O
of	O
stereospecificity	O
in	O
binding	O
to	O
the	O
ascorbate	S-chem
sites	O
of	O
both	O
PAM	S-geneY
and	O
dopamine	B-geneY
-	I-geneY
beta	I-geneY
-	I-geneY
hydroxylase	E-geneY
.	O

Steroid	S-chem
hormone	O
synthesis	O
in	O
mitochondria	O
.	O

Mitochondria	O
are	O
essential	O
sites	O
for	O
steroid	S-chem
hormone	O
biosynthesis	O
.	O

Mitochondria	O
in	O
the	O
steroidogenic	O
cells	O
of	O
the	O
adrenal	O
,	O
gonad	O
,	O
placenta	O
and	O
brain	O
contain	O
the	O
cholesterol	S-chem
side	O
-	O
chain	O
cleavage	O
enzyme	O
,	O
P450scc	S-geneY
,	O
and	O
its	O
two	O
electron	O
-	O
transfer	O
partners	O
,	O
ferredoxin	B-geneN
reductase	E-geneN
and	O
ferredoxin	S-geneN
.	O

This	O
enzyme	O
system	O
converts	O
cholesterol	S-chem
to	O
pregnenolone	S-chem
and	O
determines	O
net	O
steroidogenic	O
capacity	O
,	O
so	O
that	O
it	O
serves	O
as	O
the	O
chronic	O
regulator	O
of	O
steroidogenesis	O
.	O

Several	O
other	O
steroidogenic	O
enzymes	O
,	O
including	O
3β	B-geneY
-	I-geneY
hydroxysteroid	I-geneY
dehydrogenase	E-geneY
,	O
11β	B-geneY
-	I-geneY
hydroxylase	E-geneY
and	O
aldosterone	B-geneY
synthase	E-geneY
also	O
reside	O
in	O
mitochondria	O
.	O

Similarly	O
,	O
the	O
mitochondria	O
of	O
renal	O
tubular	O
cells	O
contain	O
two	O
key	O
enzymes	O
participating	O
in	O
the	O
activation	O
and	O
degradation	O
of	O
vitamin	B-chem
D	E-chem
.	O

The	O
access	O
of	O
cholesterol	S-chem
to	O
the	O
mitochondria	O
is	O
regulated	O
by	O
the	O
steroidogenic	B-geneY
acute	I-geneY
regulatory	I-geneY
protein	E-geneY
,	O
StAR	S-geneY
,	O
serving	O
as	O
the	O
acute	O
regulator	O
of	O
steroidogenesis	O
.	O

StAR	S-geneY
action	O
requires	O
a	O
complex	O
multi	O
-	O
component	O
molecular	O
machine	O
on	O
the	O
outer	O
mitochondrial	O
membrane	O
(	O
OMM	O
)	O
.	O

Components	O
of	O
this	O
machine	O
include	O
the	O
18kDa	O
translocator	B-geneY
protein	E-geneY
(	O
TSPO	S-geneY
)	O
,	O
the	O
voltage	B-geneN
-	I-geneN
dependent	I-geneN
anion	I-geneN
chanel	E-geneN
(	O
VDAC	B-geneY
-	I-geneY
1	E-geneY
)	O
,	O
TSPO	B-geneY
-	I-geneY
associated	I-geneY
protein	I-geneY
7	E-geneY
(	O
PAP7	S-geneY
,	O
ACBD3	S-geneY
)	O
,	O
and	O
protein	B-geneY
kinase	I-geneY
A	I-geneY
regulatory	I-geneY
subunit	I-geneY
1α	E-geneY
(	O
PKAR1A	S-geneY
)	O
.	O

The	O
precise	O
fashion	O
in	O
which	O
these	O
proteins	O
interact	O
and	O
move	O
cholesterol	S-chem
from	O
the	O
OMM	O
to	O
P450scc	S-geneY
,	O
and	O
the	O
means	O
by	O
which	O
cholesterol	S-chem
is	O
loaded	O
into	O
the	O
OMM	O
,	O
remain	O
unclear	O
.	O

Human	O
deficiency	O
diseases	O
have	O
been	O
described	O
for	O
StAR	S-geneY
and	O
for	O
all	O
the	O
mitochondrial	O
steroidogenic	O
enzymes	O
,	O
but	O
not	O
for	O
the	O
electron	O
transfer	O
proteins	O
or	O
for	O
the	O
components	O
of	O
the	O
cholesterol	S-chem
import	O
machine	O
.	O

EphB1	S-geneY
null	O
mice	O
exhibit	O
neuronal	O
loss	O
in	O
substantia	O
nigra	O
pars	O
reticulata	O
and	O
spontaneous	O
locomotor	O
hyperactivity	O
.	O

The	O
molecular	O
mechanisms	O
that	O
regulate	O
basal	O
ganglia	O
development	O
are	O
largely	O
unknown	O
.	O

Eph	B-geneN
receptor	E-geneN
tyrosine	B-geneN
kinases	E-geneN
are	O
potential	O
participants	O
in	O
this	O
process	O
as	O
they	O
regulate	O
development	O
of	O
other	O
CNS	O
regions	O
and	O
are	O
expressed	O
in	O
basal	O
ganglia	O
nuclei	O
,	O
such	O
as	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
and	O
striatum	O
.	O

To	O
address	O
the	O
role	O
of	O
Eph	B-geneN
receptors	E-geneN
in	O
the	O
development	O
of	O
these	O
nuclei	O
,	O
we	O
analysed	O
anatomical	O
changes	O
in	O
the	O
SN	O
and	O
striatum	O
of	O
mice	O
with	O
null	O
mutations	O
for	O
EphB1	S-geneY
.	O

These	O
mice	O
express	O
beta	O
-	O
galactosidase	O
as	O
a	O
marker	O
for	O
cells	O
normally	O
expressing	O
EphB1	S-geneY
.	O

In	O
situ	O
hybridization	O
data	O
and	O
a	O
direct	O
comparison	O
of	O
SN	O
neurons	O
expressing	O
tyrosine	B-geneY
hydroxylase	E-geneY
(	O
TH	S-geneY
)	O
and	O
/	O
or	O
the	O
beta	O
-	O
gal	O
marker	O
for	O
EphB1	S-geneY
revealed	O
that	O
EphB1	S-geneY
is	O
not	O
expressed	O
in	O
TH	S-geneY
+	O
neurons	O
of	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
but	O
is	O
restricted	O
to	O
neurons	O
in	O
pars	O
reticulata	O
(	O
SNr	O
)	O
.	O

Consistent	O
with	O
this	O
,	O
we	O
find	O
that	O
EphB1	S-geneY
null	O
mice	O
exhibit	O
a	O
significant	O
decrease	O
in	O
the	O
volume	O
and	O
number	O
of	O
neurons	O
(	O
40	O
%	O
decrease	O
)	O
in	O
SNr	O
,	O
whereas	O
the	O
volume	O
and	O
number	O
of	O
TH	S-geneY
+	O
neurons	O
in	O
SNc	O
is	O
not	O
significantly	O
affected	O
nor	O
are	O
there	O
changes	O
in	O
the	O
distribution	O
of	O
nigrostriatal	O
dopamine	S-chem
neurons	O
.	O

Although	O
EphB1	S-geneY
is	O
expressed	O
in	O
the	O
striatum	O
,	O
EphB1	S-geneY
-	O
/	O
-	O
mice	O
exhibit	O
no	O
significant	O
changes	O
in	O
striatal	O
volume	O
and	O
TH	S-geneY
fiber	O
density	O
,	O
and	O
have	O
no	O
obvious	O
alterations	O
in	O
striatal	O
patch	O
/	O
matrix	O
organization	O
.	O

Behavioral	O
evaluation	O
of	O
EphB1	S-geneY
null	O
mice	O
in	O
an	O
open	O
-	O
field	O
environment	O
revealed	O
that	O
these	O
mice	O
exhibited	O
spontaneous	O
locomotor	O
hyperactivity	O
.	O

These	O
results	O
suggest	O
that	O
EphB1	S-geneY
is	O
necessary	O
for	O
the	O
proper	O
formation	O
of	O
SNr	O
,	O
and	O
that	O
neuronal	O
loss	O
in	O
SNr	O
is	O
associated	O
with	O
altered	O
locomotor	O
functions	O
.	O

Selective	O
activation	O
of	O
thyroid	B-chem
hormone	E-chem
signaling	O
pathways	O
by	O
GC	O
-	O
1	O
:	O
a	O
new	O
approach	O
to	O
controlling	O
cholesterol	S-chem
and	O
body	O
weight	O
.	O

The	O
current	O
report	O
describes	O
progress	O
in	O
development	O
of	O
a	O
selective	O
thyroid	B-geneN
hormone	I-geneN
receptor	E-geneN
modulator	O
,	O
GC	O
-	O
1	O
.	O

This	O
compound	O
binds	O
selectively	O
to	O
the	O
beta	B-geneY
-	I-geneY
isoform	I-geneY
of	I-geneY
the	I-geneY
thyroid	I-geneY
hormone	I-geneY
receptor	E-geneY
,	O
and	O
its	O
uptake	O
into	O
the	O
heart	O
is	O
relatively	O
low	O
.	O

Studies	O
in	O
rats	O
,	O
mice	O
and	O
monkeys	O
show	O
that	O
GC	O
-	O
1	O
lowers	O
cholesterol	S-chem
with	O
600	O
-	O
to	O
1400	O
-	O
fold	O
more	O
potency	O
and	O
approximately	O
two	O
-	O
to	O
threefold	O
more	O
efficacy	O
than	O
atorvastatin	S-chem
,	O
a	O
compound	O
that	O
blocks	O
HMG	B-geneY
-	I-geneY
CoA	I-geneY
reductase	E-geneY
.	O

GC	O
-	O
1	O
also	O
decreases	O
plasma	O
levels	O
of	O
triglyceride	S-chem
and	O
lipoprotein	B-geneN
(	I-geneN
a	I-geneN
)	E-geneN
,	O
and	O
induces	O
loss	O
of	O
fat	O
.	O

These	O
effects	O
can	O
be	O
observed	O
under	O
conditions	O
where	O
there	O
is	O
either	O
no	O
or	O
minimal	O
effect	O
on	O
heart	O
rate	O
,	O
and	O
no	O
detectable	O
loss	O
of	O
muscle	O
.	O

Although	O
more	O
study	O
is	O
required	O
,	O
compounds	O
of	O
this	O
class	O
deserve	O
further	O
investigation	O
for	O
treating	O
lipid	O
disorders	O
and	O
obesity	O
.	O

Tamoxifen	S-chem
and	O
fluoxymesterone	S-chem
versus	O
tamoxifen	S-chem
and	O
danazol	S-chem
in	O
metastatic	O
breast	O
cancer	O
-	O
-	O
a	O
randomized	O
study	O
.	O

A	O
prospective	O
randomized	O
trial	O
of	O
tamoxifen	S-chem
and	O
fluoxymesterone	S-chem
versus	O
tamoxifen	S-chem
and	O
danazol	S-chem
in	O
metastatic	O
breast	O
cancer	O
was	O
conducted	O
from	O
December	O
1980	O
to	O
September	O
1985	O
.	O

Patients	O
were	O
eligible	O
regardless	O
of	O
site	O
of	O
disease	O
,	O
estrogen	B-geneY
receptor	E-geneY
status	O
,	O
or	O
age	O
.	O

Sixty	O
-	O
two	O
of	O
sixty	O
-	O
three	O
randomized	O
patients	O
were	O
evaluable	O
for	O
response	O
.	O

Overall	O
response	O
for	O
tamoxifen	S-chem
and	O
fluoxymesterone	S-chem
was	O
11	O
%	O
with	O
61	O
%	O
stabilization	O
of	O
disease	O
,	O
versus	O
12	O
%	O
response	O
rate	O
for	O
tamoxifen	S-chem
and	O
danazol	S-chem
with	O
59	O
%	O
stabilization	O
.	O

Toxicities	O
with	O
tamoxifen	S-chem
and	O
fluoxymesterone	S-chem
were	O
greater	O
with	O
an	O
increase	O
in	O
masculinization	O
.	O

We	O
conclude	O
that	O
the	O
response	O
rates	O
to	O
the	O
combinations	O
of	O
tamoxifen	S-chem
and	O
fluoxymesterone	S-chem
or	O
tamoxifen	S-chem
and	O
danazol	S-chem
reported	O
are	O
equivalent	O
in	O
this	O
study	O
but	O
that	O
the	O
increased	O
toxicity	O
with	O
tamoxifen	S-chem
and	O
fluoxymesterone	S-chem
would	O
make	O
tamoxifen	S-chem
and	O
danazol	S-chem
the	O
treatment	O
of	O
choice	O
if	O
a	O
combination	O
were	O
to	O
be	O
used	O
.	O

Fibrillar	O
Morphology	O
of	O
Derivatives	O
of	O
Poly	B-chem
(	I-chem
3	I-chem
-	I-chem
alkylthiophene	I-chem
)	I-chem
s	E-chem
by	O
Solvent	O
Vapor	O
Annealing	O
:	O
Effects	O
of	O
Conformational	O
Transition	O
and	O
Conjugate	O
Length	O
.	O

A	O
fibrillar	O
morphology	O
was	O
obtained	O
,	O
compared	O
to	O
the	O
featherless	O
pristine	O
films	O
,	O
via	O
solvent	O
annealing	O
the	O
films	O
of	O
a	O
series	O
of	O
derivatives	O
of	O
poly	B-chem
(	I-chem
3	I-chem
-	I-chem
alkylthiophene	I-chem
)	I-chem
s	E-chem
(	O
P3ATs	S-chem
)	O
:	O
poly	B-chem
(	I-chem
3	I-chem
-	I-chem
dodecylthiophene	I-chem
)	E-chem
(	O
P3DDT	S-chem
)	O
,	O
poly	B-chem
(	I-chem
3,3‴	I-chem
-	I-chem
didodecyl	I-chem
-	I-chem
quaterthiophene	I-chem
)	E-chem
(	O
PQT12	S-chem
)	O
,	O
and	O
poly	B-chem
(	I-chem
2,5	I-chem
-	I-chem
bis	I-chem
(	I-chem
3	I-chem
-	I-chem
dodecylthiophen	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
)	I-chem
thieno	I-chem
[	I-chem
3,2	I-chem
-	I-chem
b	I-chem
]	I-chem
thiophene	I-chem
)	E-chem
(	O
pBTTT12	S-chem
)	O
.	O

Among	O
the	O
solvents	O
used	O
,	O
including	O
dichloromethane	S-chem
,	O
chloroform	S-chem
,	O
tetrahydrofuran	S-chem
,	O
and	O
carbon	B-chem
disulfide	E-chem
(	O
CS2	S-chem
)	O
,	O
CS2	S-chem
was	O
the	O
best	O
to	O
induce	O
fibril	O
formation	O
because	O
its	O
solubility	O
parameter	O
is	O
closest	O
to	O
those	O
of	O
the	O
P3AT	S-chem
derivatives	O
.	O

It	O
was	O
found	O
that	O
higher	O
critical	O
CS2	S-chem
vapor	O
pressures	O
were	O
needed	O
to	O
form	O
crystal	O
nuclei	O
with	O
increasing	O
conjugation	O
length	O
and	O
molecular	O
weight	O
of	O
the	O
P3AT	S-chem
derivatives	O
;	O
i.e	O
.	O
,	O
the	O
critical	O
vapor	O
pressures	O
for	O
P3DDT	S-chem
13.9k	O
and	O
PQT12	S-chem
15.5k	O
were	O
59.0	O
%	O
and	O
80.7	O
%	O
,	O
respectively	O
,	O
and	O
there	O
were	O
no	O
nuclei	O
of	O
fibrils	O
for	O
pBTTT12	S-chem
15.6k	O
with	O
the	O
highest	O
conjugation	O
length	O
,	O
even	O
at	O
a	O
CS2	S-chem
vapor	O
pressure	O
of	O
98.3	O
%	O
.	O

Meanwhile	O
,	O
at	O
the	O
highest	O
vapor	O
pressure	O
,	O
the	O
fibril	O
density	O
decreased	O
with	O
increasing	O
conjugation	O
length	O
and	O
molecular	O
weight	O
of	O
the	O
P3AT	S-chem
derivatives	O
.	O

This	O
is	O
attributed	O
to	O
the	O
rod	O
-	O
like	O
conformation	O
prevailing	O
for	O
polymers	O
with	O
larger	O
conjugation	O
length	O
and	O
higher	O
molecular	O
weight	O
during	O
solvent	O
annealing	O
,	O
making	O
the	O
conformational	O
transition	O
toward	O
coils	O
more	O
difficult	O
and	O
hindering	O
diffusion	O
of	O
molecules	O
.	O

The	O
results	O
presented	O
here	O
are	O
expected	O
to	O
be	O
helpful	O
for	O
the	O
design	O
and	O
processing	O
of	O
conjugated	O
semiconductor	O
polymers	O
.	O

Effect	O
of	O
low	O
dose	O
Bisphenol	B-chem
A	E-chem
on	O
the	O
early	O
differentiation	O
of	O
human	O
embryonic	O
stem	O
cells	O
into	O
mammary	O
epithelial	O
cells	O
.	O

It	O
has	O
been	O
previously	O
reported	O
that	O
Bisphenol	B-chem
A	E-chem
(	O
BPA	S-chem
)	O
can	O
disturb	O
the	O
development	O
of	O
mammary	O
structure	O
and	O
increase	O
the	O
risk	O
of	O
breast	O
cancer	O
in	O
experimental	O
animals	O
.	O

In	O
this	O
study	O
,	O
an	O
in	O
vitro	O
model	O
of	O
human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
differentiation	O
into	O
mammary	O
epithelial	O
cells	O
was	O
applied	O
to	O
investigate	O
the	O
effect	O
of	O
low	O
dose	O
BPA	S-chem
on	O
the	O
early	O
stages	O
of	O
mammogenesis	O
.	O

A	O
newly	O
established	O
hESC	O
line	O
was	O
directionally	O
differentiated	O
into	O
mammary	O
epithelial	O
cells	O
by	O
a	O
well	O
-	O
established	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
culture	O
system	O
.	O

The	O
differentiated	O
mammary	O
epithelial	O
cells	O
were	O
characterized	O
by	O
immunofluorescence	O
and	O
western	O
blotting	O
assay	O
,	O
and	O
were	O
called	O
induced	O
differentiated	O
mammary	O
epithelial	O
cells	O
(	O
iDMECs	O
)	O
based	O
on	O
these	O
data	O
.	O

The	O
hESCs	O
were	O
treated	O
with	O
low	O
doses	O
of	O
BPA	S-chem
range	O
10	O
(	O
-	O
9	O
)	O
-	O
10	O
(	O
-	O
6	O
)	O
M	O
during	O
the	O
differentiation	O
process	O
,	O
with	O
DMSO	S-chem
as	O
the	O
solvent	O
control	O
and	O
17	B-chem
-	I-chem
β	I-chem
-	I-chem
estrodiol	E-chem
(	O
E2	O
)	O
as	O
the	O
estrogen	O
-	O
positive	O
control	O
.	O

Our	O
results	O
showed	O
that	O
low	O
dose	O
BPA	S-chem
and	O
E2	O
could	O
influence	O
the	O
mammosphere	O
area	O
of	O
iDMECs	O
and	O
upregulate	O
the	O
expression	O
level	O
of	O
Oct4	S-geneY
and	O
Nanog	S-geneY
proteins	O
,	O
while	O
only	O
BPA	S-chem
could	O
downregulate	O
the	O
expression	O
of	O
E	B-geneY
-	I-geneY
cadherin	E-geneY
protein	O
.	O

Taken	O
together	O
,	O
this	O
study	O
provides	O
some	O
insights	O
into	O
the	O
effects	O
of	O
low	O
dose	O
BPA	S-chem
on	O
the	O
early	O
differentiation	O
stage	O
of	O
mammary	O
epithelial	O
cells	O
and	O
suggests	O
an	O
easier	O
canceration	O
status	O
of	O
iDMECs	O
under	O
the	O
effect	O
of	O
low	O
dose	O
BPA	S-chem
during	O
its	O
early	O
differentiation	O
stage	O
.	O

A	O
structural	O
and	O
functional	O
perspective	O
into	O
the	O
mechanism	O
of	O
Ca2	B-chem
+	E-chem
-	O
sensitizers	O
that	O
target	O
the	O
cardiac	O
troponin	B-geneN
complex	E-geneN
.	O

The	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
dependent	O
interaction	O
between	O
troponin	B-geneN
I	E-geneN
(	O
cTnI	S-geneN
)	O
and	O
troponin	B-geneN
C	E-geneN
(	O
cTnC	S-geneN
)	O
triggers	O
contraction	O
in	O
heart	O
muscle	O
.	O

Heart	O
failure	O
is	O
characterized	O
by	O
a	O
decrease	O
in	O
cardiac	O
output	O
,	O
and	O
compounds	O
that	O
increase	O
the	O
sensitivity	O
of	O
cardiac	O
muscle	O
to	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
have	O
therapeutic	O
potential	O
.	O

The	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
sensitizer	O
,	O
levosimendan	S-chem
,	O
targets	O
cTnC	O
;	O
however	O
,	O
detailed	O
understanding	O
of	O
its	O
mechanism	O
has	O
been	O
obscured	O
by	O
its	O
instability	O
.	O

In	O
order	O
to	O
understand	O
how	O
this	O
class	O
of	O
positive	O
inotropes	O
function	O
,	O
we	O
investigated	O
the	O
mode	O
of	O
action	O
of	O
two	O
fluorine	S-chem
containing	O
novel	O
analogs	O
of	O
levosimendan	S-chem
;	O
2',4	B-chem
'	I-chem
-	I-chem
difluoro	I-chem
(	I-chem
1,1	I-chem
'	I-chem
-	I-chem
biphenyl	I-chem
)	I-chem
-	I-chem
4	I-chem
-	I-chem
yloxy	I-chem
acetic	I-chem
acid	E-chem
(	O
dfbp	B-chem
-	I-chem
o	E-chem
)	O
and	O
2',4	B-chem
'	I-chem
-	I-chem
difluoro	I-chem
(	I-chem
1,1	I-chem
'	I-chem
-	I-chem
biphenyl	I-chem
)	I-chem
-	I-chem
4	I-chem
-	I-chem
yl	I-chem
acetic	I-chem
acid	E-chem
(	O
dfbp	S-chem
)	O
.	O

The	O
affinities	O
of	O
dfbp	S-chem
and	O
dfbp	B-chem
-	I-chem
o	E-chem
for	O
the	O
regulatory	O
domain	O
of	O
cTnC	S-geneN
were	O
measured	O
in	O
the	O
absence	O
and	O
presence	O
of	O
cTnI	O
by	O
NMR	O
spectroscopy	O
,	O
and	O
dfbp	B-chem
-	I-chem
o	E-chem
was	O
found	O
to	O
bind	O
more	O
strongly	O
than	O
dfbp	S-chem
.	O

Dfbp	B-chem
-	I-chem
o	E-chem
also	O
increased	O
the	O
affinity	O
of	O
cTnI	S-geneN
for	O
cTnC	S-geneN
.	O

Dfbp	B-chem
-	I-chem
o	E-chem
increased	O
the	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
sensitivity	O
of	O
demembranated	O
cardiac	O
trabeculae	O
in	O
a	O
manner	O
similar	O
to	O
levosimendan	S-chem
.	O

The	O
high	O
resolution	O
NMR	O
solution	O
structure	O
of	O
the	O
cTnC	S-geneN
-	O
cTnI	S-geneN
-	O
dfbp	B-chem
-	I-chem
o	E-chem
ternary	O
complex	O
showed	O
that	O
dfbp	B-chem
-	I-chem
o	E-chem
bound	O
at	O
the	O
hydrophobic	O
interface	O
formed	O
by	O
cTnC	S-geneN
and	O
cTnI	S-geneN
making	O
critical	O
interactions	O
with	O
residues	O
such	O
as	O
Arg147	O
of	O
cTnI	S-geneN
.	O

In	O
the	O
absence	O
of	O
cTnI	S-geneN
,	O
docking	O
localized	O
dfbp	B-chem
-	I-chem
o	E-chem
to	O
the	O
same	O
position	O
in	O
the	O
hydrophobic	O
groove	O
of	O
cTnC	S-geneN
.	O

The	O
structural	O
and	O
functional	O
data	O
reveal	O
that	O
the	O
levosimendan	S-chem
class	O
of	O
Ca	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
-	O
sensitizers	O
work	O
by	O
binding	O
to	O
the	O
regulatory	O
domain	O
of	O
cTnC	S-geneN
and	O
stabilizing	O
the	O
pivotal	O
cTnC	S-geneN
-	O
cTnI	S-geneN
regulatory	O
unit	O
via	O
a	O
network	O
of	O
hydrophobic	O
and	O
electrostatic	O
interactions	O
,	O
in	O
contrast	O
to	O
the	O
destabilizing	O
effects	O
of	O
antagonists	O
such	O
as	O
W7	O
at	O
the	O
same	O
interface	O
.	O

Artemisinic	B-chem
acid	E-chem
inhibits	O
melanogenesis	O
through	O
downregulation	O
of	O
C	B-geneY
/	I-geneY
EBP	I-geneY
α	E-geneY
-	O
dependent	O
expression	O
of	O
HMG	B-geneY
-	I-geneY
CoA	I-geneY
reductase	E-geneY
gene	O
.	O

Cholesterol	S-chem
is	O
associated	O
with	O
the	O
regulation	O
of	O
melanogenesis	O
which	O
is	O
the	O
major	O
physiological	O
defense	O
against	O
solar	O
irradiation	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
determine	O
the	O
effects	O
of	O
artemisinic	B-chem
acid	E-chem
on	O
melanogenesis	O
and	O
its	O
mechanisms	O
of	O
action	O
in	O
human	O
epidermal	O
melanocytes	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
artemisinic	B-chem
acid	E-chem
inhibited	O
melanin	O
content	O
.	O

The	O
mRNA	O
levels	O
of	O
microphthalmia	B-geneY
-	I-geneY
associated	I-geneY
transcription	I-geneY
factor	E-geneY
(	O
MITF	S-geneY
)	O
and	O
its	O
downstream	O
genes	O
tyrosinase	S-geneY
,	O
tyrosinase	B-geneY
-	I-geneY
related	I-geneY
protein	I-geneY
(	I-geneY
TRP	I-geneY
)	I-geneY
-	I-geneY
1	E-geneY
,	O
and	O
TRP	B-geneY
-	I-geneY
2	E-geneY
were	O
reduced	O
by	O
artemisinic	B-chem
acid	E-chem
treatment	O
.	O

Additionally	O
,	O
the	O
mRNA	O
levels	O
of	O
melanogenesis	O
-	O
related	O
genes	O
(	O
c	B-geneY
-	I-geneY
KIT	E-geneY
,	O
stem	B-geneY
cell	I-geneY
factor	E-geneY
(	O
SCF	S-geneY
)	O
,	O
and	O
macrophage	B-geneY
migration	I-geneY
inhibitory	I-geneY
factor	E-geneY
(	O
MIF	S-geneY
)	O
)	O
were	O
down	O
-	O
regulated	O
by	O
artemisinic	B-chem
acid	E-chem
.	O

Furthermore	O
,	O
cAMP	S-chem
production	O
and	O
protein	B-geneN
kinase	I-geneN
A	E-geneN
(	O
PKA	S-geneN
)	O
activity	O
were	O
suppressed	O
by	O
artemisinic	B-chem
acid	E-chem
.	O

Moreover	O
,	O
attempts	O
to	O
elucidate	O
a	O
possible	O
mechanism	O
underlying	O
the	O
artemisinic	B-chem
acid	E-chem
-	O
mediated	O
effects	O
revealed	O
that	O
artemisinic	B-chem
acid	E-chem
regulated	O
melanogenesis	O
by	O
inhibiting	O
cholesterol	S-chem
synthesis	O
through	O
downregulation	O
of	O
the	O
hydroxymethylglutaryl	B-geneY
CoA	I-geneY
(	I-geneY
HMG	I-geneY
CoA	I-geneY
)	I-geneY
reductase	E-geneY
gene	O
,	O
which	O
was	O
mediated	O
through	O
reduced	O
expression	O
of	O
the	O
CCAAT	B-geneY
/	I-geneY
enhancer	I-geneY
-	I-geneY
binding	I-geneY
protein	I-geneY
(	I-geneY
C	I-geneY
/	I-geneY
EBP	I-geneY
)	I-geneY
α	E-geneY
gene	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
inhibition	O
of	O
melanogenesis	O
by	O
artemisinic	B-chem
acid	E-chem
occurs	O
through	O
reduced	O
expression	O
of	O
the	O
HMG	B-geneY
CoA	I-geneY
reductase	E-geneY
gene	O
,	O
which	O
is	O
mediated	O
by	O
C	B-geneY
/	I-geneY
EBP	I-geneY
α	E-geneY
inhibition	O
and	O
suggest	O
that	O
artemisinic	B-chem
acid	E-chem
may	O
be	O
useful	O
as	O
a	O
hyperpigmentation	O
inhibitor	O
.	O

Effects	O
of	O
long	O
-	O
term	O
administration	O
of	O
UFT	O
plus	O
leucovorin	S-chem
on	O
colorectal	O
tumors	O
induced	O
with	O
1,2	B-chem
-	I-chem
dimethylhydrazine	E-chem
in	O
rats	O
.	O

Thymidylate	B-geneY
synthase	E-geneY
and	O
thymidine	B-geneY
kinase	E-geneY
are	O
key	O
enzymes	O
involved	O
in	O
the	O
de	O
novo	O
and	O
salvage	O
pathways	O
for	O
pyrimidine	B-chem
nucleotide	E-chem
synthesis	O
,	O
respectively	O
.	O

Thymidylate	B-geneY
synthase	E-geneY
is	O
inhibited	O
by	O
5	B-chem
-	I-chem
fluorodeoxyuridine	I-chem
monophosphate	E-chem
,	O
forming	O
an	O
inactive	O
ternary	O
complex	O
with	O
intracellular	O
folate	S-chem
.	O

We	O
investigated	O
the	O
effects	O
of	O
1	B-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
tetrahydrofuryl	I-chem
)	I-chem
-	I-chem
5	I-chem
-	I-chem
FU	E-chem
plus	O
uracil	S-chem
(	O
UFT	S-chem
)	O
with	O
or	O
without	O
leucovorin	S-chem
on	O
1,2	B-chem
-	I-chem
dimethylhydrazine	E-chem
-	O
induced	O
rat	O
colorectal	O
carcinomas	O
.	O

Thirty	O
-	O
week	O
administration	O
of	O
UFT	S-chem
with	O
or	O
without	O
leucovorin	S-chem
markedly	O
suppressed	O
both	O
colorectal	O
carcinogenesis	O
and	O
tumor	O
growth	O
,	O
resulted	O
in	O
the	O
increase	O
of	O
thymidylate	B-geneY
synthase	E-geneY
inhibition	O
and	O
the	O
decrease	O
of	O
thymidine	B-geneY
kinase	E-geneY
activity	O
in	O
the	O
tumor	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
the	O
combination	O
of	O
UFT	S-chem
with	O
leucovorin	S-chem
could	O
be	O
useful	O
in	O
the	O
development	O
of	O
pre	O
-	O
and	O
post	O
-	O
operative	O
adjuvant	O
chemotherapy	O
programs	O
.	O

Influence	O
of	O
nitrogen	S-chem
supply	O
on	O
the	O
production	O
of	O
higher	O
alcohols	S-chem
/	O
esters	S-chem
and	O
expression	O
of	O
flavour	O
-	O
related	O
genes	O
in	O
cachaça	O
fermentation	O
.	O

This	O
study	O
provides	O
the	O
first	O
attempt	O
to	O
analyse	O
the	O
influence	O
of	O
ammonium	S-chem
supplements	O
on	O
sugar	S-chem
-	O
cane	O
juice	O
fermentation	O
and	O
the	O
flavour	O
profile	O
in	O
a	O
cachaça	O
industrial	O
process	O
.	O

The	O
objective	O
was	O
to	O
find	O
a	O
relationship	O
between	O
higher	O
alcohol	S-chem
/	O
ester	S-chem
content	O
and	O
the	O
transcription	O
levels	O
of	O
the	O
main	O
genes	O
involved	O
in	O
production	O
of	O
these	O
compounds	O
under	O
cachaça	O
fermentation	O
.	O

Sugar	S-chem
-	O
cane	O
juice	O
with	O
a	O
low	O
amount	O
of	O
assimilable	O
nitrogen	S-chem
(	O
81	O
mg	O
N	O
/	O
L	O
)	O
,	O
was	O
further	O
supplemented	O
with	O
mid	O
-	O
range	O
or	O
high	O
concentrations	O
of	O
ammonium	B-chem
sulfate	E-chem
.	O

Overall	O
,	O
higher	O
alcohol	S-chem
production	O
was	O
reduced	O
by	O
ammonium	S-chem
supplementation	O
,	O
and	O
this	O
can	O
be	O
correlated	O
with	O
a	O
general	O
downregulation	O
of	O
genes	O
encoding	O
decarboxylases	S-geneN
and	O
dehydrogenases	S-geneN
of	O
the	O
Ehrlich	B-geneN
pathway	E-geneN
.	O

The	O
production	O
of	O
acetate	B-chem
esters	E-chem
was	O
enhanced	O
by	O
mid	O
-	O
range	O
ammonium	S-chem
supplementation	O
and	O
the	O
production	O
of	O
acyl	B-chem
esters	E-chem
by	O
high	O
ammonium	S-chem
supplementation	O
.	O

The	O
acyl	B-chem
esters	E-chem
could	O
be	O
correlated	O
with	O
expression	O
of	O
alcohol	B-geneY
acyl	I-geneY
-	I-geneY
transferase	I-geneY
EEB1	E-geneY
and	O
the	O
acyl	B-geneY
esterase	I-geneY
IAH1	E-geneY
.	O

Betaxolol	S-chem
,	O
a	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
antagonist	O
,	O
reduces	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
influx	O
into	O
cortical	O
synaptosomes	O
by	O
direct	O
interaction	O
with	O
Na	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
channels	E-geneN
:	O
comparison	O
with	O
other	O
beta	B-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonists	O
.	O

Betaxolol	S-chem
,	O
a	O
beta	B-geneY
(	I-geneY
1	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
antagonist	O
used	O
for	O
the	O
treatment	O
of	O
glaucoma	O
,	O
is	O
known	O
to	O
be	O
neuroprotective	O
in	O
paradigms	O
of	O
ischaemia	O
/	O
excitotoxicity	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
betaxolol	S-chem
and	O
other	O
beta	B-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonists	O
interact	O
directly	O
with	O
neurotoxin	O
binding	O
to	O
sites	O
1	O
and	O
2	O
of	O
the	O
voltage	B-geneN
-	I-geneN
sensitive	I-geneN
sodium	I-geneN
channel	E-geneN
(	O
Na	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
channel	E-geneN
)	O
in	O
rat	O
cerebrocortical	O
synaptosomes	O
.	O

Betaxolol	S-chem
inhibited	O
specific	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
batrachotoxinin	I-chem
-	I-chem
A	I-chem
20	I-chem
-	I-chem
alpha	I-chem
-	I-chem
benzoate	E-chem
(	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
BTX	I-chem
-	I-chem
B	E-chem
)	O
binding	O
to	O
neurotoxin	B-geneN
site	I-geneN
2	E-geneN
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
9.8	O
microM	O
.	O

Comparison	O
of	O
all	O
the	O
beta	B-geneN
-	I-geneN
adrenoceptor	E-geneN
antagonists	O
tested	O
revealed	O
a	O
potency	O
order	O
of	O
propranolol	S-chem
>	O
betaxolol	S-chem
approximately	O
levobetaxolol	S-chem
>	O
levobunolol	S-chem
approximately	O
carteolol	S-chem
>	O
/	O
=	O
timolol	S-chem
>	O
atenolol	S-chem
.	O

None	O
of	O
the	O
drugs	O
caused	O
a	O
significant	O
inhibition	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
saxitoxin	E-chem
binding	O
to	O
neurotoxin	B-geneN
receptor	I-geneN
site	I-geneN
1	E-geneN
,	O
even	O
at	O
concentrations	O
as	O
high	O
as	O
250	O
microM	O
.	O

Saturation	O
experiments	O
showed	O
that	O
betaxolol	S-chem
increased	O
the	O
K	O
(	O
D	O
)	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
BTX	I-chem
-	I-chem
B	E-chem
binding	O
but	O
had	O
no	O
effect	O
on	O
the	O
B	O
(	O
max	O
)	O
.	O

The	O
association	O
kinetics	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
BTX	I-chem
-	I-chem
B	E-chem
were	O
unaffected	O
by	O
betaxolol	S-chem
,	O
but	O
the	O
drug	O
significantly	O
accelerated	O
the	O
dissociation	O
rate	O
of	O
the	O
radioligand	O
.	O

These	O
findings	O
argue	O
for	O
a	O
competitive	O
,	O
indirect	O
,	O
allosteric	O
mode	O
of	O
inhibition	O
of	O
[	B-chem
(	I-chem
3	I-chem
)	I-chem
H	I-chem
]	I-chem
-	I-chem
BTX	I-chem
-	I-chem
B	E-chem
binding	O
by	O
betaxolol	S-chem
.	O

Betaxolol	S-chem
inhibited	O
veratridine	S-chem
-	O
stimulated	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
influx	O
in	O
rat	O
cortical	O
synaptosomes	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
28	O
.	O

3	O
microM	O
.	O

Carteolol	S-chem
,	O
levobunolol	S-chem
,	O
timolol	S-chem
and	O
atenolol	S-chem
were	O
significantly	O
less	O
effective	O
than	O
betaxolol	S-chem
at	O
reducing	O
veratridine	S-chem
-	O
evoked	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
influx	O
.	O

The	O
ability	O
of	O
betaxolol	S-chem
to	O
interact	O
with	O
neurotoxin	O
site	O
2	O
of	O
the	O
Na	B-geneN
(	I-geneN
+	I-geneN
)	I-geneN
channel	E-geneN
and	O
inhibit	O
Na	B-chem
(	I-chem
+	I-chem
)	E-chem
influx	O
may	O
have	O
a	O
role	O
in	O
its	O
neuroprotective	O
action	O
in	O
paradigms	O
of	O
excitotoxicity	O
/	O
ischaemia	O
and	O
in	O
its	O
therapeutic	O
effect	O
in	O
glaucoma	O
.	O

Tetrahydropyrroloquinolinone	S-chem
type	O
dual	O
inhibitors	O
of	O
aromatase	S-geneY
/	O
aldosterone	B-geneY
synthase	E-geneY
as	O
a	O
novel	O
strategy	O
for	O
breast	O
cancer	O
patients	O
with	O
elevated	O
cardiovascular	O
risks	O
.	O

The	O
application	O
of	O
aromatase	O
inhibitors	O
to	O
postmenopausal	O
breast	O
cancer	O
patients	O
increases	O
the	O
risk	O
of	O
cardiovascular	O
diseases	O
(	O
CVD	O
)	O
,	O
which	O
is	O
believed	O
to	O
be	O
caused	O
by	O
the	O
abnormally	O
high	O
concentrations	O
of	O
aldosterone	S-chem
as	O
a	O
consequence	O
of	O
the	O
estrogen	S-chem
deficiency	O
.	O

Dual	O
inhibitors	O
of	O
aromatase	S-geneY
(	O
CYP19	S-geneY
)	O
and	O
aldosterone	B-geneY
synthase	E-geneY
(	O
CYP11B2	S-geneY
)	O
are	O
therefore	O
proposed	O
as	O
a	O
novel	O
strategy	O
for	O
the	O
adjuvant	O
therapy	O
to	O
reduce	O
the	O
CVD	O
risk	O
for	O
these	O
patients	O
.	O

By	O
combining	O
decisive	O
structural	O
features	O
of	O
CYP11B2	S-geneY
and	O
CYP19	S-geneY
inhibitors	O
into	O
a	O
common	O
template	O
,	O
a	O
series	O
of	O
pyridinylmethyl	B-chem
substituted	I-chem
1,2,5,6	I-chem
-	I-chem
tetrahydro	I-chem
-	I-chem
pyrrolo	I-chem
[	I-chem
3,2,1	I-chem
-	I-chem
ij	I-chem
]	I-chem
quinolin	I-chem
-	I-chem
4	I-chem
-	I-chem
ones	E-chem
were	O
designed	O
and	O
synthesized	O
.	O

Interestingly	O
,	O
the	O
substituents	O
on	O
the	O
methylene	S-chem
bridge	O
showed	O
strong	O
influences	O
on	O
the	O
inhibitory	O
activities	O
leading	O
to	O
opposite	O
effects	O
,	O
that	O
is	O
,	O
a	O
given	O
substituent	O
showed	O
an	O
increase	O
in	O
inhibition	O
of	O
one	O
enzyme	O
,	O
while	O
it	O
led	O
to	O
a	O
decrease	O
for	O
the	O
other	O
enzyme	O
.	O

The	O
compromise	O
of	O
this	O
conflict	O
led	O
to	O
compounds	O
3j	O
,	O
3k	O
,	O
3n	O
,	O
and	O
3p	O
as	O
potent	O
and	O
selective	O
dual	O
inhibitors	O
of	O
CYP19	S-geneY
and	O
CYP11B2	S-geneY
,	O
especially	O
compound	O
3p	O
,	O
which	O
exhibited	O
IC	O
(	O
50	O
)	O
values	O
of	O
32	O
and	O
41	O
nM	O
for	O
CYP19	S-geneY
and	O
CYP11B2	S-geneY
,	O
respectively	O
,	O
and	O
a	O
high	O
selectivity	O
toward	O
CYP17	S-geneY
and	O
CYP11B1	S-geneY
.	O

This	O
compound	O
is	O
considered	O
as	O
a	O
candidate	O
for	O
further	O
evaluation	O
in	O
vivo	O
.	O

A	O
cocaine	S-chem
-	O
sensitive	O
Drosophila	B-geneY
serotonin	I-geneY
transporter	E-geneY
:	O
cloning	O
,	O
expression	O
,	O
and	O
electrophysiological	O
characterization	O
.	O

A	O
cocaine	S-chem
-	O
sensitive	O
,	O
high	O
-	O
affinity	O
Drosophila	B-geneY
serotonin	I-geneY
(	I-geneY
5	I-geneY
-	I-geneY
hydroxytryptamine	I-geneY
;	I-geneY
5HT	I-geneY
)	I-geneY
transporter	E-geneY
cDNA	O
,	O
denoted	O
dSERT1	S-geneY
,	O
was	O
isolated	O
and	O
characterized	O
in	O
oocytes	O
.	O
dSERT1	S-geneY
shows	O
little	O
transport	O
of	O
other	O
monoamines	S-chem
and	O
is	O
Na	B-chem
+	E-chem
and	O
Cl	B-chem
-	E-chem
dependent	O
.	O

Sequence	O
analysis	O
indicates	O
12	O
putative	O
transmembrane	O
domains	O
and	O
strong	O
homologies	O
(	O
approximately	O
50	O
%	O
)	O
among	O
dSERT1	S-geneY
and	O
mammalian	B-geneN
5HT	I-geneN
,	I-geneN
norepinephrine	I-geneN
,	I-geneN
and	I-geneN
dopamine	I-geneN
transporters	E-geneN
.	O

Interestingly	O
,	O
the	O
pharmacological	O
properties	O
of	O
dSERT1	S-geneY
,	O
including	O
sensitivity	O
to	O
antidepressants	O
,	O
are	O
more	O
similar	O
to	O
those	O
of	O
mammalian	B-geneN
catecholamine	I-geneN
transporters	E-geneN
than	O
to	O
mammalian	B-geneN
5HT	I-geneN
transporters	E-geneN
.	O

Two	O
-	O
electrode	O
voltage	O
-	O
clamp	O
analysis	O
demonstrated	O
5HT	S-chem
-	O
induced	O
,	O
voltage	O
-	O
dependent	O
currents	O
.	O

Cloning	O
and	O
characterization	O
of	O
dSERT1	S-geneY
adds	O
significantly	O
to	O
our	O
knowledge	O
of	O
the	O
diversity	O
of	O
5HT	B-geneY
transporters	E-geneY
with	O
regard	O
to	O
primary	O
sequence	O
,	O
pharmacological	O
profile	O
,	O
and	O
permeation	O
properties	O
.	O

Long	O
range	O
effect	O
of	O
mutations	O
on	O
specific	O
conformational	O
changes	O
in	O
the	O
extracellular	O
loop	O
2	O
of	O
angiotensin	B-geneY
II	I-geneY
type	I-geneY
1	I-geneY
receptor	E-geneY
.	O

The	O
topology	O
of	O
the	O
second	O
extracellular	O
loop	O
(	O
ECL2	O
)	O
and	O
its	O
interaction	O
with	O
ligands	O
is	O
unique	O
in	O
each	O
G	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptor	E-geneN
.	O

When	O
the	O
orthosteric	O
ligand	O
pocket	O
located	O
in	O
the	O
transmembrane	O
(	O
TM	O
)	O
domain	O
is	O
occupied	O
,	O
ligand	O
-	O
specific	O
conformational	O
changes	O
occur	O
in	O
the	O
ECL2	O
.	O

In	O
more	O
than	O
90	O
%	O
of	O
G	B-geneN
protein	I-geneN
-	I-geneN
coupled	I-geneN
receptors	E-geneN
,	O
ECL2	O
is	O
tethered	O
to	O
the	O
third	O
TM	O
helix	O
via	O
a	O
disulfide	O
bond	O
.	O

Therefore	O
,	O
understanding	O
the	O
extent	O
to	O
which	O
the	O
TM	O
domain	O
and	O
ECL2	O
conformations	O
are	O
coupled	O
is	O
useful	O
.	O

To	O
investigate	O
this	O
,	O
we	O
examined	O
conformational	O
changes	O
in	O
ECL2	O
of	O
the	O
angiotensin	B-geneY
II	I-geneY
type	I-geneY
1	I-geneY
receptor	E-geneY
(	O
AT1R	S-geneY
)	O
by	O
introducing	O
mutations	O
in	O
distant	O
sites	O
that	O
alter	O
the	O
activation	O
state	O
equilibrium	O
of	O
the	O
AT1R	S-geneY
.	O

Differential	O
accessibility	O
of	O
reporter	O
cysteines	S-chem
introduced	O
at	O
four	O
conformation	O
-	O
sensitive	O
sites	O
in	O
ECL2	O
of	O
these	O
mutants	O
was	O
measured	O
.	O

Binding	O
of	O
the	O
agonist	O
angiotensin	B-geneY
II	E-geneY
(	O
AngII	S-geneY
)	O
and	O
inverse	O
agonist	O
losartan	S-chem
in	O
wild	O
-	O
type	O
AT1R	S-geneY
changed	O
the	O
accessibility	O
of	O
reporter	O
cysteines	S-chem
,	O
and	O
the	O
pattern	O
was	O
consistent	O
with	O
ligand	O
-	O
specific	O
``	O
lid	O
``	O
conformations	O
of	O
ECL2	O
.	O

Without	O
agonist	O
stimulation	O
,	O
the	O
ECL2	O
in	O
the	O
gain	O
of	O
function	O
mutant	O
N111G	S-geneN
assumed	O
a	O
lid	O
conformation	O
similar	O
to	O
AngII	S-geneY
-	O
bound	O
wild	O
-	O
type	O
AT1R	S-geneY
.	O

In	O
the	O
presence	O
of	O
inverse	O
agonists	O
,	O
the	O
conformation	O
of	O
ECL2	O
in	O
the	O
N111G	S-geneN
mutant	O
was	O
similar	O
to	O
the	O
inactive	O
state	O
of	O
wild	O
-	O
type	O
AT1R	S-geneY
.	O

In	O
contrast	O
,	O
AngII	S-geneY
did	O
not	O
induce	O
a	O
lid	O
conformation	O
in	O
ECL2	O
in	O
the	O
loss	O
of	O
function	O
D281A	S-geneN
mutant	O
,	O
which	O
is	O
consistent	O
with	O
the	O
reduced	O
AngII	S-geneY
binding	O
affinity	O
in	O
this	O
mutant	O
.	O

However	O
,	O
a	O
lid	O
conformation	O
was	O
induced	O
by	O
[	O
Sar	S-chem
(	O
1	O
)	O
,	O
Gln	S-chem
(	O
2	O
)	O
,	O
Ile	S-chem
(	O
8	O
)	O
]	O
AngII	S-geneY
,	O
a	O
specific	O
analog	O
that	O
binds	O
to	O
the	O
D281A	S-geneN
mutant	O
with	O
better	O
affinity	O
than	O
AngII	S-geneY
.	O

These	O
results	O
provide	O
evidence	O
for	O
the	O
emerging	O
paradigm	O
of	O
domain	O
coupling	O
facilitated	O
by	O
long	O
range	O
interactions	O
at	O
distant	O
sites	O
on	O
the	O
same	O
receptor	O
.	O

Estimation	O
of	O
warfarin	S-chem
maintenance	O
dose	O
based	O
on	O
VKORC1	S-geneY
(	O
-	B-geneN
1639	I-geneN
G	I-geneN
>	I-geneN
A	E-geneN
)	O
and	O
CYP2C9	S-geneY
genotypes	O
.	O

BACKGROUND	O
:	O
CYP2C9	S-geneY
polymorphisms	O
are	O
associated	O
with	O
decreased	O
S	B-chem
-	I-chem
warfarin	E-chem
clearance	O
and	O
lower	O
maintenance	O
dosage	O
.	O

Decreased	O
expression	O
of	O
VKORC1	S-geneY
resulting	O
from	O
the	O
-	B-geneN
1639G	I-geneN
>	I-geneN
A	E-geneN
substitution	O
has	O
also	O
been	O
implicated	O
in	O
lower	O
warfarin	S-chem
dose	O
requirements	O
.	O

We	O
investigated	O
the	O
additional	O
contribution	O
of	O
this	O
polymorphism	O
to	O
the	O
variance	O
in	O
warfarin	S-chem
dose	O
.	O

METHODS	O
:	O
Sixty	O
-	O
five	O
patients	O
with	O
stable	O
anticoagulation	O
were	O
genotyped	O
for	O
CYP2C9	S-geneY
and	O
VKORC1	S-geneY
with	O
Tag	O
-	O
It	O
allele	O
-	O
specific	O
primer	O
extension	O
technology	O
.	O

Plasma	O
S	B-chem
-	I-chem
warfarin	E-chem
concentrations	O
and	O
warfarin	S-chem
maintenance	O
dose	O
were	O
compared	O
among	O
patients	O
on	O
the	O
basis	O
of	O
the	O
VKORC1	S-geneY
-	B-geneN
1639G	I-geneN
>	I-geneN
A	E-geneN
genotype	O
.	O

RESULTS	O
:	O
Eighty	O
percent	O
of	O
CYP2C9	S-geneY
*	O
1	O
/	O
*	O
1	O
patients	O
stabilized	O
on	O
<	O
4.0	O
mg	O
/	O
day	O
warfarin	S-chem
had	O
at	O
least	O
1	O
VKORC1	S-geneY
-	O
1639A	O
allele	O
.	O

Mean	O
warfarin	S-chem
doses	O
(	O
SD	O
)	O
were	O
6.7	O
(	O
3.3	O
)	O
,	O
4.3	O
(	O
2.2	O
)	O
,	O
and	O
2.7	O
(	O
1.2	O
)	O
mg	O
/	O
day	O
for	O
patients	O
with	O
the	O
VKORC1	S-geneY
-	O
1639GG	O
,	O
GA	O
,	O
and	O
AA	O
genotypes	O
,	O
respectively	O
.	O

Steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
S	B-chem
-	I-chem
warfarin	E-chem
were	O
lowest	O
in	O
patients	O
with	O
the	O
VKORC1	S-geneY
-	O
1639AA	O
genotype	O
and	O
demonstrated	O
a	O
positive	O
association	O
with	O
the	O
VKORC1	S-geneY
-	O
1639G	O
allele	O
copy	O
number	O
(	O
trend	O
P	O
=	O
0.012	O
)	O
.	O

A	O
model	O
including	O
VKORC1	S-geneY
and	O
CYP2C9	S-geneY
genotypes	O
,	O
age	O
,	O
sex	O
,	O
and	O
body	O
weight	O
accounted	O
for	O
61	O
%	O
of	O
the	O
variance	O
in	O
warfarin	S-chem
daily	O
maintenance	O
dose	O
.	O

CONCLUSIONS	O
:	O
The	O
VKORC1	S-geneY
-	O
1639A	O
allele	O
accounts	O
for	O
low	O
dosage	O
requirements	O
of	O
most	O
patients	O
without	O
a	O
CYP2C9	S-geneY
variant	O
.	O

Higher	O
plasma	O
S	B-chem
-	I-chem
warfarin	E-chem
concentrations	O
corresponding	O
to	O
increased	O
warfarin	S-chem
maintenance	O
dosages	O
support	O
a	O
hypothesis	O
for	O
increased	O
expression	O
of	O
the	O
VKORC1	S-geneY
-	O
1639G	O
allele	O
.	O

VKORC1	S-geneY
and	O
CYP2C9	S-geneY
genotypes	O
,	O
age	O
,	O
sex	O
,	O
and	O
body	O
weight	O
account	O
for	O
the	O
majority	O
of	O
variance	O
in	O
warfarin	S-chem
dose	O
among	O
our	O
study	O
population	O
.	O

Neoechinulin	B-chem
A	E-chem
suppresses	O
amyloid	B-geneY
-	I-geneY
β	E-geneY
oligomer	O
-	O
induced	O
microglia	O
activation	O
and	O
thereby	O
protects	O
PC	O
-	O
12	O
cells	O
from	O
inflammation	O
-	O
mediated	O
toxicity	O
.	O

A	O
pathological	O
hallmark	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
aggregation	O
and	O
deposition	O
of	O
amyloid	B-geneY
-	I-geneY
β	I-geneY
peptides	E-geneY
,	O
has	O
been	O
recognized	O
as	O
a	O
potent	O
activator	O
of	O
microglia	O
-	O
mediated	O
neuroinflammation	O
and	O
neuronal	O
dysfunction	O
.	O

Therefore	O
,	O
downregulation	O
of	O
microglial	O
activation	O
has	O
a	O
significant	O
therapeutic	O
demand	O
.	O

In	O
this	O
study	O
,	O
focus	O
was	O
given	O
to	O
evaluate	O
the	O
ability	O
of	O
neoechinulin	B-chem
A	E-chem
,	O
an	O
indole	S-chem
alkaloid	O
isolated	O
from	O
marine	O
-	O
derived	O
Microsporum	O
sp	O
.	O
,	O
to	O
attenuate	O
microglial	O
activation	O
by	O
oligomeric	O
amyloid	B-geneY
-	I-geneY
β	I-geneY
1	I-geneY
-	I-geneY
42	E-geneY
(	O
Aβ42	S-geneY
)	O
.	O

Neoechinulin	B-chem
A	E-chem
treatment	O
significantly	O
inhibited	O
the	O
generation	O
of	O
reactive	O
oxygen	S-chem
and	O
nitrogen	S-chem
species	O
in	O
Aβ42	S-geneY
-	O
activated	O
BV	O
-	O
2	O
microglia	O
cells	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
neoechinulin	B-chem
A	E-chem
significantly	O
suppressed	O
the	O
production	O
of	O
neurotoxic	O
inflammatory	O
mediator	O
tumour	B-geneY
necrosis	I-geneY
factor	I-geneY
-	I-geneY
α	E-geneY
(	O
TNF	B-geneY
-	I-geneY
α	E-geneY
)	O
,	O
interleukin	B-geneY
-	I-geneY
1β	E-geneY
(	O
IL	B-geneY
-	I-geneY
1β	E-geneY
)	O
,	O
interleukin	B-geneY
-	I-geneY
6	E-geneY
(	O
IL	B-geneY
-	I-geneY
6	E-geneY
)	O
,	O
and	O
prostaglandin	B-chem
E2	E-chem
(	O
PGE2	S-chem
)	O
in	O
activated	O
BV	O
-	O
2	O
cells	O
.	O

Moreover	O
,	O
the	O
treatment	O
downregulated	O
the	O
protein	O
and	O
gene	O
expressions	O
of	O
inducible	B-geneY
nitric	I-geneY
oxide	I-geneY
synthase	E-geneY
(	O
iNOS	S-geneY
)	O
,	O
cyclooxygenase	B-geneY
-	I-geneY
2	E-geneY
(	O
COX	B-geneY
-	I-geneY
2	E-geneY
)	O
,	O
TNF	B-geneY
-	I-geneY
α	E-geneY
,	O
IL	B-geneY
-	I-geneY
1β	E-geneY
and	O
IL	B-geneY
-	I-geneY
6	E-geneY
.	O

Further	O
,	O
activated	O
microglia	O
-	O
mediated	O
apoptosis	O
of	O
PC	O
-	O
12	O
pheochromocytoma	O
cells	O
was	O
significantly	O
repressed	O
by	O
neoechinulin	B-chem
A	E-chem
.	O

The	O
molecular	O
mechanism	O
studies	O
suggested	O
that	O
neoechinulin	B-chem
A	E-chem
may	O
block	O
the	O
phosphorylation	O
of	O
mitogen	B-geneN
-	I-geneN
activated	I-geneN
protein	I-geneN
kinase	E-geneN
(	O
MAPK	S-geneN
)	O
molecule	O
p38	S-geneN
,	O
apoptosis	B-geneY
signal	I-geneY
-	I-geneY
regulating	I-geneY
kinase	I-geneY
1	E-geneY
(	O
ASK	B-geneY
-	I-geneY
1	E-geneY
)	O
and	O
nuclear	O
translocation	O
of	O
nuclear	B-geneN
factor	I-geneN
-	I-geneN
κB	E-geneN
(	O
NF	B-geneN
-	I-geneN
κB	E-geneN
)	O
p65	S-geneY
and	O
p50	S-geneY
subunits	O
.	O

Regulation	O
of	O
these	O
signalling	O
pathways	O
have	O
most	O
probably	O
contributed	O
to	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
neoechinulin	B-chem
A	E-chem
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
with	O
further	O
studies	O
neoechinulin	B-chem
A	E-chem
have	O
a	O
potential	O
to	O
be	O
developed	O
as	O
a	O
modulator	O
of	O
neuroinflammatory	O
process	O
in	O
AD	O
.	O

Global	O
analysis	O
of	O
Drosophila	B-geneN
Cys2	I-geneN
-	I-geneN
His2	I-geneN
zinc	I-geneN
finger	I-geneN
proteins	E-geneN
reveals	O
a	O
multitude	O
of	O
novel	O
recognition	O
motifs	O
and	O
binding	O
determinants	O
.	O

Cys2	B-geneN
-	I-geneN
His2	I-geneN
zinc	I-geneN
finger	I-geneN
proteins	E-geneN
(	O
ZFPs	S-geneN
)	O
are	O
the	O
largest	O
group	O
of	O
transcription	O
factors	O
in	O
higher	O
metazoans	O
.	O

A	O
complete	O
characterization	O
of	O
these	O
ZFPs	S-geneN
and	O
their	O
associated	O
target	O
sequences	O
is	O
pivotal	O
to	O
fully	O
annotate	O
transcriptional	O
regulatory	O
networks	O
in	O
metazoan	O
genomes	O
.	O

As	O
a	O
first	O
step	O
in	O
this	O
process	O
,	O
we	O
have	O
characterized	O
the	O
DNA	O
-	O
binding	O
specificities	O
of	O
129	O
zinc	B-geneN
finger	E-geneN
sets	O
from	O
Drosophila	O
using	O
a	O
bacterial	O
one	O
-	O
hybrid	O
system	O
.	O

This	O
data	O
set	O
contains	O
the	O
DNA	O
-	O
binding	O
specificities	O
for	O
at	O
least	O
one	O
encoded	O
ZFP	S-geneN
from	O
70	O
unique	O
genes	O
and	O
23	O
alternate	O
splice	O
isoforms	O
representing	O
the	O
largest	O
set	O
of	O
characterized	O
ZFPs	S-geneN
from	O
any	O
organism	O
described	O
to	O
date	O
.	O

These	O
recognition	O
motifs	O
can	O
be	O
used	O
to	O
predict	O
genomic	O
binding	O
sites	O
for	O
these	O
factors	O
within	O
the	O
fruit	O
fly	O
genome	O
.	O

Subsets	O
of	O
fingers	O
from	O
these	O
ZFPs	S-geneN
were	O
characterized	O
to	O
define	O
their	O
orientation	O
and	O
register	O
on	O
their	O
recognition	O
sequences	O
,	O
thereby	O
allowing	O
us	O
to	O
define	O
the	O
recognition	O
diversity	O
within	O
this	O
finger	O
set	O
.	O

We	O
find	O
that	O
the	O
characterized	O
fingers	O
can	O
specify	O
47	O
of	O
the	O
64	O
possible	O
DNA	O
triplets	O
.	O

To	O
confirm	O
the	O
utility	O
of	O
our	O
finger	O
recognition	O
models	O
,	O
we	O
employed	O
subsets	O
of	O
Drosophila	O
fingers	O
in	O
combination	O
with	O
an	O
existing	O
archive	O
of	O
artificial	O
zinc	B-geneN
finger	E-geneN
modules	O
to	O
create	O
ZFPs	S-geneN
with	O
novel	O
DNA	O
-	O
binding	O
specificity	O
.	O

These	O
hybrids	O
of	O
natural	O
and	O
artificial	O
fingers	O
can	O
be	O
used	O
to	O
create	O
functional	O
zinc	B-geneN
finger	I-geneN
nucleases	E-geneN
for	O
editing	O
vertebrate	O
genomes	O
.	O

Interactions	O
of	O
PGH	B-geneN
synthase	I-geneN
isozymes	I-geneN
-	I-geneN
1	I-geneN
and	I-geneN
-	I-geneN
2	E-geneN
with	O
NSAIDs	O
.	O

There	O
are	O
two	O
isozymes	O
of	O
prostaglandin	B-geneN
endoperoxide	I-geneN
(	I-geneN
PGH	I-geneN
)	I-geneN
synthase	E-geneN
(	O
cyclooxygenase	S-geneN
)	O
called	O
PGH	B-geneN
synthase	I-geneN
-	I-geneN
1	I-geneN
and	I-geneN
-	I-geneN
2	E-geneN
or	O
COX	B-geneN
I	I-geneN
and	I-geneN
II	E-geneN
.	O

Both	O
isozymes	O
catalyze	O
the	O
same	O
two	O
reactions	O
:	O
oxygenation	O
of	O
arachidonate	S-chem
to	O
yield	O
PGG2	O
and	O
reduction	O
of	O
PGG2	O
to	O
PGH2	O
.	O

PGH	B-geneY
synthase	I-geneY
-	I-geneY
1	E-geneY
is	O
expressed	O
constitutively	O
and	O
is	O
found	O
in	O
most	O
tissues	O
.	O

PGH	B-geneY
synthase	I-geneY
-	I-geneY
2	E-geneY
is	O
undetectable	O
in	O
most	O
cells	O
but	O
can	O
be	O
induced	O
in	O
fibroblasts	O
,	O
endothelial	O
cells	O
,	O
ovarian	O
follicles	O
,	O
and	O
macrophages	O
by	O
various	O
mitogens	O
,	O
cytokines	S-geneN
,	O
and	O
tumor	O
promoters	O
.	O

PGH	B-geneY
synthase	I-geneY
-	I-geneY
1	E-geneY
(	O
PGHS	B-geneY
-	I-geneY
1	E-geneY
)	O
has	O
been	O
presumed	O
to	O
be	O
the	O
site	O
of	O
action	O
of	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
.	O

However	O
,	O
the	O
discovery	O
of	O
the	O
second	O
isozyme	O
,	O
PGH	B-geneY
synthase	I-geneY
-	I-geneY
2	E-geneY
(	O
PGHS	B-geneY
-	I-geneY
2	E-geneY
)	O
,	O
and	O
its	O
association	O
with	O
inflammation	O
has	O
suggested	O
that	O
this	O
latter	O
enzyme	O
may	O
be	O
the	O
therapeutic	O
target	O
of	O
NSAIDs	O
functioning	O
in	O
their	O
antiinflammatory	O
capacities	O
.	O

We	O
have	O
cloned	O
cDNAs	O
for	O
murine	O
PGHS	B-geneY
-	I-geneY
1	E-geneY
and	O
PGHS	B-geneY
-	I-geneY
2	E-geneY
,	O
expressed	O
these	O
enzymes	O
in	O
cos	O
-	O
1	O
cells	O
,	O
and	O
compared	O
the	O
relative	O
sensitivities	O
of	O
the	O
two	O
isozymes	O
to	O
some	O
common	O
NSAIDs	O
.	O

Indomethacin	S-chem
,	O
piroxicam	S-chem
,	O
and	O
sulindac	B-chem
sulfide	E-chem
were	O
found	O
to	O
preferentially	O
inhibit	O
PGHS	B-geneY
-	I-geneY
1	E-geneY
.	O

Ibuprofen	S-chem
and	O
meclofenamate	O
inhibit	O
both	O
enzymes	O
with	O
comparable	O
potencies	O
.	O

6	B-chem
-	I-chem
Methoxy	I-chem
-	I-chem
2	I-chem
-	I-chem
naphthylacetic	I-chem
acid	E-chem
,	O
the	O
active	O
metabolite	O
of	O
Relafen	S-chem
,	O
inhibits	O
murine	O
PGHS	B-geneY
-	I-geneY
2	E-geneY
preferentially	O
.	O

Aspirin	S-chem
irreversibly	O
inhibits	O
PGHS	B-geneY
-	I-geneY
1	E-geneY
,	O
preventing	O
this	O
isozyme	O
from	O
forming	O
PGH2	O
or	O
any	O
other	O
oxygenated	O
product	O
;	O
in	O
contrast	O
,	O
aspirin	S-chem
treatment	O
of	O
PGHS	B-geneY
-	I-geneY
2	E-geneY
causes	O
this	O
enzyme	O
to	O
form	O
15	B-chem
-	I-chem
hydroxy	I-chem
-	I-chem
5c,8c,11c,13t	I-chem
-	I-chem
eicosatetraenoic	I-chem
acid	E-chem
(	O
15	B-chem
-	I-chem
HETE	E-chem
)	O
instead	O
of	O
PGH2	O
.	O

Our	O
results	O
indicate	O
mouse	O
PGHS	B-geneY
-	I-geneY
1	E-geneY
and	O
PGHS	B-geneY
-	I-geneY
2	E-geneY
are	O
pharmacologically	O
distinct	O
.	O

Thus	O
,	O
it	O
should	O
be	O
possible	O
to	O
develop	O
agents	O
highly	O
selective	O
for	O
each	O
PGHS	S-geneN
isozyme	O
.	O

PGHS	B-geneY
-	I-geneY
2	E-geneY
is	O
not	O
expressed	O
in	O
stomach	O
but	O
is	O
increased	O
by	O
inflammatory	O
cytokines	S-geneN
in	O
cells	O
such	O
as	O
macrophages	O
.	O

Thus	O
,	O
a	O
selective	O
inhibitor	O
of	O
PGHS	B-geneY
-	I-geneY
2	E-geneY
could	O
be	O
an	O
antiinflammatory	O
agent	O
but	O
without	O
being	O
ulcerogenic	O
.	O

Serum	O
carvedilol	S-chem
concentration	O
and	O
its	O
relation	O
to	O
change	O
in	O
plasma	O
brain	B-geneY
natriuretic	I-geneY
peptide	E-geneY
level	O
in	O
the	O
treatment	O
of	O
heart	O
failure	O
:	O
a	O
preliminary	O
study	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
influence	O
of	O
carvedilol	S-chem
dose	O
and	O
concentration	O
in	O
serum	O
on	O
plasma	O
brain	B-geneY
natriuretic	I-geneY
peptide	E-geneY
(	O
BNP	S-geneY
)	O
,	O
a	O
measure	O
of	O
heart	O
failure	O
progression	O
.	O

METHODS	O
:	O
12	O
patients	O
with	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
functional	O
class	O
II	O
-	O
III	O
chronic	O
heart	O
failure	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

They	O
received	O
carvedilol	S-chem
at	O
daily	O
doses	O
of	O
1	O
-	O
20	O
mg	O
with	O
a	O
1	O
-	O
2	O
weekly	O
adjustment	O
.	O

Serum	O
carvedilol	S-chem
trough	O
concentrations	O
were	O
measured	O
in	O
steady	O
-	O
state	O
using	O
a	O
specific	O
fluorescence	O
HPLC	O
method	O
.	O

The	O
degree	O
of	O
improvement	O
in	O
heart	O
failure	O
was	O
assessed	O
from	O
the	O
ratio	O
of	O
change	O
in	O
the	O
plasma	O
BNP	S-geneY
concentration	O
,	O
2	O
weeks	O
,	O
1	O
month	O
and	O
3	O
months	O
after	O
the	O
commencement	O
of	O
carvedilol	S-chem
administration	O
.	O

RESULTS	O
:	O
From	O
the	O
pharmacokinetic	O
aspect	O
,	O
there	O
was	O
no	O
valid	O
correlation	O
between	O
the	O
trough	O
serum	O
carvedilol	S-chem
concentration	O
(	O
Cmin	O
)	O
and	O
daily	O
dose	O
per	O
body	O
weight	O
(	O
Dd	O
/	O
BW	O
)	O
,	O
indicating	O
that	O
there	O
was	O
a	O
wide	O
difference	O
in	O
the	O
carvedilol	S-chem
elimination	O
capacity	O
among	O
individuals	O
.	O

A	O
significant	O
decrease	O
in	O
the	O
BNP	S-geneY
was	O
observed	O
at	O
the	O
3rd	O
month	O
in	O
patients	O
treated	O
with	O
the	O
high	O
dose	O
(	O
>	O
750	O
mg	O
/	O
3	O
months	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
patients	O
with	O
a	O
mean	O
serum	O
carvedilol	S-chem
level	O
(	O
Cmin	O
)	O
of	O
less	O
than	O
2.5	O
nmol	O
/	O
l	O
up	O
to	O
2	O
weeks	O
after	O
the	O
start	O
ofcarvedilol	O
therapy	O
,	O
the	O
degree	O
of	O
reduction	O
in	O
the	O
BNP	S-geneY
value	O
after	O
the	O
3rd	O
month	O
was	O
significantly	O
larger	O
,	O
relative	O
to	O
the	O
patient	O
group	O
with	O
Cmin	O
over	O
2.5	O
nmol	O
/	O
l	O
.	O

CONCLUSIONS	O
:	O
The	O
total	O
carvedilol	S-chem
dose	O
was	O
confirmed	O
to	O
be	O
one	O
of	O
the	O
determinants	O
for	O
improvement	O
in	O
heart	O
failure	O
,	O
and	O
it	O
was	O
suggested	O
that	O
the	O
initial	O
serum	O
level	O
also	O
plays	O
an	O
important	O
role	O
in	O
therapeutic	O
outcome	O
.	O

Therefore	O
,	O
it	O
may	O
be	O
important	O
to	O
monitor	O
the	O
serum	O
carvedilol	S-chem
level	O
at	O
the	O
introductory	O
period	O
to	O
determine	O
the	O
daily	O
dose	O
requirements	O
because	O
of	O
the	O
wide	O
inter	O
-	O
individual	O
variability	O
in	O
its	O
metabolic	O
clearance	O
.	O

Biosynthesis	O
,	O
assembly	O
and	O
secretion	O
of	O
coagulation	B-geneY
factor	I-geneY
VIII	E-geneY
.	O

Factor	B-geneY
VIII	E-geneY
is	O
a	O
large	O
complex	O
glycoprotein	O
that	O
is	O
deficient	O
in	O
hemophilia	O
A	O
.	O

It	O
has	O
a	O
domain	O
organization	O
consisting	O
of	O
A1	B-geneN
-	I-geneN
A2	I-geneN
-	I-geneN
B	I-geneN
-	I-geneN
A3	I-geneN
-	I-geneN
C1	I-geneN
-	I-geneN
C2	E-geneN
where	O
the	O
B	B-geneN
domain	E-geneN
is	O
a	O
heavily	O
glycosylated	O
region	O
that	O
is	O
dispensable	O
for	O
procoagulant	O
activity	O
.	O

Factor	B-geneY
VIII	E-geneY
expression	O
is	O
10	O
-	O
to	O
20	O
-	O
fold	O
lower	O
than	O
the	O
homologous	O
coagulation	B-geneY
factor	I-geneY
V	E-geneY
.	O

Factor	B-geneY
VIII	E-geneY
expression	O
is	O
limited	O
due	O
to	O
a	O
low	O
level	O
of	O
steady	O
-	O
state	O
messenger	O
RNA	O
in	O
the	O
cytoplasm	O
and	O
inefficient	O
transport	O
of	O
the	O
primary	O
translation	O
product	O
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
apparatus	O
.	O

Within	O
the	O
secretory	O
pathway	O
,	O
factor	B-geneY
VIII	E-geneY
is	O
processed	O
to	O
a	O
heterodimer	O
of	O
the	O
heavy	O
chain	O
(	O
domains	B-geneN
A1	I-geneN
-	I-geneN
A2	I-geneN
-	I-geneN
B	E-geneN
)	O
in	O
a	O
metal	O
ion	O
association	O
with	O
the	O
light	O
chain	O
(	O
domains	B-geneN
A3	I-geneN
-	I-geneN
C1	I-geneN
-	I-geneN
C2	E-geneN
)	O
.	O

Upon	O
secretion	O
from	O
the	O
cell	O
,	O
von	B-geneY
Willebrand	I-geneY
factor	E-geneY
binds	O
the	O
light	B-geneY
chain	I-geneY
of	I-geneY
factor	I-geneY
VIII	E-geneY
and	O
stabilizes	O
the	O
factor	O
,	O
preventing	O
degradation	O
.	O

Protein	O
folding	O
within	O
the	O
mammalian	O
secretory	O
pathway	O
is	O
facilitated	O
by	O
molecular	B-geneN
chaperones	E-geneN
.	O

Within	O
the	O
endoplasmic	O
reticulum	O
,	O
factor	B-geneY
VIII	E-geneY
exhibits	O
stable	O
interaction	O
with	O
protein	O
chaperones	O
identified	O
as	O
the	O
immunoglobulin	B-geneY
-	I-geneY
binding	I-geneY
protein	E-geneY
(	O
BiP	S-geneY
)	O
,	O
calnexin	S-geneY
and	O
calreticulin	S-geneY
.	O

BiP	S-geneY
is	O
a	O
peptide	O
-	O
dependent	O
ATPase	S-geneN
that	O
interacts	O
with	O
exposed	O
hydrophobic	O
surfaces	O
on	O
unfolded	O
proteins	O
or	O
unassembled	O
protein	O
subunits	O
.	O

A	O
potential	O
BiP	B-geneN
binding	I-geneN
site	E-geneN
within	O
factor	B-geneY
VIII	E-geneY
has	O
been	O
identified	O
.	O

Mutation	O
of	O
a	O
single	O
amino	B-chem
acid	E-chem
residue	O
in	O
the	O
potential	O
BiP	B-geneN
binding	I-geneN
site	E-geneN
increased	O
the	O
secretion	O
efficiency	O
of	O
factor	B-geneY
VIII	E-geneY
by	O
threefold	O
.	O

Interestingly	O
,	O
the	O
proposed	O
BiP	B-geneN
binding	I-geneN
site	E-geneN
is	O
adjacent	O
to	O
a	O
type	B-geneN
-	I-geneN
1	I-geneN
copper	I-geneN
binding	I-geneN
site	E-geneN
within	O
the	O
A1	B-geneN
domain	E-geneN
that	O
is	O
required	O
for	O
interaction	O
between	O
the	O
factor	B-geneN
VIII	I-geneN
A1	I-geneN
domain	E-geneN
and	O
the	O
A3	B-geneN
domain	E-geneN
.	O

We	O
propose	O
that	O
Cu	B-chem
(	I-chem
I	I-chem
)	E-chem
binds	O
the	O
type	B-geneN
-	I-geneN
1	I-geneN
copper	I-geneN
ion	I-geneN
-	I-geneN
binding	I-geneN
site	E-geneN
in	O
the	O
A1	B-geneN
domain	E-geneN
and	O
provides	O
the	O
essential	O
requirement	O
for	O
a	O
stable	O
interaction	O
between	O
the	O
heavy	O
and	O
light	O
chains	O
.	O

Calnexin	S-geneY
and	O
calreticulin	S-geneY
are	O
transmembrane	O
and	O
lumenal	O
proteins	O
,	O
respectively	O
,	O
localized	O
to	O
the	O
endoplasmic	O
reticulum	O
,	O
which	O
associate	O
transiently	O
with	O
many	O
soluble	O
and	O
membrane	O
glycoproteins	O
during	O
folding	O
and	O
subunit	O
assembly	O
.	O

The	O
calnexin	S-geneY
and	O
calreticulin	S-geneY
interaction	O
with	O
factor	B-geneY
VIII	E-geneY
occurs	O
primarily	O
through	O
amino	S-chem
-	O
terminal	O
linked	O
oligosaccharides	O
within	O
the	O
heavily	O
glycosylated	O
factor	B-geneN
VIII	I-geneN
B	I-geneN
domain	E-geneN
and	O
this	O
interaction	O
appears	O
to	O
be	O
required	O
for	O
factor	B-geneY
VIII	E-geneY
secretion	O
.	O

The	O
findings	O
suggest	O
that	O
factor	B-geneY
VIII	E-geneY
cycles	O
through	O
interactions	O
with	O
BiP	S-geneY
,	O
calnexin	S-geneY
and	O
calreticulin	S-geneY
.	O

Although	O
the	O
interaction	O
with	O
BiP	S-geneY
does	O
not	O
appear	O
to	O
be	O
required	O
for	O
factor	B-geneY
VIII	E-geneY
secretion	O
,	O
data	O
suggest	O
that	O
the	O
calnexin	S-geneY
and	O
/	O
or	O
calreticulin	S-geneY
interaction	O
is	O
required	O
for	O
secretion	O
.	O

The	O
observations	O
suggest	O
a	O
unique	O
requirement	O
for	O
carbohydrate	S-chem
processing	O
and	O
calnexin	S-geneY
/	O
calreticulin	S-geneY
interaction	O
that	O
may	O
limit	O
the	O
productive	O
secretion	O
of	O
factor	B-geneY
VIII	E-geneY
and	O
have	O
implications	O
for	O
approaches	O
towards	O
somatic	O
cell	O
gene	O
therapy	O
for	O
hemophilia	O
A	O
.	O

Characterization	O
of	O
the	O
omega	B-geneN
class	I-geneN
of	I-geneN
glutathione	I-geneN
transferases	E-geneN
.	O

The	O
Omega	B-geneN
class	I-geneN
of	I-geneN
cytosolic	I-geneN
glutathione	I-geneN
transferases	E-geneN
was	O
initially	O
recognized	O
by	O
bioinformatic	O
analysis	O
of	O
human	O
sequence	O
databases	O
,	O
and	O
orthologous	O
sequences	O
were	O
subsequently	O
discovered	O
in	O
mouse	O
,	O
rat	O
,	O
pig	O
,	O
Caenorhabditis	O
elegans	O
,	O
Schistosoma	O
mansoni	O
,	O
and	O
Drosophila	O
melanogaster	O
.	O

In	O
humans	O
and	O
mice	O
,	O
two	O
GSTO	S-geneN
genes	O
have	O
been	O
recognized	O
and	O
their	O
genetic	O
structures	O
and	O
expression	O
patterns	O
identified	O
.	O

In	O
both	O
species	O
,	O
GSTO1	S-geneY
mRNA	O
is	O
expressed	O
in	O
liver	O
and	O
heart	O
as	O
well	O
as	O
a	O
range	O
of	O
other	O
tissues	O
.	O

GSTO2	S-geneY
is	O
expressed	O
predominantly	O
in	O
the	O
testis	O
,	O
although	O
moderate	O
levels	O
of	O
expression	O
are	O
seen	O
in	O
other	O
tissues	O
.	O

Extensive	O
immunohistochemistry	O
of	O
rat	O
and	O
human	O
tissue	O
sections	O
has	O
demonstrated	O
cellular	O
and	O
subcellular	O
specificity	O
in	O
the	O
expression	O
of	O
GSTO1	B-geneY
-	I-geneY
1	E-geneY
.	O

The	O
crystal	O
structure	O
of	O
recombinant	O
human	B-geneY
GSTO1	I-geneY
-	I-geneY
1	E-geneY
has	O
been	O
determined	O
,	O
and	O
it	O
adopts	O
the	O
canonical	O
GST	B-geneN
fold	E-geneN
.	O

A	O
cysteine	S-chem
residue	O
in	O
place	O
of	O
the	O
catalytic	O
tyrosine	S-chem
or	O
serine	S-chem
residues	O
found	O
in	O
other	O
GSTs	S-geneN
was	O
shown	O
to	O
form	O
a	O
mixed	O
disulfide	S-chem
with	O
glutathione	S-chem
.	O

Omega	B-geneN
class	I-geneN
GSTs	E-geneN
have	O
dehydroascorbate	B-geneN
reductase	E-geneN
and	O
thioltransferase	S-geneN
activities	O
and	O
also	O
catalyze	O
the	O
reduction	O
of	O
monomethylarsonate	S-chem
,	O
an	O
intermediate	O
in	O
the	O
pathway	O
of	O
arsenic	S-chem
biotransformation	O
.	O

Other	O
diverse	O
actions	O
of	O
human	B-geneY
GSTO1	I-geneY
-	I-geneY
1	E-geneY
include	O
modulation	O
of	O
ryanodine	B-geneN
receptors	E-geneN
and	O
interaction	O
with	O
cytokine	S-geneN
release	O
inhibitory	O
drugs	O
.	O

In	O
addition	O
,	O
GSTO1	S-geneY
has	O
been	O
linked	O
to	O
the	O
age	O
at	O
onset	O
of	O
both	O
Alzheimer	O
's	O
and	O
Parkinson	O
's	O
diseases	O
.	O

Several	O
polymorphisms	O
have	O
been	O
identified	O
in	O
the	O
coding	O
regions	O
of	O
the	O
human	B-geneY
GSTO1	E-geneY
and	O
GSTO2	S-geneY
genes	O
.	O

Our	O
laboratory	O
has	O
expressed	O
recombinant	O
human	B-geneY
GSTO1	I-geneY
-	I-geneY
1	E-geneY
and	O
GSTO2	B-geneY
-	I-geneY
2	E-geneY
proteins	O
,	O
as	O
well	O
as	O
a	O
number	O
of	O
polymorphic	O
variants	O
.	O

The	O
expression	O
and	O
purification	O
of	O
these	O
proteins	O
and	O
determination	O
of	O
their	O
enzymatic	O
activity	O
is	O
described	O
.	O

The	O
inhibitory	O
effect	O
of	O
ginseng	B-chem
saponins	E-chem
on	O
the	O
stress	O
-	O
induced	O
plasma	O
interleukin	B-geneY
-	I-geneY
6	E-geneY
level	O
in	O
mice	O
.	O

The	O
effect	O
of	O
ginseng	B-chem
saponins	E-chem
on	O
plasma	O
interleukin	B-geneY
-	I-geneY
6	E-geneY
(	O
IL	B-geneY
-	I-geneY
6	E-geneY
)	O
in	O
non	O
-	O
stressed	O
and	O
immobilization	O
-	O
stressed	O
mice	O
were	O
investigated	O
.	O

Ginseng	O
total	O
saponins	S-chem
,	O
ginsenosides	B-chem
Rb2	I-chem
,	I-chem
Rg1	I-chem
and	I-chem
Rd	E-chem
administered	O
intraperitoneally	O
attenuated	O
the	O
immobilization	O
stress	O
-	O
induced	O
increase	O
in	O
plasma	O
IL	B-geneY
-	I-geneY
6	E-geneY
level	O
.	O

But	O
,	O
intracerebroventricular	O
injection	O
of	O
each	O
ginsenoside	S-chem
did	O
not	O
affect	O
plasma	O
IL	B-geneY
-	I-geneY
6	E-geneY
level	O
induced	O
by	O
immobilization	O
stress	O
.	O

Ginsenosides	B-chem
Rb2	I-chem
,	I-chem
Rd	I-chem
and	I-chem
Rg1	E-chem
significantly	O
decreased	O
norepinephrine	S-chem
and	O
/	O
or	O
epinephrine	S-chem
-	O
induced	O
increase	O
of	O
IL	B-geneY
-	I-geneY
6	E-geneY
level	O
in	O
macrophage	O
cell	O
line	O
(	O
RAW	O
264.7	O
)	O
.	O

Thus	O
,	O
it	O
can	O
be	O
suggested	O
that	O
the	O
inhibitory	O
action	O
of	O
ginseng	B-chem
saponins	E-chem
against	O
the	O
immobilization	O
stress	O
-	O
induced	O
increase	O
of	O
plasma	O
IL	B-geneY
-	I-geneY
6	E-geneY
level	O
would	O
be	O
in	O
periphery	O
;	O
at	O
least	O
in	O
part	O
,	O
mediated	O
by	O
blocking	O
norepinephrine	S-chem
-	O
and	O
/	O
or	O
epinephrine	S-chem
-	O
induced	O
increase	O
of	O
IL	B-geneY
-	I-geneY
6	E-geneY
level	O
in	O
macrophage	O
rather	O
than	O
in	O
the	O
brain	O
.	O

Ginseng	B-chem
saponins	E-chem
might	O
be	O
proposed	O
as	O
a	O
possible	O
candidate	O
in	O
the	O
research	O
or	O
therapeutic	O
modulation	O
of	O
stress	O
-	O
related	O
disorders	O
.	O

Competition	O
between	O
24	O
:	O
5n	O
-	O
3	O
and	O
ALA	O
for	O
Delta	B-geneY
6	I-geneY
desaturase	E-geneY
may	O
limit	O
the	O
accumulation	O
of	O
DHA	O
in	O
HepG2	O
cell	O
membranes	O
.	O

The	O
use	O
of	O
Delta	B-geneY
6	I-geneY
desaturase	E-geneY
(	O
D6D	S-geneY
)	O
twice	O
in	O
the	O
conversion	O
of	O
alpha	B-chem
-	I-chem
linolenic	I-chem
acid	E-chem
(	O
ALA	S-chem
;	O
18	O
:	O
3n	O
-	O
3	O
)	O
to	O
docosahexaenoic	B-chem
acid	E-chem
(	O
DHA	S-chem
;	O
22	O
:	O
6n	O
-	O
3	O
)	O
suggests	O
that	O
this	O
enzyme	O
may	O
play	O
a	O
key	O
regulatory	O
role	O
in	O
the	O
synthesis	O
and	O
accumulation	O
of	O
DHA	S-chem
from	O
ALA	S-chem
.	O

We	O
examined	O
this	O
using	O
an	O
in	O
vitro	O
model	O
of	O
fatty	B-chem
acid	E-chem
metabolism	O
to	O
measure	O
the	O
accumulation	O
of	O
the	O
long	O
-	O
chain	O
metabolites	O
of	O
ALA	S-chem
in	O
HepG2	O
cell	O
phospholipids	O
.	O

The	O
accumulation	O
of	O
ALA	S-chem
,	O
eicosapentaenoic	B-chem
acid	E-chem
(	O
20	O
:	O
5n	O
-	O
3	O
)	O
,	O
docosapentaenoic	B-chem
acid	E-chem
(	O
22	O
:	O
5n	O
-	O
3	O
)	O
,	O
and	O
24	O
:	O
5n	O
-	O
3	O
in	O
cell	O
phospholipids	O
was	O
linearly	O
related	O
to	O
the	O
concentration	O
of	O
supplemented	O
ALA	S-chem
over	O
the	O
range	O
tested	O
(	O
1.8	O
-	O
72	O
microM	O
)	O
.	O

The	O
accumulation	O
of	O
the	O
post	O
-	O
D6D	S-geneY
products	O
of	O
22	O
:	O
5n	O
-	O
3	O
,	O
24	O
:	O
6n	O
-	O
3	O
and	O
DHA	S-chem
,	O
in	O
cell	O
phospholipids	O
was	O
saturated	O
at	O
concentrations	O
of	O
>	O
18	O
microM	O
ALA	S-chem
.	O

Supplementation	O
of	O
HepG2	O
cells	O
with	O
preformed	O
DHA	S-chem
revealed	O
that	O
,	O
although	O
the	O
accumulation	O
of	O
DHA	S-chem
in	O
cell	O
phospholipids	O
approached	O
saturation	O
,	O
the	O
level	O
of	O
DHA	S-chem
in	O
cell	O
phospholipids	O
was	O
significantly	O
greater	O
compared	O
with	O
the	O
accumulation	O
of	O
DHA	S-chem
from	O
ALA	S-chem
,	O
indicating	O
that	O
the	O
accumulation	O
of	O
DHA	S-chem
from	O
ALA	S-chem
was	O
not	O
limited	O
by	O
incorporation	O
.	O

The	O
parallel	O
pattern	O
of	O
accumulation	O
of	O
24	O
:	O
6n	O
-	O
3	O
and	O
DHA	S-chem
in	O
response	O
to	O
increasing	O
concentrations	O
of	O
ALA	S-chem
suggests	O
that	O
the	O
competition	O
between	O
24	O
:	O
5n	O
-	O
3	O
and	O
ALA	S-chem
for	O
D6D	S-geneY
may	O
contribute	O
to	O
the	O
limited	O
accumulation	O
of	O
DHA	S-chem
in	O
cell	O
membranes	O
.	O

Mutational	O
consequences	O
of	O
dNTP	O
pool	O
imbalances	O
in	O
E.	O
coli	O
.	O

The	O
accuracy	O
of	O
DNA	O
synthesis	O
depends	O
on	O
the	O
accuracy	O
of	O
the	O
polymerase	S-geneN
as	O
well	O
as	O
the	O
quality	O
and	O
concentration	O
(	O
s	O
)	O
of	O
the	O
available	O
5	B-chem
'	I-chem
-	I-chem
deoxynucleoside	I-chem
-	I-chem
triphosphate	E-chem
DNA	O
precursors	O
(	O
dNTPs	S-chem
)	O
.	O

The	O
relationships	O
between	O
dNTPs	S-chem
and	O
error	O
rates	O
have	O
been	O
studied	O
in	O
vitro	O
,	O
but	O
only	O
limited	O
insights	O
exist	O
into	O
these	O
correlations	O
during	O
in	O
vivo	O
replication	O
.	O

We	O
have	O
investigated	O
this	O
issue	O
in	O
the	O
bacterium	O
Escherichia	O
coli	O
by	O
analyzing	O
the	O
mutational	O
properties	O
of	O
dcd	S-geneY
and	O
ndk	S-geneY
strains	O
.	O

These	O
strains	O
,	O
defective	O
in	O
dCTP	B-geneY
deaminase	E-geneY
and	O
nucleoside	B-geneY
diphosphate	I-geneY
kinase	E-geneY
,	O
respectively	O
,	O
are	O
characterized	O
by	O
both	O
disturbances	O
of	O
dNTP	S-chem
pools	O
and	O
a	O
mutator	O
phenotype	O
.	O
ndk	S-geneY
strains	O
have	O
been	O
studied	O
before	O
,	O
but	O
were	O
included	O
in	O
this	O
study	O
,	O
as	O
controversies	O
exist	O
regarding	O
the	O
source	O
of	O
its	O
mutator	O
phenotype	O
.	O

We	O
show	O
that	O
dcd	S-geneY
strains	O
suffer	O
from	O
increased	O
intracellular	O
levels	O
of	O
dCTP	S-chem
(	O
4	O
-	O
fold	O
)	O
and	O
reduced	O
levels	O
of	O
dGTP	S-chem
(	O
2	O
-	O
fold	O
)	O
,	O
while	O
displaying	O
,	O
as	O
measured	O
using	O
a	O
set	O
of	O
lacZ	O
reversion	O
markers	O
in	O
a	O
mismatch	O
-	O
repair	O
defective	O
(	O
mutL	O
)	O
background	O
,	O
a	O
strong	O
mutator	O
effect	O
for	O
G	B-geneN
·	I-geneN
C	I-geneN
→	I-geneN
T	I-geneN
·	I-geneN
A	E-geneN
and	O
A	B-geneN
·	I-geneN
T	I-geneN
→	I-geneN
T	I-geneN
·	I-geneN
A	E-geneN
transversions	O
(	O
27	O
-	O
and	O
42	O
-	O
fold	O
enhancement	O
,	O
respectively	O
)	O
.	O

In	O
contrast	O
,	O
ndk	S-geneY
strains	O
possess	O
a	O
lowered	O
dATP	S-chem
level	O
(	O
4	O
-	O
fold	O
)	O
and	O
modestly	O
enhanced	O
dCTP	S-chem
level	O
(	O
2	O
-	O
fold	O
)	O
,	O
while	O
its	O
mutator	O
effect	O
is	O
specific	O
for	O
just	O
the	O
A	B-geneN
·	I-geneN
T	I-geneN
→	I-geneN
T	I-geneN
·	I-geneN
A	E-geneN
transversions	O
.	O

The	O
two	O
strains	O
also	O
display	O
differential	O
mutability	O
for	O
rifampicin	S-chem
-	O
resistant	O
mutants	O
.	O

Overall	O
,	O
our	O
analysis	O
reveals	O
for	O
both	O
strains	O
a	O
satisfactory	O
correlation	O
between	O
dNTP	S-chem
pool	O
alterations	O
and	O
the	O
replication	O
error	O
rates	O
,	O
and	O
also	O
suggests	O
that	O
a	O
minimal	O
explanation	O
for	O
the	O
ndk	S-geneY
mutator	O
does	O
not	O
require	O
assumptions	O
beyond	O
the	O
predicted	O
effect	O
of	O
the	O
dNTP	S-chem
pools	O
.	O

Phenolic	O
profiles	O
and	O
antioxidant	O
activity	O
of	O
litchi	O
pulp	O
of	O
different	O
cultivars	O
cultivated	O
in	O
Southern	O
China	O
.	O

The	O
phenolic	O
profiles	O
and	O
antioxidant	O
activity	O
of	O
litchi	O
pulp	O
of	O
13	O
varieties	O
were	O
investigated	O
.	O

The	O
free	O
,	O
bound	O
and	O
total	O
phenolic	O
contents	O
were	O
66.17	O
-	O
226.03	O
,	O
11.18	O
-	O
40.54	O
,	O
and	O
101.51	O
-	O
259.18	O
mg	O
of	O
gallic	B-chem
acid	E-chem
equivalents	O
/	O
100	O
g	O
,	O
respectively	O
.	O

The	O
free	O
,	O
bound	O
and	O
total	O
flavonoid	S-chem
contents	O
were	O
16.68	O
-	O
110.33	O
,	O
10.48	O
-	O
22.75	O
,	O
and	O
39.43	O
-	O
129.86	O
mg	O
of	O
catechin	S-chem
equivalents	O
/	O
100	O
g	O
,	O
respectively	O
.	O

Free	O
phenolics	S-chem
and	O
flavonoids	S-chem
contributed	O
averagely	O
80.1	O
%	O
and	O
75	O
%	O
to	O
their	O
total	O
contents	O
,	O
respectively	O
.	O

Six	O
individual	O
phenolics	S-chem
(	O
gallic	B-chem
acid	E-chem
,	O
chlorogenic	B-chem
acid	E-chem
,	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
catechin	E-chem
,	O
caffeic	B-chem
acid	E-chem
,	O
(	B-chem
-	I-chem
)	I-chem
-	I-chem
epicatechin	E-chem
,	O
and	O
rutin	S-chem
)	O
were	O
detected	O
in	O
litchi	O
pulp	O
by	O
HPLC	O
.	O

The	O
contents	O
of	O
each	O
compound	O
in	O
free	O
and	O
bound	O
fractions	O
were	O
determined	O
.	O

Significant	O
varietal	O
discrepancy	O
in	O
antioxidant	O
activity	O
was	O
also	O
found	O
by	O
FRAP	O
and	O
DPPH	S-chem
scavenging	O
capacity	O
methods	O
.	O

Antioxidant	O
activity	O
was	O
significantly	O
correlated	O
with	O
phenolic	O
and	O
flavonoid	S-chem
contents	O
.	O

Thus	O
,	O
phenolics	S-chem
and	O
flavonoids	S-chem
exist	O
mainly	O
in	O
the	O
free	O
form	O
in	O
litchi	O
pulp	O
.	O

There	O
were	O
significant	O
varietal	O
differences	O
in	O
phytochemical	O
contents	O
and	O
antioxidant	O
activity	O
of	O
litchi	O
pulp	O
.	O

Stereospecific	O
inhibition	O
of	O
monoamine	B-geneN
uptake	I-geneN
transporters	E-geneN
by	O
meta	B-chem
-	I-chem
hydroxyephedrine	E-chem
isomers	O
.	O

Meta	B-chem
-	I-chem
hydroxyephedrine	E-chem
(	O
HED	S-chem
)	O
comprises	O
four	O
stereoisomers	O
consisting	O
of	O
two	O
enantiomeric	O
pairs	O
related	O
to	O
ephedrine	S-chem
and	O
pseudoephedrine	S-chem
.	O

HED	S-chem
is	O
transported	O
into	O
adrenergic	O
neurons	O
and	O
radiolabeled	O
HED	S-chem
has	O
been	O
employed	O
in	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
to	O
image	O
adrenergic	O
neurons	O
in	O
vivo	O
.	O

To	O
extend	O
structure	O
-	O
activity	O
analyses	O
of	O
binding	O
sites	O
within	O
monoamine	B-geneN
transporters	E-geneN
and	O
to	O
determine	O
which	O
stereoisomer	O
displayed	O
the	O
best	O
selectivity	O
for	O
PET	O
imaging	O
applications	O
,	O
we	O
tested	O
the	O
HED	S-chem
compounds	O
for	O
their	O
abilities	O
to	O
inhibit	O
[	O
(	B-chem
3	I-chem
)	I-chem
H	E-chem
]	O
neurotransmitter	O
uptake	O
into	O
platelets	O
,	O
transfected	O
cells	O
,	O
and	O
chromaffin	O
vesicles	O
.	O

We	O
hypothesized	O
that	O
the	O
HED	S-chem
compounds	O
would	O
be	O
most	O
potent	O
at	O
the	O
norepinephrine	B-geneY
transporter	E-geneY
(	O
NET	S-geneY
)	O
compared	O
to	O
the	O
serotonin	B-geneN
or	I-geneN
dopamine	I-geneN
transporters	E-geneN
and	O
that	O
the	O
1R	O
diastereomers	O
would	O
be	O
more	O
effective	O
than	O
1S	O
diastereomers	O
.	O

Supporting	O
the	O
hypotheses	O
,	O
all	O
stereoisomers	O
were	O
most	O
potent	O
at	O
the	O
NET	S-geneY
and	O
the	O
1R,2S	O
stereoisomer	O
was	O
the	O
most	O
potent	O
inhibitor	O
overall	O
.	O

However	O
,	O
the	O
1S,2R	O
isomer	O
may	O
be	O
preferred	O
for	O
PET	O
applications	O
because	O
of	O
better	O
selectivity	O
among	O
the	O
transporters	O
and	O
reduced	O
neuronal	O
recycling	O
.	O

A	O
high	O
throughput	O
assay	O
for	O
the	O
glucuronidation	O
of	O
7	B-chem
-	I-chem
hydroxy	I-chem
-	I-chem
4	I-chem
-	I-chem
trifluoromethylcoumarin	E-chem
by	O
recombinant	O
human	B-geneN
UDP	I-geneN
-	I-geneN
glucuronosyltransferases	E-geneN
and	O
liver	O
microsomes	O
.	O

Abstract	O
1	O
.	O
UDP	O
-	I-geneN
glucuronosyltransferases	I-geneN
(	E-geneN
UGTs	O
)	E-geneN
are	O
versatile	O
and	O
important	O
conjugation	O
enzymes	O
in	O
the	O
metabolism	O
of	O
drugs	O
and	O
other	O
xenobiotics	O
.	O

2	O
.	O
We	O
have	O
developed	O
a	O
convenient	O
quantitative	O
multi	O
-	O
well	O
plate	O
assay	O
to	O
measure	O
the	O
glucuronidation	O
rate	O
of	O
7	O
-	B-chem
hydroxy	I-chem
-	I-chem
4	I-chem
-	I-chem
trifluoromethylcoumarin	I-chem
(	E-chem
HFC	O
)	E-chem
for	O
several	O
UGTs	O
.	E-geneN

3	O
.	O
We	O
have	O
used	O
this	O
method	O
to	O
screen	O
11	O
recombinant	O
human	O
UGTs	I-geneN
for	O
HFC	O
glucuronidation	O
activity	O
and	O
studied	O
the	O
reaction	O
kinetics	O
with	O
the	O
most	O
active	O
enzymes	O
.	O

We	O
have	O
also	O
examined	O
the	O
HFC	S-chem
glucuronidation	O
activity	O
of	O
liver	O
microsomes	O
from	O
human	O
,	O
pig	O
,	O
rabbit	O
and	O
rat	O
.	O

4	O
.	O
At	O
a	O
substrate	O
concentration	O
of	O
20	O
µM	O
,	O
the	O
most	O
active	O
HFC	O
glucuronidation	O
catalysts	O
were	O
UGT1A10	O
followed	O
by	O
UGT1A6	O
>	I-geneY
UGT1A7	O
>	I-geneY
UGT2A1	O
,	I-geneY
whereas	O
at	O
300	O
µM	O
UGT1A6	O
was	E-geneY
about	O
10	O
times	O
better	O
catalyst	O
than	O
the	O
other	O
recombinant	O
UGTs	O
.	I-geneN

The	O
activities	O
of	O
UGTs	B-geneN
1A3	I-geneN
,	I-geneN
1A8	I-geneN
,	I-geneN
1A9	I-geneN
,	I-geneN
2B4	I-geneN
and	I-geneN
2B7	E-geneN
were	O
low	O
,	O
whereas	O
UGT1A1	S-geneY
and	O
UGT2B17	S-geneY
exhibited	O
no	O
HFC	S-chem
glucuronidation	O
activity	O
.	O

UGT1A6	S-geneY
exhibited	O
a	O
significantly	O
higher	O
Vmax	O
and	O
Km	O
values	O
toward	O
both	O
HFC	S-chem
and	O
UDP	S-chem
-	O
glucuronic	B-chem
acid	E-chem
than	O
the	O
other	O
UGTs	S-geneN
.	O

5	O
.	O
Human	O
,	O
pig	O
and	O
rabbit	O
,	O
but	O
not	O
rat	O
liver	O
microsomes	O
,	O
catalyzed	O
HFC	O
glucuronidation	O
at	O
high	O
rates	O
.	O

6	O
.	O
This	O
new	O
method	O
is	O
particularly	O
suitable	O
for	O
fast	O
activity	O
screenings	O
of	O
UGTs	O
1A6	I-geneN
,	I-geneN
1A7	I-geneN
,	I-geneN
1A10	I-geneN
and	I-geneN
2A1	I-geneN
and	O
HFC	O
glucuronidation	O
activity	O
determination	O
from	O
various	O
samples	O
.	O

[	O
Treatment	O
of	O
androgen	S-chem
-	O
independent	O
hormone	O
refractory	O
prostate	O
cancer	O
using	O
docetaxel	S-chem
]	O
.	O

Although	O
prostate	O
cancer	O
patients	O
with	O
metastatic	O
lesion	O
initially	O
respond	O
to	O
androgen	S-chem
ablation	O
therapy	O
,	O
almost	O
patients	O
develop	O
to	O
hormone	O
-	O
refractory	O
states	O
.	O

The	O
optimal	O
treatment	O
for	O
men	O
with	O
hormone	O
refractory	O
prostate	O
cancer	O
(	O
HRPC	O
)	O
has	O
not	O
been	O
established	O
.	O

Docetaxel	S-chem
is	O
a	O
semisynthetic	O
taxane	S-chem
that	O
inhibit	O
tumor	O
growth	O
by	O
induction	O
of	O
microtubule	O
stabilization	O
and	O
promotion	O
of	O
bcl	B-geneY
-	I-geneY
2	E-geneY
inactivation	O
,	O
which	O
induce	O
apoptosis	O
.	O

Docetaxel	S-chem
as	O
single	O
agent	O
has	O
significant	O
anti	O
-	O
tumor	O
effect	O
in	O
HRPC	O
patients	O
.	O

Docetaxel	S-chem
combined	O
with	O
estramustine	S-chem
or	O
other	O
antimicrotubular	O
agents	O
have	O
shown	O
further	O
significant	O
cytotoxicity	O
in	O
HRPC	O
patients	O
.	O

In	O
the	O
United	O
States	O
,	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approved	O
docetaxel	S-chem
,	O
injection	O
in	O
combination	O
with	O
prednisone	S-chem
for	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	O
metastatic	O
prostate	O
cancer	O
in	O
2004	O
.	O

Mutation	O
of	O
arginine	S-chem
228	O
to	O
lysine	S-chem
enhances	O
the	O
glucosyltransferase	S-geneN
activity	O
of	O
bovine	B-geneY
beta	I-geneY
-	I-geneY
1,4	I-geneY
-	I-geneY
galactosyltransferase	I-geneY
I	E-geneY
.	O

Beta	B-geneY
-	I-geneY
1,4	I-geneY
-	I-geneY
galactosyltransferase	I-geneY
I	E-geneY
(	O
beta4Gal	B-geneY
-	I-geneY
T1	E-geneY
)	O
normally	O
transfers	O
Gal	S-chem
from	O
UDP	B-chem
-	I-chem
Gal	E-chem
to	O
GlcNAc	S-chem
in	O
the	O
presence	O
of	O
Mn	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
ion	O
(	O
Gal	B-geneN
-	I-geneN
T	E-geneN
activity	O
)	O
and	O
also	O
transfers	O
Glc	S-chem
from	O
UDP	B-chem
-	I-chem
Glc	E-chem
to	O
GlcNAc	S-chem
(	O
Glc	B-geneN
-	I-geneN
T	E-geneN
activity	O
)	O
,	O
albeit	O
at	O
only	O
0.3	O
%	O
efficiency	O
.	O

In	O
addition	O
,	O
alpha	B-geneY
-	I-geneY
lactalbumin	E-geneY
(	O
LA	S-geneY
)	O
enhances	O
this	O
Glc	B-geneN
-	I-geneN
T	E-geneN
activity	O
more	O
than	O
25	O
times	O
.	O

Comparison	O
of	O
the	O
crystal	O
structures	O
of	O
UDP	B-chem
-	I-chem
Gal	E-chem
-	O
and	O
UDP	B-chem
-	I-chem
Glc	E-chem
-	O
bound	O
beta4Gal	B-geneY
-	I-geneY
T1	E-geneY
reveals	O
that	O
the	O
O4	B-chem
hydroxyl	E-chem
group	O
in	O
both	O
Gal	S-chem
and	O
Glc	S-chem
moieties	O
forms	O
a	O
hydrogen	S-chem
bond	O
with	O
the	O
side	O
chain	O
carboxylate	S-chem
group	O
of	O
Glu317	O
.	O

The	O
orientation	O
of	O
the	O
O4	B-chem
hydroxyl	I-chem
of	I-chem
glucose	E-chem
causes	O
a	O
steric	O
hindrance	O
to	O
the	O
side	O
chain	O
carboxylate	S-chem
group	O
of	O
Glu317	O
,	O
accounting	O
for	O
the	O
enzyme	O
's	O
low	O
Glc	B-geneN
-	I-geneN
T	E-geneN
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
mutation	O
of	O
Arg228	O
,	O
a	O
residue	O
in	O
the	O
vicinity	O
of	O
Glu317	O
,	O
to	O
lysine	S-chem
(	O
R228K	S-geneN
-	O
Gal	B-geneN
-	I-geneN
T1	E-geneN
)	O
results	O
in	O
a	O
15	O
-	O
fold	O
higher	O
Glc	B-geneN
-	I-geneN
T	E-geneN
activity	O
,	O
which	O
is	O
further	O
enhanced	O
by	O
LA	O
to	O
nearly	O
25	O
%	O
of	O
the	O
Gal	B-geneN
-	I-geneN
T	E-geneN
activity	O
of	O
the	O
wild	O
type	O
.	O

The	O
kinetic	O
parameters	O
indicate	O
that	O
the	O
main	O
effect	O
of	O
the	O
mutation	O
of	O
Arg228	O
to	O
lysine	S-chem
is	O
on	O
the	O
k	O
(	O
cat	O
)	O
of	O
Glc	B-geneN
-	I-geneN
T	E-geneN
,	O
which	O
increases	O
3	O
-	O
4	O
-	O
fold	O
,	O
both	O
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
LA	O
;	O
simultaneously	O
,	O
the	O
k	O
(	O
cat	O
)	O
for	O
the	O
Gal	B-geneN
-	I-geneN
T	E-geneN
reaction	O
is	O
reduced	O
30	O
-	O
fold	O
.	O

The	O
crystal	O
structure	O
of	O
R228K	S-geneN
-	O
Gal	B-geneN
-	I-geneN
T1	E-geneN
complexed	O
with	O
LA	O
,	O
UDP	B-chem
-	I-chem
Gal	E-chem
,	O
and	O
Mn	B-chem
(	I-chem
2	I-chem
+	I-chem
)	E-chem
determined	O
at	O
1.9	O
A	O
resolution	O
shows	O
that	O
the	O
Asp318	O
side	O
chain	O
exhibits	O
a	O
minor	O
alternate	O
conformation	O
,	O
compared	O
to	O
that	O
in	O
the	O
wild	O
type	O
.	O

This	O
alternate	O
conformation	O
now	O
causes	O
a	O
steric	O
hindrance	O
to	O
the	O
O4	B-chem
hydroxyl	E-chem
group	O
of	O
the	O
Gal	S-chem
moiety	O
of	O
UDP	B-chem
-	I-chem
Gal	E-chem
,	O
probably	O
causing	O
the	O
dissociation	O
of	O
UDP	B-chem
-	I-chem
Gal	E-chem
and	O
the	O
reduced	O
k	O
(	O
cat	O
)	O
of	O
the	O
Gal	B-geneN
-	I-geneN
T	E-geneN
reaction	O
.	O

Meclofenamic	B-chem
acid	E-chem
and	O
diclofenac	S-chem
,	O
novel	O
templates	O
of	O
KCNQ2	B-geneN
/	I-geneN
Q3	E-geneN
potassium	B-geneN
channel	E-geneN
openers	O
,	O
depress	O
cortical	O
neuron	O
activity	O
and	O
exhibit	O
anticonvulsant	O
properties	O
.	O

The	O
voltage	O
-	O
dependent	O
M	O
-	O
type	O
potassium	S-chem
current	O
(	O
M	O
-	O
current	O
)	O
plays	O
a	O
major	O
role	O
in	O
controlling	O
brain	O
excitability	O
by	O
stabilizing	O
the	O
membrane	O
potential	O
and	O
acting	O
as	O
a	O
brake	O
for	O
neuronal	O
firing	O
.	O

The	O
KCNQ2	B-geneN
/	I-geneN
Q3	E-geneN
heteromeric	O
channel	O
complex	O
was	O
identified	O
as	O
the	O
molecular	O
correlate	O
of	O
the	O
M	O
-	O
current	O
.	O

Furthermore	O
,	O
the	O
KCNQ2	S-geneY
and	O
KCNQ3	B-geneY
channel	I-geneY
alpha	I-geneY
subunits	E-geneY
are	O
mutated	O
in	O
families	O
with	O
benign	O
familial	O
neonatal	O
convulsions	O
,	O
a	O
neonatal	O
form	O
of	O
epilepsy	O
.	O

Enhancement	O
of	O
KCNQ2	B-geneN
/	I-geneN
Q3	E-geneN
potassium	S-chem
currents	O
may	O
provide	O
an	O
important	O
target	O
for	O
antiepileptic	O
drug	O
development	O
.	O

Here	O
,	O
we	O
show	O
that	O
meclofenamic	B-chem
acid	E-chem
(	O
meclofenamate	S-chem
)	O
and	O
diclofenac	S-chem
,	O
two	O
related	O
molecules	O
previously	O
used	O
as	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
act	O
as	O
novel	O
KCNQ2	B-geneN
/	I-geneN
Q3	E-geneN
channel	O
openers	O
.	O

Extracellular	O
application	O
of	O
meclofenamate	S-chem
(	O
EC	O
(	O
50	O
)	O
=	O
25	O
microM	O
)	O
and	O
diclofenac	S-chem
(	O
EC	O
(	O
50	O
)	O
=	O
2.6	O
microM	O
)	O
resulted	O
in	O
the	O
activation	O
of	O
KCNQ2	B-geneN
/	I-geneN
Q3	E-geneN
K	O
(	O
+	O
)	O
currents	O
,	O
heterologously	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

Both	O
openers	O
activated	O
KCNQ2	B-geneN
/	I-geneN
Q3	E-geneN
channels	O
by	O
causing	O
a	O
hyperpolarizing	O
shift	O
of	O
the	O
voltage	O
activation	O
curve	O
(	O
-	O
23	O
and	O
-	O
15	O
mV	O
,	O
respectively	O
)	O
and	O
by	O
markedly	O
slowing	O
the	O
deactivation	O
kinetics	O
.	O

The	O
effects	O
of	O
the	O
drugs	O
were	O
stronger	O
on	O
KCNQ2	S-geneY
than	O
on	O
KCNQ3	B-geneY
channel	I-geneY
alpha	I-geneY
subunits	E-geneY
.	O

In	O
contrast	O
,	O
they	O
did	O
not	O
enhance	O
KCNQ1	S-geneY
K	O
(	O
+	O
)	O
currents	O
.	O

Both	O
openers	O
increased	O
KCNQ2	B-geneN
/	I-geneN
Q3	E-geneN
current	O
amplitude	O
at	O
physiologically	O
relevant	O
potentials	O
and	O
led	O
to	O
hyperpolarization	O
of	O
the	O
resting	O
membrane	O
potential	O
.	O

In	O
cultured	O
cortical	O
neurons	O
,	O
meclofenamate	S-chem
and	O
diclofenac	S-chem
enhanced	O
the	O
M	O
-	O
current	O
and	O
reduced	O
evoked	O
and	O
spontaneous	O
action	O
potentials	O
,	O
whereas	O
in	O
vivo	O
diclofenac	S-chem
exhibited	O
an	O
anticonvulsant	O
activity	O
(	O
ED	O
(	O
50	O
)	O
=	O
43	O
mg	O
/	O
kg	O
)	O
.	O

These	O
compounds	O
potentially	O
constitute	O
novel	O
drug	O
templates	O
for	O
the	O
treatment	O
of	O
neuronal	O
hyperexcitability	O
including	O
epilepsy	O
,	O
migraine	O
,	O
or	O
neuropathic	O
pain	O
.	O

LIVER	B-geneN
X	I-geneN
RECEPTORS	E-geneN
,	O
NERVOUS	O
SYSTEM	O
AND	O
LIPID	O
METABOLISM	O
.	O

Lipids	O
in	O
the	O
nervous	O
system	O
are	O
represented	O
by	O
cholesterol	S-chem
and	O
phospholipids	O
as	O
constituents	O
of	O
cell	O
membranes	O
and	O
,	O
in	O
particular	O
,	O
of	O
myelin	O
.	O

Therefore	O
,	O
lipids	O
are	O
finely	O
regulated	O
to	O
guarantee	O
physiological	O
functions	O
.	O

In	O
the	O
central	O
nervous	O
system	O
,	O
cholesterol	S-chem
is	O
locally	O
synthesized	O
due	O
to	O
the	O
presence	O
of	O
the	O
blood	O
brain	O
barrier	O
.	O

In	O
the	O
peripheral	O
nervous	O
system	O
cholesterol	S-chem
is	O
either	O
uptaken	O
by	O
lipoproteins	O
and	O
/	O
or	O
produced	O
by	O
de	O
novo	O
biosynthesis	O
.	O

Defects	O
in	O
lipid	O
homeostasis	O
in	O
these	O
tissues	O
lead	O
to	O
structural	O
and	O
functional	O
changes	O
that	O
often	O
result	O
in	O
different	O
pathological	O
conditions	O
depending	O
on	O
the	O
affected	O
pathways	O
(	O
i.e	O
.	O
cholesterol	S-chem
biosynthesis	O
,	O
cholesterol	S-chem
efflux	O
,	O
fatty	B-chem
acid	E-chem
biosynthesis	O
etc	O
.	O
)	O
.	O

Alterations	O
in	O
cholesterol	S-chem
metabolism	O
in	O
the	O
central	O
nervous	O
system	O
are	O
linked	O
to	O
several	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
Huntington	O
disease	O
,	O
Parkinson	O
disease	O
,	O
Multiple	O
Sclerosis	O
,	O
Smith	O
-	O
Lemli	O
-	O
Opitz	O
syndrome	O
,	O
Niemann	O
-	O
Pick	O
type	O
C	O
disease	O
,	O
and	O
glioblastoma	O
.	O

In	O
the	O
peripheral	O
nervous	O
system	O
changes	O
in	O
lipid	O
metabolism	O
are	O
associated	O
with	O
the	O
development	O
of	O
peripheral	O
neuropathy	O
that	O
may	O
be	O
caused	O
by	O
metabolic	O
disorders	O
,	O
injuries	O
,	O
therapeutics	O
and	O
autoimmune	O
diseases	O
.	O

Transcription	O
factors	O
,	O
such	O
as	O
the	O
Liver	B-geneN
X	I-geneN
receptors	E-geneN
(	O
LXRs	S-geneN
)	O
,	O
regulate	O
both	O
cholesterol	S-chem
and	O
fatty	B-chem
acid	E-chem
metabolism	O
in	O
several	O
tissues	O
including	O
the	O
nervous	O
system	O
.	O

In	O
the	O
last	O
few	O
years	O
several	O
studies	O
elucidated	O
the	O
biology	O
of	O
LXRs	S-geneN
in	O
nervous	O
system	O
due	O
to	O
the	O
availability	O
of	O
knock	O
-	O
out	O
mice	O
and	O
the	O
development	O
of	O
synthetic	O
ligands	O
.	O

Here	O
,	O
we	O
review	O
a	O
survey	O
of	O
the	O
literature	O
focused	O
on	O
central	O
and	O
peripheral	O
nervous	O
system	O
and	O
in	O
physiological	O
and	O
pathological	O
settings	O
with	O
particular	O
attention	O
on	O
the	O
roles	O
played	O
by	O
LXRs	S-geneN
in	O
both	O
districts	O
.	O

A	O
disorder	O
to	O
order	O
transition	O
accompanies	O
catalysis	O
in	O
retinaldehyde	B-geneY
dehydrogenase	I-geneY
type	I-geneY
II	E-geneY
.	O

Retinaldehyde	B-geneY
dehydrogenase	I-geneY
II	E-geneY
(	O
RalDH2	S-geneY
)	O
converts	O
retinal	O
to	O
the	O
transcriptional	O
regulator	O
retinoic	O
acid	O
in	O
the	O
developing	O
embryo	O
.	O

The	O
x	O
-	O
ray	O
structure	O
of	O
the	O
enzyme	O
revealed	O
an	O
important	O
structural	O
difference	O
between	O
this	O
protein	O
and	O
other	O
aldehyde	B-geneN
dehydrogenases	E-geneN
of	O
the	O
same	O
enzyme	O
superfamily	O
;	O
a	O
20	O
-	O
amino	B-chem
acid	E-chem
span	O
in	O
the	O
substrate	O
access	O
channel	O
in	O
retinaldehyde	B-geneY
dehydrogenase	I-geneY
II	E-geneY
is	O
disordered	O
,	O
whereas	O
in	O
other	O
aldehyde	B-geneN
dehydrogenases	E-geneN
this	O
region	O
forms	O
a	O
well	O
defined	O
wall	O
of	O
the	O
substrate	O
access	O
channel	O
.	O

We	O
asked	O
whether	O
this	O
disordered	O
loop	O
might	O
order	O
during	O
the	O
course	O
of	O
catalysis	O
and	O
provide	O
a	O
means	O
for	O
an	O
enzyme	O
that	O
requires	O
a	O
large	O
substrate	O
access	O
channel	O
to	O
restrict	O
access	O
to	O
the	O
catalytic	O
machinery	O
by	O
smaller	O
compounds	O
that	O
might	O
potentially	O
enter	O
the	O
active	O
site	O
and	O
be	O
metabolized	O
.	O

Our	O
experiments	O
,	O
a	O
combination	O
of	O
kinetic	O
,	O
spectroscopic	O
,	O
and	O
crystallographic	O
techniques	O
,	O
suggest	O
that	O
a	O
disorder	O
to	O
order	O
transition	O
is	O
linked	O
to	O
catalytic	O
activity	O
.	O

Direct	O
multiplex	O
assay	O
of	O
lysosomal	O
enzymes	O
in	O
dried	O
blood	O
spots	O
for	O
newborn	O
screening	O
.	O

BACKGROUND	O
:	O
Newborn	O
screening	O
for	O
deficiency	O
in	O
the	O
lysosomal	O
enzymes	O
that	O
cause	O
Fabry	O
,	O
Gaucher	O
,	O
Krabbe	O
,	O
Niemann	O
-	O
Pick	O
A	O
/	O
B	O
,	O
and	O
Pompe	O
diseases	O
is	O
warranted	O
because	O
treatment	O
for	O
these	O
syndromes	O
is	O
now	O
available	O
or	O
anticipated	O
in	O
the	O
near	O
feature	O
.	O

We	O
describe	O
a	O
multiplex	O
screening	O
method	O
for	O
all	O
five	O
lysosomal	O
enzymes	O
that	O
uses	O
newborn	O
-	O
screening	O
cards	O
containing	O
dried	O
blood	O
spots	O
as	O
the	O
enzyme	O
source	O
.	O

METHODS	O
:	O
We	O
used	O
a	O
cassette	O
of	O
substrates	O
and	O
internal	O
standards	O
to	O
directly	O
quantify	O
the	O
enzymatic	O
activities	O
,	O
and	O
tandem	O
mass	O
spectrometry	O
for	O
enzymatic	O
product	O
detection	O
.	O

Rehydrated	O
dried	O
blood	O
spots	O
were	O
incubated	O
with	O
the	O
enzyme	O
substrates	O
.	O

We	O
used	O
liquid	O
-	O
liquid	O
extraction	O
followed	O
by	O
solid	O
-	O
phase	O
extraction	O
with	O
silica	O
gel	O
to	O
remove	O
buffer	O
components	O
.	O

Acarbose	S-chem
served	O
as	O
inhibitor	O
of	O
an	O
interfering	O
acid	B-geneY
alpha	I-geneY
-	I-geneY
glucosidase	E-geneY
present	O
in	O
neutrophils	O
,	O
which	O
allowed	O
the	O
lysosomal	O
enzyme	O
implicated	O
in	O
Pompe	O
disease	O
to	O
be	O
selectively	O
analyzed	O
.	O

RESULTS	O
:	O
We	O
analyzed	O
dried	O
blood	O
spots	O
from	O
5	O
patients	O
with	O
Gaucher	O
,	O
5	O
with	O
Niemann	O
-	O
Pick	O
A	O
/	O
B	O
,	O
11	O
with	O
Pompe	O
,	O
5	O
with	O
Fabry	O
,	O
and	O
12	O
with	O
Krabbe	O
disease	O
,	O
and	O
in	O
all	O
cases	O
the	O
enzyme	O
activities	O
were	O
below	O
the	O
minimum	O
activities	O
measured	O
in	O
a	O
collection	O
of	O
heterozygous	O
carriers	O
and	O
healthy	O
noncarrier	O
individuals	O
.	O

The	O
enzyme	O
activities	O
measured	O
in	O
5	O
-	O
9	O
heterozygous	O
carriers	O
were	O
approximately	O
one	O
-	O
half	O
those	O
measured	O
with	O
15	O
-	O
32	O
healthy	O
individuals	O
,	O
but	O
there	O
was	O
partial	O
overlap	O
of	O
each	O
condition	O
between	O
the	O
data	O
sets	O
for	O
carriers	O
and	O
healthy	O
individuals	O
.	O

CONCLUSION	O
:	O
For	O
all	O
five	O
diseases	O
,	O
the	O
affected	O
individuals	O
were	O
detected	O
.	O

The	O
assay	O
can	O
be	O
readily	O
automated	O
,	O
and	O
the	O
anticipated	O
reagent	O
and	O
supply	O
costs	O
are	O
well	O
within	O
the	O
budget	O
limits	O
of	O
newborn	O
-	O
screening	O
centers	O
.	O

Synergistic	O
effects	O
of	O
new	O
chemopreventive	O
agents	O
and	O
conventional	O
cytotoxic	O
agents	O
against	O
human	O
lung	O
cancer	O
cell	O
lines	O
.	O

Non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
cells	O
have	O
constitutively	O
high	O
expression	O
of	O
cytosolic	B-geneY
phospholipase	I-geneY
A2	E-geneY
(	O
cPLA2	S-geneY
)	O
and	O
cyclooxygenase	B-geneY
(	I-geneY
COX	I-geneY
)	I-geneY
2	E-geneY
.	O

These	O
NSCLC	O
cells	O
also	O
have	O
increased	O
prostaglandin	S-chem
expression	O
(	O
PGE2	S-chem
)	O
.	O

Many	O
lung	O
cancers	O
also	O
express	O
12	B-geneY
-	I-geneY
lipoxygenase	E-geneY
RNA	O
and	O
12	B-geneY
-	I-geneY
lipoxygenase	E-geneY
protein	O
and	O
biosynthesize	O
12	B-chem
(	I-chem
S	I-chem
)	I-chem
-	I-chem
hydroxyeicosatetraenoic	I-chem
acid	E-chem
,	O
which	O
correlates	O
with	O
their	O
metastatic	O
potential	O
.	O

Several	O
studies	O
have	O
demonstrated	O
that	O
COX	B-geneY
-	I-geneY
1	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitors	O
could	O
inhibit	O
the	O
in	O
vitro	O
growth	O
of	O
human	O
lung	O
cancer	O
cell	O
lines	O
.	O

In	O
this	O
report	O
,	O
we	O
evaluated	O
the	O
growth	O
-	O
inhibitory	O
effects	O
of	O
sulindac	B-chem
sulfide	E-chem
,	O
a	O
COX	B-geneY
-	I-geneY
1	E-geneY
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
inhibitor	O
;	O
exisulind	S-chem
(	O
sulindac	B-chem
sulfone	E-chem
)	O
,	O
a	O
novel	O
proapoptotic	O
agent	O
that	O
does	O
not	O
inhibit	O
COX	S-geneN
enzymes	O
;	O
and	O
nordihydroguaiaretic	B-chem
acid	E-chem
(	O
NDGA	S-chem
)	O
,	O
a	O
lipoxygenase	S-geneN
inhibitor	O
on	O
human	O
lung	O
cancer	O
cell	O
lines	O
.	O

We	O
compared	O
these	O
effects	O
with	O
those	O
of	O
13	B-chem
-	I-chem
cis	I-chem
-	I-chem
retinoic	I-chem
acid	E-chem
,	O
a	O
chemoprevention	O
agent	O
,	O
and	O
with	O
the	O
cytotoxic	O
chemotherapeutic	O
agents	O
paclitaxel	S-chem
and	O
cisplatin	S-chem
,	O
alone	O
or	O
in	O
combination	O
.	O

Our	O
goal	O
was	O
to	O
develop	O
new	O
chemoprevention	O
and	O
treatment	O
strategies	O
.	O

Each	O
of	O
the	O
six	O
agents	O
tested	O
inhibited	O
the	O
in	O
vitro	O
growth	O
of	O
three	O
NSCLC	O
and	O
three	O
SCLC	O
cell	O
lines	O
at	O
the	O
highest	O
concentration	O
.	O

Paclitaxel	S-chem
was	O
the	O
most	O
potent	O
agent	O
(	O
IC50	O
=	O
0.003	O
-	O
0.150	O
microM	O
)	O
;	O
sulindac	B-chem
sulfide	E-chem
,	O
NDGA	S-chem
,	O
and	O
13	B-chem
-	I-chem
cis	I-chem
-	I-chem
retinoic	I-chem
acid	E-chem
had	O
intermediate	O
potency	O
(	O
IC50	O
=	O
4	O
-	O
80	O
microM	O
)	O
,	O
and	O
cisplatin	S-chem
and	O
exisulind	S-chem
were	O
the	O
least	O
potent	O
(	O
IC50	O
=	O
150	O
-	O
500	O
microM	O
)	O
.	O

Combination	O
studies	O
showed	O
synergistic	O
interactions	O
for	O
sulindac	B-chem
sulfide	E-chem
,	O
exisulind	S-chem
,	O
and	O
NDGA	S-chem
with	O
paclitaxel	S-chem
,	O
cisplatin	S-chem
,	O
and	O
13	B-chem
-	I-chem
cis	I-chem
-	I-chem
retinoic	I-chem
acid	E-chem
,	O
regardless	O
of	O
drug	O
-	O
resistance	O
phenotype	O
.	O

At	O
high	O
concentrations	O
,	O
the	O
combination	O
of	O
13	B-chem
-	I-chem
cis	I-chem
-	I-chem
retinoic	I-chem
acid	E-chem
and	O
each	O
of	O
the	O
five	O
other	O
drugs	O
resulted	O
in	O
a	O
strong	O
synergistic	O
effect	O
.	O

These	O
studies	O
provide	O
a	O
rationale	O
for	O
chemoprevention	O
(	O
exisulind	S-chem
+	O
/	O
-	O
retinoic	B-chem
acid	E-chem
+	O
/	O
-	O
NDGA	S-chem
)	O
and	O
therapeutic	O
(	O
exisulind	S-chem
+	O
/	O
-	O
paclitaxel	S-chem
+	O
/	O
-	O
cisplatin	S-chem
)	O
studies	O
in	O
patients	O
at	O
risk	O
for	O
,	O
or	O
with	O
,	O
lung	O
cancer	O
.	O

Effect	O
of	O
thiazolidinediones	S-chem
on	O
equilibrative	B-geneY
nucleoside	I-geneY
transporter	I-geneY
-	I-geneY
1	E-geneY
in	O
human	O
aortic	O
smooth	O
muscle	O
cells	O
.	O

Thiazolidinediones	S-chem
are	O
a	O
new	O
class	O
of	O
anti	O
-	O
diabetic	O
agents	O
which	O
increase	O
insulin	S-geneY
sensitivity	O
by	O
binding	O
to	O
the	O
peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
gamma	E-geneY
(	O
PPAR	B-geneY
(	I-geneY
gamma	I-geneY
)	E-geneY
)	O
and	O
stimulating	O
the	O
expression	O
of	O
insulin	S-geneY
-	O
responsive	O
genes	O
involved	O
in	O
glucose	S-chem
and	O
lipid	O
metabolism	O
.	O

These	O
drugs	O
also	O
have	O
vasodilatory	O
and	O
anti	O
-	O
proliferative	O
effects	O
on	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

However	O
the	O
mechanisms	O
for	O
these	O
actions	O
are	O
not	O
fully	O
understood	O
.	O

Adenosine	O
is	O
a	O
vasodilator	O
and	O
a	O
substrate	O
of	O
equilibrative	B-geneN
nucleoside	I-geneN
transporters	E-geneN
(	O
ENT	S-geneN
)	O
.	O

The	O
present	O
study	O
studied	O
the	O
effects	O
of	O
three	O
thiazolidinediones	S-chem
,	O
troglitazone	S-chem
,	O
pioglitazone	S-chem
and	O
ciglitazone	S-chem
,	O
on	O
ENT1	S-geneY
in	O
the	O
human	O
aortic	O
smooth	O
muscle	O
cells	O
(	O
HASMCs	O
)	O
.	O

Although	O
incubating	O
HASMCs	O
for	O
48h	O
with	O
thiazolidinediones	S-chem
had	O
no	O
effect	O
on	O
ENT1	S-geneY
mRNA	O
and	O
protein	O
levels	O
,	O
troglitazone	S-chem
acutely	O
inhibited	O
[	B-chem
3H	I-chem
]	I-chem
adenosine	E-chem
uptake	O
and	O
[	B-chem
3H	I-chem
]	I-chem
NBMPR	E-chem
binding	O
of	O
HASMCs	O
with	O
IC50	O
values	O
of	O
2.35	O
+	O
/	O
-	O
0.35	O
and	O
3.99	O
+	O
/	O
-	O
0.57microM	O
,	O
respectively	O
.	O

The	O
effect	O
of	O
troglitazone	S-chem
on	O
ENT1	S-geneY
was	O
PPAR	B-geneY
(	I-geneY
gamma	I-geneY
)	E-geneY
-	O
independent	O
and	O
kinetic	O
studies	O
revealed	O
that	O
troglitazone	S-chem
was	O
a	O
competitive	O
inhibitor	O
of	O
ENT1	S-geneY
.	O

In	O
contrast	O
,	O
pioglitazone	S-chem
and	O
ciglitazone	S-chem
had	O
minimal	O
effects	O
on	O
[	B-chem
3H	I-chem
]	I-chem
adenosine	E-chem
uptake	O
by	O
HASMCs	O
.	O

Troglitazone	S-chem
differs	O
from	O
pioglitazone	S-chem
and	O
ciglitazone	S-chem
in	O
that	O
its	O
side	O
-	O
chain	O
contains	O
a	O
Vitamin	B-chem
E	E-chem
moiety	O
.	O

The	O
difference	O
in	O
structure	O
of	O
troglitazone	S-chem
did	O
not	O
account	O
for	O
its	O
inhibitory	O
effect	O
on	O
ENT1	S-geneY
because	O
Vitamin	B-chem
E	E-chem
did	O
not	O
inhibit	O
[	B-chem
3H	I-chem
]	I-chem
adenosine	E-chem
uptake	O
by	O
HASMCs	O
.	O

Using	O
the	O
nucleoside	B-geneN
transporter	E-geneN
deficient	O
PK15NTD	O
cells	O
stably	O
expressing	O
ENT1	S-geneY
and	O
ENT2	S-geneY
,	O
it	O
was	O
found	O
that	O
troglitazone	S-chem
inhibited	O
ENT1	S-geneY
but	O
had	O
no	O
effect	O
on	O
ENT2	S-geneY
.	O

From	O
these	O
results	O
,	O
it	O
is	O
suggested	O
that	O
troglitazone	S-chem
may	O
enhance	O
the	O
vasodilatory	O
effect	O
of	O
adenosine	S-chem
by	O
inhibiting	O
ENT1	S-geneY
.	O

Pharmacologically	O
,	O
troglitazone	S-chem
is	O
a	O
novel	O
inhibitor	O
of	O
ENT1	S-geneY
.	O

Acute	O
Macrovascular	O
Dysfunction	O
in	O
Patients	O
With	O
Type	O
2	O
Diabetes	O
Induced	O
by	O
Ingestion	O
of	O
Advanced	O
Glycated	B-geneN
β	I-geneN
-	I-geneN
Lactoglobulins	E-geneN
.	O

OBJECTIVE	O
Recent	O
evidence	O
indicates	O
that	O
heat	O
-	O
enhanced	O
food	O
advanced	O
glycation	O
end	O
products	O
(	O
AGEs	O
)	O
adversely	O
affect	O
vascular	O
function	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
acute	O
effects	O
of	O
an	O
oral	O
load	O
of	O
heat	O
-	O
treated	O
,	O
AGE	O
-	O
modified	O
β	B-geneN
-	I-geneN
lactoglobulins	E-geneN
(	O
AGE	O
-	O
BLG	S-geneN
)	O
compared	O
with	O
heat	O
-	O
treated	O
,	O
nonglycated	B-geneN
BLG	E-geneN
(	O
C	B-geneN
-	I-geneN
BLG	E-geneN
)	O
on	O
vascular	O
function	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
In	O
a	O
double	O
-	O
blind	O
,	O
controlled	O
,	O
randomized	O
,	O
crossover	O
study	O
,	O
19	O
patients	O
with	O
T2DM	O
received	O
,	O
on	O
two	O
different	O
occasions	O
,	O
beverages	O
containing	O
either	O
AGE	O
-	O
BLG	S-geneN
or	O
C	B-geneN
-	I-geneN
BLG	E-geneN
.	O

We	O
measured	O
macrovascular	O
[	O
brachial	O
ultrasound	O
of	O
flow	O
-	O
mediated	O
dilatation	O
(	O
FMD	O
)	O
]	O
and	O
microvascular	O
(	O
laser	O
-	O
Doppler	O
measurements	O
of	O
reactive	O
hyperemia	O
in	O
the	O
hand	O
)	O
functions	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
90	O
(	O
T90	O
)	O
,	O
and	O
180	O
(	O
T180	O
)	O
min	O
.	O

RESULTS	O
Following	O
the	O
AGE	O
-	O
BLG	S-geneN
,	O
FMD	O
decreased	O
at	O
T90	O
by	O
80	O
%	O
from	O
baseline	O
and	O
remained	O
decreased	O
by	O
42	O
%	O
at	O
T180	O
(	O
P	O
<	O
0.05	O
vs.	O
baseline	O
,	O
P	O
<	O
0.05	O
vs	O
.	O

C	B-geneN
-	I-geneN
BLG	E-geneN
at	O
T90	O
)	O
.	O

By	O
comparison	O
,	O
following	O
C	B-geneN
-	I-geneN
BLG	E-geneN
,	O
FMD	O
decreased	O
by	O
27	O
%	O
at	O
T90	O
and	O
51	O
%	O
at	O
T180	O
(	O
P	O
<	O
0.05	O
vs.	O
baseline	O
at	O
T180	O
)	O
.	O

A	O
significant	O
decrease	O
in	O
nitrite	S-chem
(	O
T180	O
)	O
and	O
nitrate	S-chem
(	O
T90	O
and	O
T180	O
)	O
,	O
as	O
well	O
as	O
a	O
significant	O
increase	O
in	O
N	B-chem
(	I-chem
ε	I-chem
)	I-chem
-	I-chem
carboxymethyllisine	E-chem
,	O
accompanied	O
intake	O
of	O
AGE	O
-	O
BLG	S-geneN
.	O

There	O
was	O
no	O
change	O
in	O
microvascular	O
function	O
caused	O
by	O
either	O
beverage	O
.	O

CONCLUSIONS	O
In	O
patients	O
with	O
T2DM	O
,	O
acute	O
oral	O
administration	O
of	O
a	O
single	O
AGE	O
-	O
modified	O
protein	O
class	O
significantly	O
though	O
transiently	O
impaired	O
macrovascular	O
function	O
in	O
concert	O
with	O
decreased	O
nitric	B-chem
oxide	E-chem
bioavailability	O
.	O

These	O
AGE	O
-	O
related	O
changes	O
were	O
independent	O
of	O
heat	O
treatment	O
.	O

Macrophage	O
cathepsin	B-geneY
K	E-geneY
promotes	O
prostate	O
tumor	O
progression	O
in	O
bone	O
.	O

Bone	O
marrow	O
macrophages	O
(	O
BMMs	O
)	O
share	O
common	O
progenitors	O
with	O
osteoclasts	O
and	O
are	O
critical	O
components	O
of	O
bone	O
-	O
tumor	O
microenvironment	O
;	O
however	O
,	O
their	O
function	O
in	O
prostate	O
tumor	O
growth	O
in	O
the	O
skeleton	O
has	O
not	O
been	O
explored	O
.	O

BMMs	O
are	O
the	O
major	O
source	O
of	O
inflammatory	O
factors	O
and	O
proteases	S-geneN
,	O
including	O
cysteine	B-geneN
protease	E-geneN
cathepsin	B-geneY
K	E-geneY
(	O
CTSK	S-geneY
)	O
.	O

In	O
this	O
study	O
,	O
utilizing	O
mice	O
deficient	O
in	O
CTSK	S-geneY
,	O
we	O
demonstrate	O
the	O
critical	O
involvement	O
of	O
this	O
potent	O
collagenase	S-geneN
in	O
tumor	O
progression	O
in	O
bone	O
.	O

We	O
present	O
the	O
evidence	O
that	O
tumor	O
growth	O
and	O
progression	O
in	O
the	O
bone	O
are	O
impaired	O
in	O
the	O
absence	O
of	O
CTSK	S-geneY
.	O

Most	O
importantly	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
BMM	O
-	O
supplied	O
CTSK	S-geneY
may	O
be	O
involved	O
in	O
CCL2	S-geneY
-	O
and	O
COX	B-geneY
-	I-geneY
2	E-geneY
-	O
driven	O
pathways	O
that	O
contribute	O
to	O
tumor	O
progression	O
in	O
bone	O
.	O

Together	O
,	O
our	O
data	O
unravel	O
novel	O
roles	O
for	O
CTSK	S-geneY
in	O
macrophage	O
-	O
regulated	O
processes	O
,	O
and	O
provide	O
evidence	O
for	O
close	O
interplay	O
between	O
inflammatory	O
,	O
osteolytic	O
and	O
tumor	O
cell	O
-	O
driven	O
events	O
in	O
the	O
bone	O
-	O
tumor	O
microenvironment	O
.	O

Chemokine	S-geneN
expression	O
is	O
upregulated	O
in	O
chondrocytes	O
in	O
diabetic	O
fracture	O
healing	O
.	O

Chemokines	S-geneN
are	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
several	O
aspects	O
of	O
bone	O
metabolism	O
including	O
the	O
recruitment	O
of	O
leukocytes	O
and	O
the	O
formation	O
of	O
osteoclasts	O
.	O

We	O
investigated	O
the	O
impact	O
of	O
diabetes	O
on	O
chemokine	S-geneN
expression	O
in	O
normal	O
and	O
diabetic	O
fracture	O
healing	O
.	O

Fracture	O
of	O
the	O
femur	O
was	O
performed	O
in	O
streptozotocin	S-chem
-	O
induced	O
diabetic	O
and	O
matched	O
normoglycemic	O
control	O
mice	O
.	O

Microarray	O
analysis	O
was	O
carried	O
out	O
and	O
chemokine	S-geneN
mRNA	O
levels	O
in	O
vivo	O
were	O
assessed	O
.	O

CCL4	S-geneY
were	O
examined	O
in	O
fracture	O
calluses	O
by	O
immunohistochemistry	O
and	O
the	O
role	O
of	O
TNF	S-geneN
in	O
diabetes	O
-	O
enhanced	O
expression	O
was	O
investigated	O
by	O
treatment	O
of	O
animals	O
with	O
the	O
TNF	S-geneN
-	O
specific	O
inhibitor	O
,	O
pegsunercept	O
.	O

In	O
vitro	O
studies	O
were	O
conducted	O
with	O
ATDC5	O
chondrocytes	O
.	O

Diabetes	O
significantly	O
upregulated	O
mRNA	O
levels	O
of	O
several	O
chemokines	S-geneN
in	O
vivo	O
including	O
CCL4	S-geneY
,	O
CCL8	S-geneY
,	O
CCL6	S-geneY
,	O
CCL11	S-geneY
,	O
CCL20	S-geneY
,	O
CCL24	S-geneY
,	O
CXCL2	S-geneY
,	O
CXCL5	S-geneY
and	O
chemokine	B-geneN
receptors	E-geneN
CCR5	S-geneY
and	O
CXCR4	S-geneY
.	O

Chondrocytes	O
were	O
identified	O
as	O
a	O
significant	O
source	O
of	O
CCL4	S-geneY
and	O
its	O
expression	O
in	O
diabetic	O
fractures	O
was	O
dependent	O
on	O
TNF	S-geneN
(	O
P	O
<	O
0.05	O
)	O
.	O

TNF	B-geneY
-	I-geneY
α	E-geneY
significantly	O
increased	O
mRNA	O
levels	O
of	O
several	O
chemokines	S-geneN
in	O
vitro	O
which	O
were	O
knocked	O
down	O
with	O
FOXO1	S-geneY
siRNA	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CCL4	S-geneY
expression	O
at	O
the	O
mRNA	O
and	O
proteins	O
levels	O
was	O
induced	O
by	O
FOXO1	S-geneY
over	O
-	O
expression	O
and	O
reduced	O
by	O
FOXO1	S-geneY
knockdown	O
.	O

The	O
current	O
studies	O
point	O
to	O
the	O
importance	O
of	O
TNF	B-geneY
-	I-geneY
α	E-geneY
as	O
a	O
mechanism	O
for	O
diabetes	O
enhanced	O
chemokine	S-geneN
expression	O
by	O
chondrocytes	O
,	O
which	O
may	O
contribute	O
to	O
the	O
accelerated	O
loss	O
of	O
cartilage	O
observed	O
in	O
diabetic	O
fracture	O
healing	O
.	O

Moreover	O
,	O
in	O
vitro	O
results	O
point	O
to	O
FOXO1	S-geneY
as	O
a	O
potentially	O
important	O
transcription	O
factor	O
in	O
mediating	O
this	O
effect	O
.	O

Cyperi	O
Rhizoma	O
inhibits	O
the	O
1	B-chem
-	I-chem
methyl	I-chem
-	I-chem
4	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
1,2,3,6	I-chem
-	I-chem
tetrahydropyridine	E-chem
-	O
induced	O
reduction	O
in	O
nigrostriatal	O
dopaminergenic	O
neurons	O
in	O
estrogen	S-chem
-	O
deprived	O
mice	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Cyperi	O
Rhizoma	O
has	O
commonly	O
been	O
used	O
for	O
the	O
treatment	O
of	O
gynecological	O
and	O
neuropsychiatric	O
disorders	O
in	O
traditional	O
medicine	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
estrogenic	O
properties	O
and	O
neuroprotective	O
effects	O
of	O
Cyperi	O
Rhizoma	O
under	O
estrogen	S-chem
-	O
deprived	O
condition	O
in	O
female	O
mice	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
To	O
determine	O
the	O
estrogen	S-chem
-	O
like	O
effect	O
of	O
Cyperi	O
Rhizoma	O
extract	O
(	O
CRE	O
)	O
,	O
we	O
measured	O
luciferase	O
expression	O
after	O
transfection	O
of	O
a	O
promoter	O
construct	O
containing	O
an	O
estrogen	B-geneN
response	I-geneN
element	E-geneN
(	O
ERE	S-geneN
)	O
and	O
treatment	O
of	O
CRE	O
.	O

To	O
evaluate	O
the	O
neuroprotective	O
effect	O
of	O
CRE	O
,	O
we	O
measured	O
striatal	O
dopamine	S-chem
,	O
movement	O
ability	O
,	O
tyrosine	B-geneY
hydroxylase	E-geneY
(	O
TH	S-geneY
)	O
immunoreactivity	O
,	O
and	O
apoptosis	O
-	O
related	O
protein	O
expression	O
levels	O
after	O
treatment	O
of	O
CRE	O
either	O
with	O
or	O
without	O
1	B-chem
-	I-chem
methyl	I-chem
-	I-chem
4	I-chem
-	I-chem
phenyl	I-chem
-	I-chem
1,2,3,6	I-chem
-	I-chem
tetrahydropyridine	E-chem
(	O
MPTP	S-chem
)	O
in	O
ovariectomized	O
female	O
mice	O
.	O

RESULTS	O
:	O
CRE	O
significantly	O
induced	O
the	O
luciferase	O
expression	O
driven	O
by	O
an	O
ERE	S-geneN
in	O
PC12	O
cells	O
,	O
a	O
dopaminergic	O
cell	O
line	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
mice	O
,	O
MPTP	S-chem
significantly	O
decreased	O
the	O
levels	O
of	O
dopamine	S-chem
in	O
the	O
striatum	O
and	O
behavior	O
performance	O
;	O
in	O
contrast	O
,	O
both	O
CRE	O
and	O
17β	B-chem
-	I-chem
estradiol	I-chem
benzoate	E-chem
(	O
EB	O
)	O
recovered	O
these	O
parameters	O
to	O
normal	O
levels	O
.	O

CRE	O
and	O
EB	O
treatment	O
also	O
recovered	O
TH	S-geneY
immunopositive	O
fibers	O
and	O
cells	O
,	O
respectively	O
,	O
from	O
MPTP	S-chem
toxicity	O
.	O

Additionally	O
,	O
MPTP	S-chem
significantly	O
down	O
-	O
regulated	O
Bcl	B-geneY
-	I-geneY
2	E-geneY
expression	O
in	O
the	O
mitochondria	O
of	O
dopaminergic	O
cells	O
in	O
the	O
SN	O
,	O
followed	O
by	O
an	O
increase	O
in	O
Bax	S-geneY
expression	O
,	O
cytochrome	B-geneY
C	E-geneY
translocation	O
to	O
the	O
cytosol	O
,	O
andcleaved	O
-	O
caspase	B-geneY
-	I-geneY
3	E-geneY
expression	O
,	O
whereas	O
these	O
were	O
inhibited	O
by	O
CRE	O
or	O
EB	O
treatment	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
provide	O
the	O
first	O
evidence	O
that	O
CRE	O
has	O
estrogen	S-chem
-	O
like	O
and	O
neuroprotective	O
effects	O
on	O
dopaminergic	O
neurons	O
in	O
estrogen	S-chem
-	O
deprived	O
mice	O
treated	O
with	O
MPTP	S-chem
-	O
toxin	O
.	O

[	O
Disorders	O
with	O
eosinophilia	O
,	O
treatment	O
of	O
hypereosinophilic	O
syndrome	O
]	O
.	O

Eosinophilia	O
may	O
be	O
associated	O
with	O
reactive	O
conditions	O
and	O
with	O
clonal	O
disorders	O
of	O
the	O
hematopoietic	O
cells	O
.	O

The	O
hypereosinophilic	O
syndrome	O
takes	O
an	O
intermedier	O
place	O
in	O
this	O
group	O
.	O

In	O
this	O
disease	O
a	O
sustained	O
eosinophilia	O
with	O
end	O
organ	O
damage	O
can	O
occur	O
.	O

The	O
author	O
summarized	O
the	O
diagnostic	O
procedures	O
and	O
differential	O
diagnosis	O
in	O
the	O
group	O
of	O
these	O
diseases	O
focusing	O
on	O
characteristics	O
and	O
treatment	O
of	O
hypereosinophilic	O
syndrome	O
.	O

The	O
treatment	O
has	O
been	O
varied	O
and	O
included	O
steroids	S-chem
,	O
hydroxyurea	S-chem
,	O
interferon	B-geneN
-	I-geneN
alpha	E-geneN
,	O
and	O
in	O
some	O
cases	O
chemotherapy	O
.	O

On	O
the	O
basis	O
of	O
FIP1L1	S-geneY
-	O
PDGFRa	S-geneY
fusion	O
gene	O
hypereosinophilic	O
syndrome	O
would	O
be	O
classified	O
as	O
a	O
clonal	O
disease	O
and	O
in	O
the	O
FIP1L1	S-geneY
-	O
PDGFRa	S-geneY
positive	O
cases	O
the	O
tyrosine	B-geneN
kinase	E-geneN
inhibitor	O
imatinib	B-chem
mesylate	E-chem
(	O
Glivec	O
)	O
would	O
be	O
effective	O
.	O

The	O
primary	O
structure	O
of	O
porcine	B-geneY
aminoacylase	I-geneY
1	E-geneY
deduced	O
from	O
cDNA	O
sequence	O
.	O

A	O
cDNA	O
encoding	O
the	O
complete	O
amino	B-chem
acid	E-chem
sequence	O
of	O
aminoacylase	B-geneY
1	E-geneY
(	O
N	B-geneY
-	I-geneY
acylamino	I-geneY
acid	I-geneY
aminohydrolase	E-geneY
,	O
ACY	B-geneY
-	I-geneY
1	E-geneY
)	O
[	O
EC	B-geneY
3.5.1.14	E-geneY
]	O
,	O
a	O
dimeric	O
metalloprotein	S-geneN
having	O
two	O
Zn2	B-chem
+	E-chem
in	O
the	O
molecule	O
,	O
which	O
catalyzes	O
the	O
deacylation	O
of	O
N	B-chem
-	I-chem
acylated	I-chem
L	I-chem
-	I-chem
amino	I-chem
acids	E-chem
except	O
L	B-chem
-	I-chem
aspartic	I-chem
acid	E-chem
,	O
has	O
been	O
isolated	O
from	O
porcine	O
kidney	O
lambda	O
gt10	O
cDNA	O
library	O
and	O
sequenced	O
.	O

From	O
sequence	O
analysis	O
of	O
the	O
cDNA	O
and	O
the	O
N	S-chem
-	O
and	O
C	S-chem
-	O
terminal	O
amino	B-chem
acid	E-chem
analyses	O
of	O
the	O
purified	O
protein	O
,	O
it	O
is	O
deduced	O
that	O
porcine	B-geneY
kidney	I-geneY
ACY	I-geneY
-	I-geneY
1	E-geneY
consists	O
of	O
two	O
identical	O
subunits	O
(	O
M	O
(	O
r	O
)	O
45,260	O
)	O
,	O
each	O
of	O
which	O
consists	O
of	O
a	O
single	O
chain	O
of	O
406	O
amino	B-chem
acids	E-chem
with	O
acetylalanine	S-chem
at	O
the	O
N	S-chem
-	O
terminus	O
.	O

A	O
cDNA	O
encoding	O
porcine	B-geneY
liver	I-geneY
ACY	I-geneY
-	I-geneY
1	E-geneY
was	O
also	O
cloned	O
.	O

The	O
amino	B-chem
acid	E-chem
sequence	O
deduced	O
from	O
the	O
nucleotide	S-chem
sequence	O
of	O
the	O
cDNA	O
from	O
porcine	O
liver	O
was	O
identical	O
to	O
that	O
deduced	O
for	O
porcine	B-geneY
kidney	I-geneY
ACY	I-geneY
-	I-geneY
1	E-geneY
.	O

Northern	O
blot	O
analysis	O
suggested	O
that	O
ACY	B-geneY
-	I-geneY
1	E-geneY
is	O
more	O
highly	O
expressed	O
in	O
kidney	O
than	O
in	O
liver	O
.	O

Comparison	O
of	O
the	O
amino	B-chem
acid	E-chem
sequence	O
of	O
porcine	B-geneY
ACY	I-geneY
-	I-geneY
1	E-geneY
with	O
those	O
of	O
other	O
Zn2	B-geneN
+	I-geneN
-	I-geneN
binding	I-geneN
metalloenzymes	E-geneN
showed	O
no	O
significant	O
homologies	O
in	O
either	O
the	O
overall	O
sequence	O
or	O
the	O
consensus	O
sequences	O
for	O
the	O
metal	O
binding	O
sites	O
.	O

This	O
indicates	O
that	O
ACY	B-geneY
-	I-geneY
1	E-geneY
is	O
a	O
new	O
type	O
of	O
metalloprotein	S-geneN
.	O

Identification	O
of	O
an	O
Allosteric	O
Modulator	O
of	O
Serotonin	B-geneY
Transporter	E-geneY
with	O
Novel	O
Mechanism	O
of	O
Action	O
.	O

Serotonin	B-geneY
transporters	E-geneY
(	O
SERT	S-geneY
)	O
play	O
an	O
essential	O
role	O
in	O
the	O
termination	O
and	O
regulation	O
of	O
serotonin	S-chem
signaling	O
in	O
the	O
brain	O
.	O

SERT	S-geneY
is	O
also	O
the	O
target	O
of	O
antidepressants	O
and	O
psychostimulants	O
.	O

Molecules	O
with	O
novel	O
activities	O
and	O
modes	O
of	O
interaction	O
with	O
regard	O
to	O
SERT	S-geneY
function	O
are	O
of	O
great	O
scientific	O
and	O
clinical	O
interest	O
.	O

We	O
explored	O
structural	O
regions	O
outside	O
the	O
putative	O
serotonin	S-chem
translocation	O
pathway	O
to	O
identify	O
potential	O
binding	O
sites	O
for	O
allosteric	O
transporter	O
modulators	O
(	O
ATMs	O
)	O
.	O

Mutational	O
studies	O
revealed	O
a	O
pocket	O
of	O
amino	B-chem
acids	E-chem
outside	O
the	O
orthosteric	O
substrate	O
binding	O
sites	O
located	O
in	O
the	O
interface	O
between	O
extracellular	O
loops	O
1	O
and	O
3	O
that	O
when	O
mutated	O
affect	O
transporter	O
function	O
.	O

Using	O
the	O
structure	O
of	O
the	O
bacterial	O
transporter	O
homologue	O
leucine	B-geneN
transporter	E-geneN
as	O
a	O
template	O
,	O
we	O
developed	O
a	O
structural	O
model	O
of	O
SERT	S-geneY
.	O

We	O
performed	O
molecular	O
dynamics	O
simulations	O
to	O
further	O
characterize	O
the	O
allosteric	O
pocket	O
that	O
was	O
identified	O
by	O
site	O
-	O
directed	O
mutagenesis	O
studies	O
and	O
employed	O
this	O
pocket	O
in	O
a	O
virtual	O
screen	O
for	O
small	O
-	O
molecule	O
modulators	O
of	O
SERT	S-geneY
function	O
.	O

In	O
functional	O
transport	O
assays	O
,	O
we	O
found	O
that	O
one	O
of	O
the	O
identified	O
molecules	O
,	O
ATM7	O
,	O
increased	O
the	O
reuptake	O
of	O
serotonin	S-chem
,	O
possibly	O
by	O
facilitating	O
the	O
interaction	O
of	O
serotonin	S-chem
with	O
transport	O
-	O
ready	O
conformations	O
of	O
SERT	S-geneY
when	O
concentrations	O
of	O
serotonin	S-chem
were	O
low	O
and	O
rate	O
limiting	O
.	O

In	O
addition	O
,	O
ATM7	O
potentiates	O
3,4	B-chem
-	I-chem
methylenedioxy	I-chem
-	I-chem
N	I-chem
-	I-chem
methylamphetamine	E-chem
(	O
MDMA	S-chem
,	O
``	O
Ecstasy	O
``	O
)	O
-	O
induced	O
reversed	O
transport	O
by	B-geneY
SERT	O
.	O

Taking	O
advantage	O
of	O
a	O
conformationally	O
sensitive	O
residue	O
in	O
transmembrane	O
domain	O
6	O
,	O
we	O
demonstrate	O
that	O
ATM7	O
mechanistically	O
stabilizes	O
an	O
outward	O
-	O
facing	O
conformation	O
of	O
SERT	S-geneY
.	O

Taken	O
together	O
these	O
observations	O
demonstrate	O
that	O
ATM7	O
acts	O
through	O
a	O
novel	O
mechanism	O
that	O
involves	O
allosteric	O
modulation	O
of	O
SERT	S-geneY
function	O
.	O

Integrated	O
chemical	O
and	O
biological	O
analysis	O
to	O
explain	O
estrogenic	O
potency	O
in	O
bile	O
extracts	O
of	O
red	O
mullet	O
(	O
Mullus	O
barbatus	O
)	O
.	O

A	O
biological	O
screening	O
was	O
performed	O
to	O
establish	O
the	O
total	O
exposure	O
to	O
estrogenic	O
compounds	O
of	O
red	O
mullet	O
(	O
Mullus	O
barbatus	O
)	O
collected	O
at	O
several	O
sites	O
along	O
the	O
Spanish	O
Mediterranean	O
coast	O
by	O
testing	O
male	O
fish	O
bile	O
extracts	O
using	O
the	O
in	O
vitro	O
ER	S-geneY
-	O
LUC	O
reporter	O
gene	O
assay	O
.	O

In	O
addition	O
,	O
major	O
metabolites	O
were	O
identified	O
and	O
measurements	O
of	O
OH	B-chem
-	I-chem
PAHs	E-chem
(	O
1	B-chem
-	I-chem
naphthol	E-chem
,	O
9	B-chem
-	I-chem
phenantrol	E-chem
,	O
9	B-chem
-	I-chem
fluorenol	E-chem
,	O
1	B-chem
-	I-chem
pyrenol	E-chem
,	O
1OH	B-chem
-	I-chem
BaP	E-chem
and	O
3OH	B-chem
-	I-chem
BaP	E-chem
)	O
and	O
alkylphenols	S-chem
(	O
4	B-chem
-	I-chem
n	I-chem
-	I-chem
nonylphenol	E-chem
(	O
4	B-chem
-	I-chem
n	I-chem
-	I-chem
NP	E-chem
)	O
and	O
4	B-chem
-	I-chem
tertoctylphenol	E-chem
(	O
4	B-chem
-	I-chem
tert	I-chem
-	I-chem
OP	E-chem
)	O
)	O
in	O
the	O
same	O
fish	O
bile	O
extracts	O
were	O
taken	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
in	O
electron	O
ionization	O
mode	O
(	O
GC	O
-	O
EI	O
-	O
MS	O
)	O
.	O

Relative	O
in	O
vitro	O
estrogenic	O
potencies	O
of	O
the	O
chemically	O
quantified	O
compounds	O
were	O
also	O
tested	O
.	O

The	O
highest	O
biliary	O
concentrations	O
of	O
1	B-chem
-	I-chem
pyrenol	E-chem
,	O
9	B-chem
-	I-chem
fluorenol	E-chem
and	O
4	B-chem
-	I-chem
n	I-chem
-	I-chem
NP	E-chem
were	O
found	O
in	O
fish	O
from	O
Barcelona	O
and	O
from	O
the	O
Mar	O
Menor	O
coastal	O
lagoon	O
.	O

However	O
,	O
these	O
concentrations	O
can	O
be	O
considered	O
relatively	O
low	O
compared	O
to	O
values	O
reported	O
in	O
red	O
mullet	O
from	O
other	O
polluted	O
waters	O
in	O
the	O
Mediterranean	O
Sea	O
.	O

The	O
contribution	O
of	O
1	B-chem
-	I-chem
pyrenol	E-chem
,	O
4	B-chem
-	I-chem
n	I-chem
-	I-chem
NP	E-chem
and	O
4	B-chem
-	I-chem
tert	I-chem
-	I-chem
OP	E-chem
to	O
the	O
total	O
estrogenic	O
potency	O
measured	O
in	O
male	O
fish	O
bile	O
was	O
found	O
to	O
be	O
negligible	O
,	O
indicating	O
the	O
presence	O
of	O
other	O
estrogenic	O
compounds	O
in	O
red	O
mullet	O
bile	O
.	O

Estrogenic	O
potency	O
in	O
bile	O
from	O
male	O
fish	O
was	O
markedly	O
elevated	O
in	O
Mar	O
Menor	O
lagoon	O
(	O
234.8±5.7pgE2EQ	O
/	O
μl	O
)	O
,	O
and	O
further	O
research	O
will	O
be	O
necessary	O
to	O
explain	O
whether	O
the	O
presence	O
of	O
natural	O
and	O
synthetic	O
-	O
hormones	O
in	O
the	O
lagoon	O
contributed	O
to	O
this	O
finding	O
.	O

Values	O
of	O
approximately	O
15	O
-	O
16E2EQpg	O
/	O
mg	O
bile	O
can	O
be	O
regarded	O
as	O
preliminary	O
baseline	O
levels	O
of	O
bile	O
estrogenicity	O
in	O
male	O
red	O
mullet	O
from	O
the	O
western	O
Mediterranean	O
Sea	O
.	O

Turnover	O
of	O
type	B-geneN
II	I-geneN
collagen	E-geneN
and	O
aggrecan	S-geneY
in	O
cartilage	O
matrix	O
at	O
the	O
onset	O
of	O
inflammatory	O
arthritis	O
in	O
humans	O
:	O
relationship	O
to	O
mediators	O
of	O
systemic	O
and	O
local	O
inflammation	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
in	O
vivo	O
the	O
extent	O
of	O
damage	O
to	O
,	O
and	O
changes	O
in	O
turnover	O
of	O
,	O
articular	O
cartilage	O
type	B-geneN
II	I-geneN
collagen	E-geneN
(	O
CII	S-geneN
)	O
and	O
the	O
proteoglycan	S-geneN
aggrecan	S-geneY
following	O
the	O
onset	O
of	O
inflammatory	O
arthritis	O
in	O
humans	O
,	O
and	O
to	O
examine	O
the	O
hypothesis	O
that	O
there	O
are	O
direct	O
relationships	O
between	O
cartilage	O
biomarkers	O
of	O
damage	O
/	O
turnover	O
and	O
clinical	O
,	O
histologic	O
,	O
and	O
molecular	O
markers	O
of	O
inflammation	O
.	O

METHODS	O
:	O
Synovial	O
fluid	O
(	O
SF	O
)	O
and	O
synovial	O
membrane	O
(	O
SM	O
)	O
were	O
obtained	O
by	O
arthroscopy	O
,	O
and	O
a	O
synovitis	O
score	O
was	O
determined	O
,	O
in	O
32	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
(	O
13	O
with	O
early	O
untreated	O
disease	O
,	O
19	O
with	O
established	O
disease	O
)	O
,	O
18	O
with	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
,	O
and	O
10	O
with	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

Systemic	O
disease	O
activity	O
markers	O
were	O
recorded	O
,	O
and	O
SM	O
CD3	O
+	O
T	O
cells	O
,	O
CD4	O
+	O
T	O
cells	O
,	O
CD68	O
+	O
macrophages	O
,	O
and	O
lining	O
layer	O
hyperplasia	O
were	O
quantified	O
.	O

SF	O
levels	O
of	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
alpha	E-geneY
(	O
TNFalpha	S-geneY
)	O
,	O
interleukin	B-geneY
-	I-geneY
10	E-geneY
(	O
IL	B-geneY
-	I-geneY
10	E-geneY
)	O
,	O
matrix	B-geneY
metalloproteinase	I-geneY
1	E-geneY
(	O
MMP	B-geneY
-	I-geneY
1	E-geneY
)	O
,	O
MMP	B-geneY
-	I-geneY
3	E-geneY
,	O
Col2	B-geneN
-	I-geneN
3	I-geneN
/	I-geneN
4C	O
(	I-geneN
Long	I-geneN
mono	I-geneN
)	I-geneN
neoepitope	E-geneN
(	O
C2C	S-geneN
)	O
(	O
reflecting	O
collagenase	S-geneN
cleavage	O
of	O
cartilage	O
CII	S-geneN
)	O
,	O
C	B-geneN
-	I-geneN
propeptide	I-geneN
of	I-geneN
type	I-geneN
II	I-geneN
procollagen	E-geneN
(	O
PIICP	S-geneN
)	O
(	O
a	O
biosynthesis	O
marker	O
)	O
,	O
keratan	O
sulfate	S-chem
(	O
KS	O
)	O
,	O
and	O
the	O
846	O
epitope	O
of	O
aggrecan	S-geneY
(	O
turnover	O
)	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
or	O
radioimmunoassay	O
.	O

RESULTS	O
:	O
Levels	O
of	O
cartilage	O
degradation	O
products	O
in	O
early	O
RA	O
or	O
early	O
PsA	O
were	O
not	O
elevated	O
above	O
levels	O
in	O
OA	O
,	O
although	O
in	O
early	O
inflammatory	O
arthritis	O
,	O
TNFalpha	S-geneY
and	O
MMP	B-geneY
-	I-geneY
1	E-geneY
levels	O
were	O
similar	O
to	O
those	O
observed	O
in	O
late	O
inflammatory	O
disease	O
and	O
higher	O
than	O
those	O
in	O
OA	O
.	O

PIICP	S-geneN
was	O
reduced	O
in	O
early	O
RA	O
.	O

Correlations	O
were	O
observed	O
between	O
the	O
SF	O
C2C	B-geneN
neoepitope	E-geneN
level	O
and	O
the	O
Health	O
Assessment	O
Questionnaire	O
score	O
,	O
C	B-geneY
-	I-geneY
reactive	I-geneY
protein	E-geneY
level	O
,	O
plasma	O
viscosity	O
,	O
synovitis	O
score	O
,	O
and	O
SF	O
TNFalpha	S-geneY
and	O
MMP	B-geneY
-	I-geneY
1	E-geneY
levels	O
.	O

KS	O
epitope	O
content	O
was	O
reduced	O
in	O
direct	O
relation	O
to	O
SM	O
macrophage	O
infiltration	O
in	O
the	O
sublining	O
and	O
lining	O
layers	O
and	O
in	O
the	O
presence	O
of	O
elevated	O
SF	O
MMP	B-geneY
-	I-geneY
3	E-geneY
.	O

Both	O
SF	O
MMP	B-geneY
-	I-geneY
1	E-geneY
and	O
SF	O
MMP	B-geneY
-	I-geneY
3	E-geneY
levels	O
correlated	O
with	O
CD4	O
+	O
T	O
cell	O
infiltration	O
and	O
lining	O
layer	O
hyperplasia	O
in	O
the	O
SM	O
,	O
and	O
MMP	B-geneY
-	I-geneY
1	E-geneY
levels	O
correlated	O
with	O
lining	O
layer	O
CD68	S-geneY
levels	O
,	O
but	O
TNFalpha	S-geneY
and	O
IL	B-geneY
-	I-geneY
10	E-geneY
levels	O
did	O
not	O
.	O

CONCLUSION	O
:	O
Except	O
for	O
CII	S-geneN
synthesis	O
,	O
there	O
were	O
no	O
significant	O
changes	O
in	O
extracellular	O
matrix	O
turnover	O
of	O
aggrecan	S-geneY
or	O
CII	S-geneN
in	O
the	O
early	O
stages	O
of	O
human	O
inflammatory	O
arthritis	O
.	O

However	O
,	O
the	O
direct	O
correlation	O
between	O
the	O
increases	O
in	O
TNFalpha	S-geneY
and	O
MMP	B-geneY
-	I-geneY
1	E-geneY
production	O
and	O
collagen	S-geneN
degradation	O
suggests	O
that	O
collagenase	S-geneN
cleavage	O
of	O
cartilage	O
collagen	S-geneN
is	O
related	O
to	O
the	O
activities	O
of	O
TNFalpha	S-geneY
and	O
MMP	B-geneY
-	I-geneY
1	E-geneY
.	O

The	O
reduction	O
in	O
CII	S-geneN
synthesis	O
in	O
early	O
RA	O
may	O
contribute	O
to	O
the	O
developing	O
pathology	O
,	O
since	O
a	O
lack	O
of	O
synthesis	O
of	O
this	O
molecule	O
would	O
inhibit	O
maintenance	O
of	O
cartilage	O
matrix	O
.	O

Pharmacotherapy	O
for	O
the	O
core	O
symptoms	O
in	O
autistic	O
disorder	O
:	O
current	O
status	O
of	O
the	O
research	O
.	O

The	O
current	O
review	O
covers	O
extant	O
literature	O
on	O
pharmacotherapy	O
for	O
core	O
symptoms	O
of	O
autism	O
.	O

The	O
core	O
symptoms	O
of	O
autism	O
include	O
impairments	O
in	O
social	O
interaction	O
and	O
communication	O
,	O
as	O
well	O
as	O
the	O
presence	O
of	O
restricted	O
and	O
repetitive	O
behaviors	O
.	O

There	O
are	O
no	O
known	O
efficacious	O
treatments	O
for	O
the	O
core	O
social	O
symptoms	O
,	O
although	O
effects	O
on	O
repetitive	O
behaviors	O
are	O
indicated	O
with	O
some	O
data	O
.	O

While	O
studies	O
of	O
fenfluramine	S-chem
,	O
secretin	S-geneY
,	O
opiates	O
,	O
and	O
mood	O
stabilizers	O
generally	O
find	O
no	O
effect	O
,	O
mixed	O
results	O
suggest	O
more	O
research	O
is	O
needed	O
on	O
antidepressants	O
and	O
atypical	O
antipsychotics	O
.	O

Newer	O
lines	O
of	O
research	O
,	O
including	O
cholinergic	O
and	O
glutamatergic	O
agents	O
and	O
oxytocin	S-geneY
,	O
will	O
be	O
of	O
considerable	O
interest	O
in	O
the	O
future	O
.	O

However	O
,	O
research	O
on	O
the	O
treatment	O
of	O
core	O
symptoms	O
is	O
plagued	O
by	O
limitations	O
in	O
study	O
design	O
,	O
statistical	O
power	O
,	O
and	O
other	O
issues	O
inherent	O
to	O
the	O
study	O
of	O
treatments	O
for	O
autism	O
(	O
e.g	O
.	O
,	O
heterogeneity	O
of	O
the	O
disorder	O
)	O
that	O
continue	O
to	O
prevent	O
the	O
elucidation	O
of	O
efficacious	O
treatments	O
.	O

Different	O
effects	O
of	O
clopidogrel	S-chem
and	O
clarithromycin	S-chem
on	O
the	O
enantioselective	O
pharmacokinetics	O
of	O
sibutramine	S-chem
and	O
its	O
active	O
metabolites	O
in	O
healthy	O
subjects	O
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
the	O
effects	O
of	O
clopidogrel	S-chem
and	O
clarithromycin	S-chem
,	O
known	O
CYP2B6	S-geneY
and	O
CYP3A	S-geneN
inhibitors	O
,	O
respectively	O
,	O
on	O
the	O
enantioselective	O
disposition	O
of	O
racemic	B-chem
sibutramine	E-chem
in	O
conjunction	O
with	O
CYP2B6	S-geneY
polymorphisms	O
in	O
humans	O
.	O

Sibutramine	S-chem
showed	O
enantioselective	O
plasma	O
profiles	O
with	O
consistently	O
higher	O
concentrations	O
of	O
R	O
-	O
enantiomers	O
.	O

Clopidogrel	S-chem
and	O
clarithromycin	S-chem
significantly	O
increased	O
the	O
sibutramine	S-chem
plasma	O
concentration	O
,	O
but	O
their	O
effects	O
differed	O
between	O
enantiomers	O
;	O
a	O
2.2	O
-	O
fold	O
versus	O
4.1	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
in	O
S	O
-	O
enantiomer	O
and	O
1.8	O
-	O
fold	O
versus	O
2.0	O
-	O
fold	O
for	O
the	O
R	O
-	O
enantiomer	O
,	O
respectively	O
.	O

The	O
AUCs	O
of	O
S	O
-	O
and	O
R	O
-	O
desmethyl	O
metabolites	O
changed	O
significantly	O
during	O
the	O
clopidogrel	S-chem
phase	O
(	O
P	O
<	O
.001	O
and	O
P	O
<	O
.001	O
,	O
respectively	O
)	O
but	O
not	O
during	O
the	O
clarithromycin	O
phase	O
(	O
P	O
=	O
.099	O
and	O
P	O
=	O
.090	O
,	O
respectively	O
)	O
.	O

Exposure	O
to	O
sibutramine	S-chem
was	O
higher	O
in	O
subjects	O
with	O
the	O
CYP2B6	S-geneY
*	O
6	O
/	O
*	O
6	O
genotype	O
,	O
but	O
no	O
statistical	O
difference	O
was	O
observed	O
among	O
the	O
CYP2B6	S-geneY
genotypes	O
.	O

These	O
results	O
suggest	O
that	O
the	O
enantioselective	O
disposition	O
of	O
sibutramine	S-chem
and	O
its	O
active	O
metabolites	O
are	O
influenced	O
by	O
the	O
altered	O
genetic	O
and	O
environmental	O
factors	O
of	O
CYP2B6	S-geneY
and	O
CYP3A	S-geneN
activity	O
in	O
vivo	O
.	O

LDL	S-geneN
Cholesterol	S-chem
Goals	O
in	O
High	O
-	O
Risk	O
Patients	O
:	O
How	O
Low	O
Do	O
We	O
Go	O
and	O
How	O
Do	O
We	O
Get	O
There	O
?	O

It	O
is	O
widely	O
recognised	O
that	O
low	B-geneN
-	I-geneN
density	I-geneN
lipoprotein	E-geneN
cholesterol	S-chem
(	O
LDL	S-geneN
-	O
C	O
)	O
is	O
one	O
of	O
the	O
most	O
important	O
and	O
modifiable	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

Statins	O
(	O
HMG	B-geneY
-	I-geneY
CoA	I-geneY
reductase	E-geneY
inhibitors	O
)	O
have	O
consistently	O
been	O
shown	O
to	O
decrease	O
both	O
LDL	S-geneN
-	O
C	O
and	O
CVD	O
risk	O
in	O
almost	O
all	O
patient	O
categories	O
,	O
with	O
the	O
exception	O
of	O
heart	O
and	O
kidney	O
failure	O
as	O
well	O
as	O
advanced	O
aortic	O
stenosis	O
.	O

As	O
a	O
consequence	O
,	O
statins	O
have	O
become	O
the	O
cornerstone	O
in	O
current	O
prevention	O
guidelines	O
.	O

In	O
patients	O
who	O
do	O
not	O
reach	O
the	O
LDL	S-geneN
-	O
C	O
target	O
,	O
combination	O
therapy	O
with	O
additional	O
LDL	S-geneN
-	O
C	O
lowering	O
drugs	O
(	O
e.g	O
.	O
ezetimibe	S-chem
,	O
bile	B-chem
acid	E-chem
sequestrants	O
or	O
fibrates	S-chem
)	O
should	O
be	O
considered	O
.	O

Guidelines	O
provide	O
different	O
LDL	S-geneN
-	O
C	O
levels	O
to	O
strive	O
for	O
,	O
depending	O
on	O
the	O
CVD	O
risk	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
rationale	O
for	O
these	O
LDL	S-geneN
-	O
C	O
targets	O
and	O
how	O
these	O
goals	O
might	O
be	O
reached	O
by	O
current	O
and	O
future	O
therapies	O
.	O

Binding	O
of	O
dimemorfan	S-chem
to	O
sigma	B-geneY
-	I-geneY
1	I-geneY
receptor	E-geneY
and	O
its	O
anticonvulsant	O
and	O
locomotor	O
effects	O
in	O
mice	O
,	O
compared	O
with	O
dextromethorphan	S-chem
and	O
dextrorphan	S-chem
.	O

Dextromethorphan	S-chem
(	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
methoxy	I-chem
-	I-chem
N	I-chem
-	I-chem
methylmorphinan	E-chem
,	O
DM	S-chem
)	O
has	O
been	O
shown	O
to	O
have	O
both	O
anticonvulsant	O
and	O
neuroprotective	O
effects	O
.	O

The	O
mechanisms	O
of	O
these	O
CNS	O
effects	O
of	O
DM	S-chem
have	O
been	O
suggested	O
to	O
be	O
associated	O
with	O
the	O
low	O
-	O
affinity	O
,	O
noncompetitive	O
,	O
N	B-chem
-	I-chem
methyl	I-chem
-	I-chem
d	I-chem
-	I-chem
aspartate	E-chem
(	O
NMDA	S-chem
)	O
antagonism	O
of	O
DM	S-chem
and	O
/	O
or	O
the	O
high	O
-	O
affinity	O
DM	S-chem
/	O
sigma	O
receptors	O
.	O

DM	S-chem
is	O
largely	O
O	S-chem
-	O
demethylated	O
into	O
the	O
phencyclidine	S-chem
(	O
PCP	S-chem
)	O
-	O
like	O
compound	O
dextrorphan	S-chem
(	O
DR	S-chem
)	O
,	O
which	O
may	O
limit	O
its	O
therapeutic	O
use	O
by	O
producing	O
PCP	S-chem
-	O
like	O
adverse	O
effects	O
,	O
such	O
as	O
hyperlocomotion	O
.	O

Dimemorfan	S-chem
(	O
(	B-chem
+	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
methyl	I-chem
-	I-chem
N	I-chem
-	I-chem
methylmorphinan	E-chem
,	O
DF	S-chem
)	O
,	O
an	O
analog	O
of	O
DM	S-chem
,	O
which	O
has	O
been	O
safely	O
used	O
as	O
an	O
antitussive	O
for	O
more	O
than	O
20	O
years	O
,	O
is	O
also	O
known	O
not	O
to	O
form	O
DR	S-chem
.	O

This	O
study	O
therefore	O
characterized	O
the	O
binding	O
of	O
DF	S-chem
to	O
the	O
sigma	B-geneN
receptors	E-geneN
and	O
NMDA	S-chem
-	O
linked	O
PCP	S-chem
sites	O
and	O
examined	O
the	O
anticonvulsant	O
as	O
well	O
as	O
locomotor	O
effects	O
of	O
DF	S-chem
in	O
mice	O
in	O
comparison	O
with	O
those	O
of	O
DM	S-chem
and	O
DR	S-chem
.	O

We	O
found	O
that	O
DF	S-chem
,	O
DM	S-chem
,	O
and	O
DR	S-chem
were	O
relative	O
high	O
-	O
affinity	O
ligands	O
at	O
sigma	B-geneY
-	I-geneY
1	I-geneY
receptors	E-geneY
(	O
Ki	O
=	O
151	O
,	O
205	O
,	O
144	O
nM	O
,	O
respectively	O
)	O
while	O
all	O
of	O
them	O
were	O
with	O
low	O
affinity	O
at	O
sigma	B-geneN
-	I-geneN
2	I-geneN
receptors	E-geneN
(	O
Ki	O
=	O
4	O
-	O
11	O
microM	O
)	O
.	O

Only	O
DR	S-chem
exhibited	O
moderate	O
affinity	O
for	O
PCP	S-chem
sites	O
(	O
Ki	O
=	O
0.9	O
microM	O
)	O
,	O
whereas	O
DF	S-chem
(	O
Ki	O
=	O
17	O
microM	O
)	O
and	O
DM	S-chem
(	O
Ki	O
=	O
7	O
microM	O
)	O
were	O
much	O
less	O
active	O
.	O

DF	O
,	O
DM	S-chem
and	O
DR	S-chem
produced	O
prominent	O
anticonvulsant	O
effects	O
in	O
mice	O
as	O
measured	O
by	O
the	O
supramaximal	O
electroshock	O
test	O
with	O
comparable	O
potency	O
(	O
ED50	O
approximately	O
70	O
micromol	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

At	O
the	O
tested	O
doses	O
(	O
20	O
-	O
260	O
micromol	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
DM	S-chem
and	O
DR	S-chem
exhibited	O
biphasic	O
effects	O
on	O
the	O
locomotor	O
activity	O
whereas	O
DF	S-chem
produced	O
a	O
consistent	O
dose	O
-	O
dependent	O
decrease	O
.	O

These	O
results	O
revealed	O
that	O
,	O
unlike	O
DM	S-chem
and	O
DR	S-chem
,	O
DF	S-chem
did	O
not	O
cause	O
a	O
PCP	S-chem
-	O
like	O
hyperlocomotion	O
adverse	O
effect	O
that	O
is	O
parallel	O
with	O
the	O
PCP	S-chem
sites	O
binding	O
data	O
.	O

Furthermore	O
,	O
since	O
they	O
have	O
equipotent	O
anticonvulsant	O
effects	O
and	O
similar	O
binding	O
affinities	O
to	O
sigma	B-geneY
-	I-geneY
1	I-geneY
receptors	E-geneY
,	O
the	O
very	O
low	O
affinity	O
of	O
DF	S-chem
at	O
PCP	S-chem
sites	O
may	O
suggest	O
that	O
acting	O
on	O
the	O
PCP	S-chem
sites	O
may	O
not	O
be	O
the	O
requisite	O
for	O
mediating	O
the	O
anticonvulsant	O
activity	O
of	O
these	O
DM	S-chem
analogs	O
.	O

With	O
the	O
history	O
of	O
safety	O
and	O
relative	O
less	O
adverse	O
effects	O
,	O
DF	S-chem
appears	O
to	O
be	O
worth	O
further	O
studying	O
on	O
its	O
CNS	O
effects	O
other	O
than	O
the	O
antitussive	O
effect	O
.	O

β	O
-	O
Cells	O
Are	O
Not	O
Generated	O
in	O
Pancreatic	O
Duct	O
Ligation	O
-	O
Induced	O
Injury	O
in	O
Adult	O
Mice	O
.	O

The	O
existence	O
of	O
adult	O
β	O
-	O
cell	O
progenitors	O
remains	O
the	O
most	O
controversial	O
developmental	O
biology	O
topic	O
in	O
diabetes	O
research	O
.	O

It	O
has	O
been	O
reported	O
that	O
β	O
-	O
cell	O
progenitors	O
can	O
be	O
activated	O
by	O
ductal	O
ligation	O
-	O
induced	O
injury	O
of	O
adult	O
mouse	O
pancreas	O
and	O
apparently	O
act	O
in	O
a	O
cell	O
-	O
autonomous	O
manner	O
to	O
double	O
the	O
functional	O
β	O
-	O
cell	O
mass	O
within	O
a	O
week	O
by	O
differentiation	O
and	O
proliferation	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
pancreatic	O
duct	O
ligation	O
(	O
PDL	O
)	O
does	O
not	O
activate	O
progenitors	O
to	O
contribute	O
to	O
β	O
-	O
cell	O
mass	O
expansion	O
.	O

Rather	O
,	O
PDL	O
stimulates	O
massive	O
pancreatic	O
injury	O
,	O
which	O
alters	O
pancreatic	O
composition	O
and	O
thus	O
complicates	O
accurate	O
measurement	O
of	O
β	O
-	O
cell	O
content	O
via	O
traditional	O
morphometry	O
methodologies	O
that	O
superficially	O
sample	O
the	O
pancreas	O
.	O

To	O
overcome	O
this	O
potential	O
bias	O
,	O
we	O
quantified	O
β	O
-	O
cells	O
from	O
the	O
entire	O
pancreas	O
and	O
observed	O
that	O
β	O
-	O
cell	O
mass	O
and	O
insulin	S-geneN
content	O
are	O
totally	O
unchanged	O
by	O
PDL	O
-	O
induced	O
injury	O
.	O

Lineage	O
-	O
tracing	O
studies	O
using	O
sequential	O
administration	O
of	O
thymidine	S-chem
analogs	O
,	O
rat	B-geneN
insulin	I-geneN
2	I-geneN
promoter	E-geneN
-	O
driven	O
cre	S-geneN
-	O
lox	S-geneN
,	O
and	O
low	O
-	O
frequency	O
ubiquitous	O
cre	S-geneN
-	O
lox	S-geneN
reveal	O
that	O
PDL	O
does	O
not	O
convert	O
progenitors	O
to	O
the	O
β	O
-	O
cell	O
lineage	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
β	O
-	O
cells	O
are	O
not	O
generated	O
in	O
injured	O
adult	O
mouse	O
pancreas	O
.	O

Interaction	O
of	O
human	B-geneY
alpha	I-geneY
-	I-geneY
lactalbumin	E-geneY
with	O
fatty	B-chem
acids	E-chem
:	O
determination	O
of	O
binding	O
parameters	O
.	O

The	O
interaction	O
of	O
holo	O
-	O
and	O
apo	O
-	O
forms	O
of	O
human	B-geneY
alpha	I-geneY
-	I-geneY
lactalbumin	E-geneY
with	O
fatty	B-chem
acids	E-chem
was	O
studied	O
by	O
a	O
partition	O
equilibrium	O
method	O
.	O

Apo	B-geneY
-	I-geneY
alpha	I-geneY
-	I-geneY
lactalbumin	E-geneY
,	O
obtained	O
by	O
treatment	O
with	O
EDTA	S-chem
,	O
displays	O
one	O
binding	O
site	O
for	O
fatty	B-chem
acids	E-chem
,	O
the	O
association	O
constants	O
for	O
oleic	B-chem
and	I-chem
palmitic	I-chem
acids	E-chem
being	O
1.9.10	O
(	O
6	O
)	O
and	O
4.2.10	O
(	O
5	O
)	O
M	O
(	O
-	O
1	O
)	O
,	O
respectively	O
.	O

However	O
,	O
holo	B-geneY
-	I-geneY
alpha	I-geneY
-	I-geneY
lactalbumin	E-geneY
was	O
unable	O
to	O
bind	O
fatty	B-chem
acids	E-chem
as	O
measured	O
by	O
this	O
technique	O
.	O

Likewise	O
,	O
no	O
fatty	B-chem
acids	E-chem
bound	O
to	O
holo	B-geneY
-	I-geneY
alpha	I-geneY
-	I-geneY
lactalbumin	E-geneY
,	O
isolated	O
using	O
nondenaturing	O
conditions	O
,	O
were	O
detected	O
by	O
gas	O
chromatography	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
conformational	O
change	O
induced	O
in	O
alpha	B-geneY
-	I-geneY
lactalbumin	E-geneY
by	O
the	O
removal	O
of	O
calcium	S-chem
enables	O
the	O
protein	O
to	O
interact	O
with	O
fatty	O
acids	O
.	O

Neuroactive	O
effects	O
of	O
cotinine	S-chem
on	O
the	O
hippocampus	O
:	O
Behavioral	O
and	O
biochemical	O
parameters	O
.	O

The	O
present	O
work	O
evaluated	O
the	O
effects	O
of	O
nicotine	S-chem
(	O
NIC	S-chem
)	O
,	O
cotinine	S-chem
(	O
COT	S-chem
)	O
,	O
mecamylamine	S-chem
(	O
MEC	S-chem
)	O
,	O
methyllycaconitine	S-chem
(	O
MLA	S-chem
)	O
and	O
dihydro	B-chem
-	I-chem
beta	I-chem
-	I-chem
eritroidine	E-chem
(	O
DHβE	S-chem
)	O
on	O
memory	O
extinction	O
and	O
the	O
following	O
biochemical	O
parameters	O
of	O
the	O
hippocampus	O
:	O
lipid	O
peroxidation	O
(	O
LPO	O
)	O
,	O
antioxidant	O
capacity	O
(	O
AC	O
)	O
and	O
the	O
phosphorylation	O
of	O
Extracellular	B-geneN
-	I-geneN
Signal	I-geneN
-	I-geneN
Regulated	I-geneN
Kinase	E-geneN
(	O
ERK	B-geneN
1	I-geneN
/	I-geneN
2	E-geneN
)	O
.	O

Young	O
male	O
rats	O
that	O
were	O
implanted	O
bilaterally	O
with	O
cannulae	O
were	O
submitted	O
to	O
memory	O
extinction	O
tests	O
sessions	O
,	O
and	O
their	O
hippocampi	O
were	O
dissected	O
for	O
biochemical	O
assays	O
.	O

The	O
extinction	O
of	O
fear	O
memory	O
was	O
significantly	O
improved	O
by	O
both	O
nicotine	S-chem
and	O
its	O
metabolite	O
.	O

Cotinine	S-chem
significantly	O
increased	O
LPO	O
,	O
while	O
nicotine	S-chem
significantly	O
decreased	O
it	O
.	O

Antioxidant	O
capacity	O
was	O
increased	O
by	O
all	O
treatments	O
.	O

Our	O
results	O
showed	O
that	O
cotinine	S-chem
,	O
unlike	O
nicotine	S-chem
,	O
may	O
increase	O
oxidative	O
stress	O
in	O
the	O
hippocampus	O
,	O
but	O
this	O
increase	O
depends	O
upon	O
the	O
dose	O
used	O
and	O
happens	O
without	O
causing	O
corresponding	O
impairments	O
in	O
cognitive	O
function	O
.	O

Cotinine	S-chem
also	O
increased	O
the	O
phosphorylation	O
of	O
ERK	B-geneN
1	I-geneN
/	I-geneN
2	E-geneN
in	O
a	O
similar	O
fashion	O
as	O
nicotine	S-chem
.	O

Considering	O
these	O
results	O
,	O
it	O
is	O
plausible	O
to	O
wonder	O
to	O
what	O
extent	O
nicotine	S-chem
-	O
attributed	O
effects	O
are	O
really	O
due	O
to	O
the	O
actions	O
of	O
this	O
alkaloid	O
and	O
whether	O
they	O
could	O
be	O
due	O
instead	O
to	O
cotinine	S-chem
or	O
to	O
cotinine	S-chem
-	O
nicotine	S-chem
interactions	O
within	O
the	O
brain	O
.	O

Cytosolic	B-geneY
aspartate	I-geneY
aminotransferase	E-geneY
,	O
a	O
new	O
partner	O
in	O
adipocyte	O
glyceroneogenesis	O
and	O
an	O
atypical	O
target	O
of	O
thiazolidinedione	S-chem
.	O

We	O
show	O
that	O
cytosolic	B-geneY
aspartate	I-geneY
aminotransferase	E-geneY
(	O
cAspAT	S-geneY
)	O
is	O
involved	O
in	O
adipocyte	O
glyceroneogenesis	O
,	O
a	O
regulated	O
pathway	O
that	O
controls	O
fatty	B-chem
acid	E-chem
homeostasis	O
by	O
promoting	O
glycerol	B-chem
3	I-chem
-	I-chem
phosphate	E-chem
formation	O
for	O
fatty	B-chem
acid	E-chem
re	O
-	O
esterification	O
during	O
fasting	O
.	O
cAspAT	S-geneY
activity	O
,	O
as	O
well	O
as	O
the	O
incorporation	O
of	O
[	B-chem
(	I-chem
14	I-chem
)	I-chem
C	I-chem
]	I-chem
aspartate	E-chem
into	O
the	O
neutral	O
lipid	O
fraction	O
of	O
3T3	O
-	O
F442A	S-geneN
adipocytes	O
was	O
stimulated	O
by	O
the	O
thiazolidinedione	S-chem
(	O
TZD	S-chem
)	O
rosiglitazone	S-chem
.	O

Conversely	O
,	O
the	O
ratio	O
of	O
fatty	B-chem
acid	E-chem
to	O
glycerol	S-chem
released	O
into	O
the	O
medium	O
decreased	O
.	O

Regulation	O
of	O
cAspAT	S-geneY
gene	O
expression	O
was	O
specific	O
to	O
differentiated	O
adipocytes	O
and	O
did	O
not	O
require	O
any	O
peroxisome	B-geneY
proliferator	I-geneY
-	I-geneY
activated	I-geneY
receptor	I-geneY
gamma	E-geneY
(	O
PPARgamma	S-geneY
)	O
/	O
retinoid	B-geneY
X	I-geneY
receptor	I-geneY
-	I-geneY
alpha	E-geneY
direct	O
binding	O
.	O

Nevertheless	O
,	O
PPARgamma	S-geneY
is	O
indirectly	O
necessary	O
for	O
both	O
cAspAT	S-geneY
basal	O
expression	O
and	O
TZD	S-chem
responsiveness	O
because	O
they	O
are	O
,	O
respectively	O
,	O
diminished	O
and	O
abolished	O
by	O
ectopic	O
overexpression	O
of	O
a	O
dominant	O
negative	O
PPARgamma	S-geneY
.	O

The	O
cAspAT	S-geneY
TZD	S-chem
-	O
responsive	O
site	O
was	O
restricted	O
to	O
a	O
single	O
AGGACA	S-chem
hexanucleotide	S-chem
located	O
at	O
-	O
381	O
to	O
-	O
376	O
bp	O
whose	O
mutation	O
impaired	O
the	O
specific	O
RORalpha	S-geneY
binding	O
.	O

RORalpha	S-geneY
ectopic	O
expression	O
activated	O
the	O
cAspAT	S-geneY
gene	O
transcription	O
in	O
absence	O
of	O
rosiglitazone	S-chem
,	O
and	O
its	O
protein	O
amount	O
in	O
nuclear	O
extracts	O
is	O
1.8	O
-	O
fold	O
increased	O
by	O
rosiglitazone	S-chem
treatment	O
of	O
adipocytes	O
.	O

Finally	O
,	O
the	O
amounts	O
of	O
RORalpha	S-geneY
and	O
cAspAT	S-geneY
mRNAs	O
were	O
similarly	O
increased	O
by	O
TZD	S-chem
treatment	O
of	O
human	O
adipose	O
tissue	O
explants	O
,	O
confirming	O
coordinated	O
regulation	O
.	O

Our	O
data	O
identify	O
cAspAT	S-geneY
as	O
a	O
new	O
member	O
of	O
glyceroneogenesis	O
,	O
transcriptionally	O
regulated	O
by	O
TZD	S-chem
via	O
the	O
control	O
of	O
RORalpha	S-geneY
expression	O
by	O
PPARgamma	S-geneY
in	O
adipocytes	O
.	O

Impact	O
of	O
quaternary	O
structure	O
dynamics	O
on	O
allosteric	O
drug	O
discovery	O
.	O

The	O
morpheein	O
model	O
of	O
allosteric	O
regulation	O
draws	O
attention	O
to	O
proteins	O
that	O
can	O
exist	O
as	O
an	O
equilibrium	O
of	O
functionally	O
distinct	O
assemblies	O
where	O
:	O
one	O
subunit	O
conformation	O
assembles	O
into	O
one	O
multimer	O
;	O
a	O
different	O
subunit	O
conformation	O
assembles	O
into	O
a	O
different	O
multimer	O
;	O
and	O
the	O
various	O
multimers	O
are	O
in	O
a	O
dynamic	O
equilibrium	O
whose	O
position	O
can	O
be	O
modulated	O
by	O
ligands	O
that	O
bind	O
to	O
a	O
multimer	O
-	O
specific	O
ligand	O
binding	O
site	O
.	O

The	O
case	O
study	O
of	O
porphobilinogen	B-geneY
synthase	E-geneY
(	O
PBGS	S-geneY
)	O
illustrates	O
how	O
such	O
an	O
equilibrium	O
holds	O
lessons	O
for	O
disease	O
mechanisms	O
,	O
drug	O
discovery	O
,	O
understanding	O
drug	O
side	O
effects	O
,	O
and	O
identifying	O
proteins	O
wherein	O
drug	O
discovery	O
efforts	O
might	O
focus	O
on	O
quaternary	O
structure	O
dynamics	O
.	O

The	O
morpheein	O
model	O
of	O
allostery	O
has	O
been	O
proposed	O
as	O
applicable	O
for	O
a	O
wide	O
assortment	O
of	O
disease	O
-	O
associated	O
proteins	O
(	O
Selwood	O
,	O
T.	O
,	O
Jaffe	O
,	O
E.	O
,	O
(	O
2012	O
)	O
Arch	O
.	O

Bioch	O
.	O

Biophys	O
,	O
519	O
:	O
131	O
-	O
143	O
)	O
.	O

Herein	O
we	O
discuss	O
quaternary	O
structure	O
dynamics	O
aspects	O
to	O
drug	O
discovery	O
for	O
the	O
disease	O
-	O
associated	O
putative	O
morpheeins	O
phenylalanine	B-geneY
hydroxylase	E-geneY
,	O
HIV	B-geneY
integrase	E-geneY
,	O
pyruvate	B-geneN
kinase	E-geneN
,	O
and	O
tumor	B-geneY
necrosis	I-geneY
factor	I-geneY
α	E-geneY
.	O

Also	O
highlighted	O
is	O
the	O
quaternary	O
structure	O
equilibrium	O
of	O
transthyretin	S-geneY
and	O
successful	O
drug	O
discovery	O
efforts	O
focused	O
on	O
controlling	O
its	O
quaternary	O
structure	O
dynamics	O
.	O

Both	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
and	O
5	B-geneY
-	I-geneY
HT1F	E-geneY
receptors	O
modulate	O
c	B-geneY
-	I-geneY
fos	E-geneY
expression	O
within	O
rat	O
trigeminal	O
nucleus	O
caudalis	O
.	O

A	O
possible	O
mechanism	O
of	O
action	O
of	O
antimigraine	O
drugs	O
such	O
as	O
sumatriptan	S-chem
is	O
inhibition	O
of	O
the	O
trigeminovascular	O
pathway	O
.	O

Sumatriptan	O
's	O
effects	O
might	O
be	O
mediated	O
by	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
,	O
5	B-geneY
-	I-geneY
HT1D	E-geneY
or	O
5	B-geneY
-	I-geneY
HT1F	E-geneY
receptors	O
.	O

To	O
establish	O
the	O
relative	O
importance	O
of	O
these	O
subtypes	O
,	O
we	O
compared	O
the	O
effects	O
of	O
sumatriptan	S-chem
with	O
those	O
of	O
a	O
selective	O
5	B-geneY
-	I-geneY
HT1F	E-geneY
receptor	O
agonist	O
(	O
LY	B-chem
344864	E-chem
)	O
on	O
c	B-geneY
-	I-geneY
fos	E-geneY
protein	O
expression	O
in	O
the	O
trigeminal	O
nucleus	O
caudalis	O
.	O
c	B-geneY
-	I-geneY
fos	E-geneY
expression	O
was	O
induced	O
in	O
urethane	S-chem
-	O
anaesthetized	O
rats	O
by	O
intracisternal	O
capsaicin	S-chem
administration	O
.	O

Sumatriptan	S-chem
and	O
LY	B-chem
344864	E-chem
decreased	O
the	O
number	O
of	O
capsaicin	S-chem
-	O
induced	O
c	B-geneY
-	I-geneY
fos	E-geneY
-	O
like	O
immunoreactive	O
cells	O
within	O
trigeminal	O
nucleus	O
caudalis	O
(	O
ID50	O
=	O
0.04	O
and	O
0.6	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
effect	O
of	O
sumatriptan	S-chem
,	O
but	O
not	O
of	O
LY	B-chem
344864	E-chem
,	O
was	O
prevented	O
by	O
pretreatment	O
with	O
the	O
antagonist	O
SDZ	B-chem
21	I-chem
-	I-chem
009	E-chem
,	O
which	O
displays	O
high	O
affinity	O
for	O
rat	B-geneY
5	I-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
.	O

LY	B-chem
344864	E-chem
appears	O
to	O
attenuate	O
c	O
-	O
fos	O
-	O
like	O
immunoreactivity	O
via	O
5	B-geneY
-	I-geneY
HT1F	E-geneY
receptors	O
,	O
while	O
sumatriptan	S-chem
acts	O
via	O
5	B-geneY
-	I-geneY
HT1B	E-geneY
receptors	O
.	O

The	O
fact	O
that	O
activation	O
of	O
5	B-geneY
-	I-geneY
HT1F	E-geneY
receptors	O
is	O
sufficient	O
to	O
modulate	O
the	O
activity	O
of	O
the	O
trigeminal	O
system	O
suggests	O
that	O
this	O
receptor	O
may	O
be	O
a	O
target	O
for	O
antimigraine	O
drugs	O
with	O
improved	O
safety	O
profile	O
.	O

Moxifloxacin	S-chem
enhances	O
etoposide	S-chem
-	O
induced	O
cytotoxic	O
,	O
apoptotic	O
and	O
anti	O
-	O
topoisomerase	B-geneY
II	E-geneY
effects	O
in	O
a	O
human	O
colon	O
carcinoma	O
cell	O
line	O
.	O

Etoposide	S-chem
(	O
VP	B-chem
-	I-chem
16	E-chem
)	O
is	O
a	O
topoisomerase	B-geneY
-	I-geneY
II	E-geneY
(	O
topo	B-geneY
II	E-geneY
)	O
inhibitor	O
chemotherapeutic	O
agent	O
.	O

Studies	O
have	O
shown	O
that	O
a	O
combination	O
of	O
VP	B-chem
-	I-chem
16	E-chem
with	O
other	O
drugs	O
demonstrates	O
better	O
clinical	O
responses	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
moxifloxacin	S-chem
(	O
MXF	S-chem
)	O
and	O
VP	B-chem
-	I-chem
16	E-chem
on	O
cellular	O
topo	B-geneY
II	E-geneY
activity	O
in	O
drug	O
-	O
treated	O
cells	O
and	O
evaluate	O
the	O
influence	O
of	O
MXF	S-chem
on	O
the	O
mode	O
of	O
action	O
of	O
VP	B-chem
-	I-chem
16	E-chem
,	O
on	O
proliferation	O
and	O
apoptosis	O
of	O
HT	O
-	O
29	O
cells	O
.	O

Decatenation	O
assay	O
,	O
band	O
depletion	O
and	O
Western	O
blot	O
analysis	O
,	O
cytotoxic	O
assay	O
(	O
MTT	S-chem
)	O
,	O
flow	O
cytometric	O
studies	O
(	O
cell	O
cycle	O
and	O
survivin	O
expression	O
)	O
,	O
apoptosis	O
(	O
DAPI	S-chem
-	O
sulforhodamine	S-chem
staining	O
and	O
caspase	B-geneY
3	E-geneY
activity	O
)	O
and	O
IL	B-geneY
-	I-geneY
8	E-geneY
and	O
VEGF	S-geneY
secretion	O
were	O
determined	O
.	O

MXF	S-chem
or	O
VP	B-chem
-	I-chem
16	E-chem
slightly	O
affected	O
cellular	O
topo	B-geneY
II	E-geneY
activity	O
in	O
nuclear	O
extracts	O
derived	O
from	O
drug	O
-	O
treated	O
cells	O
while	O
the	O
combination	O
enhanced	O
inhibitory	O
activity	O
and	O
the	O
reduction	O
in	O
band	O
depletion	O
of	O
topo	B-geneY
II	E-geneY
.	O

VP	B-chem
-	I-chem
16	E-chem
induced	O
cell	O
cycle	O
arrest	O
at	O
G2	O
/	O
M	O
and	O
the	O
appearance	O
of	O
the	O
subG1	O
peak	O
which	O
was	O
increased	O
by	O
the	O
addition	O
of	O
MXF	S-chem
.	O

Apoptosis	O
studies	O
(	O
DAPI	S-chem
staining	O
and	O
caspase	B-geneY
3	E-geneY
activity	O
)	O
showed	O
a	O
marked	O
increase	O
in	O
the	O
presence	O
of	O
MXF	S-chem
and	O
VP	B-chem
-	I-chem
16	E-chem
compared	O
to	O
VP	B-chem
-	I-chem
16	E-chem
alone	O
.	O

VP	B-chem
-	I-chem
16	E-chem
induced	O
the	O
release	O
of	O
IL	B-geneY
-	I-geneY
8	E-geneY
,	O
and	O
addition	O
of	O
MXF	S-chem
reduced	O
enhanced	O
release	O
and	O
the	O
spontaneous	O
release	O
of	O
VEGF	S-geneY
from	O
the	O
cells	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
suggest	O
that	O
the	O
enhancement	O
in	O
the	O
reduction	O
of	O
topo	B-geneY
II	E-geneY
activity	O
by	O
the	O
combined	O
MXF	S-chem
/	O
VP	B-chem
-	I-chem
16	E-chem
treatments	O
was	O
probably	O
due	O
to	O
the	O
increase	O
in	O
the	O
level	O
of	O
the	O
DNA	O
-	O
enzyme	O
cleavable	O
complexes	O
formed	O
by	O
both	O
drugs	O
.	O

The	O
unique	O
combination	O
of	O
MXF	S-chem
/	O
VP	B-chem
-	I-chem
16	E-chem
may	O
have	O
clinical	O
benefits	O
and	O
a	O
cytotoxic	O
drug	O
'	O
sparing	O
effect	O
'	O
and	O
should	O
be	O
further	O
studied	O
in	O
vivo	O
.	O

Carbonic	B-geneN
anhydrase	E-geneN
inhibitors	O
:	O
aromatic	B-chem
and	I-chem
heterocyclic	I-chem
sulfonamides	E-chem
incorporating	O
adamantyl	S-chem
moieties	O
with	O
strong	O
anticonvulsant	O
activity	O
.	O

A	O
series	O
of	O
aromatic	B-chem
/	I-chem
heterocyclic	I-chem
sulfonamides	E-chem
incorporating	O
adamantyl	S-chem
moieties	O
were	O
prepared	O
by	O
reaction	O
of	O
aromatic	B-chem
/	I-chem
heterocyclic	I-chem
aminosulfonamides	E-chem
with	O
the	O
acyl	B-chem
chlorides	E-chem
derived	O
from	O
adamantyl	B-chem
-	I-chem
1	I-chem
-	I-chem
carboxylic	I-chem
acid	E-chem
and	O
1	B-chem
-	I-chem
adamantyl	I-chem
-	I-chem
acetic	I-chem
acid	E-chem
.	O

Related	O
derivatives	O
were	O
obtained	O
from	O
the	O
above	O
-	O
mentioned	O
aminosulfonamides	S-chem
with	O
adamantyl	B-chem
isocyanate	E-chem
and	O
adamantyl	B-chem
isothiocyanate	E-chem
,	O
respectively	O
.	O

Some	O
of	O
these	O
derivatives	O
showed	O
good	O
inhibitory	O
potency	O
against	O
two	O
human	B-geneN
CA	E-geneN
isozymes	O
involved	O
in	O
important	O
physiological	O
processes	O
,	O
CA	B-geneY
I	E-geneY
,	O
and	O
CA	B-geneY
II	E-geneY
,	O
of	O
the	O
same	O
order	O
of	O
magnitude	O
as	O
the	O
clinically	O
used	O
drugs	O
acetazolamide	S-chem
and	O
methazolamide	S-chem
.	O

The	O
lipophilicity	O
of	O
the	O
best	O
CA	S-geneN
inhibitors	O
was	O
determined	O
and	O
expressed	O
as	O
their	O
experimental	O
log	O
k	O
'	O
IAM	O
and	O
theoretical	O
ClogP	O
value	O
.	O

Their	O
lipophilicity	O
was	O
propitious	O
with	O
the	O
crossing	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
log	O
k	O
'	O
>	O
IAM	O
>	O
1.35	O
)	O
.	O

The	O
anticonvulsant	O
activity	O
of	O
some	O
of	O
the	O
best	O
CA	S-geneN
inhibitors	O
reported	O
here	O
has	O
been	O
evaluated	O
in	O
a	O
MES	O
test	O
in	O
mice	O
.	O

After	O
intraperitoneal	O
injection	O
(	O
30	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
compounds	O
A8	O
and	O
A9	O
exhibited	O
a	O
high	O
protection	O
against	O
electrically	O
induced	O
convulsions	O
(	O
>	O
90	O
%	O
)	O
.	O

Their	O
ED50	O
was	O
3.5	O
and	O
2.6	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
respectively	O
.	O

Cyclin	B-geneY
E	E-geneY
-	O
cdk2	S-geneY
activation	O
is	O
associated	O
with	O
cell	O
cycle	O
arrest	O
and	O
inhibition	O
of	O
DNA	O
replication	O
induced	O
by	O
the	O
thymidylate	B-geneY
synthase	E-geneY
inhibitor	O
Tomudex	S-chem
.	O

Tomudex	S-chem
(	O
ZD1694	S-chem
)	O
is	O
a	O
specific	O
antifolate	O
-	O
based	O
thymidylate	B-geneY
synthase	E-geneY
inhibitor	O
active	O
in	O
a	O
variety	O
of	O
solid	O
tumor	O
malignancies	O
.	O

Studies	O
were	O
carried	O
out	O
in	O
vitro	O
to	O
evaluate	O
downstream	O
molecular	O
alterations	O
induced	O
as	O
a	O
consequence	O
of	O
the	O
potent	O
and	O
sustained	O
inhibition	O
of	O
thymidylate	B-geneY
synthase	E-geneY
by	O
Tomudex	S-chem
.	O

Twenty	O
-	O
four	O
hours	O
following	O
the	O
initial	O
2	O
-	O
h	O
treatment	O
with	O
Tomudex	S-chem
,	O
human	O
A253	O
head	O
and	O
neck	O
squamous	O
carcinoma	O
cells	O
,	O
not	O
expressing	O
p53	S-geneY
and	O
p21	S-geneY
(	O
WAF1	S-geneY
)	O
,	O
were	O
accumulated	O
with	O
DNA	O
content	O
characteristic	O
of	O
early	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
with	O
a	O
concomitant	O
reduction	O
of	O
cells	O
in	O
G1	O
and	O
G2	O
/	O
M	O
phases	O
.	O

The	O
changes	O
in	O
cyclin	S-geneN
and	O
cdk	S-geneN
protein	O
expression	O
and	O
their	O
kinase	S-geneN
activities	O
were	O
examined	O
in	O
control	O
and	O
drug	O
-	O
treated	O
A253	O
cells	O
.	O

Tomudex	S-chem
treatment	O
resulted	O
in	O
the	O
decrease	O
in	O
p27	B-geneY
(	I-geneY
kip1	I-geneY
)	E-geneY
expression	O
,	O
with	O
an	O
increase	O
in	O
cyclin	B-geneY
E	E-geneY
and	O
cdk2	S-geneY
protein	O
expression	O
and	O
kinase	S-geneN
activities	O
24	O
h	O
after	O
a	O
2	O
-	O
h	O
exposure	O
.	O

Although	O
cyclin	B-geneY
A	E-geneY
protein	O
expression	O
was	O
markedly	O
increased	O
,	O
cyclin	B-geneY
A	E-geneY
kinase	S-geneN
activity	O
was	O
only	O
slightly	O
increased	O
.	O

Cyclin	B-geneY
D1	E-geneY
,	O
cyclin	B-geneY
B	E-geneY
,	O
cdk4	S-geneY
,	O
and	O
cdc2	S-geneY
protein	O
expression	O
and	O
kinase	S-geneN
activities	O
remain	O
constant	O
.	O

Lack	O
of	O
activation	O
of	O
cyclin	B-geneN
A	I-geneN
-	I-geneN
and	I-geneN
B	E-geneN
-	O
cdc2	S-geneY
was	O
associated	O
with	O
a	O
reduced	O
proportion	O
of	O
cells	O
in	O
G2	O
/	O
M	O
phases	O
.	O

Increased	O
cyclin	B-geneY
E	E-geneY
-	O
cdk2	S-geneY
protein	O
expression	O
was	O
accompanied	O
by	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
,	O
with	O
a	O
decrease	O
in	O
E2F	B-geneY
-	I-geneY
1	E-geneY
expression	O
.	O

These	O
results	O
propose	O
that	O
cyclin	B-geneY
E	E-geneY
-	O
cdk2	S-geneY
kinase	S-geneN
can	O
negatively	O
regulate	O
DNA	O
replication	O
.	O

The	O
studies	O
with	O
dThyd	O
rescue	O
from	O
cyclin	B-geneY
E	E-geneY
-	O
cdk2	S-geneY
protein	O
overexpression	O
and	O
growth	O
inhibition	O
by	O
Tomudex	S-chem
indicate	O
that	O
increased	O
cyclin	B-geneY
E	E-geneY
-	O
cdk2	S-geneY
protein	O
expression	O
is	O
associated	O
with	O
effective	O
inhibition	O
of	O
thymidylate	B-geneY
synthase	E-geneY
and	O
resultant	O
dNTP	O
pool	O
imbalance	O
.	O

Provision	O
of	O
dThyd	O
more	O
than	O
24	O
h	O
after	O
exposure	O
to	O
Tomudex	S-chem
allowed	O
cells	O
to	O
replicate	O
DNA	O
for	O
a	O
single	O
cycle	O
back	O
to	O
G1	O
,	O
but	O
did	O
not	O
prevent	O
the	O
profound	O
growth	O
-	O
inhibitory	O
effect	O
manifested	O
in	O
the	O
following	O
5	O
days	O
.	O

Tomudex	S-chem
treatment	O
resulted	O
in	O
a	O
time	O
-	O
dependent	O
induction	O
of	O
the	O
megabase	O
DNA	O
fragments	O
,	O
followed	O
by	O
secondary	O
50	O
-	O
to	O
300	O
-	O
kb	O
DNA	O
fragmentation	O
.	O

The	O
50	O
-	O
to	O
300	O
-	O
kb	O
DNA	O
fragmentation	O
may	O
be	O
derived	O
from	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
associated	O
with	O
cyclin	B-geneY
E	E-geneY
-	O
cdk2	S-geneY
activation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
megabase	O
DNA	O
fragmentation	O
is	O
induced	O
as	O
a	O
consequence	O
of	O
inhibition	O
of	O
thymidylate	B-geneY
synthase	E-geneY
by	O
Tomudex	S-chem
and	O
kilobase	O
DNA	O
fragmentation	O
may	O
correlate	O
with	O
the	O
reduction	O
of	O
p27	B-geneY
(	I-geneY
kip1	I-geneY
)	E-geneY
expression	O
and	O
the	O
increase	O
in	O
cyclin	B-geneY
E	E-geneY
and	O
cdk2	S-geneY
kinase	S-geneN
activities	O
.	O

Activation	O
of	O
cyclin	B-geneY
E	E-geneY
and	O
cdk2	S-geneY
kinases	S-geneN
allows	O
cells	O
to	O
transit	O
from	O
G1	O
to	O
S	O
phase	O
accompanied	O
by	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O

The	O
changes	O
in	O
cell	O
cycle	O
regulatory	O
proteins	O
associated	O
with	O
growth	O
inhibition	O
and	O
DNA	O
damage	O
by	O
Tomudex	S-chem
are	O
not	O
p53	S-geneY
dependent	O
.	O

Reduction	O
of	O
dimethylarsinic	B-chem
acid	E-chem
to	O
the	O
highly	O
toxic	O
dimethylarsinous	B-chem
acid	E-chem
by	O
rats	O
and	O
rat	O
liver	O
cytosol	O
.	O

Dimethylarsinic	B-chem
acid	E-chem
(	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
)	O
,	O
the	O
major	O
urinary	O
metabolite	O
of	O
inorganic	O
arsenic	S-chem
,	O
is	O
weakly	O
cytotoxic	O
,	O
whereas	O
its	O
reduced	O
form	O
,	O
dimethylarsinous	B-chem
acid	E-chem
(	O
DMAs	B-chem
(	I-chem
III	I-chem
)	E-chem
)	O
,	O
is	O
highly	O
toxic	O
.	O

Although	O
glutathione	B-geneY
S	I-geneY
-	I-geneY
transferase	I-geneY
omega	I-geneY
1	E-geneY
(	O
GSTO1	S-geneY
)	O
and	O
arsenic	B-geneY
methyltransferase	E-geneY
have	O
been	O
shown	O
or	O
thought	O
to	O
catalyze	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
reduction	O
,	O
their	O
role	O
in	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
reduction	O
in	O
vivo	O
,	O
or	O
in	O
cell	O
extracts	O
is	O
uncertain	O
.	O

Therefore	O
,	O
the	O
reduction	O
of	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
to	O
DMAs	B-chem
(	I-chem
III	I-chem
)	E-chem
in	O
rats	O
and	O
in	O
rat	O
liver	O
cytosol	O
was	O
studied	O
to	O
better	O
understand	O
its	O
mechanism	O
.	O

To	O
assess	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
reduction	O
in	O
rats	O
,	O
a	O
novel	O
procedure	O
was	O
devised	O
based	O
on	O
following	O
the	O
accumulation	O
of	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
-	O
bound	O
dimethylarsenic	S-chem
(	O
DMAs	S-chem
)	O
,	O
which	O
represents	O
DMAs	B-chem
(	I-chem
III	I-chem
)	E-chem
,	O
in	O
the	O
blood	O
of	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
-	O
injected	O
anesthetized	O
rats	O
.	O

These	O
studies	O
indicated	O
that	O
rats	O
reduced	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
to	O
DMAs	B-chem
(	I-chem
III	I-chem
)	E-chem
to	O
a	O
significant	O
extent	O
,	O
as	O
in	O
90	O
min	O
31	O
%	O
of	O
the	O
injected	O
50	O
μmol	O
/	O
kg	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
dose	O
was	O
converted	O
to	O
DMAs	B-chem
(	I-chem
III	I-chem
)	E-chem
that	O
was	O
sequestered	O
by	O
the	O
circulating	O
erythrocytes	O
.	O

Pretreatment	O
of	O
rats	O
with	O
glutathione	S-chem
(	O
GSH	S-chem
)	O
depletors	O
(	O
phorone	S-chem
or	O
BSO	S-chem
)	O
delayed	O
the	O
elimination	O
of	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
and	O
the	O
accumulation	O
of	O
RBC	O
-	O
bound	O
DMAs	S-chem
,	O
whereas	O
the	O
indirect	O
methyltransferase	S-geneN
inhibitor	O
periodate	S-chem
-	O
oxidized	O
adenosine	S-chem
was	O
without	O
effect	O
.	O

Assessment	O
of	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
-	O
reducing	O
activity	O
of	O
rat	O
liver	O
cytosol	O
revealed	O
that	O
reduction	O
of	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
required	O
cytosolic	O
protein	O
and	O
GSH	S-chem
and	O
was	O
inhibited	O
by	O
thiol	S-chem
reagents	O
,	O
GSSG	S-chem
and	O
dehydroascorbate	S-chem
.	O

Although	O
thioredoxin	B-geneN
reductase	E-geneN
(	O
TRR	S-geneN
)	O
inhibitors	O
(	O
aurothioglucose	S-chem
and	O
Sb	B-chem
(	I-chem
III	I-chem
)	E-chem
)	O
inhibited	O
cytosolic	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
reduction	O
,	O
recombinant	O
rat	B-geneN
TRR	E-geneN
plus	O
NADPH	S-chem
,	O
alone	O
or	O
when	O
added	O
to	O
the	O
cytosol	O
,	O
failed	O
to	O
support	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
reduction	O
.	O

On	O
ultrafiltration	O
of	O
the	O
cytosol	O
through	O
a	O
3	O
kDa	O
filter	O
,	O
the	O
reducing	O
activity	O
in	O
the	O
retentate	O
was	O
lost	O
but	O
was	O
largely	O
restored	O
by	O
NADPH	S-chem
.	O

Such	O
experiments	O
also	O
suggested	O
that	O
the	O
reducing	O
enzyme	O
was	O
larger	O
than	O
100	O
kDa	O
and	O
was	O
not	O
GSTO1	S-geneY
.	O

In	O
summary	O
,	O
reduction	O
of	O
DMAs	B-chem
(	I-chem
V	I-chem
)	E-chem
to	O
the	O
highly	O
toxic	O
DMAs	B-chem
(	I-chem
III	I-chem
)	E-chem
in	O
rats	O
and	O
rat	O
liver	O
cytosol	O
is	O
a	O
GSH	S-chem
-	O
dependent	O
enzymatic	O
process	O
,	O
yet	O
its	O
mechanism	O
remains	O
uncertain	O
.	O

Antiobesity	O
action	O
of	O
peripheral	O
exenatide	O
(	O
exendin	O
-	O
4	O
)	O
in	O
rodents	O
:	O
effects	O
on	O
food	O
intake	O
,	O
body	O
weight	O
,	O
metabolic	O
status	O
and	O
side	O
-	O
effect	O
measures	O
.	O

BACKGROUND	O
:	O
Exenatide	O
(	O
exendin	O
-	O
4	O
)	O
is	O
an	O
incretin	S-geneY
mimetic	O
currently	O
marketed	O
as	O
an	O
antidiabetic	O
agent	O
for	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

In	O
preclinical	O
models	O
,	O
a	O
reduction	O
in	O
body	O
weight	O
has	O
also	O
been	O
shown	O
in	O
low	O
-	O
fat	O
-	O
fed	O
,	O
leptin	B-geneN
receptor	E-geneN
-	O
deficient	O
rodents	O
.	O

OBJECTIVE	O
:	O
To	O
more	O
closely	O
model	O
the	O
polygenic	O
and	O
environmental	O
state	O
of	O
human	O
obesity	O
,	O
we	O
characterized	O
the	O
effect	O
of	O
exenatide	O
on	O
food	O
intake	O
and	O
body	O
weight	O
in	O
high	O
-	O
fat	O
-	O
fed	O
,	O
normal	O
(	O
those	O
with	O
an	O
intact	O
leptin	S-geneN
signaling	O
system	O
)	O
rodents	O
.	O

As	O
glucagon	B-geneN
-	I-geneN
like	I-geneN
peptide	I-geneN
-	I-geneN
1	I-geneN
receptor	E-geneN
agonism	O
has	O
been	O
found	O
to	O
elicit	O
behaviors	O
associated	O
with	O
visceral	O
illness	O
in	O
rodents	O
,	O
we	O
also	O
examined	O
the	O
effect	O
of	O
peripheral	O
exenatide	O
on	O
kaolin	S-chem
consumption	O
and	O
locomotor	O
activity	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
High	O
-	O
fat	O
-	O
fed	O
C57BL	O
/	O
6	O
mice	O
and	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
with	O
exenatide	O
(	O
3	O
,	O
10	O
and	O
30	O
microg	O
/	O
kg	O
/	O
day	O
)	O
for	O
4	O
weeks	O
via	O
subcutaneously	O
implanted	O
osmotic	O
pumps	O
.	O

Food	O
intake	O
and	O
body	O
weight	O
were	O
assessed	O
weekly	O
.	O

At	O
4	O
weeks	O
,	O
body	O
composition	O
and	O
plasma	O
metabolic	O
profiles	O
were	O
measured	O
.	O

Kaolin	S-chem
consumption	O
and	O
locomotor	O
activity	O
were	O
measured	O
in	O
fasted	O
Sprague	O
-	O
Dawley	O
rats	O
following	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
exenatide	O
(	O
0.1	O
-	O
10	O
microg	O
/	O
kg	O
)	O
.	O

Exenatide	O
treatment	O
in	O
mice	O
and	O
rats	O
dose	O
-	O
dependently	O
decreased	O
food	O
intake	O
and	O
body	O
weight	O
;	O
significant	O
reductions	O
in	O
body	O
weight	O
gain	O
were	O
observed	O
throughout	O
treatment	O
at	O
10	O
and	O
30	O
microg	O
/	O
kg	O
/	O
day	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Decreased	O
body	O
weight	O
gain	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
fat	O
mass	O
(	O
P	O
<	O
0.05	O
)	O
with	O
sparing	O
of	O
lean	O
tissue	O
.	O

Plasma	O
cholesterol	S-chem
,	O
triglycerides	S-chem
and	O
insulin	S-geneN
were	O
also	O
significantly	O
reduced	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Exenatide	O
at	O
10	O
microg	O
/	O
kg	O
significantly	O
reduced	O
food	O
intake	O
(	O
P	O
<	O
0.05	O
)	O
but	O
failed	O
to	O
induce	O
kaolin	S-chem
intake	O
.	O

In	O
general	O
,	O
locomotor	O
activity	O
was	O
reduced	O
at	O
doses	O
of	O
exenatide	O
that	O
decreased	O
food	O
intake	O
,	O
although	O
a	O
slightly	O
higher	O
dose	O
was	O
required	O
to	O
produce	O
significant	O
changes	O
in	O
activity	O
.	O

CONCLUSION	O
:	O
Systemic	O
exenatide	O
reduces	O
body	O
weight	O
gain	O
in	O
normal	O
,	O
high	O
-	O
fat	O
-	O
fed	O
rodents	O
,	O
a	O
model	O
that	O
parallels	O
human	O
genetic	O
variation	O
and	O
food	O
consumption	O
patterns	O
,	O
and	O
may	O
play	O
a	O
role	O
in	O
metabolic	O
pathways	O
mediating	O
food	O
intake	O
.	O

Antimyeloma	O
effects	O
of	O
a	O
novel	O
synthetic	O
retinoid	S-chem
Am80	S-chem
(	O
Tamibarotene	S-chem
)	O
through	O
inhibition	O
of	O
angiogenesis	O
.	O

In	O
multiple	O
myeloma	O
(	O
MM	O
)	O
,	O
the	O
interaction	O
between	O
myeloma	O
cells	O
and	O
bone	O
marrow	O
microenvironment	O
has	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
MM	O
.	O

We	O
first	O
examined	O
the	O
inducing	O
effect	O
of	O
myeloma	O
cells	O
on	O
migration	O
of	O
human	O
umbilical	O
vein	O
vascular	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

Five	O
myeloma	O
cell	O
lines	O
produced	O
varying	O
amounts	O
of	O
VEGF	S-geneY
,	O
and	O
migration	O
of	O
HUVECs	O
was	O
induced	O
by	O
coculture	O
with	O
myeloma	O
cells	O
.	O

We	O
next	O
examined	O
the	O
inhibitory	O
effect	O
of	O
a	O
novel	O
synthetic	O
retinoid	S-chem
Am80	S-chem
(	O
Tamibarotene	S-chem
)	O
on	O
both	O
myeloma	O
cells	O
and	O
HUVECs	O
.	O

Am80	S-chem
is	O
specific	O
for	O
the	O
retinoic	B-geneN
-	I-geneN
acid	I-geneN
receptor	I-geneN
-	I-geneN
alpha	I-geneN
/	I-geneN
beta	E-geneN
,	O
and	O
has	O
therapeutic	O
effects	O
in	O
all	B-chem
-	I-chem
trans	I-chem
retinoic	I-chem
acid	E-chem
resistant	O
acute	O
promyelocytic	O
leukemia	O
.	O

Am80	S-chem
slightly	O
inhibited	O
the	O
growth	O
of	O
both	O
myeloma	O
cells	O
and	O
HUVECs	O
,	O
and	O
remarkably	O
inhibited	O
the	O
growth	O
of	O
HUVECs	O
stimulated	O
by	O
VEGF	S-geneY
.	O

Am80	S-chem
showed	O
little	O
growth	O
inhibition	O
of	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSCs	O
)	O
,	O
but	O
it	O
markedly	O
inhibited	O
migration	O
of	O
HUVECs	O
by	O
cocultured	O
myeloma	O
cells	O
.	O

Am80	S-chem
inhibited	O
VEGF	S-geneY
-	O
induced	O
phosphorylation	O
of	O
VEGF	B-geneN
receptor	E-geneN
.	O

In	O
addition	O
,	O
VEGF	S-geneY
-	O
induced	O
formation	O
of	O
tube	O
-	O
like	O
structures	O
in	O
vitro	O
and	O
neovascularization	O
in	O
mouse	O
corneas	O
were	O
significantly	O
inhibited	O
by	O
Am80	S-chem
.	O

These	O
findings	O
clearly	O
demonstrate	O
that	O
Am80	S-chem
is	O
a	O
potential	O
inhibitor	O
of	O
angiogenesis	O
caused	O
by	O
the	O
interaction	O
between	O
vascular	O
endothelial	O
cells	O
and	O
myeloma	O
cells	O
,	O
and	O
might	O
be	O
a	O
useful	O
therapeutic	O
agent	O
against	O
MM	O
.	O

Altered	O
methionine	S-chem
metabolism	O
in	O
long	O
living	O
Ames	O
dwarf	O
mice	O
.	O

Ames	O
dwarf	O
mice	O
(	O
df	O
/	O
df	O
)	O
are	O
deficient	O
in	O
growth	B-geneY
hormone	E-geneY
,	O
prolactin	S-geneY
,	O
and	O
thyroid	B-geneN
-	I-geneN
stimulating	I-geneN
hormone	E-geneN
and	O
live	O
significantly	O
longer	O
than	O
their	O
normal	O
siblings	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
found	O
that	O
the	O
hormone	O
deficiencies	O
affect	O
methionine	S-chem
metabolism	O
.	O

We	O
previously	O
reported	O
that	O
the	O
dwarf	O
mice	O
exhibit	O
enzyme	O
activities	O
and	O
levels	O
that	O
combat	O
oxidative	O
stress	O
more	O
efficiently	O
than	O
those	O
of	O
normal	O
mice	O
.	O

Moreover	O
,	O
methionine	S-chem
or	O
metabolites	O
of	O
methionine	S-chem
are	O
involved	O
in	O
antioxidative	O
processes	O
.	O

Thus	O
,	O
we	O
performed	O
an	O
experiment	O
that	O
compared	O
various	O
parameters	O
of	O
methionine	S-chem
metabolism	O
between	O
18	O
-	O
month	O
old	O
male	O
dwarf	O
(	O
N	O
=	O
6	O
)	O
and	O
wild	O
type	O
(	O
N	O
=	O
5	O
)	O
mice	O
.	O

The	O
specific	O
activity	O
of	O
liver	B-geneN
methionine	I-geneN
adenosyltransferase	E-geneN
(	O
MAT	S-geneN
)	O
was	O
significantly	O
elevated	O
(	O
205	O
%	O
,	O
p	O
<	O
0.0001	O
)	O
in	O
the	O
dwarf	O
mice	O
,	O
as	O
were	O
cystathionine	B-geneN
synthase	E-geneN
(	O
50	O
%	O
,	O
p	O
<	O
0.01	O
)	O
,	O
cystathionase	S-geneY
(	O
83	O
%	O
,	O
p	O
<	O
0.001	O
)	O
,	O
and	O
glycine	B-geneY
N	I-geneY
-	I-geneY
methyltransferase	E-geneY
(	O
GNMT	S-geneY
,	O
91	O
%	O
,	O
p	O
<	O
0.001	O
)	O
activities	O
.	O

Even	O
though	O
the	O
activities	O
of	O
MAT	S-geneN
and	O
GNMT	S-geneY
were	O
elevated	O
,	O
the	O
concentration	O
of	O
liver	O
S	B-chem
-	I-chem
adenosylmethionine	E-chem
was	O
decreased	O
(	O
24	O
%	O
,	O
p	O
<	O
0.001	O
)	O
and	O
S	B-chem
-	I-chem
adenosylhomocysteine	E-chem
increased	O
(	O
113	O
%	O
,	O
p	O
<	O
0.001	O
)	O
in	O
the	O
dwarf	O
mice	O
.	O

These	O
data	O
indicate	O
that	O
dwarf	O
mice	O
,	O
compared	O
to	O
wild	O
type	O
mice	O
,	O
have	O
a	O
markedly	O
different	O
metabolism	O
of	O
methionine	S-chem
.	O

Altered	O
methionine	S-chem
metabolism	O
may	O
partially	O
explain	O
earlier	O
reports	O
indicating	O
less	O
oxidative	O
damage	O
to	O
proteins	O
in	O
dwarf	O
mice	O
.	O

Taken	O
together	O
,	O
the	O
data	O
suggest	O
that	O
methionine	S-chem
metabolism	O
may	O
play	O
a	O
role	O
in	O
oxidative	O
defense	O
in	O
the	O
dwarf	O
mouse	O
and	O
should	O
be	O
studied	O
as	O
a	O
potential	O
mechanism	O
of	O
extended	O
lifespan	O
.	O

Thyroid	B-geneN
hormone	I-geneN
receptors	E-geneN
/	O
THR	S-geneN
genes	O
in	O
human	O
cancer	O
.	O

Thyroid	B-chem
hormone	E-chem
(	O
triiodothyronine	S-chem
,	O
T3	O
)	O
is	O
a	O
pleiotropic	O
regulator	O
of	O
growth	O
,	O
differentiation	O
and	O
tissue	O
homeostasis	O
in	O
higher	O
organisms	O
that	O
acts	O
through	O
the	O
control	O
of	O
target	O
gene	O
expression	O
.	O

Most	O
,	O
if	O
not	O
all	O
,	O
major	O
T3	O
actions	O
are	O
mediated	O
by	O
specific	O
high	O
affinity	O
nuclear	B-geneN
receptors	E-geneN
(	O
TR	S-geneN
)	O
which	O
are	O
encoded	O
by	O
two	O
genes	O
,	O
THRA	S-geneY
and	O
THRB	S-geneY
.	O

Several	O
TRalpha	S-geneY
and	O
TRbeta	S-geneY
receptor	O
isoforms	O
are	O
expressed	O
.	O

Abundant	O
and	O
contradictory	O
literature	O
exists	O
on	O
the	O
relationship	O
between	O
circulating	O
thyroid	B-chem
hormone	E-chem
levels	O
,	O
thyroid	O
diseases	O
and	O
human	O
cancer	O
.	O

In	O
1986	O
,	O
a	O
connection	O
between	O
TR	S-geneN
and	O
cancer	O
became	O
evident	O
when	O
the	O
chicken	B-geneY
TRalpha1	E-geneY
was	O
characterized	O
as	O
the	O
c	B-geneY
-	I-geneY
erbA	E-geneY
proto	O
-	O
oncogene	O
,	O
the	O
cellular	O
counterpart	O
of	O
the	O
retroviral	O
v	B-geneN
-	I-geneN
erbA	E-geneN
oncogene	O
.	O

V	B-geneN
-	I-geneN
erbA	E-geneN
causes	O
erythroleukemias	O
and	O
sarcomas	O
in	O
birds	O
,	O
and	O
hepatocellular	O
carcinomas	O
in	O
transgenic	O
mice	O
.	O

In	O
recent	O
years	O
,	O
many	O
studies	O
have	O
analyzed	O
the	O
presence	O
of	O
quantitative	O
(	O
abnormal	O
levels	O
)	O
or	O
qualitative	O
(	O
mutations	O
)	O
alterations	O
in	O
the	O
expression	O
of	O
THR	S-geneN
genes	O
in	O
different	O
types	O
of	O
human	O
neoplasias	O
.	O

While	O
their	O
role	O
in	O
tumor	O
generation	O
or	O
progression	O
is	O
currently	O
unclear	O
,	O
both	O
gross	O
chromosomal	O
and	O
minor	O
mutations	O
(	O
deletions	O
,	O
aberrant	O
splicing	O
,	O
point	O
mutations	O
)	O
and	O
changes	O
in	O
the	O
level	O
of	O
expression	O
of	O
THRA	S-geneY
and	O
THRB	S-geneY
genes	O
have	O
been	O
found	O
.	O

Together	O
with	O
other	O
in	O
vitro	O
data	O
indicating	O
connections	O
between	O
TR	S-geneN
and	O
p53	S-geneY
,	O
Rb	S-geneY
,	O
cyclin	B-geneN
D	E-geneN
and	O
other	O
cell	O
cycle	O
regulators	O
and	O
oncogenes	O
,	O
these	O
results	O
suggest	O
that	O
THRA	S-geneY
and	O
THRB	S-geneY
may	O
be	O
involved	O
in	O
human	O
cancer	O
.	O

Role	O
of	O
tachykinin	B-geneN
and	I-geneN
bradykinin	I-geneN
receptors	E-geneN
and	O
mast	O
cells	O
in	O
gaseous	O
formaldehyde	S-chem
-	O
induced	O
airway	O
microvascular	O
leakage	O
in	O
rats	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
CP	B-chem
-	I-chem
99,994	E-chem
[	B-chem
(	I-chem
+	I-chem
)	I-chem
-	I-chem
(	I-chem
2s,3s	I-chem
)	I-chem
-	I-chem
3	I-chem
-	I-chem
(	I-chem
2	I-chem
-	I-chem
methoxybenzylamino	I-chem
)	I-chem
-	I-chem
2	I-chem
-	I-chem
phenylpiperidine	I-chem
]	E-chem
,	O
a	O
tachykinin	B-geneY
NK1	I-geneY
receptor	E-geneY
antagonist	O
,	O
HOE	B-chem
140	E-chem
(	B-chem
D	I-chem
-	I-chem
Arg	I-chem
[	I-chem
Hyp3	I-chem
,	I-chem
Thi5	I-chem
,	I-chem
D	I-chem
-	I-chem
Tic7	I-chem
,	I-chem
Oic8	I-chem
]	I-chem
bradykinin	I-chem
)	E-chem
,	O
a	O
bradykinin	B-geneY
B2	I-geneY
receptor	E-geneY
antagonist	O
,	O
and	O
ketotifen	S-chem
(	B-chem
4	I-chem
-	I-chem
(	I-chem
1	I-chem
-	I-chem
methyl	I-chem
-	I-chem
4	I-chem
-	I-chem
piperidylidene	I-chem
)	I-chem
4	I-chem
H	I-chem
-	I-chem
benzo	I-chem
[	I-chem
4,5	I-chem
]	I-chem
cycloheptal	I-chem
[	I-chem
1,2	I-chem
-	I-chem
b	I-chem
]	I-chem
thiophen	I-chem
-	I-chem
10	I-chem
(	I-chem
9H	I-chem
)	I-chem
-	I-chem
one	I-chem
hydrogen	I-chem
fumarate	I-chem
)	E-chem
,	O
a	O
histamine	B-geneY
H1	I-geneY
receptor	E-geneY
antagonist	O
with	O
mast	O
cell	O
-	O
stabilizing	O
properties	O
,	O
on	O
microvascular	O
leakage	O
induced	O
by	O
gaseous	O
formaldehyde	S-chem
.	O

Extravasation	O
of	O
Evans	B-chem
blue	I-chem
dye	E-chem
into	O
airway	O
tissues	O
was	O
used	O
as	O
an	O
index	O
of	O
airway	O
microvascular	O
leakage	O
.	O

Leakage	O
of	O
dye	O
in	O
the	O
trachea	O
and	O
main	O
bronchi	O
increased	O
significantly	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
after	O
10	O
min	O
inhalation	O
of	O
formaldehyde	S-chem
(	O
5	O
-	O
45	O
parts	O
per	O
million	O
(	O
ppm	O
)	O
)	O
.	O

The	O
airway	O
response	O
induced	O
by	O
10	O
min	O
inhalation	O
of	O
15	O
ppm	O
formaldehyde	S-chem
(	O
trachea	O
:	O
119.5	O
+	O
/	O
-	O
13.9	O
ng	O
/	O
mg	O
,	O
n	O
=	O
7	O
;	O
main	O
bronchi	O
:	O
139.6	O
+	O
/	O
-	O
7.9	O
ng	O
/	O
mg	O
,	O
n	O
=	O
7	O
)	O
was	O
abolished	O
by	O
the	O
administration	O
of	O
CP	B-chem
-	I-chem
99,994	E-chem
(	O
3	O
and	O
6	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
,	O
but	O
not	O
by	O
the	O
administration	O
of	O
HOE	B-chem
140	E-chem
(	O
0.65	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
nor	O
ketotifen	S-chem
(	O
1	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
.	O

The	O
increase	O
in	O
vascular	O
permeability	O
induced	O
by	O
formaldehyde	S-chem
in	O
the	O
rat	O
airway	O
was	O
mediated	O
predominantly	O
by	O
NK1	B-geneY
receptor	E-geneY
stimulation	O
.	O

Activation	O
of	O
bradykinin	B-geneN
receptors	E-geneN
and	O
mast	O
cells	O
did	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
this	O
airway	O
response	O
.	O

Synthesis	O
,	O
dihydrofolate	B-geneY
reductase	E-geneY
inhibition	O
,	O
antitumor	O
testing	O
,	O
and	O
molecular	O
modeling	O
study	O
of	O
some	O
new	O
4	B-chem
(	I-chem
3H	I-chem
)	I-chem
-	I-chem
quinazolinone	E-chem
analogs	O
.	O

In	O
order	O
to	O
produce	O
potent	O
new	O
leads	O
for	O
anticancer	O
drugs	O
,	O
a	O
new	O
series	O
of	O
quinazoline	S-chem
analogs	O
was	O
designed	O
to	O
resemble	O
methotrexate	S-chem
(	O
MTX	S-chem
,	O
1	O
)	O
structure	O
features	O
and	O
fitted	O
with	O
functional	O
groups	O
believed	O
to	O
enhance	O
inhibition	O
of	O
mammalian	B-geneN
DHFR	E-geneN
activity	O
.	O

Molecular	O
modeling	O
studies	O
were	O
used	O
to	O
assess	O
the	O
fit	O
of	O
these	O
compounds	O
within	O
the	O
active	O
site	O
of	O
human	B-geneY
DHFR	E-geneY
.	O

The	O
synthesized	O
compounds	O
were	O
evaluated	O
for	O
their	O
ability	O
to	O
inhibit	O
mammalian	B-geneN
DHFR	E-geneN
in	O
vitro	O
and	O
for	O
their	O
antitumor	O
activity	O
in	O
a	O
standard	O
in	O
vitro	O
tissue	O
culture	O
assay	O
panel	O
.	O

Compounds	O
28	O
,	O
30	O
,	O
and	O
31	O
were	O
the	O
most	O
active	O
DHFR	S-geneY
inhibitors	O
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
0.5	O
,	O
0.4	O
,	O
and	O
0.4microM	O
,	O
respectively	O
.	O

The	O
most	O
active	O
antitumor	O
agents	O
in	O
this	O
study	O
were	O
compounds	O
19	O
,	O
31	O
,	O
41	O
,	O
and	O
47	O
with	O
median	O
growth	O
inhibitory	O
concentrations	O
(	O
GI	O
(	O
50	O
)	O
)	O
of	O
20.1	O
,	O
23.5	O
,	O
26.7	O
,	O
and	O
9.1microM	O
,	O
respectively	O
.	O

Of	O
this	O
series	O
of	O
compounds	O
,	O
only	O
compound	O
31	O
combined	O
antitumor	O
potency	O
with	O
potent	O
DHFR	S-geneY
inhibition	O
;	O
the	O
other	O
active	O
antitumor	O
compounds	O
(	O
19	O
,	O
41	O
,	O
and	O
47	O
)	O
all	O
had	O
DHFR	S-geneY
IC	O
(	O
50	O
)	O
values	O
above	O
15microM	O
,	O
suggesting	O
that	O
they	O
might	O
exert	O
their	O
antitumor	O
potency	O
through	O
some	O
other	O
mode	O
of	O
action	O
.	O

Alternatively	O
,	O
the	O
compounds	O
could	O
differ	O
significantly	O
in	O
uptake	O
or	O
concentration	O
within	O
mammalian	O
cells	O
.	O

Polymethoxyflavones	S-chem
as	O
agents	O
that	O
prevent	O
formation	O
of	O
cataract	O
:	O
nobiletin	S-chem
congeners	O
show	O
potent	O
growth	O
inhibitory	O
effects	O
in	O
human	O
lens	O
epithelial	O
cells	O
.	O

Posterior	O
capsular	O
opacification	O
(	O
PCO	O
)	O
is	O
the	O
most	O
frequent	O
complication	O
and	O
the	O
primary	O
reason	O
for	O
visual	O
decrease	O
after	O
extracapsular	O
cataract	O
surgery	O
.	O

The	O
proliferation	O
and	O
migration	O
of	O
leftover	O
lens	O
epithelial	O
cells	O
(	O
LECs	O
)	O
after	O
surgery	O
may	O
contribute	O
to	O
the	O
development	O
of	O
PCO	O
.	O

To	O
prevent	O
PCO	O
,	O
a	O
rational	O
approach	O
would	O
be	O
to	O
inhibit	O
both	O
the	O
proliferation	O
and	O
the	O
migration	O
of	O
LECs	O
using	O
nontoxic	O
xenobiotics	O
.	O

Nobiletin	S-chem
,	O
one	O
of	O
the	O
most	O
abundant	O
polymethoxyflavones	S-chem
(	O
PMFs	S-chem
)	O
in	O
citrus	O
peel	O
,	O
and	O
its	O
synthetic	O
congeners	O
displayed	O
a	O
potent	O
inhibition	O
of	O
LEC	O
proliferation	O
.	O

Structural	O
features	O
which	O
enhance	O
anti	O
-	O
proliferative	O
activity	O
have	O
also	O
been	O
discussed	O
.	O

The	O
effects	O
of	O
mitiglinide	S-chem
(	O
KAD	B-chem
-	I-chem
1229	E-chem
)	O
,	O
a	O
new	O
anti	O
-	O
diabetic	O
drug	O
,	O
on	O
ATP	B-geneN
-	I-geneN
sensitive	I-geneN
K	I-geneN
+	I-geneN
channels	E-geneN
and	O
insulin	S-geneY
secretion	O
:	O
comparison	O
with	O
the	O
sulfonylureas	S-chem
and	O
nateglinide	S-chem
.	O

Mitiglinide	S-chem
(	O
KAD	B-chem
-	I-chem
1229	E-chem
)	O
,	O
a	O
new	O
anti	O
-	O
diabetic	O
drug	O
,	O
is	O
thought	O
to	O
stimulate	O
insulin	S-geneY
secretion	O
by	O
closing	O
the	O
ATP	B-geneN
-	I-geneN
sensitive	I-geneN
K	I-geneN
+	I-geneN
(	I-geneN
K	I-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
)	I-geneN
channels	E-geneN
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O

However	O
,	O
its	O
selectivity	O
for	O
the	O
various	O
K	B-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
channels	E-geneN
is	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
mitiglinide	S-chem
on	O
various	O
cloned	O
K	B-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
channels	E-geneN
(	O
Kir6.2	S-geneY
/	O
SUR1	S-geneY
,	O
Kir6.2	S-geneY
/	O
SUR2A	S-geneY
,	O
and	O
Kir6.2	S-geneY
/	O
SUR2B	S-geneY
)	O
reconstituted	O
in	O
COS	O
-	O
1	O
cells	O
,	O
and	O
compared	O
them	O
to	O
another	O
meglitinide	S-chem
-	O
related	O
compound	O
,	O
nateglinide	S-chem
.	O

Patch	O
-	O
clamp	O
analysis	O
using	O
inside	O
-	O
out	O
recording	O
configuration	O
showed	O
that	O
mitiglinide	S-chem
inhibits	O
the	O
Kir6.2	S-geneY
/	O
SUR1	S-geneY
channel	O
currents	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC50	O
value	O
,	O
100	O
nM	O
)	O
but	O
does	O
not	O
significantly	O
inhibit	O
either	O
Kir6.2	S-geneY
/	O
SUR2A	S-geneY
or	O
Kir6.2	S-geneY
/	O
SUR2B	S-geneY
channel	O
currents	O
even	O
at	O
high	O
doses	O
(	O
more	O
than	O
10	O
microM	O
)	O
.	O

Nateglinide	S-chem
inhibits	O
Kir6.2	S-geneY
/	O
SUR1	S-geneY
and	O
Kir6.2	S-geneY
/	O
SUR2B	S-geneY
channels	O
at	O
100	O
nM	O
,	O
and	O
inhibits	O
Kir6.2	S-geneY
/	O
SUR2A	S-geneY
channels	O
at	O
high	O
concentrations	O
(	O
1	O
microM	O
)	O
.	O

Binding	O
experiments	O
on	O
mitiglinide	S-chem
,	O
nateglinide	S-chem
,	O
and	O
repaglinide	S-chem
to	O
SUR1	S-geneY
expressed	O
in	O
COS	O
-	O
1	O
cells	O
revealed	O
that	O
they	O
inhibit	O
the	O
binding	O
of	O
[	B-chem
3H	I-chem
]	I-chem
glibenclamide	E-chem
to	O
SUR1	S-geneY
(	O
IC50	O
values	O
:	O
mitiglinide	S-chem
,	O
280	O
nM	O
;	O
nateglinide	S-chem
,	O
8	O
microM	O
;	O
repaglinide	S-chem
,	O
1.6	O
microM	O
)	O
,	O
suggesting	O
that	O
they	O
all	O
share	O
a	O
glibenclamide	S-chem
binding	O
site	O
.	O

The	O
insulin	S-geneN
responses	O
to	O
glucose	S-chem
,	O
mitiglinide	S-chem
,	O
tolbutamide	S-chem
,	O
and	O
glibenclamide	S-chem
in	O
MIN6	O
cells	O
after	O
chronic	O
mitiglinide	S-chem
,	O
nateglinide	S-chem
,	O
or	O
repaglinide	S-chem
treatment	O
were	O
comparable	O
to	O
those	O
after	O
chronic	O
tolbutamide	S-chem
and	O
glibenclamide	S-chem
treatment	O
.	O

These	O
results	O
indicate	O
that	O
,	O
similar	O
to	O
the	O
sulfonylureas	S-chem
,	O
mitiglinide	S-chem
is	O
highly	O
specific	O
to	O
the	O
Kir6.2	S-geneY
/	O
SUR1	S-geneY
complex	O
,	O
i.e	O
.	O
,	O
the	O
pancreatic	O
beta	O
-	O
cell	O
K	B-geneN
(	I-geneN
ATP	I-geneN
)	I-geneN
channel	E-geneN
,	O
and	O
suggest	O
that	O
mitiglinide	S-chem
may	O
be	O
a	O
clinically	O
useful	O
anti	O
-	O
diabetic	O
drug	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
xanthine	S-chem
derivatives	O
on	O
dipeptidyl	B-geneY
peptidase	I-geneY
4	E-geneY
.	O

A	O
series	O
of	O
xanthine	S-chem
derivatives	O
in	O
which	O
a	O
methylene	S-chem
was	O
inserted	O
at	O
position	O
8	O
of	O
xanthine	S-chem
scaffold	O
was	O
synthesized	O
and	O
evaluated	O
as	O
inhibitors	O
of	O
dipeptidyl	B-geneY
peptidase	I-geneY
4	E-geneY
(	O
DPP	B-geneY
-	I-geneY
4	E-geneY
)	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O

As	O
the	O
results	O
of	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
study	O
of	O
the	O
series	O
,	O
the	O
compounds	O
with	O
4	B-chem
-	I-chem
methyl	I-chem
-	I-chem
quinazoline	I-chem
-	I-chem
2	I-chem
-	I-chem
yl	I-chem
-	I-chem
methyl	E-chem
group	O
at	O
N	O
-	O
1	O
position	O
and	O
2	B-chem
-	I-chem
aminoethylaminomethyl	E-chem
group	O
gave	O
better	O
activities	O
.	O

Compounds	O
H4	O
and	O
H9	O
showed	O
good	O
DPP	B-geneY
-	I-geneY
4	E-geneY
inhibition	O
and	O
more	O
than	O
100	O
-	O
fold	O
selectivity	O
over	O
DPP	B-geneY
-	I-geneY
7	E-geneY
and	O
DPP	B-geneY
-	I-geneY
8	E-geneY
.	O

Arsenic	B-chem
trioxide	E-chem
depletes	O
cancer	O
stem	O
-	O
like	O
cells	O
and	O
inhibits	O
repopulation	O
of	O
neurosphere	O
derived	O
from	O
glioblastoma	O
by	O
downregulation	O
of	O
Notch	S-geneN
pathway	O
.	O

Notch	S-geneN
signaling	O
has	O
been	O
demonstrated	O
to	O
have	O
a	O
central	O
role	O
in	O
cancer	O
stem	O
-	O
like	O
cells	O
(	O
CSLCs	O
)	O
in	O
glioblastoma	O
multiforme	O
(	O
GBM	O
)	O
.	O

We	O
have	O
recently	O
demonstrated	O
the	O
inhibitory	O
effect	O
of	O
arsenic	B-chem
trioxide	E-chem
(	O
ATO	S-chem
)	O
on	O
CSLCs	O
in	O
glioblastoma	O
cell	O
lines	O
.	O

In	O
this	O
study	O
we	O
used	O
neurosphere	O
recovery	O
assay	O
that	O
measured	O
neurosphere	O
formation	O
at	O
three	O
time	O
points	O
to	O
assess	O
the	O
capacity	O
of	O
the	O
culture	O
to	O
repopulate	O
after	O
ATO	S-chem
treatment	O
.	O

Our	O
results	O
provided	O
strong	O
evidence	O
that	O
ATO	S-chem
depleted	O
CSLCs	O
in	O
GBM	O
,	O
and	O
inhibited	O
neurosphere	O
recovery	O
and	O
secondary	O
neurosphere	O
formation	O
.	O

ATO	S-chem
inhibited	O
the	O
phosphorylation	O
and	O
activation	O
of	O
AKT	S-geneN
and	O
STAT3	S-geneY
through	O
Notch	S-geneN
signaling	O
blockade	O
.	O

These	O
data	O
show	O
that	O
the	O
ATO	S-chem
is	O
a	O
promising	O
new	O
approach	O
to	O
decrease	O
glioblastoma	O
proliferation	O
and	O
recurrence	O
by	O
downregulation	O
of	O
Notch	S-geneN
pathway	O
.	O

[	O
Construction	O
of	O
the	O
flavinogenic	O
yeast	O
Candida	O
famata	O
strains	O
with	O
high	O
riboflavin	B-geneN
kinase	E-geneN
activity	O
using	O
gene	O
engineering	O
]	O
.	O

The	O
recombinant	O
strains	O
of	O
the	O
flavinogenic	O
yeast	O
Candida	O
famata	O
,	O
which	O
contain	O
the	O
DNA	O
fragment	O
consisting	O
of	O
the	O
FMN1	S-geneN
gene	O
(	O
encoding	O
the	O
riboflavin	B-geneN
kinase	E-geneN
,	O
enzyme	O
that	O
converts	O
riboflavin	S-chem
to	O
flavinmononucleotide	S-chem
)	O
driven	O
by	O
the	O
strong	O
promoters	O
(	O
the	O
regulated	O
RIB1	S-geneN
or	O
constitutive	O
TEF1	B-geneN
promoter	E-geneN
)	O
were	O
isolated	O
.	O

Riboflavin	B-geneN
kinase	E-geneN
activity	O
in	O
the	O
isolated	O
transformants	O
was	O
tested	O
.	O

The	O
6	O
-	O
8	O
-	O
fold	O
increase	O
of	O
the	O
riboflavin	B-geneN
kinase	E-geneN
activity	O
was	O
shown	O
in	O
the	O
recombinant	O
strains	O
containing	O
the	O
integrated	O
Debaryomyces	B-geneN
hansenii	I-geneN
FMN1	E-geneN
gene	O
under	O
the	O
strong	O
constitutive	O
TEF1	B-geneN
promoter	E-geneN
.	O

The	O
recombinant	O
strains	O
can	O
be	O
used	O
for	O
the	O
following	O
construction	O
of	O
flavinmononucleotide	S-chem
overproducers	O
.	O

Evaluation	O
of	O
biological	O
activities	O
of	O
a	O
groundnut	O
(	O
Apios	O
americana	O
Medik	O
)	O
extract	O
containing	O
a	O
novel	O
isoflavone	S-chem
.	O

Groundnut	O
(	O
Apios	O
americana	O
Medik	O
)	O
contains	O
a	O
novel	O
isoflavone	S-chem
,	O
genistein	B-chem
-	I-chem
7	I-chem
-	I-chem
O	I-chem
-	I-chem
gentiobioside	E-chem
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
biological	O
activities	O
of	O
an	O
alcohol	S-chem
extract	O
of	O
groundnut	O
containing	O
genistein	B-chem
-	I-chem
7	I-chem
-	I-chem
O	I-chem
-	I-chem
gentiobioside	E-chem
as	O
the	O
main	O
component	O
.	O

Although	O
the	O
groundnut	O
extract	O
by	O
itself	O
did	O
not	O
show	O
antioxidative	O
activity	O
,	O
it	O
drove	O
the	O
antioxidative	O
system	O
in	O
cells	O
.	O

Pretreatment	O
of	O
human	O
breast	O
carcinoma	O
MCF	O
-	O
7	O
cells	O
for	O
24	O
h	O
with	O
the	O
groundnut	O
extract	O
and	O
soybean	O
isoflavone	S-chem
increased	O
gene	O
expression	O
of	O
heme	B-geneY
oxygenase	I-geneY
-	I-geneY
1	E-geneY
(	O
HO	B-geneY
-	I-geneY
1	E-geneY
)	O
,	O
a	O
major	O
antioxidative	O
stress	O
enzyme	O
.	O

These	O
groundnut	O
extract	O
-	O
treated	O
cells	O
showed	O
antioxidative	O
activity	O
against	O
free	O
radicals	O
derived	O
from	O
a	O
radical	O
initiator	O
.	O

Pretreatment	O
of	O
cells	O
with	O
100	O
μg	O
/	O
mL	O
groundnut	O
extract	O
prevented	O
the	O
depletion	O
of	O
glutathione	S-chem
by	O
the	O
radical	O
initiator	O
;	O
however	O
,	O
treatment	O
with	O
100	O
μg	O
/	O
mL	O
of	O
soybean	O
isoflavone	S-chem
injured	O
the	O
cell	O
membrane	O
,	O
indicating	O
that	O
glutathione	S-chem
might	O
be	O
released	O
to	O
the	O
extracellular	O
environment	O
.	O

These	O
results	O
suggest	O
that	O
the	O
groundnut	O
extract	O
had	O
isoflavone	S-chem
-	O
like	O
activity	O
.	O

Like	O
soybean	O
,	O
groundnuts	O
are	O
a	O
good	O
source	O
of	O
isoflavones	S-chem
.	O

Effects	O
of	O
bambuterol	S-chem
and	O
terbutaline	S-chem
on	O
isolated	O
rat	O
's	O
tracheal	O
smooth	O
muscle	O
.	O

Terbutaline	S-chem
(	O
Bricanyl	S-chem
)	O
and	O
its	O
prodrug	O
Bambuterol	S-chem
(	O
Bambec	S-chem
)	O
are	O
highly	O
potent	O
beta	B-geneY
(	I-geneY
2	I-geneY
)	I-geneY
-	I-geneY
adrenoceptor	E-geneY
agonists	O
often	O
used	O
in	O
asthma	O
patients	O
.	O

Terbutaline	S-chem
in	O
the	O
form	O
of	O
inhaled	O
short	O
-	O
acting	O
bronchodilator	O
relieves	O
asthmatic	O
symptoms	O
.	O

However	O
,	O
the	O
effects	O
of	O
bambuterol	S-chem
given	O
intratracheally	O
have	O
rarely	O
been	O
explored	O
.	O

To	O
verify	O
the	O
effect	O
of	O
bambuterol	S-chem
and	O
terbutaline	S-chem
,	O
which	O
act	O
on	O
the	O
tracheal	O
smooth	O
muscle	O
directly	O
in	O
vitro	O
,	O
we	O
used	O
our	O
preparation	O
to	O
test	O
the	O
effects	O
of	O
bambuterol	S-chem
on	O
isolated	O
rat	O
's	O
tracheal	O
smooth	O
muscle	O
compared	O
with	O
terbutaline	S-chem
.	O

The	O
following	O
assessments	O
of	O
bambuterol	S-chem
and	O
terbutaline	S-chem
were	O
performed	O
:	O
(	O
1	O
)	O
effect	O
on	O
tracheal	O
smooth	O
muscle	O
resting	O
tension	O
;	O
(	O
2	O
)	O
effect	O
on	O
contraction	O
caused	O
by	O
10	O
(	O
-	O
6	O
)	O
M	O
methacholine	S-chem
as	O
a	O
parasympathetic	O
mimetic	O
;	O
(	O
3	O
)	O
effect	O
of	O
the	O
drugs	O
on	O
electrically	O
induced	O
tracheal	O
smooth	O
muscle	O
contractions	O
.	O

The	O
results	O
indicated	O
that	O
adding	O
bambuterol	S-chem
induced	O
a	O
significant	O
further	O
contraction	O
to	O
10	O
(	O
-	O
6	O
)	O
M	O
methacholine	S-chem
-	O
induced	O
contraction	O
when	O
the	O
preparation	O
was	O
increased	O
to	O
10	O
(	O
-	O
4	O
)	O
M	O
.	O

But	O
terbutaline	S-chem
elicited	O
a	O
relaxation	O
response	O
at	O
a	O
dose	O
of	O
10	O
(	O
-	O
6	O
)	O
M	O
or	O
more	O
.	O

Both	O
bambuterol	S-chem
and	O
terbutaline	S-chem
could	O
inhibit	O
electrical	O
field	O
stimulation	O
(	O
EFS	O
)	O
induced	O
spike	O
contraction	O
.	O

Terbutaline	S-chem
had	O
an	O
anti	O
-	O
cholinergic	O
effect	O
that	O
could	O
relieve	O
asthmatic	O
symptoms	O
.	O

But	O
the	O
effect	O
of	O
bambuterol	O
acting	O
on	O
tracheal	O
smooth	O
muscle	O
directly	O
was	O
controversial	O
.	O

Identification	O
of	O
a	O
new	O
interaction	O
mode	O
between	O
the	O
Src	B-geneN
homology	I-geneN
2	I-geneN
(	I-geneN
SH2	I-geneN
)	I-geneN
domain	E-geneN
of	O
C	B-geneY
-	I-geneY
terminal	I-geneY
Src	I-geneY
kinase	E-geneY
(	O
Csk	S-geneY
)	O
and	O
Csk	B-geneY
-	I-geneY
binding	I-geneY
protein	E-geneY
(	O
Cbp	S-geneY
)	O
/	O
phosphoprotein	B-geneY
associated	I-geneY
with	I-geneY
glycosphingolipid	I-geneY
microdomains	E-geneY
(	O
PAG	S-geneY
)	O
.	O

Proteins	O
with	O
Src	B-geneN
homology	I-geneN
2	I-geneN
(	I-geneN
SH2	I-geneN
)	I-geneN
domains	E-geneN
play	O
major	O
roles	O
in	O
tyrosine	B-geneN
kinase	E-geneN
signaling	O
.	O

Structures	O
of	O
many	O
SH2	B-geneN
domains	E-geneN
have	O
been	O
studied	O
,	O
and	O
the	O
regions	O
involved	O
in	O
their	O
interactions	O
with	O
ligands	O
have	O
been	O
elucidated	O
.	O

However	O
,	O
these	O
analyses	O
have	O
been	O
performed	O
using	O
short	O
peptides	O
comprising	O
phosphotyrosine	S-chem
followed	O
by	O
a	O
few	O
amino	B-chem
acids	E-chem
,	O
which	O
are	O
described	O
as	O
the	O
canonical	O
recognition	O
sites	O
.	O

Here	O
we	O
report	O
the	O
solution	O
structure	O
of	O
the	O
SH2	B-geneN
domain	E-geneN
of	O
C	B-geneY
-	I-geneY
terminal	I-geneY
Src	I-geneY
kinase	E-geneY
(	O
Csk	S-geneY
)	O
in	O
complex	O
with	O
a	O
longer	O
phosphopeptide	O
from	O
Csk	B-geneY
-	I-geneY
binding	I-geneY
protein	E-geneY
(	O
Cbp	S-geneY
)	O
.	O

This	O
structure	O
,	O
together	O
with	O
biochemical	O
experiments	O
,	O
revealed	O
the	O
existence	O
of	O
a	O
novel	O
binding	O
region	O
in	O
addition	O
to	O
the	O
canonical	O
phosphotyrosine	S-chem
-	O
314	O
binding	O
site	O
of	O
Cbp	S-geneY
.	O

Mutational	O
analysis	O
of	O
this	O
second	O
region	O
in	O
cells	O
showed	O
that	O
both	O
canonical	O
and	O
novel	O
binding	O
sites	O
are	O
required	O
for	O
tumor	O
suppression	O
through	O
the	O
Cbp	S-geneY
-	O
Csk	S-geneY
interaction	O
.	O

Furthermore	O
,	O
the	O
data	O
indicate	O
an	O
allosteric	O
connection	O
between	O
Cbp	S-geneY
binding	O
and	O
Csk	S-geneY
activation	O
that	O
arises	O
from	O
residues	O
in	O
the	O
βB	O
/	O
βC	O
loop	O
of	O
the	O
SH2	B-geneN
domain	E-geneN
.	O

Activation	O
of	O
an	O
apoptotic	O
signal	O
transduction	O
pathway	O
involved	O
in	O
the	O
upregulation	O
of	O
calpain	S-geneN
and	O
apoptosis	B-geneY
-	I-geneY
inducing	I-geneY
factor	E-geneY
in	O
aldosterone	S-chem
-	O
induced	O
primary	O
cultured	O
cardiomyocytes	O
.	O

In	O
this	O
study	O
,	O
aldosterone	S-chem
(	O
ALD	S-chem
)	O
-	O
induced	O
apoptosis	O
of	O
cardiomyocyte	O
was	O
evaluated	O
based	O
on	O
the	O
previous	O
studies	O
,	O
and	O
the	O
roles	O
of	O
calpain	S-geneN
signaling	O
were	O
clarified	O
.	O

Primary	O
cultured	O
rat	O
cardiomyocytes	O
were	O
injured	O
by	O
ALD	S-chem
(	O
0.01	O
-	O
10	O
μM	O
)	O
for	O
varying	O
time	O
periods	O
.	O

Then	O
,	O
the	O
effects	O
of	O
ethylene	B-chem
glycol	I-chem
tetraacetic	I-chem
acid	E-chem
(	O
EGTA	S-chem
)	O
(	O
0.5	O
mM	O
)	O
,	O
calpeptin	S-chem
(	O
2.5	O
μM	O
)	O
,	O
and	O
spironoclactone	S-chem
(	O
10	O
μM	O
)	O
were	O
evaluated	O
on	O
cardiomyocytes	O
activated	O
by	O
ALD	S-chem
.	O

Cardiomyocytes	O
that	O
were	O
injured	O
by	O
ALD	S-chem
were	O
assayed	O
by	O
the	O
MTT	S-chem
and	O
LDH	S-geneN
leakage	O
ratio	O
.	O

Apoptosis	O
was	O
evaluated	O
by	O
a	O
TUNEL	O
assay	O
,	O
annexin	O
V	O
/	O
PI	O
staining	O
,	O
and	O
caspase	B-geneY
-	I-geneY
3	E-geneY
activity	O
.	O

The	O
expression	O
of	O
cleavage	O
of	O
Bid	S-geneY
(	O
tBid	S-geneY
)	O
,	O
calpain	S-geneN
and	O
apoptosis	B-geneY
-	I-geneY
inducing	I-geneY
factor	E-geneY
(	O
AIF	S-geneY
)	O
was	O
evaluated	O
by	O
western	O
blot	O
analysis	O
.	O

ALD	S-chem
increased	O
calpain	S-geneN
expression	O
and	O
caspase	B-geneY
-	I-geneY
3	E-geneY
activity	O
and	O
promoted	O
Bid	O
cleavage	O
.	O

It	O
also	O
induced	O
the	O
release	O
of	O
AIF	S-geneY
from	O
mitochondria	O
into	O
the	O
cytosol	O
.	O

The	O
upregulation	O
of	O
calpain	S-geneN
,	O
tBid	S-geneY
and	O
caspase	B-geneY
-	I-geneY
3	E-geneY
activity	O
were	O
further	O
inhibited	O
by	O
treatment	O
with	O
EGTA	S-chem
in	O
the	O
presence	O
of	O
ALD	S-chem
.	O

Additionally	O
,	O
AIF	S-geneY
levels	O
in	O
the	O
cytosol	O
decreased	O
due	O
to	O
EGTA	S-chem
but	O
not	O
due	O
to	O
calpeptin	S-chem
.	O

This	O
was	O
also	O
accompanied	O
by	O
a	O
significant	O
decrease	O
in	O
apoptosis	O
.	O

Furthermore	O
,	O
treatment	O
with	O
spironoclactone	S-chem
not	O
only	O
attenuated	O
the	O
pro	O
-	O
apoptotic	O
effect	O
of	O
ALD	S-chem
but	O
reversed	O
the	O
ALD	S-chem
-	O
induced	O
increase	O
of	O
calpain	S-geneN
and	O
AIF	S-geneY
levels	O
.	O

AKRs	S-geneN
expression	O
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
smokers	O
:	O
The	O
role	O
of	O
body	O
mass	O
index	O
.	O

Aldo	B-geneN
-	I-geneN
keto	I-geneN
reductases	E-geneN
(	O
AKRs	S-geneN
)	O
metabolize	O
a	O
wide	O
range	O
of	O
substrates	O
,	O
including	O
polycyclic	B-chem
aromatic	I-chem
hydrocarbons	E-chem
(	O
PAHs	S-chem
)	O
,	O
generating	O
metabolites	O
(	O
o	B-chem
-	I-chem
quinones	E-chem
)	O
and	O
reactive	O
oxygen	S-chem
species	O
(	O
ROS	O
)	O
,	O
which	O
are	O
capable	O
of	O
initiating	O
and	O
promoting	O
carcinogenesis	O
.	O

Exposure	O
to	O
PAHs	S-chem
,	O
their	O
metabolites	O
,	O
and	O
ROS	O
further	O
increase	O
AKRs	S-geneN
isoform	O
expression	O
that	O
may	O
amplify	O
oxidative	O
damage	O
.	O

Human	B-geneN
AKR	E-geneN
enzymes	O
are	O
highly	O
polymorphic	O
,	O
and	O
allelic	O
variants	O
may	O
contribute	O
to	O
different	O
AKRs	S-geneN
expression	O
in	O
individuals	O
.	O

Despite	O
the	O
importance	O
of	O
AKRs	S-geneN
in	O
PAHs	S-chem
metabolism	O
,	O
there	O
are	O
no	O
studies	O
that	O
evaluate	O
,	O
in	O
general	O
human	O
populations	O
,	O
the	O
effect	O
of	O
PAHs	S-chem
on	O
AKRs	S-geneN
expression	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
tobacco	O
smoke	O
exposure	O
,	O
and	O
AKR1A1	B-geneY
*	I-geneY
2	E-geneY
and	O
AKR1C3	B-geneY
*	I-geneY
2	E-geneY
polymorphisms	O
,	O
on	O
AKR1A1	S-geneY
and	O
AKR1C1	S-geneY
-	O
AKR1C3	S-geneY
messenger	O
RNA	O
(	O
mRNA	O
)	O
levels	O
in	O
PBLs	O
from	O
smokers	O
.	O

In	O
the	O
smoker	O
group	O
,	O
there	O
is	O
a	O
statistically	O
significant	O
positive	O
association	O
between	O
AKR1A1	S-geneY
,	O
AKR1C1	S-geneY
,	O
and	O
AKR1C3	S-geneY
mRNA	O
induction	O
and	O
urine	O
cotinine	S-chem
levels	O
in	O
individuals	O
with	O
a	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
less	O
than	O
25	O
.	O

However	O
,	O
AKR1A1	B-geneY
*	I-geneY
2	E-geneY
and	O
AKR1C3	B-geneY
*	I-geneY
2	E-geneY
alleles	O
did	O
not	O
influence	O
AKR1A1	S-geneY
and	O
AKR1C1	S-geneY
-	O
AKR1C3	S-geneY
mRNA	O
levels	O
.	O

These	O
results	O
suggest	O
that	O
AKRs	S-geneN
induction	O
by	O
PAHs	S-chem
in	O
smokers	O
'	O
PBLs	O
is	O
associated	O
with	O
BMI	O
;	O
therefore	O
,	O
the	O
role	O
of	O
adipose	O
tissue	O
accumulation	O
in	O
PAHs	S-chem
'	O
effects	O
needs	O
further	O
investigation	O
.	O

Gliotransmission	O
and	O
brain	O
glucose	S-chem
sensing	O
:	O
critical	O
role	O
of	O
endozepines	S-geneN
.	O

Hypothalamic	O
glucose	S-chem
sensing	O
is	O
involved	O
in	O
the	O
control	O
of	O
feeding	O
behavior	O
and	O
peripheral	O
glucose	S-chem
homeostasis	O
,	O
and	O
glial	O
cells	O
are	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
this	O
process	O
.	O

Diazepam	B-geneY
-	I-geneY
binding	I-geneY
inhibitor	E-geneY
(	O
DBI	S-geneY
)	O
and	O
its	O
processing	O
product	O
the	O
octadecaneuropeptide	S-geneN
(	O
ODN	S-geneN
)	O
,	O
collectively	O
named	O
endozepines	S-geneN
,	O
are	O
secreted	O
by	O
astroglia	O
,	O
and	O
ODN	S-geneN
is	O
a	O
potent	O
anorexigenic	O
factor	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
involvement	O
of	O
endozepines	O
in	O
brain	O
glucose	S-chem
sensing	O
.	O

First	O
,	O
we	O
showed	O
that	O
intracerebroventricular	O
administration	O
of	O
glucose	S-chem
in	O
rats	O
increases	O
DBI	S-geneY
expression	O
in	O
hypothalamic	O
glial	O
-	O
like	O
tanycytes	O
.	O

We	O
then	O
demonstrated	O
that	O
glucose	S-chem
stimulates	O
endozepine	O
secretion	O
from	O
hypothalamic	O
explants	O
.	O

Feeding	O
experiments	O
indicate	O
that	O
the	O
anorexigenic	O
effect	O
of	O
central	O
administration	O
of	O
glucose	S-chem
was	O
blunted	O
by	O
coinjection	O
of	O
an	O
ODN	S-geneN
antagonist	O
.	O

Conversely	O
,	O
the	O
hyperphagic	O
response	O
elicited	O
by	O
central	O
glucoprivation	O
was	O
suppressed	O
by	O
an	O
ODN	S-geneN
agonist	O
.	O

The	O
anorexigenic	O
effects	O
of	O
centrally	O
injected	O
glucose	S-chem
or	O
ODN	S-geneN
agonist	O
were	O
suppressed	O
by	O
blockade	O
of	O
the	O
melanocortin	B-geneN
-	I-geneN
3	I-geneN
/	I-geneN
4	I-geneN
receptors	E-geneN
,	O
suggesting	O
that	O
glucose	S-chem
sensing	O
involves	O
endozepinergic	O
control	O
of	O
the	O
melanocortin	S-geneN
pathway	O
.	O

Finally	O
,	O
we	O
found	O
that	O
brain	O
endozepines	S-geneN
modulate	O
blood	O
glucose	S-chem
levels	O
,	O
suggesting	O
their	O
involvement	O
in	O
a	O
feedback	O
loop	O
controlling	O
whole	O
-	O
body	O
glucose	S-chem
homeostasis	O
.	O

Collectively	O
,	O
these	O
data	O
indicate	O
that	O
endozepines	S-geneN
are	O
a	O
critical	O
relay	O
in	O
brain	O
glucose	S-chem
sensing	O
and	O
potentially	O
new	O
targets	O
in	O
treatment	O
of	O
metabolic	O
disorders	O
.	O

